0000741815-14-000017.txt : 20140515 0000741815-14-000017.hdr.sgml : 20140515 20140515140251 ACCESSION NUMBER: 0000741815-14-000017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20140331 FILED AS OF DATE: 20140515 DATE AS OF CHANGE: 20140515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOOPER HOLMES INC CENTRAL INDEX KEY: 0000741815 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 221659359 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09972 FILM NUMBER: 14845866 BUSINESS ADDRESS: STREET 1: 560 N. ROGERS ROAD CITY: OLATHE STATE: KS ZIP: 66062 BUSINESS PHONE: 9137641045 MAIL ADDRESS: STREET 1: 560 N. ROGERS ROAD CITY: OLATHE STATE: KS ZIP: 66062 10-Q 1 hh03311410q.htm 10-Q HH.033114.10Q


 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
x        Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
For the quarterly period ended March 31, 2014
 
or
 
o        Transition Report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
For the transition period from         to         
__________________
 
Commission File Number: 001-09972
 
HOOPER HOLMES, INC.
(Exact name of registrant as specified in its charter)

 
New York
 
22-1659359
 
 
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
 
 
 
 
 
 
560 N. Rogers Road, Olathe, KS
 
66062
 
 
(Address of principal executive offices)
 
(Zip code)
 
 
Registrant's telephone number, including area code:   (913) 764-1045
 
Former name, former address and former fiscal year, if changed since last report
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes x
 
No o
 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (sec. 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
 
Yes x
 
No o
 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer o
 
Accelerated Filer o 
 
Non-accelerated Filer o
 
Smaller Reporting Company x

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes o
 
No x
 

The number of shares outstanding of the Registrant's common stock as of April 30, 2014 was:
Common Stock, $.04 par value - 70,410,649 shares

1




HOOPER HOLMES, INC. AND SUBSIDIARIES
INDEX


 
 
 
Page No.
PART I –
Financial Information
 
 
 
 
 
 
ITEM 1 –
Financial Statements (unaudited)
 
 
 
 
 
 
 
Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013
 
 
 
 
 
 
Consolidated Statements of Operations for the Three Months Ended March 31, 2014 and 2013
 
 
 
 
 
 
Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2014 and 2013
 
 
 
 
 
 
Notes to Unaudited Consolidated Financial Statements
 
 
 
 
 
ITEM 2 –
Management's Discussion and Analysis of Financial Condition and Results of Operations
 
 
 
 
 
ITEM 3 –
Quantitative and Qualitative Disclosures About Market Risk
 
 
 
 
 
ITEM 4 –
Controls and Procedures
 
 
 
 
PART II –
Other Information
 
 
 
 
 
ITEM 1 –
Legal Proceedings
 
 
 
 
 
ITEM 1A –
Risk Factors
 
 
 
 
 
ITEM 2 –
Unregistered Sales of Equity Securities and Use of Proceeds
 
 
 
 
 
ITEM 3 –
Defaults Upon Senior Securities
 
 
 
 
 
ITEM 4 –
Mine Safety Disclosures
 
 
 
 
 
ITEM 5 –
Other Information
 
 
 
 
 
ITEM 6 –
Exhibits
 
 
 
 
 
 
Signatures



2



PART I - Financial Information

Item 1. Financial Statements (unaudited)

Hooper Holmes, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share and per share data)
 
March 31, 2014
December 31, 2013
ASSETS
 
(unaudited)
 
 
 
 
Current assets:
 
 
 
 
 
 
Cash and cash equivalents
 
$
2,667

 
 
$
3,970

 
Accounts receivable, net of allowance for doubtful accounts of $124 and $153 at March 31, 2014 and December 31, 2013, respectively
 
9,099

 
 
8,398

 
Inventories
 
1,457

 
 
1,376

 
Other current assets
 
1,650

 
 
1,597

 
Assets held for sale
 
714

 
 
714

 
Total current assets 
 
15,587

 
 
16,055

 
 
 
 
 
 
 
 
Property, plant and equipment
 
16,345

 
 
16,018

 
Less: Accumulated depreciation and amortization
 
12,617

 
 
12,257

 
Property, plant and equipment, net
 
3,728

 
 
3,761

 
 
 
 
 
 
 
 
Other assets
 
1,029

 
 
1,830

 
Total assets  
 
$
20,344

 
 
$
21,646

 
 
 
 
 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
Accounts payable
 
$
3,234

 
 
$
3,440

 
Accrued expenses
 
5,605

 
 
4,036

 
Total current liabilities 
 
8,839

 
 
7,476

 
Other long-term liabilities
 
796

 
 
870

 
Commitments and contingencies (Note 10)
 

 
 

 
 
 
 
 
 
 
 
Stockholders' Equity:
 
 
 
 
 
 
Common stock, par value $.04 per share; Authorized: 240,000,000 shares; Issued: 70,420,044 shares and 70,382,544 shares at March 31, 2014 and December 31, 2013, respectively; Outstanding: 70,410,649 shares and 70,373,149 shares at March 31, 2014 and December 31, 2013, respectively.
 
2,817

 
 
2,815

 
Additional paid-in capital
 
150,327

 
 
150,235

 
Accumulated deficit 
 
(142,364
)
 
 
(139,679
)
 
 
 
10,780

 
 
13,371

 
Less: Treasury stock, at cost; 9,395 shares at March 31, 2014 and December 31, 2013
 
(71
)
 
 
(71
)
 
Total stockholders' equity
 
10,709

 
 
13,300

 
Total liabilities and stockholders' equity
 
$
20,344

 
 
$
21,646

 
 
 
 
 
 
 
 
See accompanying notes to consolidated financial statements.
 
 
 
 
 
 

3



Hooper Holmes, Inc. and Subsidiaries
Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share data)

 
 
 
Three Months Ended
 
 
 
March 31
 
 
 
2014
 
2013
Revenues
 
 
$
12,599

 
$
12,359

Cost of operations
 
 
9,985

 
9,160

 Gross profit
 
 
2,614

 
3,199

Selling, general and administrative expenses
 
 
5,036

 
5,206

Restructuring charges 
 
 
92

 
4

 Operating loss from continuing operations
 
 
(2,514
)
 
(2,011
)
Other expense:
 
 
 
 
 
Interest expense
 
 
(1
)
 
(2
)
Interest income
 
 
1

 
3

Other expense, net
 
 
(46
)
 
(13
)
 
 
 
(46
)
 
(12
)
Loss from continuing operations before income taxes
 
 
(2,560
)
 
(2,023
)
Income tax expense
 
 
5

 
4

Loss from continuing operations
 
 
(2,565
)
 
(2,027
)
 
 
 
 
 
 
Discontinued operations:
 
 
 
 
 
Adjustment to gain on sale of Portamedic and subsidiary
 
 
(150
)
 

     Gain (loss) from discontinued operations, including income taxes
 
 
30

 
(533
)
    Loss from discontinued operations
 
 
(120
)
 
(533
)
Net loss
 
 
$
(2,685
)
 
$
(2,560
)
Basic and diluted earnings (loss) per share:
 
 
 
 
 
Continuing operations
 
 
 
 
 
Basic
 
 
$
(0.04
)
 
$
(0.03
)
Diluted
 
 
$
(0.04
)
 
$
(0.03
)
Discontinued operations
 
 
 
 
 
Basic
 
 
$

 
$
(0.01
)
Diluted
 
 
$

 
$
(0.01
)
Net loss
 
 
 
 
 
Basic
 
 
$
(0.04
)
 
$
(0.04
)
Diluted
 
 
$
(0.04
)
 
$
(0.04
)
 
 
 
 
 
 
Weighted average number of shares - Basic
 
 
70,410,649

 
69,835,387

Weighted average number of shares - Diluted
 
 
70,410,649

 
69,835,387

 
 
 
 
 
 
See accompanying notes to consolidated financial statements.



4



Hooper Holmes, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(unaudited, in thousands)
 
Three Months Ended March 31,
 
2014
 
2013
Cash flows from operating activities:
 
 
 
Net loss
$
(2,685
)
 
$
(2,560
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Adjustment to gain on sale of Portamedic and subsidiary
150

 

Depreciation and amortization
360

 
646

Amortization of deferred financing fees
83

 

Provision for bad debt expense
(30
)
 
26

Share-based compensation expense
77

 
235

Impairment of long-lived assets and loss on disposal of fixed assets

 
123

Change in assets and liabilities:
 
 
 
Accounts receivable
(672
)
 
(1,742
)
Inventories
(81
)
 
(102
)
Other assets
(229
)
 
(502
)
Accounts payable, accrued expenses and other liabilities
1,292

 
720

Net cash used in operating activities
(1,735
)
 
(3,156
)
Cash flows from investing activities:
 
 
 
Capital expenditures
(327
)
 
(311
)
Proceeds from the sale of Portamedic
743

 

Net cash provided by (used in) investing activities
416

 
(311
)
Cash flows from financing activities:
 
 
 
Reduction in capital lease obligations
(1
)
 
(48
)
Proceeds related to the exercise of stock options
17

 

Debt financing fees

 
(967
)
Net cash provided by (used in) financing activities
16

 
(1,015
)
 
 
 
 
Net decrease in cash and cash equivalents
(1,303
)
 
(4,482
)
Cash and cash equivalents at beginning of period
3,970

 
8,319

Cash and cash equivalents at end of period
$
2,667

 
$
3,837

 
 
 
 
Supplemental disclosure of non-cash investing activities:
 
 
 
Fixed assets vouchered but not paid
$
230

 
$
182

     Fixed assets acquired by capital lease
$

 
$
62

 
 
 
 
See accompanying notes to consolidated financial statements.
 
 
 

5



Hooper Holmes, Inc. and Subsidiaries

Notes to Unaudited Consolidated Financial Statements
March 31, 2014
(unaudited)

Note 1: Basis of Presentation

Hooper Holmes, Inc. (“Hooper Holmes” or the "Company”) mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, insurance companies, employers, government organizations and academic institutions. The Company also conducts laboratory testing, assembles collection kits, conducts telephone interviews of life insurance applicants, compiles health histories, collects medical records and provides underwriting services to help life insurance companies evaluate underwriting risks.

As a provider of services to the health and insurance industries, the Company's business is subject to seasonality, with second and third quarter sales typically dropping below the other quarters due to a decline in activity during the summer months and fourth quarter sales typically the strongest quarter due to annual benefit renewal cycles.

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2013 Annual Report on Form 10-K, filed with the SEC on March 31, 2014.

Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented.

The results of operations for the three month periods ended March 31, 2014 and 2013 are not necessarily indicative of the results to be expected for any other interim period or the full year. See “Management's Discussion and Analysis of Financial Condition and Results of Operations” for additional information.

On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. For further discussion on Discontinued Operations, refer to Note 6.

Following the sale of the Portamedic service line, the Company reassessed its segment reporting. Beginning in the fourth quarter of 2013, the Company has reported its financial results in three segments: Health and Wellness, Heritage Labs and Hooper Holmes Services. Previously reported financial statement amounts have been reclassified to reflect the new segment determination for all periods presented in this Report. For further discussion on Segments, refer to Note 13.

Subsequent Events

On April 16, 2014, the Company entered into a Strategic Alliance Agreement (the “Alliance Agreement”) with Clinical Reference Laboratory, Inc. (“CRL”) pursuant to which, among other things, the Company has agreed to sell certain assets comprising the Company’s Heritage Labs and Hooper Holmes Services business units (the “Business”) to CRL. Under the terms of the Alliance Agreement, CRL has agreed to pay $3.7 million in cash (the “Purchase Price”) for certain assets of the Business, which such assets exclude, among others, all accounts receivable, and to assume specified liabilities related to the Business. The net book value of assets to be sold was approximately $1.5 million as of March 31, 2014, consisting primarily of inventory and property, plant and equipment, qualified as assets held for sale subsequent to March 31, 2014. The transaction is expected to close in the late second quarter or early third quarter of 2014. The Company will retain certain aspects of its sample kit assembly operations centering around the Health and Wellness segment and all other supply chain fulfillment capabilities, which continue to support Health and Wellness operations and other customers.

The Company also entered into a Limited Laboratory and Administrative Services Agreement (the “LLASA”) with CRL pursuant to which, among other things, CRL will become the Company’s exclusive provider, subject to certain exceptions, of

6



laboratory testing and reporting services and will also provide administrative services in support of the Company’s Health and Wellness operations. The Company will become a member of CRL’s preferred provider network for wellness programs during the term of the LLASA. The LLASA will become effective upon the closing of the transaction contemplated by the Alliance Agreement (the “Effective Date”), and will continue for five years from such date and auto-renew for an additional five year renewal period unless sooner terminated by either party in accordance with the LLASA.

On May 13, 2014, the Company entered into a Purchase and Sale Agreement (the “Purchase and Sale Agreement”) for the sale to McElroy Deutsch Mulvaney & Carpenter, LLP (the “MDMC”) of the buildings, land, certain personal property and other interests comprising the Company’s Basking Ridge, New Jersey property (the “Property”) for an aggregate purchase price of $3.05 million (the “Purchase Price”). Upon entering into the Purchase and Sale Agreement, MDMC made an initial deposit of $75,000 of the Purchase Price with an escrow agent and will deposit an additional $75,000 of the Purchase Price with the escrow agent following the completion of a 40-day inspection period (the “Inspection Period”). The remaining $2.9 million of the Purchase Price will be paid by MDMC to the Company at the closing. Subject to satisfaction of customary closing conditions, the closing is expected to occur five days after the end of the Inspection Period but no later than July 11, 2014. The deposit is refundable to MDMC in certain circumstances. The Basking Ridge real estate was classified as assets held for sale as of March 31, 2014.

New Accounting Pronouncements

In April 2014, accounting guidance was issued to change the criteria for reporting discontinued operations. Under the new guidance, only disposals of components of an entity that represent strategic shifts that have, or will have, a major effect on an entity’s operations should be reported as discontinued operations in the financial statements. Additionally, the new guidance removes the condition that an entity may not have any significant continuing involvement in the operations of the component after the disposal transaction. The new guidance requires expanded disclosures for discontinued operations, as well as disclosures about the financial effects of significant disposals that do not qualify for discontinued operations. The guidance will be effective for the Company on January 1, 2015, however early adoption is permitted. The Company currently expects to early adopt this accounting guidance in its second fiscal quarter of 2014 concurrent with meeting the criteria for assets held for sale of the Company’s Heritage Labs and Hooper Holmes Services segments.
    
Note 2: Liquidity

The Company's primary sources of liquidity are cash and cash equivalents and the 2013 Loan and Security Agreement. At March 31, 2014, the Company had $2.7 million in cash and cash equivalents, $6.7 million of working capital and no outstanding debt.

For the three month periods ended March 31, 2014 and 2013, the Company incurred losses from continuing operations of $2.6 million and $2.0 million, respectively. The Company’s net cash used in operating activities for the three months ended March 31, 2014 was $1.7 million. The Company has managed its liquidity through the sale of Portamedic and a series of cost reduction and accounts receivable collection initiatives.

Transition Initiatives

During the three month period ended March 31, 2014, the Company incurred $1.1 million of costs, which are recorded in selling, general and administrative expenses in the consolidated statement of operations, in connection with the relocation of its corporate headquarters to Olathe, Kansas, and contributed to the loss from continuing operations during the quarter. The Company relocated its headquarters to Olathe, Kansas during the first quarter of 2014, where the Health and Wellness facilities are located. As of March 31, 2014, the Basking Ridge, New Jersey real estate continued to be classified as assets held for sale. On May 13, 2014, the Company entered into an agreement for the sale of the Basking Ridge, New Jersey real estate.
 
Holdback Related to the Sale of Portamedic

On September 30, 2013, the Company completed the sale of Portamedic. Approximately $2.0 million (“Holdback Amount”) of the purchase price was held back by the acquirer as security for the Company’s obligations under the agreements between the Company and the acquirer. (Refer to Note 6). The Holdback Amount includes two components of $1.0 million each. During the first quarter of 2014, the Company received $0.7 million of the first Holdback Amount. The Company currently anticipates finalization and collection on the second Holdback Amount in the first quarter of 2015. The Company has recorded the remaining receivable related to the second Holdback Amount at the amount it believes will be collected. There cannot be any assurance that the remaining Holdback Amounts will be collected by the Company.


7



2013 Loan and Security Agreement
    
The Company maintains a three year 2013 Loan and Security Agreement, as amended, (collectively, the “2013 Loan and Security Agreement”), with Keltic Financial Partners II, LP (“Keltic Financial”) (refer to Note 9). Borrowings under the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The amount available for borrowing may be less than the $10 million under this facility at any given time due to the manner in which the maximum available amount is calculated.  The Company has an available borrowing base subject to reserves established at the lender's discretion of 85% of Eligible Receivables (as defined in the 2013 Loan and Security Agreement) up to $10 million under this facility.   Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, and other receivables deemed ineligible by the lender. Eligible Receivables include only billed receivables and concentration limits such that borrowing capacity may be affected by the Company's billing and revenue cycles. As of March 31, 2014, the lender applied a discretionary reserve of $0.5 million. Available borrowing capacity, net of this discretionary reserve was $3.1 million based on Eligible Receivables as of March 31, 2014. As of March 31, 2014, there were no borrowings outstanding under the 2013 Loan and Security Agreement.

The Company is also working with Keltic Financial to modify the financial covenants of the 2013 Loan and Security Agreement in an effort to be more in-line with the Company's operations and strategy going forward. If the Company is not able to successfully execute favorable amendments to the existing credit facility, the Company's borrowing capacity may be limited.

The 2013 Loan and Security Agreement contains various covenants, including financial covenants which required the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The lender recently waived the quarterly minimum EBITDA covenants for the fiscal period ended December 31, 2014. The Company continues to have limitations on the maximum amount of unfunded capital expenditures for each fiscal year.

Subsequent Events

On April 16, 2014 under the Alliance Agreement (refer to Note 1), CRL has agreed to pay $3.7 million in cash for certain assets of the Business, which such assets exclude, among others, all accounts receivable, and to assume specified liabilities related to the Business. The Company will retain certain aspects of its sample kit assembly operations centering around the Health and Wellness segment and all other supply chain fulfillment capabilities, which continue to support Health and Wellness operations and other customers.

On May 13, 2014 under the Purchase and Sale Agreement (refer to Note 1), MDMC has agreed to pay $3.05 million in cash for the Property.

These transactions will provide the Company with additional capital to invest as it focuses on growth supporting Health and Wellness operations.

Other Considerations

The Company's Health and Wellness business sells through wellness, disease management and insurance companies who ultimately have the relationship with the end customer. The Company's current services are aggregated with its partners' offerings to provide a total solution. As such, the Company's success is largely dependent on that of its partners.

Through the focus on the Health and Wellness sector, the Company believes it will be able to capitalize on the opportunities that exist in the Health and Wellness sector given the macro-economic focus on health care costs and improving the efficiency of health care delivery in the United States to grow revenue.
    
If the Company is not able to realize the benefits from the consolidation in Kansas and control the costs of transition, grow the Health and Wellness business as it seeks to streamline operations and improve efficiency through increased revenue and cost reduction initiatives, the Company may not have sufficient Eligible Receivables and the lender may increase reserves such that the Company may not be able to borrow under the 2013 Loan and Security Agreement. These and other factors could adversely affect liquidity and the Company's ability to generate cash flow in the future.

Based on the Company's anticipated level of future revenues and gross profits, anticipated cost reduction initiatives, cash proceeds in connection with the Alliance Agreement, the sale of the Basking Ridge, New Jersey real estate, and existing cash and cash equivalents and borrowing capacity, the Company believes it has sufficient funds to meet its cash needs to fund operation expenses and capital expenditures for the twelve months following March 31, 2014.

8




Note 3:
(Loss) Earnings Per Share

Basic (loss) earnings per share equals net (loss) income divided by the weighted average common shares outstanding during the period.  Diluted (loss) earnings per share equals net (loss) income divided by the sum of the weighted average common shares outstanding during the period plus dilutive common stock equivalents. The calculation of (loss) earnings per common share on a basic and diluted basis was the same because the inclusion of dilutive common stock equivalents would have been anti-dilutive for all periods presented.

Outstanding stock options to purchase approximately 3,917,000 and 5,607,500 shares of the Company's common stock were excluded from the calculation of diluted loss per share for the three month periods ended March 31, 2014 and 2013, respectively, because their exercise prices exceeded the average market price of the Company's common stock for such periods and, therefore, were antidilutive.

Note 4: Impairment of Long-lived Assets

The Company evaluates the recovery of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of assets may not be recoverable. For the three month period ended March 31, 2014, the Company evaluated the long-lived assets associated with Heritage Labs and Hooper Holmes Services in connection with the anticipated sale of certain assets under the Alliance Agreement with CRL. The Company concluded these long-lived assets were not impaired. There were no impairment charges recorded for these assets in continuing operations during the three month periods ended March 31, 2014 or 2013.

Note 5: Share-Based Compensation

Employee Share-Based Compensation Plans - On May 29, 2008, the Company's shareholders approved the 2008 Omnibus Employee Incentive Plan (the “2008 Plan”) providing for the grant of stock options, stock appreciation rights, non-vested stock and performance shares. The 2008 Plan provides for the issuance of an aggregate of 5,000,000 shares. For the three months ended March 31, 2014, the Company granted 162,600 options to purchase shares under the 2008 Plan. For the three months ended March 31, 2013, there were no options for the purchase of shares granted under the 2008 Plan. As of March 31, 2014, approximately 3,209,300 shares remain available for grant under the 2008 Plan.
    
On May 24, 2011, the Company's shareholders approved the 2011 Omnibus Employee Incentive Plan (the "2011 Plan") providing for the grant of stock options and non-vested stock awards. On May 29, 2013, the Company's shareholders approved an amendment and restatement of the 2011 Plan which increased the number of shares of the Company's common stock available for issuance from 1,500,000 shares to 3,500,000 shares (subject to adjustment as provided in the Amended and Restated Omnibus Plan). During the three months ended March 31, 2014, the Company granted 300,000 options to purchase shares under the 2011 Plan. There were no options for the purchase of shares granted under the 2011 Plan during the three month periods ended March 31, 2013. As of March 31, 2014, approximately 1,166,750 shares remain available for grant under the 2011 Plan as amended.

Options awarded under the 2008 and 2011 Plans (as amended) are granted at fair value on the date of grant, are exercisable in accordance with a vesting schedule specified in the grant agreement, and have contractual lives of 10 years from the date of grant. Options to purchase an aggregate of 500,000 shares of the Company's stock granted to certain executives of the Company in December 2010 vested 50% on each of the first and second anniversaries of the grant. Options to purchase an aggregate of 1,344,100 shares of the Company's stock granted to certain employees of the Company vest one-third on each of the first, second and third anniversaries of the grant. Options to purchase 2,000,000 shares of the Company's stock granted to the Chief Executive Officer of the Company in September 2013, vest 25% upon receipt of the grant and 25% on the first, second and third anniversary of the grant. Other options granted by the Company vest 25% on each of the second through fifth anniversaries of the grant.

The fair value of the stock options granted during the three month period ended March 31, 2014 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:


9



 
Three Months Ended March 31,
 
2014
Expected life (years)
5.24
Expected volatility
85.0%
Expected dividend yield
—%
Risk-free interest rate
1.8%
Weighted average fair value of options granted during the period
$0.38

The following table summarizes stock option activity for the three month period ended March 31, 2014:
 
 
Number of Shares
 
Weighted Average Exercise Price Per Share
 
Weighted Average remaining Contractual Life (years)
 
Aggregate Intrinsic Value (in thousands)
Outstanding balance at December 31, 2013
 
4,150,550

 
$
0.75

 
 
 
 
Granted
 
462,600

 
0.56

 
 
 
 
Exercised
 
(37,500
)
 
0.45

 
 
 
 
Expired
 
(505,550
)
 
1.20

 
 
 
 
Forfeited
 
(83,500
)
 
0.57

 
 
 
 
Outstanding balance at March 31, 2014
 
3,986,600

 
0.68

 
8.5
 
$222
Options exercisable at March 31, 2014
 
1,388,700

 
$
0.99

 
6.8
 
$51

The aggregate intrinsic value disclosed in the table above represents the difference between the Company's closing stock price on the last trading day of the quarter ended March 31, 2014 and the exercise price, multiplied by the number of in-the-money stock options.
During the three ended March 31, 2014, an aggregate of 37,500 stock options valued with a weighted average exercise price of $0.45 were exercised. No stock options were exercised during the three months ended March 31, 2013. Options for the purchase of an aggregate of 24,400 shares of common stock vested during the three month period ended March 31, 2014, and the aggregate fair value at grant date of these options was $0.01 million. As of March 31, 2014, there was approximately $0.7 million of total unrecognized compensation cost related to stock options. The cost is expected to be recognized over a weighted average period of 2.0 years.
In July 2009, an aggregate of 500,000 shares of non-vested stock were granted under the 2008 Plan. The fair value of these non-vested stock awards were based on the grant date fair value of $0.45 per share. The shares vest as follows: 25% after two years and 25% on each of the next three anniversary dates thereafter. As of March 31, 2014, an aggregate of 343,750 shares of such non-vested stock were forfeited and 150,000 were vested. In July 2011, an aggregate of 305,000 shares of non-vested stock were granted under the 2008 Plan. The fair value of these non-vested stock awards were based on the grant date fair value of $1.06 per share. As of March 31, 2014, an aggregate of 141,400 shares of such non-vested stock were forfeited and 155,100 were vested. The shares vest as follows: 33% on each of the first and second anniversary dates and 34% on the third anniversary. As of March 31, 2014, there was approximately $0.03 million of total unrecognized compensation cost related to non-vested stock awards. The cost is expected to be recognized over a weighted average period of 0.6 years.
Employee Stock Purchase Plan - The Company's 2004 Employee Stock Purchase Plan (the "2004 Plan") provides for the granting of purchase rights for up to 2,000,000 shares of the Company's stock to eligible employees of the Company. The 2004 Plan provides employees with the opportunity to purchase shares on the date thirteen months from the grant date (“the purchase date”) at a purchase price equal to 95% of the closing price of the Company’s common stock on the NYSE MKT on the grant date. During the period between the grant date and the purchase date, up to 10% of a participating employee's compensation, not to exceed $0.025 million, is withheld to fund the purchase of shares. Employees can cancel their purchases at any time during the period without penalty. In February 2013, under the 2004 Plan, purchase rights for approximately 233,000 shares were granted with an aggregate fair value of $0.03 million, based on the Black-Scholes option pricing model. The February 2013 offering period concluded in March 2014 and, in accordance with the 2004 Plan's automatic termination provision, there will be 36,154 shares issued. In February 2012, under the 2004 Plan, purchase rights for approximately 273,000 shares were granted with an aggregate grant date fair value of $0.05 million, based on the Black-Scholes pricing model. This offering period concluded in March 2013

10



and, in accordance with the 2004 Plan's automatic termination provision, no shares were issued. Unless terminated earlier by the Board of Directors, the 2014 Plan will terminate December 31, 2024.
Other Stock Awards - On May 30, 2007, the Company's shareholders approved the Hooper Holmes, Inc. 2007 Non-Employee Director Restricted Stock Plan (the “2007 Plan”), which provides for the automatic grant, on an annual basis for 10 years, of shares of the Company's stock to the Company's non-employee directors. The total number of shares that may be awarded under the 2007 Plan is 600,000. As of March 31, 2014, there remain available for grant approximately 360,000 shares under the 2007 Plan. Each non-employee member of the Board of Directors other than the non-executive chair receives 5,000 shares annually and the non-executive chair receives 10,000 shares annually of the Company's stock, with such shares vesting immediately upon issuance. The Company believes that the shares awarded under the 2007 Plan are “restricted securities”, as defined in SEC Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"). The Company filed a Registration Statement on Form S-8 with respect to the 2007 Plan on April 16, 2008. The directors who receive shares under the 2007 Plan are "affiliates" as defined in Rule 144 under the Securities Act and thus remain subject to the applicable provisions of Rule 144. In addition, the terms of the awards (whether or not restricted) specify that the shares may not be sold or transferred by the recipient until the director ceases to serve on the Board or, if at that time the director has not served on the Board for at least four years, on the fourth anniversary of the date the director first became a Board member. During the three months ended March 31, 2014 and 2013, no shares were awarded under the 2007 Plan.

The Company recorded $0.1 million and $0.2 million of share-based compensation expense in selling, general and administrative expenses for the three month periods ended March 31, 2014 and 2013.

Note 6: Discontinued Operations

On September 30, 2013, the Company completed the sale of certain assets comprising the Portamedic service line to Piston Acquisition, Inc., a subsidiary of American Para Professional Systems, Inc., (“Piston”). Pursuant to the terms of the Asset Purchase Agreement, the Company sold assets associated with the Portamedic service line to Piston, including, among other things, fixed assets, inventory and intellectual property, and Piston assumed certain specified liabilities. The adjusted purchase price (the "Purchase Price") was approximately $8.1 million in cash, adjusted from $8.4 million at announcement due to changes in working capital. Piston held back $2.0 million of the Purchase Price as security for the obligations under the Asset Purchase Agreement and certain other agreements between the Company and Piston.

The Holdback Amount includes two components. The first holdback is $1.0 million, subject to adjustments, and is released in total as follows: within three business days after the date on which final closing adjustments for inventory and other current assets are determined and paid (the “Closeout Date”). The remaining $1.0 million of the Holdback Amount, less any deductions or adjustments with respect to fixed assets, indemnification claims and any amounts in respect of any indemnification claims then in dispute, will be paid on the first anniversary of the Closeout Date. During the first quarter of 2014, the Company received $0.7 million of the first Holdback Amount. As a result, the amount remaining related to the first Holdback Amount was written off during the three months ended March 31, 2014 as a charge to the adjustment to gain on sale of Portamedic and subsidiary in the statement of operations. The Company has recorded the receivable related to the second Holdback Amount at the amount it believes will be collected. There cannot be any assurance that the remaining the Holdback Amounts will be collected by the Company. The Company currently anticipates finalization and collection on the second Holdback Amount in the first quarter of 2015.

The table below summarizes the operating results of Portamedic which are reported in discontinued operations in the accompanying consolidated statement of operations. Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than $0.1 million for the three month period ended March 31, 2013.

 
Three Months Ended
 
March 31
(in thousands)
2014
2013
Revenues
$

$
23,648

Gain (loss) from discontinued operations
$
30

$
(533
)
Adjustment to gain on sale of Portamedic and subsidiary
$
(150
)
$

    
As of March 31, 2014, the Basking Ridge, New Jersey real estate continued to be classified as assets held for sale as the Board authorized the sale of the real estate during the fourth quarter of 2013. The land and building owned in Basking Ridge, New Jersey of $0.7 million are recorded as assets held for sale at March 31, 2014 and December 31, 2013. On May 13, 2014, the Company entered into an agreement for the sale of the Basking Ridge, New Jersey real estate.

11



  
Note 7: Inventories

Included in inventories at March 31, 2014 and December 31, 2013 are $0.6 million and $0.4 million, respectively, of finished goods and $0.8 million and $1.0 million, respectively, of components.

Note 8: Restructuring Charges

During the three month periods ended March 31, 2014, the Company recorded restructuring charges in continuing operations totaling $0.1 million. The restructuring charges for the three month period ended March 31, 2014 consisted of employee severance.

At March 31, 2014, there was a total of $0.7 million related to restructuring charges, including employee severance and branch closure costs, are recorded in accrued expenses in the accompanying consolidated balance sheet. The following table provides a summary of the activity in the restructure accrual for the three months ended March 31, 2014:

 
As of
 
 
 
 
 
As of
(In thousands)
December 31, 2013
 
Charges
 
Payments
 
March 31, 2014
Severance
$
531

 
$
92

 
$
(213
)
 
$
410

Branch closure obligation
415

 

 
(148
)
 
267

     Total
$
946

 
$
92

 
$
(361
)
 
$
677

  
Note 9: Loan and Security Agreement

The Company maintains a three year 2013 Loan and Security Agreement, as amended on March 28, 2013 by the First Amendment, with Keltic Financial. Borrowings under the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The amount available for borrowing may be less than the $10 million under this facility at any given time due to the manner in which the maximum available amount is calculated.  The Company has an available borrowing base subject to reserves established at the lender's discretion of 85% of Eligible Receivables up to $10 million under this facility.  Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, and other receivables deemed ineligible by Keltic Financial. Eligible Receivables include only billed receivables such that borrowing capacity may be affected by the Company's billing cycles. As of March 31, 2014, the lender applied a discretionary reserve of $0.5 million. Available borrowing capacity, net of this discretionary reserve was $3.1 million based on Eligible Receivables as of March 31, 2014. As of March 31, 2014, there were no borrowings outstanding under the 2013 Loan and Security Agreement.

Interest on revolving credit loans is calculated based on the greatest of (i) the annualized prime rate plus 2.75%, (ii) the 90 day LIBOR rate plus 5.25%, and (iii) 6% per annum. The interest rate on the 2013 Loan and Security Agreement was 6.00% as of March 31, 2014. The Company is obligated to pay, on a monthly basis in arrears, an annual facility fee equal to 1% of the revolving credit limit of $10 million. During the three month periods ended March 31, 2014 and 2013, in connection with the 2013 Loan and Security Agreement, the Company incurred $0.01 million in facility fees.

The revolving credit loans are payable in full, together with all accrued interest and fees, on February 28, 2016. The 2013 Loan and Security Agreement provides for the prepayment of the entire outstanding balance of the revolving credit loans. The Company would be required to pay an early termination fee equal to 3% of the revolving credit limit if the termination occurs prior to February 28, 2015, and 2% if the termination occurs after February 28, 2015 but prior to February 28, 2016.

As security for payment and other obligations under the 2013 Loan and Security Agreement, the Company granted Keltic Financial a security interest in all of its, and its subsidiary guarantors, existing and after-acquired property, including receivables (which are subject to a lockbox account arrangement), inventory, equipment and the Basking Ridge, New Jersey real estate.  The aforementioned security interest is collectively referred to herein as the “collateral”.

The 2013 Loan and Security Agreement contains various covenants, including financial covenants which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The lender recently waived the quarterly minimum EBITDA covenants for the fiscal period ended December 31, 2014. The Company continues to have limitations on the maximum amount of unfunded capital expenditures for each fiscal year.
    

12



Note 10: Commitments and Contingencies

The Company leases its corporate headquarters in Olathe, Kansas, continuing laboratory facility and operations centers under operating leases which expire in various years through 2018. These leases generally contain renewal options and require the Company to pay all executory costs (such as property taxes, maintenance and insurance). The Company also leases copiers and other miscellaneous equipment. These leases expire in various years through 2017.

The Company is still the primary lessee under operating leases for 12 Portamedic branch offices with terms extending through September 2016, which are subleased by the acquirer of the former Portamedic business. The acquirer pays 100% of the rent and other executory costs for these 12 offices in the form of a contractual obligation for the remaining lease term. If the Company is unable to assign these leases to the acquirer of the former Portamedic business, the Company will let the leases expire with no intent of renewal.

In addition, the Company is still the primary lessee under 17 operating leases related to former Portamedic offices not utilized for continuing operations, which are not subleased by the acquirer of the former Portamedic business. The Company has accrued in previous periods approximately $0.3 million as branch closure obligations. The accrual is included as a component of the restructure reserve in the consolidated balance sheet as of March 31, 2014.

The Company has employment agreements with its Chief Executive Officer and Chief Financial Officer that provide for payment of base salary for a one year period in the event their employment with the Company is terminated in certain circumstances, including following a change in control, as further defined in the agreements.

In the past, some federal and state agencies have claimed that the Company improperly classified its health professionals as independent contractors for purposes of federal and state unemployment and/or worker's compensation tax laws and that the Company was therefore liable for taxes in arrears, or for penalties for failure to comply with their interpretation of the laws.  There are no assurances that the Company will not be subject to similar claims in the future. The Company has determined that losses related to the remaining complaint are not probable or estimable.

Note 11: Litigation

On April 23, 2012, a complaint was filed against the Company in U.S. District Court for the District of New Jersey on behalf of a purported class of employee examiners alleging, among other things, that the Company had failed to pay overtime compensation to certain employees as required by federal law. On May 24, 2012, a related complaint was filed against the Company in the same court alleging, among other things, that the Company similarly failed to pay overtime compensation to a purported class of certain independent contractor examiners who, the complaint alleges, should be treated as employees for purposes of federal law. The complaints seek award of an unspecified amount of allegedly unpaid overtime wages to certain examiners. The Company believes the allegations in the cases are without merit, has filed answers in both cases denying the substantive allegations therein. By Consent Order filed March 11, 2013, the court approved a settlement of $0.05 million between the Company and the named plaintiffs in the employee case, and the case was dismissed with prejudice. Preliminary discovery and motion practice are being conducted in the contractor case. The claim is not covered by insurance, and the Company is incurring legal costs to defend the litigation which are recorded in continuing operations. This matter relates to the former Portamedic service line for which the Company retained liability. The Company has determined that losses related to the remaining complaint are not probable or estimable.

On July 30, 2013, a complaint was filed against the Company in the California Superior Court, San Bernadino County, on behalf of a putative class of employees alleging, among other things, that the Company failed to pay wages and other compensation as required by state law. The complaint seeks award of an unspecified amount of damages and penalties. The Company has denied all of the allegations in the case and believes them to be without merit. In January 2014, the Superior Court referred the parties to mediation and a mediation date of July 17, 2014 is scheduled. The Superior Court also set a trial date of August 10, 2015. The Company has determined that the losses related to these matters are not probable or estimable. The claim is not covered by insurance, and as a result, the Company is incurring legal costs to defend the litigation.

The Company is a party to a number of other legal actions arising in the ordinary course of its business. In the opinion of management, the Company has substantial legal defenses and/or insurance coverage with respect to all of its pending legal actions. Accordingly, none of these actions is expected to have a material adverse effect on the Company’s liquidity, its consolidated results of operations or its consolidated financial position.

Note 12: Income Taxes


13



The Company recorded tax expense of less than $0.01 million in continuing operations for each of three month periods ended March 31, 2014 and 2013 reflecting a state tax liability to one state. No amounts were recorded for unrecognized tax benefits or for the payment of interest and penalties during the three month periods ended March 31, 2014 and 2013. No federal or state tax benefits were recorded relating to the current year loss, as the Company continues to believe that a full valuation allowance is required on its net deferred tax assets.
The 2011 federal income tax return is currently under examination by the Internal Revenue Service. The remaining tax years 2010 through 2013 may be subject to federal examination and assessment. Tax years from 2006 through 2009 remain open solely for purposes of federal and certain state examination of net operating loss and credit carryforwards. State income tax returns may be subject to examination for tax years 2009 through 2013, depending on state tax statute of limitations.

As of December 31, 2013, the Company has U.S. federal and state net operating loss carryforwards of $140.0 million and $127.2 million, respectively. There has been no significant change in these balances as of March 31, 2014. The net operating loss carryforwards, if unutilized, will expire in the years 2014 through 2033.

Note 13: Segments

Following the sale of the Portamedic service line, the Company reassessed its segment reporting to align with the information that the Company's chief operating decision maker regularly reviews since the sale of Portamedic. Beginning in the fourth quarter of 2013, the Company reports financial results in three segments: Health and Wellness (health risk assessments including biometric screenings), Heritage Labs (laboratory testing and kit assembly for third parties) and Hooper Holmes Services (health information services). Financial statement amounts have been recast to reflect the new segment determination for all periods presented in this Report, including certain revenues and costs previously reported as a part of discontinued Portamedic operations which have been reclassified to Hooper Holmes Services to conform to current period presentation. The determination of segment assets involves a degree of management judgment and estimates as the Company has not historically prepared balance sheets by service line. Segment asset information is not provided as of March 31, 2013, as previously indicated, the Company reported one segment through September 30, 2013 and did not historically separate working capital by service line. As of March 31, 2014, substantially all of the Company's services are provided within the United States, and substantially all of the Company's assets are located within the United States.

The table presented below provides disclosures by segment for the three month periods ended March 31, 2014 and 2013. Intercompany revenue for the three month periods ended March 31, 2013 was $0.5 million, representing Heritage Lab revenue for kit sales to the discontinued Portamedic operations at arms' length sales prices. Heritage Lab also performs services to Health and Wellness. These services are recorded at Heritage Labs' cost directly within the Health and Wellness segment, and thus, no intercompany elimination is required.

Three Months Ended March 31, 2014
Health and Wellness
Heritage Labs
Hooper Holmes Services
Unallocated Corporate
 
Total
Revenues
$
7,089

$
2,522

$
2,988

$

 
$
12,599

Operating income (loss)
497

338

(62
)
(3,287
)
(a) 
(2,514
)
Segment assets
7,223

3,786

2,847

6,488

 
20,344

 
 
 
 
 
 
 
a) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments. For the three month period ended March 31, 2014, the Company incurred $1.1 million of costs, which are recorded in unallocated corporate in the table above in connection with the relocation of its corporate headquarters to Olathe, Kansas.
Three Months Ended March 31, 2013
Health and Wellness
Heritage Labs
Hooper Holmes Services
Unallocated Corporate
 
Total
Revenues
$
5,150

$
3,145

$
4,064

$

 
$
12,359

Operating income (loss)
(15
)
196

(470
)
(1,722
)
(b) 
(2,011
)


14



b) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments.
ITEM 2
Management's Discussion and Analysis of Financial Condition and Results of Operations

In this Report, the terms “Hooper Holmes,” “Company,” “we,” “us” and “our” refer to Hooper Holmes, Inc. and its subsidiaries.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (this "Report") contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including, but not limited to, statements about our plans, strategies and prospects. When used in this Report, the words “expects,” “anticipates,” “believes,” “estimates,” “plans,” “intends,” “could,” “will,” “may” and similar expressions are intended to identify forward-looking statements.  These are statements that relate to future periods and include statements as to our operating results, revenues, sources of revenues, cost of revenues, gross margins, operating and net profits and losses, and changes in certain segment offerings.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expected. These risks and uncertainties include, but are not limited to, risks related to customer concerns about our financial health, our liquidity and ability to comply with financial covenants in our 2013 Loan and Security Agreement, declines in our business, our competition, and our ability to successfully expand our Health and Wellness business and its related impact on revenue, along with other cost reduction initiatives. The section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, entitled “Risk Factors” and similar discussions in our other filings with the Securities and Exchange Commission (“SEC”) discuss these and other important risks that may affect our business, results of operations, cash flows and financial condition. Investors should consider these factors before deciding to make or maintain an investment in our securities. The forward-looking statements included in this Report are based on information available to us as of the date of this Report. We expressly disclaim any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.

Overview

Our Company was founded in 1899. We are a publicly-traded New York corporation whose shares of common stock are listed on the NYSE MKT.  Our corporate headquarters are located in Olathe, Kansas, where our Health and Wellness and lab facilities are located. Over the last 40 years, our business focus has been on providing health risk assessment services.  We are currently engaged in the following segments:

Health and Wellness - performs risk assessment and risk management services, including biometric screenings, health risk assessments and onsite wellness coaching for health and care management companies, including wellness companies, disease management organizations, clinical research organizations and, health plans as they manage the health services of corporate and government employees;

Heritage Labs - performs tests of blood, urine and oral fluid specimens, primarily generated in connection with the paramedical exams and wellness screenings performed by third party paramedical service providers and our Health and Wellness segment, respectively, and assembles and sells specimen collection kits; and

Hooper Holmes Services - provides telephone interviews of insurance candidates, retrieval of medical records and inspections, risk management solutions and underwriting services for simplified issue products and products requiring full underwriting on behalf of insurance companies.

As a provider of services to the health and insurance industries; our business is subject to seasonality, with second and third quarter sales typically dropping below other quarters due to a decline in activity during the summer months and fourth quarter sales typically the strongest of any quarter due to annual benefit renewal cycles.
    
We believe that the overall market for our wellness services is growing and we expect it will continue to grow with the increased focus nationally on healthcare initiatives. Our Health and Wellness segment supports health and care management companies including health plans, disease management organizations, reward administrators, third party administrators, brokers and wellness companies, all of whom generally focus on employers as their customers in providing total population health management services.

    Under the wellness rules for the Affordable Care Act that took effect in January 2014, companies are permitted to offer a reward of up to 30 percent of health costs for employees who complete participatory programs including risk assessments or

15



biometric tests such as Body Mass Index and waist measurements. The 2013 RAND Workplace Wellness Program Study also indicates that approximately half of all employers with 50 or more employees offer wellness programs, and almost half of employers with a wellness program conduct biometric screenings such as those provided by us. According to the 2013 Towers Watson-National Business Group on Health Employer Survey, more employers are considering offering financial rewards to encourage participation by employees and spouses in health management programs.

On September 30, 2013, we completed the sale of certain assets comprising our Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. The operating results of Portamedic are segregated and reported as discontinued operations in the consolidated statements of operations for all periods presented.

Subsequent Events

On April 16, 2014, we entered into a Strategic Alliance Agreement (the “Alliance Agreement”) with Clinical Reference Laboratory, Inc. (“CRL”) pursuant to which, among other things, we have agreed to sell certain assets comprising the Heritage Labs and Hooper Holmes Services business units (the “Business”) to CRL. Under the terms of the Alliance Agreement, CRL has agreed to pay $3.7 million in cash (the “Purchase Price”) for certain assets of the Business, which such assets exclude, among others, all accounts receivable, and to assume specified liabilities related to the Business. We will retain certain aspects of the sample kit assembly operations centering around the Health and Wellness segment and all other supply chain fulfillment capabilities, which continue to support Health and Wellness operations and other customers.

We also entered into a Limited Laboratory and Administrative Services Agreement (the “LLASA”) with CRL pursuant to which, among other things, CRL will become our exclusive provider, subject to certain exceptions, of laboratory testing and reporting services and will also provide administrative services in support of the Health and Wellness operations. We will become a member of CRL’s preferred provider network for wellness programs during the term of the LLASA. The LLASA will become effective upon the closing of the transaction contemplated by the Alliance Agreement (the “Effective Date”), and will continue for five years from such date and auto-renew for an additional five year renewal period unless sooner terminated by either party in accordance with the LLASA.

On May 13, 2014, we entered into a Purchase and Sale Agreement (the “Purchase and Sale Agreement”) for the sale to McElroy Deutsch Mulvaney & Carpenter, LLP (the “MDMC”) of the buildings, land, certain personal property and other interests comprising our Basking Ridge, New Jersey property (the “Property”) for an aggregate purchase price of $3.05 million (the “Purchase Price”). Upon entering into the Purchase and Sale Agreement, MDMC made an initial deposit of $75,000 of the Purchase Price with an escrow agent and will deposit an additional $75,000 of the Purchase Price with the escrow agent following the completion of a 40-day inspection period (the “Inspection Period”). The remaining $2.9 million of the Purchase Price will be paid by MDMC to the Company at the closing. Subject to satisfaction of customary closing conditions, the closing is expected to occur five days after the end of the Inspection Period but no later than July 11, 2014. The deposit is refundable to MDMC in certain circumstances. See Item 5 of Part II of this Report for additional disclosure regarding the Purchase and Sale Agreement.
 
Highlights for the Three Month Periods Ended March 31, 2014

Consolidated Financial Performance for the First Quarter of 2014

The following table summarizes the consolidated results of operations for the three month periods ended March 31, 2014 and 2014:

16



 
Three Months Ended March 31,
(in thousands)
2014
 
2013
Revenues
$
12,599

 
$
12,359

Cost of operations
9,985

 
9,160

Gross profit
$
2,614

 
$
3,199

Selling, general and administrative expense
5,036

 
5,206

Restructuring
92

 
4

Other, net
(46
)
 
(12
)
Income tax expense
5

 
4

Loss from continuing operations
$
(2,565
)
 
$
(2,027
)
Loss from discontinued operations, net of tax
(120
)
 
(533
)
Net loss
$
(2,685
)
 
$
(2,560
)

For the three month period ended March 31, 2014, consolidated revenues were $12.6 million, representing an increase of approximately 1.9% from the prior year of $12.4 million. An increase in the Health and Wellness segment of $1.9 million was partially offset by decreases in Heritage Labs and Hooper Holmes Services of $0.6 million and $1.1 million, respectively.

Gross profit decreased by $0.6 million during the three month period ended March 31, 2014, primarily due to lower profits for Heritage Labs of $0.4 million and Hooper Holmes Services of $0.2 million. Gross profit for Health and Wellness was essentially flat for the three month periods ended March 31, 2014 and 2013.

Selling, general and administrative expense ("SG&A") for the three month period ended March 31, 2014 decreased $0.2 million to $5.0 million compared to the prior year period. The decrease is due to reduced consulting fees and efficiencies achieved in connection with the relocation of the corporate headquarters. The improvement in SG&A was offset by $1.1 million of transition costs, which were incurred in connection with the transition of the corporate headquarters to Olathe, Kansas.

Health & Wellness

Health & Wellness revenues in the first quarter of 2014 were $7.1 million, an increase of $1.9 million, or 37.7%, from the prior year period, reflecting higher volume in existing customers as well as the addition of new customer contracts. In the first quarter of 2014, Health & Wellness performed approximately 125,000 health screenings, compared to 93,000 health screenings in the prior year period, which represents an increase of 34.4% in the number of screenings performed. We have conducted screening events in every state in the U.S. as well as the District of Columbia and Puerto Rico. To date, we have certified approximately 4,000 of the examiners in our network to be “wellness certified” examiners.

Health and Wellness services include event scheduling, provision and fulfillment of all supplies (e.g., examination kits, blood pressure cuffs, stadiometers, scales, centrifuges, lab coats, bandages, etc.) at screening events, event management, biometric screenings (height, weight, body mass index, hip, waist, neck, pulse, blood pressure), blood draws via venipuncture or finger stick, lab testing, participant and aggregate reporting, data processing and data transmission.  Heritage Labs does all of the testing on the venipuncture samples we collect at Health and Wellness screenings.

We believe the market for health and wellness is likely to grow over the next three to five years, and that we are well positioned to increase revenues from our biometric screening and other related services given our unique set of assets, including our proprietary Health and Wellness technology platform and our national network of certified health professionals. However, the success of Health and Wellness will also depend in part upon the success of our sponsors and their health and care management initiatives to employers.

Heritage Labs

Heritage Labs services consist principally of performing tests of blood, urine and oral fluid specimens and the assembly and sale of kits used in the collection and transportation of such specimens. Heritage Labs revenues in the first quarter of 2014 were $2.5 million, a decrease of 19.8% as compared to the prior year period due to decreased revenue from both lab testing and kit assembly. The decline is due in large part to a decrease in demand for the Company's life insurance lab testing services and the

17



loss of several life insurance customers. In the first quarter of 2014, approximately 60% of Heritage Labs revenue came from third-party lab testing and 40% came from the sale of specimen kits to third parties.

Hooper Holmes Services

Hooper Holmes Services revenues for the first quarter 2014 were $3.0 million, a decrease of 26.5% in comparison to the prior year period. Hooper Holmes Services qualifies and interviews insurance applicants by compiling health histories and collecting medical records. We also provide outsourced underwriting services to several large insurance companies.

Business Outlook for 2014

We see the Health and Wellness business as the cornerstone of our growth opportunities. The United States spends more on healthcare than any other country, with more than 75% of healthcare costs due to chronic conditions. With the focus on health care cost management and the risk of reduced productivity in the workplace from health issues arising in an employee population, we believe employers of all sizes will adopt health and wellness programs at an increasing rate.

In employers where wellness programs focus principally on targeted weight loss and smoking cessation, participation rates are generally under 50%. We believe we can grow our business by offering expanded testing and broader wellness programs based on our biometric screening, risk assessment and support services. This more comprehensive approach could increase participation rates among our existing customer base and help us to attract new customers in the large and mid-size employer population.

A key strength of ours is a network of health professionals in all 50 states. We have signed national agreements with retail clinics and local lab offices, giving our customers more options for remote screenings. Due to our national network of health professionals, we have a presence in locations across the United States, with supply chain capabilities that allow us to stock, calibrate, pack and ship the materials our people need to collect accurate health information.

We monitor operational performance and are constantly refining metrics to improve operational performance. We believe our attention to the details of a Health and Wellness event, from the set-up, staffing, and follow-up post event, contributes to making our services efficient and effective.

We continue to focus our attention on our long-term strategy and believe we have the necessary assets to make the most of our immediate opportunities while positioning the Company for long-term growth. We are also transitioning out of the life insurance industry to focus on the Health and Wellness business. As a part of the transition, we plan to reduce our legacy fixed cost structure previously required to support the life insurance aspects of our operations.

Key Financial and Other Metrics Monitored by Management

In our periodic reports filed with the SEC, we provide certain financial information and metrics about our businesses, and information that our management uses in evaluating our performance and financial condition.   Our objective in providing this information is to help our shareholders and investors generally understand our overall performance and assess the profitability of and prospects for our business.

In the first quarter of 2014, we tracked:

the number of health screenings completed by Health and Wellness;
the quality scores of our Health Professionals;
the number and type of specimens tested by Heritage Labs;
the number of tele-interviewing and underwriting reports we generate by Hooper Holmes Services and;
budget to actual performance at the segment level as well as on a consolidated basis.

Certain of the above-cited metrics are discussed in the comparative discussion and analysis of our results of operations that follows.

Results of Operations    
    
Comparative Discussion and Analysis of Results of Operations for the three month periods ended March 31, 2014 and 2013

The table below sets forth our revenue by segment for the periods indicated.
        

18



 
 (in thousands)
 
For the Three Months Ended March 31,
 
2014
 
2013
 
% Change
 
 
 
 
 
 
 
Health and Wellness
 
$
7,089

 
$
5,150

 
37.7
 %
Heritage Labs
 
2,522

 
3,145

 
(19.8
)%
Hooper Holmes Services
 
2,988

 
4,064

 
(26.5
)%
   Total
 
$
12,599

 
$
12,359

 
1.9
 %

Consolidated revenues for the three month period ended March 31, 2014 were $12.6 million, an increase of $0.2 million, or 1.9%, from the prior year period. An increase in the Health and Wellness segment of $1.9 million was partially offset by decreases in Heritage Labs and Hooper Holmes Services of $0.6 million and $1.1 million, respectively.

Health & Wellness

Health & Wellness revenues in the first quarter of 2014 were $7.1 million, an increase of $1.9 million, or 37.7%, compared to $5.2 million in the prior year period. The increase is due to higher volume in existing customers as well as the addition of new customer contracts.

Our revenue increase in the three month period ended March 31, 2014, as compared to the prior year period, is primarily due to an increased number of screenings. Health & Wellness performed 34.4% more health screenings in the first quarter of 2014 compared to the first quarter of 2013 (125,000 in first quarter of 2014 vs. 93,000 in first quarter of 2013).   

Heritage Labs

Heritage Labs revenues in the first quarter of 2014 were $2.5 million, a decrease of $0.6 million, or 19.8%, compared to the prior year period.

During the first quarter of 2014, revenue from lab testing (approximately 60% of total Heritage Labs revenue in the first quarter of 2014) decreased 20.4% in comparison to the prior year period. Heritage Labs tested 20.9% fewer specimens in the first quarter of 2014 compared to the prior year period (91,000 in the first quarter of 2014 vs. 115,000 in the first quarter of 2013), These declines are due in large part to a decrease in demand for the Company's life insurance lab testing services and the loss of several life insurance customers. Heritage Labs average revenue per specimen tested was consistent in the first quarter of 2014 compared to the prior year period ($16.59 in the first quarter of 2014 vs. $16.55 in the first quarter of 2013).

During the first quarter of 2014, revenue from lab kit assembly (approximately 40% of Heritage Labs revenue in the first quarter of 2014) decreased 19.0% as compared to the prior year period. The decline in lab kit assembly is also due to decreased demand for life insurance lab testing services and the loss of life insurance customers.

Hooper Holmes Services

Hooper Holmes Services revenues for the first quarter of 2014 were $3.0 million, a decrease of 26.5% from the prior year period. The segment experienced declines across all service lines due to a decrease in the demand for our services in the life insurance industry. The decrease is primarily attributable to the attending physician statements, tele-underwriting/interviewing and underwriting service lines.

Cost of Operations

Consolidated cost of operations for the three month period ended March 31, 2014 was $10.0 million, compared to $9.2 million for the prior year period. The table below sets forth our costs of operations by segment.


19



(in thousands)
 
For the Three Months Ended March 31,
 
 
2014
 
% of Revenue
 
2013
 
% of Revenue
Health & Wellness
 
$
5,520

 
77.9
%
 
$
3,551

 
69.0
%
Heritage Labs
 
1,883

 
74.7
%
 
2,131

 
67.8
%
Hooper Holmes Services
 
2,582

 
86.4
%
 
3,478

 
85.6
%
     Total
 
$
9,985

 
79.3
%
 
$
9,160

 
74.1
%

Cost of operations, as a percentage of revenue, increased to 79.3% for the three month periods ended March 31, 2014 compared to 74.1% for the prior year period.

Health & Wellness cost of operations increased as a percentage of revenues to 77.9% for the three months ended March 31, 2014 as compared to the prior year periods. A portion of the increase corresponds to the product mix, where we saw a higher volume in events with fingerstick testing, which has a higher per unit cost per screening than venipuncture. Health and Wellness also experienced increases in the cost of materials as a result of product mix and higher per unit labor and travel costs for field specialists and examiners.

Heritage Labs cost of operations increased as a percentage of revenues to 74.7% for the three months ended March 31, 2014 as compared to the prior year period. The increase is primarily attributable to the effect of reduced sample volume and reduced life-insurance related revenues against the fixed costs needed to provide laboratory testing services.

Hooper Holmes Services cost of operations increased as a percentage of revenues to 86.4% for the three month periods ended March 31, 2014 compared to the prior year period. The increase is primarily attributable to revenues declining at a rate greater than its associated costs, a significant component of which is fixed.
    
Selling, General and Administrative Expenses from Operations

(in thousands)
 
For the Three Months Ended March 31,
 
Increase
 
 
2014
 
2013
 
2014 vs. 2013
Selling, general and administrative expenses
 
$
5,036

 
$
5,206

 
$
(170
)
    
Consolidated SG&A expenses for the three month period ended March 31, 2014 decreased $0.2 million to $5.0 million compared to the prior year period. The decrease is due to reduced corporate headcount at the headquarters in Olathe, Kansas, lower consulting services, and reduced legal fees. These improvements were partially offset by an increase in salaries within the Health and Wellness segment.

Included in consolidated SG&A for the three month period ended March 31, 2014 were $1.1 million of transition costs, which were incurred in connection with the relocation of the corporate headquarters to Olathe, Kansas. The Company relocated its headquarters to Olathe, Kansas during the first quarter of 2014, where the Health and Wellness facilities are located. The transition costs primarily include the salaries of individuals located in the former corporate headquarters as well as costs associated with operating the real estate that was held for sale in Basking Ridge, New Jersey.
  
Operating Loss

Our consolidated operating loss for the three month period ended March 31, 2014 was $2.5 million, compared to a consolidated operating loss for the three month period ended March 31, 2013 of $2.0 million. The increase is due to lower gross profit primarily from the Heritage Labs and Hooper Holmes Services segments.

Loss from Continuing Operations

Loss from continuing operations for the three month period ended March 31, 2014 was $2.6 million, or $0.04 per share on both a basic and diluted basis, compared to a net loss of $2.0 million, or $0.03 per share on both a basic and diluted basis, in the same period of the prior year.

20




Discontinued Operations
    
Discontinued operations, net, was a loss of $0.1 million and $0.5 million for the three month periods ended March 31, 2014 and 2013, respectively. The loss for the three month period ended March 31, 2014 relates primarily to the write off of the remaining balance on the first Holdback Amount that was recorded in adjustment to gain on sale of Portamedic and subsidiary in the consolidated results of operations. The loss for the three month period ended March 31, 2013 represents the results of operations during that period for the Company's Portamedic service line that was sold to Piston on September 30, 2013.

Net Loss
    
Net loss for each of the three month periods ended March 31, 2014 was $2.7 million, or $0.04 per share on both a basic and diluted basis, compared to a net loss of $2.6 million, or $0.04 per share on both a basic and diluted basis for the three month periods ended March 31, 2013.

Liquidity and Capital Resources

Our primary sources of liquidity are our cash and cash equivalents and our 2013 Loan and Security Agreement, as amended (collectively the “2013 Loan and Security Agreement”) . At March 31, 2014, our working capital was $6.7 million before adjustment for assets and liabilities held for sale. Our current ratio as of March 31, 2014 was 1.8 to 1. Available borrowing capacity was $3.1 million based on Eligible Receivables as of March 31, 2014. As of March 31, 2014, there were no borrowings outstanding under the 2013 Loan and Security Agreement. We have managed our liquidity during this period through a series of cost reduction initiatives along with access to the 2013 Loan and Security Agreement.
    
We present and discuss our cash flows inclusive of the Portamedic service line, which is the way our cash flows have been presented historically. Given the nature of our business, we have not historically separated much of our working capital by service line and thus we are not able to reliably distinguish between continuing and discontinued operations in our consolidated statements of cash flows for the three months ended March 31, 2013. As such, changes in accounts payable, accounts receivable, inventory and other financial line items associated with the Portamedic service line may impact future cash flow statement presentation. We provide information about the impact of Portamedic on our cash flows below in the discussion of our cash flows from operating, investing and financing activities. Activity affecting our cash flows for the three month period ended March 31, 2014 include:

a net loss of $2.7 million offset by non-cash charges of $0.4 million in depreciation expense and $0.1 million in share-based compensation expense;

an increase in accounts receivable of $0.7 million; and
 
capital expenditures of $0.3 million.

These uses of cash were partially offset by a combined net increase in accounts payable and accrued expenses of $1.3 million. In addition, we received $0.7 million for payment of the first Holdback Amount during the three month period ended March 31, 2014.

2013 Loan and Security Agreement
    
We maintain a three year 2013 Loan and Security Agreement with Keltic Financial Partners II, LP (“Keltic Financial”). Borrowings under the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The amount available for borrowing may be less than the $10 million under this facility at any given time due to the manner in which the maximum available amount is calculated.  We have an available borrowing base subject to reserves established at the lender's discretion of 85% of Eligible Receivables (as defined in the 2013 Loan and Security Agreement) up to $10 million under this facility.   Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, and other receivables deemed ineligible by the lender. Eligible Receivables include only billed receivables and concentration limits such that borrowing capacity may be affected by the our billing and revenue cycles. As of March 31, 2014, the lender applied a discretionary reserve of $0.5 million.

We are also working with Keltic Financial to modify the financial covenants of the 2013 Loan and Security Agreement in an effort to be more in-line with the operations and strategy going forward. If we are not able to successfully execute favorable amendments to the existing credit facility, our borrowing capacity may be limited. Because unbilled receivables are not considered Eligible Receivables, our borrowing capacity can fluctuate in accordance with our monthly billing cycles.

21




The 2013 Loan and Security Agreement contains various covenants, including financial covenants which required us to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The lender recently waived the quarterly minimum EBITDA covenants for the fiscal period ended December 31, 2014. We continue to have limitations on the maximum amount of unfunded capital expenditures for each fiscal year.

Sale of Assets - Heritage Labs and Hooper Holmes Services
    
On April 16, 2014, we entered into a Strategic Alliance Agreement with CRL pursuant to which, among other things, we have agreed to sell certain assets comprising the Heritage Labs and Hooper Holmes Services business units to CRL. Under the Alliance Agreement, CRL has agreed to pay $3.7 million in cash for certain assets of the Business, which such assets exclude, among others, all accounts receivable, and to assume specified liabilities related to the Business. This transaction will provide us with additional capital to invest as we focus on growth supporting Health and Wellness operations. We will retain certain aspects of the sample kit assembly operations centering around the Health and Wellness segment and all other supply chain fulfillment capabilities, which continue to support Health and Wellness operations and other customers.

Sale of Basking Ridge Real Estate

On May 13, 2014, we entered into a Purchase and Sale Agreement with MDMC for the sale of the Company’s Basking Ridge, New Jersey property for an aggregate purchase price of $3.05 million. Upon entering into the Purchase and Sale Agreement, MDMC made an initial deposit of $75,000 of the Purchase Price with an escrow agent and will deposit an additional $75,000 of the Purchase Price with the escrow agent following the completion of a 40-day Inspection Period. The remaining $2.9 million of the Purchase Price will be paid by MDMC to the Company at the closing. Subject to satisfaction of customary closing conditions, the closing is expected to occur five days after the end of the Inspection Period but no later than July 11, 2014. This transaction will provide us with additional capital to invest as we focus on growth supporting Health and Wellness operations.

Liquidity Considerations

The Health and Wellness business sells through wellness, disease management and insurance companies who ultimately have the relationship with the end customer. Our current services are aggregated with its partners' offerings to provide a total solution. As such, our success is largely dependent on that of its partners. The loss of business from key customers can negatively affect our financial condition, results of operations or cash flows.

Through the focus on the Health and Wellness sector, we believe we will be able to capitalize on the opportunities that exist in the Health and Wellness sector given the macro-economic focus on health care costs and improving the efficiency of health care delivery in the United States to grow revenue.
    
We may not realize the benefits from the consolidation in Kansas and control the costs of transition, grow the Health and Wellness business as we seeks to streamline operations and improve efficiency through increased revenue and cost reduction initiatives. We may also not have sufficient Eligible Receivables and the lender may increase reserves such that we may not be able to borrow under the 2013 Loan and Security Agreement. These and other factors could adversely affect liquidity and the ability to generate cash flow in the future.

Based on the anticipated level of future revenues and gross profits, anticipated cost reduction initiatives, cash proceeds in connection with the Alliance Agreement, the sale of the Basking Ridge, New Jersey real estate, and existing cash and cash equivalents and borrowing capacity, we believe we have sufficient funds to meet our cash needs to fund operation expenses and capital expenditures for the twelve months following March 31, 2014.
    
Cash Flows from Operating, Investing and Financing Activities

We discuss below the cash flows from operating, investing and financing activities for the three months ended March 31, 2013, inclusive of discontinued operations relating to the sale of Portamedic. As a result of our relocation to Kansas and related restructuring activities, future cash flows from operating, investing and financing activities may be materially different from the cash flows from operating, investing and financing activities for the three months ended March 31, 2014. Since we historically have not tracked accounts receivable, accounts payable and other accounts by service line, our continuing operations and the Portamedic service line had customers and suppliers in common, and our continuing and discontinued operations shared certain selling, general and administrative services, we do not have reliable information for the historical impact of Portamedic on our

22



cash flows. We also feel that without the discontinued Portamedic operations and with planned selling, general and administrative cost reductions, cash flow from operations will improve.
        
Cash Flows from Operating Activities

For the three month period ended March 31, 2014, net cash used in operating activities was $1.7 million, compared to $3.2 million in the prior year period.
    
The net cash used in operating activities for the three month period ended March 31, 2014 reflects a net loss of $2.7 million, and non-cash charges of $0.4 million in depreciation expense and $0.1 million in share-based compensation expense. Changes in working capital included:

an increase in accounts receivable of $0.7 million. Our consolidated days sales outstanding (“DSO”), measured on a rolling 90-day basis, was 61.5 days at March 31, 2014, compared to 47.8 days at December 31, 2013 and 48.5 days at March 31, 2013. The increase in DSO at March 31, 2014 was a result of several Health and Wellness customers with extended payment terms. Historically, our accounts receivable balances and our DSO are near their highest point in September and their lowest point in December as many of our customers utilize the remainder of their operating budgets before their year-end budget close-out.

a combined net increase in accounts payable and accrued expenses of $1.3 million.
 
Cash Flows provided by (used in) Investing Activities

We used $0.3 million for the three month periods ended March 31, 2014 and 2013 for capital expenditures. For the three month period ended March 31, 2014, we also received $0.7 million for payment of the first Holdback Amount.

Cash Flows provided by (used in) Financing Activities

Cash provided by financing activities for the three month period ended March 31, 2014 includes $0.02 million related to proceeds from stock option exercises. Cash used in financing activities for the three month period ended March 31, 2013 primarily represents costs associated with our 2009 Loan and Security Agreement and a reduction in capital lease obligations.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Share Repurchases

We did not purchase any shares of our common stock during the three month periods ended March 31, 2014 and 2013.

Dividends

No dividends were paid during the three month periods ended March 31, 2014 and 2013. We are precluded from declaring or making any dividend payments or other distributions of assets with respect to any class of our equity securities under the terms of our 2013 Loan and Security Agreement with Keltic Financial described in Note 9 to the unaudited interim consolidated financial statements.

Contractual Obligations

The following table sets forth our schedule of contractual obligations at March 31, 2014, including future minimum lease payments under non-cancelable operating leases and employment contract payments.


23



(In thousands)
Total
Less than
1 year
1-3 years
3-5 years
More than
5 years
Operating Lease Obligations
$
7,438

$
1,712

$
4,622

$
1,104

$

Employment Contracts
595

595




Total
$
8,033

$
2,307

$
4,622

$
1,104

$


Inflation

Inflation has not had, nor is it expected to have, a material impact on our consolidated financial results.

Critical Accounting Policies

There were no changes to our critical accounting policies during the three month period ended March 31, 2014. Such policies are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

ITEM 3
Quantitative and Qualitative Disclosures About Market Risk

We are exposed to interest rate risk primarily through our borrowing activities, which are described in Note 9 to the unaudited interim consolidated financial statements and Item 2 of Part I included in this Report. Our credit facility is based on variable rates and is therefore subject to interest rate fluctuations. Accordingly, our interest expense will vary as a result of interest rate changes and the level of any outstanding borrowings. As of March 31, 2014, there were no in borrowings outstanding.

As of March 31, 2014, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.

ITEM 4
Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

The Company's Chief Executive Officer and Chief Financial Officer, with the assistance of our disclosure committee, have conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2014. The Company's disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports the Company files under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, to allow for timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Based on this evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2014, the Company's disclosure controls and procedures were not effective because of a material weakness in our internal control over financial reporting as described below. Notwithstanding the material weakness described below, management has concluded that our consolidated financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with generally accepted accounting principles in the United States for each of the periods presented and that they may still be relied upon.

As of December 31, 2013, management has assessed the effectiveness of the Company’s internal control over financial reporting based on the framework established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992).  Based on this assessment, management concluded that as of` December 31, 2013 our internal controls over financial reporting were not effective because of the material weakness in internal control over financial reporting discussed below.


24



On September 30, 2013, the Company completed the sale of the Portamedic line of business. In connection with the sale, the Company had difficulty completing the accounting for such sale and the reclassification of the Portamedic business line as discontinued operations without having to avail itself of an extension of the reporting deadline for the Form 10-Q. In connection with these events, the Company has identified certain deficiencies in its internal control over financial reporting that it deemed to be a material weakness. A material weakness is a control deficiency, or a combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. The Company determined that the turnover of personnel and the associated loss of institutional knowledge adversely affected management’s review of the accounting for non-routine, complex technical accounting matters to ensure proper application of generally accepted accounting principles in a timely manner, as well as its timely identification of certain transactions subject to reporting.

While the material weakness continues to exist, the Company has taken steps to address this weakness in internal control. The Company has hired consulting resources to assist with financial reporting and accounting tasks, has hired a new Controller and are adding additional finance and accounting staff in the new headquarters in Olathe, Kansas. The Company has also increased the internal training and awareness with the management team to ensure that our control environment is continually improving.

(b) Changes in Internal Control over Financial Reporting

During the quarter ended March 31, 2014, there have not been any changes in our internal controls over financial reporting, other than the following:

As noted in this Report, the Company relocated its headquarters to Olathe, Kansas during the first quarter of 2014. In conjunction with this move, the Company reassigned and transitioned individual responsibilities to personnel located in Olathe, Kansas from the previous corporate headquarters in Basking Ridge, New Jersey.  These measures impacted the internal control over financial reporting process as individual responsibilities have been re-assigned to address financial reporting needs.




25



PART II - Other Information

ITEM 1
Legal Proceedings

On April 23, 2012, a complaint was filed against the Company in U.S. District Court for the District of New Jersey on behalf of a purported class of employee examiners alleging, among other things, that the Company had failed to pay overtime compensation to certain employees as required by federal law. On May 24, 2012, a related complaint was filed against the Company in the same court alleging, among other things, that the Company similarly failed to pay overtime compensation to a purported class of certain independent contractor examiners who, the complaint alleges, should be treated as employees for purposes of federal law. The complaints seek award of an unspecified amount of allegedly unpaid overtime wages to certain examiners. The Company believes the allegations in the cases are without merit, has filed answers in both cases denying the substantive allegations therein. By Consent Order filed March 11, 2013, the court approved a settlement between the Company and the named plaintiffs in the employee case, and the case was dismissed with prejudice. Preliminary discovery and motion practice are being conducted in the contractor case. The claim is not covered by insurance, and as a result, the Company is incurring legal costs to defend the litigation.

On July 30, 2013, a complaint was filed against the Company in the California Superior Court, San Bernadino County, on behalf of a putative class of employees alleging, among other things, that the Company failed to pay wages and other compensation as required by state law. The complaint seeks award of an unspecified amount of damages and penalties. The Company has denied all of the allegations in the case and believes them to be without merit. In January 2014, the Superior Court referred the parties to mediation and a mediation date of July 17, 2014 is scheduled. The Superior Court also set a trial date of August 10, 2015. The claim is not covered by insurance, and as a result, the Company is incurring legal costs to defend the litigation.

The Company is a party to a number of other legal actions arising in the ordinary course of its business. In the opinion of management, the Company has substantial legal defenses and/or insurance coverage with respect to all of its pending legal actions. Accordingly, none of these actions is expected to have a material adverse effect on the Company’s liquidity, its consolidated results of operations or its consolidated financial position.

ITEM 1A
Risk Factors

Readers should carefully consider, in connection with the other information in this Report, the risk factors disclosed in Item 1A. “Risk Factors” in our 2013 Annual Report on Form 10-K. There are no material changes to such risk factors, other than the addition of the following risk factor:

Failure to complete the sale of our Heritage Labs and Hooper Holmes Services businesses could negatively impact our stock price and our future business and financial results.
On April 16, 2014, we entered into an agreement with Clinical Reference Laboratory, Inc. to sell the assets and businesses of Heritage Labs and Hooper Holmes Services. The closing of this transaction is subject to various conditions which both sides are required to satisfy. Although the conditions are customary for a transaction of this type and we expect the sale to be completed in the late second quarter or early third quarter of 2014, there can be no assurance that the transaction will close in a timely manner or at all. Until the closing of the sale, the focus of our management on completing the transaction may preclude us from pursuing, or limit our ability to pursue, other opportunities that could be beneficial to the Company. In addition, if the transaction is not completed, our Health and Wellness business may be adversely affected and become subject to several risks, including the following:
We would not be able to focus exclusively on our Health and Wellness operations, which could negatively impact our ability to execute our strategy. We may need to direct management and financial resources to the Heritage Labs and Hooper Holmes Services businesses, which would reduce the resources we could devote to the Health and Wellness business;
We intend to use the net proceeds from the sale to invest in Health and Wellness; if the sale does not close, there cannot be any assurance that we could obtain equivalent funding from our operations or other sources; and
We would be required to pay costs and expenditures relating to the transaction, including legal, accounting and financial advisory and other costs, without receiving proceeds from the transaction, which would reduce the funds available for investment in the Health and Wellness business. Our operating results also would be adversely affected, as such fees, expenses and other costs would be expensed, without any offsetting income.


26



If the sale does not close, we cannot assure you that these risks and others will not materialize and will not materially adversely affect our business operations, our financial results and the price of our stock.
ITEM 2
Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales or repurchases of equity securities during the fiscal quarter ended March 31, 2014.

ITEM 3
Defaults Upon Senior Securities

There were no defaults upon senior securities during the fiscal quarter ended March 31, 2014.

ITEM 4
Mine Safety Disclosure

Not applicable.
ITEM 5
Other Information

The information set forth below is included herewith for the purpose of providing the disclosure required by Form 8-K with respect to the event described below, which occurred within four (4) business days of the filing of this Report. The Company is providing such disclosure in this Report in lieu of filing a Current Report on Form 8-K to report such event. The item number and heading referenced below corresponds to the applicable item number and heading of Form 8-K under which such event is required to be disclosed.

Item 1.01.    Entry into a Material Definitive Agreement.

On May 13, 2014, the Company entered into a Purchase and Sale Agreement (the “Purchase and Sale Agreement”) for the sale to McElroy Deutsch Mulvaney & Carpenter, LLP (the “MDMC”) of the buildings, land, certain personal property and other interests comprising the Company’s Basking Ridge, New Jersey property (the “Property”) for an aggregate purchase price of $3.05 million (the “Purchase Price”). Upon entering into the Purchase and Sale Agreement, MDMC made an initial deposit of $75,000 of the Purchase Price with an escrow agent and will deposit an additional $75,000 of the Purchase Price with the escrow agent following the completion of a 40-day inspection period (the “Inspection Period”). The remaining $2.9 million of the Purchase Price will be paid by MDMC to the Company at the closing. Subject to satisfaction of customary closing conditions, the closing is expected to occur five days after the end of the Inspection Period but no later than July 11, 2014. The Company has agreed to not solicit or enter into any other contract or contract negotiations regarding the Property prior to closing.

MDMC may terminate the Purchase and Sale Agreement: (i) for any reason at any time prior to the end of the Inspection Period; (ii) if there are any items with respect to the Property (excluding certain permitted exceptions) that would prevent MDMC from receiving title to the Property free and clear of any mortgages, liens, claims, or encumbrances and such items remain uncured for the period of time set forth in the Purchase and Sale Agreement; or (iii) if, prior to the closing date, all or any portion of the Property is taken by eminent domain or is damaged, destroyed by fire or other casualty. In each such event, MDMC will be entitled to a refund of any amounts deposited pursuant to the Purchase and Sale Agreement. MDMC will be entitled to a refund of, or the Company will be entitled to retain, such deposited amounts if the other party fails or refuses to close title as required by the terms of the Purchase and Sale Agreement, or the other party otherwise is in default under the Purchase and Sale Agreement so that MDMC or the Company, as applicable, has the right to refuse to close title.

The Purchase and Sale Agreement also contains representations, warranties and indemnification obligations of the parties customary for transactions similar to those contemplated by the Purchase and Sale Agreement. Such representations and warranties are made solely for purposes of the Purchase and Sale Agreement and, in some cases, may be subject to qualifications and limitations agreed to by the parties in connection with the negotiated terms of the Purchase and Sale Agreement and may have been qualified by disclosures that were made in connection with the parties’ entry into the Purchase and Sale Agreement.

In addition, certain representations and warranties set forth in the Purchase and Sale Agreement may have been used for purposes of risk-allocation between the parties rather than establishing matters of fact. The representations and warranties contained in the Purchase and Sale Agreement were made solely for the benefit of the parties thereto. Persons not party to the Purchase and Sale Agreement, including, without limitation, the Company’s shareholders and other investors, should not rely on the representations and warranties contained in the Purchase and Sale Agreement, or any descriptions thereof, including those contained

27



in this Item 5 of Part II of this Report, as characterizations of the actual facts or conditions applicable to the Company or the Property.

The foregoing description of the Purchase and Sale Agreement is qualified in its entirety by reference to the full text of the Purchase and Sale Agreement, a copy of which is filed as Exhibit 10.2 to this Report and is incorporated herein by reference.


28



ITEM 6
Exhibits

Exhibit No.
 
Description of Exhibit
 
 
 
2.1
 
Strategic Alliance Agreement dated April 16, 2014 by and among Hooper Holmes, Inc., Heritage Labs International, LLC (“HLI”), Mid-America Agency Services, Incorporated and Clinical Reference Laboratory, Inc.
 
 
 
10.1
 
Limited Laboratory and Administrative Services Agreement dated April 16, 2014 by and between Hooper Holmes, Inc. and Clinical Reference Laboratory, Inc.**
 
 
 
10.2
 
Purchase and Sale Agreement dated May 13, 2014 by and between Hooper Holmes, Inc. and McElroy Deutsch Mulvaney & Carpenter, LLP
 
 
 
31.1
 
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
 
 
 
31.2
 
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
 
 
 
32.1
 
Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
 
 
 
32.2
 
Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
 
 
 
101.INS
 
XBRL Instance Document*
 
 
 
101.SCH
 
XBRL Taxonomy Extension Schema Document*
 
 
 
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document*
 
 
 
101.DEF
 
XBRL Taxonomy Extension Label Linkbase Document*
 
 
 
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document*
 
 
 
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document*

* Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 hereto are not to be deemed "filed" or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, and are not to be deemed "filed" for purposes of Section 18 of the Exchange Act, and otherwise are not subject to liability under those sections, except as shall be expressly set forth by specific reference in such filing.

** Portions of this exhibit containing confidential information have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

29



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

Hooper Holmes, Inc.

Dated: May 15, 2014

 
 
By: /s/ Henry E. Dubois
 
 
 
Henry E. Dubois
 
 
 
Chief Executive Officer and President
(Principal Executive Officer)
 
 
 
 
 
 
 
By: /s/ Tom Collins
 
 
 
Tom Collins
 
 
 
Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
 


30
EX-2.1 2 exhibit21q12014.htm EXHIBIT 2.1 exhibit21q12014
Execution Version

STRATEGIC ALLIANCE AGREEMENT
by and among
Hooper Holmes, Inc.,
Heritage Labs International, LLC,
Mid-America Agency Services, Incorporated,
as Sellers,
and
Clinical Reference Laboratory, Inc.,
as Buyer

Dated April 16, 2014



21619879v1

Table of Contents

Page

ARTICLE 1
DEFINITIONS AND USAGE    2
1.1
Definitions    2
1.2
Usage    10
ARTICLE 2
SALE AND TRANSFER OF ASSETS; CLOSING    11
2.1
Purchased Assets    11
2.2
Excluded Assets    12
2.3
Consideration    13
2.4
Liabilities    14
2.5
Allocation    14
2.6
Closing    14
2.7
Closing Obligations    14
2.8
Customer Contracts Not Assigned at Closing    16
ARTICLE 3
REPRESENTATIONS AND WARRANTIES OF SELLERS    17
3.1
Organization and Good Standing    17
3.2
Enforceability; Authority; No Conflict    17
3.3
Financial Statements    18
3.4
Books and Records    19
3.5
Customers    19
3.6
Sufficiency of Assets    19
3.7
Regulatory Compliance    19
3.8
Title to Assets; Encumbrances    19
3.9
Condition of Tangible Personal Property; IT Systems    20

i

Table of Contents
(continued)
Page

3.10
Inventories    20
3.11
Taxes    20
3.12
No Material Adverse Effect    21
3.13
Employee Benefits    21
3.14
Compliance with Legal Requirements; Governmental Authorizations    22
3.15
Legal Proceedings; Orders    23
3.16
Absence of Certain Changes and Events    24
3.17
Contracts; No Defaults    24
3.18
Employees    26
3.19
Labor Disputes; Compliance    27
3.20
Intellectual Property Assets    28
3.21
Relationships with Related Persons    31
3.22
Brokers or Finders    31
3.23
Solvency    31
3.24
Disclosure    32
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF BUYER    32
4.1
Organization and Good Standing    32
4.2
Authority; No Conflict    32
4.3
Certain Proceedings    33
4.4
Brokers or Finders    33
4.5
Sufficiency of Funds    33
ARTICLE 5
COVENANTS OF SELLERS BEFORE CLOSING    33

ii

Table of Contents
(continued)
Page

5.1
Access and Review    33
5.2
Operation of the Business    34
5.3
Negative Covenant    35
5.4
Required Approvals    35
5.5
Notification    36
5.6
No Negotiation    36
5.7
Best Efforts    41
5.8
Interim Financial Statements    41
5.9
Change of Name    41
5.10
Payment of Liabilities    41
5.11
Transitional Services Agreement    41
5.12
Lenexa Sublease    42
5.13
Omaha Facility    42
5.14
Administrative Services SOW    42
5.15
License Agreement    42
ARTICLE 6
COVENANTS OF BUYER BEFORE CLOSING    42
6.1
Required Approvals    42
6.2
Best Efforts    42
6.3
Transitional Services Agreement    42
6.4
Administrative Services SOW    42
6.5
License Agreement    42

iii

Table of Contents
(continued)
Page

ARTICLE 7
CONDITIONS PRECEDENT TO BUYER’S OBLIGATION TO CLOSE    43
7.1
Accuracy of Representations and Warranties    43
7.2
Sellers’ Performance    43
7.3
Additional Documents    43
7.4
No Proceedings    43
7.5
No Injunction    44
7.6
No Conflict    44
7.7
Limited Laboratory and Administrative Services Agreement    44
7.8
WARN Act    44
ARTICLE 8
CONDITIONS PRECEDENT TO SELLERS’ OBLIGATION TO CLOSE    44
8.1
Accuracy of Representations and Warranties    44
8.2
Buyer’s Performance    44
8.3
Consents    44
8.4
No Injunction    44
8.5
Limited Laboratory Services Agreement    45
ARTICLE 9
TERMINATION    45
9.1
Termination Events    45
9.2
Effect of Termination    46
9.3
Termination Fee; Expenses    46
ARTICLE 10
ADDITIONAL COVENANTS    47

iv

Table of Contents
(continued)
Page

10.1
Employees and Employee Benefits    47
10.2
Payment of Taxes Owed from Sale of Assets by Seller    49
10.3
Payment of other Retained Liabilities    49
10.4
Reports and Returns    50
10.5
Assistance in Proceedings    50
10.6
Noncompetition, Nonsolicitation and Nondisparagement    50
10.7
Customer and Other Business Relationships    52
10.8
Retention of and Access to Records    52
10.9
Remittance of Payments Received    52
10.10
Use of Name    52
10.11
Further Assurances    52
ARTICLE 11
INDEMNIFICATION; REMEDIES    52
11.1
Survival    52
11.2
Indemnification and Reimbursement by Sellers    53
11.3
Indemnification and Reimbursement by Buyer    54
11.4
Time Limitations    55
11.5
Limitation on Amounts    55
11.6
Third-Party Claims    55
11.7
Other Claims    57
11.8
Other Limitations    58
11.9
Indemnification in case of Strict Liability or Indemnitee Negligence    59
ARTICLE 12
CONFIDENTIALITY    59

v

Table of Contents
(continued)
Page

12.1
Definition of Confidential Information    59
12.2
Restricted Use of Confidential Information    60
12.3
Exceptions    61
12.4
Legal Proceedings    61
12.5
Return or Destruction of Confidential Information    62
12.6
Attorney-Client Privilege    62
ARTICLE 13
GENERAL PROVISIONS    63
13.1
Expenses    63
13.2
Public Announcements    63
13.3
Notices    63
13.4
Jurisdiction; Service of Process    64
13.5
Enforcement of Agreement    64
13.6
Waiver; Remedies Cumulative    65
13.7
Entire Agreement and Modification    65
13.8
Disclosure Schedule    65
13.9
Assignments, Successors and No Third-Party Rights    66
13.10
Severability    66
13.11
Construction    66
13.12
Governing Law    66
13.13
Execution of Agreement    66
13.14
Seller Obligations    66
TABLE OF EXHIBITS


vi

Table of Contents
(continued)
Page

Exhibit    Name

2.5        Purchase Price Allocation
2.7(a)(i)    Form of Bill of Sale
2.7(a)(ii)    Form of Assignment and Assumption Agreement
2.7(a)(iii)    Forms of IP Assignments
5.15        Form of License Agreement
8.3        Sellers’ Consents Required


TABLE OF SCHEDULES





vii



STRATEGIC ALLIANCE AGREEMENT
This Strategic Alliance Agreement (“Agreement”) is dated as of April 16, 2014, by and among Clinical Reference Laboratory, Inc., a Kansas corporation (“Buyer”), Heritage Labs International, LLC, a Kansas limited liability company (“HLI”), Hooper Holmes, Inc., a New York corporation (“HH”), and Mid-America Agency Services, Incorporated, a Nebraska corporation (“MAS”). HLI, HH and MAS are individually a “Seller” and collectively the “Sellers” for purposes of this Agreement. Buyer and each of the Sellers are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
Recitals
HLI and MAS are wholly owned subsidiaries of HH.
HLI is engaged in the business of (a) providing laboratory testing services (tests of blood, urine and oral fluid specimens), (b) conducting biostatistical data analysis, (c) assembling and selling blood, urine, Dried Blood Spot and saliva kits to paramedical examination customers and other customers for use in the collection and transportation of blood, urine and oral fluid specimens, (d) providing custom-designed specimen collection kits for specialized clinical and medical trials, and (e) using blood, urine and oral fluid test results in connection with life insurance underwriting process, biometric screening and health insurance underwriting activities (collectively, the “HLI Business”).
MAS is engaged in the business of (i) collecting and providing applicant health information to insurance company underwriters through telephonic interviews of insurance candidates, retrieval and inspections of medical records, fraud detection searches, credit checks and employment verification; and (ii) providing risk management consultative support and underwriting services to insurance companies (collectively, the “HHS Business”, together with the HLI Business, the “Business”).
Sellers desire to sell, and Buyer desires to purchase, the Assets (as defined in this Agreement) of Sellers for the consideration and on the terms set forth in this Agreement.
HH is also engaged in certain other businesses, including without limitation the business of: organizing health and wellness events; performing biometric screenings; administering health risk assessments; compiling data and analytics on screening participants for individual use and for aggregated purposes including risk assessments and risk management services, sourcing and training health professionals to perform the biometric screenings; and providing participant coaching, managing and performing onsite wellness coaching; in each case for employers and health and care management companies, including wellness companies, disease management organizations, clinical research organizations and health plans as they manage the health services of corporate and government employees and plan participants (the “H&W Business”).
Sellers and Buyer also desire to enter into commercial arrangements for, among other things, the provision of certain laboratory services and other support services by Buyer to HH.





The parties, intending to be legally bound, agree as follows:
ARTICLE 1
DEFINITIONS AND USAGE
1.1    Definitions. For purposes of this Agreement, the following terms and variations thereof have the meanings specified or referred to in this Section 1.1:
(a)    Acquisition Proposal” is defined in Section 5.6(g).
(b)    Active Employees” is defined in Section 10.1(a)(i).
(c)    Agreed Amount” is defined in Section 11.7(b)(ii).
(d)    Agreement” is defined in the first paragraph of this Agreement.
(e)    Alternative Reimbursement” is defined in Section 11.8(a).
(f)    Assets” is defined in Section 2.1.
(g)    Assignment and Assumption Agreement” is defined in Section 2.7(a)(ii).
(h)    Assumed Liabilities” is defined in Section 2.4(a).
(i)    Balance Sheet” is defined in Section 3.3(a).
(j)    Best Efforts” means the commercially reasonable efforts a prudent Person desirous of achieving a result would use in similar circumstances to achieve that result as expeditiously as reasonably possible, provided, however, that a Person required to use Best Efforts under this Agreement will not be thereby required to take actions that would adversely affect the benefits to such Person of this Agreement and the Contemplated Transactions or to dispose of or make any change to its business, expend any material funds, incur any other material burden or make any commitment to do any of the foregoing.
(k)    Bill of Sale” is defined in Section 2.7(a)(i).
(l)    Breach” means any breach of, or any inaccuracy in, any representation or warranty or any breach of, or failure to perform or comply with, any covenant or obligation, in or of this Agreement or any other Contract, or any event that with the passing of time or the giving of notice, or both, would constitute such a breach, inaccuracy or failure.
(m)    Business” is defined in the Recitals.

2



(n)    Business Day” means any day other than (a) Saturday or Sunday or (b) any other day on which banks in the State of Kansas are permitted or required to be closed.
(o)    Buyer” is defined in the first paragraph of this Agreement.
(p)    Buyer Contact” is defined in Section 12.2(a)(iii).
(q)    Buyer Expenses” is defined in Section 9.3.
(r)    Buyer Group” is defined in Section 5.1(a).
(s)    Buyer Indemnified Persons” is defined in Section 11.2.
(t)    Buyer’s Closing Documents” is defined in Section 4.2(a).
(u)    Claimed Amount” is defined in Section 11.7(a)(i).
(v)    Claim Notice” is defined in Section 11.7(a).
(w)    Closing” is defined in Section 2.6.
(x)    Closing Date” means the date on which the Closing actually takes place.
(y)    COBRA” is defined in Section 10.1(c)(iii).
(z)    Code” means the Internal Revenue Code of 1986, as amended from time to time.
(aa)    Competing Business” is defined in Section 3.21(a).
(bb)    Confidential Information” is defined in Section 12.1(a).
(cc)    Consent” means any approval, consent, ratification, waiver or other authorization.
(dd)    Contemplated Transactions” means all of the transactions contemplated by this Agreement.
(ee)    Contract” means any agreement, contract, Lease, consensual obligation, promise or undertaking (whether written or oral and whether express or implied), whether or not legally binding, other than any Contract relating to any Employee Plan.
(ff)    Copyrights” is defined in Section 3.20(a)(iii).
(gg)    Customer Contract” and “Customer Contracts” are defined in Section 3.17(a)(i).

3



(hh)    Damages” is defined in Section 11.2.
(ii)    Data Room” is the electronic data room maintained by RR Donnelley on Sellers’ behalf.
(jj)    Disclosing Party” is defined in Section 12.1(a).
(kk)    Disclosure Schedule” means the Disclosure Schedule delivered by Sellers to Buyer concurrently with the execution and delivery of this Agreement, which Disclosure Schedule is incorporated into this Agreement by this reference.
(ll)    Effective Time” means 12:01 a.m. on the Closing Date.
(mm)    Employee Plan” and “Employee Plans” are defined in Section 3.13(a)(ii).
(nn)    Encumbrance” means any charge, claim, community or other marital property interest, condition, equitable interest, lien, option, pledge, security interest, mortgage, right of way, easement, encroachment, servitude, right of first option, right of first refusal or similar restriction, including any restriction on use, voting (in the case of any security or equity interest), transfer, receipt of income or exercise of any other attribute of ownership.
(oo)    End Date” is defined in Section 9.1(f).
(pp)    ERISA” is defined in Section 3.13(a).
(qq)    ERISA Affiliate” is defined in Section 3.13(a)(i).
(rr)    Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time.
(ss)    Excluded Assets” is defined in Section 2.2.
(tt)    Financial Statements” is defined in Section 3.3.
(uu)    Fundamental Representations” is defined in Section 11.4(a).
(vv)    GAAP” means generally accepted accounting principles for financial reporting in the United States, applied on a consistent basis.
(a)    Good Reason” means either (i) the termination of the LLASA either (A) by HH upon the breach of such agreement by Buyer or (B) by Buyer without cause, or (ii) the partial termination of the LLASA by HH pursuant to Section 3(b)(iii) of the LLASA.
(b)    Governing Documents” means, with respect to any particular entity, (i) if a corporation, the articles or certificate of incorporation and the bylaws; (ii) if a general

4



partnership, the partnership agreement and any statement of partnership; (iii) if a limited partnership, the limited partnership agreement and the certificate of limited partnership; (iv) if a limited liability company, the articles of organization and operating agreement; (v) if another type of Person, any other charter or similar document adopted or filed in connection with the creation, formation or organization of the Person; (vi) all equityholders’ agreements, voting agreements, voting trust agreements, joint venture agreements, registration rights agreements or other agreements or documents relating to the organization, management or operation of any Person or relating to the rights, duties and obligations of the equityholders of any Person; and (vii) any amendment or supplement to any of the foregoing.
(c)    Governmental Authorization” means any Consent, license, registration or permit issued, granted, given or otherwise made available by or under the authority of any Governmental Body or under any Legal Requirement.
(d)    Governmental Body” means any: (i) nation, state, county, city, town, borough, village, district or other jurisdiction; (ii) federal, state, local, municipal, foreign or other government; (iii) governmental or quasi-governmental authority of any nature (including any agency, branch, department, board, commission, court, tribunal or other entity exercising governmental or quasi-governmental powers); (iv) multinational organization or body; (v) body exercising, or entitled or purporting to exercise, any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power; or (vi) official of any of the foregoing.
(e)    H&W Business” is defined in the Recitals.
(f)    HH” is defined in the first paragraph of this Agreement.
(g)    HHS Business” is defined in the Recitals.
(h)    Hired Active Employees” is defined in Section 10.1(a)(i).
(i)    HLI” is defined in the first paragraph of this Agreement.
(j)    HLI Business” is defined in the Recitals.
(k)    Indemnified Person” means as defined in Section 11.6(a).
(l)    Indemnifying Person” means as defined in Section 11.6(a).
(m)    Intellectual Property Assets” is defined in Section 3.20(a).
(n)    Inventories” means all inventories of Sellers of products sold in the Business or supplies and materials used in the Business, including collection kits and laboratory reagents, wherever located; provided, however, that for the avoidance of doubt, “Inventories” shall not include any inventories of Sellers used in connection with

5



the Retained Kit Assembly Business and related supplies or materials of Sellers used in connection with the H&W Business.
(o)    IP Assignments” is defined in Section 2.7(a)(iii).
(p)    IRS” means the United States Internal Revenue Service and, to the extent relevant, the United States Department of the Treasury.
(q)    IT Systems” is defined in Section 3.9(b).
(r)    Knowledge” (i) an individual will be deemed to have Knowledge of a particular fact or other matter if that individual is actually aware of that fact or matter assuming careful review of this Agreement and reasonable inquiry; (ii) “Knowledge of Sellers,” “Sellers’ Knowledge” and other correlative terms mean the Knowledge of the individuals named on Part 1.1(nnn)(ii); and (iii) “Knowledge of Buyer,” Buyer’s Knowledge” and other correlative terms mean the Knowledge of the individuals named on Part 1.1(nnn)(iii).
(s)    Lease” means any lease of real property or any lease or rental agreement, license, right to use or installment and conditional sale agreement to which any Seller is a party, and any other Contract pertaining to the leasing or use of any Tangible Personal Property.
(t)    Legal Requirement” means any federal, state, local, municipal, foreign, international, multinational or other constitution, law, ordinance, principle of common law, code, regulation, statute or treaty.
(u)    Liability” means, with respect to any Person, any liability or obligation of such Person of any kind, character or description, whether known or unknown, absolute or contingent, accrued or unaccrued, disputed or undisputed, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise, and whether or not the same is required to be accrued on the financial statements of such Person.
(v)    License Agreement” is defined in Section 5.15.
(w)    LIMS Data” is defined in Section 2.1(e).
(x)    LLASA” is defined in Section 7.7.
(y)    Marks” is defined in Section 3.20(a)(i).
(z)    MAS” is defined in the first paragraph of this Agreement.
(aa)    Material Adverse Effect” means any change, occurrence, development or effect that, individually or taken together with all other such changes, occurrences, developments or effects that have occurred prior to the date of determination of the

6



Material Adverse Effect, as applicable, has had or could reasonably be expected to have a material adverse change to or effect on the Business or the Assets, or a material adverse change to or effect on the ability of Sellers to perform their obligations under this Agreement, in each case, other than any effect caused by or arising out of
(i)    any event, change, or development in general economic or political conditions or financial or capital markets;
(ii)    any change to GAAP (or interpretation thereof) or Legal Requirements;
(iii)    any event, change, or development resulting from natural disasters, hostilities, acts of war, sabotage or terrorism;
(i)    the announcement of this Agreement or the pendency or consummation of the Contemplated Transactions, including (1) the identity of Buyer or (2) any HLI Business employee attrition or any loss, diminution or disruption of Sellers’ business or relationship with existing or prospective clients, customers or suppliers, in each case to the extent resulting from the public announcement of this Agreement or the pendency of the Contemplated Transactions;
(ii)    any action taken by Sellers at the written request of Buyer or with Buyer’s written consent (including the deferral or cancellation of implementation of programs intended to achieve cost savings in the Business); and
(iii)    change in the Business’s industry or in markets generally,
so long as, in the case of each of clauses (i), (ii), (iii) and (vi) such matters do not adversely affect Sellers’ Business or the Assets in a materially disproportionate manner relative to other companies operating in the Business.
(bb)    Material Contracts” means those Contracts of Sellers relating to the Business providing for payments in excess of $50,000 per annum.
(cc)    Material Customers” means those Customers of the Business from which Sellers realized gross revenue in calendar year 2013 equal to or exceeding $50,000.
(a)    Material Interest” means direct or indirect beneficial ownership (as defined in Rule 13d-3 under the Exchange Act) of voting securities or other voting interests representing at least ten percent (10%) of the outstanding voting power of a Person or equity securities or other equity interests representing at least ten percent (10%) of the outstanding equity securities or equity interests in a Person (other than another Seller).

7



(a)    Material Suppliers” means those suppliers of the Business from which Sellers purchased supplies for the Business in calendar year 2013 in amounts equal to or exceeding $50,000.
(b)    Net Cash Consideration” is defined in Section 2.3.
(c)    Net Names” is defined in Section 3.20(a)(vi).
(d)    Order” means any order, injunction, judgment, decree, ruling, assessment or arbitration award of any Governmental Body or arbitrator.
(e)    Ordinary Course of Business” with respect to any Person means an action taken by such Person that:
(i)    is consistent in all material respects in nature, scope and magnitude with the past practices of such Person and is taken in the ordinary course of the normal, day-to-day operations of such Person; and
(ii)    does not require authorization by the board of directors or shareholders of such Person (or by any Person or group of Persons exercising similar authority) and does not require any other separate or special authorization of any nature.
(f)    Other Businesses” means the (x) H&W Business, (y) the Retained Kit Assembly Business and (z) such other businesses that Sellers engage in from time to time other than the Business, in the case clauses (x) and (z) above, to the extent they are not Competing Businesses.
(g)    Other Claim” is defined in Section 11.7(a).
(h)    Part” means a part or section of the Disclosure Schedule.
(i)    Party” and “Parties” are defined in the Preamble.
(j)    Patents” is defined in Section 3.20(a)(ii).
(k)    Permitted Encumbrance” means: (i) encumbrances which do not materially and adversely affect the use, operation or disposition of the property subject thereto; (ii) statutory or contractual liens of landlords under Leases pursuant to which any Seller is a lessee and not in material default; and (iii) liens arising solely by action of Buyer.
(l)    Person” means an individual, partnership, corporation, business trust, limited liability company, limited liability partnership, joint stock company, trust, unincorporated association, joint venture or other entity or a Governmental Body.

8



(m)    Proceeding” means any action, arbitration, audit, hearing, investigation, litigation or suit (whether civil, criminal, administrative, judicial or investigative, whether public or private) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Body or arbitrator.
(n)    Prudential” means The Prudential Insurance Company of America.
(o)    Purchase Price” is defined in Section 2.3.
(p)    Receiving Party” is defined in Section 12.1(a).
(q)    Record” means information that is inscribed on a tangible medium or that is stored in an electronic or other medium and is retrievable in perceivable form.
(r)    Related Person” means a director, officer, agent or, with respect to an individual, an immediate family member (spouse, parent, child or sibling) of such Person or any Person, to Sellers’ Knowledge, that holds a Material Interest in such Person.
(s)    Representative” means, with respect to a particular Person, any director, officer, manager, employee, agent, consultant, advisor, accountant, financial advisor, legal counsel or other representative of that Person or any Person, to Sellers’ Knowledge, that holds a Material Interest in such Person.
(t)    Restricted Period” is defined in Section 10.6(a).
(u)    Retained Kit Assembly Business” means the business of (i) assembling for, acquiring for sale to, and selling to, third party customers (x) FDA Class 3 registered devices and (y) the Aripiprazole Demo Kit (for OAPI only), and (ii) assembling or acquiring wellness collection kits for use in connection with sample collection services as part of the H&W Business.
(v)    Retained Liabilities” is defined in Section 2.4(b).
(w)    Seller” and “Sellers” are defined in the Preamble of this Agreement.
(x)    Seller Adverse Recommendation Change” is defined in Section 5.6(e).
(y)    Seller Contact” is defined in Section 12.2(a)(iii).
(z)    Seller’s Closing Documents” is defined in Section 3.2(a).
(aa)    Seller Representatives” is defined in Section 5.6(a).
(bb)    Software” means all computer software and subsequent versions thereof, including source code, object, executable or binary code, objects, comments, screens, user interfaces, report formats, templates, menus, buttons and icons and all files, data,

9



materials, manuals, design notes and other items and documentation related thereto or associated therewith.
(cc)    “SOW” is defined in Section 5.14.
(dd)    Superior Proposal” is defined in Section 5.6(h).
(ee)    Tangible Personal Property” means all machinery, equipment, tools, furniture, office equipment, computer hardware, supplies, materials, vehicles and other items of tangible personal property (other than Inventories) of every kind owned or leased by any Seller (wherever located and whether or not carried on such Seller’s books) and used primarily in the Business, together with any express or implied warranty by the manufacturers or sellers or lessors of any item or component part thereof and all maintenance records and other documents relating thereto.
(ff)    Tax” means any income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, property, environmental, windfall profit, customs, vehicle, airplane, boat, vessel or other title or registration, capital stock, franchise, employees’ income withholding, foreign or domestic withholding, social security, unemployment, disability, real property, personal property, sales, use, transfer, value added, alternative, add-on minimum and other tax, fee, assessment, levy, tariff, charge or duty of any kind whatsoever and any interest, penalty, addition or additional amount thereon imposed, assessed or collected by or under the authority of any Governmental Body or payable under any tax-sharing agreement or any other Contract.
(gg)    Tax Return” means any return (including any information return), report, statement, schedule, notice, form, declaration, claim for refund or other document or information filed with or submitted to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Legal Requirement relating to any Tax.
(hh)    Termination Fee” is defined in Section 9.3(a).
(ii)    Third Party” means a Person that is not a party to this Agreement.
(jj)    Third-Party Claim” means any claim against any Indemnified Person by a Third Party, whether or not involving a Proceeding.
(kk)    Trade Secrets” is defined in Section 3.20(a)(v).
(ll)    TSA” is defined in Section 5.11.
(mm)    WARN Act” is defined in Section 3.18(b).

10



1.2    Usage.
(a)    Interpretation. In this Agreement, unless a clear contrary intention appears:
(i)    the singular number includes the plural number and vice versa;
(ii)    reference to any Person includes such Person’s successors and assigns but, if applicable, only if such successors and assigns are not prohibited by this Agreement, and reference to a Person in a particular capacity excludes such Person in any other capacity or individually;
(iii)    reference to any gender includes each other gender;
(iv)    reference to any agreement, document or instrument means such agreement, document or instrument as amended or modified and in effect from time to time in accordance with the terms thereof;
(v)    reference to any Legal Requirement means such Legal Requirement as amended, modified, codified, replaced or reenacted, in whole or in part, and in effect from time to time, including rules and regulations promulgated thereunder, and reference to any section or other provision of any Legal Requirement means that provision of such Legal Requirement from time to time in effect and constituting the substantive amendment, modification, codification, replacement or reenactment of such section or other provision;
(vi)    including” (and with correlative meaning “include”) means including without limiting the generality of any description preceding such term;
(vii)    or” is used in the inclusive sense of “and/or”;
(viii)    with respect to the determination of any period of time, “from” means “from and including” and “to” means “to but excluding”; and
(ix)    references to documents, instruments or agreements shall be deemed to refer as well to all addenda, exhibits, schedules or amendments thereto.
(b)    Accounting Terms and Determinations. Unless otherwise specified in this Agreement, all accounting terms used in this Agreement shall be interpreted and all accounting determinations under this Agreement shall be made in accordance with GAAP.
(c)    Legal Representation of the Parties. This Agreement was negotiated by the parties with the benefit of legal representation, and any rule of construction or interpretation otherwise requiring this Agreement to be construed or interpreted against any party shall not apply to any construction or interpretation of this Agreement.

11



ARTICLE 2    
SALE AND TRANSFER OF ASSETS; CLOSING
2.1    Purchased Assets. Upon the terms and subject to the conditions set forth in this Agreement, at the Closing and effective as of the Effective Time, Sellers shall sell, convey, assign, transfer and deliver to Buyer, and Buyer shall purchase and acquire from Sellers, free and clear of any Encumbrances, all of Sellers’ respective rights, title and interest in and to all of the property and assets, real, personal or mixed, tangible and intangible, of every kind and description, wherever located, belonging to any Seller and used in the Business, as well as any goodwill associated therewith (collectively, the “Assets”), including the following as they relate to, or are used in, the Business:
(d)    all Tangible Personal Property, including those items described in Part 2.1(a), but expressly excluding the items set forth on Part 2.2(b);
(e)    all Inventories of Sellers as they exist on the Closing Date, other than those Inventories set forth on Part 2.2(c);
(f)    all Customer Contracts, including those listed in Part 3.17(a), all outstanding offers or solicitations made by or to any Seller to enter into any Customer Contract, and all Records and specimens required under any Customer Contract or by any Legal Requirement to be maintained by any Seller;
(a)    the Contracts of Sellers that both (i) are not Customer Contracts and (ii) are listed on Part 2.1(d);
(b)    all data and Records related to the operations of the Business, including client and customer lists and Records, customer samples and related Records, referral sources, research and development reports and Records, production reports and Records, service and warranty Records, equipment logs, operating guides and manuals, financial and accounting Records, creative materials, advertising materials, promotional materials, studies, reports, correspondence and other similar documents and Records and, subject to Legal Requirements, copies of all personnel Records and other Records described in Section 2.2(k); provided that Sellers shall be entitled to retain, subject to compliance with the terms and conditions of Sellers’ confidentiality obligations hereunder, archival and production copies of any such data and Records, including but not limited to the archival and production copy of the data as of the Closing contained in the software system commonly known as the Laboratory Information Management System (the “LIMS Data”);
(a)    all of the intangible rights and property of Sellers, including Intellectual Property Assets, going concern value, goodwill, telephone, telecopy and e-mail addresses and listings used in the conduct of the Business and those items listed in Parts 3.20(d), (e), (g) and (h), other than the Intellectual Property Assets set forth on Part 2.2(o); and

12



(b)    all other properties and assets of every kind, character, and description, tangible or intangible, owned by any Seller and primarily used or held for use in connection with the Business, whether or not similar to the items specifically set forth above.
Notwithstanding the foregoing, the transfer of the Assets under this Agreement shall not include (A) the assumption of any Liability related to the Assets unless Buyer expressly assumes that Liability under Section 2.4(a) or (B) any of the Excluded Assets described in Section 2.2.
2.2    Excluded Assets. Notwithstanding anything to the contrary contained in Section 2.1 or elsewhere in this Agreement, the following assets of Sellers (collectively, the “Excluded Assets”) are not part of the sale and purchase contemplated under this Agreement, are excluded from the Assets and shall remain the property of Sellers after the Closing:
(a)    all cash, cash equivalents and short-term investments;
(b)    the items of Tangible Personal Property set forth on Part 2.2(b);
(c)    the Inventories set forth on Part 2.2(c);
(d)    all accounts receivable of Sellers;
(e)    all minute books, stock Records and corporate seals;
(f)    all Governmental Authorizations and all pending applications therefor or renewals thereof, including those listed in Part 3.14(b);
(g)    the shares of capital stock of Sellers;
(h)    all rights of Sellers relating to deposits and prepaid expenses, claims for refunds and rights to offset in respect thereof, including those listed in Part 2.2(h);
(i)    all insurance policies and rights thereunder;
(j)    all of the Customer Contracts listed in Part 2.2(j) and all other Contracts of Sellers that either are not Customer Contracts or are not listed on Part 2.1(d); and
(k)    all Records (including personnel Records) that Sellers are required by law to retain in their possession, and an archival copy of all data and Records as contemplated by Section 2.2(g);
(l)    all claims for refund of Taxes and other governmental charges of whatever nature;
(m)    except as provided in Section 10.1 of this Agreement, all rights in connection with and assets of the Employee Plans;

13



(n)    all rights of Sellers under this Agreement, the Bill of Sale, the Assignment and Assumption Agreement or any other agreements, documents or instrument entered into in connection herewith;
(o)    all data collected from customers and other participants in connection with the health and wellness screening and other specimen collection activities conducted by the H&W Business, and such other Intellectual Property Assets set forth in Part 2.2(o);
(p)    the property and assets described in Part 2.2(p);
(q)    the “Hooper Holmes” trademark and tradename;
(r)    the real property interests of Sellers in Basking Ridge, New Jersey, Olathe, Kansas and such other real property interests as set forth on Part 2.2(r); and
(s)    the Other Businesses and all assets primarily used therein (for clarity, Part 2.2(p) lists all such assets that are also used in the Business).
2.3    Consideration. The consideration for the Assets (the “Purchase Price”) shall be (a) Three Million Seven Hundred Thousand dollars ($3,700,000) (the “Net Cash Consideration”) and (b) the assumption of the Assumed Liabilities.
2.4    Liabilities.
(a)    Assumed Liabilities. On the Closing Date, but effective as of the Effective Time, Buyer shall assume and agree to discharge only the Liability of any Seller arising after the Effective Time under each Contract described in either Section 2.1(c) or Section 2.1(d) (including any such Contract that is entered into by any Seller after the date of this Agreement in accordance with this Agreement), but only to the extent such Contract is assigned by such Seller to Buyer under this Agreement as of the Effective Time, and excluding any Liability arising out of or relating to a Breach that occurred before the Effective Time (the “Assumed Liabilities”).
(b)    Retained Liabilities. “Retained Liabilities” shall mean every Liability of Sellers other than the Assumed Liabilities. The Retained Liabilities shall remain the sole responsibility of and shall be retained, paid, performed and discharged solely by Sellers.
2.5    Allocation. The Purchase Price shall be allocated in accordance with Exhibit 2.5. After the Closing, the parties shall make consistent use of the allocation, fair market value and useful lives specified in Exhibit 2.5 for all Tax purposes and in all filings, declarations and reports with the IRS in respect thereof, including the reports required to be filed under Section 1060 of the Code. Buyer shall prepare and deliver IRS Form 8594 to Sellers within forty-five (45) days after the Closing Date to be filed with the IRS. In any Proceeding related to the determination of any Tax, neither Buyer nor any Seller shall contend or represent that such allocation is not a correct allocation except as otherwise required pursuant to a “determination” within the meaning of Section 1313(a) of the Code (or any analogous provision of state, local or

14



foreign laws). Sellers or Buyer, as the case may be, shall promptly notify the other if any tax authority disputes the allocation.
2.6    Closing. The purchase and sale provided for in this Agreement (the “Closing”) will take place on the first Business Day that is two (2) Business Days after the satisfaction or waiver of all conditions to Closing identified in ARTICLE 7 or in ARTICLE 8 (other than those conditions that by their nature are to be satisfied at Closing, but subject to the fulfillment or waiver of such conditions), or if the parties agree to another date in writing, then on such other mutually agreed upon date. Subject to ARTICLE 9, failure to consummate the purchase and sale provided for in this Agreement on the date and time and at the place determined under this Section 2.6 will not result in the termination of this Agreement and will not relieve any party of any obligation under this Agreement. In such a situation, the Closing will occur as soon as practicable, subject to ARTICLE 9. The Closing shall be held at the offices of Lathrop & Gage LLP, 2345 Grand Boulevard, Kansas City, Missouri 64108, commencing at 10:00 a.m. (local time) on the Closing Date, or at such other time and location as Sellers and Buyer mutually agree.
2.7    Closing Obligations. In addition to any other documents to be delivered under other provisions of this Agreement, at the Closing:
(a)    Sellers’ Deliveries. Sellers shall deliver to Buyer, together with funds sufficient to pay all Taxes necessary for the transfer, filing or recording thereof:
(i)    a bill of sale for all of the Assets that are Tangible Personal Property substantially in the form of Exhibit 2.7(a)(i) (the “Bill of Sale”), duly executed by Sellers;
(ii)    an assignment of all of the Assets that are intangible property substantially in the form of Exhibit 2.7(a)(ii), which assignment shall also contain Buyer’s undertaking and assumption of the Assumed Liabilities (the “Assignment and Assumption Agreement”), duly executed by Sellers;
(iii)    assignments of all Intellectual Property Assets and separate assignments of all registered Marks, Patents and Copyrights substantially in the form of Exhibits 2.7(a)(iii)(A), 2.7(a)(iii)(B) and 2.7(a)(iii)(C) (collectively, the “IP Assignments”), duly executed by Sellers;
(iv)    the License Agreement, duly executed by HLI;
(v)    the TSA, duly executed by Sellers;
(vi)    an electronic copy of the Data Room as it exists as of the Closing;
(vii)    such other documents and other instruments of transfer and conveyance that Buyer reasonably requests, each in form and substance

15



reasonably satisfactory to Buyer, Sellers and their respective legal counsel and duly executed by Sellers and Buyer;
(viii)    the LLASA, duly executed by HH;
(ix)    a certificate executed by Sellers as to the accuracy of their representations and warranties as required under Section 7.1 and as to their compliance with and performance of their covenants and obligations as required under Section 7.2; and
(x)    a certificate of the Secretary of each Seller certifying, as complete and accurate as of the Closing, and attaching, all requisite resolutions or actions of each Seller’s board of directors approving the execution and delivery of this Agreement and the consummation of the Contemplated Transactions and the change of name contemplated by Section 5.9 and certifying to the incumbency and signatures of the officers of such Seller executing this Agreement and any other document relating to the Contemplated Transactions and accompanied by the requisite documents for amending the relevant Governing Documents of Sellers required to effect such change of name in form sufficient for filing with the appropriate Governmental Body.
(b)    Buyer’s Deliveries. Buyer shall deliver to Sellers:
(i)    An amount equal to the Net Cash Consideration by wire transfer to an account or accounts specified by Sellers in a writing delivered to Buyer at least three (3) Business Days before the Closing Date;
(ii)    the Assignment and Assumption Agreement, duly executed by Buyer;
(iii)    the LLASA, duly executed by Buyer;
(iv)    the TSA, duly executed by Buyer or its assignee;
(v)    the License Agreement, duly executed by Buyer;
(i)    applicable sales tax resale certificates with respect to the Inventories being purchased pursuant to this Agreement;
(ii)    a certificate executed by Buyer as to the accuracy of its representations and warranties as required under Section 8.1 and as to its compliance in all material respects with and performance of its covenants and obligations as required under Section 8.2; and
(iii)    a certificate of the Secretary of Buyer certifying, as complete and accurate as of the Closing, and attaching all requisite resolutions or actions of Buyer’s board of directors approving the execution and delivery of this

16



Agreement and the consummation of the Contemplated Transactions and certifying to the incumbency and signatures of the officers of Buyer executing this Agreement and any other document relating to the Contemplated Transactions.
2.1    Customer Contracts Not Assigned at Closing.
(c)    With respect to any Customer Contract that is intended to be assigned to, and assumed by, Buyer under this Agreement, but is not assignable (and therefore is not assigned) to Buyer at Closing, neither this Agreement nor the Assignment and Assumption Agreement nor any other document related to the consummation of the Contemplated Transactions shall constitute a sale, assignment, assumption, transfer, conveyance or delivery or an attempted sale, assignment, assumption, transfer, conveyance or delivery of such Customer Contract, and following the Closing, the parties shall use their respective Best Efforts, and cooperate with each other, to obtain any Consent relating to each such Customer Contract as quickly as practicable.
(d)    Pending the obtaining of such Consent(s), the parties shall cooperate with each other in any reasonable and lawful arrangements designed to provide to Buyer the benefits of use of such Customer Contract (net of all expenses incurred by Sellers in the Ordinary Course of Business with respect to such Customer Contract) for its term (or any right or benefit arising thereunder, including the enforcement for the benefit of Buyer of all rights of Seller against a third party thereunder, net of all costs, fees and expenses incurred to enforce such rights).
(e)    When all necessary Consents for the sale, assignment, assumption, transfer, conveyance and delivery of a Customer Contract described in clause (a) above are obtained, Sellers shall promptly assign, transfer, convey and deliver such Customer Contract to Buyer, and Buyer shall assume the obligations under such Customer Contract assigned to Buyer from and after the date of assignment to Buyer under a special-purpose assignment and assumption agreement substantially similar in terms to those of the Assignment and Assumption Agreement (which special-purpose agreement the parties shall prepare, execute and deliver in good faith at the time of such transfer, all at no additional cost to Buyer).
ARTICLE 3    
REPRESENTATIONS AND WARRANTIES OF SELLERS
Sellers represent and warrant, jointly and severally, to Buyer as follows:
3.1    Organization and Good Standing. Each Seller:
(t)    is a corporation duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation, with full corporate power and authority to conduct its business as it is now being conducted, to own or use the properties and assets that it purports to own or use, and to perform all its obligations under the Contracts; and

17



(u)    is duly qualified to do business as a foreign corporation and is in good standing under the laws of each state or other jurisdiction in which either the ownership or use of the properties owned or used by it, or the nature of the activities conducted by it, requires such qualification, except where the failure to so qualify would not have a Material Adverse Effect.
3.2    Enforceability; Authority; No Conflict.
(a)    This Agreement constitutes the legal, valid and binding obligation of Sellers, enforceable against each of them in accordance with its terms. Upon the execution and delivery by Sellers of each other agreement to be executed or delivered by any or all of Sellers at the Closing (collectively, the “Seller’s Closing Documents”), each of Seller’s Closing Documents will constitute the legal, valid and binding obligation of each of Sellers who are parties thereto, enforceable against each of them in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency or similar Legal Requirements affecting the enforcement of creditors’ rights generally. Each of Sellers have the absolute and unrestricted right, power and authority to execute and deliver this Agreement and the Seller’s Closing Documents to which it is a party and to perform its obligations under this Agreement and such Seller’s Closing Documents, except as disclosed in Part 3.2(a) and such action has been duly authorized by all necessary action by such Seller’s board of directors and, to the extent required under applicable law, such Seller’s shareholders.
(b)    Except as set forth in Part 3.2(b), neither the execution and delivery of this Agreement nor the consummation or performance of any of the Contemplated Transactions will, directly or indirectly (with or without notice or lapse of time):
(i)    Breach (A) any provision of any of the Governing Documents of any Seller or (B) any resolution adopted by the board of directors or the shareholders of any Seller;
(ii)    Breach or give any Governmental Body or other Person the right to challenge any of the Contemplated Transactions or to exercise any remedy or obtain any relief under any Legal Requirement or any Order to which any Seller, or any of the Assets, may be subject;
(iii)    Contravene, conflict with or result in a violation or breach of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Seller or that otherwise relates to the Assets or to the Business;
(i)    Breach any provision of, or give any Person the right to declare a default or exercise any remedy under, or to accelerate the maturity or performance of, or payment under, or to cancel, terminate or modify, any Contract; or

18



(ii)    Result in the imposition or creation of any Encumbrance upon or with respect to any of the Assets.
(c)    Except as set forth in Part 3.2(c), no Seller is required to give any notice to or obtain any Consent from any Person in connection with the execution and delivery of this Agreement or the consummation or performance of any of the Contemplated Transactions.
3.3    Financial Statements. Seller has delivered to Buyer the following financial statements (collectively, the “Financial Statements”):
(c)    the unaudited consolidated balance sheets of HH as at December 31, 2012 and December 31, 2013 (the “Balance Sheet”);
(d)    the unaudited consolidated and consolidating (separated for Attending Physician Statements, Physician Information Lines, tele-interviewing and inspections, underwriting, and gross margin expense and detail relating to the Prudential Contract) income statements of HHS for the years ending December 31, 2012, and December 31, 2013, and for the two month period ending February 28, 2014; and
(e)    the unaudited consolidated and consolidating (separated for laboratory services and kit gross margin expense and detail) income statements of HLI for the years ending December 31, 2012, and December 31, 2013, and for the two month period ending February 28, 2014.
Such Financial Statements fairly present (and the Financial Statements delivered under Section 5.8 will fairly present) the results of operations of the Business for the periods referred to in such Financial Statements, all in accordance with GAAP (subject, with respect to unaudited statements, to the absence of footnotes and year-end adjustments). Such Financial Statements reflect (and the Financial Statements delivered under Section 5.8 will reflect) the consistent application of such accounting principles throughout the periods involved. Such Financial Statements have been prepared (and the Financial Statements delivered under Section 5.8 will be prepared) from and are in accordance with the accounting Records of Sellers.
The documentation provided by Sellers to Buyer in Sections 1.1.5, 1.1.16, 1.2.9 and 1.2.12 of the Data Room is complete and accurate in all material respects (except with respect to 2014 estimated revenues in Sections 1.1.5 and 1.2.9, which information represents a reasonable forecast based on available information known to Sellers at the time such forecasts were prepared).
3.4    Books and Records. The books of account and other financial Records of Sellers relating to the Business or the Assets, all of which have been made available to Buyer, are complete and correct in all material respects and represent actual, bona fide transactions and have been maintained in accordance with sound business practices and the requirements of Section 13(b)(2) of the Exchange Act (regardless of whether Sellers are subject to that Section or not), including the maintenance of an adequate system of internal controls.

19



3.5    Customers.
Except as set forth in Part 3.5,
(i)    none of Sellers is engaged in any outstanding dispute or complaint with any of the Materials Customers of the Business, other than disputes or complaints arising in the Ordinary Course of Business; and
(ii)    to Sellers’ Knowledge, none of the Material Customers of the Business who were Material Customers of the Business as of January 1, 2014, have ceased or materially reduced, or intend to cease or materially reduce, their respective level of business with Sellers from the revenues attributable to such Material Customer during the 12 months ended December 31, 2013.
3.6    Sufficiency of Assets. Except as set forth in Part 3.6, the Assets (a) constitute all of the assets, tangible and intangible, of any nature whatsoever, reasonably necessary to operate the Business in the manner presently operated by Sellers and (b) include all of the operating assets of the Business.
3.7    Regulatory Compliance. Except as set forth in Part 3.7, there is not now issued, outstanding or, to Sellers’ Knowledge, threatened, any notice by any regulatory authority of any violation or compliance, or any application, complaint or proceeding relating to the Business or operations of the Business.
3.8    Title to Assets; Encumbrances. Sellers own good and transferable title to all of the Assets free and clear of any Encumbrances other than those described in Part 3.8. Sellers warrant to Buyer that, at the time of Closing, all of the Assets shall be free and clear of all Encumbrances, other than those arising solely by action of Buyer.
3.9    Condition of Tangible Personal Property; IT Systems.
(a)    Each item of Tangible Personal Property is in all material respects good repair and good operating condition, ordinary wear and tear excepted, is suitable for immediate use in the Ordinary Course of Business and is free from latent and patent defects. Except as disclosed in Part 3.9(a), no item of Tangible Personal Property is in need of repair or replacement other than as part of routine maintenance in the Ordinary Course of Business. Except as disclosed in Part 3.9(a), all Tangible Personal Property used in the Business is in the possession of Sellers.
(b)    Except as disclosed in Part 3.9(b), the information technology systems used by Sellers in the Business (including computer hardware and supporting equipment such as servers, communications equipment, terminals and hook-ups that interface with third party software or systems, the “IT Systems”):
(i)    have been properly maintained by technically competent personnel, in accordance in all material respects with applicable standards set by

20



the manufacturers or, if such standards are not appropriate or available, otherwise in accordance with standards prudent in the pharmaceutical industry, to ensure proper operation, monitoring and use;
(ii)    are in good working condition to effectively perform all information technology operations necessary or advisable for the conduct of the Business; and
(iii)    provide sufficient redundancy and speed to meet standards prudent in the laboratory industry relating to high availability.
(c)    Sellers have taken commercially reasonable actions for the backup and recovery of the data and information critical to the conduct of the Business or that is required to be made available to third parties in the course of the Business (including such data and information that is stored on magnetic or optical media in the ordinary course) without material disruption to, or material interruption in, the conduct of the Business.
3.10    Inventories. All items included in the Inventories consist of a quality and quantity usable and, with respect to finished goods, saleable, in the Ordinary Course of Business of Sellers except for obsolete items and items of below-standard quality, all of which have been or will be written off or written down to net realizable value in the Balance Sheet or the Interim Balance Sheet or on the accounting Records of Sellers as of the Closing Date, as the case may be. All of the Inventories have been valued at lower of average cost or market. Work-in-process Inventories are now valued, and will be valued on the Closing Date, at cost according to GAAP.
3.11    Taxes. Sellers have filed or caused to be filed on a timely basis all Tax Returns that were required to be filed under applicable Legal Requirements. All Tax Returns filed by Sellers are true, correct and complete in all material respects. Sellers have paid, or made provision for the payment of, all Taxes that have or may have become due for all periods covered by the Tax Returns or otherwise, or under any assessment received by Sellers, except such Taxes, if any, as are listed in Part 3.11 and that are being contested in good faith and as to which adequate reserves (determined in accordance with GAAP) have been provided in HH’s balance sheet. There are no Encumbrances on any of the Assets that arose in connection with any failure (or alleged failure) to pay any Tax, and Sellers have no Knowledge of any reasonably foreseeable basis for assertion of any claims attributable to Taxes that, if adversely determined, would result in any such Encumbrance.
3.12    No Material Adverse Effect. Except as described in Part 3.12, since December 31, 2013, there has not been any Material Adverse Effect and to Sellers’ Knowledge, no event has occurred or circumstance exists that would reasonably be expected to result in such a Material Adverse Effect.
3.13    Employee Benefits.

21



(a)    Set forth in Part 3.13(a) is a complete and correct list of all “employee benefit plans” as defined by Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended from time to time (“ERISA”), all specified fringe benefit plans as defined in Section 6039D of the Code, and all other bonus, incentive-compensation, deferred-compensation, profit-sharing, stock-option, stock-appreciation-right, stock-bonus, stock-purchase, employee-stock-ownership, savings, severance, change-in-control, supplemental-unemployment, layoff, salary-continuation, retirement, pension, health, life-insurance, disability, accident, group-insurance, vacation, holiday, sick-leave, fringe-benefit or welfare plan, and any other employee compensation or benefit plan, agreement, policy, practice, commitment, contract or understanding (whether qualified or nonqualified, currently effective or terminated, written or unwritten) and any trust, escrow or other agreement related thereto that
(i)    is or has been maintained or contributed to by any Seller or any person or entity that is or at any relevant time was considered a single employer with any Seller under Section 414 of the Code or Section 4001 of ERISA (such person or entity being referred to hereinafter as an “ERISA Affiliate”) or with respect to which any Seller or any ERISA Affiliate has or may have any liability, and
(ii)    provides benefits, or describes policies or procedures applicable to any current or former director, manager, officer, employee or service provider of any Seller or any ERISA Affiliate, or the dependents of any thereof, engaged in the Business, regardless of how (or whether) liabilities for the provision of benefits are accrued or assets are acquired or dedicated with respect to the funding thereof (individually an “Employee Plan” and collectively the “Employee Plans”).
(b)    Each Employee Plan intended to be “qualified” within the meaning of Section 401(a) of the Code has received a favorable determination letter as to such qualification from the IRS and to Sellers’ Knowledge nothing has occurred or failed to occur that jeopardizes or could reasonably be expected to jeopardize the qualified status of such Employee Plan. None of Sellers nor any ERISA Affiliate maintains, participates in or contributes to, nor have any of them ever maintained, participated in or contributed to, any “multiemployer plan” (as defined in ERISA Section 3(37) or 4001(a)(3)) or any “pension plan” (as defined in Section 3(2) of ERISA) that is or has ever been subject to Title IV of ERISA or Section 302 of ERISA or Section 412 of the Code. To Sellers’ Knowledge, no event has occurred and no condition exists or will exist upon execution of this Agreement or the consummation of the transactions contemplated by this Agreement that would subject any Seller or any of the Assets to any tax, fine, lien, penalty or other liability imposed by ERISA, the Code or other applicable laws in connection with any of the Employee Plans.
(c)    Except as set forth in Part 3.13(c), no Employee Plan exists that, as a result of the execution of this Agreement or the consummation of the transactions contemplated by this Agreement (whether alone or in connection with any subsequent

22



event(s)), would (i) result in severance pay, termination indemnity or any similar payment or any increase in compensation, severance pay, termination indemnity or any similar payment being made to any individual employed in the Business, (ii) accelerate the time of payment or vesting or result in any payment or funding (through a grantor trust or otherwise) of compensation or benefits under, increase the amount payable or result in any other obligation pursuant to, any of the Employee Plans with respect to any individual employed in the Business or (iii) result in payments that would not be deductible under Section 280G of the Code.
(d)    There is no charge, complaint, claim, grievance, investigation, inquiry or controversy of any kind, pending or, to Sellers’ Knowledge, threatened, before any Governmental Body or arbitrator, relating to an alleged violation or breach by any Seller (or its officers, directors or managers) of any Employee Plan, or any law applicable thereto.
3.14    Compliance with Legal Requirements; Governmental Authorizations.
(a)    Except as set forth in Part 3.14(a):
(i)    Each Seller is, and at all times since January 1, 2011, has been, in compliance in all material respects with each Legal Requirement that is or was applicable to it or to the conduct or operation of the Business or the ownership or use of any of the Assets;
(ii)    To Sellers’ Knowledge, no event has occurred or circumstance exists that (with or without notice or lapse of time) may (A) constitute or result in a violation by any Seller of, or a failure on the part of any Seller to comply in all material respects with, any Legal Requirement or (B) give rise to any obligation on the part of any Seller to undertake, or to bear all or any portion of the cost of, any remedial action of any nature; and
(iii)    No Seller has received, at any time since January 1, 2011, any notice or other communication (whether written or, to Sellers’ Knowledge, oral) from any Governmental Body or any other Person regarding (A) any actual, alleged, possible or potential violation of, or failure to comply with, any Legal Requirement in connection with the Business or the Assets or (B) any actual, alleged, possible or potential obligation on the part of any Seller to undertake, or to bear all or any portion of the cost of, any remedial action of any nature in connection with the Business or the Assets.
(b)    Part 3.14(b) contains a complete and accurate list of each Governmental Authorization that is held by each Seller and relates to the Business or the Assets. Each Governmental Authorization listed or required to be listed in Part 3.14(b) is in full force and effect in accordance with its terms. Except as set forth in Part 3.14(b):

23



(i)    Each Seller is, and at all times since January 1, 2011, has been, in compliance in all material respects with the terms and requirements of each Governmental Authorization identified in Part 3.14(b);
(ii)    To Sellers’ Knowledge, no event has occurred or circumstance exists that would reasonably be expected to (with or without notice or lapse of time) (A) constitute or result in a violation of or a failure to comply with any material term or requirement of any Governmental Authorization listed in Part 3.14(b) or (B) result in the revocation, withdrawal, suspension, cancellation or termination of, or any modification to, any Governmental Authorization listed in Part 3.14(b); and
(c)    The Governmental Authorizations listed in Part 3.14(b) collectively constitute all of the Governmental Authorizations necessary to permit Sellers to lawfully conduct and operate the Business in the manner in which they conduct and operate the Business and to permit Sellers to own and use the Assets in the manner in which they own and use the Assets.
The representations and warranties contained in this Section 3.14 shall not relate to matters arising under the Code or ERISA, as such matters are covered by the representations and warranties contained in Sections 3.11 and 3.13 respectively.
3.15    Legal Proceedings; Orders.
(a)    Except as set forth in Part 3.15(a), there is no Proceeding pending or, to Sellers’ Knowledge, threatened:
(iii)    by or against any Seller or that otherwise relates to or may materially adversely affect the Business or any of the Assets; or
(iv)    that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, any of the Contemplated Transactions;
and to Sellers’ Knowledge, no event has occurred or circumstance exists that is reasonably likely to give rise to or serve as a basis for the commencement of any such Proceeding. Sellers have delivered to Buyer copies of all pleadings, correspondence and other documents relating to each Proceeding listed in Part 3.15(a). There are no Proceedings listed or required to be listed in Part 3.15(a) that could have a Material Adverse Effect on the Business or any of the Assets.
(b)    Except as set forth in Part 3.15(b), (i) there is no Order to which any Seller, the Business or any of the Assets is subject; and (ii) no officer, director, agent or employee of any Seller is subject to any Order that prohibits such officer, director, agent or employee from engaging in or continuing any conduct, activity or practice relating to the Business.

24



(c)    Except as set forth in Part 3.15(c), in each case as relating to the Business or the Assets:
(i)    Each Seller is, and, at all times since January 1, 2010, has been in compliance in all material respects with all of the terms and requirements of each Order to which it or any of the Assets is or has been subject;
(ii)    to Sellers’ Knowledge, no event has occurred or circumstance exists that is reasonably likely to constitute or result in (with or without notice or lapse of time) a violation of or failure to comply with any term or requirement of any Order to which any Seller or any of the Assets is subject; and
(iii)    No Seller has received, at any time since January 1, 2010, any notice or other communication (whether oral or written) from any Governmental Body or any other Person regarding any actual, alleged, possible or potential violation of, or failure to comply with, any term or requirement of any Order to which any Seller or any of the Assets is or has been subject.
3.16    Absence of Certain Changes and Events. Except as set forth in Part 3.16, since December 31, 2013, Sellers have conducted the Business only in the Ordinary Course of Business and there has not been any: (a) material damage to or destruction or loss of any Asset, whether or not covered by insurance; (b) creation of any Encumbrance (other than any Permitted Encumbrance) on any Asset; (c) notice in writing or, to Sellers’ Knowledge, verbally by any Material Customer or Material Supplier of an intention to discontinue or materially change its relationship with any Seller; (d) change in the accounting methods used by any Seller for the Business (except for any such change in compliance with GAAP or any Legal Requirement); or (e) Contract by any Seller to do any of the foregoing.
3.17    Contracts; No Defaults.
(a)    Part 3.17(a) contains an accurate and complete list, and Sellers have delivered to Buyer accurate and complete copies, of:
(iv)    each Contract that involves performance of services or delivery of goods or materials by any Seller as part of the Business (together with any amendment, supplement or modification described in clause (v) below, each a “Customer Contract” and collectively the “Customer Contracts”);
(v)    each Contract under which any Seller leases real property in Lenexa, Kansas or Omaha, Nebraska as part of the Business;
(vi)    each Contract affecting the ownership of, leasing of, title to, use of or any leasehold or other interest in any personal property as part of the Business;

25



(vii)    each written warranty, guaranty and/or other similar undertaking with respect to contractual performance extended by any Seller in connection with the Business, other than in the Ordinary Course of Business; and
(viii)    each amendment, supplement and modification (whether oral or written) in respect of any of the foregoing.
Part 3.17(a) sets forth, for each such Contract, the parties to the Contract and the location of Sellers’ office where details relating to such Contract are located.
(b)    Except as set forth in Part 3.17(b), each Contract that is identified or required to be identified in Part 3.17(a) or that is to be assigned to or assumed by Buyer under this Agreement (i) is in full force and effect and is valid and enforceable in accordance with its terms (except as enforceability may be limited by bankruptcy, insolvency or similar laws affecting the enforcement of creditors’ rights generally and by equitable principles, including those limiting the availability of specific performance, injunctive relief and other equitable remedies and those providing equitable defenses); and (ii) is assignable by the Seller party thereto to Buyer without the consent of any other Person; and
(c)    Except as set forth in Part 3.17(c), with respect to each Contract that is to be assigned to or assumed by Buyer under this Agreement:
(i)    The Seller party thereto is in compliance in all material respects with all terms and requirements of such Contract;
(ii)    To Sellers’ Knowledge, each other Person that has or had any obligation or liability under such Contract is in compliance in all material respects with all applicable terms and requirements of such Contract;
(iii)    To Sellers’ Knowledge, no event has occurred or circumstance exists that (with or without notice or lapse of time) would reasonably be expected to contravene, conflict with or result in a Breach of, or give any Seller or other Person the right to declare a default or exercise any remedy under, or to accelerate the maturity or performance of, or payment under, or to cancel, terminate or modify, such Contract;
(iv)    To Sellers’ Knowledge, no event has occurred or circumstance exists under or by virtue of such Contract that (with or without notice or lapse of time) would reasonably be expected to cause the creation of any Encumbrance affecting any of the Assets;
(v)    Since December 31, 2012, no Seller has given to, or received from, any other Person at any time any written notice or other written communication (or, to Sellers’ Knowledge, any verbal notice or other verbal communication)

26



regarding any actual, alleged, possible or potential violation or Breach of, or default under, such Contract which violation or Breach has not been resolved; and
(vi)    Other than in the Ordinary Course of Business, there are no renegotiations of, attempts to renegotiate or outstanding rights to renegotiate any amounts paid or payable to any Seller under such Contract with any Person having the contractual or statutory right to demand or require such renegotiation and no such Person has made written demand on any Seller for such renegotiation.
(d)    Each Contract relating to the sale, design, manufacture or provision of products or services by any Seller and relating to the Business has been entered into in the Ordinary Course of Business of such Seller and has been entered into without the commission of any act alone or in concert with any other Person, or any consideration having been paid or promised, that is or would be in violation of any Legal Requirement. Sellers have complied in all material respects with all record-keeping and specimen retention requirements under any Customer Contract.
(a)    Part 3.17(e) sets forth true and complete lists of the twenty (20) largest vendors for each of the HLI Business and the HHS Business, based on aggregate expenditures attributable to each such vendor (i) during the twelve month period ended December 31, 2012 and (ii) during the twelve month period ended December 31, 2013, together with the aggregate amount of expenditures attributable to such vendor for each such period.
3.18    Employees.
(a)    Part 3.18(a) contains a complete and accurate list of the following information for each employee, director, independent contractor, consultant and agent of Sellers engaged in the Business, including each employee on leave of absence or layoff status: employer; name; job title; date of commencement of employment or engagement; current compensation paid or payable and any change in compensation since December 31, 2013; sick and vacation leave that is accrued but unused; and service credited for purposes of vesting and eligibility to participate under any Employee Plan, or any other employee or director benefit plan.
(b)    Sellers have not violated the Worker Adjustment and Retraining Notification Act (the “WARN Act”) or any similar state or local Legal Requirement.
(c)    Sellers have not received notice in writing or, to Sellers’ Knowledge, verbally that any officer, director, agent, employee, consultant, or contractor of any Seller is bound by any Contract that purports to limit the ability of such officer, director, agent, employee, consultant, or contractor (i) to engage in or continue or perform any conduct, activity, duties or practice relating to the Business or (ii) to assign to any Seller or to any other Person any rights to any invention, improvement, or discovery. Sellers have not received notice in writing or, to Sellers’ Knowledge, verbally that any former or current

27



employee of any Seller is a party to, or is otherwise bound by, any Contract that in any way adversely affected, affects, or will affect the ability of any Seller or Buyer to conduct the Business as heretofore carried on by Sellers.
3.19    Labor Disputes; Compliance.
(a)    Sellers have complied in all material respects with all Legal Requirements relating to employment practices, terms and conditions of employment, equal employment opportunity, nondiscrimination, immigration, wages, hours, benefits, collective bargaining, the payment of social security and similar Taxes and occupational safety and health, in each case, in connection with the Business. Sellers are not liable for the payment of any Taxes, fines, penalties or other amounts, however designated, for failure to comply with any of the foregoing Legal Requirements.
(b)    Except as disclosed in Part 3.19(b),
(i)    Sellers have not been, and are not now, a party to any collective bargaining agreement or other labor contract with respect to the Business or any employees thereof;
(ii)    since December 31, 2013, there has not been, there is not presently pending or existing, and to Sellers’ Knowledge there is not threatened, any strike, slowdown, picketing, work stoppage or employee grievance process involving any Seller and the Business, and to Sellers’ Knowledge no event has occurred or circumstance exists that could provide the basis for any work stoppage or other labor dispute involving the Business;
(iii)    there is not pending or, to Sellers’ Knowledge, threatened against or affecting any Seller any Proceeding relating to the alleged violation of any Legal Requirement pertaining to labor relations or employment matters, including any charge or complaint filed with the National Labor Relations Board or any comparable Governmental Body, and there is no organizational activity or other labor dispute against or affecting any Seller;
(iv)    no grievance or arbitration Proceeding exists that would reasonably be expected to have, if decided in whole or in part, adversely to Sellers, a Material Adverse Effect upon the Sellers, taken as a whole, or the conduct of the Business; and
(v)    there are no pending and, since January 1, 2012, there have been no charges of discrimination filed against or, to Sellers’ Knowledge, threatened against any Seller with the Equal Employment Opportunity Commission or similar state and federal Governmental Body.

28



3.20    Intellectual Property Assets. Except as related to Excluded Assets:
(a)    The term “Intellectual Property Assets” means all intellectual property relating to or used in the Business and owned or licensed (as licensor or licensee) by any Seller or in which any Seller has a proprietary interest, including:
(vi)    Sellers’ names, all assumed fictional business names, trade names, registered and unregistered trademarks, service marks and applications relating to or used in the Business (collectively, the “Marks”);
(vii)    all patents, patent applications and inventions and discoveries that may be patentable relating to or used in the Business (collectively, the “Patents”);
(viii)    all registered and unregistered copyrights in both published works and unpublished works used in or relating to the Business (collectively, the “Copyrights”);
(ix)    all rights in mask works relating to or used in the Business;
(x)    all know-how, trade secrets, confidential or proprietary information, customer lists, Software, technical information, data, process technology, plans, drawings and blue prints relating to or used in the Business (collectively, the “Trade Secrets”); and
(xi)    all rights in internet web sites and internet domain names relating to or used in the Business (collectively the “Net Names”).
(b)    Part 3.20(b) contains a complete and accurate list and summary description, including any royalties paid or received by any Seller, and Sellers have delivered to Buyer accurate and complete copies, of all Contracts relating to the Intellectual Property Assets. There are no outstanding or, to Sellers’ Knowledge, threatened disputes with respect to any such Contract.
(c)    Except as set forth in Part 3.20(c),
(i)    the Intellectual Property Assets include all intellectual property rights that are necessary for the operation of the Business as it is currently conducted, and a Seller is the owner or licensee of all right, title and interest in and to each of the Intellectual Property Assets, free and clear of all Encumbrances, except for Permitted Encumbrances, and has the right to use without payment to any third party all of the Intellectual Property Assets; and
(ii)    all current or former employees of the HLI Business have executed written Contracts (including, without limitation, employee manuals) with Sellers that assign to Sellers all rights to any inventions, improvements, discoveries, trade secrets, works of authorship or information relating to the Business.

29



(d)    With respect to the Marks:
(i)    Part 3.20(d) contains a complete and accurate list and summary description of all Marks;
(ii)    Except as disclosed in Part 3.20(d), all Marks have been registered with the United States Patent and Trademark Office, are in compliance in all material respects with all formal Legal Requirements (including the timely post-registration filing of affidavits of use and incontestability and renewal applications) and are valid and enforceable and are not subject to any maintenance fees or taxes or actions falling due within ninety (90) days after the Closing Date;
(iii)    No Mark has been since December 31, 2012 or is now involved in any opposition, invalidation or cancellation Proceeding and, to Sellers’ Knowledge, no such action is threatened with respect to any of the Marks;
(iv)    To Sellers’ Knowledge, there is no potentially interfering trademark or trademark application of any other Person; and
(v)    To Sellers’ Knowledge, no Mark is infringed or has been challenged or threatened in any way and none of the Marks infringes or is alleged to infringe any trade name, trademark or service mark of any other Person.
(e)    With respect to the Copyrights:
(i)    Part 3.20(e) contains a complete and accurate list and summary description of all registered Copyrights;
(ii)    All of the registered Copyrights are in compliance in all material respects with formal Legal Requirements, are valid and enforceable, and are not subject to any maintenance fees or taxes or actions falling due within ninety (90) days after the date of Closing; and
(iii)    To Sellers’ Knowledge, no Copyright is infringed or has been challenged or threatened in any way and none of the subject matter of any of the Copyrights infringes or is alleged to infringe any copyright of any Third Party or is a derivative work based upon the work of any other Person.
(f)    With respect to the Trade Secrets:
(i)    The documentation relating to the Trade Secrets is, or as of the Closing will be, reasonably sufficient in detail and content, in all material respects, to allow its use in the operation of the Business without reliance on the knowledge or memory of any individual; if either party discovers between the date of this Agreement and the Closing that any such documentation does not exist or is not so reasonably sufficient, then upon Buyer’s reasonable request, Sellers shall promptly provide such documentation.

30



(ii)    Sellers have taken all reasonable precautions to protect the secrecy, confidentiality and value of all Trade Secrets; and
(iii)    Sellers have good title to and an absolute right to use the Trade Secrets; the Trade Secrets are not part of the public knowledge or literature and no Trade Secret is subject to any adverse claim or has been challenged or threatened in any way in writing or, to Sellers’ Knowledge, verbally, or infringes any intellectual property right of any other Person.
(g)    With respect to Software:
(i)    Part 3.20(g) sets forth a complete and accurate list and general description of all Software used, sold or otherwise made available by any Seller in the Business (excluding software that is licensed under “shrink-wrap” or "click-through” contracts or that is generally commercially available);
(ii)    All of the Software performs substantially in conformance with its documentation and is free from any material software defect;
(iii)    To Seller’s Knowledge, no person has gained unauthorized access to the Software;
(iv)    To Seller’s Knowledge, none of the Software owned by, or developed by or for the benefit of, sold or otherwise made available by any Seller in the Business contains or requires use of any “open source” code, shareware or other software that is made generally available to the public without requiring payment of fees or royalties or that does or may require disclosure or licensing to any other Person of any software owned or developed by or on behalf of any Seller;
(v)    With respect to each item of Software, Sellers are in possession and control of the applicable source code, object code, documentation, and know-how to the extent required for use, distribution, maintenance and support of the Software as used, distributed, maintained, or supported in the Business;
(vi)    No one other than Sellers has any rights to use, sell, license, transfer, or otherwise exploit the Software (except for portions thereof that may consist of embedded third party products licensed from others); and
(vii)    Sellers have not disclosed Software source code to anyone other than pursuant to an enforceable confidentiality agreement that protects Sellers’ rights in the Software.
(h)    With respect to the Net Names:
(i)    Part 3.20(h) contains a complete and accurate list and summary description of all Net Names;

31



(ii)    All Net Names have been registered in the name of a Seller and are in compliance in all material respects with all formal Legal Requirements;
(iii)    No Net Name has been since December 31, 2012, or is now involved in any dispute, opposition, invalidation or cancellation Proceeding and, to Sellers’ Knowledge, no such action is threatened with respect to any Net Name;
(iv)    To Sellers’ Knowledge, there is no domain name application pending of any other person that would or would potentially interfere with or infringe any Net Name; and
(v)    To Sellers’ Knowledge, no Net Name is infringed or has been challenged, interfered with or threatened in any way; no Net Name infringes, interferes with or is alleged to interfere with or infringe the trademark, copyright or domain name of any other Person.
3.21    Relationships with Related Persons. Except as disclosed in Part 3.21,
(a)    no Seller nor any Related Person of any Seller owns, or since December 31, 2013, has owned, of record or as a beneficial owner, an equity interest or any other financial or profit interest in any Person (other than a Seller) that has engaged in the provision of any products or services similar in function or nature to the products and services of the Business (a “Competing Business”) in any market presently served by the Business, except for ownership of less than one percent (1%) of the outstanding capital stock of any Competing Business that is publicly traded on any recognized exchange or in the over-the-counter market; and
(b)    no Related Person of any Seller has any claim or right under any Contract that is being assigned to, and assumed by, Buyer under this Agreement.
Sellers make no representations in this Section 3.21 with respect to those shareholders that own a Material Interest in HH as of the date of this Agreement, so long as such shareholders, or any of their directors or executive employees, are not actively involved in the management of the Business.
3.22    Brokers or Finders. Except as set forth in Part 3.22, none of Sellers nor any of their respective Representatives has incurred any obligation or liability, contingent or otherwise, for brokerage or finders’ fees or agents’ commissions or other similar payments in connection with the sale of the Business or the Assets or the Contemplated Transactions. Sellers shall be fully responsible for all obligations to the parties listed on Part 3.22.
3.23    Solvency.
(a)    Sellers are not now insolvent and will not be rendered insolvent by any of the Contemplated Transactions. As used in this Section, “insolvent” means that the sum

32



of the debts and other probable Liabilities of any Seller exceeds the present fair saleable value of such Seller’s assets.
(b)    Immediately after giving effect to the consummation of the Contemplated Transactions:
(iv)    each Seller will be able to pay its Liabilities as they become due in the usual course of its business;
(v)    each Seller will not have unreasonably small capital with which to conduct its present or proposed business;
(vi)    each Seller will have assets (calculated at fair market value) that exceed its Liabilities; and
(i)    taking into account all pending and threatened litigation, final judgments against any Seller in actions for money damages are not reasonably anticipated to be rendered at a time when, or in amounts such that, such Seller will be unable to satisfy any such judgments promptly in accordance with their terms (taking into account the maximum probable amount of such judgments in any such actions and the earliest reasonable time at which such judgments might be rendered) as well as all other obligations of such Seller.
Upon the Effective Time, after taking into account all other anticipated uses of the cash by such Seller, the cash available to each Seller will be sufficient to pay all of such Seller’s debts and judgments promptly in accordance with their terms.
3.24    Disclosure. Sellers do not have Knowledge of any fact that has specific application to Sellers, taken as a whole, other than general economic or industry conditions, and that would reasonably be expected to constitute a Material Adverse Effect that has not been set forth in this Agreement or the Disclosure Schedule.
ARTICLE 4    
REPRESENTATIONS AND WARRANTIES OF BUYER
Buyer represents and warrants to Sellers as follows:
4.1    Organization and Good Standing. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Kansas, with full corporate power and authority to conduct its business as it is now conducted.
4.2    Authority; No Conflict.
(a)    This Agreement constitutes the legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms. Upon the execution and delivery by Buyer of the Assignment and Assumption Agreement and each other agreement to be executed or delivered by Buyer at Closing (collectively, the “Buyer’s

33



Closing Documents”), each of the Buyer’s Closing Documents will constitute the legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance with its respective terms. Buyer has the absolute and unrestricted right, power and authority to execute and deliver this Agreement and the Buyer’s Closing Documents and to perform its obligations under this Agreement and the Buyer’s Closing Documents, and such action has been duly authorized by all necessary corporate action.
(b)    Neither the execution and delivery of this Agreement by Buyer nor the consummation or performance of any of the Contemplated Transactions by Buyer will give any Person the right to prevent, delay or otherwise interfere with any of the Contemplated Transactions under (i) any provision of Buyer’s Governing Documents; (ii) any resolution adopted by the board of directors or the shareholders of Buyer; (iii) any Legal Requirement or Order to which Buyer may be subject; or (iv) any Contract to which Buyer is a party or by which Buyer may be bound. Buyer is not and will not be required to obtain any Consent from any Person in connection with the execution and delivery of this Agreement or the consummation or performance of any of the Contemplated Transactions.
(c)    Neither the consummation nor the performance of any of the Contemplated Transactions will, directly or indirectly (with or without notice or lapse of time), contravene or conflict with or result in a violation of or cause Buyer to suffer any adverse consequence under (a) any applicable Legal Requirement or Order or (b) any Legal Requirement or Order that has been published, introduced or otherwise proposed by or before any Governmental Body that is applicable to Buyer.
4.3    Certain Proceedings. There is no Proceeding pending or, to Buyer’s Knowledge, threatened against Buyer that challenges, or may have the effect of preventing, delaying, making illegal or otherwise interfering with, any of the Contemplated Transactions. To Buyer’s Knowledge, no event has occurred or circumstances exist that would reasonably be expected to give rise or serve as a basis for any such Proceeding.
4.4    Brokers or Finders. Neither Buyer nor any of its Representatives have incurred any obligation or liability, contingent or otherwise, for brokerage or finders’ fees or agents’ commissions or other similar payment in connection with the Contemplated Transactions.
4.1    Sufficiency of Funds. Buyer has sufficient cash on hand to make payment of the Purchase Price and its ability to fund payment of the Net Cash Consideration is not dependent or contingent upon obtaining any third party financing.
ARTICLE 5    
COVENANTS OF SELLERS BEFORE CLOSING
5.1    Access and Review. Between the date of this Agreement and the Closing Date, and upon reasonable advance notice received from Buyer and subject to Legal Requirements, Sellers shall:

34



(d)    afford Buyer and its Representatives and prospective lenders and their Representatives (collectively, “Buyer Group”) reasonable access, during regular business hours, to Seller personnel, properties, Contracts, Governmental Authorizations, Tangible Personal Property, books and Records and other documents and data, such rights of access to be exercised in a manner that does not unreasonably interfere with the operations of the Business;
(e)    furnish Buyer Group with copies of all such Contracts, Governmental Authorizations, books and Records and other existing documents and data relating to the Business or the Assets that Buyer reasonably requests; and
(f)    furnish Buyer Group with such additional financial, operating and other relevant data and information relating to the Business or the Assets that Buyer reasonably requests; and
(d)    otherwise cooperate and assist, to the extent reasonably requested by Buyer, with Buyer’s review of the Business and the Assets.
All information received from Sellers pursuant to this Section 5.1 shall be deemed to be confidential and shall be held by the Receiving Party in accordance with the terms of the Section 12.1.
5.2    Operation of the Business. Between the date of this Agreement and the Closing, Sellers shall:
(a)    conduct the Business only in the Ordinary Course of Business;
(b)    except as otherwise directed by Buyer in writing, and without making any commitment on Buyer’s behalf, use their respective Best Efforts to preserve intact the current business organization of the Business, keep available the services of the employees and agents of the Business, and maintain their respective relations and good will with suppliers, customers, landlords, creditors, employees, agents and others having relationships with the Business; provided, that notwithstanding the foregoing,
(i)    Sellers may (A) provide any notices required by the WARN Act, and (B) take any other actions, including making such filings and applications or giving such notices, as may be required by Legal Requirements, and
(ii)    any action taken by Sellers pursuant to this Agreement or otherwise as requested in writing by Buyer shall not be a violation hereof.
(c)    confer with Buyer before implementing material operational decisions of a material nature affecting the Business;
(d)    from time to time at Buyer’s reasonable request provide to Buyer information requested by it in writing concerning the status of the Business and the respective operations and finances relating to the Business;

35



(e)    not initiate any changes in the Business’s management personnel without prior consultation with Buyer;
(f)    maintain the Assets in a state of repair and condition that complies in all material respects with Legal Requirements and is consistent with the conduct of the Business by Sellers in the Ordinary Course of Business;
(g)    keep in full force and effect, without amendment, all material rights relating to the Business;
(h)    comply in all material respects with all Legal Requirements and contractual obligations applicable to the operations of the Business;
(i)    continue in full force and effect the insurance coverage existing as of the date of this Agreement other than changes made in the Ordinary Course of Business;
(j)    cooperate with Buyer and assist Buyer in identifying the Governmental Authorizations required by Buyer to operate the Business from and after the Closing Date, and transfer existing required Governmental Authorizations of Sellers to Buyer, where permissible;
(k)    upon request by Buyer from time to time, execute and deliver all documents, request that responsible officers of Sellers testify in any Proceedings and do all other acts that may be reasonably necessary in Buyer’s opinion to consummate the Contemplated Transactions, all without further consideration; and
(l)    maintain all books and Records of Sellers relating to the Business.
5.3    Negative Covenant. Except as otherwise expressly permitted in this Agreement, between the date of this Agreement and the Closing Date, Sellers shall not, without Buyer’s prior written Consent which shall not be withheld unreasonably,
(a)    take any affirmative action, or fail to take any reasonable action within its control, as a result of which any of the changes or events listed in Sections 3.12 or 3.16 would be likely to occur;
(b)    make any material modification to any Material Contract to be assigned to, and assumed by, Buyer under this Agreement;
(c)    allow the levels of raw materials, supplies or other materials included in the Inventories to vary materially from the levels customarily maintained; or
(d)    enter into any compromise or settlement of any litigation, proceeding or governmental investigation relating to the Assets, the Business or the Assumed Liabilities.
5.4    Required Approvals. Sellers shall:

36



(a)    make all filings required by Legal Requirements to be made by any of them in order to consummate the Contemplated Transactions, in each case as promptly as practicable after the date of this Agreement;
(b)    cooperate with Buyer and its Representatives with respect to all filings that Buyer elects to make or, under Legal Requirements, shall be required to make in connection with the Contemplated Transactions; and
(c)    cooperate with Buyer and its Representatives in obtaining all Consents;
provided, however, Sellers shall not be required to expend any material funds or incur any other material burden to comply with this Section 5.4.
5.1    Notification. Between the date of this Agreement and the Closing, each of the parties shall promptly notify the other in writing if any of them becomes aware of:
(g)    any fact or condition that is reasonably likely to cause or constitute a Breach of any of its representations and warranties made as of the date of this Agreement; or
(h)    the occurrence after the date of this Agreement of any fact or condition that would be reasonably likely to (except as expressly contemplated by this Agreement) cause or constitute a Breach of any such representation or warranty had that representation or warranty been made as of the time of the occurrence of, or such party’s discovery of, such fact or condition.
If any such fact or condition requires any change to the Disclosure Schedule, Sellers shall promptly deliver to Buyer a supplement to the Disclosure Schedule specifying such change. Such delivery shall not affect any rights of Buyer under Section 9.1 and Article 11. During the same period, each party also shall promptly notify the other of the occurrence of any Breach of any of its covenants or of the occurrence of any event that may make the satisfaction of the conditions in ARTICLE 7 or ARTICLE 8, as the case may be, impossible or unlikely.
5.2    No Negotiation.
(m)    Sellers shall (and shall cause their respective officers, directors, employees, agents, advisors, Affiliates and other representatives (collectively, the “Seller Representatives”) to) immediately cease and cause to be terminated any discussions, negotiations or encouragements with any Person conducted heretofore with respect to an Acquisition Proposal and shall immediately request to be returned or immediately destroyed all information provided heretofore by or on behalf of Sellers to such Person. Sellers shall not, and shall cause the Seller Representatives not to, directly or indirectly
(i)    initiate, facilitate, solicit, encourage (including, without limitation, by way of furnishing non-public information) or accept any inquiries regarding, or

37



the making of any proposal or offer that constitutes, or could reasonably be expected to result in, an Acquisition Proposal or
(ii)    engage in, continue or otherwise participate in any discussions, communications or negotiations regarding an Acquisition Proposal.
Sellers shall not grant any waiver, amendment or release under any standstill agreement or confidentiality agreement.
(n)    Sellers shall promptly (and in any event within twenty-four (24) hours after receipt by or notification from any Seller Representative) notify Buyer in writing of the receipt (or notification) of any Acquisition Proposal or any inquiries relating to an Acquisition Proposal or any request for information from, or any negotiations sought to be initiated or continued with, either Sellers or the Seller Representatives concerning an Acquisition Proposal. Sellers’ notice shall include
(i)    a copy of any written Acquisition Proposal and any other documents provided to Sellers with respect to such Acquisition Proposal, or
(ii)    in respect of any Acquisition Proposal, any inquiry relating to an Acquisition Proposal or any request for information relating to an Acquisition Proposal not made in writing, a written summary of the material terms of such Acquisition Proposal, inquiry or request, including the identity of the Person or group of Persons making the Acquisition Proposal, inquiry or request.
Sellers shall keep Buyer informed on a current basis of the status, discussions, negotiations, or developments regarding any Acquisition Proposal, inquiry or request.
(a)    Sellers shall notify Buyer in writing within one (1) Business Day of receipt of any of the following:
(i)    any written indication by any Person that could reasonably be expected to result in an Acquisition Proposal,
(ii)    any request for non-public information relating to Sellers, and
(iii)    any inquiry or request for discussions or negotiations regarding an Acquisition Proposal.
Sellers shall not, after the date of this Agreement, enter into any agreement that would prohibit them from providing such information to Buyer.
(b)    Notwithstanding anything to the contrary in Section 5.6(a), if Sellers or any of their Subsidiaries or any Seller Representative receives an Acquisition Proposal from any Person whom the HH board of directors believes in good faith to be bona fide, and Sellers have not breached any of their obligations under this Section 5.6,

38



(i)    Sellers may contact and engage in discussions with such Person solely for the purpose of clarifying such Acquisition Proposal and any material terms and conditions thereof so as to determine whether such Acquisition Proposal is, or could reasonably be expected to result in, a Superior Proposal so long as Sellers have informed such Person of the provisions of this Agreement; and
(ii)    If the HH board of directors determines in good faith (after consultation with its independent financial advisor and outside legal counsel) that failure to take such action would be inconsistent with the directors’ fiduciary duties under applicable law and that such Acquisition Proposal constitutes, or is reasonably expected to result in, a Superior Proposal, then Sellers and Seller Representatives may
(A)    furnish, pursuant to a confidentiality agreement similar to that entered into with Buyer (with respect to the confidentiality provisions contained therein), information with respect to Sellers and the Business to the Person making such Acquisition Proposal; provided that Sellers shall promptly (but not later than 24 hours) provide to Buyer any information concerning Sellers or the Business that is provided to any Person given such access which was not previously provided to Buyer or its representatives, and
(B)    participate in discussions or negotiations regarding such Acquisition Proposal.
(c)    Neither the HH board of directors nor any committee thereof shall
(i)    approve or recommend, or publicly propose to approve or recommend, to shareholders of HH any Acquisition Proposal,
(ii)    approve, authorize or permit or allow Sellers to enter into any letter of intent, asset purchase agreement, merger or acquisition agreement, share purchase agreement, share exchange agreement, option agreement or any other agreement, arrangement or understanding with respect to any Acquisition Proposal (other than an acceptable confidentiality agreement permitted under Section 5.6(b)),
(iii)    enter into any agreement, arrangement or understanding in principle requiring Sellers to abandon, terminate or fail to consummate the Contemplated Transactions or breach any of their respective obligations under this Agreement or
(iv)    resolve, propose (whether or not to a third party) or agree to take any of the foregoing actions set forth in clauses (i), (ii) or (iii)

39



(each of the items described in clauses (i) through (iv) inclusive being referred to herein as a “Seller Adverse Recommendation Change”); provided, however, if the HH board of directors determines in good faith, after consultation with outside legal counsel and its independent financial advisor, that a written Acquisition Proposal received by Sellers in compliance with Section 5.6(b) (which has not been withdrawn) constitutes a Superior Proposal, the HH board of directors may, only after termination of this Agreement in accordance with Section 9.1(g) and payment of all amounts due pursuant to Section 9.3(a), approve and enter into an agreement relating to a Superior Proposal, subject to the satisfaction of the following further conditions precedent:
(A)    Sellers shall have provided prior written notice to Buyer, at least five (5) Business Days in advance of the HH board of directors’ final determination whether to take such actions, which notice shall specify the reasons therefor and the material terms of the Acquisition Proposal received by Sellers that constitutes a Superior Proposal, including a copy of the relevant proposed transaction agreements and other material documents with, and the identity of, the Person(s) making the Acquisition Proposal;
(B)    after providing such notice and prior to taking such actions, Sellers shall, and shall cause Seller Representatives to, negotiate with Buyer in good faith (unless Buyer states in writing that it does not desire to negotiate) during such five (5) Business Day period to make such adjustments in the terms and conditions of this Agreement that Buyer may desire to make, if any, so that such Acquisition Proposal would cease to constitute a Superior Proposal;
(C)    Buyer and its financial and legal advisors shall be permitted to make a presentation to the HH board of directors regarding this Agreement and any adjustments thereto (to the extent Buyer desires to make such a presentation); and
(D)    the HH board of directors shall have considered in good faith any changes to this Agreement that may be offered in writing by Buyer by 11:59 PM Eastern Time on the fifth Business Day of such five (5) Business Day period in a manner that could form a binding contract (including the complete form of definitive acquisition agreement executed by Buyer) and shall have determined in good faith after consultation with outside legal counsel and independent financial advisors that the Acquisition Proposal received by Sellers has not been withdrawn and continues to constitute a Superior Proposal if such changes offered in writing by Buyer were given effect.
In the event of any material revisions to the Superior Proposal (it being agreed that material revisions shall include any change in the purchase price, form of consideration, transaction timing, transaction financing or transaction structure for such

40



Superior Proposal), Sellers shall be required to deliver a new written notice to Buyer pursuant to the foregoing clause (A) and to comply again with the requirements of this Section 5.6(e) with respect to such new written notice.
(d)    Nothing contained in this Agreement shall prohibit the HH board of directors from
(i)    taking and disclosing to the HH shareholders a position with respect to a tender or exchange offer by a Third Party pursuant to Rules 14d-9 and 14e-2(a) promulgated under the Exchange Act, or
(ii)    disclosing the fact that the HH board of directors has received an Acquisition Proposal if the HH board of directors determines after consultation with its outside legal counsel that failure to take such actions would be inconsistent with its fiduciary duties under applicable Law (provided, however, that any such disclosures set forth in clauses (i) and (ii) of this Section 5.6(f) (other than a factually accurate “stop, look and listen” communication contemplated by Rule 14d-9(f) under the Exchange Act) shall be deemed to constitute a “Seller Adverse Recommendation Change” for purposes of this Agreement (including for purposes of Section 9.1(h)) unless the HH board of directors expressly publicly reaffirms its Seller Board Recommendation within three (3) Business Days after a written request by Buyer to do so (provided, that if such written notice is delivered to the Sellers less than three (3) Business Days prior to the meeting of the HH shareholders, the HH board of directors shall so re-affirm its Seller Board Recommendation at least one (1) Business Day prior to the meeting of the HH shareholders.
In no event shall the HH board of directors recommend that Sellers’ shareholders tender their shares in connection with any tender or exchange offer (or otherwise approve or recommend any Acquisition Proposal), which, for purposes of clarity, shall be deemed to be a Seller Adverse Recommendation Change for all purposes under this Agreement.
(e)    As used in this Agreement, “Acquisition Proposal” shall mean any proposal or offer from any Person or group (as defined under Section 13(d) of the Exchange Act) (other than Buyer) relating to, in a single transaction or series of related transactions, and whether or not pursuant to a bankruptcy or similar proceeding, any
(i)    acquisition of any assets or properties used or held for use in the Business (including, without limitation, the Assets),
(ii)    acquisition of all or substantially all of the assets of Sellers,
(iii)    acquisition of twenty-five percent (25%) or more of any class of capital stock or other equity securities of HH,

41



(iv)    tender offer or exchange offer that, if consummated, would result in any Person or group beneficially owning twenty-five percent (25%) or more of any class of capital stock or other equity securities of HH, or
(v)    merger, consolidation, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving HH.
(f)    As used in this Agreement, a “Superior Proposal” means any bona fide written Acquisition Proposal that
(i)    is on terms that the HH board of directors determines in good faith (after consultation with outside legal counsel and independent financial advisors) are more beneficial and favorable to HH shareholders from a financial point of view, taking into account all of the legal, financial (including the financing terms of such proposal), regulatory and other aspects of such Acquisition Proposal (including the likelihood and timing of consummation thereof) and this Agreement (including any changes in the terms of this Agreement committed to by Buyer to Sellers in writing in response to such Acquisition Proposal or otherwise), and
(ii)    the HH board of directors has determined in its good faith judgment (after consultation with outside legal counsel and independent financial advisor and after taking into account all legal, financial (including the financing terms of such proposal), regulatory and other aspects of the proposal) is reasonably likely to be consummated (if accepted by Sellers), except that
(A)    the references to “twenty-five percent (25%)” in the definition of “Acquisition Proposal” shall be deemed to be references to “fifty percent (50%)” and
(B)    a “Superior Proposal” shall not include any acquisition consisting (whether in one step or a series of related steps) primarily of the assets or properties used or held for use in the Business; it being the parties’ intent that a Superior Proposal shall be limited to an Acquisition Proposal the ultimate purpose and intent of which is to purchase and sell all or substantially all of the assets and businesses of HH (whether through the acquisition of equity, assets, a merger, consolidation or otherwise).
(g)    If any “fair price,” “moratorium,” “control share acquisition” or other similar anti-takeover Law is or may become applicable to the transactions contemplated by this Agreement, the Sellers and the HH board of directors shall grant such approvals and take such actions as are necessary so that the transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such statute or regulation on such transactions.

42



5.3    Best Efforts. Sellers shall use their Best Efforts to cause the conditions in ARTICLE 7 and Section 8.3 to be satisfied.
5.1    Interim Financial Statements. Until the Closing Date, Sellers shall deliver to Buyer within twenty (20) Business Days after the end of each month a copy of the type of financial reports described in Section 3.3(b) and Section 3.3(c) for such month (and as of the end of such month) prepared in a manner and containing information consistent with Sellers’ current practices. All of such financial reports, when delivered, shall constitute “Financial Statements” for purposes of this Agreement.
5.2    Change of Name. On or before the Closing Date, HLI shall amend its Governing Documents and take all other actions necessary to change its name to a name that is sufficiently dissimilar to its present name, in Buyer’s judgment, to avoid confusion.
5.3    Payment of Liabilities. Sellers shall pay or otherwise satisfy in the Ordinary Course of Business all of their respective Liabilities and obligations.
5.4    Transitional Services Agreement. Subject to Buyer’s notice under Section 6.3, as promptly as practicable after the date hereof, Sellers shall execute and deliver to Buyer a Transitional Services Agreement (the “TSA”) in form and substance mutually acceptable to the parties, under which Sellers shall provide certain transitional services to Buyer in connection with the conveyance of the Business to Buyer and services at the Lenexa location if Buyer cannot obtain a Lenexa sublease as contemplated under Section 5.12.
5.1    Lenexa Sublease. As promptly as practicable after the date hereof, Sellers shall cooperate with and assist Buyer in approaching the landlord and current sub-tenant with respect to Seller’s Lenexa, Kansas location in connection with Buyer’s desire to enter into a sublease or other arrangement with respect to the use of such premises by Buyer.
5.2    Omaha Facility. As promptly as practicable after the date hereof, Sellers shall cooperate with and assist Buyer in approaching the landlord with respect to Seller’s Omaha, Nebraska location in connection with Buyer’s desire to enter into a lease or other arrangement with respect to the use of such premises by Buyer.
5.3    Administrative Services SOW. HH shall negotiate in good faith with Buyer, and use its Best Efforts, to develop, execute and deliver to Buyer a Statement of Work under the LLASA concerning the administrative services to be provided thereunder (the “SOW”).
5.4    License Agreement. HLI shall execute and deliver to Buyer at the Closing a License Agreement in the form attached hereto as Exhibit 5.15 (the “License Agreement”) concerning HLI’s Laboratory Information Management System and related databases and materials.

43



ARTICLE 1    
COVENANTS OF BUYER BEFORE CLOSING
1.1    Required Approvals. As promptly as practicable after the date of this Agreement, Buyer shall make, or cause to be made, all filings required by Legal Requirements to be made by it to consummate the Contemplated Transactions. Buyer also shall cooperate with Sellers (a) with respect to all filings Sellers are required by Legal Requirements to make with respect to the Contemplated Transactions and (b) in obtaining all Consents identified in Part 3.2(c), provided, however, that Buyer shall not be required to dispose of or make any change to its business, expend any material funds or incur any other burden in order to comply with this Section 6.1.
1.2    Best Efforts. Buyer shall use its Best Efforts to cause the conditions in ARTICLE 8 to be satisfied.
1.3    Transitional Services Agreement. As promptly as practicable after the date hereof, Buyer shall cooperate with Sellers and use its Best Efforts to enter into the TSA, unless Buyer has notified Sellers on or before the Closing that it does not desire a TSA.
1.4    Administrative Services SOW. Buyer shall negotiate in good faith with HH, and use its Best Efforts, to develop, execute and deliver to HH the SOW.
1.5    License Agreement. Buyer shall execute and deliver to HLI at the Closing the License Agreement.
ARTICLE 2    
CONDITIONS PRECEDENT TO BUYER’S OBLIGATION TO CLOSE
Buyer’s obligation to purchase the Assets and to take the other actions required to be taken by Buyer at the Closing is subject to the satisfaction, at or before the Closing, of each of the following conditions (any of which may be waived by Buyer, in whole or in part):
2.1    Accuracy of Representations and Warranties. All of Sellers’ representations and warranties in this Agreement (considered collectively), and each of such representations and warranties (considered individually), shall have been accurate in all material respects as of the date of this Agreement, and shall be accurate in all material respects as of the time of the Closing as if then made, after giving effect to any mutually agreed upon (in writing) supplement to the Disclosure Schedule and disregarding any materiality qualifier thereto (except for representations and warranties that expressly speak as of a specific date, in which case which representations and warranties shall be true and correct as of such other specific date).
2.2    Sellers’ Performance. All of the covenants and obligations that Sellers are required to perform or to comply with under this Agreement at or before the Closing (considered collectively), and each of these covenants and obligations (considered individually), shall have been duly performed and complied with in all material respects.

44



2.1    Additional Documents. Sellers shall have caused the documents and instruments required by Section 2.7(a) and the following documents to be delivered to Buyer:
(a)    If requested by Buyer, any Consents or other instruments that may be required from Sellers to permit Buyer’s qualification in each jurisdiction in which each Seller is licensed or qualified to do business as a foreign corporation under the name “Heritage Laboratory” or “Heritage Labs” or any derivative thereof;
(b)    Releases of all Encumbrances on the Assets;
(c)    Certificates dated as of a date not earlier than the third business day before the Closing as to the good standing of each Seller executed by the appropriate officials of the States of Kansas, Nebraska, New Jersey and New York; and
(d)    Such other documents as Buyer may reasonably request for the purpose of (i) evidencing the accuracy of any of Sellers’ representations and warranties; (ii) evidencing the performance by Sellers of, or the compliance by Sellers with, any covenant or obligation required to be performed or complied with by Sellers; (iii) evidencing the satisfaction of any condition referred to in this ARTICLE 7; or (iv) otherwise facilitating the consummation or performance of any of the Contemplated Transactions.
2.2    No Proceedings. Since the date of this Agreement, there shall not have been commenced or threatened against Buyer any Proceeding (a) involving any challenge to, or seeking Damages or other relief in connection with, any of the Contemplated Transactions or (b) that may have the effect of preventing, delaying, making illegal, imposing limitations or conditions on or otherwise interfering with any of the Contemplated Transactions.
2.3    No Injunction. There shall not be in effect any injunction or other Order that (a) prohibits the consummation of the Contemplated Transactions and (b) has been adopted or issued or has become effective since the date of the Agreement and related to the Business.
2.4    No Conflict. Neither the consummation nor the performance of any of the Contemplated Transactions will, directly or indirectly (with or without notice or lapse of time), contravene or conflict with or result in a violation of or cause Buyer to suffer any adverse consequence under (a) any applicable Legal Requirement or Order or (b) any Legal Requirement or Order that has been published, introduced or otherwise proposed by or before any Governmental Body.
2.5    Limited Laboratory and Administrative Services Agreement. Buyer and HH shall have entered into a Limited Laboratory and Administrative Services Agreement in substantially the form of Exhibit 7.7 hereto (the “LLASA”), under which Buyer shall provide to HH certain wellness testing, other laboratory services and administrative services.

45



2.6    WARN Act. All requisite notice periods under the WARN Act shall have expired, if and to the extent the WARN Act is applicable in connection with the Contemplated Transactions.
ARTICLE 3    
CONDITIONS PRECEDENT TO SELLERS’ OBLIGATION TO CLOSE
Sellers’ obligations to sell the Assets and to take the other actions required to be taken by Sellers at the Closing is subject to the satisfaction, at or before the Closing, of each of the following conditions (any of which may be waived by Sellers in whole or in part):
3.1    Accuracy of Representations and Warranties. All of Buyer’s representations and warranties in this Agreement (considered collectively), and each of these representations and warranties (considered individually), shall have been accurate in all material respects as of the date of this Agreement and shall be accurate in all material respects as of the time of the Closing as if then made (except for representations and warranties that expressly speak as of a specific date, in which case which representations and warranties shall be true and correct as of such other specific date).
3.2    Buyer’s Performance. All of the covenants and obligations that Buyer is required to perform or to comply with under this Agreement at or before the Closing (considered collectively), and each of these covenants and obligations (considered individually), shall have been performed and complied with in all material respects.
3.3    Consents. Each of the Consents identified in Exhibit 8.3 shall have been obtained and shall be in full force and effect.
3.4    No Injunction. There shall not be in effect any Legal Requirement or any injunction or other Order that (a) prohibits the consummation of the Contemplated Transactions and (b) has been adopted or issued, or has otherwise become effective, since the date of this Agreement.
3.5    Limited Laboratory Services Agreement. Buyer and HH shall have entered into the LLASA.
ARTICLE 4    
TERMINATION
4.1    Termination Events. By notice given before or at the Closing, subject to Section 9.2, this Agreement may be terminated as follows:
(a)    by Buyer if a material Breach of any provision of this Agreement has been committed by any Seller, which has not been waived by Buyer, and such Breach would reasonably be expected to cause any of the conditions to set forth in ARTICLE 7 not to be satisfied by the End Date and such Breach is not cured prior to the earlier of (A) the Business Day immediately preceding the End Date or (B) within fifteen (15) days after

46



written notice of such Breach has been given by Buyer to the Sellers; provided, however that Buyer is not then in material breach of this Agreement;
(b)    by Sellers if a material Breach of any provision of this Agreement has been committed by Buyer, which has not been waived by Sellers, and such Breach would reasonably be expected to cause any of the conditions set forth in ARTICLE 8 not to be satisfied by the End Date and such Breach is not cured prior to the earlier of (A) the Business Day immediately preceding the End Date or (B) within fifteen (15) days after written notice of such Breach has been given to Buyer; provided that Sellers are not then in material breach of this Agreement;
(c)    by Buyer if any condition in ARTICLE 7 has not been satisfied as of the date specified for Closing in the first sentence of Section 2.6 or if satisfaction of such a condition by such date is or becomes impossible (other than through the failure of Buyer to comply with its obligations under this Agreement), and Buyer has not waived such condition on or before such date;
(d)    by Sellers if any condition in ARTICLE 8 has not been satisfied as of the date specified for Closing in the first sentence of Section 2.6 or if satisfaction of such a condition by such date is or becomes impossible (other than through the failure of any Seller to comply with its obligations under this Agreement), and Sellers have not waived such condition on or before such date;
(e)    by mutual written consent of Buyer and Sellers;
(f)    by either Buyer or Seller if the Closing has not occurred on or before September 30, 2014 (the “End Date”), or such later date as the parties may agree upon, provided that such termination right shall not be available to any party whose breach of any provisions of this Agreement results in the failure of the Contemplated Transactions to be consummated by the End Date;
(g)    by Sellers if the HH board of directors authorizes HH (or the Sellers or any of them) to enter into a binding definitive agreement in respect of a Superior Proposal, subject to Sellers complying with the terms of Section 5.6 and Section 9.3; or
(h)    by Buyer if
(iii)    there shall have occurred any Seller Adverse Recommendation Change,
(iv)    a tender offer or exchange offer for shares of capital stock of any Seller that constitutes an Acquisition Proposal is commenced prior to the Closing and the HH board of directors fails to recommend against acceptance of such tender offer or exchange offer by the Sellers’ shareholders (including, for these purposes, by taking no position with respect to the acceptance of such tender offer or exchange offer by the shareholders, which shall constitute a failure to

47



recommend against acceptance of such tender offer or exchange offer) within three (3) Business Days after commencement,
(v)    Sellers breach their obligations in Section 5.6, or
(vi)    Sellers publicly announce their intention to do any of the foregoing.
4.2    Effect of Termination. Each party’s right of termination under Section 9.1 is in addition to any other rights it may have under this Agreement or otherwise, and the exercise of such right of termination will not be an election of remedies. If this Agreement is terminated under Section 9.1, all obligations of the parties under this Agreement will terminate, except that the obligations of the parties in this Section 9.2 and ARTICLE 12 and ARTICLE 13 (except for those in Section 13.5) will survive, provided, however, that, if this Agreement is terminated because of a Breach of this Agreement by the nonterminating party or because one or more of the conditions to the terminating party’s obligations under this Agreement is not satisfied as a result of the party’s failure to comply with its obligations under this Agreement, the terminating party’s right to pursue all legal remedies will survive such termination unimpaired.
4.3    Termination Fee; Expenses. Notwithstanding any other provisions of this Agreement,
(h)    if this Agreement is terminated by Sellers pursuant to Section 9.1(g), Sellers shall, concurrently with such termination, pay to Buyer (i) a fee of $250,000 (the “Termination Fee”) and (ii) an amount equal to the Buyer Expenses, in each case, by wire transfer of immediately available funds to an account designated in writing by Buyer;
(i)    if this Agreement is terminated by Buyer pursuant to Section 9.1(h), Sellers shall immediately pay to Buyer (i) the Termination Fee and (ii) an amount equal to the Buyer Expenses, in each case, by wire transfer of immediately available funds to an account designated in writing by Buyer; and
(j)    if (i) this Agreement is terminated pursuant to any provision of this Agreement (other than Sections 9.1(b), 9.1(g) or 9.1(h)) and (ii) within 12 months after the date of such termination Sellers enter into or consummate a definitive agreement with respect to any Acquisition Proposal, then within one (1) Business Day after entering into such definitive agreement, Sellers shall pay to Buyer the Termination Fee and an amount equal to the Buyer Expenses, in each case, by wire transfer of immediately available funds to an account designated in writing by Buyer.
For purposes of this Agreement, “Buyer Expenses” means all out-of-pocket costs and expenses incurred by or on behalf of Buyer in connection with entering into and performing under this Agreement and the Transactions (including, without limitation, all fees and expenses of counsel, accountants, experts and consultants) and expressly including the costs and expenses of enforcing Buyer’s rights hereunder.

48



ARTICLE 5    
ADDITIONAL COVENANTS
5.1    Employees and Employee Benefits.
(a)    Definitions. For the purpose of this Agreement,
(i)    Active Employees” mean all employees employed on the Closing Date by any Seller and working in the Business as currently conducted, including employees on temporary leave of absence, including family medical leave, military leave, temporary disability or sick leave, but excluding employees on long-term disability leave; and
(ii)    Hired Active Employees” means Active Employees who accept employment with the Buyer or any of its affiliates effective as of the Closing.
(b)    Employment of Active Employees by Buyer.
(iv)    Buyer is not obligated to hire any Active Employee but may interview all Active Employees in its discretion. Buyer, by no later than five (5) Business Days prior to the Closing, shall provide to Sellers a list of Active Employees to whom Buyer has made an offer of employment that has been accepted to be effective on the Closing Date. Subject to Legal Requirements, Sellers shall provide to Buyer reasonable access to Sellers’ facilities, personnel Records and Active Employees during normal business hours (including, but not limited to, performance appraisals, disciplinary actions, grievances and similar documentation) for the purpose of preparing for and conducting employment interviews with all Active Employees. Buyer shall conduct such interviews as expeditiously as possible before the Closing Date.
(v)    Effective immediately before the Closing, Sellers shall terminate the employment of all Hired Active Employees. No officer, manager, executive or other salaried personnel of any Seller or their Related Persons shall offer continued employment to any Active Employee unless and until Buyer has informed Sellers in writing, not later than 3 Business Days before the Closing Date, that the particular Active Employee will not receive any employment offer from Buyer.
(iii)    Buyer’s expressed intention to extend offers of employment as set forth in this Section shall not constitute any commitment, Contract or understanding (express or implied) of any obligation on the part of Buyer to a post-Closing employment relationship of any fixed term or duration or upon any terms or conditions other than those that Buyer establishes under individual offers of employment. Employment offered by Buyer is “at will” and may be terminated by Buyer or by an employee at any time for any reason (subject to any written commitments to the contrary made by Buyer or an employee and Legal

49



Requirements). Nothing in this Agreement shall be deemed to prevent or restrict in any way the right of Buyer to terminate, reassign, promote or demote any of the Hired Active Employees after the Closing or to change adversely or favorably the title, powers, duties, responsibilities, functions, locations, salaries, other compensation or terms or conditions of employment of such employees.
(c)    Salaries and Benefits.
(iii)    Sellers shall be solely responsible for (A) the payment of all wages and other remuneration due to Active Employees with respect to their services as employees of Seller through the Effective Time, including pro rata bonus payments and all vacation pay earned before the Effective Time; (B) the payment of any termination or severance payments, and (C) all payments to employees required under the WARN Act.
(iv)    Sellers shall be solely responsible for, and shall retain all liability for claims incurred under, all of the Employee Plans, including (A) any Employee Plans that are welfare benefit plans, regardless of whether claims under such plans have been reported to Sellers before, on or after the Closing Date, and (B) any Employee Plans, programs or arrangements that pay retirement, bonus, severance, change-in-control or similar payments.
(v)    Sellers shall retain all responsibility and liability for all health care continuation coverage and notice requirements under Section 4980B of the Code and Part 6 of Subtitle B of Title I of ERISA (“COBRA”) arising before, on or after the Closing Date with respect to any Employee Plan, including with respect to all Hired Active Employees and all Active Employees who do not receive an offer of employment or who decline an offer of employment from Buyer. Sellers shall maintain such Employee Plan for so long as is necessary for Sellers to satisfy their respective obligations under this paragraph. Sellers shall prevent all actions and omissions to act that would directly or indirectly give rise to any liability or other obligation on the part of Buyer (or any group health plan of Buyer) as a “successor employer” under COBRA or other applicable law or in connection with any Employee Plan.
(iv)    All liabilities, obligations and claims arising before, on or after the Closing Date under or in connection with all Employee Plans and all other “employee benefit plans” (as defined in Section 3(3) of ERISA), “multiemployer plans” (as defined in Section 3(37) or 4001(a)(3) of ERISA), profit sharing, deferred compensation, retirement, bonus, equity compensation, vacation, welfare benefit, severance, change-in-control, scholarship or incentive benefit plans, programs, agreements and arrangements, written or unwritten, established, maintained or contributed to by any Seller or any ERISA Affiliate shall be the sole and complete responsibility of such Seller and its ERISA Affiliates and neither Buyer nor the Business shall have any responsibility for any such Liabilities, obligations and claims.

50



(d)    Employment Terms. Buyer shall, in its sole discretion, set its own initial terms and conditions of employment for the Hired Active Employees and others it may hire, including work rules, benefits and salary and wage structure. Sellers shall be solely liable for any severance payment required to be made to Active Employees due to the Contemplated Transactions.
(e)    General Employee Provisions.
(i)    Sellers shall give any notices required by Legal Requirements and take whatever other actions with respect to the plans, programs and policies described in this Section 10.1 as may be necessary to carry out the arrangements described in this Section 10.1.
(vi)    Sellers shall provide Buyer with completed I-9 forms and attachments with respect to all Hired Active Employees, except for such employees as Sellers certify in writing to Buyer are exempt from such requirement.
(vii)    Buyer shall not have any responsibility, liability or obligation, whether to Active Employees, former employees, their beneficiaries or to any other Person, with respect to any employee benefit plans, practices, programs or arrangements (including the establishment, operation or termination thereof and the notification and provision of COBRA coverage extension) maintained by any of Seller.
5.2    Payment of Taxes Owed from Sale of Assets by Seller. Sellers shall pay in a timely manner all Taxes owed from or payable in connection with the sale of the Assets under this Agreement, regardless of the Person on whom such Taxes are imposed by Legal Requirements.
5.3    Payment of other Retained Liabilities. In addition to payment of Taxes under Section 10.2, Sellers shall pay, or make adequate provision for the payment, in full all of the Retained Liabilities and other Liabilities of Sellers under this Agreement. If Buyer reasonably determines that failure to make any such payments will impair materially Buyer’s use or enjoyment of the Assets or conduct of the Business previously conducted by Sellers with the Assets, Buyer may, at any time after the Closing Date, after not less than twenty (20) Business Days’ notice to Sellers of its intent to do so, elect to make all such payments directly (but shall have no obligation to do so) and thereafter recover the full amount of all such payments from Sellers without setoff or delay.
5.4    Reports and Returns.
(a)    Sellers shall promptly after the Closing prepare and file all reports and returns required by Legal Requirements relating to the Business, to and including the Effective Time.

51



(b)    Sellers and Buyer shall provide each other with such cooperation and information as each of them may reasonably request in preparing and filing any Tax
Return, amended Tax Return or claim for refund, determining or contesting a liability for Taxes or a right to a refund of Taxes, participating in or conducting any audit or other proceeding in respect of Taxes. Such cooperation and information shall include providing copies of relevant Tax Returns or portions thereof, together with accompanying schedules, related work papers and documents relating to rulings or other determinations by Tax authorities. Sellers and Buyer shall make their respective officers, employees, agents and representatives available on a basis mutually convenient to Buyer or Sellers, as the case may be, to provide explanations of any documents or information provided hereunder. Sellers and Buyer shall each retain all Tax Returns, schedules and work papers, records and other documents in its possession relating to Tax matters of the Assets for each taxable period first ending after the Closing Date and for all prior taxable periods until the later of
(iii)    the expiration of the statute of limitations of the taxable periods to which such Tax Returns and other documents relate, without regard to extensions except to the extent notified by the other Party in writing of such extensions for the respective Tax periods, or
(iv)    six (6) years following the due date (without extension) for filing such Tax Returns.
5.5    Assistance in Proceedings. Sellers will cooperate with Buyer, and Buyer will cooperate with Sellers, and their respective counsel in the contest or defense of, and make available its personnel and provide any testimony and access to their respective books and Records in connection with, any Proceeding involving or relating to (a) any Contemplated Transaction or (b) any action, activity, circumstance, condition, conduct, event, fact, failure to act, incident, occurrence, plan, practice, situation, status or transaction on or before the Closing Date involving Sellers, the Business or any of the Assets.
5.6    Noncompetition, Nonsolicitation and Nondisparagement.
(a)    Noncompetition. For a period of five (5) years after the Closing Date (the “Restricted Period”), Sellers shall not, anywhere in the United States of America, directly or indirectly (i) invest in, own, manage, operate, finance or control any Competing Business, or (ii) advise, render services to or guarantee the obligations of, or, without Buyer’s Consent, sublease Sellers’ existing Olathe premises to, any Person engaged in or, to Sellers’ Knowledge, planning to become engaged in any Competing Business, provided, however, that Sellers may collectively purchase or otherwise acquire up to (but not more than) an aggregate of one percent (1%) of any class of the securities of any Person (but may not otherwise participate in the activities of such Person) if such securities are listed on any national or regional securities exchange or have been registered under Section 12(g) of the Exchange Act. Notwithstanding the foregoing, if the LLASA is terminated for Good Reason before the expiration of such five (5) year period, this Section 10.6(a) shall not prohibit Sellers from thereafter owning and

52



operating a laboratory solely for the purpose of wellness testing for their own account in support of H&W services provided by Seller.
(b)    Nonsolicitation. During the Restricted Period, Sellers shall not, directly or indirectly:
(vii)    solicit the business of any Person who is a customer of Buyer for the provision of goods or services substantially similar to, or in competition with, the goods and services now offered through the Business by Sellers;
(viii)    cause, induce or attempt to cause or induce any customer, supplier, licensee, licensor, franchisee, employee, consultant or other business relation of Buyer to cease doing business with Buyer, to deal with any competitor of Buyer or in any way interfere with its relationship with Buyer;
(ix)    cause, induce or attempt to cause or induce any customer, supplier, licensee, licensor, franchisee, employee, consultant or other business relation of any Seller on the Closing Date or within the year preceding the Closing Date to cease doing business with Buyer, to deal with any competitor of Buyer or in any way interfere with its relationship with Buyer; or
(x)    hire, retain or attempt to hire or retain any employee of Buyer or in any way interfere with the relationship between Buyer and any of its employees; provided, that this clause (iv) shall not (x) apply to any employee whose employment has been terminated with Buyer after a period of 180 days following such termination and (y) prohibit any Seller from engaging in general solicitation efforts not targeted towards any employee of Buyer.
For the avoidance of doubt, Buyer acknowledges and agrees that the mere ownership, management, control and operation of the Other Businesses, as presently constituted, managed, controlled and operated, shall not be a violation of the covenants contained in Section 10.6(a) and Section 10.6(b).
(c)    Modification of Covenant. If a final judgment of a court or tribunal of competent jurisdiction determines that any term or provision contained in Section 10.6(a) or (b) is invalid or unenforceable, then the court or tribunal shall have the power to reduce the scope, duration or geographic area of the term or provision, to delete specific words or phrases or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision. This Section 10.6 will be enforceable as so modified after the expiration of the time within which the judgment may be appealed. This Section 10.6 is reasonable and necessary to protect and preserve Buyer’s legitimate business interests and the value of the Business and the Assets and to prevent any unfair advantage conferred on any Seller.

53



5.7    Customer and Other Business Relationships. After the Closing, Sellers shall (a) reasonably cooperate with Buyer, at Buyer’s expense, in its efforts to continue and maintain for Buyer’s benefit those business relationships of Sellers existing before the Closing and relating to the Business, including relationships with lessors, employees, regulatory authorities, licensors, customers, suppliers and others, (b) satisfy the Retained Liabilities in a manner that is not materially detrimental to any of such relationships (provided that nothing herein contained shall, in any way, limit the right or ability of Sellers to contest, deny, negotiate or compromise the amount of any such Retained Liability), (c) refer to Buyer all inquiries relating to the Business, and (d) not take any action that would tend to diminish the value of the Assets or the Business, including disparaging the name or business of Buyer.
5.8    Retention of and Access to Records. After the Closing Date, Buyer shall retain for not less than seven (7) years Records of Sellers delivered to Buyer. Buyer also shall provide Sellers reasonable access thereto, during normal business hours and on at least three days’ prior written notice, to enable them to prepare financial statements or tax returns or deal with tax audits. After the Closing Date, Sellers shall provide Buyer and its Representatives reasonable access to Records that are Excluded Assets, during normal business hours and on at least three days’ prior written notice, for any reasonable business purpose specified by Buyer in such notice.
5.9    Remittance of Payments Received. If Sellers receive any payment belonging to Buyer pursuant to this Agreement, Sellers promptly shall notify Buyer in writing and remit (and cause to be remitted) such payment to Buyer. If Buyer receives any payment belonging to any Seller pursuant to this Agreement, Buyer promptly shall notify Sellers in writing and remit (and cause to be remitted) such payment to Sellers.
5.1    Use of Name. Except as permitted under the TSA, neither Buyer nor any of its Affiliates shall use the “Hooper Holmes” trademark or tradename, including, without limitation, in any websites, materials, corporate names or elsewhere.
5.2    Further Assurances. Subject to the proviso in Section 6.1, the parties shall cooperate reasonably with each other in connection with any steps required to be taken as part of their respective obligations under this Agreement, and shall: (a) furnish upon request to each other such further information; (b) execute and deliver to each other such other documents; and (c) do such other acts and things, all as the other party may reasonably request for the purpose of carrying out the intent of this Agreement and the Contemplated Transactions.
ARTICLE 6    
INDEMNIFICATION; REMEDIES
6.1    Survival. All representations, warranties, covenants and obligations in this Agreement, the Disclosure Schedule, the supplements to the Disclosure Schedule, the certificates delivered under Section 2.7 and any other certificate or document delivered under this Agreement shall survive the Closing and the consummation of the Contemplated Transactions, subject to Section 11.4. The right to indemnification, reimbursement or other remedy based upon such representations, warranties, covenants and obligations shall not be affected by any investigation (including any environmental investigation or assessment) conducted with respect

54



to, or any Knowledge acquired (or capable of being acquired) at any time, whether before or after the execution and delivery of this Agreement or the Closing Date, with respect to the accuracy or inaccuracy of or compliance with any such representation, warranty, covenant or obligation. The waiver of any condition based upon the accuracy of any representation or warranty, or on the performance of or compliance with any covenant or obligation, will not affect the right to indemnification, reimbursement or other remedy based upon such representations, warranties, covenants and obligations.
6.2    Indemnification and Reimbursement by Sellers. Sellers, jointly and severally, shall indemnify and hold harmless Buyer, and its Representatives, shareholders, subsidiaries and Related Persons (collectively, the “Buyer Indemnified Persons”), and will reimburse the Buyer Indemnified Persons for any loss, liability, claim, damage, expense (including costs of investigation and defense and reasonable attorneys’ fees and expenses) or diminution of value, whether or not involving a Third-Party Claim (collectively, “Damages”), arising from or in connection with:
(a)    any Breach of any representation or warranty made by any Seller in (i) this Agreement (after giving effect to any mutually agreed upon (in writing) supplement to the Disclosure Schedule), (ii) the Disclosure Schedule, (iii) the supplements to the Disclosure Schedule, (iv) the certificates delivered under Section 2.7 (for this purpose, each such certificate will be deemed to have stated that Sellers’ representations and warranties in this Agreement fulfill the requirements of Section 7.1 as of the Closing Date as if made on the Closing Date giving effect to any mutually agreed upon (in writing) supplement to the Disclosure Schedule, unless the certificate expressly states that the matters disclosed in a supplement have caused a condition specified in Section 7.1 not to be satisfied), (v) any transfer instrument or (vi) any other certificate, document, writing or instrument delivered by any Seller under this Agreement;
(b)    any Breach of any covenant or obligation of any Seller in this Agreement or in any other certificate, document, writing or instrument delivered by any Seller under this Agreement;
(c)    any Liability arising out of the ownership or operation of the Assets or the Business before the Effective Time other than the Assumed Liabilities;
(d)    any brokerage or finder’s fees or commissions or similar payments based upon any agreement or understanding made, or alleged to have been made, by any Person with any Seller (or any Person acting on their behalf) in connection with any of the Contemplated Transactions;
(e)    any product or component thereof manufactured by or shipped, or any services provided by, any Seller, in whole or in part, before the Closing Date;
(f)    any claim by any employee of the HHS Business, any former employee or any former or existing consultant of any Sellers to any rights concerning or affecting any inventions, improvements, discoveries, trade secrets, works of authorship or information

55



(to the extent such rights allegedly accrued while such employee or consultant was employed or retained, as applicable, by any Seller) relating to the Business;
(g)    any claim arising from the use, disclosure or appropriation of any Trade Secret on or before the Closing either for the benefit of any Person (other than Sellers) or to the detriment of Sellers.
(h)    any noncompliance with any fraudulent transfer law in respect of the Contemplated Transactions;
(i)    any liability under the WARN Act or any similar state or local Legal Requirement that may result from an “Employment Loss”, as defined by 29 U.S.C. §2101(a)(6), caused by any action of any Seller before the Closing or by Buyer’s decision not to hire any current or former employees of any Seller;
(j)    any Employee Plan established or maintained by any Seller; or
(k)    any Retained Liabilities; or
(l)    any Liability arising out of the use after the Closing by any Seller (or any of their Affiliates) of any archival or production copy of the LIMS Data.
6.3    Indemnification and Reimbursement by Buyer. Buyer will indemnify and hold harmless Sellers, and will reimburse Sellers, for any Damages arising from or in connection with:
(c)    any Breach of any representation or warranty made by Buyer in this Agreement or in any certificate, document, writing or instrument delivered by Buyer under this Agreement;
(d)    any Breach of any covenant or obligation of Buyer in this Agreement or in any other certificate, document, writing or instrument delivered by Buyer under this Agreement;
(e)    any claim by any Person for brokerage or finder’s fees or commissions or similar payments based upon any agreement or understanding alleged to have been made by such Person with Buyer (or any Person acting on Buyer’s behalf) in connection with any of the Contemplated Transactions;
(f)    any other Liability arising out of the ownership or operation of the Assets or the Business after the Effective Time (unless Buyer is entitled to indemnity and defense against such Liability under Section 11.2 above), other than the Excluded Liabilities;
(g)    any Assumed Liabilities.

56



6.4    Time Limitations.
(a)    If the Closing occurs, Sellers shall have liability (for indemnification or otherwise) with respect to any Breach of a representation or warranty (other than those in Sections 3.2 (“Enforceability; Authority; No Conflict”), 3.8 (“Title to Assets; Encumbrances”), 3.11 (“Taxes”) and 3.22 (“Brokers or Finders”) (collectively, the “Fundamental Representations”), as to which a claim may be made at any time), only if Buyer notifies Sellers in writing on or before the twenty-four (24) month anniversary of the Closing Date of a claim specifying the factual basis of the claim in reasonable detail to the extent then known by Buyer.
(b)    If the Closing occurs, Buyer will have liability (for indemnification or otherwise) with respect to any Breach of a representation or warranty (other than that set forth in Section 4.4 (“Brokers or Finders”), as to which a claim may be made at any time), only if Sellers notify Buyer in writing on or before the twenty-four (24) month anniversary of the Closing Date of a claim specifying the factual basis of the claim in reasonable detail to the extent then known by any Seller.
6.5    Limitation on Amounts. Sellers shall have no liability (for indemnification or otherwise) with respect to claims under Section 11.2 until the total of all Damages with respect to such matters exceed Fifty Thousand Dollars ($50,000) (after which point Sellers will be liable for only those Damages in excess of $50,000); provided, however that the maximum aggregate of all amounts for which the Buyer Indemnified Persons shall be entitled shall in no event exceed an amount equal to twenty-five percent (25%) of the Net Cash Consideration. However, the limitations set forth in this Section 11.5 will not apply (a) in the event of fraud, (b) to inaccuracies and/or breaches of any Fundamental Representation, (c) to any Seller’s willful breach of the covenants contained in ARTICLE 5; (d) to any Seller’s obligations under Section 10.6, or (d) to any Seller’s obligations under Section 11.2(c), (d), (i), (j) or (m).
6.6    Third-Party Claims.
(a)    Promptly after receipt by a Person entitled to indemnity under Section 11.2 or Section 11.3 (an “Indemnified Person”) of notice of the assertion of a Third-Party Claim against it, such Indemnified Person shall give written notice to the Person obligated to indemnify under such Section (an “Indemnifying Person”) of the assertion of such Third-Party Claim, provided that the failure to notify the Indemnifying Person will not relieve the Indemnifying Person of any liability that it may have to any Indemnified Person, except to the extent that the Indemnifying Person demonstrates that the defense of such Third-Party Claim is prejudiced by the Indemnified Person’s failure to give such notice.
(b)    If an Indemnified Person gives notice to the Indemnifying Person under Section 11.6(a) of the assertion of a Third-Party Claim, the Indemnifying Person shall be entitled to participate in the defense of such Third-Party Claim and, to the extent that it wishes (unless (i) the Indemnifying Person is also a Person against whom the Third-Party Claim is made and the Indemnified Person determines in good faith that joint

57



representation would be inappropriate or (ii) the Indemnifying Person fails to provide reasonable assurance to the Indemnified Person of its financial capacity to defend such Third-Party Claim and provide indemnification with respect to such Third-Party Claim), to assume the defense of such Third-Party Claim with counsel reasonably satisfactory to the Indemnified Person. After notice from the Indemnifying Person to the Indemnified Person of its election to assume the defense of such Third-Party Claim, the Indemnifying Person shall not, so long as it diligently conducts such defense, be liable to the Indemnified Person under this ARTICLE 11 for any fees of other counsel or any other expenses with respect to the defense of such Third-Party Claim, in each case subsequently incurred by the Indemnified Person in connection with the defense of such Third-Party Claim, other than reasonable costs of investigation. If the Indemnifying Person assumes the defense of a Third-Party Claim,
(i)    such assumption will conclusively establish for purposes of this Agreement that the claims made in that Third-Party Claim are within the scope of and subject to indemnification, and
(ii)    no compromise or settlement of such Third-Party Claims may be effected by the Indemnifying Person without the Indemnified Person’s Consent unless (A) there is no finding or admission of any violation of Legal Requirement or any violation of the rights of any Person; (B) the sole relief provided is monetary damages that are paid in full by the Indemnifying Person; and (C) the Indemnified Person shall have no liability with respect to any compromise or settlement of such Third-Party Claims effected without its Consent.
If notice is given to an Indemnifying Person of the assertion of any Third-Party Claim and the Indemnifying Person does not, within twenty (20) days after the Indemnified Person’s notice is given, give notice to the Indemnified Person of its election to assume the defense of such Third-Party Claim, the Indemnifying Person will be bound by any determination made in such Third-Party Claim or any compromise or settlement effected by the Indemnified Person.
(c)    Notwithstanding the foregoing, if an Indemnified Person determines in good faith that there is a reasonable probability that a Third-Party Claim may adversely affect it or its Related Persons other than as a result of monetary damages for which it would be entitled to indemnification under this Agreement, the Indemnified Person may, by notice to the Indemnifying Person, assume the exclusive right to defend, compromise or settle such Third-Party Claim, but the Indemnifying Person will not be bound by any determination of any Third-Party Claim so defended for the purposes of this Agreement or any compromise or settlement effected without its Consent (which may not be unreasonably withheld).
(d)    Notwithstanding Section 13.4, each Seller
(i)    consents to the nonexclusive jurisdiction of any court in which a Proceeding in respect of a Third-Party Claim is brought against any Buyer

58



Indemnified Person for purposes of any claim that a Buyer Indemnified Person may have under this Agreement with respect to such Proceeding or the matters alleged therein and
(ii)    agrees that process may be served on such Seller with respect to such a claim anywhere in the world.
(e)    With respect to any Third-Party Claim subject to indemnification under this ARTICLE 11,
(i)    both the Indemnified Person and the Indemnifying Person, as the case may be, shall keep the other Person fully informed of the status of such Third-Party Claim and any related Proceedings at all stages thereof where such Person is not represented by its own counsel, and
(ii)    the parties agree (each at its own expense) to render to each other such assistance as they may reasonably require of each other and to cooperate in good faith with each other in order to ensure the proper and adequate defense of any Third-Party Claim, including without limitation the Indemnified Person’s making available to the Indemnifying Person all witnesses, pertinent records, materials and information in its possession or under its control relating thereto as is reasonably required by the Indemnifying Person.
(f)    With respect to any Third-Party Claim subject to indemnification under this ARTICLE 11, the parties agree to cooperate in such a manner as to preserve in full (to the extent possible) the confidentiality of all Confidential Information and the attorney-client and work-product privileges. In connection therewith, each party agrees that: (i) it will use its Best Efforts, in respect of any Third-Party Claim in which it has assumed or participated in the defense, to avoid production of Confidential Information (consistent with applicable law and rules of procedure), and (ii) all communications between any party to this Agreement and counsel responsible for or participating in the defense of any Third-Party Claim shall, to the extent possible, be made so as to preserve any applicable attorney-client or work-product privilege.
6.7    Other Claims.
(a)    A party wishing to assert a claim for indemnification under this ARTICLE 11 which is not subject to Section 11.6 (an “Other Claim”) shall deliver to the Indemnifying Person a written notice (a “Claim Notice”) which contains
(iii)    a description and, if then known or estimated, the amount (the “Claimed Amount”) of any Damages incurred by the Indemnified Person with respect to such Other Claim or, if then known, the method of computation of the amount of such Damages,

59



(iv)    a statement that the Indemnified Person is entitled to indemnification under this ARTICLE 11 and an explanation of the then-known basis therefor, and
(v)    a demand for payment in the amount of such Damages (including wire instructions if payment is requested to be made by wire transfer).
(b)    Within thirty (30) days after delivery of a Claim Notice, the Indemnifying Person shall deliver to the Indemnified Person a written response in which the Indemnifying Person shall:
(i)    agree that the Indemnified Person is entitled to receive all of the Claimed Amount (in which case such response shall be accompanied by a payment by the Indemnifying Person to the Indemnified Person of the Claimed Amount, by wire transfer);
(ii)    agree that the Indemnified Person is entitled to receive part, but not all, of the Claimed Amount (the “Agreed Amount”) (in which case such response shall be accompanied by a payment by the Indemnifying Person to the Indemnified Person of the Agreed Amount, by wire transfer); or
(iii)    contest that the Indemnified Person is entitled to receive any of the Claimed Amount (or any part of the Claimed Amount other than the Agreed Amount) including the reasonably detailed reasons therefor.
(c)    If the Indemnifying Person in such response contests the payment of all or part of the Claimed Amount, the Indemnifying Person and the Indemnified Person shall use good faith efforts to resolve such dispute. If such dispute is not resolved within thirty (30) days following the delivery by the Indemnifying Person of such response, the Indemnifying Person and the Indemnified Person shall each have the right to submit such dispute to a court of competent jurisdiction in accordance with the provisions of Section 13.4.
6.8    Other Limitations.
(a)    The amount of any Damages attributable to any Third-Party Claim or Other Claim as to which any Indemnified Person is entitled to indemnification under this ARTICLE 11 shall be reduced by the amount, if any, actually received by the Indemnified Person claiming indemnification in respect of such Third-Party Claim or Other Claim from any Person (including any third-party insurance provider) less any out-of-pocket cost associated with receiving such amount (such amount being referred to herein as an “Alternative Reimbursement”), with respect to the Damages suffered thereby.
(b)    If, after receipt by such Indemnified Person of any indemnification payment hereunder in respect of such Third-Party Claim or Other Claim, such Indemnified Person receives an Alternative Reimbursement in respect of the same

60



Damages for which indemnification was made and such Alternative Reimbursement was not taken into account in assessing the amount of Damages, then such Indemnified Person shall accept such Alternative Reimbursement for the account of the Indemnifying Person and shall turn over all of such Alternative Reimbursement to the Indemnifying Person up to the amount of the indemnification paid by the Indemnifying Person pursuant to this Agreement in respect of the applicable claim for indemnification.
(c)    The parties shall reasonably cooperate with each other to maximize the availability of any Alternative Reimbursements for indemnifiable claims hereunder, and, if any insurance provider for a party agrees to defend any such third-party claim, such Person may tender the defense to such third-party insurance provider.
6.9    Indemnification in case of Strict Liability or Indemnitee Negligence. THE INDEMNIFICATION PROVISIONS IN THIS ARTICLE 11 SHALL BE ENFORCEABLE REGARDLESS OF WHETHER THE LIABILITY IS BASED UPON PAST, PRESENT OR FUTURE ACTS, CLAIMS OR LEGAL REQUIREMENTS (INCLUDING ANY PAST, PRESENT OR FUTURE BULK SALES LAW, ENVIRONMENTAL LAW, FRAUDULENT TRANSFER ACT, OCCUPATIONAL SAFETY AND HEALTH LAW OR PRODUCTS LIABILITY, SECURITIES OR OTHER LEGAL REQUIREMENT) AND REGARDLESS OF WHETHER ANY PERSON (INCLUDING THE PERSON FROM WHOM INDEMNIFICATION IS SOUGHT) ALLEGES OR PROVES THE SOLE, CONCURRENT, CONTRIBUTORY OR COMPARATIVE NEGLIGENCE OF THE PERSON SEEKING INDEMNIFICATION OR THE SOLE OR CONCURRENT STRICT LIABILITY IMPOSED UPON THE PERSON SEEKING INDEMNIFICATION.
ARTICLE 7    
CONFIDENTIALITY
7.1    Definition of Confidential Information.
(m)    As used in this ARTICLE 12, the term “Confidential Information” means all of the following information of Sellers or Buyer that has been or may hereafter be disclosed in any form, whether in writing, orally, electronically or otherwise, or otherwise made available by observation, inspection or otherwise by either party (Buyer on the one hand or Sellers, collectively, on the other hand) or its Representatives (collectively, a “Disclosing Party”) to the other party or its Representatives (collectively, a “Receiving Party”):
(iii)    all information that is a trade secret under applicable trade secret or other law;
(iv)    all information concerning product specifications, data, know-how, formulae, compositions, processes, designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current and planned research and development, current and planned manufacturing or distribution methods and processes, customer lists, current and anticipated customer requirements, price

61



lists, market studies, business plans, computer hardware, Software and computer software and database technologies, systems, structures and architectures;
(v)    all information concerning the business and affairs of the Disclosing Party (which includes historical and current financial statements, financial projections and budgets, tax returns and accountants’ materials, historical, current and projected sales, capital spending budgets and plans, business plans, strategic plans, marketing and advertising plans, publications, client and customer lists and files, contracts, the names and backgrounds of key personnel and personnel training techniques and materials, however documented), and all information obtained from review of the Disclosing Party’s documents or property or discussions with the Disclosing Party regardless of the form of the communication;
(vi)    all notes, analyses, compilations, studies, summaries and other material prepared by the Receiving Party to the extent containing or based, in whole or in part, upon any information included in the foregoing; and
(vii)    all information provided to Buyer or its financial and legal advisors pursuant to Section 5.6.
(n)    Any trade secrets of a Disclosing Party shall also be entitled to all of the protections and benefits under applicable trade secret law and any other applicable law. If any information that a Disclosing Party deems to be a trade secret is found by a court of competent jurisdiction not to be a trade secret for purposes of this ARTICLE 12, such information shall still be considered Confidential Information of that Disclosing Party for purposes of this ARTICLE 12 to the extent included within the definition. In the case of trade secrets, each of Buyer and Sellers waives any requirement that the other party submit proof of the economic value of any trade secret or post a bond or other security.
(o)    Sellers have not disclosed any Confidential Information to Buyer concerning Sellers’ wellness business, which is an Excluded Asset, other than disclosure to Buyer of the types of laboratory tests Sellers currently perform and the related historical and projected volumes thereof. Buyer represents that Seller has not disclosed any other Confidential Information of Sellers relating to Sellers’ wellness business.
7.2    Restricted Use of Confidential Information.
(h)    Each Receiving Party acknowledges the confidential and proprietary nature of the Confidential Information of the Disclosing Party and agrees that such Confidential Information
(iii)    shall be kept confidential by the Receiving Party;
(iv)    shall not be used for any reason or purpose other than to evaluate and consummate the Contemplated Transactions; and

62



(v)    without limiting the foregoing, shall not be disclosed by the Receiving Party to any Person, except in each case as otherwise expressly permitted by this Agreement or with the prior written consent of an authorized representative of Sellers with respect to Confidential Information of Sellers (each, a “Seller Contact”) or an authorized representative of Buyer with respect to Confidential Information of Buyer (each, a “Buyer Contact”).
(i)    Each of Buyer and Sellers shall disclose the Confidential Information of the other party only to its Representatives who require such material for the purpose of evaluating the Contemplated Transactions and are informed by Buyer or Sellers, as the case may be, of the obligations of this ARTICLE 12 with respect to such information. Each of Buyer and Sellers shall
(i)    enforce this ARTICLE 12 as to its respective Representatives;
(ii)    take such action to the extent necessary to cause its Representatives to comply with the terms and conditions of this ARTICLE 12; and
(iii)    be responsible and liable for any breach of this ARTICLE 12 by it or its Representatives.
(j)    Unless and until this Agreement is terminated, Sellers shall maintain as confidential any Confidential Information (including for this purpose any information of Sellers of the type referred to in Sections 12.1(a)(i), (ii) and (iii), whether or not disclosed to Buyer) of Sellers relating to any of the Assets or the Assumed Liabilities. Notwithstanding the preceding sentence, Sellers may use any Confidential Information of Sellers before the Closing in the Ordinary Course of Business in connection with the transactions permitted by Section 5.2.
(k)    From and after the Closing, Section 12.2(a), (b) and (c) above shall not apply to or restrict in any manner Buyer’s use of any Confidential Information of Sellers relating to the Business, any of the Assets or the Assumed Liabilities.
7.3    Exceptions. Sections 12.2(a), (b) and (c) above do not apply to that part of the Confidential Information of a Disclosing Party that a Receiving Party demonstrates
(c)    was, is or becomes generally available to the public other than as a result of a breach of this ARTICLE 12 or the Confidentiality Agreement by the Receiving Party or its Representatives;
(d)    was or is developed by the Receiving Party independently of and without reference to any Confidential Information of the Disclosing Party; or

63



(e)    was, is or becomes available to the Receiving Party on a non-confidential basis from a Third Party not bound by a confidentiality agreement or any legal, fiduciary or other obligation restricting disclosure.
No Seller shall disclose any Confidential Information of Sellers relating to any of the Assets or the Assumed Liabilities in reliance on the exceptions in clauses (b) or (c) above.
7.4    Legal Proceedings. If a Receiving Party becomes compelled in any Proceeding or is requested by a Governmental Body having regulatory jurisdiction over the Contemplated Transactions to make any disclosure that is prohibited or otherwise constrained by this ARTICLE 12, that Receiving Party shall provide the Disclosing Party with prompt notice of such compulsion or request so that it may seek an appropriate protective order or other appropriate remedy or waive compliance with this ARTICLE 12. In the absence of a protective order or other remedy, the Receiving Party may disclose that portion (and only that portion) of the Confidential Information of the Disclosing Party that, based upon advice of the Receiving Party’s counsel, the Receiving Party is legally compelled to disclose or that has been requested by such Governmental Body, provided, however, that the Receiving Party shall use reasonable efforts to obtain reliable assurance that confidential treatment will be accorded by any Person to whom any Confidential Information is so disclosed. This Section 12.4 does not apply to any Proceedings between the parties to this Agreement.
7.5    Return or Destruction of Confidential Information. If this Agreement is terminated, each Receiving Party shall
(g)    destroy all Confidential Information of the Disclosing Party prepared or generated by the Receiving Party without retaining a copy of any such material;
(h)    promptly deliver to the Disclosing Party all other Confidential Information of the Disclosing Party, together with all copies thereof, in the possession, custody or control of the Receiving Party or, alternatively, with the written consent of a Seller Contact or a Buyer Contact (whichever represents the Disclosing Party) destroy all such Confidential Information; and
(i)    certify all such destruction in writing to the Disclosing Party,
provided, however, that the Receiving Party may retain a list that contains general descriptions of the information it has returned or destroyed to facilitate the resolution of any controversies after the Disclosing Party’s Confidential Information is returned.
7.6    Attorney-Client Privilege. The Disclosing Party is not waiving, and will not be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges as a result of disclosing its Confidential Information (including Confidential Information related to pending or threatened litigation) to the Receiving Party, regardless of whether the Disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The parties

64



(d)    share a common legal and commercial interest in all of the Disclosing Party’s Confidential Information that is subject to such privileges and protections;
(e)    are or may become joint defendants in Proceedings to which the Disclosing Party’s Confidential Information covered by such protections and privileges relates;
(f)    intend that such privileges and protections remain intact should either party become subject to any actual or threatened Proceeding to which the Disclosing Party’s Confidential Information covered by such protections and privileges relates; and
(g)    intend that after the Closing the Receiving Party shall have the right to assert such protections and privileges.
No Receiving Party shall admit, claim or contend, in Proceedings involving either party or otherwise, that any Disclosing Party waived any of its attorney work-product protections, attorney-client privileges or similar protections and privileges with respect to any information, documents or other material not disclosed to a Receiving Party due to the Disclosing Party disclosing its Confidential Information (including Confidential Information related to pending or threatened litigation) to the Receiving Party.
ARTICLE 8    
GENERAL PROVISIONS
8.1    Expenses. Except as otherwise provided in this Agreement, each party to this Agreement will bear its respective fees and expenses incurred in connection with the preparation, negotiation, execution and performance of this Agreement and the Contemplated Transactions, including all fees and expense of its Representatives. If this Agreement is terminated, the obligation of each party to pay its own fees and expenses will be subject to any rights of such party arising from a Breach of this Agreement by another party.
8.2    Public Announcements. The initial press release with respect to the execution of this Agreement shall be a joint press release to be reasonably agreed upon by Buyer and Sellers. Thereafter neither Buyer nor Sellers shall issue any press release or other public statement with respect to the Contemplated Transactions or this Agreement without the prior written consent of the other party (which consent shall not be unreasonably withheld, conditioned or delayed), except as may be required by Legal Requirements or stock exchanges rules as determined in the good judgment of the party proposing to make such release, in which case the parties shall, to the extent lawful and practical, consult with one another and cooperate as to the timing and contents of any such press release or announcement. Subject to the foregoing, Sellers and Buyer will consult with each other concerning the means by which Sellers’ employees, customers, suppliers and others having dealings with Sellers will be informed of the Contemplated Transactions, and Buyer will have the right to be present for any such communication.

65



8.3    Notices. All notices, Consents, waivers and other communications required or permitted by this Agreement shall be in writing and shall be deemed to have been given to a party when
(d)    delivered to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid);
(e)    sent by facsimile or e-mail with confirmation of transmission by the transmitting equipment; or
(f)    received or rejected by the addressee, if sent by certified mail, return receipt requested, in each case to the following addresses, facsimile numbers or e-mail addresses and marked to the attention of the person (by name or title) designated below (or to such other address, facsimile number, e-mail address or person as a party may designate by notice to the other parties):
Sellers:
Hooper Holmes, Inc.
560 N. Rogers Road
Olathe, KS 66062
Attention: General Counsel
Fax no.: (913) 764-4878
E-mail address: tracy.mackey@hooperholmes.com

with a copy to (which shall
not constitute notice):
Sills Cummis & Gross P.C.
30 Rockefeller Plaza, 29th Floor
New York, NY 10112
Attention: David E. Weiss, Esq.
Fax no.: (212) 643-6500
E-mail address: dweiss@sillscummis.com

Buyer:
Clinical Reference Laboratory, Inc.
8433 Quivira Road
Lenexa, KS 66215
Attention: Timothy S. Sotos
Fax no.: (913) 492-2057
E-mail address: sotost@crlcorp.com


66



with a copy to (which shall
not constitute notice):
Lathrop & Gage LLP
2345 Grand Boulevard, Suite 2800
Kansas City, MO 64108
Attention: Dale A. Werts, Esq.
Fax no.: (816) 292-2001
E-mail address: dwerts@lathropgage.com

8.4    Jurisdiction; Service of Process. Any Proceeding arising out of or relating to this Agreement or any Contemplated Transaction may be brought in the courts of the State of Kansas, County of Johnson, or, if it has or can acquire jurisdiction, in the United States District Court for the District of Kansas, and each of the parties irrevocably submits to the exclusive jurisdiction of each such court in any such Proceeding, waives any objection it may now or hereafter have to venue or to convenience of forum, agrees that all claims in respect of the Proceeding shall be heard and determined only in any such court and agrees not to bring any Proceeding arising out of or relating to this Agreement or any Contemplated Transaction in any other court. The parties agree that either or both of them may file a copy of this paragraph with any court as written evidence of the knowing, voluntary and bargained agreement between the parties irrevocably to waive any objections to venue or to convenience of forum. Process in any Proceeding referred to in the first sentence of this section may be served on any party anywhere in the world.
8.5    Enforcement of Agreement. Sellers acknowledge and agree that Buyer would be irreparably damaged if any of the provisions of this Agreement are not performed in accordance with their specific terms and that any Breach of this Agreement by Sellers could not be adequately compensated in all cases by monetary damages alone. Accordingly, in addition to any other right or remedy to which Buyer may be entitled, at law or in equity, it shall be entitled to enforce any provision of this Agreement by a decree of specific performance and to temporary, preliminary and permanent injunctive relief to prevent Breaches or threatened Breaches of this Agreement, without posting any bond or other undertaking.
8.6    Waiver; Remedies Cumulative. The rights and remedies of the parties to this Agreement are cumulative and not alternative. Neither any failure nor any delay by any party in exercising any right, power or privilege under this Agreement or any of the documents referred to in this Agreement will operate as a waiver of such right, power or privilege, and no single or partial exercise of any such right, power or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. To the maximum extent permitted by applicable law,
(d)    no claim or right arising out of this Agreement or any of the documents referred to in this Agreement can be discharged by one party, in whole or in part, by a waiver or renunciation of the claim or right unless in writing signed by the other party;
(e)    no waiver that may be given by a party will be applicable except in the specific instance for which it is given; and

67



(f)    no notice to or demand on one party will be deemed to be a waiver of any obligation of that party or of the right of the party giving such notice or demand to take further action without notice or demand as provided in this Agreement or the documents referred to in this Agreement.
8.7    Entire Agreement and Modification. This Agreement supersedes all prior agreements, whether written or oral, between the parties with respect to its subject matter (including any letter of intent and any confidentiality agreement between Buyer and Sellers) and constitutes (along with the Disclosure Schedule, Exhibits and other documents delivered under this Agreement, which are incorporated into this Agreement by this reference) a complete and exclusive statement of the terms of the agreement between the parties with respect to its subject matter. This Agreement may not be amended, supplemented, or otherwise modified except by a written agreement executed by the party to be charged with the amendment.
8.8    Disclosure Schedule.
(a)    The information in the Disclosure Schedule constitutes (i) exceptions to particular representations, warranties, covenants and obligations of Sellers as set forth in this Agreement or (ii) descriptions or lists of assets and liabilities and other items referred to in this Agreement. The Disclosure Schedule (and exhibits to this Agreement) shall be deemed part of this Agreement and incorporated herein, as if fully set forth herein.
(b)    Sellers shall be entitled to make disclosure on any Part of the Disclosure Schedule by way of cross-reference to information disclosed in any other Part of the Disclosure Schedule if the applicability of such other information is apparent on the face of such disclosure. The statements in the Disclosure Schedule, and those in any supplement thereto, relate only to the provisions in the Section of this Agreement to which they expressly relate and not to any other provision in this Agreement, unless the disclosure in any Part of the Disclosure Schedule (or any supplement thereto) qualifies other Parts of the Disclosure Schedule for which the relevance or applicability of such disclosure is reasonably apparent on the face of such disclosure. No disclosure on any Part of the Disclosure Schedule relating to a possible breach or violation of any Contract, Legal Requirement or Order shall be construed as an admission or indication to any party that a breach or violation exists or has actually occurred.
8.9    Assignments, Successors and No Third-Party Rights. No party may assign any of its rights or delegate any of its obligations under this Agreement without the prior written consent of the other parties, except that Buyer may assign any of its rights and delegate any of its obligations under this Agreement to any subsidiary of Buyer; provided that Buyer shall not be relieved of its obligations to Sellers hereunder by any such assignment. Subject to the preceding sentence, this Agreement will apply to, be binding in all respects upon and inure to the benefit of the successors and permitted assigns of the parties. Nothing expressed or referred to in this Agreement will be construed to give any Person other than the parties to this Agreement any legal or equitable right, remedy or claim under or with respect to this Agreement or any provision of this Agreement, except such rights as shall inure to a successor or permitted assignee under this Section 13.9 and as provided in ARTICLE 11.

68



8.10    Severability. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.
8.11    Construction. The headings of Articles and Sections in this Agreement are provided for convenience only and will not affect its construction or interpretation. All references to “Articles,” “Sections” and “Parts” refer to the corresponding Articles, Sections and Parts of this Agreement and the Disclosure Schedule.
8.12    Governing Law. This Agreement will be governed by and construed under the laws of the State of Kansas as they apply to contracts entered into and performed wholly within Kansas, without regard to conflicts-of-laws principles that would require the application of any other law.
8.13    Execution of Agreement. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. The exchange of copies of this Agreement and of signature pages by facsimile transmission shall constitute effective execution and delivery of this Agreement as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile shall be deemed to be their original signatures for all purposes.
8.14    Seller Obligations. The liability of each Seller under this Agreement shall be joint and several with each other Seller. Without limiting the generality of the foregoing, (a) where provision is made in this Agreement for any action to be taken or not taken by a Seller, Sellers jointly and severally undertake to take or not take such action, as the case may be, and (b) Sellers shall be jointly and severally liable for the indemnities set forth in ARTICLE 11.
[Signature page follows.]


69



IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
Buyer:
Sellers:
CLINICAL REFERENCE
LABORATORY, INC.
HOOPER HOLMES, INC.

By:    /s/ John R. Martin         
Name: John R. Martin         
Title:    EVP-CAO            

By:    /s/ Henry E. Dubois         
Name: Henry E. Dubois         
Title:    CEO _             
 
HERITAGE LABS INTERNATIONAL, LLC
 

By:    /s/ Henry E. Dubois         
Name: Henry E. Dubois         
Title:    CEO                
 
MID-AMERICA AGENCY SERVICES, INCORPORATED
 

By:    /s/ Henry E. Dubois         
Name: Henry E. Dubois         
Title:     CEO               








Exhibit 2.5

Purchase Price Allocation

 
 
 
Inventory
 
650,000
 
 
 
 
 
 
Equipment
 
250,000
Furniture and Fixtures
 
300,000
Hardware
 
100,000
Software
 
200,000
Intangibles
 
2,200,000
Total Purchase Price
 
3,700,000






Exhibit 2.7(a)(i)
Bill of Sale
(attached)







BILL OF SALE
This Bill of Sale (the “Bill of Sale”) is effective as of         , 2014 (the “Effective Date”), and is by Heritage Labs International, LLC, a Kansas limited liability company, Hooper Holmes, Inc., a New York corporation, and Mid-America Agency Services, Incorporated, a Nebraska corporation (collectively, the “Sellers”), for the benefit of Clinical Reference Laboratory, Inc., a Kansas corporation (“Buyer”).
Sellers and Buyer entered into a Strategic Alliance Agreement dated         , 2014 (the “Agreement”), providing for, among other things, the sale by Sellers to Buyer of the Assets. This Bill of Sale is the bill of sale required under Section 2.7(a) of the Agreement.
Therefore, in consideration of the mutual covenants and agreements contained in the Agreement, the Seller agrees as follows:
1.Definitions. Capitalized terms used but not defined in this Bill of Sale have the meanings given to them in the Agreement.
2.Assignment of Assets. Effective as of the Effective Date, Sellers assign and deliver to Buyer all of Sellers’ right, title and interest in and to the Assets, free and clear of all liens and other encumbrances.
3.Strategic Alliance Agreement. Nothing in this Assignment, express or implied, is intended to or will be construed to supersede, modify, replace, rescind, waive, expand or limit in any way the rights, remedies, obligations or liabilities of the parties under, and the terms of, the Agreement. To the extent that any provision of this Assignment conflicts with or is inconsistent with the terms of the Agreement, the Agreement will govern, including with respect to the enforcement of the rights and obligations of the parties to this Assignment.
4.Successors and Assigns. This Assignment binds and will inure to the benefit of the parties and their respective successors and assigns.
5.Counterparts. This Assignment may be executed in several counterparts, each of which will be deemed an original and all of which will constitute the same instrument. This Assignment may be delivered by facsimile transmission or by scanned e-mail transmission.
6.Further Assurances. Each of the parties, upon reasonable request from the other party, will from time to time after the Effective Date, execute and deliver such further instruments of transfer and take such other actions to more effectively consummate the transaction contemplated by this Assignment.
7.Third Parties. This Assignment is for the sole benefit of Buyer and not for the benefit of any third party.
8.Governing Law. This Assignment will be governed by the laws of the State of Kansas without regard to conflict of law principles.
[Signature Page Follows]





Each Seller caused its duly authorized representative to execute this Bill of Sale as of the Effective Date.

HOOPER HOLMES, INC.


By:                             
Name:
Title:


HERITAGE LABS INTERNATIONAL, LLC


By:                             
Name:
Title:


MID-AMERICA AGENCY SERVICES, INCORPORATED


By:                             
Name:
Title:








Exhibit 2.7(a)(ii)
Assignment and Assumption Agreement
(attached)



21415298v2



ASSIGNMENT AND ASSUMPTION AGREEMENT
This Assignment and Assumption Agreement (the “Assignment”) is effective as of     ___     , 2014 (the “Effective Date”) and is by and among Heritage Labs International, LLC, a Kansas limited liability company, Hooper Holmes, Inc., a New York corporation, Mid-America Agency Services, Incorporated, a Nebraska corporation (collectively, the “Assignors”), and Clinical Reference Laboratory, Inc., a Kansas corporation (“Assignee”).
Assignors and Assignee entered into a Strategic Alliance Agreement dated         ___    , 2014 (the “Agreement”), providing for, among other things, Assignee’s acquisition of the Assets and assumption of the Assumed Liabilities. This Assignment is the assignment and assumption agreement required under Section 2.7(a) of the Agreement.
Therefore, in consideration of the mutual covenants and agreements contained in the Agreement, the parties agree as follows:
1.Definitions. Capitalized terms used but not defined in this Assignment have the meanings given to them in the Agreement.
2.Assignment of Assets. Effective as of the Effective Date, Assignors assign and deliver to Assignee all of Assignors’ right, title, and interest in and to the Assets, whether tangible or intangible, free and clear of all liens and other encumbrances.
3.Assignment of Liabilities. Effective as of the Effective Date, Assignee hereby assumes the Assumed Liabilities, and agrees to observe, perform, pay, and discharge such Assumed Liabilities from and after the Effective Date. Assignee does not assume or have any responsibility of any nature for any liabilities other than the Assumed Liabilities.
4.Strategic Alliance Agreement. Nothing in this Assignment, express or implied, is intended to or will be construed to supersede, modify, replace, rescind, waive, expand or limit in any way the rights, remedies, obligations or liabilities of the parties under, and the terms of, the Agreement. To the extent that any provision of this Assignment conflicts with or is inconsistent with the terms of the Agreement, the Agreement will govern, including with respect to the enforcement of the rights and obligations of the parties to this Assignment.
5.Successors and Assigns. This Assignment binds and will inure to the benefit of the parties and their respective successors and assigns.
6.Counterparts. This Assignment may be executed in several counterparts, each of which will be deemed an original and all of which will constitute the same instrument. This Assignment may be delivered by facsimile transmission or by scanned e-mail transmission.
7.Further Assurances. Each of the parties, upon reasonable request from the other party, will from time to time after the Effective Date, execute and deliver such further instruments of transfer and take such other actions to more effectively consummate the transaction contemplated by this Assignment.


76



8.Third Parties. This Assignment is not for the benefit of any third party.
9.Governing Law. This Assignment will be governed by the laws of the State of Kansas without regard to conflict of law principles.





[Signature page follows.]

21415298v2



Each party caused its duly authorized representatives to execute this Assignment as of the Effective Date.
ASSIGNORS:

HOOPER HOLMES, INC.


By:                             
Name:
Title:


HERITAGE LABS INTERNATIONAL, LLC


By:                             
Name:
Title:


MID-AMERICA AGENCY SERVICES, INCORPORATED


By:                             
Name:
Title:


ASSIGNEE:

CLINICAL REFERENCE LABORATORY, INC.


By:                             
Name:
Title:



78



Exhibit 2.7(a)(iii)
IP Assignments
(attached)



79



ASSIGNMENT OF TRADEMARKS
For $10.00 (Ten and no/100 Dollars) and other good and valuable consideration, the receipt of which is acknowledged,
Hooper Holmes, Inc., a New York corporation
170 Mount Airy Road
Basking Ridge, New Jersey 07920
grants, conveys and assigns to
Clinical Reference Laboratory, Inc., a Kansas corporation
8433 Quivira Road
Lenexa, KS 66215

all right, title, and interest in and to the trademarks listed on the attached Exhibit A (the Marks), together with the goodwill of the business symbolized by the Marks, the registrations of the Marks, all common law rights associated with the Marks, all claims for damages by reason of past infringement of the Marks, and the right to sue and collect for any past infringement of the Marks.

    Signed: _____________________, 2014.

HOOPER HOLMES, INC.

By _______________________________
Authorized Officer
                        
State of _________________    )
)     ss.
County of _______________    )

On this ___ day of ____________2014, before me, a Notary Public in and for said county and state, personally appeared _________________________ the ________________________ of Hooper Holmes, Inc., known to me to be the person and authorized officer of said corporation who executed the above Assignment on behalf of said company and acknowledged to me that the same was executed as the free and voluntary act and deed of said officer and as the free and voluntary act and deed of said company.
_____________________
My Commission Expires:                    NOTARY PUBLIC


80



EXHIBIT A
(United States)

Mark
Registration No
Application No.
Class
Goods/Services
MATURE ASSESSMENT
3,475,625
77/345,652
44 Int.
Medical testing services for use with respect to insurance underwriting and risk assessment

PROACTIVE HEALTH ASSESSMENT
3,834,031
77/842,086
44 Int.
Medical and healthcare information analysis services for insurance providers

HEALTHDEX
2,079,142
75/133,190
42 Int.
Gathering and dissemination of health information



 

81



ASSIGNMENT OF COPYRIGHTS
For $10.00 (Ten and no/100 Dollars) and other good and valuable consideration, including an asset transfer between the parties and their related companies, the receipt of which consideration is hereby acknowledged,
Hooper Holmes, Inc., a New York corporation
170 Mount Airy Road
Basking Ridge, New Jersey 07920
grants, conveys, and assigns to
Clinical Reference Laboratory, Inc., a Kansas corporation
8433 Quivira Road
Lenexa, KS 66215

all right, title, and interest in and to the copyrights, copyright registrations, and copyright applications listed on the attached Exhibit A, including without limitation (a) all claims for damages by reason of past infringement of the copyrights, (b) the rights to reproduce the copyrighted works, (c) the rights to prepare derivative works of the copyrighted works, (d) the rights to distribute copies of the copyrighted works by rental, lease, lending, sale, or other transfer of ownership, and (e) the rights to sue and collect for any past, present, and future infringement of the copyrights.
Signed ______________, 2014
Hooper Holmes, Inc.
By _____________________
Authorized Officer
State of         )
) ss.
County         )

On this ___ day of ________________2014, before me, a Notary Public in and for said county and state, personally appeared _________________________ the _____________________ of Hooper Holmes, Inc., known to me to be the person and authorized officer of said company who executed the above Assignment on behalf of said company and acknowledged to me that the same was executed as the free and voluntary act and deed of said officer and as the free and voluntary act and deed of said company.
    
_____________________
My Commission Expires:                NOTARY PUBLIC


82




EXHIBIT A

Registration #
Registration Date
Title of Work
TX0006917890
December 5, 2007
Mature Assessment




83



Exhibit 5.15
License Agreement
(attached)



    





21618575v4



LICENSE AGREEMENT
THIS LICENSE AGREEMENT (this “Agreement”), dated as of [*], 2014, by and between HERITAGE LABS INTERNATIONAL, LLC, a Kansas limited liability company with an address at 560 N. Rogers Road, Olathe KS 66062 (the “Licensor”), and CLINICAL REFERENCE LABORATORY, INC., a Kansas corporation with an address at 8433 Quivira Road, Lenexa, KS 66215 (the “Licensee”).

RECITALS
WHEREAS, the Licensor is the original owner and developer of the reference commonly referred to as the Laboratory Information Management System (the “Software”), which Software is utilized to enter, aggregate and report laboratory and other operating information for the Licensor’s Health & Wellness Business (the “Business”) and the Heritage Labs International Business (the “HLI Business”); and

WHEREAS, the Licensor desires to grant to the Licensee, and the Licensee desires to obtain from the Licensor, an exclusive license to use the Software, solely in accordance with the terms and on the conditions set forth in this Agreement.
AGREEMENT
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:
1. GRANT OF RIGHTS.
1.1    Software License.
1.1.1    The Licensor hereby grants, and the Licensee hereby accepts, subject to the terms and conditions of this Agreement, a “read only”, exclusive (other than as to Licensor and its affiliates), and perpetual license to use the Software and the Software Materials (the “License”) in the normal course of business of the Licensee for a period of five (5) years (subject to Section 8 below).
1.1.2    Except for this License and the rights granted to Licensee under this Agreement, the Licensor hereby retains all of its right, title and interest in and to: (1) the copyright for the Software; (2) all manuals, instruction materials, specifications, explanations or guides, and any other related materials pertaining to the Software that are furnished to the Licensee by the Licensor in connection with the Software and relevant to the HLI Business (the “Software Materials”); and (3) all copies of the Software and Software Materials delivered to the Licensee or made by the Licensee in its use of the Software.
1.2    Sublicense. No license to sublicense the Software or any portion thereof is granted to Licensee hereunder, provided, that Licensee may sublicense the Software to any of its affiliates.
2.    ACCESS TO, AND SUPPORT OF, THE SOFTWARE.
2.1    Access. Upon the execution of this Agreement, or shortly thereafter, the Licensor shall provide remote access to the Software and the Software Materials.
2.3    Support. Licensor shall use commercially reasonable efforts to maintain the Software on Licensor’s servers during the Term. Licensee acknowledges that the Software is being licensed to Licensee

2





21618575v4



on an “as is” basis and that Licensor shall not have any obligation to maintain or repair the Software, other than consistent with Licensor’s internal use thereof.
3.    RESPONSIBILITIES OF THE LICENSEE.
3.1    General Use of Software. The Licensee shall use the Software in accordance with the Licensor’s written recommendations regarding operating procedures, audit controls, accuracy and security of input and output of data, restart and recovery routines, and any other procedures necessary for the Licensee’s intended use of the Software.
3.2    Modifications. The Licensor shall have the exclusive right to modify and enhance the Software, and the Licensee hereby agrees that it will not reverse engineer, decompile or disassemble the Software, or make any modifications or enhancements thereto, without the express written consent of the Licensor. Notwithstanding the foregoing, any modifications or enhancements to the Software made by the Licensee after having obtained the express written consent of the Licensor shall be deemed the exclusive property of the Licensor (and thereafter be part of the Software), and the Licensee hereby agrees to provide to Licensor, without charge, any such modification or enhancement and take any and all steps necessary to transfer and assign any and all rights to such modifications or enhancements to the Licensor.
3.3    Use of Software by Employees. The Licensee is responsible for ensuring that its employees are at all times educated and trained in the proper use and operation of the Software in accordance with the Licensor’s written recommendations and that the Software is used in accordance with the Software Materials.
4.    LICENSE FEE AND PAYMENT.
4.1    License Fee. The License shall be royalty free.
4.2    Taxes and Other Charges. The Licensee shall be responsible for paying all (i) sales, use, excise, value-added, or other tax or governmental charges imposed on the licensing or use of the Software and Software Materials hereunder and (ii) freight, insurance and installation charges.
5.    PROPRIETARY RIGHTS.
5.1    Ownership. The Software and Software Materials and all copyright, patent, trade secret, trademark and other proprietary or intellectual property rights of any kind arising therein, and in all other written or oral information provided by the Licensor to the Licensee for the purposes of this Agreement, including any Licensee modifications or enhancements to the Software, as specified in Section 3.2, are and shall remain the exclusive property of the Licensor.
5.2    Infringement of Rights. The Licensee shall notify the Licensor immediately if the Licensee becomes aware of any unauthorized use or infringement of the whole or any part of the Software or the Software Materials by any person or entity. If the Software or the Software Materials may have violated a third party’s intellectual property rights, the Licensor shall either modify them or obtain a license to allow for continued use, or, if these alternatives are not commercially reasonable, the Licensor may terminate the Licenses for the Software, the Software Materials, in whole or in part, as necessary.
6.    CONFIDENTIALITY.

3





21618575v4



6.1    Acknowledgement. Licensee hereby acknowledges and agrees that the Software and the Software Materials constitute and contain valuable proprietary products and trade secrets of Licensor, embodying substantial creative efforts and confidential information, ideas, and expressions. Accordingly, Licensee agrees to treat (and take precautions to ensure that its employees and consultants treat) the Software and the Software Materials as confidential in accordance with the confidentiality requirements and conditions set forth below.
6.2    Maintenance of Confidential Information. Each party agrees to keep confidential all confidential information disclosed to it by the other party in accordance herewith, and to protect the confidentiality thereof in the same manner it protects the confidentiality of similar information and data of its own (at all times exercising at least a reasonable degree of care in the protection of confidential information); provided, however, that neither party shall have any such obligation with respect to use by or disclosure to others not parties to this Agreement of such confidential information as can be established to: (a) have been known publicly; (b) have been known generally in the industry before communication by the disclosing party to the recipient; (c) have been known otherwise by the recipient before communication by the disclosing party; or (d) have been received by the recipient without any obligation of confidentiality from a source (other than the disclosing party) lawfully having possession of such information.
6.3    Injunctive Relief. Licensee acknowledges that the unauthorized use, transfer or disclosure of the Software, the Software Materials or copies thereof will: (a) substantially diminish the value to Licensor of the Software, the Software Materials, trade secrets and other proprietary interests that are the subject of this Agreement; (b) render Licensor’s remedy at law for such unauthorized use, disclosure or transfer inadequate; and (c) cause irreparable injury in a short period of time. If Licensee breaches any of its obligations with respect to the use or confidentiality of the Software, the Software Materials, trade secrets and other proprietary interests that are the subject of this Agreement, Licensor shall be entitled to equitable relief to protect its interests therein, including, but not limited to, preliminary and permanent injunctive relief.
7.    REMEDIES; WARRANTIES.
7.1    Licensee’s Sole Remedy. Notwithstanding anything to the contrary contained in this Agreement but subject to Section 5.2, the Licensor’s entire liability and the Licensee’s sole remedy hereunder, at the Licensor’s option, shall be to repair or replace the Software. The Licensor’s obligations with respect to such remedies shall be contingent on the Licensee’s use of the Software in accordance with this Agreement and in accordance with the Licensor’s instructions as provided by the Licensor in the Software Materials as such instructions may be amended, supplemented, or modified by the Licensor in writing to Licensee from time to time. The Software will be warranted in accordance with Section 7.2 below. Notwithstanding the preceding, the Licensor shall have no obligations with respect to any failures of the Software, as applicable, which are the result of accident, abuse, misapplication, extreme power surge or extreme electromagnetic field. Except in the case of third party claims of infringement under Section 9 below, the Licensor shall not be liable for any loss-of-profit, indirect, special, incidental, punitive or consequential damages, whether based on breach of contract, tort (including negligence), product liability, or otherwise, and whether or not Licensor has been advised of the possibility of such damages.
7.2    DISCLAIMER OF WARRANTIES. THE LICENSOR WARRANTS THAT THE SOFTWARE WILL SUBSTANTIALLY PERFORM AS STATED IN THIS AGREEMENT AND THE SOFTWARE MATERIALS AND WILL NOT INFRINGE UPON THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. EXCEPT AS SET FORTH IN THE PRECEDING SENTENCE,

4





21618575v4



THERE ARE NO OTHER WARRANTIES WITH RESPECT TO THE SOFTWARE, SOFTWARE MATERIALS EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, EVEN IF THE LICENSOR HAS BEEN INFORMED OF SUCH PURPOSE, OR ANY WARRANTIES THAT THE SOFTWARE AND THE SOFTWARE MATERIALS ARE OR WILL BE UNINTERRUPTED, ERROR-FREE, OR VIRUS-FREE.
8.    TERMINATION
8.1    Termination.
8.1.1    The License will automatically terminate upon the earlier of (i) the five-year anniversary of the date of this Agreement; provided, however, that the term of the License shall automatically renew at the end of the initial five (5) year term (and at the end of any subsequent renewal term) for an additional five (5) years as long as Licensor or any of its affiliates supports the Software.
8.1.2    Licensee shall have the right to purchase the Software (including the object code, source code and all related documentation and other Software Materials) from Licensor for $1.00 cash if: (i) Licensor provides written notice that Licensor intends to cease supporting the Software at a date specified therein, (ii) Licensor (or any of its affiliates) ceases to support the Software in accordance with this Agreement, (iii) this Agreement expires or is terminated for any reason, or (iv) Licensor ceases its business, becomes insolvent or files for protection under any bankruptcy or insolvency law (or has any such proceeding filed against it). Licensee shall exercise such purchase option, if at all, (A) within fifteen (15) days after the date specified in the Licensor’s notice described in clause (i) above, or (B) within fifteen (15) days after becoming aware of any circumstance described in clause (ii), (iii) or (iv) above, by written notice to Licensor. Upon receiving Licensee’s notice of exercise, Licensor shall promptly deliver the Software (including the object code and source code therefor), together with all such documentation and Software Materials, to Licensee, free and clear of all liens and encumbrances.
8.1.3    The Licensor may terminate the License (A) in the event Licensee fails to make timely notice of its intention to purchase the Software in accordance with 8.1.2, if a triggering event described in clause (i), (ii), (iii) or (iv) of Section 8.1.2 has occurred or (B) as provided in Section 8.2 in the event that the Licensee breaches any provision of this Agreement without Licensee’s cure as provided in Section 8.2.
  
8.1.4    The provisions of Sections 5, 6, 7, 8, 9, 10, 12, 13, 14 and 15 shall survive any such termination of the License. Upon termination of the Licenses, except as specifically provided herein, each party shall be responsible for its costs, fees and charges incurred through the date of termination.
8.2    Effective Date of Termination. Termination of the License due to a breach of Section 1 (Grants of Rights), Section 5 (Proprietary Rights) or Section 6 (Confidentiality) shall be effective on notice

5





21618575v4



of termination. In all other cases, termination shall be effective thirty (30) days after notice of termination to the Licensee if the defaults have not been cured within such thirty (30) day period.
8.3    Licensee Obligations on Termination. Within ten (10) days after termination of the License, the Licensee shall cease and desist all use of the Software and the Software Materials and shall destroy all full or partial copies of the Software and the Software Materials in the Licensee’s possession or under its control. The Licensor shall have a reasonable opportunity to conduct an inspection of the Licensee’s place of business to assure compliance with the terms of this Section 8.3; provided, however, that the Licensor provide the Licensee with notice forty-eight (48) hours prior to such inspection. Upon request, the Licensee shall execute an affidavit stating that all Software and Software Materials and copies thereof have been destroyed in accordance with this Agreement.
9.    INDEMNIFICATION.
9.1    The Licensor shall indemnify, defend and hold harmless the Licensee and its affiliates, and all of their respective officers, agents, employees and representatives, from and against all claims, demands and causes of action arising from and actual or alleged infringement by the Software or the Software Materials on the intellectual property rights of any third party.
9.2    The Licensee shall indemnify and hold harmless the Licensor and its affiliates, and all of their officers, agents, employees and representatives, from and against any claims, demands, or causes of action whatsoever, including without limitation those caused by, or arising out of, or resulting from, this Agreement or the use of the Software by the Licensee or its affiliates, or any of their officers, agents, employees or representatives, except to the extent covered by Licensor’s indemnity hereunder.
9.3    In no event shall Licensor’s or Licensee’s liability under this Section 9 exceed 25% of the Net Cash Consideration (as such term is defined in that certain Strategic Alliance Agreement dated as of April __, 2014, among Licensor, its affiliates Hooper Holmes, Inc. and Mid-America Agency Services, Incorporated, and Licensee, the “SAA”); provided, further, that in no event shall either party be entitled to recover for the same loss or damage under both the SAA and this Agreement.
10.    NOTICES.
All notices, authorizations, and requests in connection with this Agreement shall be deemed given (i) five (5) days after being deposited in the U.S. mail, postage prepaid, certified or registered, return receipt requested; or (ii) one (1) day after being sent by overnight courier, charges prepaid, with a confirming fax; and addressed as first set forth above or to such other address as the party to receive the notice or request so designates by written notice to the other.
11.    NON-ASSIGNABILITY.
Neither the Licensee nor the Licensor shall assign this Agreement or its rights hereunder without the prior written consent of the other party. Notwithstanding the preceding, each party may assign this Agreement to an affiliate or a purchaser of such party’s business or assets, including by merger, consolidation or other reorganization or combination, without the consent of the other party.
12.    GOVERNING LAW.
The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Kansas, without giving effect to principles of conflicts of laws.

6





21618575v4



13.    WAIVER OF REMEDIES.
No waiver of any rights arising under this Agreement shall be effective unless in writing and signed by a duly authorized signatory of the party against whom the waiver is to be enforced. No failure or delay by either party in exercising any right, power or remedy under this Agreement (except as expressly provided herein) shall operate as a waiver of any such right, power or remedy.
14.    SEVERABILITY.
If any provision of this Agreement shall be held by a court of competent jurisdiction to be illegal, invalid or unenforceable, such provision shall be deemed modified to the extent necessary to allow enforcement and the remaining provisions shall remain in full force and effect.
15.    MISCELLANEOUS.
This Agreement and its exhibits contain the entire understanding and agreement between the parties respecting the subject matter hereof. In the event of a dispute arising hereunder, the non-prevailing party shall be responsible for the costs and expenses, including reasonable attorneys’ fees, incurred by the prevailing party in connection with such dispute. This Agreement may not be supplemented, modified, amended, released or discharged except as provided in Section 8 hereof or otherwise by an instrument in writing signed by each party’s duly authorized representative. All captions and headings in this Agreement are for purposes of convenience only and shall not affect the construction or interpretation of any of its provisions. Any waiver by either party of any default or breach hereunder shall not constitute a waiver of any provision of this Agreement or of any subsequent default or breach of the same or a different kind. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Any signature page delivered by facsimile or electronic image transmission shall be binding to the same extent as an original signature page.

[Signature page follows]

IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this License Agreement as of the date first set forth below.
LICENSOR:


HERITAGE LABS INTERNATIONAL, LLC

By: ________________________________
Name:
Title:

LICENSEE:

CLINICAL REFERENCE LABORATORY, INC.

By: _______________________________
Name:
Title:


Exhibit 8.3
Sellers’ Consents Required
(attached)


Exhibit 8.3
Sellers’ Consents Required



Consent of, and Lien Release from, Keltic Financial Partners II, LP as it pertains
to the Assets. See Part 3.8.


7





21618575v4
EX-10.1 3 exhibit101q12014.htm EXHIBIT 10.1 exhibit101q12014
Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

LIMITED LABORATORY AND ADMINISTRATIVE SERVICES AGREEMENT

Company Name:
Hooper Holmes, Inc.
 
Address:
560 N. Rogers Road
 
City:
Olathe
State:
KS
Zip:
66062
 
Contact Name:
Ernie Sifford
Contact Title:
Vice President Operations
 
Telephone:
913.747.2555
Email:
Ernie.Sifford@hooperholmes.com
 
Nature of Company:
X
Corporation
o
Limited Liability Company
 
 
o
Partnership
o
Other:
     
 
 
 
 
 
 
 
 
 
 
The company identified above (on its own behalf and on behalf of its Affiliates, and their respective employees, agents and representatives, collectively referred to herein as “Company” or “Client”) agrees to engage Clinical Reference Laboratory, Inc., a Kansas corporation (hereinafter “CRL”) to furnish specific services, as set forth and defined herein. “Affiliate” means any entity that directly, or indirectly through one or more intermediaries, is controlled by, is under common control with, or controls, a party to this Agreement.
This Limited Laboratory and Administrative Services Agreement (“LLASA”), including associated Exhibits, Schedules and any Statement(s) of Work executed hereunder or attached hereto (collectively, the “Agreement”), shall become effective upon Closing and as of the Closing Date of the Strategic Alliance Agreement (“SAA”) (“Effective Date”) entered into by the parties coincident herewith. The LLASA shall be construed wherever possible to avoid conflict between the documents comprising the SAA and the documents comprising the LLASA. The fact that a clause appears in one document but not another shall not be considered a conflict.
SIGNATURES:
By signing below, the undersigned certify that they have read and understand, and agree to be legally bound by, the terms and conditions of this Agreement.


1
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

CRL:
 
 
COMPANY:
 
CLINICAL REFERENCE LABORATORY, INC.
(by its authorized representative)
 
 HOOPER HOLMES, INC.
(by its authorized representative)
 
 
 
 
 
By:
/s/ Timothy S. Sotos
 
By:
/s/ Henry E. Dubois
 
 
 
 
 
Print Name:
Timothy S. Sotos
 
Print Name:
Henry E. Dubois
 
 
 
 
 
Title:
Chairman/CEO
 
Title:
President/CEO
 
 
 
 
 
Address:
8433 Quivira Road
 
Address:
560 N Rogers Road
 
Lenexa, KS 66215
 
 
Olathe, KS 66062
 
 
 
 
 
Date:
April 16, 2014
 
Date:
April 16, 2014
 
 
 
 
 
 
 
 
 
 
CRL CONTRACT ID #
     
 
COMPANY CONTRACT ID #:
     
 
 
 
 
 

CRL is a laboratory specializing in human specimen and bodily fluid analysis for the purpose of health assessment screening. CLIENT desires to utilize CRL for laboratory testing services and related compliance services to support CLIENT’s provision of health risk assessment and wellness programs in the United States, Puerto Rico and Guam, pursuant to the provisions of this Agreement.
A G R E E M E N T:
1.
Services Performed. During the term of this Agreement, and subject to the performance of CLIENT hereunder, CRL agrees to provide and perform the following services (the “Services”) for CLIENT consistent with the agreed to performance specifications, applicable Federal and state laws, statutes, regulations, and rules (“Laws”) and commensurate with standard industry practices in the wellness laboratory testing market:
(a)
Laboratory Services, including baseline laboratory testing (blood, dried blood spot, oral fluid, and/or urine analysis) for each specimen (“Specimen”) and reporting of lab test results, as more fully described in Schedule A-Pricing attached hereto and the Specification of Lab Services Agreement (“SLSA”) entered into by the parties simultaneously herewith;
(b)
Administrative Services, including the fulfillment of responsibilities necessary for the conduct of CLIENT’s Health and Wellness events in compliance with applicable Laws, as more particularly described in Schedule B-Pricing attached hereto and the Specification of Administrative Services Agreement (“SASA”) entered into by the parties simultaneously herewith;
(c)
Any other additional or optional laboratory tests and/or services as otherwise directed by CLIENT and accepted in writing by CRL.

2
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

2.
Term. This Agreement shall become effective on the Closing Date of the SAA (the “Effective Date”) and shall expire at the end of five (5) years from the Effective Date (the “Initial Term”) unless auto-renewed or sooner terminated by either party by notice to the other party as follows:
(a)
For Cause. In the event the other party commits a material breach of this Agreement, the party wishing to terminate on the basis of a material breach shall give the breaching party written notice specifying the nature of the breach, as follows:
(i)
In the event of Chronic Failure as defined in Exhibit A to the SLSA or Exhibit B to the SASA, CRL shall have five (5) days following the date of such written notice in which to cure such default.
(ii)
For any material breach, other than a Chronic Failure, the breaching party shall have thirty (30) days following the date of such written notice in which to cure such default.
If the breaching party fails or is unable to cure such default within such period, the party wishing to terminate this Agreement may do so by written notice at the expiration of the cure period.
(b)
Contract Buy Out If CLIENT sells substantially all of its assets (or any other transaction that results in a change of control of CLIENT) during the Initial Term and the purchaser does not assume CLIENT’s obligations under this Agreement pursuant to Section 3(e) of this Agreement (or if CLIENT otherwise engages in any other transaction during the Initial Term in which the surviving entity desires to terminate this Agreement), CLIENT may terminate this Agreement by providing to CRL at least ninety (90) days before the effective date of such termination written notice of termination together with a buyout fee in cash equal to the Purchase Price (as defined in the SAA), reduced ratably on a straight line basis over a five year period for each complete month commencing from the Effective Date to the effective date of termination.
(c)
Bankruptcy. In the event a party files for protection under any bankruptcy or creditor’s rights statutes or has such action filed against it and the action is not dismissed within thirty (30) days.
(d)
Auto Renew. Unless notice to the contrary is given, by either party, at least one (1) year prior to end of the then-current term, this Agreement shall automatically renew for successive additional five (5) year terms with each such renewal a “Renewal Term”.
Following expiration or termination, this Agreement shall be of no further force or effect except that: (i) each party shall remain liable for its own liability arising prior to such expiration or termination, and (ii) the provisions of Sections 5, 9 and 11 shall survive.
3.
Pricing and Payment.
(a)
Pricing. CRL agrees to provide Services in exchange for timely payment from CLIENT. CRL shall invoice CLIENT once per calendar month for Services requested by CLIENT and performed by CRL, in accordance with the prices contained in Schedule A and Schedule B attached hereto (“Price List”).
(b)
Except as stated in this provision, the Price List is guaranteed for the Initial and any Renewal Term of this agreement:
i)
Fees for sample shipping/postage may increase, with thirty (30) days written notice by CRL to CLIENT, whenever CRL receives price increase from its vendors, and/or

3
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

i)
Prices for specimen collection kits may increase, with thirty (30) days written notice by CRL to CLIENT, whenever CRL receives price increase from its vendors.
ii)
CRL has the right to increase its prices on each anniversary date of this Agreement. Such increase shall be no greater than the increase in the Consumer Price Index (CPI-U), published by the United States Bureau of Labor Statistics from the more recent of the Effective Date or most recent date of a CRL price increase to the date CRL notifies CLIENT of the new prices. CRL will notify CLIENT at least sixty (60) days prior to the anniversary date of the Agreement on which such price increase shall become effective. If CRL notifies CLIENT of a price increase that is greater than the increase in the Consumer Price Index (CPI-U), published by the United States Bureau of Labor Statistics from the more recent of the Effective Date or most recent date of a CRL price increase to the date CRL notifies CLIENT of the new prices, CLIENT shall have the right, effective on the date the new pricing is to take effect and upon no less than thirty (30) days prior written notice to CRL,
x)        to terminate this Agreement , or
y)        to modify this Agreement in writing only insofar as to permit CLIENT to purchase such Services from CRL as CLIENT requests (subject to a renegotiated price), and to meet its remaining requirements by either in-sourcing its lab testing services insofar and only as necessary to support its H&W Business or procuring lab testing services from another vendor to the extent CLIENT determines in its discretion.
If CLIENT fails to provide CRL timely notice of termination or modification under this Section3(b), then the price increase shall become effective and CLIENT shall have no right to exercise its options under Section 3(b)) unless and until a subsequent price increase greater than the increase in the Consumer Price Index (CPI-U) is imposed.
(c)
Payment. CLIENT shall pay all undisputed CRL invoices no later than forty-five (45) days following CRL's submission to CLIENT of a correct invoice for services performed by CRL during the preceding month. If CLIENT does not make full payment to CRL within forty-five (45) days following CRL's delivery of the undisputed invoice to CLIENT, the payment shall immediately become subject to a fee equal to one and a half (1 ½ %) of the amount due, with the entire one and a half percent (1 ½%) fee accruing on the forty-sixth (46th) day after CRL delivers the invoice to CLIENT. In the event CLIENT fails to pay undisputed charges within sixty (60) days, CRL shall have the right to cease providing the Services and reporting results on CLIENT’s account until payment is brought current. CRL’s suspension of Services and reporting results shall not constitute a breach of this Agreement provided CRL resumes all Services and reporting results promptly upon CLIENT’s payment of arrears.
(d)
Disputes. CLIENT may withhold payment of charges in dispute upon notice to CRL specifically identifying the charge and the reason it is disputed. The withholding of charges in dispute will not be considered overdue and the late fees described in 3(c) shall not apply. Following resolution of the dispute, CLIENT shall pay any properly due charges promptly upon receipt of a corrected invoice.
(e)
Minimum Threshold. If CLIENT sells substantially all of its assets (or any other transaction that results in a change of control of CLIENT) during the Initial Term and the purchaser assumes CLIENT’s obligations under this Agreement, the purchaser shall be obligated to order and/or pay for a minimum of 300,000 Specimen testings per year at the Prices specified in Schedule A for each Contract Year

4
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

during the Initial Term (the “Minimum Threshold”). For purposes of this Agreement, “Contract Year” means a period beginning on the Effective Date or any anniversary of the Effective Date and ending twelve (12) months later.
4.
Exclusivity
(a)
During the term of this Agreement, CLIENT shall use CRL as its exclusive provider of the Lab Tests specifically listed in Schedule A , except that:
i)
CLIENT shall remain free to procure Lab Tests from third party walk-in laboratory providers; and
ii)
CLIENT shall remain free to in-source Lab Services or procure Lab Services from a third party vendor in accordance with Section 3(b)(iii)(y) of the Agreement;
iii)
CLIENT shall remain free to manufacture or assemble wellness specimen collection kits or kit components for its own use, or to procure wellness specimen collection kits or kit components from third party vendors. Nothing in this provision shall obligate CLIENT to use or procure CRL’s wellness specimen collection kits.
iv)
CLIENT shall remain free to maintain a Certificate of Waiver exclusively to conduct waived laboratory tests, as defined in the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), in the ordinary course of and exclusively in support of its H&W Business.
v)
In the event CRL is incapable (as a matter of law or fact) of providing Administrative Services in a particular jurisdiction and the parties are unable to achieve a mutually acceptable alternative approach despite good faith effort, CLIENT shall be free to procure Lab Services or otherwise engage a third party vendor (including another clinical laboratory) to enable CLIENT to conduct its H&W Business in accordance with the Laws of the relevant jurisdiction. In the event CRL thereafter becomes capable of providing Administrative Services for such relevant jurisdiction, CRL shall notify CLIENT and, within thirty days thereafter, CLIENT will begin to procure Lab Services and Administrative Services from CRL related to any future H&W event where CLIENT is not yet obligated to procure such services from a third party.
(b)
During the Initial Term and all Renewal Terms, CRL shall include CLIENT as a member of CRL’s preferred provider network for wellness programs.
5.
Confidentiality
(a)
Confidential Information. As used in this Agreement, “Confidential Information” shall mean any information (whether written, oral or electronic) which is confidential or proprietary information of the disclosing party, which shall be deemed to include without limitation, nonpublic personal and/or protected health information of an individual, technical information, laboratory technology or procedures, processes, techniques, formulas, compounds, methodologies, research, developments, plans, licenses, information and computer systems, data, know-how, trade secrets, customers, customer lists, business prospects, catalogs and price lists, records, policies, business plans and strategy, business alliances, budgets, financial information, and information related to the disclosing party’s business, operations, assets, liabilities, equity ownership and control, marketing programs, courier systems, billing systems, personnel, suppliers and all other confidential and

5
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

proprietary information of whatever description that may be divulged to the receiving party. Notwithstanding the foregoing, such definition of Confidential Information shall not include information that: (i) is, as of the time of its disclosure, or thereafter becomes, part of the public domain from a source other than the receiving party or its affiliates, employees and agents; (ii) was known to the receiving party as of the time of its disclosure, as established by written documentation bearing a date prior to the time of disclosure by the disclosing party; or (iii) is subsequently legally learned from a third party not subject to an obligation of confidentiality with respect to the information disclosed.
(b)
Non-Disclosure. The receiving party covenants and agrees to maintain the Confidential Information of the disclosing party in strict confidence and not disclose or divulge such Confidential Information, using the same degree of care as it uses to protect its own Confidential Information of like nature, but not less than a reasonable degree of care for the kind of information involved. Without limiting the generality of the foregoing, the receiving party shall: (i) not, directly or indirectly, disclose any such Confidential Information to any person outside its business organization, and disclose only the minimum necessary Confidential Information to persons within its business organization (including employees, officers, directors, representatives, and agents) on a “need to know” basis who have executed confidentiality agreements with the receiving party that are at least as comprehensive as the provisions of this Agreement; (ii) not disclose any Confidential Information that would violate any federal or state laws, including without limitation the Gramm-Leach-Bliley Act (“GLBA”) and/or the Health Insurance Portability and Accountability Act (“HIPAA”), (iii) maintain physical, electronic and procedural safeguards to protect the Confidential Information, (iv) comply with the provisions of Exhibit A – Business Associate Agreement, (v) not, directly or indirectly, copy, reproduce, distribute, manufacture, duplicate, reveal, report, publish, disclose, cause to be disclosed, reverse engineer, decompile, assign or otherwise transfer such Confidential Information; and ((vi) return such Confidential Information to the disclosing party upon the disclosing party’s request provided that the receiving party may retain one copy of the Confidential Information for legal archival purposes only. The receiving party shall notify the disclosing party promptly in the event the receiving party receives legal process that would require disclosure of Confidential Information.
(c)
Non-Use. The receiving party shall not use the Confidential Information of the disclosing party for its own benefit or the benefit of any person or entity other than disclosing party, and only as instructed by the disclosing party. Notwithstanding the foregoing, CRL shall have the right, without either directly or indirectly identifying CLIENT or the Specimen donor, to utilize the results or other information from CLIENT and/or Specimen donor in statistical analysis, and CLIENT shall have the right to utilize the results or other information from Specimen donor in statistical analysis.
(d)
Proprietary Rights. The receiving party recognizes and acknowledges that the Confidential Information of the disclosing party is confidential and the property of the disclosing party and comprises “trade secrets” as that term is defined in the Kansas Trade Secrets Act set forth in K.S.A. 60-3320 et. seq. and that the protections afforded the disclosing party under this Agreement concerning such Confidential Information are in addition to those provided by such act. All proprietary rights created or developed by the receiving party arising out of or related to the Confidential Information of the disclosing party shall be owned by the disclosing party. The receiving party is not granted any license or other interest in such proprietary rights or any portion thereof.
(e)
Remedies. In the event that either party is in material breach of any provision of this Agreement, it shall immediately advise the non-breaching party and take steps to remedy such breach, including

6
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

but not limited to protecting customers, the non-breaching party and its affiliates against the consequences of any disclosure or use of Confidential Information in violation of this agreement. The receiving party acknowledges that use or disclosure of the Confidential Information of the disclosing party, whether by the receiving party, its employees, or any person or other entity associated with or under the control of the receiving party, in a manner inconsistent with this Agreement, will result in irreparable and continuing damage to the disclosing party for which there will be no adequate remedy at law and that the disclosing party may therefore obtain, in addition to any other legal remedies which may be available, such equitable relief as may be necessary to protect the disclosing party against any such breach or threatened breach, including, without limitation, injunctive relief.
6.
Intellectual Property. The parties herein agree that CRL possesses certain intellectual property; including inventions, know-how, trade-secrets, analytical methods, computer technical expertise, software and statistical methodologies originated by CRL prior to or under or during the term of this Agreement without benefit of information provided by CLIENT (CRL’s “Intellectual Property”). CRL’s Intellectual Property is the sole property of CRL. Further, to the extent that any improvement to or addition to CRL’s Intellectual Property, as such improvement or addition related to performing laboratory analyses and Services, made by CRL in the course of performing the Services under this Agreement, such improvement and/or addition to CRL’s Intellectual Property shall be the sole and exclusive property of CRL. Any invention that directly relates to CLIENT’s data or Confidential Information or any unique technology developed expressly and solely for CLIENT which directly relates to the Services provided by CRL hereunder shall belong to CLIENT.
7.
Information Security and Business Continuity. CRL will comply with applicable regulations related to Information Security and Privacy as set forth in Exhibit A and use commercially reasonable efforts to ensure continuity of its business operations in support of providing the Services to CLIENT.
8.
Maintenance of records. CRL agrees to establish and maintain true and correct (in all material respects) records of all transactions and Services arising out of this Agreement. Such records shall be maintained in paper and/or electronic images for no less than seven (7) years.
9.
Indemnification.
(a)
By CRL. CRL shall indemnify and save CLIENT, and its officers, directors, employees, agents, or representatives harmless from and against all damages sustained or incurred by a third party arising from personal injuries or other claims recovered against CLIENT, as a result of any negligent act or omission of CRL, its agents, servants, or employees, arising out of or related to this Agreement, including any and all reasonable expense, legal or otherwise, incurred by CLIENT or its officers, directors, employees, agents, or representatives in the defense of any such third party claim or suit.
(b)
By CLIENT. CLIENT shall indemnify and save CRL, and its officers, directors, employees, agents or representatives harmless from and against all damages sustained or incurred by a third party arising from personal injuries or other claims recovered against CRL, as a result of any negligent act or omission of CLIENT, its agents, servants, or employees, arising out of or related to this Agreement, including any and all reasonable expense, legal or otherwise, incurred by CRL, or its officers, directors, employees, agents, or representatives in the defense of any such third party claim or suit.
(c)
Claims for indemnity under this Agreement shall be subject to the following additional terms: (i) The indemnified party shall provide prompt written notice, in reasonable detail, of any claim for which it

7
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

may seek indemnification hereunder; (ii) If such notice is not provided within the time stated above, the indemnified party nonetheless shall be entitled to indemnification by the indemnifying party, except to the extent that indemnifying party is actually prejudiced by the late receipt of such notice; (iii) The Indemnified Party agrees to cooperate with Indemnifying Party in a commercially reasonable manner in the defense of such claim. Indemnifying Party shall at all times keep the Indemnified Party reasonably apprised of the status of any such action; (iv) The Indemnifying Party shall not effect a settlement of any such claim, without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld. It shall not be considered unreasonable to withhold consent if the settlement contains any admission on the part of the Indemnified Party of wrongdoing or contains any sanctions other than the payment of money that the Indemnifying Party agrees to and is able to pay.
10.
Insurance. CRL and CLIENT each, at its sole cost and expense, shall procure and maintain policies of comprehensive general liability and other insurance in the minimum amounts of $1,000,000.00 per occurrence/$2,000,000.00 aggregate to insure such party and its officers, agents, and employees against liability, claims or damages in connection with the performance of such party’s responsibilities under this Agreement. Evidence of each party’s policies shall be submitted to the other upon the other’s written request.
11.
Consequential Damages. CRL and CLIENT shall not be liable for any indirect, consequential, incidental, special, punitive or other damages (except as specified herein) of any kind arising from any claim, whether based on contract, negligence, tort, strict liability or other theory, arising out of this Agreement.
12.
Limitation of Liability. Either Party’s entire liability and the other party’s exclusive remedy for damages on account of any claim arising out of this Agreement shall be limited as follows:
(a)
Direct damages in the case of bodily injury, death or damage to real property or to tangible personal property proximately caused by a party’s negligence;
(b)
The amount of the penalty or fine finally assessed in the case of penalties or fines imposed by a regulatory entity arising from CLIENT’s performance of delegated Administrative Services;
(c)
Direct damages in the case of all other claims, on a per claim or aggregate basis during any twelve (12) month period, not to exceed 25% of the Purchase Price as defined in the Strategic Alliance Agreement.
13.
Independent Relationship. The relationship between CRL and CLIENT pursuant to this Agreement is that of independent entities contracting with each other, and neither party shall be construed to be a joint venturer, partner, agent, employee, or representative of the other.
14.
Force Majeure. No party to this Agreement shall be liable for failure to perform any duty or obligation that said party may have under this Agreement where such failure has been occasioned by any act of God, fire, strike, inevitable accident, war or any cause outside the reasonable control of the party who had the duty to perform.
15.
Publication. Neither of the parties herein shall use the name of the other party in any advertising or promotional literature of any type without that party’s prior written approval.
16.
Notices. Any required notices under this Agreement shall be in writing and shall be deemed validly delivered if made by hand (in which case delivery will be deemed to have been effected immediately),

8
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

or by overnight mail (in which case delivery will be deemed to have been effected one (1) business day after the date of mailing), or by first class pre-paid post (in which case delivery will be deemed to have been effected five (5) days after the date of posting), or by facsimile or electronic transmission (in which case delivery will be deemed to have been effected on the day the transmission was sent). Any such notice shall be sent to the office of the recipient set forth on the cover page of this Master Agreement or to such other office or recipient as designated in writing from time to time.
17.
Assignment. Neither party’s rights or obligations under this Agreement (except the right to receive money) will be assigned or delegated without the written consent of the other party, except that either party may without such consent assign all of its rights and delegate all of its obligations under this Agreement to an entity: (a) which such party owns or controls; (b) by which such party is owned or controlled; or (c) which is under common ownership or control with such party provided, however, that the assigning party shall remain liable to the non-assigning party for the timely performance of the obligations assigned. In the case of any assignment permitted hereunder without the other party’s consent, the assignor will promptly notify the non-assigning party in writing of the assignment and will include in its notice a statement of the facts that permit assignment without consent.
18.
Solvency.
(a)    CRL is not now insolvent and will not be rendered insolvent by any of the Contemplated Transactions. As used in this Section, “insolvent” means that the sum of the debts and other probable liabilities of CRL exceeds the present fair saleable value of CRL’s assets.
(b)
Upon signing the Agreement:
(i)
CRL will be able to pay its liabilities as they become due in the usual course of its business;

(ii)
CRL will not have unreasonably small capital with which to conduct its present or proposed business;

(iii)
CRL will have assets (calculated at fair market value) that exceed its liabilities; and

(iv)
taking into account all pending and threatened litigation, final judgments against CRL in actions for money damages are not reasonably anticipated to be rendered at a time when, or in amounts such that, CRL will be unable to satisfy any such judgments promptly in accordance with their terms (taking into account the maximum probable amount of such judgments in any such actions and the earliest reasonable time at which such judgments might be rendered) as well as all other obligations of CRL.

19.
General Provisions. This Agreement shall be governed by the laws of the State of Kansas without regard to the choice-of-law principles thereof, and is the entire agreement of the parties related to the subject matter hereof. No amendment or waiver of any provision of this Agreement will be effective unless in a writing signed by the parties. The illegality or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any legal and enforceable provisions hereof. Any headings used herein are for convenience of reference only and are not a part of this Agreement, nor shall they affect the interpretation hereof. This Agreement may be executed in multiple counterparts, each of which is an original, true and correct version hereof, and shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators, successors, and permitted assigns.

9
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended


EXHIBIT A
Business Associate Agreement

WHEREAS, under the Agreement, CRL (“BA”) may perform or assists in performing function(s) or activity(s) on behalf of Client that involves the use and/or disclosure of protected health information, as defined below.
NOW THEREFORE, in consideration of the mutual promises and representations contained herein and in the Agreement, the parties hereto agree as follows:
1)
Definitions. Business Associate Agreement (hereinafter referred to as “BA Agreement”), the following definitions shall apply:
A)
Agreement
Means the agreement executed between the parties relating to the provisions of services and all amendment or addendums thereto.
B)
Business Associate Functions
Means functions performed by business associate on behalf of Client pursuant to the services Agreement which involve creating, receiving, maintaining, or transmitting NPI by business associate. Business Associate Functions shall not include any function requiring a use or disclosure that would not be permissible under the Privacy Rules if done by Client.
C)
GLBA
Gramm-Leach-Bliley Act.
D)
HIPAA
Health Insurance Portability and Accountability Act.
E)
HITECH
Health Information Technology for Economic and Clinical Health Act provisions of the American Recovery and Reinvestment Act of 2009.
F)
Individual
Means the person who is the subject of the NPI and includes a person who qualifies as a personal representative in accordance with the Privacy Rules.
G)
NPI
Any nonpublic personal information of any individual as defined in Title V of GLBA and/or any PHI of any individual as defined in HIPAA.
H)
PHI
Means protected health information as defined in 45 CFR § 164.501
I)
Required by Law
A mandate contained in law that compels an entity to make a use or disclosure of NPI and that is enforceable in a court of law.
J)
Secretary
Secretary of the U.S. Department of Health and Human Services or his/her designee.
K)
Privacy Rules
Any federal or state laws concerning the privacy and security of NPI, including, without limitation, GLBA, HIPAA, and/or HITECH
L)
All other terms used but not otherwise defined in this agreement shall have the meaning ascribed in the HIPAA regulations.
2)
Permitted Uses and Disclosure of NPI. Except as otherwise limited in this BA Agreement and/or the Agreement,

10
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

A)
BA may use NPI to perform the functions, activities or services for or on behalf of Client as specified in the Agreement provided that such use and/or disclosure would not violate any federal or state laws, including, without limitation, the Privacy Rules, if done by Client.
B)
BA may use NPI (i) as set forth in the Agreement, (ii) for proper management and administration of BA, and to carry out the legal responsibilities of BA; and (iii) for the provision of Data Aggregation services relating to the Healthcare Operations of the Covered Entity.
C)
BA may disclose NPI as set forth in section 2(b) above, provided that disclosures are (i) Required by Law, or (ii) BA obtains reasonable assurances from the person to whom the information is disclosed that it will remain confidential and used or further disclosed only as Required by Law or for the purpose for which it was disclosed to the person, and the person notifies BA of any instances of which it is aware in which the confidentiality of the information has been breached.
D)
BA may de-identify any and all NPI created or received by BA under this BA Agreement and/or the Agreement; provided however, that the de-identification conforms to the requirements of the Privacy Rules. Such resulting de-identified information would not be subject to the terms of this BA Agreement.
E)
BA may use NPI to report violations of law to appropriate Federal and State authorities, consistent with 45 C.F.R. 164.502(j)(1).
3)
Responsibility of BA. With regard to the use and/or disclosure of NPI, BA hereby agrees to do the following:
A)
Use of Disclosure of NPI. Not use and/or disclose NPI other than as permitted or required by the Agreement or this BA Agreement or as Required by Law;
B)
Safeguards. Maintain and use appropriate safeguards (including administrative, physical and technical safeguards that reasonably and appropriately protect the confidentiality, integrity and availability of the electronic NPI that BA creates, receives, maintains or transmits on behalf of Client as required by 45 CFR 164.314) to protect and prevent the use and/or disclosure of NPI other than as provided by this BA Agreement or the Agreement. BA shall document and keep these safeguards current;
C)
Mitigation. Mitigate, to the extent practicable, any harmful effect that is known to BA of a use or disclosure of NPI by BA in violation of the requirements of this BA Agreement or the Agreement;
D)
Reporting.
a)    Promptly notify Client of any use and/or disclosure of NPI not provided for by this BA Agreement or the Agreement of which it becomes aware;
b)    Report to Client any Security Incident in regard to Client’s electronic NPI of which BA becomes aware. This does not include trivial incidents that occur on a routine basis, including but not limited to scans, “pings” or unsuccessful attempts to penetrate computer networks or servers maintained by BA;
c)    With the exception of law enforcement delays that satisfy the requirements of HIPPA or as otherwise required by law, BA shall notify CLIENT promptly, in writing without unreasonable delay and in no case later than sixty (60) calendar days, upon the discovery of a breach of Unsecured NPI. Such notice shall include, to the extent possible, the name of each individual whose Unsecured NPI has been, or is reasonably believed by BA to have been accessed, acquired, or disclosed during such breach. BA shall also, to the extent possible, furnish Client with any other available information that Client is required to include in its notification to individuals under HIPPA at the time of BA’s notification to Client or promptly thereafter as such information becomes available. For purposes of this BA Agreement, a breach of Unsecured NPI shall be treated as discovered by BA as of the first day on which such breach is known to BA or should reasonably have been known to BA by exercising reasonable diligence.
E)
Agents/Subcontractors. to ensure that any agent, including subcontractors, to whom it provides NPI received from, or created or received by BA on behalf of Client, agrees to the same restrictions and conditions that apply to BA pursuant to this BA Agreement and the Agreement, including but not limited to implementing reasonable and appropriate safeguards to protect it;

11
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

F)
Access.
Provide access, at the request of Client, within two (2) weeks from the date of receipt of such request, to NPI in a Designated Record Set received from, or created or received by BA on behalf of Client, to Client in order to meet the requirements under Privacy Rules. This provision shall be applicable only if BA has NPI in a Designated Record Set;
Make internal practices, books, and records, including policies and procedures and NPI, relating to the use and/or disclosure of NPI received from, or created or received by BA on behalf of Client, available to Client, or at the request of Client, to the Secretary, in a time and manner mutually agreed upon or as is designated by the Secretary for purposes of determining Client’s compliance with the Privacy Rules;
G)
Amendments. Make any amendment(s), within two (2) weeks from the date of the receipt of such request, to NPI in a Designated Record Set that Client directs or agrees to pursuant to Privacy Rules, at the request of Client. This provision shall be applicable only if BA has NPI in a Designated Record Set;
H)
Accounting of Disclosures.
Document such disclosures of NPI and information related to such disclosures as would be required for BA to respond to a request by an individual for an accounting of disclosures of NPI in accordance with Privacy Rules; and
Provide to Client, within two (2) weeks from the date of the receipt of such request, a description of any disclosures of NPI and information related to such disclosures to permit Client to respond to a request by an individual for an accounting of disclosures of NPI in accordance with Privacy Rules.
I)
Restrictions. BA shall comply with an individual’s request to restrict disclosure of NPI of that individual and shall notify Client of individual’s request within ten (10) business days of such request; where such individual is a customer of Client. Upon request of Individual, BA will not disclose Individual’s NPI for purposes of payment or Healthcare Operations when Individual paid in full out of pocket for Services to which NPI relate (45 CFR § 164.522)
J)
Minimum Necessary. BA shall limit its use, disclosure, or request of NPI to the minimum necessary to accomplish the intended purpose of such use, disclosure or request as agreed to by the parties pursuant to the Agreement.
K)
Remuneration. BA may not receive direct or indirect remuneration in exchange for NPI, except where so authorized by the individual or by law.
L)
Alternative Communications. BA agrees to accommodate alternative means or alternative locations to communicate NPI, and document those alternate means or alternate locations, at the request of Client or an individual pursuant to 45 CFR 164.522(b), in a prompt and reasonable manner consistent with HIPAA.
4)
Obligations of Client.
A)
Client shall provide BA with any limitations in its notice of privacy practices that Client produces in accordance with Privacy Rules as well as any changes to such limitations, to the extent that such limitations may affect BA’s use or disclosure of NPI.
B)
Client shall notify BA of any changes in, restrictions to, or revocation of, use or disclose of individual’s NPI, to the extent that such changes may affect BA’s use or disclosure of NPI.
C)
Client shall obtain any consent, authorization or permission that may be required by the Privacy Rules or applicable state laws and/or regulations prior to furnishing BA the NPI pertaining to an individual.
D)
Client shall not request BA to use or disclose NPI in any manner that would not be permissible under the Privacy Rules if done by Client.
5)
Term. This BA Agreement shall survive the termination of the Agreement and shall continue for as long as BA has access to NPI. In the event that any term or provision of this BA Agreement shall conflict with any term or provisions of the Agreement, the term of provision of this BA Agreement shall govern, control and be given effect. All other terms and conditions of the Agreement shall remain in full force and effect. Client may immediately terminate any and/or all Agreements between BA and Client if Client determines that BA has violated any material

12
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

requirements of the Privacy Rules or this BA Agreement. Alternatively, at the discretion of Client, Client may grant to BA a reasonable time in which to cure any such violations to the reasonable satisfaction of Client.
A)
Except as provided in Section 5.B. below, upon termination of the Agreement and this BA Agreement, for any reason, BA shall destroy all NPI received from Client, or created or received by BA on behalf of Client. This provision shall apply to NPI that is in the possession of subcontractors or agents of BA. Notwithstanding the foregoing and to the extent permitted by law, BA may keep a copy of any NPI received from Client or received or created by BA on behalf of Client for maintaining reasonably appropriate business records, as may be required by law, or to the extent such NPI is incorporated into BA’s systems or databases.
B)
If BA determines that destroying the NPI is infeasible, BA shall provide to Client notification of the conditions that make destruction infeasible. BA shall extend the protections of this BA Agreement to such NPI and limit further uses and disclosures of such NPI to those purposes that make the destruction infeasible, for so long as BA maintains such NPI.
6)
Amendment. The parties agree to take such action as is necessary to amend the Agreement and this BA Agreement from time to time as is necessary for Client to comply with the requirements of the Privacy Rules. The parties agree to negotiate such amendments in good faith in order to bring Client into compliance with Privacy Rules. Any such amendments will be in writing and signed by both parties. In the event that Parties cannot agree on the terms of any required amendment, either party may immediately terminate the Agreement and such termination will not be considered a breach of the Agreement or this BA Agreement.
7)
Interpretation. Any ambiguity in the Agreement or this BA Agreement shall be resolved in favor of the meaning that permits Client to comply with the Privacy Rules. If there is a dispute in the interpretation, the parties will enter into good faith negations to try and resolve the dispute. If the dispute cannot be resolved, either party may immediately terminate the Agreement and such termination will not be considered a breach of the Agreement or this BA Agreement.
8)
Indemnification.
A)
By BA. BA shall indemnify and save CLIENT, and its officers, directors, employees, agents, or representatives harmless from and against all damages sustained or incurred by a third party arising from personal injuries or other claims recovered against CLIENT, as a result of any negligent act or omission of BA, its agents, servants, or employees, arising out of or related to this BA Agreement, including any and all reasonable expense, legal or otherwise, incurred by CLIENT or its officers, directors, employees, agents, or representatives in the defense of any such third party claim or suit.
B)
By CLIENT. CLIENT shall indemnify and save BA, and its officers, directors, employees, agents or representatives harmless from and against all damages sustained or incurred by a third party arising from personal injuries or other claims recovered against BA, as a result of any negligent act or omission of CLIENT, its agents, servants, or employees, arising out of or related to this BA Agreement, including any and all reasonable expense, legal or otherwise, incurred by BA, or its officers, directors, employees, agents, or representatives in the defense of any such third party claim or suit.
9)
Notices. All notices given pursuant to this BA Agreement shall be in writing and shall be accomplished by personal delivery, certified mail or overnight mail followed by postmark within two (2) days. Any such notice shall be treated as having been given on the date of actual receipt. All such notices shall be sent as follows to the addresses set forth on the signature page of this BA Agreement.
10)
Counterparts; Facsimile Signatures. This BA Agreement may be executed simultaneously in two or more counterparts (by facsimile, email or other electronic means), each of which will be considered an original, but all of which together will constitute one and the same instrument and shall be admissible in evidence.
11)
Governing Law. This Agreement shall be governed by and construed, interpreted, and enforced in accordance with the laws of the State of Kansas, without reference to its conflicts or choice of law principles. Each party hereto agrees to the exclusive and personal jurisdiction of the District Court of Johnson County, Kansas and hereby

13
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

waives any objection it may have to the laying of venue of any such proceeding and any claim or defense of inconvenient forum.
12)
Survival. The respective right and obligations of BA and Client under Section 5 of this BA Agreement shall survive termination of this BA Agreement.

14
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended


SCHEDULE A – LAB SERVICES
PRICE LIST

The pricing below is for laboratory testing only. Collection kits, kit supplies, inbound freight, outbound freight and all other services are excluded from this pricing.
Pricing includes data entry of a maximum of three (3) fields: i) CRL Unique Barcode Sequence ID; ii) date of birth and iii) gender.
Additional data entry will be priced according to the number and complexity of fields with a maximum of ten (10) fields for an additional $[***] per sample.
Pricing includes all lab test reports being reported to CLIENT only.
Pricing includes a single, consolidated invoice for all services to CLIENT only.
Panel details and test code mapping contained in the client specification document.

ROUTINE PANELS

First 300,000 Samples in Contract Year
For Samples 300,001+ in Contract Year
Basic Blood Chemistry Profile
 
 
 
$[***]
$[***]
 
 
 
Lipid Panel
 
 
 
$[***]
$[***]
 
 
 
Metabolic Profile
 
 
 
$[***]
$[***]
 
 
 
SPECIALTY PANELS

 
 
CBC
 
 
   
$[***]
$[***]
 
 
 
Comprehensive Health Profile
 
 
   
$[***]
$[***]
 
 
 
Heart Profile
 
 
 
$[***]
$[***]
 
 
 
Electrolytes
 
 
      
$[***]
$[***]
 
 
 
Comprehensive Health Profile plus Electrolytes
 
 
 
$[***]
$[***]


15
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended

Reflex, Add-on, or Stand Alone Tests

Test
Reflex or Add-on
Stand Alone
Test 001
$[***]
$[***]
Test 002
$[***]
$[***]
Test 003
$[***]
$[***]
Test 004
$[***]
$[***]
Test 005
$[***]
$[***]
Test 006
$[***]
$[***]
Test 007
$[***]
$[***]
Test 008
$[***]
$[***]
Test 009
$[***]
$[***]
Test 010
$[***]
$[***]
Test 011
$[***]
$[***]
Test 012
$[***]
$[***]
Test 013
$[***]
$[***]
Test 014
$[***]
$[***]
Test 015
$[***]
$[***]
Test 016
$[***]
$[***]
Test 017
$[***]
$[***]
Test 018
$[***]
$[***]
Test 019
$[***]
$[***]
Test 020
$[***]
$[***]

Wal-Mart ReliOn® Tests
 
 
 
Test WM001
$[***]

Testing Fees shall not be charged for:

a.
confirmatory tests requested by CLIENT (where the confirmatory test indicates that the initial testing was inaccurate);
b.
any testing performed on replacement Specimen when the original Specimen is damaged as a result of an act or omission of CRL;
c.
any Specimen reported outside the Service Level objectives set forth in section 3.1 (b), (c) and (d) herein as calculated on a monthly basis.

In the event CLIENT’s customer requires reimbursement of testing fees for improperly tested specimens, without providing replacement specimen for re-test, CRL shall reimburse CLIENT for all testing fees applicable to the original specimen testing if previously paid by CLIENT.

Minimum Volume Pricing in the event of Change of Control (Section 3(e) of the LLASA):
If the new purchaser fails to order and pay for Services, the aggregate value of which under the LLASA meets or exceed the Minimum Threshold as set forth in Section 3(e), then such purchaser shall pay CRL an amount equal to the difference between (i) the Minimum Threshold and (ii) the number of units for which CRL received revenue in the Contract Year multiplied by 40% of the then applicable Price for the Basic Blood Chemistry Profile. Purchaser shall make this payment to CRL within fifteen (15) days after the end of each Contract Year.

16
 


Confidential Information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to this omitted information pursuant to an application for confidential treatment filed with the Commission under Rule 24b-2 under the Securities Exchange Act of 1934, as amended



SCHEDULE B - ADMINISTRATIVE SERVICES
PRICE LIST


1.
CLIENT will be responsible to pay CRL for any activity or undertaking in support of CRL’s delivery of the Administrative Services, on a time and materials basis as set forth inthis Schedule, the SASA or, any applicable SOW(s), or as mutually agreed upon for any Administrative Service not specifically included in Exhibit C or an SOW.

2.
In addition, CLIENT shall reimburse CRL for all application fees and other out of pocket expenses related to advance notification or permit requirements for H&W events. For avoidance of doubt, CRL shall be solely responsible for all costs and fees associated with state lab licenses.
3.
CRL will charge no fee for the following components of Administrative Services:
a.
Provide CRL’s written documentation of testing protocols, lab credentials, equipment, proficiency testing and other supporting data requested by a regulatory body.
b.
Affix signatures of appropriate CRL personnel for the completion of applications or permits
c.
Make available CRL’s Customer Service Representative or other personnel for meetings with regulators, except that CLIENT will reimburse CRL for reasonable travel related expenses consistent with CLIENT’s travel policies.
d.
Visits by CLIENT”s customers to CRL’s facility

4.
Where a component of Administrative Services involves CRL expenditure of personnel resources that create a materially cost to CRL, CRL will advise CLIENT of such prior to providing such Administrative Services and, upon CLIENT’s approval to perform the requested Administrative Services, will charge CLIENT for such costs as follows:
a.
Lab Director/MD Pathologist/Ph.D support - $225/hour
b.
Legal/Compliance related support - $150/hour
c.
Other Lab Personnel support - $95/hour
d.
Sales support - $95/hour
e.
Event related support - $75/hour
f.
Reimbursement of reasonable travel related expenses





17
 

EX-10.2 4 exhibit102q12014.htm EXHIBIT 10.2 exhibit102q12014

PURCHASE AND SALE AGREEMENT

THIS PURCHASE AND SALE AGREEMENT (this "Agreement") is made and entered into as of the 13th day of May 2014 (“Effective Date”) by and between McElroy Deutsch Mulvaney & Carpenter, LLP or its assignee, (the "Purchaser"), and Hooper Holmes, Inc., a New York corporation (the "Seller").

W I T N E S S E T H:

For and in consideration of the mutual covenants and agreements herein contained, Seller agrees to sell and convey to Purchaser, and Purchaser agrees to purchase from Seller, subject to the terms and conditions hereof, the "Property" and the “Included Personal Property” (as hereinafter defined).

NOW, THEREFORE, the parties hereto agree as follows:


1.    Definitions    . The terms defined in this Section 1 shall have the respective meanings stated in this Section 1 for all purposes of this Agreement, except as otherwise expressly provided or unless the context otherwise requires:

1.1    Building shall mean the approximately 52,000 square foot building plus detached maintenance garage facility and all other buildings and structures as well as the generator now or at the Closing Date (as hereinafter defined) situated on the Land (as hereinafter defined).

1.2    Business Day or Business Days shall mean those days of the week which are not Saturday, Sunday or a federal, State of New Jersey or bank holiday.

1.3    Closing shall mean actions whereby Seller conveys to Purchaser and Purchaser purchases and accepts from Seller legal title to the Property, subject to and in accordance with this Agreement.

1.4    Closing Date shall mean the date as defined in Section 5.2 hereof.

1.5    Deposit shall mean the aggregate principal sum of One Hundred Fifty Thousand Dollars ($150,000) to be deposited by Purchaser with the Escrow Agent (hereafter defined) pursuant to the provisions of Sections 3.1(a) and (b) hereof.

1.6    Effective Date shall mean the date the last party to sign this Agreement delivers the fully executed Agreement to the other party.

1.7    End of the Inspection Period shall mean 5:00 p.m. New Jersey time on the date that is forty (40) days subsequent to the Effective Date.

                                    
1.8    Land shall mean all those certain tracts or parcels of land situated and lying and being designated as Lot 4 in Block 2401 on the Tax Map of Bernards Township. Somerset County, New Jersey, which are more particularly described on Schedule 1.8 annexed hereto and made a part hereof.


-1-




1.9    Other Seller Interests shall mean all of the right, title and interest, if any, of Seller in and to the following:

(a)    Any easements, rights of way, privileges, rights, appurtenances, hereditaments, oil and mineral rights, grants of right, or other agreements benefiting the Property and any and all rights and privileges to further develop the Property, the Land or any portion thereof; and

(b)    Any land lying in the bed of any street, road, alley or avenue, public or private, opened or proposed, in front of or adjoining the Property, any strips or gores adjoining or relating to the Property or any part thereof, any award made or to be made in lieu thereof, and any unpaid award for damages to said Property by reason of change of grade of any street.

1.11    Permitted Exceptions shall mean collectively the following: (i) those restrictions, encumbrances, covenants, agreements, easements, matters and things of fact or of record affecting title to the Property; (ii) real estate taxes not due and payable as of the Closing Date; (iii) encumbrances on the Property caused solely by Purchaser or its agents, employees, contractors or consultants; (iv) such state of facts as an accurate Survey of the Property would disclose; and (v) zoning ordinances and development and building regulations or requirements adopted by any governmental or municipal authority having jurisdiction over the Property, and any amendments and additions thereto now or hereinafter in force and effect that relate to the Property.

1.12    Property shall mean the Land, the Other Seller Interests, the Site Improvements, the Building, and the Included Personal Property.

1.13    Service Contracts shall mean those contracts relating to or affecting the use or operation of the Property, such as service utility, maintenance, labor, and similar agreements, which are set forth in Schedule 1.13 annexed hereto and made a part hereof. To the extent Purchaser identifies and accepts in writing other such agreements prior to Closing, those agreements shall be deemed Service Contracts for the purposes of this Agreement.

1.14    Site Improvements shall mean all of the parking lots, driveways, pavings, access cuts, parking lot striping, lighting, bumpers, drainage systems and landscaping situated upon the Land.

1.15    Title Company shall mean a reputable title insurance company selected by the Purchaser.

2.    Sale of the Property    . Upon and subject to the terms and conditions contained in this Agreement, Seller agrees to sell and convey to Purchaser, and Purchaser agrees to purchase and accept from Seller, title to the Property free and clear of any and all mortgages, liens, claims, or encumbrances affecting such title, except the Permitted Exceptions and such other matters approved in writing by Purchaser.

3.    Purchase Price and Payment; the Deposit    .

3.1    The purchase price for the Property to be sold to Purchaser pursuant to this Agreement shall be the sum of Three Million Fifty Thousand and 00/100 U.S. DOLLARS


-2-



($3,050,000.00) (the "Purchase Price"), which sum shall be payable by Purchaser to Seller as follows:

(a)    Simultaneously with the execution of this Agreement by all parties, Purchaser shall deliver Seventy-Five Thousand and 00/100 U.S. DOLLARS ($75,000.00) of the Deposit to The Garibaldi Group, LLC (the “Escrow Agent”).

(b)    One business day after the End of the Inspection Period, an additional sum of Seventy-Five Thousand and 00/100 U.S. DOLLARS ($75,000.00) shall be paid by Purchaser to Escrow Agent, which shall be part of the Deposit. The parties agree to direct the Escrow Agent to release the Deposit to Seller or return the Deposit to Purchaser, as the case may be, as provided in this Agreement.

(c)    At Closing, the sum of Two Million Nine Hundred Thousand and 00/100 U.S. DOLLARS ($2,900,000.00) shall be paid by Purchaser to Seller by certified check, official bank check or confirmed federal wire transfer of immediately available funds, as Seller shall direct.

3.2    (a)    The Escrow Agent shall hold the Deposit when received until such time as (i) the Deposit is applied at Closing to the Purchase Price; or (ii) pursuant to the provisions of this Agreement, the Deposit is to be released to Purchaser or to Seller. The Escrow Agent shall invest the Deposit into a non-interest bearing federally insured short-term trust account or accounts reasonably acceptable to the Escrow Agent. The Escrow Agent may not commingle the Deposit with other funds of the Escrow Agent. If the Purchaser terminates this Agreement as provided in Section 7.4 hereof, then the Escrow Agent shall return the Deposit to Purchaser promptly following such termination.

(b)    Escrow Agent shall not be liable to any party for an act or omission, except for bad faith or gross negligence, and the parties agree to indemnify Escrow Agent and hold Escrow Agent harmless from any and all claims, damages, losses or expenses arising in connection herewith. The parties acknowledge that Escrow Agent is acting solely as stakeholder for their mutual convenience. In the event Escrow Agent receives written notice of a dispute between the parties with respect to the Deposit and the interest earned thereon (the “Escrowed Funds”), Escrow Agent shall not release and deliver the Escrowed Funds to either party but may either (i) continue to hold the Escrowed Funds until otherwise directed in a writing signed by all parties hereto or (ii) deposit the Escrowed Funds with the clerk of any court of competent jurisdiction in Morris County, New Jersey. Upon such deposit, Escrow Agent will be released from all duties and responsibilities hereunder.
(c)    Escrow Agent may defend any legal proceeding that may be instituted against it with respect to the Escrowed Funds, the Property or the subject matter of this Agreement and shall be indemnified and held harmless by Purchaser and Seller in equal amounts against the cost and expense of such defense. Escrow Agent shall not be required to institute legal proceedings of any kind and shall have no responsibility for the genuineness or validity of any document or other item deposited with it or the collectibility of any check delivered in connection with this Agreement (except for checks issued by or on behalf of Escrow Agent). Escrow Agent shall be fully protected in acting in accordance with any written instructions given to it hereunder and believed by it to have been signed by the proper parties.




-3-



4.    Adjustments and Prorations; Closing Costs    . The items of income or expense arising from the ownership or operation of the Property set forth hereinafter shall be prorated and adjusted as of 11:59 p.m. New Jersey time on the day preceding the Closing Date. All prorations, adjustments and allocations made at the Closing shall be final, except (i) for clear errors subsequently discovered and (ii) as otherwise expressly provided in this Section 4. The parties agree to work together after Closing in good faith to promptly resolve all outstanding or continuing proration and allocation matters. At the Closing, the following items of income and expense shall be allocated between the parties in accordance with the principles set out herein above, and with the following specific provisions applying to the following specific items:

4.1    (a)    Real estate taxes for the Property shall be prorated at and as of the Closing on the basis of the most recent real estate tax bill delivered to Seller.

(b)    If on the Closing Date any assessment is a lien on all or part of the Property, and such assessment is or may be payable in installments, of which the first installment is then a charge or lien, or has been paid, then Seller shall be required to pay only those installments that are due and payable on or prior to the Closing Date and the Purchaser shall be responsible for all unpaid installments after the Closing Date.

(c)    Water, sewer, electric and other utility charges for the Property. If consumption of any of the foregoing is measured by meters, prior to the Closing Date, Seller shall obtain a reading of each such meter and a final bill as of the Closing Date. If there is no such meter or if the bill for any of the foregoing will not have been issued as of the Closing Date, the charges therefor shall be adjusted as of Closing Date on the basis of the charges of the prior period for which such bills were issued and shall be further adjusted between the parties when the bills for the correct period are issued (and this obligation shall survive the Closing). Any utility security deposits to be refunded to Seller shall be obtained by Seller from the utility company and Purchaser shall make its own deposit with such companies.

(d)    Premiums on insurance policies will not be adjusted. Seller may terminate its insurance coverage as of Closing and Purchaser will effect its own insurance coverage.

(e)     Fees, charges and deposits under any Service Contracts that are assigned by Seller to Purchaser and assumed by Purchaser at the Closing.

4.2    Seller shall pay the New Jersey realty transfer tax (or permit an appropriate credit therefor) in connection with the recordation of the deed described in Section 9.1(a) and the conveyance of the Property by Seller to Purchaser and Purchaser shall pay the Mansion Tax.

4.3    Purchaser and Seller shall each pay their respective attorney's fees.

4.4    Except as otherwise herein provided, any fee, cost, charge or expense incurred by either party hereto or for which either party hereto may be liable in connection with the negotiation, examination and consummation of this Agreement, shall be paid by the party hereto incurring, or liable for, such fee, cost, charge or expense.

4.5    The costs of any survey, any searches, and a current form owner’s ALTA title insurance policy are to be borne by Purchaser.



-4-



4.6    The Seller shall be responsible for payment of the Broker’s (hereafter defined) commission payable at Closing pursuant to a separate written agreement between seller and Broker.

4.7 The provisions of this Section 4 shall survive the Closing Date.

5.    Closing; Closing Date    .

5.1    The Closing shall take place at the offices of the McElroy, Deutsch, Mulvaney & Carpenter, LLP, or at such other place as Seller and Purchaser may agree, at 10:00 a.m. New Jersey time on the Closing Date.

5.2    The Closing Date shall occur five (5) days after the End of the Inspection Period but no later than July 11, 2014.

6.    Title.

6.1    Purchaser may, at its sole cost and expense, order (a) a title insurance commitment on the Property issued by the Title Company reporting on the condition of title to the Property and committing to issue title insurance to Purchaser, and (b) a survey of the Property (collectively, the title insurance commitment and the survey being in this Agreement referred to as the "Title Report"). Within thirty (30) days of the Effective Date, Purchaser shall provide Seller with a copy of the Title Report and written notification to Seller of any items shown in the Title Report, other than Permitted Exceptions, which would prevent Purchaser from receiving such title to the Property as provided herein (collectively, the “Title Objections”). Seller shall, at its option, be entitled to a period of twenty (20) days from its receipt of written notice from Purchaser to remove and discharge any liens, encumbrances, covenants or easements set forth on the Title Report, other than the Permitted Exceptions, which cure, at Purchaser’s option, may be by means of affirmative insurance or endorsement from the Title Company, in form and substance satisfactory to Purchaser (and paid for by Seller), insuring over and providing that any liens, encumbrances, covenants, easements or other matters which are not Permitted Exceptions shall not be collected out of, or enforced against, the Property. If Seller is unable to cure the Title Objections within the aforesaid twenty (20) day period, Seller shall be entitled to an additional ten (10) day cure period provided Seller is diligently pursuing such cure. If Seller has not cured, or elects not to cure, the Title Objections as aforesaid, Purchaser, as its only remedies, may either (a) within ten (10) days of receiving notice from Seller that it is unable or unwilling to remove such Title Objections, terminate this Agreement by written notice to Seller, receive the return of the Deposit and this Agreement shall be null and void, each party having no further obligation to the other, or (b) subject to Section 6.2 hereof, purchase the Property subject to such Title Objections (which shall be deemed Permitted Exceptions), in which case this Agreement shall remain in full force and effect and the parties shall proceed to Closing hereunder without reduction in the Purchase Price or other obligation, except as provided in Section 6.2, on the part of Seller by reason of such Title Objections. The foregoing shall not, however, be deemed to limit the unconditional obligation of Seller to discharge and remove of record all title exceptions referred to in Section 6.2 below at or prior to Closing.

6.2    Anything herein to the contrary notwithstanding, the parties agree that in the event there are any mortgages, financing statements, or similar liens placed on the Property by Seller, mechanic's or materialman's liens arising from work performed on the Property by, for or with the consent of Seller, or money judgments or other monetary liens against Seller that can be


-5-



discharged or removed by the payment of a liquidated sum, or any Title Objections placed upon the Property after the Effective Date (other than those resulting from the acts of Purchaser), then at or prior to Closing Seller shall be obligated to bond off with the Title Company or remove, satisfy and discharge of record all such matters (collectively, the "Liens"), and deliver title to the Property to the Purchaser at the Closing free of same; provided, further, Seller shall not place, caused to be placed, nor consent to the placement by any other party of, any Liens on the Property from and after the Effective Date.

7.    Inspection Period; Due Diligence.

7.1    Seller shall use its best efforts to make available to Purchaser for inspection and copying within five (5) days of the Effective Date such materials in the possession of or reasonably accessible to Seller pertaining to the Property as Purchaser may reasonably request, including but not limited to: back-title, environmental reports, surveys, plans and specifications for the Building, structural reports, the Service Contracts (if written), and statements of operating expenses (the “Property Documents”).

7.2    Commencing on the Effective Date, and continuing until the End of the Inspection Period (the “Inspection Period”), Purchaser may make, or cause to be made, at its sole cost and expense, such investigations (including physical, structural, economic, mechanical and environmental) relating to the Property as Purchaser deems prudent. Notwithstanding the foregoing, Purchaser agrees that it will use its best efforts not to interfere in any material and adverse fashion with the operation of the Property by Seller.

7.3    Seller agrees that at all times prior to the Closing or sooner termination of this Agreement, Purchaser or its designated agents or consultants shall be given reasonable access to the Property during normal business hours, and Seller shall cooperate with Purchaser in that regard. Seller shall be entitled to have a representative of Seller present at all times during any testing, examination, inspection or other activities on the Property by Purchaser. To the extent Seller has such information available, Seller will also open to Purchaser and make available for inspection and copying its files, books and records, and property management records (other than matters relating to confidential or proprietary matters) with respect to the Property.

7.4    At any time prior to the End of the Inspection Period, Purchaser may send Seller or Seller’s Attorney a written notice that Purchaser elects to terminate this Agreement for any reason whatsoever, and on Seller's or Seller’s Attorney’s receipt of such notice the Deposit shall be returned to Purchaser, and this Agreement shall become null and void as between Seller and Purchaser, each party having no further obligation to the other hereunder except (a) Purchaser shall promptly return to Seller all of the Property Documents made available to, or copied by, Purchaser, and (b) as otherwise specifically provided in this Agreement. Notwithstanding the foregoing, If Purchaser wishes to raise a claim, it shall advise Seller and Seller shall have ten (10) days from receipt of such notice to decide whether to agree to do the claimed repair or remediation or to advise that will not, in which case Purchaser may decide to either take title without the resolution of such claim(s) or terminate this contract in which event all deposits shall be returned to Purchaser. In the event that a repair or remediation is undertaken, the End of the Inspection Period shall be deemed extended from the date of such notice until the repair or remediation is completed and for such reasonable period as may be necessary for Purchaser to inspect same. In the event that such repair or remediation is not satisfactory to the Purchaser, Purchaser may again give notice to Seller as provided above.


-6-





7.5    Purchaser agrees to make all repairs to and otherwise restore the Property to its condition existing immediately prior to such damage with respect to any damage caused by or attributable to Purchaser, its agents and/or its contractors as the result of any access, inspections or investigations they or any of them make or authorize.


8.    Conditions Precedent.

8.1    The obligations of the Purchaser to close the transaction hereunder are subject to satisfaction of all the following conditions at or prior to Closing, any one or more of which may be expressly waived in writing by the Purchaser:

(a)    All of the terms, covenants and conditions of this Agreement to be complied with and performed by Seller on or before the Closing Date shall have been duly complied with and performed in all material respects, including, without limitation, the delivery by Seller of the documents enumerated in Section 9.1 hereof.

(b)    The representations and warranties made by Seller under this Agreement shall be true and correct in all material aspects on and as of the Closing Date with the same force and effect as though such representations and warranties had been made on and as of the Closing Date.

(c)    Title to the Property shall be as required by Section 4 above.

(d)    Purchaser’s satisfactory walk-through of the Property prior to but on the same day as Closing to confirm Seller’s compliance with all representations, conditions precedent and covenants of Seller contained in this Agreement.


8.2    Seller's obligations to close hereunder shall be conditioned upon the occurrence of each of the following conditions. If any of the following conditions are not satisfied, then Seller may elect to terminate this Agreement or waive noncompliance with any such condition in whole or in part:

(a)    The representations and warranties of Purchaser as set forth herein shall be true in all material respects on and as of the Closing Date with the same force and effect as if such representations and warranties had been made on and as of the Closing Date.

(b)    Purchaser shall have performed, observed and complied in all material respects with all the covenants, agreements and conditions required by this Agreement to be performed, observed and complied with, prior to or as of the Closing Date, including payment of the Purchase Price as provided pursuant to Section 3, and shall execute and/or deliver the documents to be executed and/or delivered by Purchaser pursuant to this Agreement.

9.    Documents at Closing.



-7-



9.1    Seller shall execute and deliver to Purchaser at Closing, the following instruments:

(a)    Duly executed and acknowledged Bargain and Sale Deed with Covenants Against Grantor’s Act conveying to Purchaser the fee simple title to the Property, subject only to the Permitted Exceptions and such other matters as may be approved in writing by Purchaser (the "Deed").

(b)    An affidavit of Seller setting forth that it is not a "foreign person" for purpose of the Foreign Investment in Real Property Transfer Act of 1990, as amended.

(c)    A standard form seller's affidavit of title;

(d)    Standard form of Seller’s Residency Certification and Seller’s Affidavit of Title (if require);

(e)    A settlement statement (the "Settlement Statement") documenting the Closing and reflecting the Purchase Price, charges, credits, adjustments and prorations.

(f)    Keys and/or security codes to all entrance doors to the Property.

(g)    Such affidavits and indemnities as the Title Company shall reasonably and customarily require.

(h)    All necessary and proper consents of Seller, including an appropriate resolution of the Board of Directors of the Seller, authorizing the sale of the Property in accordance with the terms of this Agreement.

(i)    A duly executed assignment (the "Assignment of Service Contracts") of all Service Contracts, if any, and such other agreements as to which Purchaser has notified Seller in writing prior to the Closing Date that Purchaser wishes to accept.


(j)    Bring Down Certificate. A certificate of Seller stating that all representations and warranties of Seller contained in this Agreement are true and correct in all material respects on and as of the Closing Date with the same force and effect as if such representations and warranties had been made on and as of the Closing Date, or if different, in what respect.

(k)    An estoppel certificate of American Educational Institute, Inc.

(l)    Such additional documents as the Seller and the Purchaser shall mutually agree are necessary to carry out the provisions of this Agreement.

9.2    In addition to payment of the Purchase Price as provided in Section 3 hereof, Purchaser shall execute and deliver to Seller at Closing, subject to full compliance by Seller with all Seller's obligations to be kept, observed and performed by Seller under this Agreement:

(a)    The Settlement Statement.


-8-




(b)    All necessary and proper consents of Purchaser consenting to and approving the within transaction and purchase by Purchaser.

(c)    Such additional documents as Seller and Purchaser shall mutually agree are necessary to carry out the provisions of this Agreement, provided that such additional documents do not expand Purchaser's liability beyond the liability of Purchaser described in or under this Agreement.

10.    Covenants of Seller. Seller covenants and agrees that, between the date hereof and the Closing Date:

10.1    At its sole cost and expense, Seller shall continue to maintain the Property in the ordinary course in accordance with its normal practices and procedures. Seller shall keep the Property and all of the Buildings and improvements thereon (and all parts thereof), including mechanical equipment of every kind used in the operation thereof, in at least the same condition as it is in as of the End of Inspection Period, reasonable wear and tear excepted. Seller will not remove any of the Included Personal Property from the Building.
  
10.2     Seller shall continue to maintain the existing insurance on the Property.

10.3    Seller shall not modify, cancel, extend, renew or otherwise change in any manner any of the terms, covenants, or conditions of any of the Service Contracts, nor enter into any other agreements (including, without limitation, cleaning, maintenance, employment, management, supply, union and similar contracts) without obtaining the consent of the Purchaser unless same is terminable without penalty or liability to Purchaser upon the Closing (any such action or act or agreement, an “Agreement Modification”). Immediately upon the occurrence of any Agreement Modification, Seller shall deliver to Purchaser a complete, certified copy thereof.
        
10.4    Seller shall not mortgage, pledge or create any contractual lien, charge or any other encumbrance (or agree to do so) in respect of the Property or any part thereof. Seller shall not sell or transfer any portion of the Property.

10.5    Seller shall deliver the Property at Closing vacant of any tenants or other occupants other than American Educational Institute, Inc. who is located on the second floor of Building A and occupying 5,672 rental square feet of space in the Building. Seller shall deliver the Lease with American Educational Institute Inc. with the other Property Documents. Seller shall deliver a customary and reasonable estoppel certificate from this tenant.

10.6    The Seller agrees to provide the Purchaser with all information needed to notify (the “Bulk Sale Notification”) the New Jersey Division of Taxation Bulk Sales Unit (the “Bulk Sales Unit”) as to the sale of the Property by the Seller to the Purchaser (as contemplated under Section 54:50-38, New Jersey Statutes, and any related sections). The Bulk Sale Notification must be delivered to the Bulk Sales Unit no less than 10 days prior the Closing Date. The Seller shall cooperate with the Purchaser in connection with the timely delivery of the Bulk Sale Notification, and the Seller shall comply with all applicable demands, or other applicable escrow demands, from the Bulk Sales Unit or other such Governmental Authority. If the Bulk Sales Unit suggests or requires a tax escrow, then a portion of the Purchase Price in an amount equal to the sum required or suggested by the Bulk Sales Unit shall be held in escrow (the “Withheld Amount”) by the


-9-



Purchaser’s attorney pending notification from the Bulk Sales Unit as to the disposition of the Withheld Amount (i.e., either payment to the Seller or to the Bulk Sales Unit). Should the Seller’s obligations to the Bulk Sales Unit exceed the Withheld Amount, the Seller shall remain responsible for the payment of any such outstanding sales tax obligations.
10.7    Immediately upon the Effective Date, Seller shall permit Purchaser to store up to 750 boxes containing legal files in a mutually agreed upon area within the Building. There will be no charge for the file storage so long as the transaction contemplated herein closes. Should the transaction not close for any reason, Purchaser shall remove its boxes from the Building unless otherwise agreed with the Seller and shall pay to Seller for the temporary storage $5,000 per month beginning on the date that Purchaser moves its boxes into the Building. This amount shall be prorated for any partial month.

10.8    Seller shall allow Purchaser early access to the Property two (2) weeks prior to Closing to install its telephone and data systems. In the event Closing does not take place after Purchaser has installed telephone and data systems, Purchaser shall remove such installations and restore the Property to it original condition without any charge to Seller.

        
11.    Representations and Warranties of Seller.

Seller represents, warrants, and agrees that:

11.1    Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of New York, and has the power to own its own properties and to carry on its business as now being conducted.

11.2    Seller has the full right, power and capacity to enter into this Agreement and to carry out the transactions contemplated hereby and, no consent or authorization of any person is required as a condition precedent to the consummation of this Agreement or the transactions contemplated herein.

11.3    The execution and delivery of this Agreement, the consummation of the transactions herein contemplated and the compliance with the terms hereof will not conflict with or result in a breach of any agreement to which Seller is a party or by which any it is bound, or any lease, indenture, mortgage, loan agreement or instrument to which Seller is a party or by which the Property or Seller is bound or, to Seller's knowledge, any applicable law or regulation or order of any governmental agency or court, domestic or foreign, having jurisdiction over the Property or Seller.

11.4    Seller has received no notice of, and, to Seller's knowledge, there is no pending or threatened action, litigation, investigation, condemnation or other proceeding (by any private person or entity or by any governmental authority) against or relating to the Property, or against Seller, which would or could (i) result in a judgment or other Lien being filed against the Property, (ii) otherwise affect the Property, any construction, use or occupancy thereof, or (iii) affect the right or ability of Seller to perform its obligations under this Agreement.

11.5    Seller is not a foreign person as that term is used and defined in Sections 1445 and 7701 of the Internal Revenue Code.



-10-



11.6    With the exception to the lease to American Educational Institute, Inc. there are no leases, subleases, or occupancy agreements in effect regarding the Property.

11.7    Seller has not received written notice from any governmental authority having jurisdiction that the Property, the use, construction, maintenance, operation or occupancy thereof, is not in compliance with any applicable laws, regulations and requirements of any such noncompliance.

11.8    To Seller’s knowledge, there are no pending or threatened condemnation proceedings regarding the Property.

11.9    Attached hereto as Schedule 1.13 is a true and correct list of all Service Contracts in connection with the Property. True, correct and complete copies of the Service Contracts have been furnished by the Seller to the Purchaser.

11.10    Seller has no knowledge of any federal, state, county or municipal or plans to change the road system in the immediate vicinity of the Property or to restrict or change access from any such roads to the Property or of any pending or threatened condemnation of the Land or the Property or any part thereof or of any plans for improvements which might result in a special assessment against the Property.

11.11    There are no facts known to Seller materially affecting the value of the Property that are not readily observable by Purchaser or that have not been disclosed to Purchaser by Seller. No representation or warranty made by the Seller in this Agreement, in any Exhibit annexed hereto, or in any letter or certificate furnished to the Purchaser pursuant to the terms hereof, each of which is incorporated herein by reference and made a part hereof, omits to state a material fact necessary to make the statements contained herein or therein not misleading.

11.12    Seller has not retained any person to file notices of protest against, or to commence actions to review, real property tax assessments against the Property.

11.13    (a) To the Seller’s knowledge, the Property has not been used intentionally or unintentionally (i) as a landfill to receive garbage, refuse or waste, whether or not hazardous or (ii) for the storage, deposit, disposal, treatment, handling or recycling of any Hazardous Materials (as defined in this Paragraph). To the Seller’s knowledge, the Property does not contain any Hazardous Materials, nor has there been a release of any Hazardous Materials on or from the Property whether or not such release emanated from the Property or any contiguous real estate, equipment, or underground storage tanks. For purposes of this Agreement, "Hazardous Materials" means and includes petroleum, petroleum products, flammable explosives, radioactive materials, asbestos or any material containing asbestos, polychlorinated biphenyl, urea formaldehyde or any pollutant or any toxic or hazardous waste or substance, regulated, prohibited, restricted or controlled by any existing applicable Federal, state, county, or local statutes, laws, regulations, rules, ordinances, directives or codes relating to environmental matters, including by way of illustration and not by way of limitation, the New Jersey Industrial Site Recovery Act, N.J.S.A. 13:1K-6 et seq.; the New Jersey Spill Compensation and Control Act, N.J.S.A. 58:10-23.11, et seq.; the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended 42 U.S.C. Sec. 9601, et seq. (“CERCLA”); the Hazardous Materials Transportation Act, as amended, 49 U.S.C. Sec. 1801, et seq. (“HMTA”); the Resource Conservation and Recovery Act, as amended, 42 U.S.C. Sec. 6901, et seq., (“RCRA”); the Federal Water Pollution Control Act, as amended, 33 U.S.C.


-11-



Sec. 1251, et seq.; the Occupational Safety and Health Act of 1970, 29 U.S.C. Sec. 651 et seq.; the Emergency Planning and Community Right-to-Know Act, 42 U.S.C. Sec. 11001 et seq.; otherwise known as the Superfund Amendments and Reauthorization Act of 1986; the Clean Air Act, 42 U.S.C. Sec. 4701 et seq.; the Toxic Substances Control Act, 15 U.S.C. Sec. 2601 et seq.; the Solid Waste Disposal Act, 42 U.S.C. Sec. 6901 et seq., as the same exist as of the date hereof (collectively, the "Environmental Laws").

(b)    Neither Seller nor, to Seller’s knowledge, any former owner or
operator of the Property, has used or introduced any Hazardous Materials on or affecting the Property or received any notice from any governmental agency, entity or person with regard to Hazardous Materials on, from or affecting the Property. To Seller’s knowledge after due inquiry, neither Seller nor any owner or operator of the Property has violated any applicable Environmental Law relating to or affecting the Property, and, to Seller's knowledge, there is no pending or threatened any action, suit, investigation or proceeding against Seller relating to the Property seeking to enforce any right or remedy under any Environmental Law.

(c)    There are no underground storage tanks on the Property.

(d)     No spillage or discharge of any Hazardous Materials has occurred
on, to or under the Property (or any part thereof) or on, to or under those portions of any other properties immediately adjoining the Property.

11.14    There is ingress and egress to the Property.

11.15    To Seller's knowledge there is no restriction, limitation or moratorium on the right of the owner of the Property to hook up to or to use any sewer utility, other than the obligation for Seller to pay ordinary and prevailing hook-up charges. Seller has not received written notice of, and Seller has no knowledge of, any threatened or actual reduction or curtailment of any utility service supplied to the Property.

11A.    The representations, warranties and covenants set forth in the following Sections shall survive the Closing without limit of duration: 11.13. The remaining representations, warranties and covenants set forth in this Agreement shall survive the Closing only for a period of two (2) years, and upon the expiration of such two-year period all such representations, warranties and covenants (and any and all claims and causes of action resulting from or on account of any breach thereof) for which Purchaser has not theretofore served upon Seller written notice of claim shall terminate and may not be asserted. Nothing herein shall limit the duration of any (i) indemnity or other agreement specified in this Agreement to survive the Closing (other than indemnity agreements relating to representations or warranties which have expired two (2) years after the Closing, and (ii) any representations, warranties, indemnities, covenants or agreements set forth in the instruments or documents delivered at Closing, except as limited in this Section 11A.


12.    Representations and Warranties of Purchaser.

12.1    Purchaser represents, warrants, covenants and agrees that:

(a) (i)    This Agreement and all agreements, instruments and documents herein provided to be executed and delivered, or actually executed and delivered, by Purchaser


-12-



to Seller at or before the Closing are, and on the Closing Date will be, binding upon Purchaser, (ii) Purchaser is (or if Purchaser assigns its rights hereunder on the Closing Date will be) a limited liability partnership or other entity duly organized and validly existing under the laws of its state of organization and (if Purchaser assigns its rights hereunder) qualified to do business in the State of New Jersey; (iii) Purchaser is duly authorized and qualified to execute and do all things required of it under this Agreement, (iv) Purchaser has the capacity and authority to enter into this Agreement and consummate the transactions contemplated hereunder, and (v) upon execution hereof by all parties this Agreement will be binding on Purchaser and enforceable against Purchaser in accordance with its terms, subject to the laws of creditors' rights, bankruptcy and insolvency laws and regulations and the availability of equitable remedies.

(b)     The execution and delivery of this Agreement, the consummation of the transactions herein contemplated and the compliance with the terms hereof will not conflict with or result in a breach of any agreement to which Purchaser is a party, or any lease, indenture, mortgage, loan agreement or instrument to which Purchaser is a party or by which Purchaser is bound or any applicable law, regulation, or order of any governmental agency or court, domestic or foreign, having jurisdiction over the Purchaser.

(c)    The Purchaser shall have available to it at Closing, sufficient funds to proceed with Closing.

(d)    Purchaser agrees to pursuant to reasonable and customary terms and conditions to retain the services of Gary Olson post-closing to manage the Building.

12.2    The representations, warranties and covenants of Purchaser set forth in this Section 12 shall survive the Closing only for a period of two (2) years, and upon the expiration of such two-year period all such representations, warranties and covenants (and any and all claims and causes of actions resulting from or on account of breach thereof) for which Seller has not theretofore served upon Purchaser written notice of claim shall terminate and may not be asserted.

13.    Condemnation and Destruction.

13.1    If, prior to the Closing Date, all or any portion of the Property or any means of ingress thereto or egress there from is taken by eminent domain (or is the subject of a pending or threatened taking which has not been consummated), then Seller shall immediately notify the Purchaser of such fact and Purchaser shall have the option to terminate this Agreement upon written notice to the Seller given not later than ten (10) Business Days after receipt of the Seller's notice. If this Agreement is terminated, as aforesaid, the Deposit shall be returned to the Purchaser. Upon such return of the Deposit, neither party shall have any further rights or obligations hereunder, except such rights or obligations specified in this Agreement to survive the termination of this Agreement. If Purchaser does not exercise this option to terminate this Agreement, Seller shall assign and turn over, and the Purchaser shall be entitled to receive and keep, all awards for the taking by eminent domain, and there shall be no abatement of the Purchase Price.

13.2    If any part of the Property or any part of any means of ingress thereto or egress there from subject to this Agreement is damaged, destroyed by fire or other casualty, Seller shall immediately notify the Purchaser of such fact and Purchaser shall have the option to terminate this Agreement upon written notice to Seller given not later than ten (10) Business Days after


-13-



receipt of the Seller's notice. Upon such termination, the Deposit shall be returned to Purchaser. Upon such return of the Deposit, neither party shall have any further rights or obligations hereunder, except such rights or obligations specified in this Agreement to survive the termination of this Agreement.

14.    Broker. Except for The Garibaldi Group, LLC (the “Broker”) Purchaser and Seller hereby represent to each other that they have not dealt with, or otherwise disclosed this Agreement or the subject matter hereof to, any real estate broker, agent, or salesman, so as to create any legal right or claim in any such broker, agent, or salesman for a real estate commission or compensation with respect to the negotiation and/or consummation of this Agreement or the conveyance of the Property by Seller to Purchaser. Payment of the Broker’s commission shall be made by the Seller in accordance with a separate written agreement between the Seller and Broker. Purchaser and Seller hereby indemnify and defend each other against, and agree to hold each other harmless from any and all claims for a real estate commission or similar fee other than the Broker’s fee arising out of or in any way connected with any claimed agency or other relationship with the indemnitor and relating to the transactions contemplated hereby. The provisions of this Section 14 shall survive the Closing or the termination of this Agreement.

15.    Default and Remedies.

15.1    If Purchaser shall fail or refuse to close title as required by the terms of this Agreement, or Purchaser otherwise is in default hereunder so that Seller has the right to refuse to close title, in either case so as to entitle Seller to a remedy under this Agreement, then, following receipt by Purchaser of five (5) Business Days prior written notice from Seller stating that Purchaser is in default hereunder, unless Purchaser shall have cured such default during the five (5) Business Day period, the sole and exclusive remedy of Seller (and the parties constituting Seller) shall be to receive and retain the Deposit (with all interest thereon, if any), as and for full liquidated damages (the parties hereto acknowledging that it is impossible to estimate more precisely the damages which might be suffered by Seller upon Purchaser's default), and neither Seller, nor either of the parties constituting Seller, shall have any other or additional right or remedy against Purchaser. The Seller's retention of the Deposit is intended not as a penalty, but as full liquidated damages and is Seller's sole and exclusive remedy in the event of default hereunder by Purchaser. Nothing in this Section 15.1 shall be deemed a limitation on the liability of Purchaser in respect of any obligations and covenants of Purchaser set forth in any instruments or documents executed and delivered by Purchaser at the Closing, or specifically and expressly set forth in this Agreement to survive the Closing.

15.2    If Seller shall fail or refuse to close title as required by the terms of this Agreement, or Seller otherwise is in default hereunder so that Purchaser has the right to refuse to close title, in either case so as to entitle Purchaser to a remedy in respect of this Agreement, then, following receipt by Seller of five (5) Business Days prior written notice from Purchaser stating that Seller is in default hereunder, unless Seller shall have cured such default during the five (5) Business Day period, subject to the provisions of Section 6 relating to uncured Title Objections, Purchaser shall have the right to (i) obtain specific performance of Seller's obligations hereunder, or (ii) cancel this Agreement and receive a return of the Deposit. In no event shall Purchaser be entitled to an award of compensatory, consequential, or other damages from Seller. Nothing in this Section 15.2 shall be deemed a limitation on the liability of Seller in respect of any obligations and covenants of Seller set forth in any instruments or documents executed and delivered by Seller at the Closing, or specifically and expressly set forth in this Agreement to survive the Closing.


-14-




16. Indemnification.    

16.1    Seller shall, and hereby does indemnify, defend and hold harmless Purchaser from and against:

(a)    Any and all claims or demands made by third parties and arising
out of any and all acts or omissions of Seller relating to the Property or any other rights, properties or interests sold by Seller hereunder and any and all liabilities and obligations of Seller to third parties including, without limitation, claims which are asserted against Purchaser or the Property (or any part thereof) by third parties by reason of Seller's (or Seller's agents', employees' or contractors') acts or wrongful omissions with respect to the Property (or any part thereof), or any other rights, properties or interests sold by Seller hereunder, agreements relating to the Property, by reason of events which occurred or causes of action which accrued prior to the Closing, specifically excluding all claims and causes of action caused by Purchaser, its agents, employees or contractors;

(b)    Subject to the provisions of Section 11.A, any misrepresentation,
breach of warranty, or nonfulfillment of any representation, warranty, covenant or agreement on the part of Seller under this Agreement, or from any misrepresentation in, or wrongful or fraudulent omission from, any certificate or other instrument furnished or to be furnished by or for Seller to Purchaser under this Agreement;

(c)    Any losses, expenses or costs incurred by or suffered by Purchaser
as a result of (i) the occurrence of any of the following prior to Purchaser’s ownership of the Property: any discharge of Hazardous Materials, or any other introduction of Hazardous Materials on, under or about the Property, or any discharge of Hazardous Materials or any other introduction of Hazardous Materials on, under or about any property adjoining the Property, which was caused by or permitted by Seller, or any of Seller's agents, employees, contractors, licensees or invitees or any person claiming through or under any of such persons; or (ii) any wrongful act of Seller prior to Purchaser’s ownership of the Property (subject to the provisions of Section 11.A). excluding the discharge, release, escape or presence of any Hazardous Materials, which occurred prior to the Seller’s ownership of the Property of which Seller had no knowledge; and

(d)    All claims, actions, suits, proceedings, demands, assessments,
judgments, costs and expenses (including reasonable attorneys' fees) incident to any of the foregoing.


16.2    The provisions of this Section 16 shall survive the Closing.


17.    Notices. Any notices required or permitted to be given hereunder shall be in writing and shall be delivered by (i) hand, (ii) overnight courier, or (iii) certified mail, return receipt requested, postage prepaid and addressed to each party at its address as set forth below. Any notice, request or other communication given by an attorney for Purchaser shall be deemed given by Purchaser; and any notice, request or other communication given by an attorney for Seller shall be deemed given by Seller. Any such notice, request, or other communication shall be considered given or delivered, as the case may be, on the date of hand delivery, one (1) Business Day after mailing


-15-



by a generally recognized overnight courier (requesting proof of delivery), or three (3) Business Days after the date of deposit in the United States mail as provided above. By giving at least ten (10) days' prior written notice thereof, any party hereto may from time to time and at any time change its mailing address.

If to Seller:                Hooper Holmes, Inc.
560 N. Rogers Road
Olathe, Kansas 66062
Attn: General Counsel

            

With a copy to:            Michael Behrens
Bevan, Mosca, Giuditta & Zarillo, PC
222 Mount Airy Rd., Suite 200
Basking Ridge, NJ 07920
                        
            
If to Purchaser:             McElroy, Deutsch Mulvaney & Carpenter, LLP
1300 Mt. Kemble Avenue
P.O. Box 2075
Morristown, New Jersey 07962-2075
Attn: Edward B. Deutsch, Esq.        

With a copy to:            McElroy, Deutsch, Mulvaney & Carpenter, LLP
1300 Mt. Kemble Avenue
P.O. Box 2075
Morristown, New Jersey 07962-2075
Attn:    Lucille J. Karp, Esq.


18.    Assignment. Purchaser may assign this Agreement to any entity controlled by Purchaser, provided Purchaser notifies Seller of such assignment prior to Closing and provides reasonable evidence of such assignment.

19.    Entire Agreement; Modification. This Agreement supersedes all prior discussions and agreements between Seller and Purchaser with respect to the Property and contains the sole and entire understanding between Seller and Purchaser with respect to the Property. All promises, inducements, offers, solicitations, agreements, commitments, representations and warranties heretofore made between such parties are merged into this Agreement. This Agreement shall not be modified or amended in any respect except by a written instrument executed by or on behalf of each of the parties to this Agreement.

20.    Exhibits. Each and every Exhibit referred to or otherwise mentioned in this Agreement is attached to this Agreement and is and shall be construed to be made a part of this Agreement by such reference or other mention at each point at which such reference or other mention occurs, in the same manner and with the same effect as if each Exhibit were set forth in full and at length every time it is referred to or otherwise mentioned.



-16-



21.    Captions. All captions, headings, Section numbers and letters and other reference numbers or letters are solely for the purpose of facilitating reference to this Agreement and shall not supplement, limit, or otherwise vary in any respect the text of this Agreement.

22.    References. All references to Sections shall be deemed to refer to the appropriate Sections of this Agreement. Unless otherwise specified in this Agreement, the terms "herein," "hereof, "hereunder," and other terms of like or similar import, shall be deemed to refer to this Agreement as a whole, and not to any particular Section hereof.

23.    Counterparts. This Agreement may be executed in several counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument.

24.    Waiver    . Any condition or right of termination, cancellation or rescission granted by this Agreement to either party may be waived by such party, but no such waiver may be relied upon or asserted by the other party unless such waiver has been made in writing by the waiving party, except as specifically provided herein.

25.    Rights Cumulative. Except as expressly limited by the terms of this Agreement, all rights, powers, and privileges conferred hereunder shall be cumulative and not restrictive of those given by law.

26.    Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

27.    Date of Performance. If the time period by which any right, option, or election provided under this Agreement must be exercised or by which any acts or payments required hereunder must be performed or paid, or by which the Closing must be held, expires on a day other than a Business Day, then such time period shall be automatically extended to the close of business on the next regularly scheduled Business Day.

28.    Governing Law. This Agreement shall be governed by the laws of the State of New Jersey. In any action or proceeding concerning this Agreement, or any agreement or instrument delivered pursuant to this Agreement, or the transactions delivered pursuant to this Agreement, or the transactions contemplated by this Agreement, all parties to this Agreement or such other agreement or instrument hereby consent (a) to the jurisdiction of the State of New Jersey over all such parties and their general partners, and the partners of such general partners and (b) that venue for all actions and proceedings shall be in the State of New Jersey.

29.    Third Party Beneficiaries. Nothing in this Agreement is intended or shall be construed to confer upon or to give to any person, firm or corporation other than the parties hereto, their successors and assigns any right, remedy, or claim under or by reason of this Agreement. All terms and conditions in this Agreement shall be for the sole and exclusive benefit of the parties hereto, their successors and assigns.

30.    Further Assurances. Purchaser and Seller each agree to execute promptly on demand without additional consideration therefor, but without cost thereto, and deliver to the other such further documents or instruments as may be reasonable and necessary in furtherance of the


-17-



performance of the terms, covenants and conditions of this Agreement. This Section 29 shall survive the Closing.

31.    Partial Invalidity. If any term or provision of this Agreement or the application thereof to any person or circumstances shall, to any extent, be invalid or unenforceable, the remainder of this Agreement, or the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby, and each term and provision of this Agreement shall be valid and be enforced to the fullest extent permitted by law.

32.    Time of the Essence    . TIME IS OF THE ESSENCE for all provisions of this Agreement, including, without limitation, the Closing Date.

33.    Waiver of Jury Trial. The parties acknowledge that disputes arising under this Agreement are likely to be complex and they desire to streamline and minimize the cost of resolving such disputes. Therefore, each party irrevocably waives all rights to a trial by jury in any action, counterclaim, dispute or proceeding based upon, or related to the subject matter of this Agreement. This waiver applies to all claims against all parties to such actions and proceedings including those involving Seller or Seller’s affiliates or related entities, or any officer, director, shareholder member, attorney or partner of any of them. It also applies whether such dispute or proceeding arise under this Agreement, any other agreement, instrument or document heretofore or hereafter executed or any other contract, whether similar or dissimilar; and whether or not it arises from intentional or unintentional conduct, from fraud, other improper actions or failure to act, or from other reasons. This Section 33 shall be deemed a covenant and enforceable independently of all other provisions of this Agreement. This waiver is knowingly, intentionally, and voluntarily made by both parties.



[the next page is the signature page]


-18-



IN WITNESS WHEREOF, this Agreement was executed as of the day and year first above written.

PURCHASER    

By:    /s/ Edward B. Deutsch    
Name:    Edward B. Deutsch
Title: Managing Partner


SELLER
.


By:    /s/ Henry E. Dubois        
Name:    ____Henry E. Dubois______
Title:        President & CEO    
                                

ESCROW AGENT
(as to Sections 3.1 and 3.2 only)

By:        /s/ Peter D. Blanchard
Name:    ___Peter D. Blanchard__    
Title:        Principal        




                



-19-



                                    
INDEX OF SCHEDULES

SCHEDULE                                 NUMBER


Land                                    1.8
                            
Service Contracts                            1.13







Schedule 1.8 Land








Schedule 1.8 (Land)
Purchase and Sale Agreement

ALL that certain tract, lot and parcel of land lying and being in the Township of Bernards, County of Somerset and State of New Jersey.

BEING known and designated as Lot No. 59 in Block 94 as shown on a Certain map entitled "Subdivision, Tax Lots 58 & 59 Block 94, Tax Map Sheet 19, Bernards Township, Somerset County, New Jersey". dated July 27, 1982, prepared by Couvrette Associates Inc., Consulting Engineers, said map being duly filed in the Somerset County Clerk's Office on November 18, 1982 as Filed Map No. 1985.

BEING further described in accordance with a survey prepared by Teunisen Surveying & Planning Co., Inc., dated January 16, 2007, as follows:

BEGINNING at a point in the southeasterly right-of-way line of Mount Airy Road, said point being the following two courses from the intersection of the .southeasterly right-of-way line of Mount Airy Road, with the northeasterly line of land now or formerly New Jersey Power and Light Company; thence

a.    Along the southeasterly right-of-way line of Mount Airy Road. North 40 degrees 58 minutes 37 seconds East, parallel with and .33.00 feet southeasterly. at a right angle, to the centerline of Mount .Airy Road, a distance of 210.86 feet; thence
b.     Continuing along the southeasterly right-of way line of Mount Airy Road, North 40 degrees 42 minutes 37 seconds East, parallel with and 33.00 feet southeasterly, at a right angle, to the centerline of Mount Airy Road, a distance of 497.31 feet to the point of BEGlNNING; thence
(1)     Along the southeasterly right-of-way line of Mount Airy Road, North 40 degrees 42 minutes 37 seconds East, parallel with and 33.00 feet southeasterly, at a right angle, to the centerline of Mount Airy Road, a distance of 100.00 feet; thence
(2)     Along the dividing line between Lot 58 and Lot 59 in Block 94, as shown on the aforementioned filed map, South 28 degrees 57 minutes 5.3 seconds East, a distance of 741.43 feet; thence
(3)     Continuing along the dividing line between Lot 58 and Lot 59 in Block 94, as show, on the aforementioned filed map, North 61 degrees 02 minutes 07 seconds East, a distance of 579.54 feet to land now or formerly Somerset Hills Y.M.C.A.; thence







(4)     Along land now or formerly Somerset Hills Y.M.C.A., South 26 degrees 56 minutes 23 seconds East, a distance of 338.83 feet to the northwesterly right-of-way line of New Jersey State Highway Route No. 287; thence
(5)     Along the northwesterly right-of-way line of New Jersey State Highway Route No. 287, South 41 degrees 39 minutes 11 seconds West, a distance of 322.13 feet, thence
(6)     Continuing along the northwesterly right-of-way line of New Jersey State Highway Route No. 287, South 45 degrees 44 minutes 45 Seconds West, a distance of 370.58 feet to land now or formerly White Airy III Associates; thence
(7)     Along land now or formerly White Airy III Associates, North 28 degrees 57 minutes 53 seconds West, a distance of 1249.94 feet to the southeasterly right-of-way line of Mount Airy Road and the point of BEGINNING.
For Information Only:
Also known as Lot(s) 4, Block 2401 on the Tax Map of the Township of Bernards, in the County of Somerset.





Schedule 1.13 Service Contracts


None


EX-31.1 5 exhibit311q12014.htm EXHIBIT 31.1 exhibit311q12014


EXHIBIT 31.1    CERTIFICATIONS

I, Henry E. Dubois, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hooper Holmes Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Henry E. Dubois
---------------------------------------------
Henry E. Dubois
Chief Executive Officer and President
May 15, 2014



EX-31.2 6 exhibit312q12014.htm EXHIBIT 31.2 exhibit312q12014


EXHIBIT 31.2     CERTIFICATIONS

I, Tom Collins, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hooper Holmes Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
                    
/s/ Tom Collins
---------------------------------------------
Tom Collins
Senior Vice-President, and Chief Financial and Accounting Officer
May 15, 2014



EX-32.1 7 exhibit321q12014.htm EXHIBIT 32.1 exhibit321q12014



EXHIBIT 32.1     CERTIFICATIONS

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Henry E. Dubois, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, the Quarterly Report of Hooper Holmes, Inc., on Form 10-Q for the quarter ended March 31, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Hooper Holmes, Inc.
Dated: May 15, 2014

/s/ Henry E. Dubois
__________________________
Henry E. Dubois
Chief Executive Officer and President
This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liability of Section 18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
A signed original of this written statement required by Section 906 has been provided to Hooper Holmes, Inc. and will be retained by Hooper Holmes, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



EX-32.2 8 exhibit322q12014.htm EXHIBIT 32.2 exhibit322q12014


EXHIBIT 32.2     CERTIFICATIONS

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Tom Collins, Senior Vice-President and Chief Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, the Quarterly Report of Hooper Holmes, Inc., on Form 10-Q for the quarter ended March 31, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Hooper Holmes, Inc.
Dated: May 15, 2014        

/s/ Tom Collins
__________________________
Tom Collins
Senior Vice President and
Chief Financial and Accounting Officer
This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liability of Section 18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
A signed original of this written statement required by Section 906 has been provided to Hooper Holmes, Inc. and will be retained by Hooper Holmes, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.INS 9 hh-20140331.xml XBRL INSTANCE DOCUMENT 0000741815 hh:July2009NonVestedStockAwardMember 2009-07-01 2009-07-31 0000741815 hh:December2010StockOptionAwardMember 2010-12-01 2010-12-31 0000741815 hh:July2011NonVestedStockAwardMember 2011-07-01 2011-07-31 0000741815 2013-03-10 2013-03-11 0000741815 hh:PortamedicServiceLineMember 2013-09-29 2013-09-30 0000741815 us-gaap:SubsequentEventMember 2014-04-15 2014-04-16 0000741815 hh:PurchaseandSaleAgreementPropertyMember us-gaap:SubsequentEventMember 2014-05-12 2014-05-13 0000741815 2013-01-01 2013-03-31 0000741815 us-gaap:StockOptionMember 2013-01-01 2013-03-31 0000741815 hh:PortamedicServiceLineMember 2013-01-01 2013-03-31 0000741815 hh:A2008PlanMember 2013-01-01 2013-03-31 0000741815 hh:A2011PlanMember 2013-01-01 2013-03-31 0000741815 hh:DirectorStockPlanMember 2013-01-01 2013-03-31 0000741815 hh:HealthWellnessMember 2013-01-01 2013-03-31 0000741815 hh:HeritageLabsMember 2013-01-01 2013-03-31 0000741815 hh:HooperHolmesServicesMember 2013-01-01 2013-03-31 0000741815 hh:UnallocatedCorporateMember 2013-01-01 2013-03-31 0000741815 hh:DirectorStockPlanMember 2013-07-01 2013-09-30 0000741815 2014-01-01 2014-03-31 0000741815 hh:Libor90DayRateMember 2014-01-01 2014-03-31 0000741815 us-gaap:PrimeRateMember 2014-01-01 2014-03-31 0000741815 hh:PriorToSecondAnniversaryMember 2014-01-01 2014-03-31 0000741815 hh:PriorToThirdAnniversaryMember 2014-01-01 2014-03-31 0000741815 us-gaap:StockOptionMember 2014-01-01 2014-03-31 0000741815 hh:July2009NonVestedStockAwardMember 2014-01-01 2014-03-31 0000741815 hh:July2011NonVestedStockAwardMember 2014-01-01 2014-03-31 0000741815 hh:NonVestedStockAwardMember 2014-01-01 2014-03-31 0000741815 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0000741815 hh:PortamedicServiceLineMember 2014-01-01 2014-03-31 0000741815 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-01-01 2014-03-31 0000741815 hh:A2008PlanMember 2014-01-01 2014-03-31 0000741815 hh:A2011PlanMember 2014-01-01 2014-03-31 0000741815 hh:AwardstoCertainEmployeesMember 2014-01-01 2014-03-31 0000741815 hh:DirectorStockPlanMember 2014-01-01 2014-03-31 0000741815 hh:FacilityClosingBranchOfficeClosureMember 2014-01-01 2014-03-31 0000741815 us-gaap:EmployeeSeveranceMember 2014-01-01 2014-03-31 0000741815 hh:HealthWellnessMember 2014-01-01 2014-03-31 0000741815 hh:HeritageLabsMember 2014-01-01 2014-03-31 0000741815 hh:HooperHolmesServicesMember 2014-01-01 2014-03-31 0000741815 hh:IntercompanyEliminationsMember 2014-01-01 2014-03-31 0000741815 hh:UnallocatedCorporateMember 2014-01-01 2014-03-31 0000741815 2012-12-31 0000741815 2013-03-31 0000741815 hh:PortamedicServiceLineMember 2013-09-30 0000741815 2013-12-31 0000741815 us-gaap:InternalRevenueServiceIRSMember 2013-12-31 0000741815 us-gaap:StateAndLocalJurisdictionMember 2013-12-31 0000741815 hh:FacilityClosingBranchOfficeClosureMember 2013-12-31 0000741815 us-gaap:EmployeeSeveranceMember 2013-12-31 0000741815 2014-03-31 0000741815 hh:AllOtherStockOptionAwardsMember 2014-03-31 0000741815 hh:December2010StockOptionAwardMember 2014-03-31 0000741815 hh:July2009NonVestedStockAwardMember 2014-03-31 0000741815 hh:July2011NonVestedStockAwardMember 2014-03-31 0000741815 hh:NonVestedStockAwardMember 2014-03-31 0000741815 us-gaap:EmployeeStockOptionMember 2014-03-31 0000741815 hh:StrategicAllianceAgreementAssetsMember us-gaap:SubsequentEventMember 2014-03-31 0000741815 hh:A2008PlanMember 2014-03-31 0000741815 hh:A2011PlanMember 2014-03-31 0000741815 hh:AmendedandRestated2011PlanMember 2014-03-31 0000741815 hh:AwardstoCertainEmployeesMember 2014-03-31 0000741815 hh:DirectorStockPlanMember 2014-03-31 0000741815 hh:FacilityClosingBranchOfficeClosureMember 2014-03-31 0000741815 us-gaap:EmployeeSeveranceMember 2014-03-31 0000741815 hh:HealthWellnessMember 2014-03-31 0000741815 hh:HeritageLabsMember 2014-03-31 0000741815 hh:HooperHolmesServicesMember 2014-03-31 0000741815 hh:UnallocatedCorporateMember 2014-03-31 0000741815 2012-02-29 0000741815 2013-02-27 0000741815 hh:A2011PlanMember 2013-05-29 0000741815 hh:AmendedandRestated2011PlanMember 2013-05-29 0000741815 2014-04-30 0000741815 hh:PurchaseandSaleAgreementPropertyMember us-gaap:SubsequentEventMember 2014-05-13 0000741815 hh:PurchaseandSaleAgreementPropertyMember us-gaap:SubsequentEventMember 2014-04-16 0000741815 hh:StrategicAllianceAgreementAssetsMember us-gaap:SubsequentEventMember 2014-04-16 hh:branch_office hh:holdback_component hh:operating_lease xbrli:pure hh:segment xbrli:shares iso4217:USD iso4217:USD xbrli:shares 3234000 3440000 8398000 9099000 12257000 12617000 150235000 150327000 200000 100000 124000 153000 0 83000 3917000 5607500 0 0 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impairment of Long-lived Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the recovery of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of assets may not be recoverable. For the three month period ended March 31, 2014, the Company evaluated the long-lived assets associated with Heritage Labs and Hooper Holmes Services in connection with the anticipated sale of certain assets under the Alliance Agreement with CRL. The Company concluded these long-lived assets were not impaired. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment charges recorded for these assets in continuing operations during the three month periods ended March 31, 2014 or 2013.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> 20344000 21646000 3786000 7223000 6488000 2847000 15587000 16055000 714000 714000 1500000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2013 Annual Report on Form 10-K, filed with the SEC on March 31, 2014. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for any other interim period or the full year. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; for additional information.</font></div></div> 1100000 230000 182000 62000 0 3970000 2667000 8319000 3837000 -4482000 -1303000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases its corporate headquarters in Olathe, Kansas, continuing laboratory facility and operations centers under operating leases which expire in various years through 2018. These leases generally contain renewal options and require the Company to pay all executory costs (such as property taxes, maintenance and insurance). The Company also leases copiers and other miscellaneous equipment. These leases expire in various years through 2017. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is still the primary lessee under operating leases for </font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;"> Portamedic branch offices with terms extending through September 2016, which are subleased by the acquirer of the former Portamedic business. The acquirer pays </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the rent and other executory costs for these </font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;"> offices in the form of a contractual obligation for the remaining lease term. If the Company is unable to assign these leases to the acquirer of the former Portamedic business, the Company will let the leases expire with no intent of renewal. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Company is still the primary lessee under </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;"> operating leases related to former Portamedic offices not utilized for continuing operations, which are not subleased by the acquirer of the former Portamedic business. The Company has accrued in previous periods approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> as branch closure obligations. The accrual is included as a component of the restructure reserve in the consolidated balance sheet as of March 31, 2014.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has employment agreements with its Chief Executive Officer and Chief Financial Officer that provide for payment of base salary for a </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;"> period in the event their employment with the Company is terminated in certain circumstances, including following a change in control, as further defined in the agreements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, some federal and state agencies have claimed that the Company improperly classified its health professionals as independent contractors for purposes of federal and state unemployment and/or worker's compensation tax laws and that the Company was therefore liable for taxes in arrears, or for penalties for failure to comply with their interpretation of the laws.&#160;&#160;There are no assurances that the Company will not be subject to similar claims in the future. The Company has determined that losses related to the remaining complaint are not probable or estimable.</font></div></div> 0.04 0.04 240000000 240000000 70420044 70382544 70410649 70373149 2815000 2817000 9985000 9160000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loan and Security Agreement</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:8pt;color:#ff0000;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains a three year 2013 Loan and Security Agreement, as amended on March 28, 2013 by the First Amendment, with Keltic Financial. Borrowings under the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The amount available for borrowing may be less than the </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> under this facility at any given time due to the manner in which the maximum available amount is calculated.&#160;&#160;The Company has an available borrowing base subject to reserves established at the lender's discretion of </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of Eligible Receivables up to </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> under this facility.&#160;&#160;Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, and other receivables deemed ineligible by Keltic Financial. Eligible Receivables include only billed receivables such that borrowing capacity may be affected by the Company's billing cycles. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the lender applied a discretionary reserve of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. Available borrowing capacity, net of this discretionary reserve was </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> based on Eligible Receivables as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the 2013 Loan and Security Agreement. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest on revolving credit loans is calculated based on the greatest of (i) the annualized prime rate plus </font><font style="font-family:inherit;font-size:10pt;">2.75%</font><font style="font-family:inherit;font-size:10pt;">, (ii) the </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> day </font><font style="font-family:inherit;font-size:10pt;">LIBOR</font><font style="font-family:inherit;font-size:10pt;"> rate plus </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;">, and (iii) </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per annum. The interest rate on the 2013 Loan and Security Agreement was </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. The Company is obligated to pay, on a monthly basis in arrears, an annual facility fee equal to </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the revolving credit limit of </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;">. During the three month periods ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and 2013, in connection with the 2013 Loan and Security Agreement, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$0.01 million</font><font style="font-family:inherit;font-size:10pt;"> in facility fees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The revolving credit loans are payable in full, together with all accrued interest and fees, on February 28, 2016. The 2013 Loan and Security Agreement provides for the prepayment of the entire outstanding balance of the revolving credit loans. The Company would be required to pay an early termination fee equal to </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> of the revolving credit limit if the termination occurs prior to February 28, 2015, and </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> if the termination occurs after February 28, 2015 but prior to February 28, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As security for payment and other obligations under the 2013 Loan and Security Agreement, the Company granted Keltic Financial a security interest in all of its, and its subsidiary guarantors, existing and after-acquired property, including receivables (which are subject to a lockbox account arrangement), inventory, equipment and the Basking Ridge, New Jersey real estate.&#160;&#160;The aforementioned security interest is collectively referred to herein as the &#8220;collateral&#8221;.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2013 Loan and Security Agreement contains various covenants, including financial covenants which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The lender recently waived the quarterly minimum EBITDA covenants for the fiscal period ended December 31, 2014. The Company continues to have limitations on the maximum amount of unfunded capital expenditures for each fiscal year.</font></div></div> 0.0275 0.0525 0.0600 10000 140000000 127200000 360000 646000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-Based Compensation Plans</font><font style="font-family:inherit;font-size:10pt;"> - On May 29, 2008, the Company's shareholders approved the 2008 Omnibus Employee Incentive Plan (the &#8220;2008 Plan&#8221;) providing for the grant of stock options, stock appreciation rights, non-vested stock and performance shares. The 2008 Plan provides for the issuance of an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares. For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company granted </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">162,600</font><font style="font-family:inherit;font-size:10pt;"> options to purchase shares under the 2008 Plan. For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> options for the purchase of shares granted under the 2008 Plan. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,209,300</font><font style="font-family:inherit;font-size:10pt;"> shares remain available for grant under the 2008 Plan. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 24, 2011, the Company's shareholders approved the 2011 Omnibus Employee Incentive Plan (the "2011 Plan") providing for the grant of stock options and non-vested stock awards. On May 29, 2013, the Company's shareholders approved an amendment and restatement of the 2011 Plan which increased the number of shares of the Company's common stock available for issuance from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares (subject to adjustment as provided in the Amended and Restated Omnibus Plan). During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company granted </font><font style="font-family:inherit;font-size:10pt;">300,000</font><font style="font-family:inherit;font-size:10pt;"> options to purchase shares under the 2011 Plan. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> options for the purchase of shares granted under the 2011 Plan during the three month periods ended March 31, 2013. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,166,750</font><font style="font-family:inherit;font-size:10pt;"> shares remain available for grant under the 2011 Plan as amended.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options awarded under the 2008 and 2011 Plans (as amended) are granted at fair value on the date of grant, are exercisable in accordance with a vesting schedule specified in the grant agreement, and have contractual lives of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. Options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's stock granted to certain executives of the Company in December 2010 vested </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> on each of the first and second anniversaries of the grant. Options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,344,100</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's stock granted to certain employees of the Company vest </font><font style="font-family:inherit;font-size:10pt;">one-third</font><font style="font-family:inherit;font-size:10pt;"> on each of the first, second and third anniversaries of the grant</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. </font><font style="font-family:inherit;font-size:10pt;">Options to purchase </font><font style="font-family:inherit;font-size:10pt;">2,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's stock granted to the Chief Executive Officer of the Company in September 2013, vest </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> upon receipt of the grant and 25% on the first, second and third anniversary of the grant. Other options granted by the Company vest </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> on each of the second through fifth anniversaries of the grant. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted during the three month period ended March 31, 2014 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:56.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="27%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options granted during the period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.38</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three month</font><font style="font-family:inherit;font-size:10pt;"> period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.8671875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="44%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding balance at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,150,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(505,550</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding balance at March 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,986,600</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$222</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at March 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,388,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$51</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value disclosed in the table above represents the difference between the Company's closing stock price on the last trading day of the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and the exercise price, multiplied by the number of in-the-money stock options.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three ended March 31, 2014, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">37,500</font><font style="font-family:inherit;font-size:10pt;"> stock options valued with a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.45</font><font style="font-family:inherit;font-size:10pt;"> were exercised. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> stock options were exercised during the three months ended March 31, 2013. Options for the purchase of an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">24,400</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock vested during the three month period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, and the aggregate fair value at grant date of these options was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.01 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to stock options. The cost is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.0</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">July 2009</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of non-vested stock were granted under the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2008 Plan</font><font style="font-family:inherit;font-size:10pt;">. The fair value of these non-vested stock awards were based on the grant date fair value of </font><font style="font-family:inherit;font-size:10pt;">$0.45</font><font style="font-family:inherit;font-size:10pt;"> per share. The shares vest as follows: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> after two years and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> on each of the next three anniversary dates thereafter. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">343,750</font><font style="font-family:inherit;font-size:10pt;"> shares of such non-vested stock were forfeited and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">150,000</font><font style="font-family:inherit;font-size:10pt;"> were vested. In July 2011, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">305,000</font><font style="font-family:inherit;font-size:10pt;"> shares of non-vested stock were granted under the 2008 Plan. The fair value of these non-vested stock awards were based on the grant date fair value of </font><font style="font-family:inherit;font-size:10pt;">$1.06</font><font style="font-family:inherit;font-size:10pt;"> per share. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">141,400</font><font style="font-family:inherit;font-size:10pt;"> shares of such non-vested stock were forfeited and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">155,100</font><font style="font-family:inherit;font-size:10pt;"> were vested. The shares vest as follows: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;"> on each of the first and second anniversary dates and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">34%</font><font style="font-family:inherit;font-size:10pt;"> on the third anniversary. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.03 million</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to non-vested stock awards. The cost is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.6</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font><font style="font-family:inherit;font-size:10pt;"> - The Company's 2004 Employee Stock Purchase Plan (the "2004 Plan") provides for the granting of purchase rights for up to </font><font style="font-family:inherit;font-size:10pt;">2,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's stock to eligible employees of the Company. The 2004 Plan provides employees with the opportunity to purchase shares on the date </font><font style="font-family:inherit;font-size:10pt;">thirteen months</font><font style="font-family:inherit;font-size:10pt;"> from the grant date (&#8220;the purchase date&#8221;) at a purchase price equal to </font><font style="font-family:inherit;font-size:10pt;">95%</font><font style="font-family:inherit;font-size:10pt;"> of the closing price of the Company&#8217;s common stock on the NYSE MKT on the grant date. During the period between the grant date and the purchase date, up to </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of a participating employee's compensation, not to exceed </font><font style="font-family:inherit;font-size:10pt;">$0.025 million</font><font style="font-family:inherit;font-size:10pt;">, is withheld to fund the purchase of shares. Employees can cancel their purchases at any time during the period without penalty. In February 2013, under the 2004 Plan, purchase rights for approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">233,000</font><font style="font-family:inherit;font-size:10pt;"> shares were granted with an aggregate fair value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.03 million</font><font style="font-family:inherit;font-size:10pt;">, based on the Black-Scholes option pricing model. The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">February 2013</font><font style="font-family:inherit;font-size:10pt;"> offering period concluded in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 2014</font><font style="font-family:inherit;font-size:10pt;"> and, in accordance with the 2004 Plan's automatic termination provision, there will be </font><font style="font-family:inherit;font-size:10pt;">36,154</font><font style="font-family:inherit;font-size:10pt;"> shares issued. In February 2012, under the 2004 Plan, purchase rights for approximately </font><font style="font-family:inherit;font-size:10pt;">273,000</font><font style="font-family:inherit;font-size:10pt;"> shares were granted with an aggregate grant date fair value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.05 million</font><font style="font-family:inherit;font-size:10pt;">, based on the Black-Scholes pricing model. This offering period concluded in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 2013</font><font style="font-family:inherit;font-size:10pt;"> and, in accordance with the 2004 Plan's automatic termination provision, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares were issued. Unless terminated earlier by the Board of Directors, the 2014 Plan will terminate December 31, 2024. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Stock Awards</font><font style="font-family:inherit;font-size:10pt;"> - On May 30, 2007, the Company's shareholders approved the Hooper Holmes, Inc. 2007 Non-Employee Director Restricted Stock Plan (the &#8220;2007 Plan&#8221;), which provides for the automatic grant, on an annual basis for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10</font><font style="font-family:inherit;font-size:10pt;"> years, of shares of the Company's stock to the Company's non-employee directors. The total number of shares that may be awarded under the 2007 Plan is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">600,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, there remain available for grant approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">360,000</font><font style="font-family:inherit;font-size:10pt;"> shares under the 2007 Plan. Each non-employee member of the Board of Directors other than the non-executive chair receives </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,000</font><font style="font-family:inherit;font-size:10pt;"> shares annually and the non-executive chair receives </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10,000</font><font style="font-family:inherit;font-size:10pt;"> shares annually of the Company's stock, with such shares vesting immediately upon issuance. The Company believes that the shares awarded under the 2007 Plan are &#8220;restricted securities&#8221;, as defined in SEC Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"). The Company filed a Registration Statement on Form S-8 with respect to the 2007 Plan on April 16, 2008. The directors who receive shares under the 2007 Plan are "affiliates" as defined in Rule 144 under the Securities Act and thus remain subject to the applicable provisions of Rule 144. In addition, the terms of the awards (whether or not restricted) specify that the shares may not be sold or transferred by the recipient until the director ceases to serve on the Board or, if at that time the director has not served on the Board for at least four years, on the fourth anniversary of the date the director first became a Board member. During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and 2013, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> shares were awarded under the 2007 Plan. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of share-based compensation expense in selling, general and administrative expenses for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and 2013.</font></div></div> 30000 -533000 -533000 30000 100000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented.</font></div></div> 23648000 0 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Discontinued Operations </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the Company completed the sale of certain assets comprising the Portamedic service line to Piston Acquisition, Inc., a subsidiary of American Para Professional Systems, Inc., (&#8220;Piston&#8221;). Pursuant to the terms of the Asset Purchase Agreement, the Company sold assets associated with the Portamedic service line to Piston, including, among other things, fixed assets, inventory and intellectual property, and Piston assumed certain specified liabilities. The adjusted purchase price (the "Purchase Price") was approximately </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, adjusted from </font><font style="font-family:inherit;font-size:10pt;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;"> at announcement due to changes in working capital. Piston held back </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Purchase Price as security for the obligations under the Asset Purchase Agreement and certain other agreements between the Company and Piston. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Holdback Amount includes </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> components. The first holdback is </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustments, and is released in total as follows: within </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> business days after the date on which final closing adjustments for inventory and other current assets are determined and paid (the &#8220;Closeout Date&#8221;). The remaining </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Holdback Amount, less any deductions or adjustments with respect to fixed assets, indemnification claims and any amounts in respect of any indemnification claims then in dispute, will be paid on the first anniversary of the Closeout Date. During the first quarter of 2014, the Company received </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the first Holdback Amount. As a result, the amount remaining related to the first Holdback Amount was written off during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> as a charge to the adjustment to gain on sale of Portamedic and subsidiary in the statement of operations. The Company has recorded the receivable related to the second Holdback Amount at the amount it believes will be collected. There cannot be any assurance that the remaining the Holdback Amounts will be collected by the Company. The Company currently anticipates finalization and collection on the second Holdback Amount in the first quarter of 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below summarizes the operating results of Portamedic which are reported in discontinued operations in the accompanying consolidated statement of operations. Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the three month period ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.70955165692008%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain (loss) from discontinued operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(533</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to gain on sale of Portamedic and subsidiary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Basking Ridge, New Jersey real estate continued to be classified as assets held for sale as the Board authorized the sale of the real estate during the fourth quarter of 2013. The land and building owned in Basking Ridge, New Jersey of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> are recorded as assets held for sale at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">. On May 13, 2014, the Company entered into an agreement for the sale of the Basking Ridge, New Jersey real estate.</font></div></div> -0.04 -0.04 -0.04 -0.04 <div style="font-family:Times New Roman;font-size:10pt;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss) Earnings Per Share</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic (loss) earnings per share equals net (loss) income divided by the weighted average common shares outstanding during the period.&#160;&#160;Diluted (loss) earnings per share equals net (loss) income divided by the sum of the weighted average common shares outstanding during the period plus dilutive common stock equivalents. The calculation of (loss) earnings per common share on a basic and diluted basis was the same because the inclusion of dilutive common stock equivalents would have been anti-dilutive for all periods presented.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">3,917,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,607,500</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock were excluded from the calculation of diluted loss per share for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and 2013, respectively, because their exercise prices exceeded the average market price of the Company's common stock for such periods and, therefore, were antidilutive. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> 0 P2Y P7M6D 700000 0 -150000 -150000 0 2614000 3199000 -2565000 -2027000 -2560000 -2023000 -0.04 -0.03 -0.04 -0.03 -120000 -533000 -0.01 0.00 0.00 -0.01 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes </font><font style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded tax expense of less than </font><font style="font-family:inherit;font-size:10pt;">$0.01 million</font><font style="font-family:inherit;font-size:10pt;"> in continuing operations for each of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and 2013 reflecting a state tax liability to one state. No amounts were recorded for unrecognized tax benefits or for the payment of interest and penalties during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">. No federal or state tax benefits were recorded relating to the current year loss, as the Company continues to believe that a full valuation allowance is required on its net deferred tax assets. </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2011 federal income tax return is currently under examination by the Internal Revenue Service. The remaining tax years 2010 through 2013 may be subject to federal examination and assessment. Tax years from 2006 through 2009 remain open solely for purposes of federal and certain state examination of net operating loss and credit carryforwards. State income tax returns may be subject to examination for tax years 2009 through 2013, depending on state tax statute of limitations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company has U.S. federal and state net operating loss carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$140.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$127.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. There has been no significant change in these balances as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. The net operating loss carryforwards, if unutilized, will expire in the years </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2033</font><font style="font-family:inherit;font-size:10pt;">. </font></div></div> 4000 5000 720000 1292000 672000 1742000 102000 81000 502000 229000 2000 1000 1457000 1376000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in inventories at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> are </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of finished goods and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of components.</font></div></div> 400000 600000 800000 1000000 3000 1000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Litigation </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 23, 2012, a complaint was filed against the Company in U.S. District Court for the District of New Jersey on behalf of a purported class of employee examiners alleging, among other things, that the Company had failed to pay overtime compensation to certain employees as required by federal law. On May 24, 2012, a related complaint was filed against the Company in the same court alleging, among other things, that the Company similarly failed to pay overtime compensation to a purported class of certain independent contractor examiners who, the complaint alleges, should be treated as employees for purposes of federal law. The complaints seek award of an unspecified amount of allegedly unpaid overtime wages to certain examiners. The Company believes the allegations in the cases are without merit, has filed answers in both cases denying the substantive allegations therein. By Consent Order filed March 11, 2013, the court approved a settlement of </font><font style="font-family:inherit;font-size:10pt;">$0.05 million</font><font style="font-family:inherit;font-size:10pt;"> between the Company and the named plaintiffs in the employee case, and the case was dismissed with prejudice. Preliminary discovery and motion practice are being conducted in the contractor case. The claim is not covered by insurance, and the Company is incurring legal costs to defend the litigation which are recorded in continuing operations. This matter relates to the former Portamedic service line for which the Company retained liability. The Company has determined that losses related to the remaining complaint are not probable or estimable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 30, 2013, a complaint was filed against the Company in the California Superior Court, San Bernadino County, on behalf of a putative class of employees alleging, among other things, that the Company failed to pay wages and other compensation as required by state law. The complaint seeks award of an unspecified amount of damages and penalties. The Company has denied all of the allegations in the case and believes them to be without merit. In January 2014, the Superior Court referred the parties to mediation and a mediation date of July 17, 2014 is scheduled. The Superior Court also set a trial date of August 10, 2015. The Company has determined that the losses related to these matters are not probable or estimable. The claim is not covered by insurance, and as a result, the Company is incurring legal costs to defend the litigation.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a party to a number of other legal actions arising in the ordinary course of its business. In the opinion of management, the Company has substantial legal defenses and/or insurance coverage with respect to all of its pending legal actions. Accordingly, none of these actions is expected to have a material adverse effect on the Company&#8217;s liquidity, its consolidated results of operations or its consolidated financial position.</font></div></div> 21646000 20344000 7476000 8839000 0 10000000 3100000 0.01 50000 -1015000 16000 -311000 416000 -1735000 -3156000 -2685000 -2560000 -12000 -46000 3 -2011000 -2514000 -470000 -15000 196000 -1722000 -62000 497000 338000 -3287000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hooper Holmes, Inc. (&#8220;Hooper Holmes&#8221; or the "Company&#8221;) mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, insurance companies, employers, government organizations and academic institutions. The Company also conducts laboratory testing, assembles collection kits, conducts telephone interviews of life insurance applicants, compiles health histories, collects medical records and provides underwriting services to help life insurance companies evaluate underwriting risks.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a provider of services to the health and insurance industries, the Company's business is subject to seasonality, with second and third quarter sales typically dropping below the other quarters due to a decline in activity during the summer months and fourth quarter sales typically the strongest quarter due to annual benefit renewal cycles. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2013 Annual Report on Form 10-K, filed with the SEC on March 31, 2014. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for any other interim period or the full year. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; for additional information.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. For further discussion on Discontinued Operations, refer to Note 6.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the sale of the Portamedic service line, the Company reassessed its segment reporting. Beginning in the fourth quarter of 2013, the Company has reported its financial results in three segments: Health and Wellness, Heritage Labs and Hooper Holmes Services. Previously reported financial statement amounts have been reclassified to reflect the new segment determination for all periods presented in this Report. For further discussion on Segments, refer to Note 13.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Subsequent Events</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 16, 2014, the Company entered into a Strategic Alliance Agreement (the &#8220;Alliance Agreement&#8221;) with Clinical Reference Laboratory, Inc. (&#8220;CRL&#8221;) pursuant to which, among other things, the Company has agreed to sell certain assets comprising the Company&#8217;s Heritage Labs and Hooper Holmes Services business units (the &#8220;Business&#8221;) to CRL. Under the terms of the Alliance Agreement, CRL has agreed to pay </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> in cash (the &#8220;Purchase Price&#8221;) for certain assets of the Business, which such assets exclude, among others, all accounts receivable, and to assume specified liabilities related to the Business. The net book value of assets to be sold was approximately </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, consisting primarily of inventory and property, plant and equipment, qualified as assets held for sale subsequent to </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. The transaction is expected to close in the late second quarter or early third quarter of 2014. The Company will retain certain aspects of its sample kit assembly operations centering around the Health and Wellness segment and all other supply chain fulfillment capabilities, which continue to support Health and Wellness operations and other customers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also entered into a Limited Laboratory and Administrative Services Agreement (the &#8220;LLASA&#8221;) with CRL pursuant to which, among other things, CRL will become the Company&#8217;s exclusive provider, subject to certain exceptions, of laboratory testing and reporting services and will also provide administrative services in support of the Company&#8217;s Health and Wellness operations. The Company will become a member of CRL&#8217;s preferred provider network for wellness programs during the term of the LLASA. The LLASA will become effective upon the closing of the transaction contemplated by the Alliance Agreement (the &#8220;Effective Date&#8221;), and will continue for </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;"> from such date and auto-renew for an additional </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> year renewal period unless sooner terminated by either party in accordance with the LLASA. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 13, 2014, the Company entered into a Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;) for the sale to McElroy Deutsch Mulvaney &amp; Carpenter, LLP (the &#8220;MDMC&#8221;) of the buildings, land, certain personal property and other interests comprising the Company&#8217;s Basking Ridge, New Jersey property (the &#8220;Property&#8221;) for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$3.05 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Purchase Price&#8221;). Upon entering into the Purchase and Sale Agreement, MDMC made an initial deposit of </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;"> of the Purchase Price with an escrow agent and will deposit an additional </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;"> of the Purchase Price with the escrow agent following the completion of a </font><font style="font-family:inherit;font-size:10pt;">40</font><font style="font-family:inherit;font-size:10pt;">-day inspection period (the &#8220;Inspection Period&#8221;). The remaining </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> of the Purchase Price will be paid by MDMC to the Company at the closing. Subject to satisfaction of customary closing conditions, the closing is expected to occur </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> days after the end of the Inspection Period but no later than July 11, 2014. The deposit is refundable to MDMC in certain circumstances. The Basking Ridge real estate was classified as assets held for sale as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">New Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, accounting guidance was issued to change the criteria for reporting discontinued operations. Under the new guidance, only disposals of components of an entity that represent strategic shifts that have, or will have, a major effect on an entity&#8217;s operations should be reported as discontinued operations in the financial statements. Additionally, the new guidance removes the condition that an entity may not have any significant continuing involvement in the operations of the component after the disposal transaction. The new guidance requires expanded disclosures for discontinued operations, as well as disclosures about the financial effects of significant disposals that do not qualify for discontinued operations. The guidance will be effective for the Company on January 1, 2015, however early adoption is permitted. The Company currently expects to early adopt this accounting guidance in its second fiscal quarter of 2014 concurrent with meeting the criteria for assets held for sale of the Company&#8217;s Heritage Labs and Hooper Holmes Services segments.</font></div></div> 5605000 4036000 1597000 1650000 1830000 1029000 796000 870000 -46000 -13000 148000 213000 361000 0 967000 311000 327000 0 743000 700000 8100000 17000 0 16345000 16018000 3728000 3761000 26000 -30000 48000 1000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Charges </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded restructuring charges in continuing operations totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">. The restructuring charges for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> month period ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> consisted of employee severance. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, there was a total of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> related to restructuring charges, including employee severance and branch closure costs, are recorded in accrued expenses in the accompanying consolidated balance sheet. The following table provides a summary of the activity in the restructure accrual for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:603px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="148px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="119px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="10px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="10px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="10px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="119px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Charges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Severance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Branch closure obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(361</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">677</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> 4000 92000 92000 0 531000 415000 946000 677000 267000 410000 -139679000 -142364000 12599000 12359000 5150000 4064000 0 3145000 2988000 2522000 7089000 0 500000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below summarizes the operating results of Portamedic which are reported in discontinued operations in the accompanying consolidated statement of operations. Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the three month period ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.70955165692008%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain (loss) from discontinued operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(533</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to gain on sale of Portamedic and subsidiary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table presented below provides disclosures by segment for the three month periods ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and 2013. Intercompany revenue for the three month periods ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, representing Heritage Lab revenue for kit sales to the discontinued Portamedic operations at arms' length sales prices. Heritage Lab also performs services to Health and Wellness. These services are recorded at Heritage Labs' cost directly within the Health and Wellness segment, and thus, no intercompany elimination is required. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:572px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="141px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="84px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="20px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Health and Wellness</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Heritage Labs</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hooper Holmes Services</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unallocated Corporate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,287</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,514</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,344</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments. For the three month period ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> of costs, which are recorded in unallocated corporate in the table above in connection with the relocation of its corporate headquarters to Olathe, Kansas. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:572px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="141px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="84px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="20px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2013</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Health and Wellness</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Heritage Labs</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hooper Holmes Services</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unallocated Corporate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,722</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,011</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of the activity in the restructure accrual for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:603px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="148px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="119px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="10px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="10px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="10px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="119px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Charges</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Severance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Branch closure obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(361</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">677</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three month</font><font style="font-family:inherit;font-size:10pt;"> period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.8671875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="44%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding balance at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,150,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(505,550</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding balance at March 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,986,600</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$222</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at March 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,388,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$51</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted during the three month period ended March 31, 2014 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:56.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="27%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options granted during the period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.38</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Segments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the sale of the Portamedic service line, the Company reassessed its segment reporting to align with the information that the Company's chief operating decision maker regularly reviews since the sale of Portamedic. Beginning in the fourth quarter of 2013, the Company reports financial results in </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> segments: Health and Wellness (health risk assessments including biometric screenings), Heritage Labs (laboratory testing and kit assembly for third parties) and Hooper Holmes Services (health information services). Financial statement amounts have been recast to reflect the new segment determination for all periods presented in this Report, including certain revenues and costs previously reported as a part of discontinued Portamedic operations which have been reclassified to Hooper Holmes Services to conform to current period presentation. The determination of segment assets involves a degree of management judgment and estimates as the Company has not historically prepared balance sheets by service line. Segment asset information is not provided as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, as previously indicated, the Company reported one segment through September 30, 2013 and did not historically separate working capital by service line. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, substantially all of the Company's services are provided within the United States, and substantially all of the Company's assets are located within the United States. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table presented below provides disclosures by segment for the three month periods ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and 2013. Intercompany revenue for the three month periods ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, representing Heritage Lab revenue for kit sales to the discontinued Portamedic operations at arms' length sales prices. Heritage Lab also performs services to Health and Wellness. These services are recorded at Heritage Labs' cost directly within the Health and Wellness segment, and thus, no intercompany elimination is required. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:572px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="141px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="84px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="20px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2014</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Health and Wellness</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Heritage Labs</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hooper Holmes Services</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unallocated Corporate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,287</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,514</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,344</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments. For the three month period ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> of costs, which are recorded in unallocated corporate in the table above in connection with the relocation of its corporate headquarters to Olathe, Kansas. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:572px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="141px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="84px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="64px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="20px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2013</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Health and Wellness</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Heritage Labs</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hooper Holmes Services</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unallocated Corporate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,722</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,011</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments.</font></div></div> 5036000 5206000 235000 77000 1.06 0.45 1344100 305000 500000 2000000 155100 150000 0.000 0.850 0.018 0.10 343750 141400 600000 5000000 3500000 1500000 3209300 360000 1166750 1388700 0.99 505550 83500 162600 0 0 300000 500000 462600 0.38 222000 4150550 3986600.0 0.68 0.75 0 0 0.45 1.20 0.57 0.56 P5Y2M27D 51000 P6Y9M18D P8Y6M 10000 0 37500 10709000 13300000 13371000 10780000 9395 9395 71000 71000 69835387 70410649 70410649 69835387 P5Y 30000 50000 P5Y P5D P10Y P10Y 0.03 0.02 300000 3050000 3700000 3050000 8400000 75000 2000000 1000000 1000000 P3D 75000 2 2900000 6700000 P13M P1Y 25000 2000000 0.95 -123000 0 P40D 0.85 500000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's primary sources of liquidity are cash and cash equivalents and the 2013 Loan and Security Agreement. At March 31, 2014, the Company had </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents, </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;"> of working capital and no outstanding debt. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and 2013, the Company incurred losses from continuing operations of </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company&#8217;s net cash used in operating activities for the three months ended March&#160;31, 2014 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">. The Company has managed its liquidity through the sale of Portamedic and a series of cost reduction and accounts receivable collection initiatives.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Transition Initiatives</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three month period ended March 31, 2014, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> of costs, which are recorded in selling, general and administrative expenses in the consolidated statement of operations, in connection with the relocation of its corporate headquarters to Olathe, Kansas, and contributed to the loss from continuing operations during the quarter. The Company relocated its headquarters to Olathe, Kansas during the first quarter of 2014, where the Health and Wellness facilities are located. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Basking Ridge, New Jersey real estate continued to be classified as assets held for sale. On May 13, 2014, the Company entered into an agreement for the sale of the Basking Ridge, New Jersey real estate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Holdback Related to the Sale of Portamedic</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the Company completed the sale of Portamedic. Approximately </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;Holdback Amount&#8221;) of the purchase price was held back by the acquirer as security for the Company&#8217;s obligations under the agreements between the Company and the acquirer. (Refer to Note 6). The Holdback Amount includes </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> components of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> each. During the first quarter of 2014, the Company received </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the first Holdback Amount. The Company currently anticipates finalization and collection on the second Holdback Amount in the first quarter of 2015. The Company has recorded the remaining receivable related to the second Holdback Amount at the amount it believes will be collected. There cannot be any assurance that the remaining Holdback Amounts will be collected by the Company. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2013 Loan and Security Agreement</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains a three year 2013 Loan and Security Agreement, as amended, (collectively, the &#8220;2013 Loan and Security Agreement&#8221;), with Keltic Financial Partners II, LP (&#8220;Keltic Financial&#8221;) (refer to Note 9). Borrowings under the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The amount available for borrowing may be less than the </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> under this facility at any given time due to the manner in which the maximum available amount is calculated.&#160;&#160;The Company has an available borrowing base subject to reserves established at the lender's discretion of </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of Eligible Receivables (as defined in the 2013 Loan and Security Agreement) up to </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> under this facility. &#160;&#160;Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, and other receivables deemed ineligible by the lender. Eligible Receivables include only billed receivables and concentration limits such that borrowing capacity may be affected by the Company's billing and revenue cycles. As of March 31, 2014, the lender applied a discretionary reserve of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. Available borrowing capacity, net of this discretionary reserve was </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> based on Eligible Receivables as of March 31, 2014. As of March 31, 2014, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the 2013 Loan and Security Agreement. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also working with Keltic Financial to modify the financial covenants of the 2013 Loan and Security Agreement in an effort to be more in-line with the Company's operations and strategy going forward. If the Company is not able to successfully execute favorable amendments to the existing credit facility, the Company's borrowing capacity may be limited.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2013 Loan and Security Agreement contains various covenants, including financial covenants which required the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The lender recently waived the quarterly minimum EBITDA covenants for the fiscal period ended December 31, 2014. The Company continues to have limitations on the maximum amount of unfunded capital expenditures for each fiscal year.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Subsequent Events</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 16, 2014 under the Alliance Agreement (refer to Note 1), CRL has agreed to pay </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> in cash for certain assets of the Business, which such assets exclude, among others, all accounts receivable, and to assume specified liabilities related to the Business. The Company will retain certain aspects of its sample kit assembly operations centering around the Health and Wellness segment and all other supply chain fulfillment capabilities, which continue to support Health and Wellness operations and other customers. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 13, 2014 under the Purchase and Sale Agreement (refer to Note 1), MDMC has agreed to pay </font><font style="font-family:inherit;font-size:10pt;">$3.05 million</font><font style="font-family:inherit;font-size:10pt;"> in cash for the Property. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These transactions will provide the Company with additional capital to invest as it focuses on growth supporting Health and Wellness operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Considerations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's Health and Wellness business sells through wellness, disease management and insurance companies who ultimately have the relationship with the end customer. The Company's current services are aggregated with its partners' offerings to provide a total solution. As such, the Company's success is largely dependent on that of its partners.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through the focus on the Health and Wellness sector, the Company believes it will be able to capitalize on the opportunities that exist in the Health and Wellness sector given the macro-economic focus on health care costs and improving the efficiency of health care delivery in the United States to grow revenue.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is not able to realize the benefits from the consolidation in Kansas and control the costs of transition, grow the Health and Wellness business as it seeks to streamline operations and improve efficiency through increased revenue and cost reduction initiatives, the Company may not have sufficient Eligible Receivables and the lender may increase reserves such that the Company may not be able to borrow under the 2013 Loan and Security Agreement. These and other factors could adversely affect liquidity and the Company's ability to generate cash flow in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the Company's anticipated level of future revenues and gross profits, anticipated cost reduction initiatives, cash proceeds in connection with the Alliance Agreement, the sale of the Basking Ridge, New Jersey real estate, and existing cash and cash equivalents and borrowing capacity, the Company believes it has sufficient funds to meet its cash needs to fund operation expenses and capital expenditures for the twelve months following March 31, 2014.</font></div></div> 12 17 677000 5000 10000 24400 0.25 0.25 0.25 0.25 0.25 0.25 0 0.5 0.33 0.00 0.25 0.33 0.25 0.25 0.25 0.33 0.25 0.34 0.25 0.25 0.5 0.33 0.33 0.25 0.25 P10Y 0.25 273000 233000 36154 0 false --12-31 Q1 2014 2014-03-31 10-Q 0000741815 70410649 Smaller Reporting Company HOOPER HOLMES INC Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments. For the three month period ended March 31, 2014, the Company incurred $1.1 million of costs, which are recorded in unallocated corporate in the table above in connection with the relocation of its corporate headquarters to Olathe, Kansas. Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments. EX-101.SCH 10 hh-20140331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2137100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2437401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1001500 - Statement - Consolidated Balance Sheet (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - DEI Document link:presentationLink link:calculationLink link:definitionLink 2131100 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 2431403 - Disclosure - Discontinued Operations Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2431402 - Disclosure - Discontinued Operations Operation Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2331301 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Impairment of Long-lived Assets link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Impairment of Long-lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2139100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2439401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2134100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2434401 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 2138100 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 2438401 - Disclosure - Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 2136100 - Disclosure - Loan and Security Agreements link:presentationLink link:calculationLink link:definitionLink 2436401 - Disclosure - Loan and Security Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - (Loss) Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - (Loss) Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2135100 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2435402 - Disclosure - Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2335301 - Disclosure - Restructuring Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2141100 - Disclosure - Segments link:presentationLink link:calculationLink link:definitionLink 2441402 - Disclosure - Segments (Details) link:presentationLink link:calculationLink link:definitionLink 2341301 - Disclosure - Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2422405 - Disclosure - Share-Based Compensation Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Share-Based Compensation Employee Share-Based Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - Share-Based Compensation Option Roll-Forward (Details) link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Share-Based Compensation Stock Option Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 hh-20140331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 hh-20140331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 hh-20140331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Discontinued Operations Discontinued Operations, Policy [Policy Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Expected life (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted average fair value of options granted during the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Commitments and Contingencies Disclosure [Abstract] Number of offices Number Of Offices Number Of Offices Number of operating leases Number of Operating Leases Number of Operating Leases Branch closure obligation Disposal Group, Including Discontinued Operation, Branch Obligation Disposal Group, Including Discontinued Operation, Branch Obligation Employment agreements, contract term employment agreements, contract term Contract term associated with employement agreements Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Income Statement [Abstract] Revenues Revenues Cost of operations Cost of Goods and Services Sold Gross profit Gross Profit Selling, general and administrative expenses Selling, General and Administrative Expense Restructuring charges Restructuring Charges Operating loss from continuing operations Operating Income (Loss) Other expense: Nonoperating Income (Expense) [Abstract] Interest expense Interest Expense Interest income Investment Income, Interest Other expense, net Other Nonoperating Income (Expense) Other expense Nonoperating Income (Expense) Loss from continuing operations before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Loss from continuing operations Income (Loss) from Continuing Operations Attributable to Parent Discontinued operations: Adjustment to gain on sale of Portamedic and subsidiary Gain (Loss) on Disposition of Business Gain (loss) from discontinued operations, including income taxes Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Loss from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net loss Net Income (Loss) Attributable to Parent Basic and diluted earnings (loss) per share: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Continuing operations Income (Loss) from Operations before Extraordinary Items, Per Basic and Diluted Share [Abstract] Basic (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Discontinued operations Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract] Basic (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Diluted (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net loss Earnings Per Share [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted average number of shares - Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted average number of shares - Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Restructuring Charges [Abstract] Restructuring Charges Restructuring and Related Activities Disclosure [Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance [Member] Employee Severance [Member] Facility Closing - Branch Office Closure [Member] Facility Closing - Branch Office Closure [Member] Closing of a facility associated with restructuring pursuant to a plan - excludes impairment of fixed assets. Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Charges, Discontinued Operations Restructuring Charges, Discontinued Operations Restructuring Charges, Discontinued Operations Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Restructuring reserve, beginning balance Restructuring Reserve Payments Payments for Restructuring Restructuring reserve, ending balance Subsequent Event [Table] Subsequent Event [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Groups, Including Discontinued Operations, Name [Domain] Disposal Groups, Including Discontinued Operations, Name [Domain] Strategic Alliance Agreement Assets [Member] Strategic Alliance Agreement Assets [Member] Strategic Alliance Agreement Assets [Member] Purchase and Sale Agreement Property [Member] Purchase and Sale Agreement Property [Member] Purchase and Sale Agreement Property [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Consideration amount Disposal Group, Including Discontinued Operation, Consideration Disposal Group, Including Discontinued Operation, Consideration Disposal Group, Including Discontinued Operation, Initial Deposit with Escrow Agent Disposal Group, Including Discontinued Operation, Initial Deposit with Escrow Agent Disposal Group, Including Discontinued Operation, Initial Deposit with Escrow Agent Disposal Group, Including Discontinued Operation, Deposit to Escrow Agent Receivable Upon Completion of Inspection Disposal Group, Including Discontinued Operation, Deposit to Escrow Agent Receivable Upon Completion of Inspection Disposal Group, Including Discontinued Operation, Deposit to Escrow Agent Receivable Upon Completion of Inspection Assets of Disposal Group, Including Discontinued Operation Assets of Disposal Group, Including Discontinued Operation Agreement Period Agreement Period Agreement Period Additional Agreement Period Additional Agreement Period Additional Agreement Period Inspection Period Related to Purchase and Sale Agreement Inspection Period Related to Purchase and Sale Agreement Inspection Period Related to Purchase and Sale Agreement Disposal Group, Including Discontinued Operation, Remaining Receivable Upon Closing Disposal Group, Including Discontinued Operation, Remaining Receivable Upon Closing Disposal Group, Including Discontinued Operation, Remaining Receivable Upon Closing Closing Period Subsequent to Inspection Period Closing Period Subsequent to Inspection Period Closing Period Subsequent to Inspection Period Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Settlement Litigation Settlement, Amount Debt Disclosure [Abstract] Loan and Security Agreements Debt Disclosure [Text Block] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Portamedic Service Line [Member] Portamedic Service Line [Member] Portamedic Service Line [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Revenues Disposal Group, Including Discontinued Operation, Revenue Gain (loss) from discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Adjustment to gain on sale of Portamedic and subsidiary Tax Effect of Discontinued Operation Discontinued Operation, Tax Effect of Discontinued Operation Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Intercompany eliminations [Member] Intercompany eliminations [Member] Intercompany eliminations [Member] Health & Wellness [Member] Health & Wellness [Member] Health & Wellness [Member] Heritage Labs [Member] Heritage Labs [Member] Heritage Labs [Member] Hooper Holmes Services [Member] Hooper Holmes Services [Member] Hooper Holmes Services [Member] Unallocated Corporate [Member] Unallocated Corporate [Member] Unallocated Corporate [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Operating income (loss) Segment assets Assets Relocation costs Business Exit Costs Number of reportable segments Number of Reportable Segments Revenue by Segment Revenue from External Customers by Products and Services [Table Text Block] (Loss) Earnings Per Share Earnings Per Share [Text Block] Schedule of Discontinued Operations Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] Schedule of Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Stock Option Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Proceeds from the sale of Portamedic Proceeds from Divestiture of Businesses Holdback amount Disposal Group, Including Discontinued Operation, Holdback Amount Disposal Group, Including Discontinued Operation, Holdback Amount Holdback release, business days after closing Disposal Group, Including Discontinued Operation, Holdback Release, Business Days after Closing Disposal Group, Including Discontinued Operation, Holdback Release, Business Days after Closing Number of holdback components Disposal Group, Including Discontinued Operation, Number of Holdback Components Disposal Group, Including Discontinued Operation, Number of Holdback Components Assets held for sale Assets Held-for-sale, Current Holdback amount, component one Disposal Group, Including Discontinued Operation, Holdback Amount, Component One Disposal Group, Including Discontinued Operation, Holdback Amount, Component One Holdback amount, component two Disposal Group, Including Discontinued Operation, Holdback Amount, Component Two Disposal Group, Including Discontinued Operation, Holdback Amount, Component Two Liquidity [Abstract] Liquidity [Abstract] Liquidity Liquidity [Text Block] The disclosure for the company's management of liquidity. Asset Impairment Charges [Abstract] Impairment of long-lived assets Asset Impairment Charges Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Options [Member] Employee Stock Option [Member] July 2009 Non-vested Stock Award [Member] July 2009 Non-vested Stock Award [Member] July 2009 Non-vested Stock Award [Member] July 2011 Non-vested Stock Award [Member] July 2011 Non-vested Stock Award [Member] July 2011 Non-vested Stock Award [Member] Non-Vested Stock Award [Member] Non-Vested Stock Award [Member] Non-Vested Stock Award [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Director Stock Plan [Member] Director Stock Plan [Member] Director Stock Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Exercised (options) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (weighted averaged exercise price) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options vested in period Share-based Compensation Arrangement by Share-based Payment Award, Options Vested in Period The number of stock options that vested during the reporting period. Aggregate fair value of options vested in period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Unrecognized compensation cost related to stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Weighted average period for recognition of compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Non-vested Stock Awards Non-vested Stock Awards [Abstract] Non-vested Stock Awards [Abstract] Aggregate shares granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Aggregate shares that vested in the period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Aggregate shares of non-vested stock forfeited Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Vesting Schedule for Equity Grants Other than Options Vesting Schedule for Equity Grants Other than Options [Abstract] Vesting Schedule for Equity Grants Other than Options [Abstract] Vesting percentage, year one Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year One The percentage of a share-based payment award that vests in year one. Vesting percentage, year two Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year Two The percentage of a share-based payment award that vests in year two. Vesting percentage, year three Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year Three The percentage of a share-based payment award that vests in year three. Vesting percentage, year four Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year Four The percentage of a share-based payment award that vests in year four. Vesting percentage, year five Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year Five The percentage of a share-based payment award that vests in year five. ESPP ESPP [Abstract] ESPP [Abstract] ESPP, number of shares authorized ESPP, number of shares authorized ESPP, number of shares authorized ESPP, purchase date ESPP, purchase date ESPP purchase date, number of months after grant date ESPP, purchase price as percentage of market value ESPP, purchase price as percentage of market value ESPP, purchase price as percentage of market value ESPP, maximum subscription rate Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate ESPP, maximum subscription amount ESPP, maximum subscription amount ESPP, maximum subscription amount Shares issued during period, Employee Stock Purchase Plan Stock Allocated During Period, Shares, Employee Stock Purchase Plan The number of shares subscribed to by employees under the Employee Stock Purchase Plan during the period. Aggregate Grant-Date Fair Value, Employee Stock Purchase Plan Aggregate Grant-Date Fair Value, Employee Stock Purchase Plan Aggregate Grant-Date Fair Value, Employee Stock Purchase Plan Shares issued in accordance with plan termination provision Stock Issued During Period In Accordance with Automatic Termination Provision, Employee Stock Purchase Plan Stock Issued During Period In Accordance with Automatic Termination Provision, Employee Stock Purchase Plan Other Stock Awards Other Stock Awards [Abstract] Other Stock Awards [Abstract] Term over which grants will occur Share-based Compensation, Term Over Which Grants Will Occur Share-based Compensation, Term Over Which Grants Will Occur Number of shares authorized under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Remaining shares available for grant under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares awarded annually to non-employee board members other than the non-executive chair Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Awarded Annually to Non-employee Board of Directors Other Than the Non-executive Chair The number of shares awarded annually to each non-employee member of the Board of Directors other than the non-executive chair. Number of shares awarded annually to non-executive chair of the board of directors Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Awarded Annually to Non-executive Chair of the Board of Directors The number of shares awarded annually to non-executive chair of the Board of Directors. Number of shares awarded Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Share-based compensation expense Allocated Share-based Compensation Expense Litigation Legal Matters and Contingencies [Text Block] Income Tax Disclosure [Abstract] Statement [Table] Statement [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Internal Revenue Service (IRS) [Member] Internal Revenue Service (IRS) [Member] State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] Statement [Line Items] Statement [Line Items] Operating loss carryforwards, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Loan and Security Agreements [Table] Line of Credit Facility [Table] Time period [Axis] Time period [Axis] Time period [Axis] Time period [Domain] Time period [Domain] [Domain] for Time period [Axis] Prior to second anniversary [Member] Prior to second anniversary [Member] Prior to second anniversary [Member] Prior to third anniversary [Member] Prior to third anniversary [Member] Prior to third anniversary [Member] Base interest rate [Axis] Base interest rate [Axis] Base interest rate Base interest rate [Domain] Base interest rate [Domain] [Domain] for Base interest rate Prime rate [Member] Prime Rate [Member] LIBOR 90 day rate [Member] LIBOR 90 day rate [Member] LIBOR 90 day rate [Member] Loan and Security Agreements [Line Items] Line of Credit Facility [Line Items] Maximum borrowing capacity under Loan and Security Agreement Line of Credit Facility, Maximum Borrowing Capacity Loan maximum defined, based on eligible receivables Line of Credit Facility, Loan Maximum Defined, Based on Eligible Receivable The contractual maximum of borrowings as defined by a percentage of eligible receivables, with consideration of all undrawn/unexpired letters of credit. Loan maximum defined, based on eligible receivables, reserve Line of Credit Facility, Loan Maximum Defined, Based on Eligible Receivable, Reserve Line of Credit Facility, Loan Maximum Defined, Based on Eligible Receivable, Reserve Additional borrowing availability under Loan and Security Agreement Line of Credit Facility, Remaining Borrowing Capacity Borrowings outstanding under Loan and Security Agreement Line of Credit Facility, Amount Outstanding Spread on variable rate Debt Instrument, Basis Spread on Variable Rate Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Unused Capacity, Commitment Fee Percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Commitment fee Debt Related Commitment Fees and Debt Issuance Costs Credit facility - early termination fee Credit facility - early termination fee Credit facility - early termination fee Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Options [Member] Equity Option [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Finished goods Inventory, Finished Goods, Gross Components Inventory, Raw Materials, Gross Income Taxes Income Tax Disclosure [Text Block] December 2010 Stock Option Award [Member] December 2010 Stock Option Award [Member] December 2010 Stock Option Award [Member] All Other Stock Option Awards [Member] All Other Stock Option Awards [Member] All Other Stock Option Awards [Member] 2008 Plan [Member] 2008 Plan [Member] 2008 Plan [Member] 2011 Plan [Member] 2011 Plan [Member] 2011 Plan [Member] name of equity-based compensation arrangement plan Awards to Certain Employees [Member] Awards to Certain Employees [Member] Awards to Certain Employees [Member] Amended and Restated 2011 Plan [Member] Amended and Restated 2011 Plan [Member] Amended and Restated 2011 Plan [Member] Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Contractual life of stock options and other awards under share-based compensation plans contractual life of stock options and other awards under share-based compensation plans Contractual life of stock options and other awards under the shared-based compensation plans Option Vesting Schedule Option Vesting Schedule [Abstract] Option Vesting Schedule [Abstract] Vesting percentage, grant date Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Grant Date Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Grant Date Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Impairment of Long-lived Assets Asset Impairment Charges [Text Block] Segments Segment Reporting Disclosure [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net of allowance for doubtful accounts of $124 and $153 at March 31, 2014 and December 31, 2013, respectively Accounts Receivable, Net, Current Inventories Inventories, Property Held-for-sale, Current Other current assets Other Assets, Current Total current assets Assets, Current Property, plant and equipment Property, Plant and Equipment, Gross Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Other assets Other Assets, Noncurrent Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Other Accrued Liabilities, Current Total current liabilities Liabilities, Current Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies (Note 10) Commitments and Contingencies Stockholders' Equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, par value $.04 per share; Authorized: 240,000,000 shares; Issued: 70,420,044 shares and 70,382,544 shares at March 31, 2014 and December 31, 2013, respectively; Outstanding: 70,410,649 shares and 70,373,149 shares at March 31, 2014 and December 31, 2013, respectively. Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Stockholders' equity Stockholders' Equity before Treasury Stock Less: Treasury stock, at cost; 9,395 shares at March 31, 2014 and December 31, 2013 Treasury Stock, Value Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity DEI [Abstract] DEI [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Stock Option Activity [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding balance (options) at December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Expired (options) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Forfeited (options) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Outstanding balance (options) at March 31, 2014 Outstanding balance (weighted average exercise price) at December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (weighted average exercise price) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Expired (weighted average exercise price) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Forfeited (weighted average exercise price) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding balance (weighted average exercise price) at March 31, 2014 Weighted Average Remaining Contractual Life, options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands), options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Number of options exercisable at March 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted average exercise price of options exercisable at March 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Life, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands), options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustment to gain on sale of Portamedic and subsidiary Gain (Loss) on Disposition of Other Assets Depreciation and amortization Depreciation Amortization of deferred financing fees Amortization of Financing Costs Provision for bad debt expense Provision for Doubtful Accounts Share-based compensation expense Share-based Compensation Impairment of long-lived assets and loss on disposal of fixed assets Impairment of long-lived assets and gain (loss) on disposal of fixed assets Impairment of long-lived assets and gain/loss on disposal of fixed assets Change in assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Reduction in capital lease obligations Repayments of Long-term Capital Lease Obligations Proceeds related to the exercise of stock options Proceeds from Stock Options Exercised Debt financing fees Payments of Financing Costs Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of non-cash investing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Fixed assets vouchered but not paid Capital Expenditures Incurred but Not yet Paid Fixed assets acquired by capital lease Capital Lease Obligations Incurred Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock (in shares) Treasury Stock, Shares Working capital Divestiture of Business, Working Capital Divestiture of Business, Working Capital Loss from continuing operations Net cash used in operating activities of continuing operations EX-101.PRE 14 hh-20140331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 15 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes (Details) (USD $)
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Internal Revenue Service (IRS) [Member]
Dec. 31, 2013
State and Local Jurisdiction [Member]
Income tax expense $ 5,000 $ 4,000    
Operating loss carryforwards, subject to expiration     $ 140,000,000 $ 127,200,000
EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`]212&\`$``&<9```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,FI8AN*['+^Z61VL_$4 MB[S;QHHU*?EOG,>ZH5['TGFR^-:9-1_'(W<=V MZ%O)C0YDKE/(A?_1`5[.WL>1Z_"KX'S,%P.!#C^%I^9_V#WQ>1"%U-)S][^K M0W].S)<*AP>^*O%IN+8P9'9D\_&:9/X/``#__P,`4$L#!!0`!@`(````(0"U M53`C]0```$P"```+``@"7W)E;',O+G)E;',@H@0"**```@`````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````C)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$ M`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ. M'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7< ME.4]AK\>4"T\U<%J"`=[!ZH^^CSYLK$SO+=N5#9@NI MS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A``GXO6,# M`@``=A@``!H`"`%X;"]?Z];OI#G6Z&0K?3S@,(6XE#$]M(FIGF[4>D@YM">YJ%N1N#9"Q]7.N<(]EW M]Z^[;?''A[CIN\K0;&X*W]5]L^G6E?GU_'!Q;8J87->X;=_YRNQ]-/?+\[.[ MGW[K4GXHMILA%GF4+E:F36FXM3;6K=^Y..L'W^4[JS[L7,K-L+:#JU_ MSQ$F]-+`VK)T!##-`M'U/H/&)=B8(#(52V_A*:'R7RC9\B5R8M&D(XK#V,8'A M,8&UCPD,CPFB;TL9YCEK)WE#+-(=GP*C,]RTOB,K0N^>4HA?T4\_B1PW(WV%MKA MB;-3>=<%]Q6DK7&"&B=MC1/4.&N+BJ&H9%)1G7`J%[AV1%M6,NK*?OA;L/P' M``#__P,`4$L#!!0`!@`(````(0"!H%0HH@,``"8,```/````>&PO=V]R:V)O M;VLN>&ULC)9=;]HP%(;O)^T_1+E?(0ED;56H6N@T)-2BT;67EIN88#6Q,]L4 M^N]WG!0XB4/5*S#AO#D?SWF3J^M=D7MO3&DNQ<@/SOJ^QT0B4RZRD?_W\=>/ M<]_3AHJ4YE*PD?_.M'\]_O[M:BO5ZXN4KQX("#WRU\:4E[V>3M:LH/I,EDS` ME954!35P5%E/EXK15*\9,T7>"_O]N%=0+OQ:X5)]14.N5CQA4YEL"B9,+:)8 M3@VDK]>\U/[X:L5S]E17Y-&RO*<%Y+W+?2^GVMREW+!TY`_A*+>L\8/:E+<; MGL/5BZ@?^;WQHW7H5S@(P]C^T[;BB;.M/@;9H[=[YB*5 M6_M7:.W[X11!`MOJTC-/S1JN]_O]PV^_&<_69O\CR/>0?M5!N$_UZ8FJO.G= MC.R[`@.S/9Y!'8'OJ4L.7]0L#6R:.&8"+9,Y3RDTA-S2G(J$D:4-U4AB@#7" MKVN0!558)D2I5+T]F5S/F_#0?&WG'$`$7\;-]O+K4F=U0)6#E-%DS! M#*AJ%(WS/6_'SXJ2R9`E(F'=RDRE6TX>2&.(E M"#K`*PIN:F2M&&P6]"$#(VW6,L1+$#CDS;GA6;OK0XQ;X/`V`[,N&'FDNV;9 M&+G`86[)LBI;7"*&+'`HZ]P*L@#_:->(*0N^BAD4\)(W*\"T@7>VS.L$;1TZ M&+K0@:Z3GPX53&'H4+COIQL88_Y"A[_NMDZ9H3S'6Q!C`$,'P(/KD(Y0#%WH M0M=M/Q]""!!XSATWJ7[H8>/[W(8@_>K/]J$4-B;KLFG=SS4B4N<2V&N/- M"!UB3Q@:61J9O!*<3V.V7R;VH;0O'4@GPJ.&0XO84_G<;*E*<3XQWMW((?84 M^;7EXGSPX".'V5,Z]U2!=2.=&#M#Y"",;+N+/DQ-Y(#;O7XNQ/9UZ6#C<&CU M]C,;)U-42]1(QW%3>/*=-O+&C###D>#BL]>M93P+IG0/(&77/MA5[2^N'_%'_\'``#__P,`4$L#!!0`!@`( M````(0`YS-1D104``&,4```8````>&PO=V]R:W-H965T&UL MC%A=;ZLX$'U?:?\#XCT!0R"D2G)UX:J[5]J55JO]>*;$25`#CH`VO?]^QXR# M&9NP?6F+YWCFS(>=-6XIZY[*E[SJ\+L2AK$\[]^^_GA>)Z[1= M7A_RBZCYSOW!6_?+_N>?MC?1O+9GSCL'/-3MSCUWW?7)\]KBS*N\78HKK\%R M%$V5=_#8G+SVVO#\T&^J+E[@^[%7Y67MHH>GYC,^Q/%8%OR;*-XJ7G?HI.&7 MO`/^[;F\MG=O5?$9=U7>O+Y=%X6HKN#BI;R4W8_>J>M4Q=/W4RV:_.4">7^P M55[$K5SWG@;#SSMMX<2,I!E=QI^W+E?V5,6AJZW MW_8%^J?DMW;TM].>Q>V7ICS\5M8)50K\?Y!)L]JS=SWT'_FB< M`S_F;Y?N3W'[E9>G?_2_;^6A.^_<,%Y&:S]D M0>0Z+[SMGDNYUW6*M[83U;\(8LH5.@F4DQ!H*GOP62<>$NH3^99W^7[;B)L# MTP$AVVLN9XT]@6.5@:(QY`2E+23ZJX3WFX!M"ZOO^SC<>N]0HT)!4H2L76>` M,(K([@A96J`Q<($$32ZA/X265AHZBJCCU(8$%)'9B'@U0`@9*,:(S#U_N0K- M&R47FR00LAI!#$0VAR`CP97:X:T9-A/V:/$(P> MQ$PWN#=G8W/(1K4AT6&`1[GW!V,TC-)JL-`U1!8(01:1'QHMRH@Y\+69L)!O M"GT\[U,H5VGTM:XA1D?("CM@GH*Q45>'!-Z0P&;ZTFH0,`YYBA!,?Q%$5A>H MW6=Z/^'!0)0G*M`OTX.X-K),%09F?3@HYB#.0B@/*I3W3C#4LO%A7%N"B!CL MQ4+GB=.H/"BKSH%&E[IESP%#.2/1=3]Q$!0&_5O!T0$:-6\:6\K51&Q4,1+; M*&_*[DHG7Q2+E9YQE3HQLT?QI5A-Q$<-(_&-`"E#C*JM'9^8V:/:4Q4TCP*\ M[ZVS8,JAP@R'8:1XJA)C15P$?O"H%M.:R&Q17)NBJ#!8"Z-1&3'J":)S0!5Q M.`&V%*Y-*61CL0,Q,-^9F0'P`UU!RF%:#QD*&HS3<-(34Q`5!EH^8*PJW'5Q M"D)YS,LCL_4Q,8Y>JC!J-EED\,V(71L)C8"*HSF:O9G*=**''.5!890"Z#@X ME\2ZB,('8QE,BV._;,37'E1\*HZ!Q8#8'S.00F:+1(#Z-A:)1(^W8H`8_%A: M!+'UM:*&TYB\-$#,W'#.0B@/*6L3/%#M2"U,P0P0 ML^D_&Q;^TC>*E5D`W4_*@8KF72SD?SO&AT.BC[KJ!V)F.)B`1QRFQ3)`L23] M,,5286;[@6ZF(;06T\(9V,*96/U`#(Z>=330J`NE)8;&GQ;-`-6.S(/5"\0\ MB(_&_X]/Q7*8!11)T@=CW-(`,=-%5A(U!R%U@,_WJ7/1+QLJ9?9!872J!M%L M!D`Y3"MEB"HWVPN%F>&`3J8`E(,4/*T/YELCE&:C'N8+76'P@V;MKY@?KPQ, M1C#Q)@FC<'36*2,I?S.,4!W'U=D8AR&%:Q[)>I[1&/.`$=[UX!5)Q9L3S_CE MTCJ%>*OANX&!,`ZK>,>4PAU3?T_C#0:X^;GF)_Y[WIS*NG4N_`A;_>4:=*O! M2R)\Z,2UO]!X$1W<^?1_GN$RC\-%B[\$\%&([OX@[TJ&Z\']?P```/__`P!0 M2P,$%``&``@````A`-?R73R#`@``!P8``!D```!X;"]W;W)K&ULC%1;;]L@%'Z?M/^`>*^QG6NC.%7C*ENE59JF79X)QC:*,1:0 MIOWW.T#BQFFT]24.A^]\YSLWEG&A?X(ARI+P?B#8GO)6QM(-&^H!?VF%ITY ML4GV$3I)]6[?W3`E.Z#8BD;85T^*D62+QZI5FFX;R/LE&5-VXO:'=_12,*V, M*FT$="0(?9_S+;DEP+1:%@(R<&5'FI<9OD\6^023U=+7Y[?@!W/V'YE:';YH M47P3+8=B0YM<`[9*[1STL7`F<";OO#>^`=\U*GA)]XW]H0Y?N:AJ"]WV\9AJ M(!+\(BG<"$#F],5_#Z*P=89'4XRVW-B-<#X8L;VQ2OX)EXF+VCNG1V?X'IV3 M-)K,XE&23CY,,CJ2P/>-))U/DLGT_RPDI./+\$`M72VU.B`8+1!N.NH&-5F, MH/S,&>^=U=]!:@:LSZMQFB[),U22'3'K@)EAU&,N$/D5Q+0G(2"@5P&%N:+" M62]5C'H"KW0=,#-?;B<]/S,,0D#9KH1P5FCE>1+)11KK@!F?829#$?F_$`,1 M0')%A+-F&(3WE1RGXV&(=<#<^E[$T5L9?17RX>V;[R`XC-J5X,YZ&?PBOW7` MG(+/A])@/1W#W$M+^KL0.BQ>F#C)=<5SWC0&,;5O(=D4?'IKV/=ULH">PO)< MV'-X![R=]!>PGAVM^!/5E6@-:G@)E'$T`STZ;'(X6-7Y*=HJ"POJ_];PX'*8 MEC@"<*F4/1W<6]$_X:N_````__\#`%!+`P04``8`"````"$`JJL=\%D$``"* M$```&0```'AL+W=O.^`.7*@)*/FVAUI5EJM]G@FQ$E0`T:8='J^_99M+IL,]/1#=U+^4:Y_5=G8 MO?_R4>3:.ZYI1LJ#CE:FKN$R)>>LO![T?_Z.7[:Z1IND/";:*)*LU(4'K_Z,#W*Y9"D.27HO<-D()S7.DP;BI[>LHIVW(OV,NR*I MW^[52TJ*"ERKDE(/N#^0D:>>;?YFX+[*T)I1`I^/^G($"EG:MQI>#_HJ\&#FZ<=SS!/V;X0<=?=;HC3Q^J[/S MMZS$D&VH$ZO`B9`WAGX],Q,\;$R>CGD%_JRU,[XD][SYBSQ^Q]GUUD"Y7?9( M2G*8"7YK1<9Z`*0G'_SO(SLWMX-NKU?NQK21Y>K:"=,FSMBSNI;>:4.*_P2$ M6E?"B=4ZL2',=MSZ:2=.ZP3^#DZLK8O<]4^$`D%S/>O>BVVM',O=;#\AR!#) MX4D-DR8Y[FORT*!303ZM$M;WR`//;3;;E/3YA3*GC'YE^$'?Z!IDCH+U_>B@ MW=YXAX*E+>-/&20304>PHC&WH3"(U#-#U!F&>:R=)7N)I\PPCP'R>HU0Q)'& M3@JS,BE=$'YG&,TISQA,B;4C(^$4L=8R$@D$HN]S:*,A,H,ZB5MT)A/ MM#&KI$TU!*HA5`V1,,AA#D&(,.<9*5!H_B>!,JL4J&H(5$.H&B)AD`.UY9S' M'<-VEG%KP*(:1<7;?VWVWK@5D/.K1=+P.9BA!?,%N^[#>.;9JFHG0,*&.A&)O)4S1^>HO`N^H_ M'A,;&9`DPO[T1"*SRA*MW496X`MF)LI@D0@7B4@0:Y[(K2,+$0MKSHE)@;I;EVNHD?@O-Z5U&PF4D MZA%V(%#?$?W@L+7\2"M[HT^;&3&SJE5N(K]E1)]M$%M3,A&TQ$PRPD4GT;*3 M>!:12\M>\H-]1"TBWNP_4#PWD5`LKFSB=E'@^HH#G.=4 M2\F]A$.%"PW86_NKXBN_*2IV'WEP18"CFFJW//\9'U@>'!.G?&AY<%ID1[[> M$5P0J^2*_TCJ:U92+<<7",U<;>#T5(N[I/C2D(K?C4ZD@:LA_WB#.S^&NXFY M`OA"2--]81/T_T4X_@\``/__`P!02P,$%``&``@````A`"AA6!7S`@``%@@` M`!D```!X;"]W;W)K&ULC%7;CMHP$'VOU'^P_`ZY M0;B(L%I8;;M2*U55+\\F<1)KDSBRS;+[]QW;),1A19<'2&:.SYRY,-[J%",MXD.)CZ&-$FY1EKB@3__O4X66(D%6DR4O&&)OB-2GRW_?QI<^+B69:4 M*@0,C4QPJ52[]CR9EK0FS5A#;8, M:_$1#I[G+*4//#W6M%&61-"**-`O2];*CJU./T)7$_%\;"U>G'TT#?@B4T9P<*_63G[Y25I0*NCW71U)>023X1C73(P"9DU?S>V*9*A,< MQ=/YPH^"<([1@4KUR/19C-*C5+S^:T'!F2"&2>_>%'23PKR"3R0!39 M;@0_(1@.""E;HD M,;MK3.`B]AU"UQ9T]&(@PX&8+J:VZIBZK%K$SAJ`I!<1C@)<(^)9#W%"0LZ# MD";_V._3U5[HU2!2%,0]D55C,;,!9NXB]K<0CA@@&8N)+F*T-\&06I_V:0A/8,C9>5(Z69#6UT)LV`L MP6)NM<,B[/`&6N18@]W#=GW55!1T3ZM*HI0?&QBX$"K96_OU?Q_JO3&R[^!: M,+O5ZQVPK5M2T.]$%*R1J*(Y4/K3!0RLL(O=OBC>FJ5YX`KVM'DLX?ZEL)?\ M*8!SSE7WHM=;?Z-O_P$``/__`P!02P,$%``&``@````A`##!JD:("P```E8` M`!D```!X;"]W;W)K&ULG-S;;MLZ%@;@^P'F'0S? MU[8.3F(CR49UH,["8&//S+7K*(E1VPILM^E^^R%%2A:7%/[I]*)MJ,]+!RY1 MU%*L^S]^'?:3G]7IO*N/#U-KMIA.JN.V?MH=7QZF__Z+?;F;3LZ7S?%ILZ^/ MU/QG_^X?Z]/W\^O5769\`C'\\/T]7)Y6\_GY^UK==B<9_5;=>1+ MGNO387/A/YY>YN>W4[5Y:CYTV,_MQ>)F?MCLCE,987WZ3(SZ^7FWK8)Z^^-0 M'2\RR*G:;RY\^\^ON[=S&^VP_4RXP^;T_.,AONWVN\O?3=#IY+!= M)R_'^K3YMN?[_-P?H/[OJ_=S[_^3\6K]'I]U3OCM6_&CS?A(] M\*VNOPN:/(DF_N'YX-.LZ8%_G29/U?/FQ_[R9_T>5[N7UPOO[J7XR+;>\S7Q MOR>'G<@!ONN;7\V_[[NGR^O#U+F9+6\7CF4OIY-OU?G"=N*ST\GVQ_E2'_XK MD:5"R2"V"N+PS53+[=\.XJH@?+77(/;=TEK>_,:FW*@H/)%5%/MV=FLM5L[M MY_=GI8+P?]L@SLQR%[^S(1;O,WEDKT?E_SBT5GM8Q'_4QCC.[+/'92Z[NTF3 M8'/9/-Z?ZO<)/_=XAY[?-N),MM8BM$H0UUTPI/AS%M_ M/CIWUOW\)\_!K3+>T!#AMT+DH0@;R`:93:(AI`VL_-1"E;(4YGWCE=#_&3JM]#;4>(9M$1 M[=YZ;<-U7VQ]3_RAN'%U$@R),P:?@N=0>61(F&PK'((8F'AFYP M,B1D1>E0.'=DM[.A(5'RH7#N2*840T.BE":A=3H?*_J=WIR6SJ(["\5BK?-I M@T\;`MH0T@8F&_I]YKBD1Z)/F/@3)ADQSD+/H73$W"UUDWW"Y&/F5H]3?,*4 M8^:NBZ-U'Q](!]WG+KON$XOY!;9W=CAWJRY2,R)ZTO"_NS.([+L/10!%"`6# M(H(BAB*!(H4B@R*'HH"B-`DM!_@THY\#[;@MFA^F?"#H^M6Y(:.G)\U-^-*L9-_.7-)YOES,L[#+'R("*$(H&!01%#$4"10I%!D4.10% M%*5):`G`9WC]!&C/>M%,.GY%3EQ/&GG6VZX[..GEZ:4]]:\#_ZG,"7RTT9`$4( M!8,B@B*&(H$BA2*#(H>B@*(T"2T#>)G`E`%B,A>'=EI@R:*/ M=C>P(F4%3R%C.L@X!A+@*"$F#),(DQB3!),4DPR3'),"D[(CHB)Z'<7T)!#5 MG[$DD%4AK1RP(@4*SY+(T,,^)@$F(28,DPB3&),$DQ23#),0(934CAW[.YSA(08(L^?V[ M'J0T!M$30I2;3`DARU']R\2@7.19III5T]L^)@$F(28,DPB3&),$DQ233!&9 M$(XK*O!Z7^8X2*$%L5S^:P,D2&D,HB>$J$*9$D)6J?@EO:L*NPM:7;),I2R5 M$)`$.$J("<,DPB3&),$DQ23#),>DP*0T$CTE1%FJEQ+=+:4L5_7'!F=)RTR6 MJ::E4@&2`$<),6&*K,3C47[O-+.O]]#-ED0X1HQ)@DF*2:9(N[%T5(#'K"`! M9@XI_I3&C=`S0%2EQC)`5JOT#""K\2R)VAT9;(>O@&$^$6`28L+HE@S[WU1] M:U(DQJM),$DQR=#&YCA&06,,4\"TPUH*V*31^UE/(F`@RCH$$.$J("<,DPB3&),$DQ213Q)`(\,`5>#6ED>B)("I[(_," M6U;\])L$.C-4R-#+/B8!)B$F#),(DQB3!),4DPR3'),"D])(]%3@_3B:"J)= M'Q/^(H9L"3`),6&81)C$F"28I)ADF.28%)B41J*G`BDR=E/% M87'179#IB">^>$$JS>Z"3";\$41(@$F("<,DPB3&),$DQ23#),>DP*0T$CT9 M0('1'BLP#N8,$G47OM[#;UE"4%&,HP,L4H8X"L,DPB3&),$DQ23#),>DP*0T M$CTA2(&Q&QUD09#/8'J%1?I`TI:H2P12>/35P,)CB*,P3"),8DP23%), M,DQR3`I,2B/1\T!4L,;FCK*RI>26PB)/O#R%3`F! M2:"(>CPW_#V/4`,CSW,97DF$28Q)@DF*289)CDF!26DD>CJ0LB,='YQA^=&E MW^_T%%(=>6/1$K6OP/@7G;J%U[D)N=\(,6&81)C$F"28I)ADF.28%)B41J*G M@JAO]2X5[=S1$>WZUQQ=B]:;%#*."#*.@00X2H@)PR3"),8DP23%),,DQZ3` MI#02/14^*#TZLO2HS18L6F]2R-#//B8!)B$F;(0X+IG>1".(#$`Q)@DF*289 M)CDF!2:ED>C)P'NR/RX,+A%BN3YC<.C7'3U'(F-20!+@*"$F3!%YN;H1\PXR MOXEPD!B3!),4DPR3'),"D])(](P@-F]5X&DNZ\)>>;I MO]H;*&'(H!`3ADF$28Q)@DF*289)CDF!B7@%)OW]@NM%7>:!?,6E?'?AH3J] M5'ZUWY\GV_K'D3^:%'W;M7:OUOSJB-?CD7;/6OO-BP9).[/6_`6!0U_P5W2. MM7OVVAN+[]MK?ZP]L-?\)6S#^*&]YN]BX^WS;H/XBSG?-B]5L3F][([GR;YZ MYKNXF(DW5Y[D.SSE#Y?ZK7F#X[?ZPE_)V?SWE;]KM>(O4%S,.'ZNZTO[@UA! M]_;6Q_\!``#__P,`4$L#!!0`!@`(````(0#TH(A!.@0``"4/```9````>&PO M=V]R:W-H965TTU(4Z"#N`(R,G9?]^QQQ`8:$ISD03[97@\,[S@S:>/(K?>155G MLMPROG"8)LLN37-=VW:=7D21U`MY%27,G&15)`T<5F>[OE8B.>J3BMQV'2>PBR0K M&4985W-BR-,I2\47F=X*4388I!)YT@!_?$*Y+J[79]265QA1"' M+,^:'SHHLXIT_?5,TK>V5# MI-WFF,$*5-JM2IRV[#-?QRYG]FZC$_0]$_>Z]]^J+_+^2Y4=?\M*`=F&.JD* M'*1\4]*O1S4$)]NCLU]U!?ZHK*,X);>\^5/>?Q79^=)`N7UU2BISN!)\6T6F M>@"6GGSHWWMV;"Y;Y@4+/W0\[OK,.HBZ>BP*^)PMVY*#8N2Z?C2](DNTTE[Q;T&(#7UT1U+%]#8),' MLY@N,U"@5*D_*[D^"=9V_>'@?=CB3M4Q&-%L.PD`QC(1@^F38`:A1[H+@8];MFV#&J40CSJ MB!"H,1"1-TX!"F8PK`8,M"_5+&6A+8$:9/%643#N"53,@.%@_[V,:)JEW_F& MGJ8X(>D.(UIA]1/.Q)[F*$(:OB#V%YOI M.3"@>0:CIDD7A=3Y.8K:U/C!:O`990KE\/U?U@OO)B.X?HM/F'!(4K'7,;:L MA0M(T\5F?@[-T(5'731AQR&U8][:[6/M7DA<,YX0/7(X<&8^M.81TH1'TWM\ MKV-L6:0]P'5)_F(S/2<_0XL>P4QX=4C]D??-FGM1%(X>6$8R!^BY7_,)PPY' M#HFBMGU6Q!9B$V0&C3OAUSV'U-/T3B/-NC>B_M6\D")-B/ZE?=SGIJVG"5)$ MG=DEZ MIV%W$[!WN29G\7M2G;.RMG)Q@E,=>)XQJ\)M#AXT\JK?I0^R@5V+_GN![:B` MEWQG`>*3E$U[H%[3NPWN[A\```#__P,`4$L#!!0`!@`(````(0"'Q'_JJ@(` M`($&```9````>&PO=V]R:W-H965TS3`REK8%;53+,_S.#7[(/WY8[I1^ M-37G%@%#:S)<6]LM"#&LYI*:0'6\A9U2:4DM+'5%3*ZADU2_;KH14[(#BK5HA'WO M23&2;/%2M4K3=0-YOT5CR@[<_>**7@JFE5&E#8".^$"O9G@5+1YGF.3+OCY_!-^9DV]D:K7[HD7Q3;0X2E&@#-@W>9).EN2 M+52)[3&/'@//`1,-"`*R@S;HG6@?))S52;@R.LU';SCEBV_S)6=\?2[C=`C= M[4)RIV%-Q@.1E_*8\0DF'1!GH0/D1NC.FF&(]YCY-!P(O(3'G$HDZ7S`G(E` M;]P0<=9+D6.!O8C'S%WRVSP,9O_)8G)3P%DO!8X5]P(>'C/?URTYMK;7\:/` M7R#)=<4_\:8QB*E-"T<>@=M@'2;0*NZ'R+`!@Z&C%?].=25:@QI>@FL83.', MM)\A?F%5UU_/M;(P$OK/&D8]ARL1!@`NE;*'A9M2PY]'_@\``/__`P!02P,$ M%``&``@````A`$"D.?I9!@``#R0``!D```!X;"]W;W)K&ULG)I;"*-XLLNW2>7EY7T M]U_FEZ_2*"^BRSXZI9=X)?V,<^G;T^^_/;ZGV8_\&,?%B"A<\I5T+(KK@RSG MNV-\CO)Q>HTOY,@AS)H7YYT/LG3R60NGZ/D(C&%A^P>C?1P M2':QGNY>S_&E8")9?(H*TO[\F%SS6NV\NT?N'&4_7J]?=NGY2B2>DU-2_"Q% MI=%Y]^"\7-(L>CZ1?G\H6K2KMGK< M)Z0'M.RC+#ZLI._*PU:92?+38UF@?Y+X/6_]/\J/Z;N5)7L_N<2DVF2C@49[C+?+CV13.3WZ)Q0 M#Y"N1Q_EW_=D7QQ7DCH?SQ8359G.I-%SG!=F0L^51KO7O$C/_S)(H=D;D6DE M0OY6(LKTET742F1Q$UF.%6TR_X6&$/NRWM""_>_N*$U1;AV:+L8+9;)4%_=7 M1:E[1`K_ZZV1V4"5`ZQ'1?3TF*7O(W+5D,;EUXA>@\H#5:Z&MAJ?9K")YW84 M_T[YE42J2H8Q)]&W)U6=/!3#;\F:HV@#MQ.4=4YW]^0,8O2YK2MVU9`)B/1 M#`>Q2'LXZJK3,*UZG71=!VY)IWS*#2-(GF:@!$+O$G.-%S&ZB"!B=@E1Q&+( M4BO=HBG:5.6SV%T-(8L#"176JD^9BI(' MT28\X][!>'V,Z(H[F*"/$6P>WL%L^YC;1GD#J]82&17,(:]::,6SHM?F4](6O^*8-*#V`S@`V M[PLG&^V3U9XRF0,G6_6Q3WUK0\*!A`L)#Q(^)`)&M*\POLPAE-@.$9P;YKP; MQ.6$'A9=(2P6:\80_WTZ93""=4B=DIMOCUEE";19LT]!STLFD2X$U@S M9L@D74+5A#5>[S+"ZF1TB8Z*V64$%0L2-B0<2+B0\"#A0R*`1`B)[1#!.85N M[[2^.]:+"PV3+_ZM*8*LI;RCUXP9<@@D=$@8D#`A84'"AH0#"1<2'B1\2`20 M""&Q'2(X=RS[W4'#POPQ$^ZXUXP9<@RH]4T=95QTA_#M>5U!0_;`B(X1HT(^K9F) M-2R,V&(:5?CBZ&`-%R,>1GRQ)1V38(U0U!!\MA6.-^L"[P^Z/]:SM-"]U,[L M(91K74'-L(GUW%3`@(%TC!AB&K%8)M:P,&)CQ,&(BQ$/(WZ%-)45NQQ@C5#4 MZ/B##7%?#MXB=!.MSR)L:UPJ`F2=)8,4U?>1" M9IN!T=E@1,>(42&?%LW$&A9&;(PX&'$QXF'$QTB`D1`CVPKIJRWO%#+,O4ZA MW$\;.*N(-&G[*B604B.E8Q,&)BQ,*(72'5-IFJ:8JXY>=@%1(O`-" M?YH;R')E][%*@)$0(_1]B\^'D M1)OW.+ZK]"&O$%\K#^3Y=S<>TO<^>N+KZ<.ZU)$;(?*6QC5ZB8,H>TDN^>@4 M'T@3)F/Z`D+&7NA@'XKT6KX4\)P6Y/V,\M\C>?$F)@^M)V,"']*TJ#^0!LG- MJSQ/_P$``/__`P!02P,$%``&``@````A`!D^`:E=`@``804``!D```!X;"]W M;W)K&ULC%3;CML@$'VOU']`O&_P)2;`-,T*`0Y\V9'A98YG\60QQ&2:=?7Y M+?C.GGPC6^O=%R.*;T)Q*#:TR3=@I?7:0]\*'X+#Y.KTLFO`=X,*7M)-XW[H MW59T3L$PP$I;4O]J,43(#XX M.,CH/4%EF4?//#S'CQB!6@O1[31-TXQLH4CL@)E?8^)SQ.*(\+4%';T8<'@B MYIC31WU.7U8O8AX"0-*+2"X27"/&PQYREA(\WTCIH]"CDPSQ^,+$/&"&)YA1 MGZ+3N?@?XDP$D-P0X:,Y!BN]S33]YR*4(F">NDY$%^EO[X7$8:3#)$AN*K[@ M36,1TQL%V1+@ZZ/]39HEO@47\3G9OI1V,?/=9PZ^,0XNC`8!+K=UQX2>E_SE._P(``/__`P!02P,$ M%``&``@````A`&>@D!WU`P``9PX``!D```!X;"]W;W)K&ULC%=-C^(X$+VOM/\ARKT)#@$:!(R&C'IWI!UIM=J=.9M@P.HDCFS3 M]/S[+7_$8">3](7NN)[+K\I5+Y7-I_>JC-X(%Y35VQA-IG%$ZH(=:7W>QO_] M^_+T'$="XOJ(2U:3;?R3B/C3[O??-C?&7\6%$!F!AUILXXN4S3I)1'$A%183 MUI`:+"?&*RSAD9\3T7""CWI352;I=+I(*DSKV'A8\X_X8*<3+<@75EPK4DOC MA),22^`O+K01K;>J^(B["O/7:_-4L*H!%P=:4OE3.XVCJEA_/=>,XT,)<;^C M#!>M;_W0<5_1@C/!3G("[A)#M!OS*EDEX&FW.5*(0*4]XN2TC3^C=9ZB.-EM M=(*^4W(3#_]'XL)N?W!Z_(O6!+(-]Z1NX,#8JX)^/:HEV)QT=K_H&_B;1T=R MPM=2_L-N?Q)ZODBX[KG:4K`23H+?J**J!B!T_*[_WNA17K;Q;#&9+Z]XWP/Q$7D7L<@7./'X]2MON9%Q6C.0]DN@T!VIE4;U?5L'=Y!>1%D:ODDL:)!(JZ%W/[]XH2%?2CM-T]74K-LTK6KJ@0C= M3[)9:'1[QH+,I),NPDG'FON+QY2HF??-F%P1?B8Y*4L1%>Q:0U4B&!K< MJOG.V,-WAI[5$V>`Z;_!9_(-\S.M1522$VR=3I;0]=Q\*)@'R1H]TQZ8A+E? M_WN!#SH"P_9T`N`38[)]4..R^T3<_0\``/__`P!02P,$%``&``@````A`'PK MBQ7!`P``N`P``!D```!X;"]W;W)K&ULC%==C]HZ M$'VOU/\0^7WS';X$K';;;ENIE:JK>V^?0S`0;1)'L5FV_[YCCW%BP[+A`8CG M>,[,\7@8EO>O=>6]T(Z7K%F1R`^)1YN";%WFSS2O6T!7Y M0SFY7W_\L#RQ[ID?*!4>>&CXBAR$:!=!P(L#K7/NLY8V8-FQKLX%/';[@+<= MS;=J4UT%<1A.@CHO&X(>%MT8'VRW*POZF17'FC8"G72TR@7$SP]ER\_>ZF*, MNSKOGH_M7<'J%EQLRJH4?Y13XM7%XON^85V^J2#OURC-B[-O]7#AOBZ+CG&V M$SZX"S#0RYSGP3P`3^OEMH0,I.Q>1W2KF7>,61"U;_ M1E"D7:&36#N!3^TDROPTSJ:S$5X"C$AE\CD7^7K9L9,'Y0&5/Y9*$)G1I!>$'8:5)9APA%6+2`:9'6*$#9!"Z M2R6M*P)Q&P62V%4),3.E813BRT1C<4&)W."25I>K#QK30LP\4V2A/^OM%M'D M)I&TND03$S$2(6:B>#*5DP%83%!`-U*25I=I:APA$V*0*4']#,*BDLW6*?!! M44BK2S4SCI`*,2F*9VP6R=PB.5>R7+6=IXFK&&+,T82]W2*(H#G=2$.972I7 M,@WJN=ZXEI&\P+UDYVS4LLOA:J5!@[*^+EAT_>ZK99=C;ES@>6C0B%L:W>X( MROQ>2]"@,6SR2E_1#6_ZL!ND:>CFA"!]-K$_S;[MD3 MTK0_"RWDN2GT+?Z-IAK9O<']J5#F=VL0N\0((6.[3YQS4LO.O4H3IP8UJ.\/ M/<#J1?'U_J"670[W5T^#QF1B=PA7MUB:W]--@\:PV9W"Z(8#@7UW>UFP%F#$ ME*'TNO7%@KKA`(EC5TV[/?U$JXI[!3LV:NI;+\VJ&5P?8C5Z&@.,DVV^IS_S M;E\VW*OH#K:&T">(U^'DB0^"M6JHVS`!@Z3Z>H!_"!0&J=`'\(XQ<7Z0LZWY MS['^"P``__\#`%!+`P04``8`"````"$`3=!)L(T"``!V!@``&0```'AL+W=O MP?-^<2*`@0E54L5MI M5ZI6>[@VCD,LXCBR36G??LXRT(4U!:MFP'+\SC1]67[\LCU+M=<6804!H=(XK8]I% M&&I:,4%T(%O6P$XIE2`&EFH7ZE8Q4KA#H@Z3*)J&@O`&>\)"?88ARY)3]B3I M0;#&>(AB-3&0OZYXJSN:H)_!":+VA_:.2M$"8LMK;MX=%"-!%\^[1BJRK:'N MMS@EM&.[Q15><*JDEJ4)`!?Z1*]KGH?S$$BK9<&A`BL[4JS,\6.\6,]QN%HZ M??YR=M07[TA7\OA-\>(';QB(#6VR#=A*N;>NSX4UP>'PZO3&->!%H8*5Y%"; M7_+XG?%=9:#;F3U"90V1X!<);D<`*B=O[GGDA:ER/)D&V2R:Q$F&T99IL^'V M+$;TH(T4_[Q3?$)Y2'*"P/,$B;,@3;+9_2`-F6,(E`26HW'^VN\P&S!NOK*DVS9?@*HM"3S_K:)^X]0HC2AP+\1:@N MA+6.0B23'N#26%_[)+W'(,3D9@AKM2%L8VQ9Z\Z`+LJ:WB:F-XG6.B!VADOB M[#81.GXAPUAQNPLMP&=0,KGO03Y][P,A^_3//1G(,1V$ZA2WUAR#IOWQ-!V' M\#ZI:WG\@=BSFW1K'=/GHP*\SXG^@4SVCCP/9I>[M0[I27(NWLOC?>8N]R@X MS])`FOD`/^Z"W1V&2;-H5(3WN>Q"FHTGWU\=_H-KR8[])&K'&XUJ5H+X43"# M5BI_`=O<$B49#8QZ=Z0=:;7:RS--2((Z0`3T M9?Y^RY2#[8+TSKYTFJI#U:ER^3C.]M-[?7%>RZZOVF;GLI7O.F53M(>J.>W< MO_Y\?$A-Y_7% MN:SS?M5>RP8\Q[:K\P$>NY/77[LR/XPOU1>/^W[DU7G5N!AAT_U(C/9XK(KR M2UN\U&4S8)"NO.0#\._/U;6_1:N+'PE7Y]WSR_6A:.LKA'BJ+M7P?0SJ.G6Q M^7IJVBY_ND#=[RS(BUOL\6$6OJZ*KNW;X[""\]M8>1-IO#Q54(-ON M=.5QYWYFFXPGKK??C@WZNRK?>N-_IS^W;[]TU>&WJBFAV[!.<@6>VO990K\> MI`E>]F9O/XXK\'OG',IC_G(9_FC??BVKTWF`Y0[E*T5[@4SPUZDK.0-0>OX^ M?KY5A^&\H:&%@J0(B5U'0VQ$MH"()H@'^2<2T!>#A",70_@3&>DE9,(I MSL@W14@\-ET6D!D&*Q,TS\AT*U=:(:592TPR("0P((1#]A'"X@!!%CA(Z\X% MWKJ?">&`D`37(XH(QQCKR/=:^DE+-93'.PU0J*1Q=I? M$W=FNA.QUC58+"*+Q6T=I-7.+G05F!TAF)T%(>V!Y1;QG7F#J35Z<,LNK20[ M([4C1&6/0D(NL]SA6I.S:I=GR'S+22O)SDEVA`1CYV-&-F1VSVOE7B_FEE:2 M6Y#<"%&5AV&B:QO7);/\D1_JW6'E9Z#4"\6/9L*`U)8*&1`12A5&K3L7LY:8&@D=T^_;#)9%DLU5,M"3I2;3U,$0Q,#6DDS% M0(:!;TRVS6!9*-E<*0.JE`J#&1(XAB@#C('^.+AW3K!EN1S-MD($5"\51HGU M6H^=VIRHE^A.[IW5W%9+JE2CF_`@JYTJC#F5,^'\&&.M";>U\W9TCF9[?Q@[ M#:="84PF=#`^A-@\I+AIU1H[PZ".B1"*GRE?`94OCA@<`I[,-)SZ-5N;RK*` M\KF`!E2^%`89L-`7G'#,*(*+>RRD6NJ&3'V09C(B9#.D'#'(XH$%7$1DBC(" M$>LHUE'L;MA".O%``377@WY[2N4M!KBJ;OAQHI4)-XT-$"+6PF-SL,5S'(X@ MU+,Q%]%01U+#BACMV*P:FQC(A?-TL MFX,MHC,)F8MI2*4,[N%R7=2]8^&0M0$+ARQ>P_'>69?=J&PO=V]R:W-H965T&ULE%;;;MLP#'T?L'\0]-[X%CMQ$*=H7'0;L`'#L,NS8LNQ4-LR)*5I M_WZ4E+B6VV9='N*(/#H\)&4JZ^O'MD$/5$C&NPP',Q\CVA6\9-T^P[]^WETM M,9**="5I>$`\'KRI6T%M>'%K:*4LB:$,4Z)0]<2<7_HKPK>]D"Q8PU33X84H[98?=EW7)!=`WD_!G-2G+G-X@5] MRPK!):_4#.@\*_1ESJF7>L"T69<,,M!E1X)6&;X)5GF*O['[SC3@NT`EK`-1()OU#)]!"!S\FB>1U:J.L-1,HL7?A2$,48[*M4=TWLQ*@Y2\?:/ M!04G*DL2GDC@>2()PO\FB4XD\'PF"9=Q$"?_EN+9M$PY;HDBF[7@1P1'#(3+ MGN@#&ZR`6=:*_!@%F"]6$3S]?>`Q2V.$&V%K+`:("$+B)_!9$, M$`]T#&*@/A?$:.]$3#SP&+U;"UF8XNL$\I'!B02I7HBDO5"'44[QLV(;R4+F M8XBK);^$<+0`R4C+N?3:FF'0/]0U7K@1MA:R-'T)PDEC)S:UT]B>_&VEJ(U;/PYS#;Y]/*N)!H&<8CB*-&7SEOOZ+:.U$33-18 MR*`F\)/YI("Y"XD643"".&I21\WYM&KK1,5D#&PMQ*I(HW3RZL*PUPRON&UT M.\GMZ&JIV-.<-HU$!3]T\(*$T/G!:B^0;;""<0`#?6+/X6(Q=F]PP+SOR9Y^ M(V+/.HD:6@&E/UO`X17V:K`+Q7LS?W9&UL[)W9;AS9F>?O!YAW"`CRE`20+&[:[+(:%"79=*E* MLDA/HS&8BV!FD`Q7+G1&IB3ZR@_1-P/,`'X6/XJ?9'[_[RQQ8LEDTBRRW-5M M5]E29,19OGT[W_GF7[Z,1]FG8E:5T\FO'^QL;3_(BLE@.BPGY[]^\(>3MYO/ M'V35/)\,\]%T4OSZP551/?B7E__]OWU35?.,;R?5KQ]7O_SZZVIP48SS M:FMZ64SXY6PZ&^=S_CH[_[JZG!7YL+HHBOEX]/7N]O;3K\=Y.7F0#::+R9QY M7^R]>)`M)N6?%L6A>[3_;/?!RV^J\N4W\Y>OWQQEKZ>#Q;B8S+_Y>O[RFZ_U MW/VVEWTWGV>__>/!I7[<[O]1<_ZO@]-J M/LL'\__=_O2K]H,WDWDYO\H^%N>E/IG,L^_S<=%^ZZO?OG__X>[SQI_W2XF,WX/'M; M5@.&^+M\WEW0YN;.[N;>3GL,OXRWY:B898=\>#Z====P/,Y'>N%C M<3F=S2&9['`ZOLPGG3<#\K*3J\ON&G:V-W_?7D#\XD,Q*Z?#I1N([Z6[?0NM M5.T1O^HC@?;G?K;^`7[?`=,!%#D4569O1_EY9\:S?%1UMNM!"Z3&TTEV/)\. M?MC(CB_R65%E[Q=S8S9`V1[L<#JIIJ-R""Z&V:M\E$\&!9_!457VZ`_'K[.' MC]N?'$VRDXOIHH)[JPVX:U1453:=7Q2SSV559-5E,2C/RB[3O"X&D6GVVH,> M'!^_.3EN/SW,JXN,>;*!_E#\:5%^RD?`I8.%@X&Q?)7-BD'!2Z>C8B.;%/-L M>I9!3-//MB]D1S:<+D[G9XM1EH=/>.7ASNZ^S?-PY\E>EL\S&'QP$3G33YQ$*GL[+H+/:]8)4-/#_E506PVSL_L*?9 M13$:9EIVQ;[;[YQ,YS#BZG$^S)";L_G51G8);N>V$\'QLD_HO0.3O\R`Y6*\ M&!E%#`M$[*#,Y\AQ^S8?BR7_;`_:ZUDYEZ&C_86#1#\$W.[Z?WMW=/#JZ-W1 MR1'2[N#[U]GQR?O#;Y%^K]]\//XJ>_/[/QR=_%M[KD@BE_F5Z*/G]]D")BB^ MH&BJ+M::T!Z5^6DY*N=+T8M>.]^<%[-QMN)5<6LY%RHJ@^X`G0.3HBH9-WOT M_71>9#O;'0[\ZF]__=M?V^LWEK^8CH9H76``CN=7OVR_Y,5#Y<3#)2(+^06T^^=B^,ML=W][`ZV@?]W/U:^RHZH"5K_,GFUO M[._RT_Z^_\FVP=.]Y[L;3Y*G_PA+_2H57&ZNG>V-I_LOVG,]V]O829[^(W-M MM2%U,!R"W>D$#KO,R^%F.4$(799P7.?-!K^@JF^#(H+N=.E67HJ?PF.N=XCA@S38J4?UM.4`,E M&/TPK0RY*TRQ@]5:HPW:98SU"+H93D>C?%;5_-5AZ.;7QH,(A,B#F49Q3]?[ MM#3VO/%GT]I.6/5MDT97O=D@AH@+K(6S[#W2QK0(KF!_;%`*R^ZPOT0'M.JI"S=JMJ3_&8VQMB[&(T0 MVQL9DIOOL2TP6?+AN)R8U2X#8:E:^5A@V"\&\\5,ANX`\7O>79X'%B^,M(JS MV72,6)"N6.BKY:MV"M:KM(XV.)J@H)@_+*Z]Y_A[:1!N_]P8?(5^]].W/W^W M>BO9:8'A4V1N[FR>?^G"Q6.>WY9MX9I)VFMZC7/CX(HE4(.U`[F#X1\7E2GN M;#[-SG$Z,PPD&6FBH@_82+AIPW+@Q.;BM"J'9=YU=7ZC#Q\)IX\=4H?]\V\( M"B-X!&2O@D>]VR4#M??[/2:RIF\_AW&O)ZY7><4.UY-PK\O10B[&NF_WHJ&] MRG\MRO,+C9H3:LC/BVRR,`L=%'@9NHE/$Q:Y1("N,TBZ^B7#K!!UYL6\Q0E9 M2]39VV?VMO&YIT(P3\2@_&0FYPIZK$20V.Q3-!W4*!]("-93_=D* MI6/9J)NGN7:!Y)>Y[AR4)8+FB.!!.0M6@!GF(T0R9..<+$EK@Q'SPS>74_A8 MBS\KO\27VJ1W>)%CIPN(Z2"U4]#%4'`W:P^U/6;;0]F0C]KP24R<3,U]3&RS M]CABZFOQW/ZH378E_FLE9V05V1TZB]@)7S3X`FW2'AC<#HIBZ+46:^\1D^UO MX@[0MY_*(5@XO<),<&3[&*AWU]8>HKV?F@!7L-''8H@J%AV"6&_N9R,LR9R'X31X!T2O1>SU`OLXY!J(U!_7 MNVM#1$,,BX$<#"-<(Y%U@BL&RKX7%2DY)30YF9@5^*5WQ/I$GSZ MOSQ>7%Z.S'Z'(Z728%-H3!],II--VT$?,72X[VW"RMFGZ8*8LJ32Z6+.0'/S M\-JK;GR2#_#9[(NK)EVTOY*Z,?OV`ZR`LV,4TW[I_>P\G_@@R@;!S1""$^$) MSNFWVNO;Z+A$&[=:X;K\=BK!GOUV.AH7U0;!7N)NC_[^E__;>/[WO_R_C+B2 MZ/0![L/<[&4\4U_DSX(<\FMGI`/RGFGZ,B%0^FE^8(4RTB!7C MR4FY>$[%#-K$MRK">Q7T5H@\6,@H/YUB71/RS>9.MA!"*ZL?3(16E0EH;;_* MQV`=T4X4V'%C5#3*X(DF.M3[(:)4PP)2MS0^2`?%F,,'$8A"+\PSMTB]%F$<#21Q6HJ M.UQ"H^K=GI3#F&!3E>[FAW+.Y/&[>3$J+B](@S`3]OBGLL!0`-*C\DR/PA9R M6`&_F5"1OAU?HMVK`.4+_`P+->HG@UJ5F?V9C\P6F"%^!2Z/I(JH+6&BSS., M"01\"ET"CI?MF2/PLD+1(CSJYO?"8=4.H"B+\\OJ,A^0W;D4+\P^%0]>'HBL M_"IFVF0ZMVC1DY<66V^]!,)X2893O73HZ/6K"@:N2B,&F*Y:G/X1>A&-B"A$ MF819-K+/)?1:R2)"X_/O_**<#;,_+?(9T#9E!%U=72HF,;K*A@1,+P65TP(; MS/C#*5S_094-B9D3!R%=QI(\8$[-D%YC8+*29@LB"&B""5'82!,QL:MQG$Q39R M;*7PS*Q[2^:.:.;F[ST6BFRV$`T+,K/B7!%G>Q>JT&S'Q0!8*L!J;[SY,G`F M%\@?$]^0K)10.WYS*+FUE1T2YI8[54YP&TD1Z@4'].E\HD!JK3\JA#ZO"-W. MKW([Z-W[JBUJRPN+V`()1BH16U4(`C`XOQ.Z.M[#<'!Q],#-+V)'F_6#TDFK?P3C M%0D>,@^GX(@,J]#+,OZXF#AQ;/C5AGS81C]>0T+"A+``JTGULNP4\AJK9FHR M:GO9@:-WEP.4G16DY2-&3,,I@,786(%#`=LK/SDQ@L7L8B:`!NR+!`DD9=?1[ M%DH[N2"6D7=(5]A?G*1*"-U10$W8*7-$!`@A8ARI!8_17V47T\],,]MPY)5^ M-RO.I)=ARQ&1KA@($6:UIQF9-T832J>71,#`C.?H&L,UR!0V0K%7!$=,2.39 M&;Y:+7ST+=IC,6(^^-J&-36)X'(VHX)R9FH5PS;.9V3YETO","PSU)&>.(D3 MJ(R@?S[P/]6?E2NAJ&#[P=FO'[Q]JZ3YMCV>O47:N_>.)L"U MG.OEKVV`^^]M? MFZ40UP#MMKN1*+F+O4CLK#7NK3>`!S/!ZPB47YH>(EJ(TD*S>FX)Y(E,00R+ MS0>2#V(";'67<(?1L&$B*P2#GO3V*+NB0&,++5ID:,GOHGV,T?0:1VKA-*A@ M>8"A=.6]EEH<'J)V7(Y$[WST+,C:WL-V3E/+A;#EU*FR1$YX@Q!B2,IJWE.: M()7H$NFN1F9OP[C:2P>S;4>%MBH1$D*J0:)ZF3C``L3LE)V&,9T&7+U!B0T[ M*9ST^U!'8],?)>^\`@]@Y8%9"=T(L)-H?.'TT9:2Y%@[S#_"PM1"ZUA:0!RP M2J9&+F*$GF/H6&)=0*UE/D9E?^`W2%(MU'PT[;BA;1.UU15DDM`]4A)5FIW) M%,4\U<2>&)#4(HVX^QK3TCD$\F1M?"]3ZFG;VG_Y%K=C^EFK2[&F/R64.0HRZE;V*<0:O7%K&-)L7`S>'OTUK(,7<#TO$\8#KR2XY(]=8L`_1':)= MCO=C!_"JC>B=O0ZFC\EF8/D0V\C>J,2E$\V"QRF!*T?9SE-7`]?$"9]8[`71 M)2?JF((TZL#PLP](HIG[<`"7.%_^D0@(\=7]R8QDLP`/X73Y;K`F)$KIA*'( M!QJ2Z,?AQW?V46HZ?[XH!Q>$6?'1R*(9/^`=6K!",P>1)#+*M2ADDIQ+@#WP M%EY7'B4?_OTO_Z=:FW!J7Y:"14@U[/V5=W%M\4S//K;P)(9B1]8H2H@>6A=. MA)<^OL-C2S=``4SV<&_K638N`3E<#P]8*"U,^6%!]5-.E/`#WDEA$XO(6GN& MX[2`L#X<;4'3V8L>+.3NR5IA$"80AL8DEKSH;59LB>5$%3*4X>'LLGE&1MTO*K3;DTQ/5H3:. M9865-4J\@%[D+I;<6H7;H^I`*X5YA;FJM@QX7_%1BT<(,@(3Q,K"ZV@'6,0L M8.7-(`C[4!FC&S]0_6>H`VB;4UVC7F:(04@TZB-U!+1L-T2Z@$FT#R`8,T_@ MK7R&5^,T>H]TC8)-(!1Q.%:L%/TEWGHAMQZ;!K>/B"9RA\A\I(=`=D%M&8?R M(3*_3Y"GR]-L;B8TX)P2@MF:4:R31#98#+`ET]Z5N.D@&541`IZ:ZZ!9$1`T M1M:5=^_>'1P?)"(.%EY3;(G;#7&G(!X>$B%XA)HT,HZL9&:&*)P\O!@X"WAV M13=0&-P*<70CMT;M43V#0!^@U3YM?H.+GZ-="Q'?!J]"LG#%+.VU]E%*35T] MQ.KWG!/[#'E@D_I(X4LS8!2J"ON.06V)MAA4YM?S68Y$30)Y$K%A?889-[7] ML0'LPOQY`7=Q"7-J/^)(645^>RGOBF(5C#9I1GY+KW<%>-0#;^+@K_E"Q($@ M#=".U*_-G&D%,O]]SLT"1$-)`[U/6=%TT\*'WI<`.\[21X?&3V%\%V!TYB.1 M`4);,/R4.#6*QYL?@).%%P18>4@DD``H*)5H3R.!VIB'F_.OZC)[;(7OT$:R MVR2`5EH*42MI%\@RSHIWHAK3B,3 MB(B%#45ST`2>)-1%-;$*[VSV9T^LH-3S11S++`X7VN/#@O0107C,;J1^)/8P MC#98D^[#ZT?4JAM#GC6\%N$!S]-'K/)L?WMS"'$2R+8J;X#@F2$`ZZC^Y0/N MP70HV#OA,./,"ML&=0]WMUY$XV+9=M%YF"CI-;WIP5PL\7'*>0&Z+%^4I,V68N?6'@QY6$7HAU(JUK);HD!I!:^_(" MP_AHY@E@YBNK6#&C3"2,A`X!9&-;I:4L-,M,>+UB)3(S0$].5W51GB&"['82-<$YX(@,\2I>[HM;582Q.8H8X(0V4*)*Z0P<6T MEX`(]5Z98:+_3[_!JJ1NH0D]AQ^C@72?88T>PT.*P`@\.C?$!=R73.XV$D@M M6#F>#&1?B'2U!*^M1!F_RTE1(G4?:PBMDJE5OP9Y'<2$*85J<0)K8_J`,&$D1DS=Z*$`"Z;WLW10QH2<^BWM5 MVVIP=_OT0M/LNR#AB-+LAB?ZIMW('CY-7F6]*E014D/YEKZ:3+.TMEW%A>OG MBMYZ2G>VZS7)C1OF3_XK(Z0T&F1SJ_R64"RR:](1^4V)$U?;"2TOKYHW@W1W MZVDTTS0@)+@='B@L6A_U:\@LDP,*.QE#+%R)8H@R0(9U/5X4F0G2T0JF$EJ! M'C,=;DUO)R7U7^8S?)R2<57V\"PGYG?E$YEI:I(06&2XM29>&VF$G-23J$D0&UR!!9S@H MVO)J(UD"\IU`8&%#V.)!=ICD\LJB#,.E5"$KW.!\(4B\&LD]5-D=;0ZU;3T.]'.>#8R+Y5 M8)(M"!>RL&8E!9:L'R4N<&'SK.3").3B1V^2CE^2`,)R5B\BC=^_7#Y/(Z0_IDV"C!6X2$M9:9,=,H99T>)I3P?RQ&7T_[IQX M:;%+OXW"?OZQ-'`M#\#$)3&0.H:?B&M?[>J7S)F$Q61N81%P+QBT@B'RT\S4 MLQWB?^L=7_%+LEWI2#2)W*@`T-0&3`K#75FD^SP@@1I%BF=5+*=1@Z$K#DEG MH4#7TE=BE>\MP^KC"!'P;A>PMF548+O/*CU-O3WD2518&,V#BZTLD55+F"!= M%/*&L_,0YL/M6AF(^_62^[ZUG"9_UM8[+A;'8"_A&!B>/"4%Q4Z4.,D0)3+" M16/[)$5K\"#&^E;^I#FSR_-Z::D1Z_"+VY0%&Y`?XN$@CI;,Z@,M9*R@&B0- M^!N5E$+AB\DM%L_G3#849L:#)M;'OWAOV(&Y%%:IR]]MB!#$E-?`?B#,3A*ZRHR/"LD1E M&:_]DG'[(XOY1Y9Z`4N]FLX(**)(?0FT0?JZQ9@"@#'!K]EWD@)M+P.10A0& M(C$*[SD6XPC64U7^*2_)J1``TU@DB=RB+&;!+!9JAW@<=SSRQ()Q=X9XA-1=C3LV%501B1\GGHX$J M<2%NT4Q*#I9$1KW$K^IUGRI9G*21%&:BWAOK%K.#@S.TZ,%XFQNT\1;9`[ZF M(@^D%[V%\?S)+R1JWG#*IA1@/L9&'J3"%0"A['G"*#Y$:O`=Y6 MIEWV3CITL1(O<%MI_%JJ8.Z$R&5_08C,.-^2Q)M&+OZ?/&9S.$#:&Z+&;=\+ M`0>LK7ZPA*59&)!3&RJ*34?U9IBRL*YB"V.;J`OZ3!7#)IQJ%"JG.I".4]Q, MDLS238S8%$?@33/)P=;POA0UEJ$GUE'+_'4[4>(=:2I+OD:_8D:>8D0":)^8 MET#+]Y!;6*N=.78*"H;H'U#*G51';6F+5@EF3_IARMLLP?FBR; M$>65%4F`(8*2$9)S](%CUPF,M"3TRY3[%/?2<9,@>/IE(Q0_ILO6F5,A=7!U M0+R4Y@?@WJOSZ_A'?*9([QD""KXUX4@LF%ZQ M@'Q0X\477Y:!,"&0%N5B(Q@@LHU2-I!/('7C"@1>'_BOA9/,>=.1GR@)H>H+ MZ\"#.CVTW8<))Y!]%;DS!X-Y"+RQWV1UP"AJ(R!Q_>;5T-E!W/H!I5<6F902SZ8[1G_GZI<*Z#*+.O_;*5&Z\7G(9NT0B(AFI@SER(V M1SRIA^A2C^59S8:+E8R^$#`I`T#J6QQ3]",.#44%72_DY`(;+TU]>5<&GUPG MMNWK&KW8\4FJ/G`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`+L)85L%@'3FI\HXB):Y7"`5-`@QZ:S!Q:OLH/[R)!K5T:D0P+0S*13Y4^4 M5-B,G\E"U5$!AP-)'H0U+G#;C1>9+G'(DB@-Y?]U>Q[)SY@B:IX4V=MXL?/, M"E>U[P[Q]Q'^#2M"GFP\W7ZV\61[>ZW!U^:J?A!$^FZ$9-`D`=L&%HMP^:,\ M'$"-MH0/%7NB"41@6=Z:[(,GL=9V;@@K2TJL-?!MX61-/"*MR?"]&^RW\LKW MLC=1LLR49I'+1LJZG,B/S:RL@%S5C%+9@$&L'OKOC?/9#XC:6&.NWPY)4I*? M:!.5Z,+,JL#`+,/T*YXKX2R2/T2SC.<#RPYHE'QVZCIM+U=P\]1)C`QPGX8AIJ8.0.P>&O=QM+4>-`4%4G1##FB8D M8S7`^+K8.6F9<^8JK\U)H=F-3H)+9/J,"5[&[$I>A;KO6.V^#^DD!JA?BNS0 M+;7*,+08?S3Z#:3E1LU(=L!3W*+#;'=+S#U5&!'46Z3PM_B5ZQR,M4WW&'=U MKEB=GPCQHAQ:H2NL)32ZB*EK";I%$!IK.,DR(RU1;KM`_W3WX>/VF&?0IWI[ MV0#07`CHN^<6S01O:LN*Q>MSS%ZJR7`W,O.;"S7%B:>3F`M==#3*OR(^1"EB MR(Z-?BSEN^DL=;%5:'S8)O+7L6OK\J\U0S[/[ M0B"+(7M83RX:[H(_$B"=>_'EX3Q32L'XX#VA:7X9/S!?,U&@5>E'7/?*Z8G[_ M%LH#"N5X,$HZV2,!L$-W1/97T-I$; MB;@VEJ+\#04,=X'GGX1YFT[Y76QK;V-WFRLW[HEQ/0I=U6)2825T.RW=B]6X M\=AA229:OZO_WN41=ZE&Q[8D82XU7/MFMH(E)L?.SGHFQP,-;*+EP6.O\J\W M-U#_.I_3-BM4*H(9$59MAE+K@,=20TD&!9:LNT%+PV.1Z+2HF?(PC#.D_%)] M75R(^3LSJ]-'WG]5PVN0QM/JDC@A+-HV%BF).%IE)]]0]^\H/G3/UHR4REWL M9>^GV,NCI%:Q[F"H++2W5)7!=0ZG"`G30&3TT9'1,'*#M"A%I:][3X0$C=02 MD`W&BT(;0>..PX?VD$D$LD>#>]IM>ZS_H)8(G'!S5W7OOS3+C9M`[FSL/'VZ M\>S)_9B$-],L@1)@!%_`[6,0"*]U=(RGWES2&Z9I*2WQ4%01KJK7S_+82JQ- MTXG75,1'R-&'NQPCJJ!,WJ&]1!Z/0(T/25KN%79MMQW)N8#4-6S2%:)#>@TG M':4\>SOE&D_,N/R@I1PL&TXJEOP1.5?5,C/Y70C`G?LAA*0?C/1?`YSHV1ZY M)O23E$(L/H>AMH[0[LE6/OM0^7TK+#1P\>5=(IE_3D9#A(`BAF=>OT!3`'$H+8>^>QL[.WO;^S$ M2P3%3PE,9;7 MXHOZ7!^,04Y),CC;Y7"'M<0BHEB4W.;GO_/B5WI!QS^? M68N788&`?&K?V^QN(1T$_PBQ19:^UK"WQ&:;03U9$V>Q4]-G]''17;G+F30N M,FIRE]M*=:UC2<>(;7BN-`][$TMVC%TZ6#W0*7CIT>2EWYTJF1("$3NJQWKH$YL5-LWU'H%F[VKH]Z M./#4F<(WH>.RWZ>!=+.Y735?[T\X-9DV,KL"CR[TVQUL>0CA!\M:`U\$N'?H: MD_2U^V)2JL$8(Q^1'IEUDTC:K<@7W=`/3A)J:PU_6PYTX/*DOM:,-]Q0RU=< M:XJU-_72LP,(2"3`]XO0*O'8XHANSIH&(W$=H/S5_Q@EX&ZU^F"=Y#X@>>W+ M:S^LS^0>JM+4V];O=,O-$NXZB.WKCM1,@%+N0?8_+0>N:P2YH=A=0M[ARO=) M9<^IO],4[M0P["P0L:&,?6)U2O\&G<#M%4? MK185=5(/Z>6QYUPZG=2C3`B5X-TP)TOH:X5I$;N4N1H+#K.=40FBW&+/07I5 ME3"2-(03/[[TQ&D:.BO,5<%L!Y?4RL^;'?[Y#0?GVQ2WD1+R52`]W5(68[N3@3,! MG42\AFC^F31Z/UVZ()8D02V!$XL0F>['>GD+#(JP;Q%#HVJ9?G/3O7?AZF^M[]WWUEI M6-R.@'0XW%@;G\5%/0N=_L2CP_HWPG+ M[._\!![]3RPEGBAMO18T;VD$.9LF2`FQPGT:*7M[/TDB5AFKX).# M;V;[*%T%+<5#'.YTG9W+$*%25M?.&+([6XJ%#A M3)`L?A#+*NJ>2=9$)B[0:Z&T@$.R;*ZV#'8T/FDQE#CAZLRKE<1QY*C9842" MT'G]V"7MK%>'`GLO7"M8?1F2>SZMY\I3_,;LYH5&K-^O[_M_.WZ3???M22@X MJ5?4J-7V(;\TJUB_&;-IC;5O^*ZR.]M4*W%RT1ILN4[7PFF`J+*22>12QR9Q M6\&5G9E7XF=[-[8XI4^C6J?-+ZP%.6]9REJ"\8;1(!'*OFHUF#VG[I^LK ML9Q0N8N]-RAQK0F@_ML5OOK6>+Z]!ZP;6@=0G;#6"FZ(7I<6A]/VUQK]MOO# M>+9;/MKU\1(QD;T16;H8E$(]:FP(H<7;Q>U`C)KVQ".)O@O^WM.-G2?[P4%Q M]]QU9,DN$C,V;XB3K2-+=I\9WX?QK^')1'#?#WM&\7T?*%S)GE*-L4)2?(DZ M"=T>[Y^D[^5TK)3SCT/2].WVMHT16*#B/[C;;@,?D&^DH1<5-/3J=YVU7TTY MX2(3X#5U7`/UZW/GNL349ONAT6E.%0=HUY[M[B'M@Q MR/L@,:S=]^Z$J.OM3`\JF17!B%1U_M*F%(V^]QOJ1K$EP?*,6I;)9C!8(J3L M&!TTJRRN-Z*QE=.F%<\,@OX*"+M3OM,_HI95QOFZ"A.BX!]N(.2.#NM#IIJ7 MM4!W0_%]GP=VV%BP_?2G%D;,,<)B;#Z6RQDL4=JL>?IT&MNYKW7]ER=^:S6D M;D*G%(WT'=YR*)&E>A<0I3_"?=EX/].(RXJ3XW=OHN\]O3?T!6G=,"H<<>(; MJ2][@_KK>^#%(EVA[5NN0OZN8-0^CH=LS[V9VM]5*KYX@-_O5C8P5FIRV-R=/,YMVGXVV*. MY^S<-4V8J*?<.#O>?.[.X+!J55@IJ"$B,FVOD)?T<'K+P?9S!ZFHAJP+NF>I M%-Z2#CZ7JAGF^ZQ(M%\^L=DQ4C%$6WV=(0E>CB6 M#0PCFRL3>M8[6TC6G+VC+;LX;O:(#G_\E=-G,XORU.A\[$\;RV`D(*-O/%4D M;?MHQHT926\[M=FFSIU#`<'$!$CE)>W#YV";DT4V0``C1U3QUREYP'S514LA MTN4E''W32Z)3FE3_HRNA-'W\6MV*)X2D[%OF=\+/?2RKB8]&3*"&_(N9JR0Q M"TN#Z%'CH%FLJK=ZTL8\+K-S2@M85I![^>MD$-^TX7?TJ"QU;!RC8^.R-SH\E;JDY:M>FI7Q;/"'^AYH*2W.-=&4@XNH4(`?,%AD=0RXB][=WNQ"$-A` M4OI<_U(JL8'M=S"&GI4V^9#/`E/<]>FZ7VS6/ZOT4)7T+EVAPIXJ:4M=BE;0^F0 M0^1#,3N/6/I9^44VG/6CU`2#![J:7S$,/WGX\=U" M=Q!RJE_WF26M4K#`N/+/[%)GS+F.2;P;,DZ,*(P\TCX>`*L!!H;N#N(A.=#N MB86'SQ.AR%RZ'('%#/^XL,ZBUC>+=_:CG,0@P8CG0E8N_))%-*0-,JAGGHG: M\C)$N!;/WYX`RAQ9U/?ZIO>YAUA*F)S MF>4W`;NU!FT3.]\*Q2EP-5=T:DYL1"#NZR^UT M[=TH)G&3*2W7W211!ZUPM9$C8W,#AL@*Y2-$W-`KS9J',5IXJ&.D2F:^]IEE M!X?ZJ'&Z_X#U%D@W,':YND09TV&X3AXS'S/8"%($YQ*TP"=Z/6UF&Q8TY:4G MADEKW>E=XBIHN1K67:]J=!J&0!SI%YI]]WT((]GM/$,D.?':(@W@-(PM-TGX?@K:U"\NBFGO&]VHTN@#]BJ@,-!4S>8OT^V1@.4 M!8*&8EH)";>.%AY,4'S&XIBS>3(8ZQQU_-M?_5GN??-X)1%HU!VFJ1&H)^<2 M:\`N:)Q$X@I1B:XP*D'`#-LVSM&MFB1C3M M;9N?AG]T-Q=.:TFM&?U-;<1Z!^$FZ^!T^ETUM^AYTH)&X58?Y,+=W.O=LC), M!KKCX419N,4H:3BAK?E.ZRA#1W_FGR>8=7)(L1;.E6-$..$&7]5&5M*LW2-> MF5*[M$`Q(%[T5V;Q[5*2(.F1W+7I9M4@V#"Z16S&Y9K9//\2K'IDKA&')O`\ MD2P#QDRWH)*Z^DKHAD<1C'TGE,T3#3D_YX\V[=M@!G&J/Z?3)">N M?N:'@9FQJK.UK7_L+:1-Z;Q\8E MT&J80?\GAHF$1;HE:P?E=%=T#G8"J\/S2.M'/IJ$[;WI:7R=XEMVS](D=I0@6J$6U9S!UI MM%N4QN)1Y8/4K30&2F.34A_WJ3=G4W(B9F2!:BTA(:F0CVP14V][30L_."*J MA?^C(X71EW6O7*(QPO5\[<&.`[&V?WBTN].)G+QJHJ%.;G0^WME_WG[VM[^& M_YY(H+1_?K3W=*?][-U4+@SFBR\_NLIB>JRC$E\7I\3QUW-&N"1ZZ/\ZPA&DZ@H$,74R0:2#:.?Q4T=U2ER%=N" M6_@"3U#>%F%LH[YLE\L#[4M?F/ZVG%&W0Z;377_C:]N^+6@!.$K*=<'?G M:(M0SFPV_8Q.J))BLNN68/SJ@D;,)FIF)Z.H/D6@0OZBOD]Y.;(X M?[UNU7&D638DBNJSD!C$WDY'SJCW`?^14#FCLEZ1T%DQ]_G']^,RO-2 MY6D?U3+]D^8!59>2P=?`P=;;^_EP:F5?+H],6D#E'6KI^RX_M21&F&6^\*T2YY5Z<^5+I(U$)AC'A`%0KMTF'O.L,"IQ-R#N2>59N8CFVE MFE;;5D,>4H,.YE<@VI6Q$W"3*U-$>4 M)!):=W27JK,D'].3J#8!XQ@D8]=!Z@#C'6ZE_P&8@/9P2 MTG67XQB8JR7`'B;\=8"RRJ7]Y\<)?^I2$\FINQ,3EQ%I@7+2:?N M(-)53KQ:%=[,+*=W.!.C%5$;L^+3=/3)N)\@:TF=*W8$9F8J[YMG80F_J@#9 M"/Q1^1@BQS:T8T:6`2'!AYY15_[L_H6L MA?\4/)1J9O#H35J$"YKR,J?("=#EKDN!M(D=#9.K0:UUKF-[9D?:L;%H2)QQ MXT+L1K!C1_T%_"[QE&-(2-Y2;9DTZBT2I^''KF7\)Y=M1MJB5OF&?AU2;H8^,`D65AV/8UKW$=;8*=;Z`W*BD"[NC/'E@$(D9L5IK,5HQ+S3 MP.W4* M%9*J98FIF`P>KRG<91MS*P@>Q^?I@F,&IWJ9(DEEEQQOB/9UL)4C"LF)[P;U M[UU'_1PT$#;3`:8#<*6K%$MY6=,.?)XXP;?["YU26/*QJRAK0_9)=JK&%DK[2B@THF[DJ787$NH[3&%?^B\P0^GTR\655E038DH5!VEDHR/D\)1)F>B2\L]:G9A:KU\8W"8 M<@C;AH7Q66\/+-0HQ>I2\=D@PUGAS\!`-8I*"5:N](""7+V)GIWE(XIR.Y@6 MDU_+<2I],,_[$W?6$']A=GQ%8`VD:QBJLLG;5TM/480QE#9&?YL3IDQ[N646)X%+$*R,]Q- MP/EW82P`,=2DV)$FNW]Q)-WJ:M\E8T5\X]R[ZZY2#@Y:3-0LAQ7V!1IL/7:E MG5^0PBP=NF$%3"0B=R&+0XN@GW/A"&ELYX'4XF3ER^O$KI8DSCA@A*?;[%>T(AG-!AZ M4GR&%L+M`EK($B9"-)M@Y**,`9U(6+X%B3/NZI40LZMYV0(>/G5TTKP61Q/W M#F21*]0`1>MOK;.-^:B:AA4.IARI8^<&$"`X@YHK6BA1A409,6&:(/'^/WOG MNA/'E>WQ5RF-H@%+V#$DL6.-QA+&9(+D!.2V)Q^B4=30;2#3-(B&.#E/QG>1(YQMT5>W+VNM^VX:>>6=K`.-IM$H2NO1'"7:#([O"=[!4D*$Y._@,`EB)MWQQ\343[0FUMUM+-9).;W/02X:&F86FH.$ M#"?D7J+Z@+4C]@^PV5?W<9LG'S,^:-6TEZ%C#6V_K`9:E36F+#1)H(F".J9+8OE(# M@`8#!]+H8,WS(X3>!-L4H=D>?C6V[#XM$F+#`HHDY.X^(KCG5(/>Z_XZ9?7I M0`J&DA-32WS1%V@5'X8SD?V;1S7$?CAYA-\O)IY=A$"N-^@ZZ<(+3(#4'4N, MH8HM9>Q(F$E4"28$_()G$56*0=ED".3K/'3PLK<]=&]_6VEMP$0`DM.`HPYN M42>-Q??NCX_IZ!TY\X;AR^UZL-&5JYCB%8A7K/]@X,)-D9$_2\[\=!FG>42# M46&'&+5=5N>.:>Y"DUC@?,<(U:F5]D8Y'?:)'@-^`@Q:'Q1K3&9;W`/`%)-! M55+TE(]CUW9_17N;C@Q7+I0J]#?+.0@R%OECGV&O+V]QNH"BN]46@R/ MF4Q1P7Q4G4I*@8OF7>*PHA6]<4.Q,M4MTJ#>32>20<9O/-\5#[<)\\;O=59I M!F.GHNRT(9*UA>J27CDC5F>!\)U1\LSC5#`&]@B9T-.DW@`PT8O8$TJ[@SZ& M08!]=TGH9=;'+^K6GW,B"J18..`,K"3ZZ[6>$-^(@#6N*'9QVK)#%BAXH&.LE0GH]^Z>O!GB[F\J M&^@K MW:]?F.?7@[:,GGTXOQC.J5:PYI7#02AX,H?5C2G&8 M_CI62954(>POS(F!HL+.:5Z,$1"@C4C('&R-KM0!G`KJEXA;W*.=>E:RY^2" M0,V(A`%.I:Q8;@R3'6?0BJ>;#W,EU`3$A=H-G!G`-MQ:!-9\?B&>8R!4L23AI0'9/IO M[U=A>*'@J>K80LI_,J9\Z@F;OY][G5D\V/>P4+/,XL[2%MJ$>DJL#_EA/,GQ M*AAP@;BI\^2A6(;8C,KV5)$+YY;\#\0P7Q`F,!OG%'51I:%\`HO]3;:-G2XU MO0@7KI>%^PAWPQP\D\.`T/9O4`O9(Q#9\2W"((SL\EGW+6"3B6.]?\#\SVX6XO M_:Q=&0<@](L!HE"8,5ZX[<]4^"KQZ`3DAT/.);`5(!:5>2WOU;6Y!6XD;E1V M*WB>LG,K59J0>,AH$>!)*MF4?EI6G"AE2#S9QN4#J#'93WF=!U"TE2F:YH0# MU@Q,0$Y1IS)XQ`(0ULA`@X**A/TX"L,"9X(GK;&F7JU2JV(UM)Y$H8`_S-`H M;&1!"BE561V+LOY;0BS'\^-R);-,@8BERS2Y?<-@\;G0[?<2*(@!NPPKU\)O M)`4$@P.2]]CH_'+;#3C/#@OIC>SL=8>=?Z<:ZR[HXR92>>DS27BM>[+M9E3\:=6(>ZSBUE3Y/QE;$A39>TF+YSG5LE MD[M8!;Z2242Z$/UIH))C70F;T5%:O`D;D@,<$Q^"^F`<2">-V3X'D#;Z+7EV M,T8<.@;#%$HG'NPN_C^15P<68[BQ2[-%C2VB7)R1]TV?)ZX"%JT0!&2=%Y]1B$OVJDZUO M368",K0KA",ILF,LA`TX2T=C$Y2*T;PG-TXBE-(F-SITUX.D!:8!?!,!`>/T M!A,!*>!2SFZE.@`%H"KM/U:Z&R;H['$AS17)XCE)1>"DM/BVI2X&HWIBDU/, MZ/,:IS0).)](XT\,U[DP([D4P`J-S;7`W;@.<-Y<.:T]D$)`K:H6?CZ#\&GF M9NMFF4+PL$]@+#^S"0;`8F80KFHPT%!H/$&T\/K4,F:BLS6`U)JLSRYQB^&1 M8`9W2Q:F,(NE[-LLX.PH:+0[?FP9S=FM3H*8N3>V@X+/:\U,,CR07F09=4QF&;^^+4FWG!'?T#2 ME,D(J8OB\#-%L-&RT!*1IQC-,LU#;Q3C-R(^>_1(MSA[*B$N'=12/@]*D!26 MUA6G&N44+_D[T0L/]8*X3.&[,4-<*2@MT5>V1_@4X/Y_!/H82<(ZLD]Q.D+* MM<;]0.HV5(YV.JB943\A;1O!37\7F2!IA,>2[3+%+,=9"@?6A1N(46@'_N@: M4U#(7$<96T*&W:QN1IY4N>OW%O!!IB5/`K)8Q*,L1(E82Q,167DI>W2PPUY3 MHO;=\S4%N0!-*9]S*SC9^S#.E\BEFEZ M[)VSU3D:-R)O65ET9[@9?V-L:U?^B+;>XH\=B,K&L]S<8J/E-,;ZTJ;8S[-B M/S+9W=VJ!7#D&1/U%UUR3`SGJ'&E7`R+]WU37M8BI@TE5@QZ?ZI:\GZ?9%<5 M-5=B>=0.NYXS;1VD`/K9[I>2<%^%3.$JQ2 MA=FL-1)<(/O]H1TTIQ!(`9ER#"5!*^0(K%HF2JDR`6+X*C1+RA%;4:E3WJ5A%]IOW)_@F M!9V$!F7KA!/&E->.NIC2I=2F'EROQG'E4D/$+'RE<-:X(IF95&H4>8V7<_B8 M[E&!1R5+.\@ZJ@^4*I2Z2;&E"8Y8-2&$-Q+^8>3S>Z(BL&K%0*<$?HBQGZG\ M+*\^KQQG9TH%"E9L?Z^5>E=:OERN,=$I6G$V"`TGXDZY#OM;CWZ)\G\@44(! M_V8[A,0PH/$L)YEDMKRW**3*`G&JV`4>#0:T]">RR[YMU9QL%\DJ2K+6&6NB M?R-3-.S5:9!9E!;@'@J>E0?VSD!I2EQ:>0SA?!5)<(EN0_]G"6Y9*K'>/4-\`2CHR,63<)QN`R'1G'+ M.4MO"/+4O*I\;O%OPP(=%0/!(-VU(:YL#N'8Q2>C0PS^R[GA7M'6EG)4DXT- M@(\GZ&/"8.T^*F^^+_Q`MBW;L^LWT8OJ8&!ED4)T>F`8+4'(M]?F@)C"W%I] M]IHT>+N-]NU$/2HGYR^;%<)'#5'29(X?"CTFNH%MPQ,Z&7;VM="VI#_5E76=C>U_',7E3YY);ETK(5;0WCFH>L;LT^T#>N<;\!N[VH7:(J1,7WH;Q<6[X54Z-E$PP-..Z&(U6CO9IY[ MOF=B.Q_)]_(G1P@[/-F_\LAB?&&WW2A(%1AI\J#\*2'TNQCM%EK$#YEBEU+2 M`Z))Q)9"N`4VR5WI2"G\MH:@(=MC3++A%B[0^3D16_^>S(VIK+H!;)$ M'+B@64FCKI)A`@83H47:R8_&K.703*^`)(*1-RQS.9-^S]A13#DCN+NXAR5@ MJ9BC+:)3"+^:'E=X&_KH7.X$R;;O"+=>+)I##?HMC(C*N@YA,7`_56\Q_S.@(=9`EF/'>NK'^=OO) M7N>G+W;VOG[:_E6,\/GV^('_^K%LC.?_\]]IP,*UL[VW\U6TR3+`6UI`#:A^ M0WK\H"D!B`<774R2&9"HZ9E0V$J)=YJ0^6RL:3Q1ACQY.\!/056&7>98_A3YY6R+=U$4.U5=N/\D*$-\3/O)HV`TY"1V=MM.8H^$E8]L%5$% M7IH_H"]H&^]`NB^?/N[\MKOS=*_"6\?0T]\-0W$]ULLZ_6/1K5X.I3ZP/?#E MI-#ZF^V3:^[-(;P=()6!?SR'#=W01?\4OA35W+:.+-:Z2>=_H4]AW;35>JE0 M`P_ENE4/WWLSP:0QH<)[K3LBY>XICD+Z@0[^G^/9O9/ROBX'N+&H>8TFY0=^G>.Q MO:CKJ"Y_(69AE\UF'$SQN*4+U?"3%/FI4>Y(]I\5^)#5Q:9TU^TA6 MB_2DAD$-6"B?0IR^'CA=YJ`C'*'%YEY#\#"1#[5#0Q]W-_F*#++F2+>"_*N> MZ0!\Q6$@`8_CS@.]]3N@:G$)BUTL$CQC_4BL-TB*&,^X*M;R(SP7Y!#O&5;A M/@K&W8=/$8=&^)8#@_"QQTSS]H8MB57`J(,4/[)T4?U7KR"<"+QBT^UV1HHU M$,V)E0W6S[>^MTW2')8HDRVT-E?_34PU&T=]<^O8G9/LYV) MOI^R"6@]BA6\-`3T#JJ62$N@['2&($-T>-%N,/D)PE'7&I=["\V MWV9+]?Y&44G_AY>9'ZCP7QO2J M+=$P0JYPWK11`V.3X99R`[C<$O[S`Z4B0H-0]5IO^'O6@__ZHKF7V$?-"*H# M7R@E#*&L]$2S!$P.:ZBL7=2C(0RC1F^60_T\72[1SP>_OS>%D-GBD6(1Q/ZI M*\9276NJT)I/-WB;RW'JM[\+U<.I^XS`YRVC[C'8;Y?U7JO'LC9ML1PY5"L5 ME[3C.O#>75A6L:?61QC"0JU8^AU`%$PP[RZT)_/6:!OO\$7N#U4``/YX)BQFC,!;,I]<8LWSMZ1?]K-6#WP>D)94UF?(>V@\+WPU]# MIW++EI"$N\<9'$1A7,?/J<]XT$VO MJ)Q16M0C[R[5_\CK^-HN>!_4Q5`,=Y>_L6^))HI0':#5(4.;N.B,/O6JK"10Q(1W[EK];B,>.UR$F@VC.QV&T:"I9\ON0Z$$3 M;HZQ0^,2RH^&MYOYKN-;4US;X50LTY:*%6YE&49*GVO1Q`XG2U[-RDR<\)?8 M'U'VJHV`>TF<=IV9T;&MH%*%NY0_6.!P81?>7[LA:@?I:=WA+EX?W&;ONU!3 M>^TH/UN@NK=89OXZ;UMB'!K. MVN_VR+:^5=BX%@-9>V3E#JS_,LRI?GG_/'A!XE7'`6_J]P9Y3\GB^_T/F>TT MV_U\,)H*#?>LND-^[VFOXCNXBG#VK\D=>8@3UJ@S<;NA:5M+C\Z/YD<-(D^N M!ND8DL=%^[L8QMX.^$V6`^UP42#B($2/%IO__\0K6ES MJT;K0B4!KOY4_:=;*^E^&R!:?[GJPP+2FW[Z'X-P^ZXRV-6BVO@ZY=MP%8L17OY!9!,%;Z@D7^'KD:$0A1`SEKMAKS9:% M7%Q:.#D/5-Q531GJM:3-]V.@]+`/&W<3H!8KK]>Y]20`]5GD:+M?]W*TS8&[ M9-9!]FC:5_+OKF;(='%[U.QYC5O',>`/GYD[L.-2H#HN^AL>/ZNA8J5SEB7\ M_?7\(4E&GN!!<[/&5SBD4!6C=J,P850TT`U'U>N2PS`C%P7+%^'0/>UZYO=S M-S;E,I7OG83F@#9R#8[C0)P!$!`3.@D-N.KW,HY0S'EKR?6F7$5,7_7]V[GB MA:3TJE6,3)P44Y![@,C'S*(@Z.8M=:U>1H?V?+66O1$FB,999Y)ZK*V]?AUN MBTO;7`-XTDLNR[=2S]*/#QV-TB22:7]J(A``7(^5#V%AUB",#VF?06\:\HKC M"U_"I.89_QWF[Z)$K^<5@LK=$]59`_U:N'CW MU9B.*D!5TJ4>VT>(+IP%CM2SVTL/7"D"L<'K_6ZOD1\KM?VZSV)R;Y7SCN([ MR5B--F4$@HS+>N:,*78^#U^RNN8;(99)S@$#V(#E5 MUM='OA%+1U-^L4=* M,^#S?LLDZ<%4A.NIJ\+IM:K&KTQ%QJ-I1K)AKNC'WK1F0NWJD MK%QE]9DD9G!(R;&[U.M??>HS[EBHH0=SZIVTO^8_GV^I>=K^YM:_X6!3S4&P M69?/E;Z;>@'[P$?1@T><6J:(0BM#"MPW\<:/&`][V+S0%Q>A%5JCWTF<'1Q@ MR34K:YSATJ^7N8TM714);(W@R6M6,K*:642A5U#TWN]<(@R)E3 MZ6QHA7X+.CP=MGR[4%^-H44<>'7ANWC<#_N[5?=LSZ?RJI&U9DJ`)5&(]`'9 MOO"IT#AN)55[!\*?O)MBO9P4??O)&&/].$N]T(QQR0N@"NP8__W-UJ[ISO7/16.SE;O'PT!&QX"#:I0Z*M53A)`J\FH= MQFFTTU-GVVP?O1X]&$0A"]C:D;XBBCFCWPHU2Q1PF&TQA'=!Z`K.*G1M%45: M.<+/)!D+EZW(T()(]>9R8DZ,D@SY#7*,BZ3$LDD3[Y\GT?1%3+_ZO9_K6N/Y'PCZO MY?/%XN[Y_PH```#__P,`4$L#!!0`!@`(````(0"]EC`B3@T``.J````-```` M>&PO"V10/4IAZ4)3F6@Y76;!?8;H.L MBQ9HBH*2*)M9/A22VM@I^M\[<_F:*XKDI7@EJD$C9"U1XMPS9\[,??!U]\V+ MZRA?K""T?6^F]J][JF)Y*W]M>T\S]:^/QM5$5<+(]-:FXWO63'VU0O6;^U__ MZBZ,7AWKT[-E10J8\,*9^AQ%VUM-"U?/EFN&U_[6\N";C1^X9@0?@RC>::MJ?&%F[=E8@1UPP^[[97*]_=FI&]M!T[>F6V5,5=W;Y_ M\OS`7#H`]:6OFZO4-OM0,._:J\`/_4UT#>8T?[.Q5U81Y52;:F#I_L[;N88; MA#^;N-[Q)$Q>();[N_" MGY4OI@-*Z".2E>_X@1)!0,$5ML4S72O^Q<)T[&5@X\\VIFL[K_'F`6Y@&DA^ MY]H0$=RHQ2V"2B1NK?3)_..`3U]:HOJTV_'%M M,2^J_9+65E$7!0[;M)7%BK03/"UGJF%`N>CW>D@K#=B)&ILN>M#>V1J[&9W- MLZ$Q-,92/>.T6(P;-C@T9%)9TZ#Q=OSN;'3*;ZS,NZ0,GRL#,.'DLFA#ZE;D M]]C`USET'D=BXPK4@OCD_V0EKF:LKY&*-1I8DR M`S`#B-XZ]I,7#^+"W1:F!*O`WK+XIN9/-RAD"@I!H+;C9./KH8[#4MAR?P=# M_<@*/`,^*,G[Q]XTHGA9L M*)S(<''S8"P>6+L$&2:""(H2HX:Q&)_`Z,-\NI"/=#&=RC8Z,.`EV>C;$;XD M&S7@OX4T3I/.2)<%,K.G1#;.4GO7X^ET.NG?3":3J3[LZSHC>9DHVO;6UHN% M$U=I-!41C`#!=#B9W@P`2$^?L*;.BF`(`,:CT634GPYT^)\5UM,CD,WI2.TZ MJ@1!1U$E"#J**IL]:1(J?Y(IL&;4<:X2!!U%E2#H**IL\"0QJN/.HTH0=!15 M@J"CJ+(QM<2HPEILQ[E*$'0458*@HZA*&WPF%7C:>50)@HZB2A"<.ZKIM&KQ M\&"P%:#BR*Q\?,PF73!W7/K!&F:MZ=&9/LX>XVWW=XZUB6!J'-A/S_@W\K?P M[]*/(CCL*NE>Z1_*_:$`V-P#&RF1L_VZC,TQDV\8[QQ$Z=J M(:M$.H[P];'>&^NCP4T\B9+4M&NM[9U;]"YK^Z!6@$;DMMYQPJ&7-9+((5\0 MU#`*2?@$]V"A9I$6W`$TD4I"<`\9/N:+XZ(^DCW$?"0["/I(]A#U$5+G4'*E M3*[]'1R3W0^P84QZO7@=4K2=:H,$^`'%'`9!]BGR6;O+`49K]VGJ*]270F[, M!_AB:P8'/*W9H^AGS0X'O*S90]1'7C=I=#GCV7("EN<#2/;XYGY^'`QH*-XQ MQ;-7!)/ZA$O1\1$2X7)WV-U:\\1KL-"LNQ+V@30BO(\D?O="V(S?I,N&$<#* M:HD-1?:S`%4,S*7 M.`XAHL!2U#4$@-,)!!*(?D?];Y]BZ*@'IFKHJ`NF$+@^^(PY02/!]9`=80`\ MG61%/D[H!&5 MK)].\=JPLJ5'"%`Z_=^/U\K@%[=K%5(+`A=WNL:`7"<8I$M` M4HI@YG9-$W22G6.@H8(.LZX8'EW-?MB%D;UY;58_<(KQ"T=4F\\D0#C5N"PZ MA.-3VN.UJ.@G50>>D]!,K+@L(#4Z3:31EYV[EQV7%NC:2[9)7$ZJT:-JJG2E MT`ZY>=:4$H0K\%5CZ'FR\%\[8FJ'KY2ND^!+Q_S'2FRXOQ)4Q:#!CMTTXN\H MQ=$0\P#K..01GBOBOZ@Z3M5_C+K^K_^V#%;('W)//$&/DK]PR#$5T\D(10R; MN<5$'N_AR:L!$RM6>\GPH8&F>#D(4LM.R M!69-0J"+\F^.6EB45`BB7@"KARHFK].B%U5"%<9;JPLA<`5=5&$34D"["TFDI! M5INR)56QNG&1FBA$UJ4%KR4>OI3(S\UBY>A26S0+B\C@4A!-5.H\;W6#/GZ8 M)=Q[5<,]DLBS(Y>JT$Z8OCAAU-9(2.1#8RZN1M8-N8Z2:>O9`0^QIB"=&*)( M3U-D4:2K.0JX:"()P2XPVSEL0'0^SD?6&TE]25/2\*179& M:WIVJ_!I5R+)(22W8ZB4KO]&X_HRJ9\DCLU7OTK)*8[X^.IPE,Z$PT=/)B^' M6"A@(CH[+7":PO@^N8L%WWL4T>A^6VA#HITCA(2_)B,J;@?3)4FA8:,$C58H)3OMX^$DQWQBY\V4#A6 MR8V%<'::C"FX]"A`$XFV$.!4E?E5!^F6VDS"_F[3]75F!,-`F#W!P!YB@%V/ M"U?@DOL9\G7.]N!FY7C"2%X+?4* M+B+SW7F\,;GZM_U0''&L17"ARR*XJ*T\CGB7 MB=S'(;C1P@1Y[[D2#W^Q655_Q`4/&QE3QV\(YPA#-E$8YB*WG4>)4/!54>6\GC MQ>M;%]1W;"6/%-@C'NGPA;A'68R&/+NZ(+MS%;Q1 M16:.#_I(T-P??3_CB+>`PQD10'^"IW;#`\$5X"5FB-F/3ZF!(#$?\<[5F0V^1,2/T4QOLYV,/S_"C:I3$G&N07(' M!_`BP/^RBPB-N!]BSGB/\+GV[/[FV7P`B%I;&W/G1(_9ES,U?_]G M]O0.$%/RJV_M+W[$3,S4_/T'?"P*9#&G-)U?ZT!I=34?S=UZMI M["'P9GCMVJO`#_U-=+V"IZWXFXV]LK1P&T!1"9\M*W(=;=#K3;6IYIKL00=@ MY#9TX%=!XFP"_E.^;::2#S%\]BP$@`UGZZ9.:"'>#/X3-G+_7P```/__`P!0 M2P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N M>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T; MVN.``<.Z89UC1" MSF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F" M\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7. M=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB( MACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO M/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1 MLFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3 M"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&< M33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PED MQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VW MA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.) M$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"L MS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5 M"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2 M]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(A MU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+ M(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F* MEV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*# M4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7G MY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]9-RDNNVI?7EXWWC]_BX>E-VG:_++/3]6EV'C? MB\;[]/SS3T_O5?VE.19%.X$1+LW&.[;M=3V=-KMC<0MO MZ]=I7CP<85U_9(SJ<"AW15KMWL[%I<5!ZN*4MQ!_ M?WF[/NRJ\Q6&>"E/9?N]&]2;G'?KWUXO59V_G,#W-S_* M=S1V]\8:_ESNZJJI#NTC##?%0&W/J^EJ"B,]/^U+<""G?5(7AXWWV5^+<.%- MGY^Z"?JW+-Z;P?^3YEB]_U*7^]_+2P&S#7F2&7BIJB^2^MM>0B">6FK19>#/ M>K(O#OG;J?VK>O^U*%^/+:1[+B6[Z@1W@K^3VO:ZOP?DGPU%`X2J$'@U3'(B#!40GA5PM7HC2+% MA],MO`G,>0/HU^=HOGJ:?H54[Q1G:W-\G9$00Z9;#IN: M0&8"`H$NK5,(G>.'E/Y(_)(NXZ<[;PGH#05&L,0@24I`+XDC79,1A32"@%X3 MQ*S1#,%2^Q%#DJX9(J"_4Q3/^%;=="?$H?!2$\A,0`P`+5Q8Z6:XX8R7B[P* M.W:X7&)C,6R1`W]Y2'<,G#2=;]!]>HNWRM?BC3FB2D48@F,AOQUD?2:':(0A.=WA=E3"&18,0U";H?V4M[/]:JPU8[WC1])(WZ M(@J%F-X794PAD6#DOB^(9N"+2ILO8;TP6+U3<7#5+69+NP\FBM*OH%03S?UN ML>IE,;-$@I'[=F2C[=/$=K#_#I>=W4#AHXSTC'ZBU<*QBZB-TT2GFN:ALV.Z M,35":=S+0%]TLMSN$N"9:%06BD$BH.WW$ MC^RX#C_8B(=^(NMXXU/[OAE:PA0*+67DIBAC"HD$(RZ1GA_9?7L_5E'`YGRG M*(QU<%6\B4(AICXAKA!5GHA"(C$JTGW)9MS[XEV$/7J8)[LH(`>773`/X"L: MXW27^-3J*;)4(2@*_4A6!7,;F2+!P[CF0+,3Z"<&LM/!>HVSBX(BJ=#"I159 MHAB#&J=I_)5VK,3D6!K!R'TW[G-"8)\3`JLH*))RLUC:H26*,K1#QP!7:,H/ M42BE@H=QB?3LP'IR++9`PGIV(FNU*9*[].#F80J%EC+B"DWYP9OWDR!&1;H? MV<+[S6,6A0`[_'A14*117SA.'V)Z7Y0QA29#,.*:#-T71#/PQ;M(PGJ>[#0A M1Q6%U=*UBY`RM#,41;/8_A"8!:9(,'+?CNS+?9K8#K;K88US%`4DH9^'V%'C MY/><,"M#.YHFDJ<+L\99(L'(?3NR+3OL8+?6[-A5`4DJ/L87B2X8N6L!OCP86NA2XR\>8>^1FXZAUSB[ M*"B2*@IAL'1\@%"<%6P,7II1O-37;ZJ/Y"\[C?F$(AIHRX0L2ZR!02"49<(MV7;/LCOO!4,%Y'0B2-^B(*A9C> M%V5,(9%@Y+XOB&;@BW>>A,T\&:M\&R))?8LOO\,V6VNB*,/UAR+XRSO1R']F MB00C+I&>)]GN^SRQ'SP%P&<7FJ-M:$&)#:4VE-F0T"`]'MF+^WBZ_1#!G?$Y MJOW,,,3>/2S@5J':*I+\>H8G$4X/>CE+>A9Y3FTHLR&A0;H;_72`)7O,C>O8 M8"TC)!ENC"=?"3Q@ERL26+T;"\ILEGPRWPO1#3YIQT>[YZ)^+9+B=&HFN^KM M`O.Y@O[#J'K"'\[A$7_WR-VX`KF`*[$,RKJRH)\%&%?@]P*?0Y?"7\.S7,=( MP3H)7'BX3ESCI,$:GDG:XX@``I+XE`."7P]<\]?BC[Q^+2_-Y%0<8`)FCPO( M:8T_-,`W;77M'G^_5"W\;J#[]P@_""G@>?3L$&PO=V]R:W-H965T M))JRF$8\/I6T4H9$ MT((HT"]S5LN.K8S?0U<2\7BJKV)>UD!Q9`53+PTI1F4"GQ%T*>0N:Z)[W@F`M[6R]:,W%TH<:_2=AH=XC1'8)B'ZM/5\?V,] M0;7B%K.;8YPQ8M\AM,V:-IH&#H.`!4I[N5",@=Q.E8YJ51W?K@O\E>E.),P1 M*V\,B0P$E/2YNJLQY/`J9"0VZM%1`M/`?AJ(3&"HSO.G\BYA MUGT*(WW0F`-]G;$Z&F+(LK=@?=W/;TJW,Y#KIA=\V[;'P_OAL#<;CLPPW/L% M)MUT>`TQR@"Z=Y#!U&$].L[$\Z>I&,PK8O9O(B*#,';`UC37V!,X&K66%N.N MX>+9NP$T(?!8_0)PU-8DHU^)R%@E44%3D&8OUI"?,*>R^5"\;@Z: M(U=PR#:O.?P\*>Q\>P'@E'/5?>@%^M_Q]@\```#__P,`4$L#!!0`!@`(```` M(0"Y1/L6)@(``*8$```9````>&PO=V]R:W-H965T*_.$@.[3CV@C5%S@*0HQXSU0E^J;`?WZO[N88&4O[BG:JYP5^XP8_ ME%^_Y'NE-Z;EW"(@]*;`K;7#DA##6BZI"=3`>[BIE9;4PE$WQ`R:T\H[R8[$ M87A/)!4]'@E+?0M#U;5@_%FQK>2]'2&:=]1"_J85@WFG278+3E*]V0YW3,D! M$&O1"?OFH1A)MGQI>J7INH.Z#U%*V3O;'R[P4C"MC*IM`#@R)GI9\X(L")#* MO!)0@6L[TKPN\&.T?$HQ*7/?G[^"[\VG;V1:M?^F1?5#]!R:#6-R`U@KM7'2 ME\J9P)E<>*_\`%XUJGA-MYW]I?;?N6A:"]/.G`M3'42")Y+"K0!43@_^O1>5 M;0N>+$=L:J^2_410=42,D/D+@?81$69#&V6Q^`X6, M&?E*GJFE9:[5'L%V0$PS4+=KT3*&#C)G?'16?P=9&;#NRC2+<[*#9K"CYNE2 M$R\^-`3X4Q!(^4H09ST+$B=G0:YHL@_-29#D)`ARPTC"J2)W"P:,IHKB9'X6 M;-2DGS39I#@)!9(K]3AK@2'C*42:I1/`-Q:VT6D6OJ5A$)[SQU4;!S30AO^D MNA&]01VO`1H&,U@7/2[:>+!J\"U<*PM[XS];^!]P&&(8@+A6RKX?W"I/?YCR M/P```/__`P!02P,$%``&``@````A``$)^7=B`P``;PH``!@```!X;"]W;W)K M`O3C^\/-+7*D(F5"ZV[]]M3EP\R8Q2Y4"&4@8H4ZI:NZZ, M,UH0.>$5+>%)RD5!%-R*@RLK04E2#RIRU_>\A5L05B*382W>DH.G*8OI/8^/ M!2V522)H3A3PRXQ5\IRMB-^2KB#BZ5C=Q+RH(,6>Y4R]UDF14\3KQT/)!=GG M,.\7/"/Q.7=],TA?L%APR5,U@72N`1W.>>6N7,BTW20,9J#;[@B:!FB'UQ&> M(G>[J1OTD]&3[%P[,N.G#X(EGUA)H=NP3HKLO]&3O("V4,`LXX@Z&@?X;9?(#2*+L*JKXB& MBBL(BU$$'>TC8-MM1M)EP+;=AI(K$.#JD3[HJ`5A^2TTDA[$Q7"U8Z*AY`J$ M/GJ&KYV.6A"V)XVD!W$I82"&DHNBYXC5*(2.6A"V*XUD7F\,,[ST;4.8YUW( M*P08]OJ1/M1AB\'R?=AHND6P9=UH1',-1.]6PP7!9A/KOJ'8FFS8:+H@ON7? M:$1S#43O:B,@9K/K@OC6&Q!BH^F!6!Z.1C370/3>=@%Q]/DXU>=N;;(=G.>V M37SK;0@;31?H4LQXM9$L:BLMO1GV%K-+@XU;S7%N3JV"B@.-:)Y+)^;'$I@P M#&VC[?=&\R'0/H`#O2('^IF(`RNED],4AGJ3)6Q=PIS]YD;QJCX3]US!45Y? M9O!A1^%$\B8@3CE7YQM]L+6?BML_````__\#`%!+`P04``8`"````"$`NJ^I*8R^'< M]?#S=?,+*.JHIV6O$2OW&+;]>? M/ZT.VCS;EG.'@$'9$K?.]4M"+&NYI':B>ZY@I]9&4@=+TQ#;&TZKX9#L2)8D M,R*I4#@P+,U'.'1="\;O-=M+KEP@,;RC#O3;5O3VQ";91^@D-<_[_H9IV0/% M3G3"O0VD&$FV?&R4-G370=VOZ92R$_>PN**7@AEM=>TF0$>"T.N:%V1!@&F] MJ@14X&U'AMR(V5QCTDO$]H3PWH*.*`8J/!-SRNFC/J?WPHO8A`"01!'9*,$U8C:-D(N4 M4/-_4OIHB8$E9LCS)!($%0$S/<,4EXCM>X@+$4!R)F*XA&D1/?>[T#!GB?)\ MY.@F8-X3\Q[B0@PTY%A,GD0Q?G?LS,C]3<#,0GLLTGF2C+R#F?0L`5',DGEQ MA@ABPLR%5I7<-'S+N\XBIO<*[B0#[AB-HWZ7^1X9Q3?P!`QS1.(&3&9/&_Y$ M32.411VO@3*9S$&5"4,<%D[WPX#LM(.9'#Y;>&LY]&`R`7"MM3LM?"O'UWO] M#P``__\#`%!+`P04``8`"````"$`('3$(@$$``"8#P``&0```'AL+W=O"`=[M% MT'EGOWJ;S`ML9[\5'?1/B>YT]-^B5WS_A92GW\H&06_#./$1.&+\QM%O)QZ" MAYVGIS,Q`G\0ZX3.^:UB?^+[KZB\7!D,]XH_4N`*6H)OJR[Y'`#K^8?XO9V=424925_UK:*&V6X_E="7BV!=8H M1-_W?N1MG7?HT:)C8LG`]XCQ5>;0,[Q?N7"B!](^,*.2]0P?4$A[R!VZS2CF8+1' MYBP^00-W&"!^5S&I!PXRH#I:JODFGV#2*6:EZF3SC&)KJ=CJYQN/@C^E^]=J M([%DX'L8(BV-@Y%(C$1J)+(Y0K$*Z\-H!'NK/+JS82(,-OPHU*Q*!AH:&-VJ M)%[$1`M"EW]4C<2HD2H:[NI9(YLC%*NP)(VLBLFZ7`V3E=_5+;^HZ<:2F;-L M)!(CD4J"KW/O^Y`[5K/(YA04P[`TZH;7C[>3W]4-1VI3L63F#!N)Q$BDDOBQ MX3D%Q3`_^#SV"7TYXG=5PX'>M[%DY@P;B402THXG9JPV@JE1(YLC%,N18KE_ M?WE4MZIOC9(96PU<;2LX/#/:.YX8B=1(9'.$8M:#(]1H@'NW(JS;?>Q88E./ M.VC>[P2D&S8CJ1G)9A'5,S]8_'A2>_+<,5ZJ`U?;0N,.&GO7;!W,2&)&T@DD M<+6FL@GH@:C>^5%$\SY:LCUY4E&]ZSMR!\UZESHS2&)623M$;G=^Q'<7,J& M6A4Z@Z2[".'T0&1E)2\8;D6]<<0,"B7Q]PH5,(*ZP%T`?,:8]1?\J#_4U/O_ M````__\#`%!+`P04``8`"````"$`?,1+Z'8"``#-!0``&0```'AL+W=O M4`?QVUJT]LPFV7OH)#7[0WO#M&R!8B<:X5X[4HPD6SY62ANZ:R#OEV1*V9F[ M.US12\&,MKIT$="1$.AUSK?DE@#3>E4(R,"7'1E>YGB3++=S3-:KKCZ_!#_: MP3>RM3Y^-J+X*A2'8D.;?`-V6N^]Z6/A(7`F5]X/70.^&53PDAX:]UT?OW!1 MU0ZZG7D7IAM0@B>2PH\`9$Y?NO=1%*[.<;J(%EDVG2WF&48[;MV#\,X8L8-U M6OX.5LF)*["D)Q9XGU@FLRB;QY,D_2\)"1%UF=Q31]D6>H!3N9;(,)/'N3I+<@0-XK0+@C"A[U"KY8 M7G(;@"%?.LXW&>7S:([AV8>3)G\)@D2PF0YLLG$),!D)V:-0IJ'_556"S=#D M'Q+0L1$)CW82?5E.",QFG]A`]*+0LU%*CUY2!F3:C?:P4=#N04C(3_-L&F7] M4/C[2Z83-14P?%"CXF>O1?FLWJ8_N+3Y=;KJ! M(?T%+%E+*_Y$326410TO@3*._%*9L(_AX'0+D<.F:0?;U7W6\-OD,'@Q9(A* MK=WY`,*D_Q&O_P```/__`P!02P,$%``&``@````A`$SM.=97!P``*QT``!D` M``!X;"]W;W)K&ULE)G;;MLX$(;O%]AW,'1?VY(= M'X0X170NT`46BSU<*[8<"[$M0U*:]NWWITB*AV&#]*9J/LX,9S@D9R3??_Y^ M.4^^56U7-]>=YT_GWJ2Z[IM#?7W>>?_\G7W:>).N+Z^'\MQKV:6LKQZW$+8?L=$4QKR=;6>P]'!_J!$!6_9)6QUWWJ,?%L&=-WNX'Q;HW[IZ MZ[3_3[I3\Y:W]>%K?:VPVL@3R\!3T[PPT2\'AJ`\(]K9D($_V\FA.I:OY_ZO MYJVHZN=3CW0/\^V;,V;"OY-+S?8`0B^_[[P`,]2'_K3S%JOIW7J^\.'>Y*GJ M^JQFNMYD_]KUS>4_+N2SV4,*1%+"99O9C:Q06J#S`:Y#0H-S!#<&"%VX:]$R,19A-*W M2`(5%R^6G&Y&)8\_B\&LU@]S=GA?ENC&/U\8S$%,PY. M`M3+<:L%<_L.&(7&/!"2$I(1DA-2Z,0(C?55ZNJ6^XA1TW]!M#P0DA"2$I(1 MDA-2Z,1P%F=0LXJI-M"0D\5FRGHTWNS0E/B\ MR.+:E8L;"60E96DE14E)Q82BE**,HIRBPD!FD*R.JB#'U/#R:@0B*JZ*+?8) M2BA**H,)`9!"MW*@CQ0C+4B?Y4[U^B!NOLC_VNSZNCD26. M6&714K*R+R0NM5H,\:*OLFZL1%B&@`IWU)$H4U+L70AFK&J4*P&I4QC(#)Z5 M3Q7\>%F)JJIGD*,5$C`&N2(Q^5`ZK!M=N+J6P]\?9@[EU.112RK2E-J2Y0&;C M(;=Y0)L+@6!=GIY8(*R&1(E$*CNI1'JXW+RFF$LII5A(1#=CX.XD!FREE;<- MV(QJR3;VBYO0P_940HZL[6):"MBT#ZF15(/[,2:6=6(K4K,HIRB91B(9#+:]9JT)LF$!V(=O,* M9)[&I77MQTI*[5)N2]M_*97**,HI*@QD+C_K450@'VGJ6O5_B) M4_)P/V+^43P*[N17<7MD$^)U%9[;?!OB3<_!_7G(WJ9<(_CRCE<0UTB`D6$' MVK,$2_@U++DU@K.%D:'ML$;P@?_1:8M-[YJ=&7+Q18CO<-3;QR7L#S>F-7$$ M7UVN1EA;I_PJQ!<9.D&T#O$YP\$1UPA* M..)QC:!L(Q[7"$HU=H5K!.^2B,>U!GC-P8@KT[&/5*.;IU['_CI,T>K2$33- MT'&-1%C1R+FB,4981T>MH7\-$^<(>E9XX-)!ZQJR-@_69N-6QR]8M_*Y^J-L MG^MK-SE71UPI^,D)MU#+?^SB?_3-C;V!3)Z:'K]=#?\]X4?)"CWGG'U8/#9- M+_]@$XP_'F^^K8_G0_'U]O!Z'HXN-J_WA\?#J^?;P?__E?VVW)P=;[L7A]VS\?7_>W@ MS_UY\/O=W__VX?OQ].7\M-]?KE##Z_EV\'2YO*UO;L[W3_N7W?GZ^+9_A>7Q M>'K97?#7T^>;\]MIOWOH"KT\WXR'P_G-R^[P.E`UK$^_4L?Q\?%POT^.]U]? M]J\75-I]>D:__QA-=_>F[NXO5/W+X?YT/!\?+]>H[D8UE/N\NEG=H*:[ M#P\']$!DOSKM'V\''T?K=C8S\^>K\=/R>GPX/S>%U#[7Q MGN0-?#H>OXAK^2`(A6^H=-:]@7^]TR*W!^? M\23\_^KE(#&`KN_^N!V,\83#P^7I=C"97\\6P\EH/!M M+\>7_RJGD:Y*53+1E4S[2D:SZ^5L-ITO%ZCE!R5A[1Z/G_KQX^OI>+98=H__ M0<&Y+HB?NN"O/G*A2^*G+OGC)F)(=$W$3_.D\:]U;J5+XJ?IW/1Z-!W.1=H? M]&V$U]T]4OY@GOF+@H[,"Y4_Z++_QQL=(1Y4$VQ@_*K`(Q,.\H>_W(0;%:!= M8">[R^[NP^GX_0JS!?IS?MO)W#-:2\TZI+60?9!CK-V+^T?QOQW@+2-\SZ#? M[D;SR8>;;Q@U]]IG$_'Q/;;&0T:.5)N$(`U!%H(\!$4(RA!4(:A#T(2@=<`- M).MUPPO\2[J)O^AF>KPQP`HY#D0R'J9($H(T!%D(\A`4(2A#4(6@#D$3@M8! MGDB()Q)I.NMC2GC1I$%XO=]];:]DRF6$$F)9$1R(@61DDA% MI";2$&E=XDF#E3TFC6!?&DU6_8RU)9(028ED1'(B!9&22$6D)M(0:5WBZ8`5 MS-6A6_0+)9EE3"B= M<;I"*;2P:"O)."1P4,(H990QRAD5C$I&%:.:4<.H]9"OBB25,554LHF"YI5O M9,KL]?KN6`[_)TN/^R.:+>4;]E'JGTPVN5 MSDC<5FFT[`YHQL-1L*M.=#7CI?3$;Y"LU4Z#^IE3K>'>@_6RCG"W?5\,_;YO M9>N.4)@,N[;,KL?4EMXA;(O,/K&V=-S/#@S"0NBT912T17M-1,]O=T.<-_H. MB76@M@1KLM%ES$NO1F-?%SK=407'Z+W3XB!#3DQ=W>KDO:CQ.TM%B4:R0]G/`;[O=1Z84+LOKQD7%=NO=RZ@LFU ML%ZFKI)1Q=77Q@O3OM/4(&=JN&`;+;BT"8GT366!E_S'+A^90;:F7*.IMT0O@P6W,%X3O>`M M@A6Q-#7;AU4&V8?5!EFOQB#KU1K4>7G2(I>+2MMQ/_70:*(^DLNGOJU!]E&) M0?;S6&J0]5CJJ@4WUU/ M,=O+V`RFMR`7V1HO.U(2@R0YZJ^7+(/$(S5>6%@=+PHYW0A;?6X*JDEO=!TN MK]9NWF9ID*VE8E0S:ABU'O*U?6<[@2"B24XA;Y+3R+8QT06G=JY*#;*+?F:0 M+9@;9`L6C$J#;,&*4\ULIS,NF!LO6[!@5!HT MZ5]QQ775[-6P5^MY^6I)3N^HU2^_*M?WYD*%9E@"[&2U"O<6V!UT,Z8=4(E& M,Y7J35;+>237TY7;Y2?CFG*-YNH$=G@]#R;4PCJ8<5&:I]N:*ZZY-@75&KZ\ M#L*YX2*M*3+M$L_QV,[!GL+(Z#V%?Q:/G;^_]=!H9C7=:N2F@\;+3GBI09./#(JN:Z*ZZI-01NU#7NUQJOKD*_6.UL/V4[*D8HS2C6:8\UPXM&^ M!35PM9<[<`U2>]W19+E7:2W[8)M!>UWB9O>XJF,U+?EAE MD)W@:X-4\,^O@]AOC-T6:35:Z"\6=JSZFLMNPYD#?AJA:G?BO0N%YC;VMK(0 MR6F!;4ZBT=P.Q52CF8V7C`OFQLO.JX5!-FA+@VQ=%==5:S2W;[9AKU:C15>] MK]8[&Y8I;U@,LH_:,DH8I8PR1CFC@E')J&)4,VH8M1[R59&-@1-#9AV1S#D< MMPKYY^VK\,A`%W3/VQFEC#)&.:."46!?T1.P+FA4R9:^,4T"A+*N&#.J&!4,JH8U8P:1JV'?`4E/0\57.`W M>]Z_Y8RKXNG`\5"D0,SQAT04_$OJ#1-66OC%'.J&!4,JH8U8P:1JV'?!$E M\7<"L5\XU(;`&[$:N,Y[!TNUZPC+3"9[3S9!D06W()R*U35$;%LF890Y+ MEWF'M:$[T=Z,T!O-0?CXX]^>-T_1%Q%&F2Z!OC4#ZQ2PX\H%N M,0M.?J!;S((S'^@6L^#H![K%+#CC7,O)';<:1YUK.SI+#(*1*7P?$AJ;5?`!#SV-6?`=#SV-63;08!/5`)^>T-.8.O@" MA9[&+/CJA)[&+!DL\BF%^X,/3NAIS(+O2HCXF`5?Q]'3V`C&1W+T-&;90`/Y M%,DMV,(B7R39@L^[Z&G,@D^ZZ&G,@L^XZ&G,@J^YZ&G,@F^VZ&G,@D^WB/B8 M!5=/T-/8*-E`@TU4`]R60$]CZN#2!'H:LZ2PR,=_5@=7)M#3F`4W)]#3F*6$ M13[_QBRX'H&(CUEP(V@MUUNX-MP"0@MB%ES_00MB%MP"0@MB%EP& M0@MB%MP)0B3&++@JO);+O]PV7,F%)99(;,9(`'!UD,O@ZMI:+J:Q!1?1UG*G MC"T;M&WS3MLP7TT$`GSX?5\ M];Q_1%X_['Z=X*3^O1+UE\OQ#?D^_BF2XP7__$CWQR?\NS)[?(\;RG'&X_%X M,7^1!_3_4LW=_P```/__`P!02P,$%``&``@````A`&LB5`1V`@``SP4``!@` M``!X;"]W;W)KOOF9&3Q_.,H&[;FQ M0JL<)U&,$5=,%T)5.?[U"-B!+SLRO,SQ,IFM MII@LYEU]?@M^L(-G9&M]^&)$\4TH#L6&-OD&;+3>^M"GPDNPF%RM7G<-^&Y0 MP4NZ:]P/??C*154[Z/;$+V&Z@4QP15+X$8"=TV-W/XC"U3D>C:-D'&?I!*,- MMVXM_%*,V,XZ+?^$F.1$"HSTQ(#[F9%%DVD\2OX/(<%/MX]'ZNAB;O0!P6Q` M2MM2/VG)+(7Z,2\NO9KC*49@RH*Z7R19/"=[*`4[Q:Q"#%Q?8_H(`O0^!?B] MD<*K/H6OE<^Y"L*0E][FC6[RO`I5'=K)DAX04H28\2!FTD=<6(:0&Y:]"G4: MKK\N2P@:QOPC!S3^1@ZO=CGZN@0E'19FF/7"=W:3Z=5+9E#&W6P/6P4='WA" M?IS39!I-^L'P`9>HDP(N7^<@>]NY<(#"X$EN*OZ9-XU%3.^43P'X7NW/[3+U M]M[JX]FRFQG2?X!CUM**/U-3"651PTM`QM$4')EP(L.+TRTXA].F'9RP[K&& M'R>'V8MAAZC4VIU?(#'I?\6+OP```/__`P!02P,$%``&``@````A`!8VBTH5 M`P``VP@``!@```!X;"]W;W)KW@M8F;#*Y\3PZ1)#QBCR(Z%:S431+)=`65SZ?J+A)%!2F. M/.?ZK4Z*41&YW])22'K,P?>KO:11E[N^N4I?\$@*)1*]@'2D$7KM>4=V!#(% M7LS!@6D[DBSQ\=YV0]O")/#J!OWE[*P&_Y'*Q/F+Y/%W7C+H-LS)3.`HQ+.A M?HL-!,'D*OJIGL!/B6*6T%.N?XGS5\;33,.X5R8D$CE4@E]4<+,&P#I]K:]G M'NO,Q\X&HR-3^HF;&(RBD]*B^-<\M-L43;#3!L.U#;:MQ6ICW=O.ZF;@?1L( MUZ[J]E8@:537;A^IIH$GQ1G!$@)]JJ)F0=HN)&MMMII[X]#_R+#WANYC,`C6 M%*`O@;U:>>0%.AFUG,,,9\P(.X89`.CHQ4`;/B+&T(T8,Q2C[M`!%W7.I'+' MF%8&ZQ^I;.@^AM]!&];C4H>&8^\&I$FGPIXRE;/\F!Q#AP'"9:!G4NS0DF[I MZ2E3/;`8!^WI%H-!Z[+]`%IDW8\D'"*C6:]G4QITG+)%+E,.6P1VVH';3=_] M4158J3/"#3JNTB*[B_`A,DII=OCI&[->+3;@M'G3K]\:$S*NUR`.;$L##]O> M0[VY]DOW3W4O7YP6+KA<@[?N&&]2J>"MBY,V\).%@GSI4U;%Q=I\_VB9Z9[VH M>;>/R2*-(]95_%AWYWW\]U\OG]9Q)(:R.Y8-[]@^_LY$_/GP\T^[.^_?Q(6Q M(0*&3NSCRS!WEG6#)NE94PZ@7USJJWBPM=6/T+5E_W:[?JIX>P6* MU[JIA^^*-([::OOUW/&^?&W@N3](7E8/;G7AT;=UU7/!3\,"Z!(MU'_F3;)) M@.FP.];P!#+M4<].^_B);)_S+$X..Y6@?VIV%[/?D;CP^Z]]??R][AAD&^HD M*_#*^9L<^O4H(9B<>+-?5`7^Z*,C.Y6W9OB3WW]C]?DR0+D+.:7B#42"SZBM M90_`HY'X<+_%HO2)XN:1%'KTP,+[6<&D?530R\_=>,,4R:@QH.^#8< MV7)1K-*,_#])HO6HY_A2#N5AU_-[!,T!(<6UE*U&MA026$GP2:+[>!5'($H` M^GX@6;9+WB$5E1GSK,?`YS1F')$`^Q@"]"(A)"I#R%S)F,\:F/-1G"]#^22Z MC^%SDI/E(X$.H[(`YQ+EE*C-J9%<]?:\5%#QF:9(MO,F';M"WK5Y##(O&LF6>$[EFN=W MFD1M3HWXVC;6?*6-Y&04)V_;1`:QQ:UP<032BZA3L,UJ(%\?@4`8A80="@/9 MS;H.*,/M0XQ=E`[=W09"E,F^GU*O4D=A61S=KGT!C3TV'3&0G;Q-0*+L^8E_ MI-56L&@-1+S.@U5SSJ$U+A>PLHUTOC74),BME<@\#:C$S4%\=Q@(223B#[HF MEDK?)`1S24X"*G&;$-\G!D)4VDX9\^<[A!C(SE]@V:6X111L]_<#LIHGG_8/ M:ZFET@Q3\ZC"Y^EFL1P+KT8X$8R#H"6F13&?EGL[`NX@ZCO(0'Y*J;2#(Y+0 M];SP:HBC$C-1'EBZ*6XB!3NTVD2(2L1#9#/MZO(UP5F*'I!=JL`*3G$'*=B1 M&-I@J.V@1V\JV*$PKK%ZDP:6;XJ[1L$.;6A[H;9K]/ZRVE@E]AVD9D$$.W\! ME1GN(`7;*@WDESA#W%*0Q6I:)M4(A\VXQ189V&\RW"T*=FBU@1"1B%L4;!#&_)(9GM$ M=R(I%K,:&V_,TV<@J\9%8)/)<+LHV!$9LDN&V<46Z;M%38(`MLC`?I/C;E&P M+?(!6;2A_09>&?VE?+9(JOL.OYSBR0[L9SGN'P4[M"'_P*N9+['(YBY70QPZ M8R!@G?;$PMT3]5%6'P%;UI_9+ZQI1%3Q6P>SY%XQHN,1^HG*US47S[=/^FB= MC'?@Q'LMS^Q;V9_K3D0-.P%G*G5'O3X M..`XF41)JIFM9EMI5UI5;?>9<4B"QC86D,GT[WL!QS$&2WV)XN/+N8=[.8"W M']_K"KUQI85L=IC,YACQII0'T9QV^/NWYP\/&&G#F@.K9,-W^"?7^./^SS^V M5ZE>]9ES@X"AT3M\-J;=9)DNS[QF>B9;WL";HU0U,_"H3IEN%6<'-ZBN,CJ? M+[.:B09[AHWZ'0YY/(J2?Y+EI>:-\22*5\R`?GT6K;ZQU>7OT-5,O5[:#Z6L M6Z!X$94P/QTI1G6Y^7)JI&(O%>-V#Q%]+4HEM3R:&=!E7F@\YW6V MSH!IOST(F($M.U+\N,./9/.4$YSMMZY`/P2_ZL%_I,_R^K<2AW]$PZ':T"?; M@1P: M@*FS]QVFD$$=AF;S"-LHMY\C'P>X_I M(S)@[U.`WD0*B]H4=IXVYY,'AGPTS9<'?,C6:U'TTNU;J,Q0%EGW1#Z5CUD, M8HH^(I`.(0GI%H5Z#]X(.F!+J724Z+ MAIP>6;CU.6P9='Z@R968DM7L7F4;$%)UR+!_A,[39;5;5[SH+!IR>B26MP[& M.WF$%`-Y-B"DZI!0'DG+(U#CA#X'AZP=%"LDD&A`X2M8%+/5O80N9$1G1P$4 MJIRP`4G[RL$C6F^MA,J$E<@2-I7>3<1;!=9ZOPYO4"@RGRBEM4'<:NN=48,Z M*"$R-(CO]IP&I8S=`CMHHI2+"95IOY#8,!V44)FP#"GR0&5L&M)!T*"[J>G$ M1D'2MG'PJ.%3QB$IYX0-CZWC!D&"4.0R74J:]HZ#0Y$=%)>2AMZYG4D.'E%T M?@EV>[J:4);V"_7F&*[P#DHH2_@E7R][M]#8+3O*HU*>6E@C[)WQ![M+\B/U)X/ M8WRQ>?07YZQ_`_?9EIWXOTR=1*-1Q8_`.;>ZD?)77_]@9`O:X58K#=QDW=\S M?*)PN"C.X7A"1RG-[0$R9_U'S_X7````__\#`%!+`P04``8`"````"$`J;.D M*$X%``#S$P``&````'AL+W=O@$U"DE:2T<"H=T?:D5:KO3S3Q$E0!QP!W>GY^RU3#K8+@OJE.W$= M5YVZ^$"\_?)17KQW43>%K'8^FX>^)ZI<'HKJM//_^?MYMO:]ILVJ0W:1E=CY M/T7C?]G_^LOV)NO7YBQ$ZX&'JMGYY[:]/@5!DY]%F35S>1456(ZR+K,6OM:G MH+G6(CMTF\I+P,,P#LJLJ'ST\%1_QH<\'HM!)L`/.VWAP(R4&7W:G'<^5_94QIQ/]AONP+]6XA; M8WWVFK.\_587AS^*2D"UH4^J`R]2OBKH]X-:@LW!8/=SUX$_:^\@CMG;I?U+ MWGX7Q>G<0KN7:DLN+Q`)_GIEH68`4L\^NO^WXM">=WX4SY>K,&)\Z7LOHFF? M"[77]_*WII7E?PABVA4ZX=I)!#2UG7_628"$ND2^96VVW];RYL%T0,CFFJE9 M8T_@6&>@:?0Y06ESA?ZJX-TF8-O`ZOM^P[;!.]0HUY`$(2O?ZR$$D=X1JK1` MH^<""5(N4=B'5E8W-%^2T",0%Y$.$?&BASADH!@6F7O^:A6:9R6WX?W^KD0) M0A86A-!,IQ`.!W`RPD&M[GS(I"_PVN2`'!"R[AHTX_&:,G#MRSCL\'>2`$HO54*9,IA,,EGN2BK*0F9.H2A"RZFK"ER;ACFMI6 M8W,8P$A;U;A/A%IU(V]H-Q""D2.KUAC9ML:+N*^@$UL],<@QM3JAK(0#J7." M$.2P)FU*;>.#Y#<.@7OR:I4$-@G@""`$`\\BXQV3MZW<;'5R9Z#+5O+WV-TR M";[JJX?!-0:CKX@U=:P\,B5SPX](I%5[AFIF'\?-FM)`#-*@)=`.T,BXZ8W+ M0BF7F8"^""AHCB!M:'3$3)U"-@5Q>2CQ&N&!F@9N^I/.0I)IPN["IYX;LWA% ME#/5]AAEBZT6!N!R4/(UP@%5S>9`YRUAB-'CN"8:D;IF%CXBX`ICWPP4,X<` MF;D$7@_4D=$$."?-2EW[\B&#:3ED0SUD(4DVT2`L-^/T099J.U)=<=--MQGC MLLB&NFB74Q]/!/4-MXX@RH/VH@$16SZ2"%]A86DUHD& M36GF),3MR+AF\C'-I(\.#=)#85J.@^E:%V:S&]_52_H>QX>ZR4*B2XD&(0]& MRI4ZUD>#,2Z:Z@<0>8=@S+C0`V&K)C&FVH,NT28VY-PJ3$LF'Y%,:[(T#P3I M*@SF$JUW.0N9.5XN$U`RHB(,BJB'$%(A`*JI.Q^FJ+H2",+?HW0X.L<['XTQG5*\>\$KBU+4)Y&* MRZ7Q`#&PO=V]R:W-H965TDV*0W8] M[=1__W&_K%6EJN/K(;X4UW2G_D@K]>OS[[\]?13E6W5.TUH!#]=JIY[K^K;5 MM"HYIWEH4KQZ+,XQI^EB>MNI5I?&ANRB^:H>M++8^SJ\H\;,M'?!3' M8Y:D=I&\Y^FU9D[*]!+7\/S5.;M5G;<\><1='I=O[[H%^?R?S..E\-S]&[O,L*8NJ.-8S<*>Q!QWW>:-M-/#T_'3( MH`2]JHO\?P8UC]X[,5HG)CQF M>]WXM)-YZP2:O3LQU@NR6'[B49:MEU7OQ31FT,]X:-C<&[]<:,T+#?$5W# M@6@(14/4&>X-WYUJ$,4^E##BAJ'L(D;--&)=D_O.<'?2 MGB'K9O(RELN5K@LSJ34DS+4Y)FR.V%!`\.$,B;5)-B/"981D<'@HX:-$@!(A M2D0R@A,%UA)3HE`S+XI)5H(JC%DVJC2:B!&U&"&)EXT2#DJX*.&AA(\2`4J$ M*!')"$X56G0-UH5=JE`SK\I*7/TQA(GRQ5@L%Z-1;/&(;DPD"T,DPCDHX:*$ MAQ(^2@0H$:)$)",X63:\+.*ZAE[FY3&).)4QANE#5N:$/$,"E@/+D8`V(V3J MH(2+$AY*^"@1H$2($I&,X-0A4!-/94UC%W41\Z:%)$&U<,3&$0='7!SQ<,3' MD0!'0AR)6J0=TP3&Z^!%P"M$J[F)>8V6OF+F&,+K>=]"4H68'PEBXUX<''%; MA'49-K*X+K.Z#??BXTB`(R&.1%*$5XC6>%,*L=ION$HS#:%4W1,&2<)OX8B- M(PZ.N#U"-TG$.K"_>%]S"JM\'T<"'`EQ))(BO#:T7)S2AI61O#9"E_>$05)M M4,3&O3@XXK9(.V%,9P_Z+#[>4(`C(8Y$4H17",([J1"U"V\@0ZBH]X1!4H50 MQ,:].#CBMHA4(?19?+RA`$="'(FD"*\0K5:G:E&R<2@S:+9/]!G:P&PB*Q:;@:ZC2,.CK@XXN&(CR,! MCH0X$DD17B=:V,IT8H4OKY.X(4H8Q%**EJOC24]6/[="H8C3MB-)2Q='/!SQ M<23`D1!'(BG""T5K7)E0K`;FA1*WXPB#F%#PK6E**5DMW2J%(D[;D%0IU(N' M>_%Q),"1$$#AU3B)U.84<@\K0\I59ZN51*4KQ? MX>L/G;IZ:W\JYF5./]X+]CW9PC&&";NQW4_QEK&%+Z%CWC:V\$%T;'>,+7P7 M!;O6-PQG9&[Q*?TS+D_9M5(NZ1$>69^M8+%=LN,T[$==W)J#':]%#:=CFC_/ M<.PIA7,5^@S@8U'4W0_:0'^0ZODG````__\#`%!+`P04``8`"````"$`?5^9 M#*L)``!(*P``&0```'AL+W=O`3.9\^^VV+>OR]S*9ER'S MZU9+ZI9::L']GS\/^]Z/XG3>E<>'OG4S[/>*X[9\WAU?'_K__LO]8][OG2^; MX_-F7QZ+A_[?Q;G_Y^,__W'_69Z^G]^*XM(C"\?S0__M3IL+O3?T^O@_'XJ-L]5H\-^,!H.IX/#9G?LUQ;LTU=LE"\ONVVQ M*KS\+:8?L5J!XISO!G<#LO1X M_[RC&;#;>Z?BY:'_S;+SD=4?/-Y7#OK/KO@\*W_WSF_EIW?:/4>[8T'>ICAQ M!)[*\CNK!L^,J/$`6KM5!+)3[[EXV7SL+_\J/_UB]_IVH7#?>Z-_> M8<=K@*:^^5E]?NZ>+V\/_?'PQIH,IZ/;?N^I.%_<'3?M][8?YTMY^&^M4XV\ MM3%J;-"GL#&]N9T-QQ8;N=)PW#2DSZ;A]*K^I-&GST;?&K6#O=(/C:*:)%EO MVHWF7VDW:]K1YY?&1[NGZH<^&_V[J_,A:>U\CF_MV:\-S&K#1G]\:6B6"!+_ MT;2PR(]7O&:)\/`?39/)SJ?;<:G/9/-Z?RL\>)3(*POE]PVG1LME8L]L:Y[;[ MC]+`EM6_L?Y#GQ1I:YV)_G@<69/[P0_:T-M&9X$ZEJZQ%!J\J=GLR@2."5P3 M>";P31"8(#3!V@21"6(3)"9(39"9(%?`@-S>^IZ6\V_YGO79]\)K"P&48!B. M%AJBR;#="8;*LE5IO0_$`>("\8#X0`(@(9`UD`A(#"0!D@+)@.0J MT6)!:?6W8L'ZE)SHH_4S9IQ&Z5HP6I4V&$`<("X0#X@/)``2`ED#B8#$0!(@ M*9`,2*X2+1AT4JG!$$F><>5SX:M%36:TP90H3/4ML6R51+,5$`>("\0#X@,) M@(1`UD`B(#&0!$@*)`.2JT1S,1WM72YFK+NX(7=M>E\"60%Q@+A`/"`^D`!( M"&0-)`(2`TF`I$`R(+E*-'_2U:/+GXQU?]9D1/=395.*+("8]W%#5&6+)`5$`>("\0# MX@,)@(1`UD`B(#&0!$@*)`.2JT3S)QU+JC^K._;H]H921EW"X"V;6^BNKHFQ MFN?&:FZ5VM4,Q`'B`O&`^$`"("&0-9`(2`PD`9("R8#D*M&\;U$&4-TOEG/% M=2Y@+G(Z$P:6^ ML8P;-)HJ'JZU%+1"+0>1B\A#Y",*$(6(UH@B1#&B!%&**$.4:TCW,%; M,OV&'S,N;[OM]T5)AYPEJ_2Z$J);L\@$"WX\X6"HG@>T0BT'D8O(0^0C"A"% MB-:((D0QH@11BBA#E&M(]SP7,HKGV^S1%#BJAVLT'K=.7_+S$SE]1LE)N83< MZ6E[);5$M!Q$;H,4\UZ#;N=MCSZB`%&(MM:H%2&*$25H*VW0]6EG4DM,.]>0 M'@>N890X_'('-#6/&I\:S>B0V:"P'X#5HI`_`>!OSI9:P%2`*T?Q::JGS&^GSBZ26,!\C2M!\VJ#6,;.1 MX9A,:@C3N8;T@'+%I`2TW5AU)44-A9$%/ZA22"9T4"B!&^L36W9I67-C^BNA M-:[">SLVO.\T\K&\T[J(/&%%'1'TY0NMNJ\[8R@!V@T1K861JUU%0HORC>(B MXV$V%EJZ+:.,3W`0:7=#8T*9T*KG.[&,K95KAO7%P.5>UV)HRD!U,=1H4GV) M5#T>+_D=G;=L_=5._9[YAKO:Z/%Q7@=IVJ]%$.[1&YN,F M?UG`FW+6Y$E#OI)RL8\=@>HO\SA.+B)/(+(OE_+0*-Q]J27,!P))\R&BM4": M^9&Q!R*I)9&PT1HR4&D`M6>&DV-J612+OK*!:JLZ''D*E.)XR_/ MP:8J57=0C>82+:T:3>7J6B%R&G2KYL:ZH8(\;.@C"M!6B&B-#2-$<8.4"25H M*\6&&:)<:ZA[GBM,Q?/M@<7:S!(;(26LTA,C$6G-/( MM0.K-JP@3UC1,[^1P'VA]?\.++`;8N]K8>1J5Y'0T@\LXT$C%EJZ+<,%"0XB M[6YHS#<36O5\IS,C0KEF6%L,_!"C+H9?;<-*7U\D#9K+3+%$M!)('E&.0/*+ M0!>1)Y`T[PLD;04"25LAHK5`TE8DD+05"R2U$H&D^50@J94))&WE`E4-=<_3 M6KCJ^;_*=RZ%*9?6/S&IO^X^%*?78EGL]^?>MOPXTLDRO:63J\7U;UL6MW9> M#94^36T.;'UAHT(:$%K?-;D0)K7&; MO8D26M77[,/2_ M3+B9U7)Y'1@)*1S2L6)Q&0A!9EC!+*1#:O9I10 M]K%Y4:-D09)%IX22NLW;&-M0(K=Y-Z.$4KC-FQHE+DEX;Z.$$KK-6QPE=.>Q M^2A%"5U];#X^44)W&YM/4930?<;FPQ0E=*VQ^0!%"=U>:,UT2:BT(&M=&XDJ M#)OON&B-J@KJITM"]03UTR59T`@6G2-8DH2O-M@/W4YMON&@A"ZIMMLIH;NJ MS9<;;$.749OO."BAJI#:=(V:"D)JTR6ANI!BVB6A\M#F.@/[H9*0HMTEH3*0 MHMTEH4J;_-8EH>K:YCH+^Z&*FCS:):%:FCS:):&2FCS:):'*VN8:#/M96)R) MNE(1O;)1/UU)AQ[(R*-=$GKN(A]T2>CQBOKIDM#3$/73E:OH98?ZZ9+0HPSU MTR6A]Q3JIY(,VM1'/V]\W[P6\>;TNCN>>_OBA0ZJ8?7,>ZI_"5G_YU*?<;VG M\D*_;.3CKO=&OU@MJ*0:\O=*+V5Y$?\A5P[:W\`^_@\``/__`P!02P,$%``& M``@````A`-<]+\S]`@``)@@``!D```!X;"]W;W)K&ULC%7);MLP%+P7Z#\0O,?:O,2&Y<-YB[9WK[Q&+U0J)IH41[,0(]ID(F=-F>(_OQ]O;C%2FC0Y MJ45#4_Q&%;[;??ZT/0GYK"I*-0*&1J6XTKK=!('**LJ)FHF6-O"F$)(3#8^R M#%0K*Y,)W@+%@=5,OUE2C'BV>2H;( M`5W@A([OO`[6`3#MMCF#&QC;D:1%BO?1YCY:X&"WM0;]9?2D!O^1JL3IJV3Y M=]90CTHZW`3XER6I!CK7^)TS?*RDI#N6V^3-20 M"7X19Z8'X.KD-<4Q9&"YKE*<+&>+59A$\0*C`U7ZD9FS&&5'I07_YX(BF]UQ M60T/1)/=5HH3@L)"M&J):9-H$\/E,P/N#9KB%4;`IP!]V<7):AN\P#6R<\R] MBX'?/B;J(P)@[U.`WHD4!C4IP!J;\]X!0[YXFB_Q^)#Q*PE[Z>8M``-9<7+; M$[E4+F8^B%GT$9YT")F0;E#P:WA^;(\+&L9,0'_UA@^S M>KJ7DYP&]3D=,K<=,BP95'Z@R5H<+:'9>I=-@$]U1KSZ)>MI6\WJ&C>=07U. MAXSEK;WS3MYJ/8,QZ!K81/A<9\33-P^G]45@\H1`"_NL9V@L,8)$`PJG<9', M5N\:;<@%G3D%$,S">Y'G5^;*1`U2=%>W\`6MFZT)E1.S%$6+0:$C-RO0['TC M=I!OY95A-5,R)=*-AT?;38Q9EL-FA&4XI+!6QN'[;\&^]AX<8G/-WNWM8/^#2SOEI3T!Y$E:Q2J M:0&&PO=V]R:W-H965T M[]K_^;?_KU&[=;EN7^ZWSZ>7_5W[[_VE_7[U.Y[)[VA^WEYO3Z_X%DH?3^;B]XM_S8^?R>MYO[W.C MXW/'O;T==([;PTN[\."=/^+C]/!PV.UGI]W/X_[E6C@Y[Y^W5[3_\G1XO8BW MX^XC[H[;\X^?K__:G8ZO..R]Z?#F=M]^?<=]_.;WM3GSG M_Y#[XV%W/EU.#]<;N.L4#>5['G?&'7CZ^N7^@#M086^=]P]W[6^.E[F#=N?K MESQ`_SWL?UUJWUN7I].OX'RXCP\O>T0;>5(9^'XZ_5"JT;U",.Z0M9]G(#VW M[OQ.S[@2_K:.!]4'<.O;O_+/7X?[Z]-=VQW> M#)W;<7?8;[>^[R]7_Z!LVZW=S\OU=/Q?H>24K@HG;ND$GZ63[N"F/[SM.BZ< MO&'8+0WQ61HZMS?NJ._T!^]8]DI+?$J[QS=.[_8].[0GOU]\EG:CCY@-2C-\ M?K*AP](2GY]J*)[$O*'X+.T^&--Q:8C/3S;503)C%T!C<] MMS\E%ZLMG;U;ZD:,[4K?WP>M*7W)T9WHK.YUBC,C'EMGVNOWZY7SZ MU<*`C>1>7K=J^'<\Y:L<52A2@8>F$\E0^FK9$@8)P)JV3$B+QIB,C/!W`2^"0(3A":(3+`PP=($ ML0D2$ZQ,L#9!:H*-";(::$0>P\VG(J_T[]KXJQ^#_J`9ZDFAXV#0KI3Z395I MI5*E@\B- M]&#:I/2X_9MJNN991%GD"9+`3@K2PX=.67_43-FT4A*S&9$Y$9](0"0D$A%9 M$%D2B8DD1%9$UD12(ALB69TT\H&E2#T?,G4KW`QZ08:]:@*9$ID1F1/QB01$ M0B(1D061)9&82$)D161-)"6R(9+522/"6/_8(JQP,\(%*;:%^4IG2F1&9$[$ M)Q(0"8E$1!9$ED1B(@F1%9$UD93(ADA6)XT(8RE:CW"Y+KU1>X#KTV'W8W+" M..%4RU*EWHQ\2?(->1%Y(C,B$^)G(J_4FY$OR`@7J`WEQAYA6BB-L2O52@-CBIY52C+>SXGX%:D[,O8; M0:4DCD(B447JCMSF#+2HE,31DDA MT_6F4A+769TT:BU:U\^8*T5E"BFF$H M6MHP$J0-%VRX%"UM&`O2AHD@MVK72I`V7#-*!6E?FQ+56I^)5NZK&72U;;4% MO=C.-H)>H!X>>=V;!N:^4Y7F5&J&^1/8&QN];:;EDLVYH*+BK%+G"RJ\=+O& M(Q%HN7@)!6DOD2`L!6HM-D:6A=827TM!]5MU1H9A+%I-]\8-)UI+W*\$O>E^ M76J-$=!:ZXU(I.*KV0CCJ=MH+6E$)NAWC6AV$[6!MG63KE=K@>]0!@0:WUE:"QZIJIL@3QTBZ=JZ+K&TF&F M%>0FYH+T:M<75#Z<0_/!"+2"N`D%:3>1H,*-.^H93\Y"*XB;I2#M)A94N!GT MS.DST0KB9B5(NUDS2@65#;SM]LSUD-80UYF@W'7S&5*[ZEHZW]MXJ'<&R!8< MBO-)B?JZDTU+-!A56C-&W);4%7W.CI!1ICYM"3W]#8?$W5ZRT8 M0DO:.&,T9^0S"AB%C")&"T9+1C&CA-&*T9I1RFC#*&N@9A[4#MV6AW+G7A]Q M"E0O,ZEW>0AZ#K$>\G(]9O)*%&STJ@+34NN=:I36DG%LSLC7J#8F#HPQ,=!: MXBMD%&E4]V6T?J&UQ->24:Q1W9>QMDRTEOA:,5J7J%Z9TEIU]^923&N)^ZR! MFNG_3:G!Y5)#B=XN3MF4J#@R*[7*XA2.+1GK\[DHZ&V%_R'/@1@699>NTS-V MY:$H:,_1ASPOQ+#PC!-31MR7HJ`]QQ_RG(A68X:GXA2[7S-*Q1?25ZT6*/X; M,93B5+=O;),ST>"]F*O*&I8I,^?&P%!60&K%J5*K7IPJ4:U*,QGR M3L"&H6AIPTB0-ERPX5*TM&$L2!LF@O1*<"5(&ZX9I8*TKTV):K>=B5;NJ_F8 MJKJ!+>A%/:&^2'<+]$YQ2K2P;*SZB3LT1JJ9UI*A9"X(LVUE2`4A7[2*#:,S M-@I&@9:+XU!0K78AJ-E(X[E;:"WQM13T9B-CT6JZ-P:,1&N)^Y6@-]VO2ZUF MU6IH1"(57\U&&`6`C=:21F2"?M>(9O_Y30'%Y0)*B>I5*T&Z?#-C-!>DQS]? MD#8,&(6"ZIDOJSC:<"%:&BT%Z2O&@K16PF@E2!NN2U2O6HF6]K5AE`FRC)1& MF4-VUNJ(KK&>%:0;-&4T8S1GY#,*&(6,(D8+1DM&,:.$T8K1FE'*:,,H:Z!F M3U>E!MM(690@&B-E@8R=M5%6GF)WI[)5WUDSFC/R&06,0D81HP6C):.84<)H MQ6C-*&6T8:3.XNO@%'DHSM87YU^/^_/C?KI_?KZT=J>?+Y@PQFK)4>'B4/_$ M[>-4?_[TDV0@Y_T-"88_2/+MN2'!3P2^Y?.SP2?XZ4`^_9K6H(9`FF,4^-A"S!U.6I`9$EF*X\-0BR9.4Z\&8+)):I\&:38+7JJ:41 M>\,*%=>Q2;`R1;YLD@G:-K&V;0J)FK'X.EC.>&KB8@F6,)Z:K%B"E8JGYBR; MQ('$UC;L,;S(*L&^`CFUV6!#@9S:)-A7>&IYRBW`7@+9MDDFD$RLDBDD4ZL$ M^S3$S>8-&S3$S2;!/LU3BW5N&_9FB*A-,G%&Z/%Y"=GH\:@:X#KY_L&0H`:` M6-LDV-$C;C8)]N?HHS9)"HG:)7.K\3K$4V5WEN"MB*=*[2S!JP_ MJH:S#0KBGBIWLP05;T_5LUF"DK:G"M8L08$:+;!)\+83$MO`-D&KU7L5]H;7 M99YZE\(2O!3#_=@D>#?FJ=+:M;<-!(D\=-^$6X/`0SBCQSP:>SARQSP>>SA!QSP=>SC^!MZI!FG\ M5O)U^[A/MN?'P\NE];Q_P.+O-C]:>BY^5EG\KOB59/[U"3]_ MW>/HRZTZW/YP.EWE'W6!Z@>U7_\/``#__P,`4$L#!!0`!@`(````(0`PSX$N MQP@``!,E```9````>&PO=V]R:W-H965T66[+4FN8G)N8/-UJ M2]VMU@(/O_XXGVK?HUL:)Y?'NM-HU6O1Y9"\QI?WQ_H?O_N_#.JU--M?7O>G MY!(]UO^.TOJO3___W\-G$8G?=I([E&%TC> MDMMYG^'?VWLSO=ZB_6O>Z'QJNJU6KWG>QY>ZM.#=OF(C>7N+#]$D.7RW;Q_670W*^PL1+?(JSOW.C]=KYX`7OE^2V M?SEAW#^D\_9+7Y=Q9<(WD:<1`1>DN2;4`U>!4+C M)FOMYQ'8W6JOT=O^XY3]EGS.H_C]F"'<7='DD)SP)ORMG6.1`QCZ_D?^_(Q? ML^-CO=UJ.)U6S^W6:R]1FOFQ:%JO'3[2+#G_)76E.A]#UW'ZOU!\V.FZW/W#$J.XT[!<-\?Q2QS!=\A?A M6>C?'_BPT'=$0*4KO]@SIPP4/E#?&NZ@ZW3S4-T9E$/Q$1^*IMVO^<.A2(D/ M15.GT7=:PW;_OB<=BIGX\)-#I?`A8:DI>GYOA`BTS&(5\?L9@KE7M%"AOA^) MIIPX^82;[+/]T\,M^:RABB$>Z74O:J+C";/%5"OZ6TX^U("#4'\6^H]U*&)> MI:#?G]Q![Z'Y';/Y4.B,N(ZC:XQ)0\QH879B@JD)?!/,3#`W06""A0F6)EB9 M8&V"C0FV)MB9(*R`)MQ>^AYI\5.^%_K"]^2U$8%*,`Q'DP8UF9A@:@+?!#,3 MS$T0F&!A@J4)5B98FV!C@JT)=B8(*T!S-*;_3SE:Z&,IJ2:YT]4].Y(Z#FIB M.1,,E7&I4GJ?D2DC/B,S1N:,!(PL&%DRLF)DS)1^=@=](QB%TKU@E"IE,!B9,N(S,F-DSDC`R(*1)2,K1M:,;!C9,K)C M)*P2+1A8HJK!H"(O<.YS\M5($A<+?R4*`ST*XU*)FDT8F3+B,S)C9,Y(P,B" MD24C*T;6C&P8V3*R8R2L$LW%6--M+A98=[$D_4Y9WL>,3!B9,N(S,F-DSDC` MR(*1)2,K1M:,;!C9,K)C)*P2S9_8>MC\*;#N3TG9GK$U5/U.I%5CW MIR3MMLI;2?IXJ.+K#/7B.RF5J/A.&?$EJ9B>2=(=E"^;,Q(PLF!VEDQGQOBJ%IU>WZ^<;L-9+<\D:D3CC7=\_9Z?`K41Z15 M.-R6'HYQH35HY6>DCM-KFP%3&C2,*4=^@=IJ69@5R-4[8!RQYDJ+S`<<+;CY MI=*JCL_5Q[=26F1^S=&&F]\6J'1,WS4I`4@E<6Q_8V*;E#(SA3TBKG8>WVS:\/RWD[6$YL7R.9F2EVB/VKCEIR7<- MC:X$W.Z"HR49N?NJ%6EA]UYQ44=WT9JT=%O&+<"&=V)K;V@,:$=:U<,2=5";*[EDGI'%U9R(0[^HDX9\HN04NBDA>2$LXN1S M-".$C8]Z?\90=DI.[PH)Y5;T.(HC826.Q;W?OV[[Q/G;+*<2#53(QX563V77A*-I M@;K5VBAM5=",-YQS%'!;"XZ6O.&*HW6!*@/:<%M;WG#'4:@UU#TO3HH5SY<+ MECQ!HB&%;R1ND,74/=\RC<\KL.5?-^ M3Z[BJ(OY)[^9E%^4G*/;>S2.3J>T=D@^+D@SU+>GAQ++KT1'72_,^V+RGA?F M'3(XLLT3X\++#`F2SA/#XY(=)&*47((4PS>R-@F^JGW.5W;C+2/Q%:[%TLCU M0JM^VPOS[8!AY[GC/5M?/.IX85[+C`:H#IY((3Z(`!*125R"^N")A.(2E`E/ MY!67H#1X(KVX!.7`$UG&):BXWL@J097UQ+SB;5!9/3&]N`0UU1.SC$M\2,1D MXQ)46$_,.2[!)@0^L'D4>Q&,U";!9@,CM4FPP4#ZV2389R#);!)L)Y`S-@GV M^K!F2QML^9',-@FV^7B/38(-/MYCDXS0@Y&U!V-(Q%Z#^PW;143!)L&N$5&P M2;!Y1([:)-@=(D=M$AS3T,;6ZP`2L=7G?<-!#3&U27!>0U[;)#BC(=HV"7M':*WK!XM/+UYB9_U"+_R>2Z4WM),OQ( M12Q!M2-^?!3A9-,2-U5O29+1/QA(L_PYT],_````__\#`%!+`P04``8`"``` M`"$`"<!]S^D)Q1N$>:5=:K?9X)AC;*,980)*9;[__IKN!/C;* MO(3XUU5%575U==,/7[\W5^.MZOJZO1U,9V6;1G4KVV-].Q_,O_]*O^Q,HQ^* MV[&XMK?J8/ZH>O/KXZ^_/+RWW4M_J:K!@(5;?S`OPW`/+*LO+U53]*OV7MTP M\]M]:4GS'7%-W+Z_U+V39WF'BNK_7P8S1J&DT9?#O?VJYXOB+N M[XY?E-SV^$,QW]1EU_;M:5C!G$4=56/>6WL+EAX?CC4B(&DWNNIT,)^<('>V MIO7X,";HG[IZ[Q?_&_VE?<^Z^OA;?:N0;K\.?[7M>U>?+@.E>$Y6RO>)-^<-:D!A%Y\/Y@NWE`?A\O!]#:K M]=;V''=M&L]5/Z0UT36-\K4?VN9?*N0P4]2(QXS@R8QL5^YN[:PWQ,@'BCY3 MQ),I.IO5UK'WWO9C18R.;N/)%->?TMLP/3Q_SM,M4\23*;IP^H/0L))&#_'\ MC(<6G9=Q/N-B*!X?NO;=P")!YOM[09:<$\`6FTCVYFEJ46$ED7XBX@<37F+2 M>M"W1W?G/UAOJ)62R82JC"-*1%R"U`LQ&\L@D4$J@TP&^0)8"&Z*$*7W,Q$2 M<1(A]RWD8!&R%`Z7X"JQ#!(9I#+(9)`O@!`.%H$KO5W,K454-0@5_:=DZT_++%)(K)!$(:E",H7D2R(X MBS:F<990T5E*W,WLK$)BA20*2162*21?$L%9"_ M@X6E"6#$8@0<+4)@:+L9]T??V;I[L;W&L\04@(I2%64JR@4D!D%VQ+EDV-Z^ M(D>?X5*7+V&+%#O3UN'0#10ME3L5,C1J3/N]O1&CB9C4QJ/G`=N1^E`\"W#+ MB8K2&8W'"MOQQ/=DLP`WDPM(#)[LGW/P?+TX=%L5@J1H@S8QE=Q&B9$*^QM_)YK.N<1H6LP' MV7@U^6#[\7+2*?+H<9XWGE15S+C4?,+*.1H5 M1:_))JKQFNVM2Z\IDG9$*3\1.2^@!?E8^-,$:::126W'/'O2^2GA1N8$I1Q] M:#?C4F)SDYI#SJ5$6W-!B@DB.[$F072#ABF^5$)RF$+H2!!'$4/(!D9I[UU$F5VMKSOY8_:FCE9+:0<:EA#?*[2!G4G39B)-+#@.:--$S@I`FBH0U M2Y&P9AE:KEE%*L6]P;A&YD+).)H5R>T"D5IZ36\+Z-=E4W7G*JJNU]XHV]<; M$N[Y6$T3IM<4B)W?4T@CN,!X&M\F\9!<;)!RE;D;X(M)P[T`GQPJ?_*#)WI! M(AOR`YS<585P'>#4J^&(8.Q;LAV$%FK?$&$DTH[$&(FU(PE&$NT(2C$@4Z9Z MAO(+R,SI1ER,Z-*"#03YU8V$CH]X=!E`4T4\NI$8(Z2CJ!Z@AR(>W0A:*>+1 MC:!]PFO="%HFO-:-A-L`)VKU_=$^P.%/PQT;EL;*E^83IQQXK"L]'%R@HQL) MD!BM<*^;Z_0=D]M._`?<->:KFH? M_P,``/__`P!02P,$%``&``@````A`.IP7IP$`P``7@@``!D```!X;"]W;W)K M&ULC%;);MLP$+T7Z#\0O,=:O,0V+`=.@[0%6J`H MNIQIB;*(2*)`TG'R]YTA94:R9#07R7P>9*"UDG-)J$E/`Z ME9FH#PG]_>OQ9DF)-JS.6"EKGM!7KNG=]N.'S4FJ)UUP;@@PU#JAA3'-.@AT M6O"*Z8EL>`T[N505,[!4AT`WBK/,'JK*(`[#15`Q45/'L%;OX9!Y+E+^(--C MQ6OC2!0OF0']NA"-/K-5Z7OH*J:>CLU-*JL&*/:B%.;5DE)2I>NOAUHJMB_A MWB_1C*5G;KL8T%!:L`F+:;3,`-,.Q$\3RANVA]'\UI ML-W8`/T1_*0[OXDNY.FS$MDW47.(-N0),["7\@E-OV8(P>%@'PD"ZK;]4EN`)GJ026`-P=?9BWR>1F2*A\7(2+^?1?!'/*=ES M;1X%'J8D/6HCJ[_.*D+WGB5N6>#=LDP7D_EM.(W^3Q(X1?8F#\RP[4;)$X'R M`)>Z85ALT3J&$*8([A!-Z"TE($H#^KR-X]4F>(9@I*W-O;.!I[>)O$4`[-X% MZ!UQ@2BZP!NBSWL'=/GB<;[I*!^B"86GEQ-/0T_@7#B;6<=F[BUZDL%D1#*B M$*?N^6%8G%'7YHH/2/R(#T2M#Q^7%H'J[-SL2J@7HYR(]CD=,K/5W4T59+RC MB6!!S\+EY';N*P,M^EPM`NGKZ+N2.IQ\PVI#M,_ID*&^5>^\U1>MWLH6M_M$ M+=(7-QU/>@0A'E%GX3YK"PWU1=@4;Q=T`A?0I3Y^UN*"K>VD7NE/9U=$8IN\ M>?`-VW:/E>2*/7+0B,A^`XV)=(T"E>ZK,&JAOL@KI8TM,B;2]4:/]MPNX*C7 M@3!'NQ2#5-O]BSBVG=*7N+B(HYOF;@967!WX)UZ6FJ3R6$/]8BUYU']%=C$& MXA*?K7=NV@=^!X9^PP[\.U,'46M2\APX0^P?HMSWP2V,;$`[3'YI8-K;GP5\ MQSG,P1"*A>12FO,"(^/_&6S_`0``__\#`%!+`P04``8`"````"$`+3M?+?P+ M```(,P``&0```'AL+W=O'8[3F)T;`6V^YAO/_\22?$H=I+=>9BD?U6D MBL5BL4@IMW_\.KX.?NS/ET-[NAL&H\EPL#_MVL?#Z?EN^.]_95]6P\'ENCT] M;E_;T_YN^.?^,OSC_N]_N_W9GK]=7O;[ZP`]G"YWPY?K]2T:CR^[E_UQ>QFU M;_L3)$_M^;B]XI_GY_'E[;S?/G:-CJ_C<#)9C(_;PVDH>HC.G^FC?7HZ[/9) MN_M^W)^NHI/S_G5[A?V7E\/;1?5VW'VFN^/V_.W[VY==>WQ#%U\/KX?KGUVG MP\%Q%Q7/I_:\_?J*-B=VTO[=!VAN[$PE(_Y9GPS1D_W MMX\'C(# M:`:^MNTW4BT>":'QF+7.NAGXQWGPN'_:?G^]_K/]N=D?GE^NF.XY-=FUKW@2 M_C\X'B@&,/3MK[MAB"<<'J\O=\/I8C1?3J9!.!\.ONXOU^Q`;8>#W??+M3W^ M5R@%LBO1R51V@I^RDV"F.WFGX4PVQ$_5,_W,<,4/$3Z`#ZO`%C M$='=2DBVU^W][;G].4!ZP6@N;UM*5D%$/Y7Q58G#M2?R#]NR%F&/%^ M`?UQ'ZZ"V_$/++.=U%ES'4F"R@6U"QH# MC.&RWF^8OO_);Z1/?E,C7BM@.-)V8ZPT5)/$!:D+,A?D+MBXH'!!Z8+*!;4+ M&@-83D(\,2?-YGTLD1BIU(BE8#&SG;`6.@&6>A]P>8R[$F_78^DC[6+'[U_PE5H>V@ME=YS8J_2.Y&1 ME)&,D9R1#2,%(R4C%2,U(XU)+"?"7Z835>XBW/E*C7$M2(C-H/=>L%C9WHM[ M)=4L821E)&,D9V3#2,%(R4C%2,U(8Q++-=C3?:XA;+M&D&57?G4Y.F8D821E M)&,D9V3#2,%(R4C%2,U(8Q++#]C!?'X@;/M!D'#19^Z8D<0DUE/HI&#LKBH0 M"=M/D<1X"B.)2:RG8%W[GD+8?HHDH1Z+("$&8"R`&WL!)+T2%H#U8*JBS"?+ MZF%$5=CUY;#[MF[1;=`G_$[?-DFBT+!)H94H+R:!LR^C)L M8463T)J2/W_<3U#QVL8FLALH,%MHO_'9(OBQE$N=MGD,SIID$2V<$H^6-_5_ZQ1E"HELPXRA[&L9U M8=VM$5],BU1K3:?,OK0*5)4<+)W9BFE7)XM#.9U39]])M`(SD-*::^![54(@ M\B`-N;- MA>Q41CG<<*E*U8'([=;TRG1O50W+A1W[L6R(VD)Y)>$HY2CC*.=HPU'!4 MH3W2YQ6Q=UKA(Y&QU]/QAO*_1@E'*4<91SE'&XX*CDJ.*HYJCAH+65ZAPMKT MRKN)M%.VBP.%C.*`HT2B$*'5)[=@N;378ZJUU'K,>%^YUC+[:Q!.,H:A5S&"4:&IM5>Z%3JRTC/A4 M2!1ILV`^F<^U.6(74#IZK\@4TCWE$LVL_=T]PFZ4UE3NENYV6JB>]<-*A?3# M*H6T5JV0UFH4ZK1LU_ZFJ$/]VJU@(_M)!->J((D5TH]*%-(W0ZE"6BOC*)=H MIO>7C4)ZN12\8C=97\U@HI'LM.:HXJCEJ+&1[ ME4I:GU=%J6MY52!X5=D84P&//077;0HE"NG`2A726AE'N4(Z2#<<%0KIODJ. M*HYJCAH+V5ZALMGG%5%.6UX1:&9M#"OWY$`O-:@.UUY)))IA4>LT[1ZW4J5E MU8$KIP[,>/>Y:J@J_QD+.6FXN9"9E27ON>*HYJBQD.U]1'-=B\42F;E0:8G/`NBU9ZJ0SG(9;Y@K+=UPPU&AT+1/ MR"7OJ^):-==J+"W;6[\Y6^#BS/>:DHM(UDEJJ$H]:8WJP6O M]92.WGXRWE,NT4)*]50A/=JY(1SS9LTJLFL6Q%A MJ'.P[6'GB/%A//*C!^X4:3+F.DG%$EENEEHZX:6JH9$I><-_)E%-Q%C#W#XD6*$F,>-2S(-YR22UKX8J^ MIN*L&TQ7JR4[>ZAFIN=D,UU8YE+K@[.NTE)GW1LGFQ?\8:5"^F&50B+X%R.G MF*B57#=I)%K*UQUZK=H^IZ.%X?,/(U0<1:RY$&BA8R_&EU[N%B710B_R5**Y MCI>,-\R5ELZK&X5TT!8*Z;Y*WEYR>JR_>%M$#ND(R1OB4P_.$*;[#\_"'6?2`MPZ>!K,(+^<]?![AS;2'8VR^ MH6VFTX@FCK?`$HAH_K@$*R&B:>02+(B(9I-+L!0BFE0NP8I0WR"ZSH)D[6T3 M0T+1S'M+($F\DA02BFW>)H.$0IQ+D$TBBG2?)(#??%-93`/XS2?!)@>_^238 MZ^`WGP2['/SFDV"S@]]\DB*\@05=I>1X%,4=+/!)4./!`I\$I1XL\$E0\<$" MGV0-V]9>VV)(:*?D'D5-@IGS25)(:-_D;5"08.9\$ARD(CHV\#8X3T5T>N`2 M'*LB.D1P"4Y76+<^R1H^6'M]@`,!1NKS3@))XI6DD%#%RBW((*'"E4MP#$`D M^B2XJ\!(?:L>5Q88J4^"FPN,U"?!P3M:>WV`PW84>R4XZ',5*?=W!-C)'Z)"DD=-W);<,E,4;JD^"N&"/U27`%C)'Z)+@)QDA] M$EP((^)]$KP#B>A"G]N&]QZPP"?!"P]8X)/@O0_3Q8H<+P13Q>UF$6?/D`K]XP'I]D#=O6?ML@H9,8W%GQ0!(FO^(J# M$!+?T_&Q#21=`3;N'X0_3WC;/N^;[?GY<+H,7O=/J"DGW9=79_&7#.(?U_8- MM2;^2*&]X@\3NE]?\!]P^3$:X4WYJVZOZ!UPR[O^&Y?XO````__\#`%!+ M`P04``8`"````"$`L)LXU,,-```:0@``&0```'AL+W=O7NT;[MM6XV;_L MCO>'EV]WC?_\._S7J'%SOFQ?[K=/QY?]7>/O_;GQQ^=__N/3S^/I^_EQO[_< MP,++^:[Q>+F\!LWF>?>X?]Z>;X^O^Q=('HZGY^T%?YZ^-<^OI_WVOBST_-3L MM%J#YO/V\-*H+`2G]]@X/CP<=OO9?]RJ8R<]D_;"^I_?CR\GL7:\^X] MYIZWI^\_7O^U.SZ_PL37P]/A\G=IM''SO`OB;R_'T_;K$][[KW9ONQ/;Y1]D M_OFP.QW/QX?++GPWUR>-G#VXB3BL#7X_&[4HWO%4+A)I4.RPCDIYO[ M_$NZ^*[(Y/>!+^O7D^J#:`5]_^57[^/-Q?'N\:G>'M ML-T:=X?]QLW7_?D2'E39QLWNQ_ER?/Y?I=2N355&.K41?-9&NH/;_K#5;7=@ MY(V"W;H@/NN"[?;MJ-_O#4;J\6^4[-4E\2F/[-YV1OUV?_";9\)N^<;XK$N. MWU=P4!?$YP= MOFU?FQ.^U&7?Z=VV-"+UY:-5EG;4-AH2G/U&^VE+`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`J--9J+5OV!O[+2VF9;+(#(75)U#JM"%@BHKW:[3)19:+E8B0=I* M+`B;0:/&SLBRU%IB:R7(?-7VR"F8B)9MWGGA5&N)^;6@-\UGM=88:PVC]HXG MD` MAH+TT<2"421(%XP%Z8)+1BM!NJJ)(%TP9;06I`MF-4*TY!UST=*V-HP*09X! M46VQ?4ZOM]YFWZP0!D2CK0R=-=!4'L]0*8F8E2)M)!%5F!CUW^DRU@IA9"])F M,D:YH+J"K6Z/5D17AXKI0@J5INT^A)YFAO.WNQ.E[_2M"O5U(YNJ'.JUAQJ%"9G*J0VC&:,XH9+1@%#&*&2T9 MK1@EC%)&:T89HYS1AE%A(=OI*DUA./UWPW^G2FM8G:)&>MJ:BI9&,T9S1B&C M!:.(48+"]GA5YD!HR]>9_\J8V#UN0I9>2=*3JFKI6J#\V9R M9%9KUB8*V'+_+\E(*5I9[K8'C M]Y4H:,O)NRRGHF7-\)2<8O,9HUQLO>G_C124Y%2W[VR3"]'@O1@F0'^+X3Q) MJ8K&8"2G:F0FIVID9&GFHF4LT@7I],Z""T:BI0O&@G3!)1=B6X%J0+9HQR0=K6ID;&:Q>B5=JRN^DOL@X=SCK4Z#?)*=%">9U2&3HCU4QK MR5`R%X3-UK4@)81"T:HVC.VQDS!::+D8C@09N0M!=B6=?K?46F)K)>C-2B:B M99MW!HQ4:XGYM:`WS6>UEIVU&CJ>R,6670DG`;#16E*)0M"O*F&W'[4]]PWS MU;;=&N8K9&:M.C72Z9L9H[D@/?Z%@G3!!:-(D!EY>N)2M+2ME2#]Q$20UDH9 MK07I@EF-S*R5:&E;&T:%(,](B=!XG:ZXL[.ND:[0M$-HQFC.*&2T8!0QBADM M&:T8)8Q21FM&&:.,W0UZGE]QV>HVEZ,T9S1B&C M!:.(4DU&05$FD%P^#HJR1[B\W0H*W#C!,UU)!S\; MPW;?)X$Q-!N/I`MK>!&68(Q%&5_-\.NT+^4BP'T^'N]_.@QYGC#IXM$>_J47 M?/%6:=(+BC(IX3ZX'Q3E^.GR05"4.V*7X\W*<M.']9\;X.5,*SY)%@0!VKUQ=:P M",9S?!(L?A$MGV2"NDV\=9M"HB9%?@Y63(&:&UF"55*@YD.68#$4J&G1)^E# MXJL;MC&!6NQR&6Q=$%.?!'L6Q-0GP=8E4"M@MH;M"J+MDTP@F7@E4TBF7@FV M@O";SQKV@/";3X*M8!!Z)=C^P:.^,I-.!S'U=4$D)O`<7Y]"F@&^]DF0-(#? M?!*D`-!&?9(<$K419X_BQ"50F7V6X.`E4-E\EN!T!2.-3S+MM/`^ON$,.7>\ MCT^"I#K>QR=!UASOXY,@!X[W\4EPH(JZ^4:7"6H]\=<:$G57(]`.?!+5`G6CA6N`^TF(J4^"BTF(J4^"^TF!NN;"UG`G"='V M22:03+P2W/T*U/T>MH;[7O";3X*+7O";3X+[7H&Z],/6<,<+'O5)<$<7,?4M M<:;M+I[C6\S@+B%\[9/@9B#\YI/@GA_:J$^"*WJH02EI7A MOAU>SC=/^P>L-5OE===3]=O^ZH_+\15K4/QL_WC!3_7+KX_X/QCVN&G34O?R M'X['B_P!MS2O_ZO#Y_\#``#__P,`4$L#!!0`!@`(````(0!.BF2VMP(``-L& M```9````>&PO=V]R:W-H965T88!5C9#M-^^]W;2<4"I7Z@N#X^-SC>Z\OFYMG M6:,GKHU038Z3*,:(-TP5HCGD^,_O^ZMKC(RE34%KU?`$&%9Q24VD6M[`2JFTI!8^]8&85G-:^$VR)FD<+XBDHL%! M8:T_HJ'*4C!^I]A1\L8&$/B4%DH]]QM8:J&2/!$4K@>@*/3YQRG$$$4MLKQ M;!'-E_$L2><8[;FQ]\+MQ8@=C57R7R!YZR1H>0]WU-+M1JL3@L("V[34M4FR M3N'PS($[A^9XB1'H&4"?MFF6;<@3'(.=.;>!`\^.DW0,`NI="/`[$<*A+H0[ MIXMY&X"^7CJM-QOH(9>O6=Q9=ZL`]&REL^M.*(0*G*S'F7>,@76@3%AW*.2K MOW^=0X>:`1G;6PWV>WOI=1+!-;@TL&,, MM<[(T-]RVE\"29XPZ.&AZAD:6X2)T9?P'I/Y+%J^>O24-W)N%T!#EZ_M&YHS MC))PC277!_Z%U[5!3!T;:`UWBSNT&V&[U!7Y+9ZM=Q`+%DBW`A.GI0?^@^J# M:`RJ>0F:L?.-=!A.X<.J%HS"W%$69HU_K>`GPN$JQQ&02Z7LY<,%Z'Y+V_\` M``#__P,`4$L#!!0`!@`(````(0#ILP[AL`(``-4&```9````>&PO=V]R:W-H M965TT8`U8Q1K;3M/]^QS@P:*C4FQ!>CI_SR6%[\R)K],RU$:K)EIDGT$)ZE^.K973,D6$`=1"_O:03&2;/-0-DK30PUYOT0)93V[ MN[G`2\&T,JJP`>"(#_0RYS59$R#MMKF`#%S9D>9%AO?1YC8*,=EMNP+]$?QD M1O^1J=3IJQ;Y=]%PJ#;TR77@H-23,WW(G02'R<7I^ZX#/S3*>4&/M?VI3M^X M*"L+[4[=$:9J\`2_2`HW`Y`Z?>FN)Y';*L.+,$CB='4=Q2E&!V[LO7"',6)' M8Y7\ZZVB,\M3XC,%KCUE&:2K&=<.-6Y<-5R M/F^],.;%\[S%+,^I4-=1.'$:#@#OPMLD(YMTL)B$#"8S(3L5ZC0^?UD6;S2V M><<'-'[&AU,['T-=S@I,YU#H.'VGU,M9IE.G3*\DW72/6P4='\6$NH%>K0,8 MTGXRG,64=58FC4O?:9W;?/^GS?.7,,0#WAE,\6<%IF.4_F*^;>L)O@_9J5.F M5R[3AV5Q&5^4CN+K+*:P7IH6('D3H5\B_M637)?\"Z]K@Y@Z-I"7>_,&=5A> M^]@UZ*V>;/9^J9'A">R:EI;\D>I2-`;5O`!F&*Q@=+1?2_[&JA9BAX6C+"R9 M[F\%GP\.KU\(2:)"*=O?@&&ULC%5;;YLP M%'Z?M/]@^;T!DY`+"JG25=TJK=(T[?+L&`-6,4:VT[3_?L=VPB!)I;X@_/&= M[UQ]6-^^R@:]<&V$:G-,)C%&O&6J$&V5X]^_'FZ6&!E+VX(VJN4Y?N,&WVX^ M?UH?E'XV-><6@4)K!Y)*EH<%#+]$0U5EH+Q>\7VDK4`OQFUITYJ0FV4?D)-7/^^Z&*=F! MQ$XTPKYY48PDRQZK5FFZ:R#O5S*C[*3M#Q?R4C"MC"KM!.2B$.AESJMH%8'2 M9ET(R,"5'6E>YGA+LCM"<+19^P+]$?Q@!N_(U.KP58OBNV@Y5!OZY#JP4^K9 M41\+!X%Q=&']X#OP0Z."EW3?V)_J\(V+JK;0[M29,-6`)W@B*=P,0.KT-<<) M>!"%K7,\G4_213PE28K1CAO[()PM1FQOK))_`\F''@4M'\,]M72SUNJ`H+'` M-AUU8T*R!))G#MPZ-,<+C$#/`/JR21:K=?0":;`CYRYPX-ES2,^(0+UW`?%> M<>%0Y\+EZ7S>!6"HEUS7FX[TD*O7+.U#=U^A,L.PR'GH@3,;<-+KKH!R)72' M0KV&]H0L>X603B`-.>_X@-X-?/ATDC2=+/ZGY!C>7U^K(S(L%DG>*==\I'_J ML$/'F@&9^5D=M@^FX#P^,H?!ZRON"&.I(S(.;]H7:#0=;HU=#J!#QYH!N0QO M-;+WY2-Q,BR?8XRUCL@XOMGU^`AMBK#N9_=3YH1]8'I@`VS-!-R"-9 M3N!JGUKF*>-$3A#L*UEUQ7_`MO&H.8VK=@-04'/=JOO&WB M!N$!U=71BC]178G6H(:7X"QVC4$Z;+EPL*J#I&"! M*0M+R[_6\#?BL!-BF#)4*F5/!^>@_[]M_@$``/__`P!02P,$%``&``@````A M`%48RS,R`0``0`(``!$`"`%D;V-0.6"@!M-N_EW5=G=&31_*^/#S?1[G8F2;[!!]T:RM$ M"X(RL+)5VM85>EHO\SG*0A16B::U4*$]!+3@EQ>E=$RV'AY\Z\!'#2%+)!N8 M=!7:QN@8QD%NP8A0I(9-X:;U1L1T]#5V0KZ+&O"$D&ML(`HEHL`'8.Y&(AJ0 M2HY(]^&;'J`DA@8,V!@P+2C^[D;P)OQYH4_.FD;'O4LS#;KG;"6/X=C>!3T6 MNZXKNFFOD?PI?EG=/_:CYMH>=B4!\<-^&A'B*JURHT'=[/GNS3=9"-L2_\Y* M)7L[)CV(""I+[[&CW2EYGM[>K9>(3PB]RLDLI[,UG3,R8V3R6N)3:[C/1Z`9 M!/Y-/`%X[_WSS_D7````__\#`%!+`P04``8`"````"$`MK>KJO4"``#L"0`` M$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"6]#.S1-54A%@:E(;$6#=H^6 MZUR"U<3.?(;1_?6[)",DK9.M>_/'W?EW7[:#ZT.6#O9@4&HU]B[.A]X`E-"1 M5,G8N]]\/OOD#=!R%?%4*QA[SX#>=?C^7;`R.@=C)>"`3"@<>UMK\RO?1[&% MC.,Y;2O:B;7)N*6I27P=QU+`3(M=!LKZE\/A1Q\.%E0$T5E>&_0JBU=[^[]& M(RT*/GS8/.<$'`:3/$^EX):\#+](833JV`[F!P%IX#`W MI\%:\!2F9#B,>8H0^*>%X!9X$;05EP;#8&^O]B"L-@.4ORALE][@D2,4.&-O MSXWDRA)6(59-RG&:HS7A=VV><`M@,?!)H%HLATW9YEB.PA&QDC"-VI+%8D5" M&VW&C;0IX%V\XL8ZD$=4"B?FDJ(BKH!F\P4[9K+)61-/M4*=RHA;B-@-3[D2 MP-:O_/H'>4:$?S]B;>FDHJZ0Z9C=Y92>VG81Z`J[1=56F?)6P&N5&XZRM+DR M@&2_K"*G\:7\L9,158Y[5R.R.3>*R@39"@Q%@QLWYB++J9`*;PIGEEHEJ=Q3 M'">(+^JBQBR-$2M)375&S8?=H#.)0BLKU8ZD*52F%'6[OU![PM"&.MWIUC>@ MHMT)2RVC$C8EEY(.R:7FBM%5PHX-QB:)@2IG3M/D1R9ME=-"CY)'S`E=4%TP M2VEETNWW@JZV#-B&'SH0UY"4QSEQG(7`5E3DG3P=22&"1^H]YRD=N>E3<::@ M3^'H9I^,V]L96"Y3-WE=_JQ7RMT&?W2<(>GOA@NG3E?DYUF>:G>#=JFLK19/ M[$VGW.7%4_,FE%]OM$S>I"./X7V8E"66D3O MYW'_M!#&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`@:!4**(#```F M#```#P````````````````"2"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``& M``@````A`#G,U&1%!0``8Q0``!@`````````````````80X``'AL+W=O&PO=V]R:W-H965T``!X;"]W;W)K&UL4$L!`BT`%``&``@````A M`/2@B$$Z!```)0\``!D`````````````````#RH``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!D^`:E=`@``804` M`!D`````````````````\3<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$W02;"-`@``=@8``!D````````````` M````J4(``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`&A7G5$!`P``6`@``!@````` M````````````LDH``'AL+W=O&UL4$L!`BT`%``&``@````A`/MB MI6V4!@``IQL``!,`````````````````,JX``'AL+W1H96UE+W1H96UE,2YX M;6Q02P$"+0`4``8`"````"$`"&R=0/D'``"G(@``&0````````````````#W MM```>&PO=V]R:W-H965T]``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`+E$^Q8F`@``I@0``!D````````` M````````0L```'AL+W=O&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`+G'_#6$`@```@8``!D` M````````````````-\8``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$SM.=97!P``*QT``!D````````````````` MU\\``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`,M,C:Z1!```6Q$``!@` M````````````````J.P``'AL+W=O&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`,@7N3_`!@``C24``!D`````````````````!/L` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`)<;F/[C#```E3L``!D`````````````````$0\!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.IP7IP$`P`` M7@@``!D`````````````````8RL!`'AL+W=O M+@$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$Z*9+:W`@``VP8``!D````````` M````````RT@!`'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`%48RS,R`0``0`(``!$`````````````````H%$!`&1O M8U!R;W!S+V-O&UL4$L!`BT`%``&``@````A`+:WJZKU`@``[`D``!`` M````````````````"50!`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````#$`,0!) )#0``-%@!```` ` end XML 17 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations Narrative (Details) (USD $)
3 Months Ended 0 Months Ended 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Sep. 30, 2013
Portamedic Service Line [Member]
holdback_component
Mar. 31, 2014
Portamedic Service Line [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from the sale of Portamedic $ 743,000 $ 0   $ 8,100,000 $ 700,000
Consideration amount       8,400,000  
Holdback amount       2,000,000  
Holdback release, business days after closing       3 days  
Number of holdback components       2  
Assets held for sale 714,000   714,000    
Adjustment to gain on sale of Portamedic and subsidiary (150,000) 0      
Holdback amount, component one       1,000,000  
Holdback amount, component two       $ 1,000,000  
XML 18 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 19 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Liquidity (Details) (USD $)
3 Months Ended 0 Months Ended 3 Months Ended 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Dec. 31, 2012
Sep. 30, 2013
Portamedic Service Line [Member]
holdback_component
Mar. 31, 2014
Portamedic Service Line [Member]
Apr. 16, 2014
Strategic Alliance Agreement Assets [Member]
Subsequent Event [Member]
May 13, 2014
Purchase and Sale Agreement Property [Member]
Subsequent Event [Member]
Apr. 16, 2014
Purchase and Sale Agreement Property [Member]
Subsequent Event [Member]
Mar. 31, 2014
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Cash and cash equivalents $ 2,667,000 $ 3,837,000 $ 3,970,000 $ 8,319,000            
Working capital 6,700,000                  
Loss from continuing operations (2,565,000) (2,027,000)                
Net cash used in operating activities of continuing operations 1,735,000 3,156,000                
Relocation costs                   1,100,000
Holdback amount         2,000,000          
Number of holdback components         2          
Holdback amount, component one         1,000,000          
Holdback amount, component two         1,000,000          
Proceeds from the sale of Portamedic 743,000 0     8,100,000 700,000        
Maximum borrowing capacity under Loan and Security Agreement 10,000,000                  
Loan maximum defined, based on eligible receivables 85.00%                  
Loan maximum defined, based on eligible receivables, reserve 500,000                  
Additional borrowing availability under Loan and Security Agreement 3,100,000                  
Borrowings outstanding under Loan and Security Agreement 0                  
Consideration amount         $ 8,400,000   $ 3,700,000 $ 3,050,000 $ 3,050,000  
XML 20 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended
Mar. 31, 2014
branch_office
operating_lease
Commitments and Contingencies Disclosure [Abstract]  
Number of offices 12
Number of operating leases 17
Branch closure obligation $ 0.3
Employment agreements, contract term 1 year
XML 21 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Impairment of Long-lived Assets
3 Months Ended
Mar. 31, 2014
Asset Impairment Charges [Abstract]  
Impairment of Long-lived Assets
Impairment of Long-lived Assets

The Company evaluates the recovery of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of assets may not be recoverable. For the three month period ended March 31, 2014, the Company evaluated the long-lived assets associated with Heritage Labs and Hooper Holmes Services in connection with the anticipated sale of certain assets under the Alliance Agreement with CRL. The Company concluded these long-lived assets were not impaired. There were no impairment charges recorded for these assets in continuing operations during the three month periods ended March 31, 2014 or 2013.

EXCEL 22 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X-68Y,C$W8E\X.3EB7S1D9F-?.38T-E\X8S=B M-C5C,S0Y968B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D1I#I%>&-E;%=O#I7;W)K5]!9W)E96UE;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O M&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I.86UE/DQO#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K M#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I7;W)K5]!9W)E96UE;G1S7T0\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K M#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-E M9VUE;G1S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-68Y,C$W8E\X M.3EB7S1D9F-?.38T-E\X8S=B-C5C,S0Y968-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO.#5F.3(Q-V)?.#DY8E\T9&9C7SDV-#9?.&,W8C8U8S,T M.65F+U=O'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO2!296=I2!#96YT M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)S`P,#`W-#$X,34\2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)U-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\'0^36%R(#,Q+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)U$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO2!#;VUM;VX@ M4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO2P@<&QA;G0@86YD(&5Q=6EP;65N=#PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPOF5D.B`R-#`L M,#`P+#`P,"!S:&%R97,[($ES'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'0^)SQS<&%N/CPOF5D("AI;B!S:&%R97,I M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#`L,#`P+#`P,#QS M<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-68Y M,C$W8E\X.3EB7S1D9F-?.38T-E\X8S=B-C5C,S0Y968-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO.#5F.3(Q-V)?.#DY8E\T9&9C7SDV-#9?.&,W M8C8U8S,T.65F+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M'!E;G-E+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO&5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XS,#QS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,"D\&5D(&%S'0^)SQS<&%N/CPO&5R8VES92!O9B!S M=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M-SQS<&%N/CPO'0^)SQS<&%N/CPO&5D(&%S M&5D(&%S2!C87!I=&%L(&QE87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#`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`R M,#$T+"!T:&4@0V]M<&%N>2!E;G1E3II;FAE6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^("AT:&4@)B,X,C(P.U!U3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&]F('1H92!0=7)C:&%S92!06QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+61A>2!I;G-P96-T:6]N('!E M3II;FAE3II;FAE2!- M1$U#('1O('1H92!#;VUP86YY(&%T('1H92!C;&]S:6YG+B`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`@("`\=&%B;&4@8VQA3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQD:78@'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^5&AE($-O;7!A;GDG2!!9W)E96UE;G0N("!!="!-87)C:"`S,2P@,C`Q M-"P@=&AE($-O;7!A;GD@:&%D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0R+C<@;6EL;&EO;CPO M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.C$P<'0[/B!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"`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`Q-#PO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/BP@=&AE($)A6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N M.FIU6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CQD:78@'0M86QI9VXZ M:G5S=&EF>3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@ M'0M86QI9VXZ:G5S=&EF>3MT M97AT+6EN9&5N=#HR-'!X.V9O;G0M2!F;W(@=&AE($-O;7!A;GDF M(S@R,3<[2!R96-E:79E9"`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`@16QI9VEB;&4@4F5C M96EV86)L97,@:6YC;'5D92!O;FQY(&)I;&QE9"!R96-E:79A8FQE2!M87D@8F4@869F96-T960@8GD@=&AE($-O;7!A;GDG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)#`N-2!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B`@079A:6QA M8FQE(&)O2P@;F5T(&]F('1H:7,@9&ES8W)E=&EO M;F%R>2!R97-E3II;FAE3II;FAE3II;FAE6QE/3-$;&EN92UH96EG M:'0Z,3(P)3MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N M=#HR-'!X.V9O;G0M2!G;VEN9R!F;W)W87)D+B`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`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`@("`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`\+V9O;G0^/&9O;G0@3II;FAE&-L=61E9"!F6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SYT:')E93PO9F]N=#X\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!M M;VYT:"!P97)I;V1S(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT M97AT+61E8V]R871I;VXZ;F]N93L^36%R8V@F(S$V,#LS,2P@,C`Q-#PO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/B!A;F0@,C`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`@/&AE860^ M#0H@("`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`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@0V]M<&%N>2!G3II;FAE3II;FAE'0M86QI9VXZ:G5S=&EF>3MT97AT M+6EN9&5N=#HR-'!X.V9O;G0M#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE2=S('-H87)E:&]L9&5R3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SXS+#4P,"PP,#`\+V9O M;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&UO;G1H3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^+"!T:&4@0V]M<&%N>2!G3II;FAE M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^;F\\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO M;CIN;VYE.SY-87)C:"8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!A<'!R M;WAI;6%T96QY(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`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`L,#`P/"]F;VYT/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M('-H87)E2=S('-T;V-K(&=R86YT960@=&\@8V5R M=&%I;B!E>&5C=71I=F5S(&]F('1H92!#;VUP86YY(&EN($1E8V5M8F5R(#(P M,3`@=F5S=&5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R M871I;VXZ;F]N93L^-3`E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&]N(&5A8V@@;V8@=&AE(&9I M3II;FAE3II M;FAE65E2!V97-T(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/F]N92UT:&ER9#PO9F]N=#X\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[ M/B!O;B!E86-H(&]F('1H92!F:7)S="P@6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^3W!T:6]N3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^,C4E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('5P;VX@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SXR-24\+V9O;G0^/&9O M;G0@3II;FAE'0M M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M M'0M:6YD96YT.C(T M<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F M;VYT/CPO9&EV/CQD:78@'0M M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$<&%D M9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R M;6%L.W!A9&1I;F6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MM87)G:6XM;&5F=#IA=71O.VUA6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY4:')E92!-;VYT M:',@16YD960@36%R8V@@,S$L/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`P,#`P,#MT97AT+61E8V]R871I;VXZ M;F]N93L^=&AR964@;6]N=&@\+V9O;G0^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P M86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB M;VQD.SY796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E(%!EF4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ:G5S=&EF>3MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^1W)A;G1E9#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^-#8R+#8P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L M96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^17AE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^1F]R9F5I=&5D/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/"]T6QE/3-$)W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3W5T M#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N M92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)O M6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R M9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E M"!S;VQI9"`C M,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^3W!T:6]N&5R8VES M86)L92!A="!-87)C:"`S,2P@,C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E"!S;VQI M9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@#MT97AT+6%L:6=N.FIU M#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY-87)C:"8C M,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"!T:&4@97AE'0M86QI9VXZ:G5S M=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M3II;FAE M&5R8VES92!P3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-T;V-K(&]P=&EO;G,@ M=V5R92!E>&5R8VES960@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@ M36%R8V@@,S$L(#(P,3,N("`@3W!T:6]N3II;FAE3II;FAE3II;FAE3II;FAE3II;FAE&EM871E;'D@/"]F;VYT/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,"XW(&UI;&QI;VX\+V9O M;G0^/&9O;G0@3II;FAEF5D(&-O;7!E;G-A=&EO;B!C M;W-T(')E;&%T960@=&\@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C M;W)A=&EO;CIN;VYE.SXR+C`\+V9O;G0^/&9O;G0@3II;FAE65A#MT97AT+6%L:6=N.FIU#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M3II;FAE6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B!4:&4@9F%I6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#`N-#4\ M+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%F=&5R('1W;R!Y96%R6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE M.SXR-24\+V9O;G0^/&9O;G0@3II;FAE3II M;FAE3II;FAE3II;FAE6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXQ-3`L,#`P/"]F;VYT/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M('=E3II;FAE3II;FAE M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)#$N,#8\+V9O;G0^/&9O;G0@3II M;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY- M87)C:"8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!A;B!A9V=R96=A=&4@ M;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SXQ-#$L-#`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`L,#`P/"]F;VYT/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^('-H87)E2=S('-T;V-K('1O(&5L:6=I8FQE M(&5M<&QO>65E2X@(%1H92`R,#`T(%!L86X@<')O M=FED97,@96UP;&]Y965S('=I=&@@=&AE(&]P<&]R='5N:71Y('1O('!U3II;FAE3II;FAE3II M;FAE3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3`E/"]F;VYT/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^(&]F(&$@<&%R=&EC:7!A=&EN9R!E;7!L;WEE92=S(&-O;7!E;G-A=&EO M;BP@;F]T('1O(&5X8V5E9"`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,"XP,R!M:6QL:6]N/"]F;VYT/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M+"!B87-E9"!O;B!T:&4@0FQA8VLM4V-H;VQE3II;FAE3II;FAE2`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^('-H87)E6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^;F\\+V9O;G0^/&9O;G0@3II;FAE2!T M:&4@0F]A'0M86QI9VXZ:G5S=&EF>3MT M97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^('EE87)S+"!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDG2=S(&YO;BUE;7!L;WEE92!D:7)E8W1O3II;FAE3II;FAE2`\+V9O;G0^/&9O;G0@3II;FAE3II M;FAE3II;FAE2!N;W0@8F4@2!T:&4@2!O M9B!T:&4@9&%T92!T:&4@9&ER96-T;W(@9FER6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE M($-O;7!A;GD@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#`N,2!M:6QL:6]N/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE3II;FAE3II;FAE M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&UO;G1H('!E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SY-87)C:"8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`R,#$S M+CPO9F]N=#X\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`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`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.C$P<'0[/B!A2!I;B!T:&4@2!H87,@2!A6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F M;VYT/CPO9&EV/CQD:78@'0M M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0MF5S('1H92!O<&5R871I M;F<@"!E>'!E;G-E3II M;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^36%R8V@F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BX\+V9O;G0^/"]D M:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIJ M=7-T:69Y.V9O;G0M'0M86QI9VXZ;&5F=#LG/CQT#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0V('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0V('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#L@'0M86QI M9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F'0M86QI9VXZ M:G5S=&EF>3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT M97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HQ<'@@#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`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`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`@/&AE M860^#0H@("`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`\+V9O;G0^/&9O;G0@ M3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,"XT(&UI;&QI;VX\+V9O;G0^/&9O;G0@ M3II;FAE2P@;V8@9FEN:7-H960@9V]O9',@86YD(#PO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#`N."!M M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE'10 M87)T7S@U9CDR,3=B7S@Y.6)?-&1F8U\Y-C0V7SAC-V(V-6,S-#EE9@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-68Y,C$W8E\X.3EB7S1D9F-? M.38T-E\X8S=B-C5C,S0Y968O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`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`R,#$T/"]F;VYT/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&5R M92!W87,@82!T;W1A;"!O9B`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O M<#HQ<'@@F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R M9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0S('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`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`S,2P@ M,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^-3,Q/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N M92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$)W9E#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#(Q M,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[8F]R M9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;FF4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@ M'0M86QI9VXZF4Z,3!P=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q M-C`[5&]T86P\+V9O;G0^/"]D:78^/"]T9#X\=&0@#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M'0M86QI9VXZF4Z,3!P=#L^.30V/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[ M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z M,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$ M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A M9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC M;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;FF4Z,3!P=#L^ M/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M'0M86QI9VXZF4Z,3!P=#L^-C6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M'1087)T7S@U9CDR,3=B7S@Y.6)?-&1F8U\Y-C0V7SAC-V(V-6,S-#EE9@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-68Y,C$W8E\X.3EB7S1D M9F-?.38T-E\X8S=B-C5C,S0Y968O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!!9W)E96UE;G1S/"]T9#X-"B`@("`@("`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`@16QI9VEB;&4@4F5C96EV86)L97,@ M:6YC;'5D92!O;FQY(&)I;&QE9"!R96-E:79A8FQE2!B92!A9F9E8W1E9"!B>2!T:&4@0V]M<&%N M>2=S(&)I;&QI;F<@8WEC;&5S+B`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`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`@1'5R:6YG('1H92!T:')E92!M;VYT:"!P97)I;V1S(&5N9&5D(#PO9F]N M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE2!!9W)E96UE;G0L('1H92!# M;VUP86YY(&EN8W5R6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N M.FIU#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE2`R."P@,C`Q-BX@5&AE(#(P,3,@3&]A;B!A;F0@ M4V5C=7)I='D@06=R965M96YT('!R;W9I9&5S(&9O6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^,R4\+V9O;G0^/&9O;G0@3II;FAE2`R."P@,C`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`R,#$T+B`@5&AE($-O;7!A;GD@8V]N=&EN=65S M('1O(&AA=F4@;&EM:71A=&EO;G,@;VX@=&AE(&UA>&EM=6T@86UO=6YT(&]F M('5N9G5N9&5D(&-A<&ET86P@97AP96YD:71U'0O:F%V87-C M3X-"B`@("`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`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`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQD:78@'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N M=#HR-'!X.V9O;G0M2!I M;B!5+E,N($1I2!O;B!B96AA;&8@;V8@82!P=7)P;W)T960@8VQA65E2!U;G!A:60@;W9E&%M M:6YE6EN9R!T:&4@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)#`N,#4@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!B971W M965N('1H92!#;VUP86YY(&%N9"!T:&4@;F%M960@<&QA:6YT:69F2!D:7-C;W9E2!R971A:6YE9"!L:6%B:6QI='DN("!4:&4@ M0V]M<&%N>2!H87,@9&5T97)M:6YE9"!T:&%T(&QO6QE/3-$;&EN92UH96EG M:'0Z,3(P)3MT97AT+6%L:6=N.FIU6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN M9&5N=#HR-'!X.V9O;G0M2P@;VX@8F5H86QF(&]F(&$@<'5T871I=F4@8VQA2!W86=E2`R M,#$T+"!T:&4@4W5P97)I;W(@0V]U2!I6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M:6YD96YT.C(T M<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE($-O;7!A;GD@:7,@82!P87)T M>2!T;R!A(&YU;6)E'!E8W1E9"!T;R!H879E(&$@;6%T97)I86P@861V97)S92!E9F9E8W0@ M;VX@=&AE($-O;7!A;GDF(S@R,3<['0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO"!$:7-C;&]S=7)E(%M!8G-T'0^)SQD:78@'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M86QI9VXZ:G5S=&EF M>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M'!E;G-E(&]F(&QE3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN(&-O;G1I;G5I M;F<@;W!E3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&UO;G1H('!E6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY-87)C:"8C,38P.S,Q+"`R,#$T/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^(&%N9"`R,#$S(')E9FQE8W1I;F<@82!S=&%T92!T87@@;&EA M8FEL:71Y('1O(&]N92!S=&%T92X@($YO(&%M;W5N=',@=V5R92!R96-OF5D('1A>"!B96YE9FET6UE;G0@;V8@:6YT97)E3II;FAE3II;FAE3II;FAE#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE2!U;F1E&%M:6YA=&EO;B!B>2!T:&4@26YT97)N M86P@4F5V96YU92!397)V:6-E+B`@5&AE(')E;6%I;FEN9R!T87@@>65A&%M:6YA=&EO;B!A;F0@87-S97-S;65N="X@(%1A>"!Y96%R2!F;W(@<'5R<&]S M97,@;V8@9F5D97)A;"!A;F0@8V5R=&%I;B!S=&%T92!E>&%M:6YA=&EO;B!O M9B!N970@;W!E69O"!R971U2!B92!S=6)J96-T('1O M(&5X86UI;F%T:6]N(&9O65A#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE3II;FAE3II;FAE M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE3II;FAE3II;FAE3II;FAE3II;FAE3II;FAE M'0O:F%V87-C3X-"B`@("`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`R,#$S+B!);G1E6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)#`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`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$)W9E#MB;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^,BPY.#@\+V9O;G0^/"]D:78^/"]T9#X\=&0@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F%C:V=R;W5N9"UC;VQO#MP M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@"!S M;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M M6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.V)A8VMG6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@ M'0M86QI9VXZF4Z,3!P=#L^-BPT.#@\+V9O;G0^/"]D:78^/"]T9#X\=&0@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`C,#`P,#`P M.R<@'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY(97)I=&%G92!,86)S/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P.R<@'0M M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ M<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+7)I9VAT.C)P>#L@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$)W9E#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-2PQ M-3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE/3-$)W9E#MB;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+7)I9VAT.C)P>#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@F4Z M,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N M9"UC;VQO#MP861D:6YG+6)O='1O M;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3W!E#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^,3DV/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O M;3HR<'@[(')O=W-P86X],T0Q/CQD:78@#L@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#L@'0M86QI M9VXZ6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#$L-S(R/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+6)O='1O M;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*3PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^/'-U<"!S='EL93TS1'9E6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#(L M,#$Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I M=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAEF4Z,3!P=#L^8BD@56YA;&QO8V%T960@8V]R<&]R871E(&EN M8VQU9&5S('-E;&QI;F'0O:F%V M87-C3X-"B`@("`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`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`C,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)#`N,S@\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/"]D M:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG M/CQD:78@#MT97AT+6%L:6=N.FIU#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC M;VQO'0M9&5C;W)A=&EO;CIN;VYE.SYT:')E92!M;VYT M:#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.C$P<'0[/B!P97)I;V0@96YD960@/"]F;VYT/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY-87)C:"8C,38P.S,Q+"`R M,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^.CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN M92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.F-E;G1EF4Z,3!P M=#L^/&1I=B!S='EL93TS1'!A9&1I;F#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@ M'0M86QI9VXZF4Z,3!P=#L^,2XR,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S M='EL93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`C,#`P,#`P.R<@'0M86QI9VXZ:G5S M=&EF>3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,RPY.#8L-C`P/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ8V5N=&5R.V9O;G0MF4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@#MP861D:6YG+7)I9VAT.C)P>#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O M<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R M.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HQ<'@@#MB;W)D97(M=&]P M.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^,"XY.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#MB M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)#4Q/"]F;VYT/CPO9&EV/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS M<&%N/CPO6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT M+6EN9&5N=#HR-'!X.V9O;G0M"!E>'!E;G-E3II;FAE3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^36%R8V@F(S$V,#LS,2P@ M,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.C$P<'0[/BX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI M;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIJ=7-T:69Y.V9O;G0M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.F-E;G1EF4Z,3!P=#L^/&1I=B!S='EL93TS1'!A9&1I;F'0M86QI9VXZ;&5F=#LG/CQT#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0V('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#L@'0M M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0V M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\ M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[ M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ M<'@@#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^,C`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`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`@("`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`C,#`P,#`P.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E'0M86QI9VXZ6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^.3(\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@"!S;VQI M9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[8F%C M:V=R;W5N9"UC;VQO6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$=&5X="UA M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE"!S;VQI9"`C M,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E#MP M861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#LG(')O=W-P86X],T0Q/CQD:78@6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\9&EV('-T>6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\ M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`P.W!A9&1I;F#MP861D:6YG M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;FF4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M,C8W/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.R<@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X M.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N M9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I M;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,2!C M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[ M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`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`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E M9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*3PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R M;W5N9"UC;VQO#MP861D:6YG+7)I9VAT.C)P>#LG M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z M,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R M;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A M9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-68Y,C$W8E\X.3EB M7S1D9F-?.38T-E\X8S=B-C5C,S0Y968-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO.#5F.3(Q-V)?.#DY8E\T9&9C7SDV-#9?.&,W8C8U8S,T.65F M+U=O'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO2!396=M96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+69A M;6EL>3I4:6UE6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M M6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO3I4:6UE3II;FAE6QE/3-$;&EN92UH96EG M:'0Z,3(P)3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H M=#IN;W)M86P[<&%D9&EN9RUT;W`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`C,#`P,#`P.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ8V5N=&5R.V9O;G0M M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R M+71O<#HQ<'@@F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([ M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY(;V]P97(@ M2&]L;65S(%-E6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$)W9E#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$)W9E#MB M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^,BPU,C(\+V9O;G0^/"]D:78^/"]T9#X\=&0@"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M)W9E#MB;W)D97(M M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.V)A8VMG6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@ M'0M86QI9VXZF4Z,3!P=#L^,BPX-#<\+V9O;G0^/"]D:78^/"]T9#X\=&0@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#LG(')O M=W-P86X],T0Q/CQD:78@6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMGF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E6QE/3-$;W9E#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^,C`L,S0T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!S;VQI9"`C M,#`P,#`P.V)A8VMGF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO M9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAEF4Z,3!P=#L^82D@ M56YA;&QO8V%T960@8V]R<&]R871E(&EN8VQU9&5S('-E;&QI;F6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^36%R8V@F(S$V M,#LS,2P@,C`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`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$)W9E#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^-"PP-C0\+V9O;G0^/"]D:78^/"]T9#X\=&0@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ M<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R M+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M)W9E#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO M6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M"!S;VQI9"`C,#`P,#`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`@ M("`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`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA65E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`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`@("`\=&%B;&4@8VQA'0^)S4@>65A3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-68Y M,C$W8E\X.3EB7S1D9F-?.38T-E\X8S=B-C5C,S0Y968-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO.#5F.3(Q-V)?.#DY8E\T9&9C7SDV-#9?.&,W M8C8U8S,T.65F+U=O'0O:'1M;#L@8VAA&-E<'0@4VAA'0^)SQS<&%N/CPO'!I'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO&5R M8VES92!P&5R8VES92!P'0^)SQS<&%N/CPO&5R8VES86)L92!A="!-87)C:"`S,2P@,C`Q-#PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S8@>65A3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-68Y,C$W8E\X.3EB7S1D9F-?.38T M-E\X8S=B-C5C,S0Y968-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.#5F.3(Q-V)?.#DY8E\T9&9C7SDV-#9?.&,W8C8U8S,T.65F+U=O'0O:'1M;#L@8VAA M2`R,#`Y M($YO;BUV97-T960@4W1O8VL@07=A'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO&5R8VES92!P'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO7,\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO&EM=6T@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E(%-T;V-K(%!U'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E(%-T;V-K(%!U'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)S$P('EE M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`\=&%B;&4@ M8VQA2!$:7-P;W-A;"!''0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\X-68Y,C$W8E\X.3EB7S1D9F-?.38T-E\X8S=B-C5C,S0Y M968-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#5F.3(Q-V)?.#DY M8E\T9&9C7SDV-#9?.&,W8C8U8S,T.65F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@Q-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X M-68Y,C$W8E\X.3EB7S1D9F-?.38T-E\X8S=B-C5C,S0Y968-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#5F.3(Q-V)?.#DY8E\T9&9C7SDV-#9? M.&,W8C8U8S,T.65F+U=O'0O:'1M;#L@8VAA2!U;F1E2!!9W)E96UE;G0\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!;365M8F5R73PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2!!9W)E96UE;G1S(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6UE;G0@86=R965M96YT'0^)S$@>65A7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S69O M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO2!I;F-U2!H87,@ M;F]T(&%L;&]C871E9"!T;R!I=',@'1087)T7S@U9CDR,3=B7S@Y.6)?-&1F8U\Y-C0V7SAC-V(V-6,S-#EE %9BTM#0H` ` end XML 23 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Stock Option Valuation Assumptions (Details) (USD $)
3 Months Ended
Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Expected life (years) 5 years 2 months 27 days
Expected volatility 85.00%
Expected dividend yield 0.00%
Risk-free interest rate 1.80%
Weighted average fair value of options granted during the period $ 0.38
XML 24 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Employee Share-Based Compensation Plans (Details)
3 Months Ended 3 Months Ended 3 Months Ended 1 Months Ended
Mar. 31, 2014
Mar. 31, 2014
2008 Plan [Member]
Mar. 31, 2013
2008 Plan [Member]
Mar. 31, 2014
2011 Plan [Member]
Mar. 31, 2013
2011 Plan [Member]
May 29, 2013
2011 Plan [Member]
Mar. 31, 2014
Awards to Certain Employees [Member]
Mar. 31, 2014
Amended and Restated 2011 Plan [Member]
May 29, 2013
Amended and Restated 2011 Plan [Member]
Sep. 30, 2013
Director Stock Plan [Member]
Mar. 31, 2014
Director Stock Plan [Member]
Dec. 31, 2010
December 2010 Stock Option Award [Member]
Mar. 31, 2014
December 2010 Stock Option Award [Member]
Mar. 31, 2014
All Other Stock Option Awards [Member]
Number of shares authorized under the plan (in shares)   5,000,000       1,500,000     3,500,000   600,000      
Options granted (in shares) 462,600 162,600 0 300,000 0             500,000    
Remaining shares available for grant under the plan (in shares)   3,209,300           1,166,750     360,000      
Contractual life of stock options and other awards under share-based compensation plans   10 years   10 years                    
Option Vesting Schedule                            
Vesting percentage, grant date                     25.00%      
Vesting percentage, year one       25.00%     33.00%       25.00%   50.00% 0.00%
Vesting percentage, year two 33.00%     25.00%             25.00%   50.00% 25.00%
Vesting percentage, year three 33.00%     25.00%             25.00%     25.00%
Vesting percentage, year four       25.00%                   25.00%
Vesting percentage, year five                           25.00%
Aggregate shares granted             1,344,100     2,000,000        
XML 25 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Option Roll-Forward (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Stock Option Activity [Roll Forward]    
Outstanding balance (options) at December 31, 2013 4,150,550  
Options granted (in shares) 462,600  
Exercised (options) (37,500) 0
Expired (options) (505,550)  
Forfeited (options) (83,500)  
Outstanding balance (options) at March 31, 2014 3,986,600  
Outstanding balance (weighted average exercise price) at December 31, 2013 $ 0.75  
Granted (weighted average exercise price) $ 0.56  
Exercised (weighted averaged exercise price) $ 0.45  
Expired (weighted average exercise price) $ 1.20  
Forfeited (weighted average exercise price) $ 0.57  
Outstanding balance (weighted average exercise price) at March 31, 2014 $ 0.68  
Weighted Average Remaining Contractual Life, options outstanding 8 years 6 months  
Aggregate Intrinsic Value (in thousands), options outstanding $ 222  
Number of options exercisable at March 31, 2014 1,388,700  
Weighted average exercise price of options exercisable at March 31, 2014 $ 0.99  
Weighted Average Remaining Contractual Life, options exercisable 6 years 9 months 18 days  
Aggregate Intrinsic Value (in thousands), options exercisable $ 51  
XML 26 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Award Activity (Details) (USD $)
3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Feb. 27, 2013
Feb. 29, 2012
Mar. 31, 2014
Director Stock Plan [Member]
Sep. 30, 2013
Director Stock Plan [Member]
Mar. 31, 2013
Director Stock Plan [Member]
Mar. 31, 2014
Stock Options [Member]
Jul. 31, 2009
July 2009 Non-vested Stock Award [Member]
Mar. 31, 2014
July 2009 Non-vested Stock Award [Member]
Jul. 31, 2011
July 2011 Non-vested Stock Award [Member]
Mar. 31, 2014
July 2011 Non-vested Stock Award [Member]
Mar. 31, 2014
Non-Vested Stock Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award                          
Exercised (options) (37,500) 0                      
Exercised (weighted averaged exercise price) $ 0.45                        
Options vested in period 24,400                        
Aggregate fair value of options vested in period $ 10,000                        
Unrecognized compensation cost related to stock options               700,000          
Weighted average period for recognition of compensation cost               2 years         7 months 6 days
Unrecognized compensation cost                         0
Non-vested Stock Awards                          
Aggregate shares granted           2,000,000     500,000   305,000    
Grant date fair value                 $ 0.45   $ 1.06    
Aggregate shares that vested in the period                   150,000   155,100  
Aggregate shares of non-vested stock forfeited                   343,750   141,400  
Vesting Schedule for Equity Grants Other than Options                          
Vesting percentage, year one         25.00%         0.00%   33.00%  
Vesting percentage, year two 33.00%       25.00%         25.00%   33.00%  
Vesting percentage, year three 33.00%       25.00%         25.00%   34.00%  
Vesting percentage, year four                   25.00%      
Vesting percentage, year five                   25.00%      
ESPP                          
ESPP, number of shares authorized 2,000,000                        
ESPP, purchase date 13 months                        
ESPP, purchase price as percentage of market value 95.00%                        
ESPP, maximum subscription rate 10.00%                        
ESPP, maximum subscription amount 25,000                        
Shares issued during period, Employee Stock Purchase Plan     233,000 273,000                  
Aggregate Grant-Date Fair Value, Employee Stock Purchase Plan     30,000 50,000                  
Shares issued in accordance with plan termination provision 36,154 0                      
Other Stock Awards                          
Term over which grants will occur         10 years                
Number of shares authorized under the plan (in shares)         600,000                
Remaining shares available for grant under the plan (in shares)         360,000                
Number of shares awarded annually to non-employee board members other than the non-executive chair         5,000                
Number of shares awarded annually to non-executive chair of the board of directors         10,000                
Aggregate shares granted           2,000,000     500,000   305,000    
Number of shares awarded         0   0            
Share-based compensation expense $ 100,000 $ 200,000                      
XML 27 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
(Loss) Earnings Per Share
3 Months Ended
Mar. 31, 2014
Earnings Per Share [Abstract]  
(Loss) Earnings Per Share
(Loss) Earnings Per Share

Basic (loss) earnings per share equals net (loss) income divided by the weighted average common shares outstanding during the period.  Diluted (loss) earnings per share equals net (loss) income divided by the sum of the weighted average common shares outstanding during the period plus dilutive common stock equivalents. The calculation of (loss) earnings per common share on a basic and diluted basis was the same because the inclusion of dilutive common stock equivalents would have been anti-dilutive for all periods presented.

Outstanding stock options to purchase approximately 3,917,000 and 5,607,500 shares of the Company's common stock were excluded from the calculation of diluted loss per share for the three month periods ended March 31, 2014 and 2013, respectively, because their exercise prices exceeded the average market price of the Company's common stock for such periods and, therefore, were antidilutive.

XML 28 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations Operation Assets (Details) (USD $)
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Adjustment to gain on sale of Portamedic and subsidiary $ (150,000) $ 0
Portamedic Service Line [Member]
   
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Revenues 0 23,648,000
Gain (loss) from discontinued operations 30,000 (533,000)
Tax Effect of Discontinued Operation   $ 100,000
XML 29 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segments (Details) (USD $)
3 Months Ended
Mar. 31, 2014
segment
Mar. 31, 2013
Dec. 31, 2013
Segment Reporting Information [Line Items]      
Revenues $ 12,599,000 $ 12,359,000  
Operating income (loss) (2,514,000) (2,011,000)  
Segment assets 20,344,000   21,646,000
Number of reportable segments 3    
Intercompany eliminations [Member]
     
Segment Reporting Information [Line Items]      
Revenues 500,000    
Health & Wellness [Member]
     
Segment Reporting Information [Line Items]      
Revenues 7,089,000 5,150,000  
Operating income (loss) 497,000 (15,000)  
Segment assets 7,223,000    
Heritage Labs [Member]
     
Segment Reporting Information [Line Items]      
Revenues 2,522,000 3,145,000  
Operating income (loss) 338,000 196,000  
Segment assets 3,786,000    
Hooper Holmes Services [Member]
     
Segment Reporting Information [Line Items]      
Revenues 2,988,000 4,064,000  
Operating income (loss) (62,000) (470,000)  
Segment assets 2,847,000    
Unallocated Corporate [Member]
     
Segment Reporting Information [Line Items]      
Revenues 0 0  
Operating income (loss) (3,287,000) [1] (1,722,000) [2]  
Segment assets 6,488,000    
Selling, General and Administrative Expenses [Member]
     
Segment Reporting Information [Line Items]      
Relocation costs $ 1,100,000    
[1] Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments. For the three month period ended March 31, 2014, the Company incurred $1.1 million of costs, which are recorded in unallocated corporate in the table above in connection with the relocation of its corporate headquarters to Olathe, Kansas.
[2] Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments.
XML 30 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2014
Dec. 31, 2013
ASSETS    
Cash and cash equivalents $ 2,667 $ 3,970
Accounts receivable, net of allowance for doubtful accounts of $124 and $153 at March 31, 2014 and December 31, 2013, respectively 9,099 8,398
Inventories 1,457 1,376
Other current assets 1,650 1,597
Assets held for sale 714 714
Total current assets 15,587 16,055
Property, plant and equipment 16,345 16,018
Less: Accumulated depreciation and amortization 12,617 12,257
Property, plant and equipment, net 3,728 3,761
Other assets 1,029 1,830
Total assets 20,344 21,646
LIABILITIES AND STOCKHOLDERS' EQUITY    
Accounts payable 3,234 3,440
Accrued expenses 5,605 4,036
Total current liabilities 8,839 7,476
Other long-term liabilities 796 870
Commitments and contingencies (Note 10)      
Stockholders' Equity:    
Common stock, par value $.04 per share; Authorized: 240,000,000 shares; Issued: 70,420,044 shares and 70,382,544 shares at March 31, 2014 and December 31, 2013, respectively; Outstanding: 70,410,649 shares and 70,373,149 shares at March 31, 2014 and December 31, 2013, respectively. 2,817 2,815
Additional paid-in capital 150,327 150,235
Accumulated deficit (142,364) (139,679)
Stockholders' equity 10,780 13,371
Less: Treasury stock, at cost; 9,395 shares at March 31, 2014 and December 31, 2013 (71) (71)
Total stockholders' equity 10,709 13,300
Total liabilities and stockholders' equity $ 20,344 $ 21,646
XML 31 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation
3 Months Ended
Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation

Hooper Holmes, Inc. (“Hooper Holmes” or the "Company”) mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, insurance companies, employers, government organizations and academic institutions. The Company also conducts laboratory testing, assembles collection kits, conducts telephone interviews of life insurance applicants, compiles health histories, collects medical records and provides underwriting services to help life insurance companies evaluate underwriting risks.

As a provider of services to the health and insurance industries, the Company's business is subject to seasonality, with second and third quarter sales typically dropping below the other quarters due to a decline in activity during the summer months and fourth quarter sales typically the strongest quarter due to annual benefit renewal cycles.

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2013 Annual Report on Form 10-K, filed with the SEC on March 31, 2014.

Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented.

The results of operations for the three month periods ended March 31, 2014 and 2013 are not necessarily indicative of the results to be expected for any other interim period or the full year. See “Management's Discussion and Analysis of Financial Condition and Results of Operations” for additional information.

On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. For further discussion on Discontinued Operations, refer to Note 6.

Following the sale of the Portamedic service line, the Company reassessed its segment reporting. Beginning in the fourth quarter of 2013, the Company has reported its financial results in three segments: Health and Wellness, Heritage Labs and Hooper Holmes Services. Previously reported financial statement amounts have been reclassified to reflect the new segment determination for all periods presented in this Report. For further discussion on Segments, refer to Note 13.

Subsequent Events

On April 16, 2014, the Company entered into a Strategic Alliance Agreement (the “Alliance Agreement”) with Clinical Reference Laboratory, Inc. (“CRL”) pursuant to which, among other things, the Company has agreed to sell certain assets comprising the Company’s Heritage Labs and Hooper Holmes Services business units (the “Business”) to CRL. Under the terms of the Alliance Agreement, CRL has agreed to pay $3.7 million in cash (the “Purchase Price”) for certain assets of the Business, which such assets exclude, among others, all accounts receivable, and to assume specified liabilities related to the Business. The net book value of assets to be sold was approximately $1.5 million as of March 31, 2014, consisting primarily of inventory and property, plant and equipment, qualified as assets held for sale subsequent to March 31, 2014. The transaction is expected to close in the late second quarter or early third quarter of 2014. The Company will retain certain aspects of its sample kit assembly operations centering around the Health and Wellness segment and all other supply chain fulfillment capabilities, which continue to support Health and Wellness operations and other customers.

The Company also entered into a Limited Laboratory and Administrative Services Agreement (the “LLASA”) with CRL pursuant to which, among other things, CRL will become the Company’s exclusive provider, subject to certain exceptions, of laboratory testing and reporting services and will also provide administrative services in support of the Company’s Health and Wellness operations. The Company will become a member of CRL’s preferred provider network for wellness programs during the term of the LLASA. The LLASA will become effective upon the closing of the transaction contemplated by the Alliance Agreement (the “Effective Date”), and will continue for five years from such date and auto-renew for an additional five year renewal period unless sooner terminated by either party in accordance with the LLASA.

On May 13, 2014, the Company entered into a Purchase and Sale Agreement (the “Purchase and Sale Agreement”) for the sale to McElroy Deutsch Mulvaney & Carpenter, LLP (the “MDMC”) of the buildings, land, certain personal property and other interests comprising the Company’s Basking Ridge, New Jersey property (the “Property”) for an aggregate purchase price of $3.05 million (the “Purchase Price”). Upon entering into the Purchase and Sale Agreement, MDMC made an initial deposit of $75,000 of the Purchase Price with an escrow agent and will deposit an additional $75,000 of the Purchase Price with the escrow agent following the completion of a 40-day inspection period (the “Inspection Period”). The remaining $2.9 million of the Purchase Price will be paid by MDMC to the Company at the closing. Subject to satisfaction of customary closing conditions, the closing is expected to occur five days after the end of the Inspection Period but no later than July 11, 2014. The deposit is refundable to MDMC in certain circumstances. The Basking Ridge real estate was classified as assets held for sale as of March 31, 2014.

New Accounting Pronouncements

In April 2014, accounting guidance was issued to change the criteria for reporting discontinued operations. Under the new guidance, only disposals of components of an entity that represent strategic shifts that have, or will have, a major effect on an entity’s operations should be reported as discontinued operations in the financial statements. Additionally, the new guidance removes the condition that an entity may not have any significant continuing involvement in the operations of the component after the disposal transaction. The new guidance requires expanded disclosures for discontinued operations, as well as disclosures about the financial effects of significant disposals that do not qualify for discontinued operations. The guidance will be effective for the Company on January 1, 2015, however early adoption is permitted. The Company currently expects to early adopt this accounting guidance in its second fiscal quarter of 2014 concurrent with meeting the criteria for assets held for sale of the Company’s Heritage Labs and Hooper Holmes Services segments.
XML 32 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Charges (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges, Discontinued Operations $ 677  
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 946  
Restructuring charges 92 4
Payments (361)  
Restructuring reserve, ending balance 677  
Employee Severance [Member]
   
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 531  
Restructuring charges 92  
Payments (213)  
Restructuring reserve, ending balance 410  
Facility Closing - Branch Office Closure [Member]
   
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 415  
Restructuring charges 0  
Payments (148)  
Restructuring reserve, ending balance $ 267  
XML 33 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Charges (Tables)
3 Months Ended
Mar. 31, 2014
Restructuring Charges [Abstract]  
Restructuring and Related Costs
The following table provides a summary of the activity in the restructure accrual for the three months ended March 31, 2014:

 
As of
 
 
 
 
 
As of
(In thousands)
December 31, 2013
 
Charges
 
Payments
 
March 31, 2014
Severance
$
531

 
$
92

 
$
(213
)
 
$
410

Branch closure obligation
415

 

 
(148
)
 
267

     Total
$
946

 
$
92

 
$
(361
)
 
$
677

XML 34 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
Loan and Security Agreements (Details) (USD $)
3 Months Ended
Mar. 31, 2014
Loan and Security Agreements [Line Items]  
Maximum borrowing capacity under Loan and Security Agreement $ 10,000,000
Loan maximum defined, based on eligible receivables 85.00%
Loan maximum defined, based on eligible receivables, reserve 500,000
Additional borrowing availability under Loan and Security Agreement 3,100,000
Borrowings outstanding under Loan and Security Agreement 0
Interest rate, stated percentage 6.00%
Unused Capacity, Commitment Fee Percentage 1.00%
Commitment fee $ 10,000
Prime rate [Member]
 
Loan and Security Agreements [Line Items]  
Spread on variable rate 2.75%
LIBOR 90 day rate [Member]
 
Loan and Security Agreements [Line Items]  
Spread on variable rate 5.25%
Prior to second anniversary [Member]
 
Loan and Security Agreements [Line Items]  
Credit facility - early termination fee 3.00%
Prior to third anniversary [Member]
 
Loan and Security Agreements [Line Items]  
Credit facility - early termination fee 2.00%
XML 35 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation (Details) (Subsequent Event [Member], USD $)
0 Months Ended 0 Months Ended
Apr. 16, 2014
Apr. 16, 2014
Strategic Alliance Agreement Assets [Member]
Mar. 31, 2014
Strategic Alliance Agreement Assets [Member]
May 13, 2014
Purchase and Sale Agreement Property [Member]
Apr. 16, 2014
Purchase and Sale Agreement Property [Member]
Subsequent Event [Line Items]          
Consideration amount   $ 3,700,000   $ 3,050,000 $ 3,050,000
Disposal Group, Including Discontinued Operation, Initial Deposit with Escrow Agent       75,000  
Disposal Group, Including Discontinued Operation, Deposit to Escrow Agent Receivable Upon Completion of Inspection       75,000  
Assets of Disposal Group, Including Discontinued Operation     1,500,000    
Agreement Period 5 years        
Additional Agreement Period 5 years        
Inspection Period Related to Purchase and Sale Agreement       40 days  
Disposal Group, Including Discontinued Operation, Remaining Receivable Upon Closing       $ 2,900,000  
Closing Period Subsequent to Inspection Period       5 days  
XML 36 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 37 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Liquidity
3 Months Ended
Mar. 31, 2014
Liquidity [Abstract]  
Liquidity
Liquidity

The Company's primary sources of liquidity are cash and cash equivalents and the 2013 Loan and Security Agreement. At March 31, 2014, the Company had $2.7 million in cash and cash equivalents, $6.7 million of working capital and no outstanding debt.

For the three month periods ended March 31, 2014 and 2013, the Company incurred losses from continuing operations of $2.6 million and $2.0 million, respectively. The Company’s net cash used in operating activities for the three months ended March 31, 2014 was $1.7 million. The Company has managed its liquidity through the sale of Portamedic and a series of cost reduction and accounts receivable collection initiatives.

Transition Initiatives

During the three month period ended March 31, 2014, the Company incurred $1.1 million of costs, which are recorded in selling, general and administrative expenses in the consolidated statement of operations, in connection with the relocation of its corporate headquarters to Olathe, Kansas, and contributed to the loss from continuing operations during the quarter. The Company relocated its headquarters to Olathe, Kansas during the first quarter of 2014, where the Health and Wellness facilities are located. As of March 31, 2014, the Basking Ridge, New Jersey real estate continued to be classified as assets held for sale. On May 13, 2014, the Company entered into an agreement for the sale of the Basking Ridge, New Jersey real estate.
 
Holdback Related to the Sale of Portamedic

On September 30, 2013, the Company completed the sale of Portamedic. Approximately $2.0 million (“Holdback Amount”) of the purchase price was held back by the acquirer as security for the Company’s obligations under the agreements between the Company and the acquirer. (Refer to Note 6). The Holdback Amount includes two components of $1.0 million each. During the first quarter of 2014, the Company received $0.7 million of the first Holdback Amount. The Company currently anticipates finalization and collection on the second Holdback Amount in the first quarter of 2015. The Company has recorded the remaining receivable related to the second Holdback Amount at the amount it believes will be collected. There cannot be any assurance that the remaining Holdback Amounts will be collected by the Company.

2013 Loan and Security Agreement
    
The Company maintains a three year 2013 Loan and Security Agreement, as amended, (collectively, the “2013 Loan and Security Agreement”), with Keltic Financial Partners II, LP (“Keltic Financial”) (refer to Note 9). Borrowings under the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The amount available for borrowing may be less than the $10 million under this facility at any given time due to the manner in which the maximum available amount is calculated.  The Company has an available borrowing base subject to reserves established at the lender's discretion of 85% of Eligible Receivables (as defined in the 2013 Loan and Security Agreement) up to $10 million under this facility.   Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, and other receivables deemed ineligible by the lender. Eligible Receivables include only billed receivables and concentration limits such that borrowing capacity may be affected by the Company's billing and revenue cycles. As of March 31, 2014, the lender applied a discretionary reserve of $0.5 million. Available borrowing capacity, net of this discretionary reserve was $3.1 million based on Eligible Receivables as of March 31, 2014. As of March 31, 2014, there were no borrowings outstanding under the 2013 Loan and Security Agreement.

The Company is also working with Keltic Financial to modify the financial covenants of the 2013 Loan and Security Agreement in an effort to be more in-line with the Company's operations and strategy going forward. If the Company is not able to successfully execute favorable amendments to the existing credit facility, the Company's borrowing capacity may be limited.

The 2013 Loan and Security Agreement contains various covenants, including financial covenants which required the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The lender recently waived the quarterly minimum EBITDA covenants for the fiscal period ended December 31, 2014. The Company continues to have limitations on the maximum amount of unfunded capital expenditures for each fiscal year.

Subsequent Events

On April 16, 2014 under the Alliance Agreement (refer to Note 1), CRL has agreed to pay $3.7 million in cash for certain assets of the Business, which such assets exclude, among others, all accounts receivable, and to assume specified liabilities related to the Business. The Company will retain certain aspects of its sample kit assembly operations centering around the Health and Wellness segment and all other supply chain fulfillment capabilities, which continue to support Health and Wellness operations and other customers.

On May 13, 2014 under the Purchase and Sale Agreement (refer to Note 1), MDMC has agreed to pay $3.05 million in cash for the Property.

These transactions will provide the Company with additional capital to invest as it focuses on growth supporting Health and Wellness operations.

Other Considerations

The Company's Health and Wellness business sells through wellness, disease management and insurance companies who ultimately have the relationship with the end customer. The Company's current services are aggregated with its partners' offerings to provide a total solution. As such, the Company's success is largely dependent on that of its partners.

Through the focus on the Health and Wellness sector, the Company believes it will be able to capitalize on the opportunities that exist in the Health and Wellness sector given the macro-economic focus on health care costs and improving the efficiency of health care delivery in the United States to grow revenue.
    
If the Company is not able to realize the benefits from the consolidation in Kansas and control the costs of transition, grow the Health and Wellness business as it seeks to streamline operations and improve efficiency through increased revenue and cost reduction initiatives, the Company may not have sufficient Eligible Receivables and the lender may increase reserves such that the Company may not be able to borrow under the 2013 Loan and Security Agreement. These and other factors could adversely affect liquidity and the Company's ability to generate cash flow in the future.

Based on the Company's anticipated level of future revenues and gross profits, anticipated cost reduction initiatives, cash proceeds in connection with the Alliance Agreement, the sale of the Basking Ridge, New Jersey real estate, and existing cash and cash equivalents and borrowing capacity, the Company believes it has sufficient funds to meet its cash needs to fund operation expenses and capital expenditures for the twelve months following March 31, 2014.
XML 38 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheet (Parentheticals) (USD $)
In Thousands, except Share data, unless otherwise specified
Mar. 31, 2014
Dec. 31, 2013
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 124 $ 153
Common stock, par value (in dollars per share) $ 0.04 $ 0.04
Common stock, shares authorized (in shares) 240,000,000 240,000,000
Common stock, shares issued (in shares) 70,420,044 70,382,544
Common stock, shares outstanding (in shares) 70,410,649 70,373,149
Treasury stock (in shares) 9,395 9,395
XML 39 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes
3 Months Ended
Mar. 31, 2014
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes

The Company recorded tax expense of less than $0.01 million in continuing operations for each of three month periods ended March 31, 2014 and 2013 reflecting a state tax liability to one state. No amounts were recorded for unrecognized tax benefits or for the payment of interest and penalties during the three month periods ended March 31, 2014 and 2013. No federal or state tax benefits were recorded relating to the current year loss, as the Company continues to believe that a full valuation allowance is required on its net deferred tax assets.
The 2011 federal income tax return is currently under examination by the Internal Revenue Service. The remaining tax years 2010 through 2013 may be subject to federal examination and assessment. Tax years from 2006 through 2009 remain open solely for purposes of federal and certain state examination of net operating loss and credit carryforwards. State income tax returns may be subject to examination for tax years 2009 through 2013, depending on state tax statute of limitations.

As of December 31, 2013, the Company has U.S. federal and state net operating loss carryforwards of $140.0 million and $127.2 million, respectively. There has been no significant change in these balances as of March 31, 2014. The net operating loss carryforwards, if unutilized, will expire in the years 2014 through 2033.
XML 40 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEI Document
3 Months Ended
Mar. 31, 2014
Apr. 30, 2014
DEI [Abstract]    
Entity Registrant Name HOOPER HOLMES INC  
Entity Central Index Key 0000741815  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Document Type 10-Q  
Document Period End Date Mar. 31, 2014  
Document Fiscal Year Focus 2014  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   70,410,649
XML 41 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segments
3 Months Ended
Mar. 31, 2014
Segment Reporting [Abstract]  
Segments
Segments

Following the sale of the Portamedic service line, the Company reassessed its segment reporting to align with the information that the Company's chief operating decision maker regularly reviews since the sale of Portamedic. Beginning in the fourth quarter of 2013, the Company reports financial results in three segments: Health and Wellness (health risk assessments including biometric screenings), Heritage Labs (laboratory testing and kit assembly for third parties) and Hooper Holmes Services (health information services). Financial statement amounts have been recast to reflect the new segment determination for all periods presented in this Report, including certain revenues and costs previously reported as a part of discontinued Portamedic operations which have been reclassified to Hooper Holmes Services to conform to current period presentation. The determination of segment assets involves a degree of management judgment and estimates as the Company has not historically prepared balance sheets by service line. Segment asset information is not provided as of March 31, 2013, as previously indicated, the Company reported one segment through September 30, 2013 and did not historically separate working capital by service line. As of March 31, 2014, substantially all of the Company's services are provided within the United States, and substantially all of the Company's assets are located within the United States.

The table presented below provides disclosures by segment for the three month periods ended March 31, 2014 and 2013. Intercompany revenue for the three month periods ended March 31, 2013 was $0.5 million, representing Heritage Lab revenue for kit sales to the discontinued Portamedic operations at arms' length sales prices. Heritage Lab also performs services to Health and Wellness. These services are recorded at Heritage Labs' cost directly within the Health and Wellness segment, and thus, no intercompany elimination is required.

Three Months Ended March 31, 2014
Health and Wellness
Heritage Labs
Hooper Holmes Services
Unallocated Corporate
 
Total
Revenues
$
7,089

$
2,522

$
2,988

$

 
$
12,599

Operating income (loss)
497

338

(62
)
(3,287
)
(a) 
(2,514
)
Segment assets
7,223

3,786

2,847

6,488

 
20,344

 
 
 
 
 
 
 
a) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments. For the three month period ended March 31, 2014, the Company incurred $1.1 million of costs, which are recorded in unallocated corporate in the table above in connection with the relocation of its corporate headquarters to Olathe, Kansas.
Three Months Ended March 31, 2013
Health and Wellness
Heritage Labs
Hooper Holmes Services
Unallocated Corporate
 
Total
Revenues
$
5,150

$
3,145

$
4,064

$

 
$
12,359

Operating income (loss)
(15
)
196

(470
)
(1,722
)
(b) 
(2,011
)

b) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments.
XML 42 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations (unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Income Statement [Abstract]    
Revenues $ 12,599 $ 12,359
Cost of operations 9,985 9,160
Gross profit 2,614 3,199
Selling, general and administrative expenses 5,036 5,206
Restructuring charges 92 4
Operating loss from continuing operations (2,514) (2,011)
Other expense:    
Interest expense (1) (2)
Interest income 1 3
Other expense, net (46) (13)
Other expense (46) (12)
Loss from continuing operations before income taxes (2,560) (2,023)
Income tax expense 5 4
Loss from continuing operations (2,565) (2,027)
Discontinued operations:    
Adjustment to gain on sale of Portamedic and subsidiary (150) 0
Gain (loss) from discontinued operations, including income taxes 30 (533)
Loss from discontinued operations (120) (533)
Net loss $ (2,685) $ (2,560)
Continuing operations    
Basic (in dollars per share) $ (0.04) $ (0.03)
Diluted (in dollars per share) $ (0.04) $ (0.03)
Discontinued operations    
Basic (in dollars per share) $ 0.00 $ (0.01)
Diluted (in dollars per share) $ 0.00 $ (0.01)
Net loss    
Basic (in dollars per share) $ (0.04) $ (0.04)
Diluted (in dollars per share) $ (0.04) $ (0.04)
Weighted average number of shares - Basic (in shares) 70,410,649 69,835,387
Weighted average number of shares - Diluted (in shares) 70,410,649 69,835,387
XML 43 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories
3 Months Ended
Mar. 31, 2014
Inventory Disclosure [Abstract]  
Inventories
Inventories

Included in inventories at March 31, 2014 and December 31, 2013 are $0.6 million and $0.4 million, respectively, of finished goods and $0.8 million and $1.0 million, respectively, of components.
XML 44 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations
3 Months Ended
Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations
Discontinued Operations

On September 30, 2013, the Company completed the sale of certain assets comprising the Portamedic service line to Piston Acquisition, Inc., a subsidiary of American Para Professional Systems, Inc., (“Piston”). Pursuant to the terms of the Asset Purchase Agreement, the Company sold assets associated with the Portamedic service line to Piston, including, among other things, fixed assets, inventory and intellectual property, and Piston assumed certain specified liabilities. The adjusted purchase price (the "Purchase Price") was approximately $8.1 million in cash, adjusted from $8.4 million at announcement due to changes in working capital. Piston held back $2.0 million of the Purchase Price as security for the obligations under the Asset Purchase Agreement and certain other agreements between the Company and Piston.

The Holdback Amount includes two components. The first holdback is $1.0 million, subject to adjustments, and is released in total as follows: within three business days after the date on which final closing adjustments for inventory and other current assets are determined and paid (the “Closeout Date”). The remaining $1.0 million of the Holdback Amount, less any deductions or adjustments with respect to fixed assets, indemnification claims and any amounts in respect of any indemnification claims then in dispute, will be paid on the first anniversary of the Closeout Date. During the first quarter of 2014, the Company received $0.7 million of the first Holdback Amount. As a result, the amount remaining related to the first Holdback Amount was written off during the three months ended March 31, 2014 as a charge to the adjustment to gain on sale of Portamedic and subsidiary in the statement of operations. The Company has recorded the receivable related to the second Holdback Amount at the amount it believes will be collected. There cannot be any assurance that the remaining the Holdback Amounts will be collected by the Company. The Company currently anticipates finalization and collection on the second Holdback Amount in the first quarter of 2015.

The table below summarizes the operating results of Portamedic which are reported in discontinued operations in the accompanying consolidated statement of operations. Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than $0.1 million for the three month period ended March 31, 2013.

 
Three Months Ended
 
March 31
(in thousands)
2014
2013
Revenues
$

$
23,648

Gain (loss) from discontinued operations
$
30

$
(533
)
Adjustment to gain on sale of Portamedic and subsidiary
$
(150
)
$


    
As of March 31, 2014, the Basking Ridge, New Jersey real estate continued to be classified as assets held for sale as the Board authorized the sale of the real estate during the fourth quarter of 2013. The land and building owned in Basking Ridge, New Jersey of $0.7 million are recorded as assets held for sale at March 31, 2014 and December 31, 2013. On May 13, 2014, the Company entered into an agreement for the sale of the Basking Ridge, New Jersey real estate.
XML 45 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segments (Tables)
3 Months Ended
Mar. 31, 2014
Segment Reporting [Abstract]  
Revenue by Segment
The table presented below provides disclosures by segment for the three month periods ended March 31, 2014 and 2013. Intercompany revenue for the three month periods ended March 31, 2013 was $0.5 million, representing Heritage Lab revenue for kit sales to the discontinued Portamedic operations at arms' length sales prices. Heritage Lab also performs services to Health and Wellness. These services are recorded at Heritage Labs' cost directly within the Health and Wellness segment, and thus, no intercompany elimination is required.

Three Months Ended March 31, 2014
Health and Wellness
Heritage Labs
Hooper Holmes Services
Unallocated Corporate
 
Total
Revenues
$
7,089

$
2,522

$
2,988

$

 
$
12,599

Operating income (loss)
497

338

(62
)
(3,287
)
(a) 
(2,514
)
Segment assets
7,223

3,786

2,847

6,488

 
20,344

 
 
 
 
 
 
 
a) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments. For the three month period ended March 31, 2014, the Company incurred $1.1 million of costs, which are recorded in unallocated corporate in the table above in connection with the relocation of its corporate headquarters to Olathe, Kansas.
Three Months Ended March 31, 2013
Health and Wellness
Heritage Labs
Hooper Holmes Services
Unallocated Corporate
 
Total
Revenues
$
5,150

$
3,145

$
4,064

$

 
$
12,359

Operating income (loss)
(15
)
196

(470
)
(1,722
)
(b) 
(2,011
)

b) Unallocated corporate includes selling, general and administrative costs that the Company has not allocated to its segments.
XML 46 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation (Policies)
3 Months Ended
Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2013 Annual Report on Form 10-K, filed with the SEC on March 31, 2014.

Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented.

The results of operations for the three month periods ended March 31, 2014 and 2013 are not necessarily indicative of the results to be expected for any other interim period or the full year. See “Management's Discussion and Analysis of Financial Condition and Results of Operations” for additional information.
Discontinued Operations
On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented.
XML 47 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies
3 Months Ended
Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies

The Company leases its corporate headquarters in Olathe, Kansas, continuing laboratory facility and operations centers under operating leases which expire in various years through 2018. These leases generally contain renewal options and require the Company to pay all executory costs (such as property taxes, maintenance and insurance). The Company also leases copiers and other miscellaneous equipment. These leases expire in various years through 2017.

The Company is still the primary lessee under operating leases for 12 Portamedic branch offices with terms extending through September 2016, which are subleased by the acquirer of the former Portamedic business. The acquirer pays 100% of the rent and other executory costs for these 12 offices in the form of a contractual obligation for the remaining lease term. If the Company is unable to assign these leases to the acquirer of the former Portamedic business, the Company will let the leases expire with no intent of renewal.

In addition, the Company is still the primary lessee under 17 operating leases related to former Portamedic offices not utilized for continuing operations, which are not subleased by the acquirer of the former Portamedic business. The Company has accrued in previous periods approximately $0.3 million as branch closure obligations. The accrual is included as a component of the restructure reserve in the consolidated balance sheet as of March 31, 2014.

The Company has employment agreements with its Chief Executive Officer and Chief Financial Officer that provide for payment of base salary for a one year period in the event their employment with the Company is terminated in certain circumstances, including following a change in control, as further defined in the agreements.

In the past, some federal and state agencies have claimed that the Company improperly classified its health professionals as independent contractors for purposes of federal and state unemployment and/or worker's compensation tax laws and that the Company was therefore liable for taxes in arrears, or for penalties for failure to comply with their interpretation of the laws.  There are no assurances that the Company will not be subject to similar claims in the future. The Company has determined that losses related to the remaining complaint are not probable or estimable.
XML 48 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Charges
3 Months Ended
Mar. 31, 2014
Restructuring Charges [Abstract]  
Restructuring Charges
Restructuring Charges

During the three month periods ended March 31, 2014, the Company recorded restructuring charges in continuing operations totaling $0.1 million. The restructuring charges for the three month period ended March 31, 2014 consisted of employee severance.

At March 31, 2014, there was a total of $0.7 million related to restructuring charges, including employee severance and branch closure costs, are recorded in accrued expenses in the accompanying consolidated balance sheet. The following table provides a summary of the activity in the restructure accrual for the three months ended March 31, 2014:

 
As of
 
 
 
 
 
As of
(In thousands)
December 31, 2013
 
Charges
 
Payments
 
March 31, 2014
Severance
$
531

 
$
92

 
$
(213
)
 
$
410

Branch closure obligation
415

 

 
(148
)
 
267

     Total
$
946

 
$
92

 
$
(361
)
 
$
677

XML 49 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Loan and Security Agreements
3 Months Ended
Mar. 31, 2014
Debt Disclosure [Abstract]  
Loan and Security Agreements
Loan and Security Agreement

The Company maintains a three year 2013 Loan and Security Agreement, as amended on March 28, 2013 by the First Amendment, with Keltic Financial. Borrowings under the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The amount available for borrowing may be less than the $10 million under this facility at any given time due to the manner in which the maximum available amount is calculated.  The Company has an available borrowing base subject to reserves established at the lender's discretion of 85% of Eligible Receivables up to $10 million under this facility.  Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, and other receivables deemed ineligible by Keltic Financial. Eligible Receivables include only billed receivables such that borrowing capacity may be affected by the Company's billing cycles. As of March 31, 2014, the lender applied a discretionary reserve of $0.5 million. Available borrowing capacity, net of this discretionary reserve was $3.1 million based on Eligible Receivables as of March 31, 2014. As of March 31, 2014, there were no borrowings outstanding under the 2013 Loan and Security Agreement.

Interest on revolving credit loans is calculated based on the greatest of (i) the annualized prime rate plus 2.75%, (ii) the 90 day LIBOR rate plus 5.25%, and (iii) 6% per annum. The interest rate on the 2013 Loan and Security Agreement was 6.00% as of March 31, 2014. The Company is obligated to pay, on a monthly basis in arrears, an annual facility fee equal to 1% of the revolving credit limit of $10 million. During the three month periods ended March 31, 2014 and 2013, in connection with the 2013 Loan and Security Agreement, the Company incurred $0.01 million in facility fees.

The revolving credit loans are payable in full, together with all accrued interest and fees, on February 28, 2016. The 2013 Loan and Security Agreement provides for the prepayment of the entire outstanding balance of the revolving credit loans. The Company would be required to pay an early termination fee equal to 3% of the revolving credit limit if the termination occurs prior to February 28, 2015, and 2% if the termination occurs after February 28, 2015 but prior to February 28, 2016.

As security for payment and other obligations under the 2013 Loan and Security Agreement, the Company granted Keltic Financial a security interest in all of its, and its subsidiary guarantors, existing and after-acquired property, including receivables (which are subject to a lockbox account arrangement), inventory, equipment and the Basking Ridge, New Jersey real estate.  The aforementioned security interest is collectively referred to herein as the “collateral”.

The 2013 Loan and Security Agreement contains various covenants, including financial covenants which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The lender recently waived the quarterly minimum EBITDA covenants for the fiscal period ended December 31, 2014. The Company continues to have limitations on the maximum amount of unfunded capital expenditures for each fiscal year.
XML 50 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Litigation
3 Months Ended
Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]  
Litigation
Litigation

On April 23, 2012, a complaint was filed against the Company in U.S. District Court for the District of New Jersey on behalf of a purported class of employee examiners alleging, among other things, that the Company had failed to pay overtime compensation to certain employees as required by federal law. On May 24, 2012, a related complaint was filed against the Company in the same court alleging, among other things, that the Company similarly failed to pay overtime compensation to a purported class of certain independent contractor examiners who, the complaint alleges, should be treated as employees for purposes of federal law. The complaints seek award of an unspecified amount of allegedly unpaid overtime wages to certain examiners. The Company believes the allegations in the cases are without merit, has filed answers in both cases denying the substantive allegations therein. By Consent Order filed March 11, 2013, the court approved a settlement of $0.05 million between the Company and the named plaintiffs in the employee case, and the case was dismissed with prejudice. Preliminary discovery and motion practice are being conducted in the contractor case. The claim is not covered by insurance, and the Company is incurring legal costs to defend the litigation which are recorded in continuing operations. This matter relates to the former Portamedic service line for which the Company retained liability. The Company has determined that losses related to the remaining complaint are not probable or estimable.

On July 30, 2013, a complaint was filed against the Company in the California Superior Court, San Bernadino County, on behalf of a putative class of employees alleging, among other things, that the Company failed to pay wages and other compensation as required by state law. The complaint seeks award of an unspecified amount of damages and penalties. The Company has denied all of the allegations in the case and believes them to be without merit. In January 2014, the Superior Court referred the parties to mediation and a mediation date of July 17, 2014 is scheduled. The Superior Court also set a trial date of August 10, 2015. The Company has determined that the losses related to these matters are not probable or estimable. The claim is not covered by insurance, and as a result, the Company is incurring legal costs to defend the litigation.

The Company is a party to a number of other legal actions arising in the ordinary course of its business. In the opinion of management, the Company has substantial legal defenses and/or insurance coverage with respect to all of its pending legal actions. Accordingly, none of these actions is expected to have a material adverse effect on the Company’s liquidity, its consolidated results of operations or its consolidated financial position.
XML 51 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Details) (USD $)
In Millions, unless otherwise specified
Mar. 31, 2014
Dec. 31, 2013
Inventory Disclosure [Abstract]    
Finished goods $ 0.6 $ 0.4
Components $ 0.8 $ 1.0
XML 52 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations (Tables)
3 Months Ended
Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Discontinued Operations
The table below summarizes the operating results of Portamedic which are reported in discontinued operations in the accompanying consolidated statement of operations. Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than $0.1 million for the three month period ended March 31, 2013.

 
Three Months Ended
 
March 31
(in thousands)
2014
2013
Revenues
$

$
23,648

Gain (loss) from discontinued operations
$
30

$
(533
)
Adjustment to gain on sale of Portamedic and subsidiary
$
(150
)
$

XML 53 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
(Loss) Earnings Per Share (Details) (Stock Options [Member])
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Stock Options [Member]
   
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of EPS (in shares) 3,917,000 5,607,500
XML 54 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (unaudited) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Cash flows from operating activities:    
Net loss $ (2,685) $ (2,560)
Adjustments to reconcile net loss to net cash used in operating activities:    
Adjustment to gain on sale of Portamedic and subsidiary 150 0
Depreciation and amortization 360 646
Amortization of deferred financing fees 83 0
Provision for bad debt expense (30) 26
Share-based compensation expense 77 235
Impairment of long-lived assets and loss on disposal of fixed assets 0 123
Change in assets and liabilities:    
Accounts receivable (672) (1,742)
Inventories (81) (102)
Other assets (229) (502)
Accounts payable, accrued expenses and other liabilities 1,292 720
Net cash used in operating activities (1,735) (3,156)
Cash flows from investing activities:    
Capital expenditures (327) (311)
Proceeds from the sale of Portamedic 743 0
Net cash provided by (used in) investing activities 416 (311)
Cash flows from financing activities:    
Reduction in capital lease obligations (1) (48)
Proceeds related to the exercise of stock options 17 0
Debt financing fees 0 (967)
Net cash provided by (used in) financing activities 16 (1,015)
Net decrease in cash and cash equivalents (1,303) (4,482)
Cash and cash equivalents at beginning of period 3,970 8,319
Cash and cash equivalents at end of period 2,667 3,837
Supplemental disclosure of non-cash investing activities:    
Fixed assets vouchered but not paid 230 182
Fixed assets acquired by capital lease $ 0 $ 62
XML 55 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation
3 Months Ended
Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation
Share-Based Compensation

Employee Share-Based Compensation Plans - On May 29, 2008, the Company's shareholders approved the 2008 Omnibus Employee Incentive Plan (the “2008 Plan”) providing for the grant of stock options, stock appreciation rights, non-vested stock and performance shares. The 2008 Plan provides for the issuance of an aggregate of 5,000,000 shares. For the three months ended March 31, 2014, the Company granted 162,600 options to purchase shares under the 2008 Plan. For the three months ended March 31, 2013, there were no options for the purchase of shares granted under the 2008 Plan. As of March 31, 2014, approximately 3,209,300 shares remain available for grant under the 2008 Plan.
    
On May 24, 2011, the Company's shareholders approved the 2011 Omnibus Employee Incentive Plan (the "2011 Plan") providing for the grant of stock options and non-vested stock awards. On May 29, 2013, the Company's shareholders approved an amendment and restatement of the 2011 Plan which increased the number of shares of the Company's common stock available for issuance from 1,500,000 shares to 3,500,000 shares (subject to adjustment as provided in the Amended and Restated Omnibus Plan). During the three months ended March 31, 2014, the Company granted 300,000 options to purchase shares under the 2011 Plan. There were no options for the purchase of shares granted under the 2011 Plan during the three month periods ended March 31, 2013. As of March 31, 2014, approximately 1,166,750 shares remain available for grant under the 2011 Plan as amended.

Options awarded under the 2008 and 2011 Plans (as amended) are granted at fair value on the date of grant, are exercisable in accordance with a vesting schedule specified in the grant agreement, and have contractual lives of 10 years from the date of grant. Options to purchase an aggregate of 500,000 shares of the Company's stock granted to certain executives of the Company in December 2010 vested 50% on each of the first and second anniversaries of the grant. Options to purchase an aggregate of 1,344,100 shares of the Company's stock granted to certain employees of the Company vest one-third on each of the first, second and third anniversaries of the grant. Options to purchase 2,000,000 shares of the Company's stock granted to the Chief Executive Officer of the Company in September 2013, vest 25% upon receipt of the grant and 25% on the first, second and third anniversary of the grant. Other options granted by the Company vest 25% on each of the second through fifth anniversaries of the grant.

The fair value of the stock options granted during the three month period ended March 31, 2014 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

 
Three Months Ended March 31,
 
2014
Expected life (years)
5.24
Expected volatility
85.0%
Expected dividend yield
—%
Risk-free interest rate
1.8%
Weighted average fair value of options granted during the period
$0.38


The following table summarizes stock option activity for the three month period ended March 31, 2014:
 
 
Number of Shares
 
Weighted Average Exercise Price Per Share
 
Weighted Average remaining Contractual Life (years)
 
Aggregate Intrinsic Value (in thousands)
Outstanding balance at December 31, 2013
 
4,150,550

 
$
0.75

 
 
 
 
Granted
 
462,600

 
0.56

 
 
 
 
Exercised
 
(37,500
)
 
0.45

 
 
 
 
Expired
 
(505,550
)
 
1.20

 
 
 
 
Forfeited
 
(83,500
)
 
0.57

 
 
 
 
Outstanding balance at March 31, 2014
 
3,986,600

 
0.68

 
8.5
 
$222
Options exercisable at March 31, 2014
 
1,388,700

 
$
0.99

 
6.8
 
$51


The aggregate intrinsic value disclosed in the table above represents the difference between the Company's closing stock price on the last trading day of the quarter ended March 31, 2014 and the exercise price, multiplied by the number of in-the-money stock options.
During the three ended March 31, 2014, an aggregate of 37,500 stock options valued with a weighted average exercise price of $0.45 were exercised. No stock options were exercised during the three months ended March 31, 2013. Options for the purchase of an aggregate of 24,400 shares of common stock vested during the three month period ended March 31, 2014, and the aggregate fair value at grant date of these options was $0.01 million. As of March 31, 2014, there was approximately $0.7 million of total unrecognized compensation cost related to stock options. The cost is expected to be recognized over a weighted average period of 2.0 years.
In July 2009, an aggregate of 500,000 shares of non-vested stock were granted under the 2008 Plan. The fair value of these non-vested stock awards were based on the grant date fair value of $0.45 per share. The shares vest as follows: 25% after two years and 25% on each of the next three anniversary dates thereafter. As of March 31, 2014, an aggregate of 343,750 shares of such non-vested stock were forfeited and 150,000 were vested. In July 2011, an aggregate of 305,000 shares of non-vested stock were granted under the 2008 Plan. The fair value of these non-vested stock awards were based on the grant date fair value of $1.06 per share. As of March 31, 2014, an aggregate of 141,400 shares of such non-vested stock were forfeited and 155,100 were vested. The shares vest as follows: 33% on each of the first and second anniversary dates and 34% on the third anniversary. As of March 31, 2014, there was approximately $0.03 million of total unrecognized compensation cost related to non-vested stock awards. The cost is expected to be recognized over a weighted average period of 0.6 years.
Employee Stock Purchase Plan - The Company's 2004 Employee Stock Purchase Plan (the "2004 Plan") provides for the granting of purchase rights for up to 2,000,000 shares of the Company's stock to eligible employees of the Company. The 2004 Plan provides employees with the opportunity to purchase shares on the date thirteen months from the grant date (“the purchase date”) at a purchase price equal to 95% of the closing price of the Company’s common stock on the NYSE MKT on the grant date. During the period between the grant date and the purchase date, up to 10% of a participating employee's compensation, not to exceed $0.025 million, is withheld to fund the purchase of shares. Employees can cancel their purchases at any time during the period without penalty. In February 2013, under the 2004 Plan, purchase rights for approximately 233,000 shares were granted with an aggregate fair value of $0.03 million, based on the Black-Scholes option pricing model. The February 2013 offering period concluded in March 2014 and, in accordance with the 2004 Plan's automatic termination provision, there will be 36,154 shares issued. In February 2012, under the 2004 Plan, purchase rights for approximately 273,000 shares were granted with an aggregate grant date fair value of $0.05 million, based on the Black-Scholes pricing model. This offering period concluded in March 2013 and, in accordance with the 2004 Plan's automatic termination provision, no shares were issued. Unless terminated earlier by the Board of Directors, the 2014 Plan will terminate December 31, 2024.
Other Stock Awards - On May 30, 2007, the Company's shareholders approved the Hooper Holmes, Inc. 2007 Non-Employee Director Restricted Stock Plan (the “2007 Plan”), which provides for the automatic grant, on an annual basis for 10 years, of shares of the Company's stock to the Company's non-employee directors. The total number of shares that may be awarded under the 2007 Plan is 600,000. As of March 31, 2014, there remain available for grant approximately 360,000 shares under the 2007 Plan. Each non-employee member of the Board of Directors other than the non-executive chair receives 5,000 shares annually and the non-executive chair receives 10,000 shares annually of the Company's stock, with such shares vesting immediately upon issuance. The Company believes that the shares awarded under the 2007 Plan are “restricted securities”, as defined in SEC Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"). The Company filed a Registration Statement on Form S-8 with respect to the 2007 Plan on April 16, 2008. The directors who receive shares under the 2007 Plan are "affiliates" as defined in Rule 144 under the Securities Act and thus remain subject to the applicable provisions of Rule 144. In addition, the terms of the awards (whether or not restricted) specify that the shares may not be sold or transferred by the recipient until the director ceases to serve on the Board or, if at that time the director has not served on the Board for at least four years, on the fourth anniversary of the date the director first became a Board member. During the three months ended March 31, 2014 and 2013, no shares were awarded under the 2007 Plan.

The Company recorded $0.1 million and $0.2 million of share-based compensation expense in selling, general and administrative expenses for the three month periods ended March 31, 2014 and 2013.
ZIP 56 0000741815-14-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000741815-14-000017-xbrl.zip M4$L#!!0````(`&%PKT3H4&V]VJ4``.^B!@`/`!P`:&@M,C`Q-#`S,S$N>&UL M550)``-6`7535@%U4W5X"P`!!"4.```$.0$``.Q=67/;2))^WXC]#UA.;,], MA"FA4#CE8P)GMZ=]Z'#/S#XY0*`H8AH$V#@D<7[]9A4.@@0/D29%48(?;!.H M(X\OLS*SJLAW?WL8A]P=2=(@CM[WT!G?XTCDQ7X0W;[O_7;3UV_,CQ][?_OP MW__U[G_Z_7\9UY\X*_;R,8DRSDR(FQ&?NP^R$?=/,G""$+JE_7[9>G)!B(2T MH3C$0V\H*HAHPR$B`TTFJHIX0?;?/%Q@["/L#I`\$%Q1ELG`'PQ=5<0"&7A8 M'9)BM(=!$@87]&\."([2"Y\$[WNC+)M'$N\`CW>=3' MJ%C.)Z09!2'8Y*>>?&8]A!Y/&L?I+$H(&6N$YLF3FZA,8_/ MRQ95!^#\]S6MZ>N!FY*J>9[V;UUW4O<8NNF`M2Y?+&&!#N@O,%V.+Y\7+YM- M@W6T1VGF1EY-S4.+^GO,6B--T\[9V[II&BQK",.B\W]]_G3CCS][MZ[B?^]%.1WG7[Z!L/I#T'Z?33Z M_O<\G-)N7^+H'ZS3#>W$FGTFXP%)"J+K^0#I038MG]5/`Y\^'P8DX1AC9$XJ M%1C-C[_V/O#P1Q&1BJ1WYXN=%X=-R2TUK?IQ^<(',AXF8>`%64$CYP?0KC#: MDM.+.4Y['T:CBXVLOCM?.OJ,JO-E9%5/YR13,@!F%<1^BZW,33(+G,4'2DZ? M5P#:]=CUNX5.)/+GNF`TF]AO=*B>-J:N'I5860,?Q%^)\20#06Z`C44\)AO: MA8GQ*^OU(G&SF==C``?Q?21L!YRBRV&`@ZXP4P.,)7Z+-^39&*CJ#X'Q0EQ"BXC_AM1%ET.9`H\0V9 M9(7OTK)1'_/9J#;$CQ#7CLE-!K-1+!EN2$.4FQ$AF1[YNN\'S'A#*TB],$[S MA*3&%#Y,XM0-?T[B?)+"$&%.8V/:!B8/HISX7X%89O=I9>&7<9*Y8^('W@U) M[@*/?`HB7O#QC5%^"(KZ`N"KLZ0+/J_3A:>.MR19# MQ0)?'1(>@P2$7B82FGQU2-B(!"M(B)?%"8L27B`B5O#7(:.%C-D"GJ>PJJ;I M3<%[';K\0MPP&_V3A"%]>]HX6#SG0AJ]3[-N=YC:`N+V!B0PQ&UO&W['VV4X(&;5+3D#,+Q`9M4^>YZ]# M1A,9WT`VEVR0>I\$/B3?XAL"O7P]B@)ZB\)-IB>+CGD6B]V,M3QV"'D40KZ- M@N2%`V0YBQT^:GQTAP]V2!)>T> X[:[@[5\[I#=9IXZ:Z\='AY'%Y>`4XZ M?.R*C^JI/9Z$\920EQ/OS(.D>KR2SPXI+:1TQR2[8Y(O'M6?Z"8:O8\]E_61 MD'[[QL\D`F&'3%_C(`K2C(K^CM@/]'KRJ6]3KQ%$(Z/;1A(=VEIHZP[E=DCH M#N5V2%B+!!JJIEEL$EC'@Z@*44]\>6D#8RV;'4XVXJ0[MM(AHT#&-8$`+/>R M/('8S(Q3FE+`,XC^:[`XKA>$P+D)R04T,A)(/T9?AT-(#\PBWSAM]&P0`0/4 M8V70(6QKA+7J1N2.4/&^=%2UZDCS?'=(:B&INVA"GN5%DY-'37?1I$-,=]'D MI"Z:G#B"V'%/^N64;C2UPV`<1$4E_J6C:#W?'9*V1U)W9>GH5Y:>$8(^PMC" ME7@2MU**;R//J#B$^>\#KM[L11SXZC2^P+4ACH4+;7L6QU&^9K#;EC_M;?EY M=#8OU>T9G2?GN_!!?9>X8*S?W`<]ST8QI''3N?(9BZP`;M?DC@",2J!\O+YY M"5:VR/6L>K:![:.8Q[/``W-,X(CH88SP[WD2I.`^3O\PWB8\;&#[!>.AV\DY MR9V<9XB4;D?FJ#LR3X0(\?3R(O&`>1&(8_7%!ST,OV8CDBS^ZLZ)U^O:UQ\V M,'H$$SB:SKM?ECK&+TL]!\UWURA?L]Z[ZY"O3>^O0-^=GKOKB<:Z M:VFO0*/=];*7I5%@P">^R^J?U$_[+U7%&QA]33KOK@:^*GUW5_Q>FH:[#=Y3 MW^!]+DCI-GB?RP;O4R&BNSI'GLO5N>>I_>X*W"O5?'>5[0A7V9XC$KJ+1,>X M2'1X)!17@I!]&7J'?Q2M`G">9/S<'!@B@>X*)9*1(P!724JY!YXHW< ME`#X;MQPMF-]F="H-)MV1P>>YD[EH]3P6H\.2'V$]V]W,#9S14CN[*ZSN\[N MEJUW2'YA=M<=E7L6=M<=E7L*N\NCH#"Z`=MV_!ZS?<<%>(Z)2U5)M3+7K!JW M>M^K=UVIRGC`EW1[?<0NJWA;J'A3I,Q M'*^8HM0,_'>GH4L(K::_;+#;X,MJ2O.$%TUV&CU/_15#!VDL"DBY^.W&VG7D MR_*7^A9F\(,[\(*+=D0[?LG'5-%QRT\\FJRFI2T?L3&=1:*8?7/8N@DWB7AQ MQO:@U=L&WVWIU:?P/2_.HRR]=*?N("1FGB2`'*YT$==DV+AUR_G$"\9NF+[O M]7&O*->[7M87D.$HHJ.;LFY(/*_RMJXKDJAJFHXURS1Z')V7C<7TCP4LPD+U M[GP]$;L12K^)916ABB2(LJ)9!I:P:IN.+:E22:@E8MML$2I2.GL"!9JXVI/K-S35,J)$RO. M!]DP#]M>=R?OKTJR@!PL"J(F.;*MR+*@5LY1YDW4=@=BBYU'D[97KM89OVEK MJN3H"".P&E$5+%[5*JZP+N&VY>"]<=5P?5^'#@1ZD5>>$DP?93=-/C0!?+** M'457D.6(C@&JJ@(*QW1:`463A35T_`C%2\QC3O(8Q*[82%4M@89!NL&7$9N" M%!FU?):Z(/C'4QW]T(^#PT3Y(JJ>S>^UKXQD#$=U>![KNNY@D"BV#*-:TVPD M.0WA5EDAUA97[WW([4E4@9^;*H2&*B0(\VE,8=NR`2NTZ/!5U*Q#7(7%):J0 M9%CS#JT*6F+[.)ZX04)#+!/:W9)'6?''+TX3:1+$%PJ2=06+EJK8&L;@<`Q) MYV5#LZV6&3>Y6DK";F2VW>,\F;KC6(8I0.!C\X9@2H;-JT"FPENB+=JF]GZZS=XN=`^#B/1' M)+@=91=(X/_W+:6O[X;!;701DF&V<@SZ?!D-032BQU@7^[&/]\4\@SCTBX%F MHN+B(?2-SD?2^*(]([K^G; M!['L]DK]MQ'AS.);[CERYX8Y1)8IE\%3R,OB.Y),J28"6,C# MF39+TQX\B"'?2V!,-X-W?D"# MU^(3G<9SDV0*7HFCDQ,Z63GZV)UR49QQ@YH4&C*=<1R$5*QG-DH(X2`-R49< M4?/FV%D9[K.;>",.HS<* M]S),26)1BB@].55Y0OD;%MH&'DO&"D'3W2.*FKC>/^)\=IMF!332I=B@L*6K MQ-G.QGIT3U+]?]/"5"\Z2U:H=,N"GR#)EJPYR)(AJ5!54ZV3<2QH3FO1%/BB MK+I`XK*U<@DEZ](T;`D:;\HV%DQ;M$Q'YRVU2A949(DM2I`LRCM3\J,7559Q M82/(I[,*N8<8!\T505308C$0S=1`YC1G2P"<%NBQE!%95',K/; M]I$F"`X2-0,+O$++$JJE5W5)25+D=G5%4I<1M+Q^LIZNM>[$P;PD.+(BR5@7 M;%.P>;FBBS?L5K4$R;PD;4?7+R3T(8"A!XIV$IVM(U%W1$%4P#6(D`YH6KD7 M82@.B+)E9&B9YVU3L2NM:W>S;!GP!6N$J2BR(-),2Z]V"D1+;.T4_`BM7X=S MATW6GS59;X$O[,#1JCJT)JF&)9J6C118+!W-0K;IF(J!%,.`9;VUZB!IL1"] MO>#G-6>X:0#]R[HH]+F,P\";%G]OE23+&J]:%A95V8!UW[%$3:^JG!B"DJ=, MDO^=IUDPG!X^:\LC%P1-\XJ`_K)$,*:"2D%V/DLVAD7ITPVYM$)R2I./9C(T M0Q4T2,G$3-A;G>C3T9GD(RS[H*2-Z69T%V304B*["@AMW1GC[4M9YM5IE@+^Z%(%"D5XR"E)[&XO_SDCB=O_Z0*`O_VQC;K M3^CM7\^X\@M2@`Z8?%P8,!UH&,<9)#B$\V>&"!D/-`G#*;0N$R3HN506ZUAV M:TA",Q@IF%#^;DD$.*:#PWLR*43/6/PM8HI@/H/QK8]!(YX[Q]AO9S=GW,^Z M?MEDKZ$#4)]/MVY\FI7$XR"C0T[R),TAB>2RF$MS2%V6BOJ,VQ41Z2C.0[]( MLEV_3*[^G4>+:6PY\.8!*654*ZR(D!`@NZF)!OK^G++4B].C*(;PB2;_1(R#(%LF#$,.=>G:BK$5O"4D#>5&<23(*(] MYGWRG].&R-YP$8'H/G63*7.\+C>$I'ZF#-H7^,C#+*WJ)+7I5V4/4%<*36G] MI[.3`R['E1Y`)8V:5*65'ZV3>7$8)Q=_8A$87S#CTPH9F^:"BJR@9$GA:S\E MNJ)Z]E1L,`]?+).08[VM7/U^6*&^X*D8H2O$C!;+DP(98(Z4+N>F<8L!VH$005Y=5[5]*?K"[/MVN?C M4HJ%-*0LM-@/0<;.":"-N_H+*2+]"2]V<&TN&R.0U$6W/Q=!(\L)[PQQ*V+W8VG*3!HB4"\3HV#-$0+$M6Q.HXH&6H>NO(,U*%_;'SB5Y* M^#J`%:TPGJKGUER8LB0:6$:*;&FB*MB::3H5%T!QJW0O+V5B%3D_2/L&0`FV M`(:`#4=2#%O6-4L1G+J<)*FM<\:[TYV.P%SI/_2HZ9T;LO)K9I8[E?]@&Y7; M'4/'FB%BS7$D9"#-UF7)$*M]"LO2VL?0-671&!Y!TU[86'N>5%!-7D.RIMO` M@(EE5:K/9CF:U"KH";*L'(D-88TVP&!-Q.O(<`1'MAU!E>7:E#&66J:L8J0= MB0V\1AN2I#H(@0846]20I?&S8^F&+CFMI0&K^$#:N&2!!%A30@W,(L6_VSLG M39(%"?/(YNGI(4-7;*"[@1I1-=KQ(`U=E M:[I2G<.6'&2TCOSV$>;QOABC5;8B!Z4#L)+L+8$P;?&X5.W#FF>/5,O0)--P M[&*CPZGO/6@*7JP0EN2DQYW_`"',"S6N&]DBAH6*YS6,!,6V M';7& M^]6-4C=]TSQ'$[J#F%UCG'+#\FN)BZ+9K);AT3)24IU7JF_,_C][3[;=T-Q82E"BQ MN2EXL$LDL72?/OLJ7_UP%T[OT.1$MQ^\[!YLU&25D4F)[J\T6=W>H1GOD]\- MDY;XC:5;'=>#GL$4OGD`0S`1_D#N[>8.Q6K\`JS<9?!(KC;VG4U7M/PII9V_ M)\]<@/XO7CVDY<%W]`\N`C1_8_)9XG/#&,@=/WWHU#*L@(LG'E^)D(F+%T@$N9H<5)F'$>[;QB[ MHEX(@(">+B@7'4S9ZH;V.M-N'GG<9TI4ETK_$CIFX%/UQ<*_(!(4BQN`,#-% MT#*,']7`JW"2P;TE+:^SCC+C\*P.6QZM"!_@25`'KER%$/>_V`4DM8CR>4V>/ MA*MQ0FY)&=,@_@^KO!C6>*C57L>%OU5?1X-GN*(:FN@JHHEU%IVRB"=W M)PV8*2D(W>@KV"4\C+O&&_.)JWP1[]B?-Y9I%QE&3L$VH2#J,F7WI!S(D%VP M!*7E.\5&02E2`JD?C(X-2DL4P=+4JZO+E=@\V<\]VQS2:NX2K[Q M[&>XXR%)_V+I3QGQ8MD\`(UD+0H>,I'9M[;FAT!D=<$K&:7=1)QRR;:FA*`T M10M7QZ`RK0LL[8A2__#3/`@CY/`@G?&MT6-!':&(2H,LY-6J4C#@8CIE)D#Y M%Z]EXL*9DH=27FRVN6A49T0A&F;]1U;=H?NAH*_0'.\X8`!H#@J4]8SO;"^/;+?)>;?D_1L^-+D'Y. M*7P](R>_K`A^-ART7CUK=5VK-['=D=-S>T[?,(O>#WW;7TM&+YMU&1W#J>_I MF74IV,A:>*Z^$;L[[)D#P_8GIC%Q>I;9[0WE1IS18'CXC="O67^5WR4IZ:4O M.PG+&0_=WM#J6;;7MTW3&\D(P]"T[?&HH9J<^G"L11FWKV>/A3\)^=ZD.^[V M`>P#V\,Z,MNPC*)YE.OYAU[X-7".%T.[CRT4>A/7L$>&U36&PV[?*GJ>^$93 M[7[7<"S#<)JQI;J45Z[W:?2>&+#.D>?`LH%DG?YD7*"WW1LU`;D+Q&"Y^Z_W M\RI'C6;&>>)+@.P/)H.!:PQ,MS^8#+U^WP>D%HL>CAVO&&7#&6S6AIGN-MIK"A@_N[@G$P[<_L0PO3%V?O*!.QM#WR^2;D;# MS?I.?ZU9R7.+R_+/\W\D8'2#-)7%=-^2Z.7)*3V_9PYMP-;QP+0'QL`?RA(4 M=^0[DXW4B%[/7P?CMK6\?LW/Q-O'@]%X-';'GC,<^N-^W_4MKZ"POKMQ]#W3 M6V>[NZUYQ&[RUX56#<>S?<,?C+J^CP6^SM"1O04'[GATDLJ>@X96?TL"GC0I MJF8>RUX`>QBM_M;W[6-7^V4B['Q.B;"[ON--)YX?PR5#44SXA\XTGO.-;@U> M4/,$"I&S(.`C97JE.8N/D%^R2NJD=##RSD_!/1B6A3%Z M(U=%+41N&/FOT6J+E:3B,]@Z<#,M-F*25,3 M&%I,N=S"3&>7!/?V44OJLN)#@&_A+B-LO&?(#/2]S>Q>!* MXYDV;FR6\*XPW!^_UM\F+2_4"[_DEH8WM6O+:&I:?1=2/'HCF5P)<)@&/M*X M4+G")(Z`B@%^;%9[."5XD"^F1$]@%0"0_%%2/J\A*T,V99$5/I#N>`3NC^RD MG[T(.9_1+>KU(0>O:=$K!(?AHPA]B4&%\-"/+N,JJFCP!Z/C*D5L/(4&GB,/ M%:OA1,`HS+;L#3V4:C9G=TRU5'M#L4/@@8W8'EPR^KT)\CG+SE@WI8:55/P1 MNVM;^^10_'U5[6N,18!*HU%%[WT2W1,C2AFHGUH$T,[J*E5)W'@F`'LL:R9> M]3[\(/K`894[.4@QK8)IE*"YC%:*^)75Z2I2B718LUBTDN?U##6D,`L4Y4+\ M=CWX_%7-FA0?HMNQE!TBL@,X2#A))0_T%.G;2TH*B%<+8<&%DM((E(*`GC4A ME8EYKZ,LN?#2)?A:+,%>G(2NV_."41KLTN;Q0)"1J1]K7MW53?=Z_54NQ MD)6FJLP=0[%)@*V)*K2R1Y;.13I*C]ZAHU&10W?DDD]WH@-911&@47++R)W! MVT%A+Y M69QCEG15_9=9D%NY&&ZL7L[R4+9YHJS565$\$VMPJ,#195(:Y8XK9]SV41AW MR'^M;H6:3V,94(@03C9.RM65-`3A2KBB36[?1C"'+S?WH-VL\NU;]%J^ACQ=L+OH0Z&?`KWK6=(S=F M%6:KFRR8VY]RN8L%/!]9^COHRCO6=BA`I(4LJ!+3!+=)JCMV->L*@VG57F MVW$2J\PG^@!/N0UCRA$*S&H5SU?T_*9P+RV(P>G(%5&?JB=1 M>C-W=DL6RF:JRC4U/.6]?\'*_;;$UIB?X_\"5$/&]Q6@O+U%U-W=_^),-NE! MQ(MK;:&^H/?O:V,#\FKOA?'$&+E^WQ@XAF\['N:U#2==<^+V7'LX'%>;>XBY MPV">6%VWOMU==G*D_-==J]X5M;N@KSU(OD\0O6AQZ_OBHOO/X+MH1"UK M`7]+LHQ:V`#3>`C26?:-*R=_)F,L.-W2`=S^#V>MO1L^F:<1YX\U$B;@QT'T ME;<:%1'QZZ_?GNGE-NA/'-L<#,>>W1]UAY9C3\:3KF,.,-6U;VV.X]Q,=-YO MUV<#04)9.&-LG!?]"L(]FX73+4/3JA"T@7M,/+,_]%S/&74'H\'$G@R\D6OV MNN;`WD0WJ[L^"50M!"O2_:49HP-GX&(F\Z1O#KN&,[*&CE\,9[7MC79FMK>^ MD?+E+UG6,TFA3L_O@YSQA\,A0'7<&_;'/;FLH3=J&'SA[;JL0O9^GE_A'UTW#*GS2FRCK&U'A^]GW*ED5NPQ,-9VHKZA!\I7W&A-)' MS>JA76#X^EK*%=4ZW`'N4BL=K'&7%@E>K7U>Q.$-6'(2H!K($#3EP8#`56KO MU\QRN@E_J;73YPY57C6;BFA\P"V,C`9HBYY"NOB(ZRAX98J(!3\!8E[=@W:% M/@1^%5AN(":H+2TO/P_*)-1B(9O>W%#H+]2H`PS`6S!@;RG0N7^$:=<6Q*X. MO^,_-<=<;'URBM;6:O90&M=OI*=UL[OP6#LS/4OW5.&7[/F%X8D50(P2C@GG M:NY307*=%@V5H*&:)N7GFTU6LQ-V67=J.S)^BG1OK(VM:78%RV>QR1" MT<>7[SI>D9.]Y$\;!H,1%(]"9%>Z'HU],7E7EB:`;Y=0O,1TSY4,\`4[+,Q+%31Y^6;?<9EX<3$.3"A'J M/IN6D,C.Y0<"8JT\D@^4`R1I-\CYF+I[ZOL=F*[@J6[*IZ),65S2ZH%+>#FOD?=>2LBEN%-ZSHW(!4Q&I M\&[AI,-MP!!8V^<&P7`R+^,!%*<-C9>KNA+/L(N<'"4I&T]NC+B%'XN$%4!> M0Q-:_O'@HBKQ->8),++9+"7_4(L_AH-CL?8"]I_B9+@2"L?$%"$K;,?1S=,A M@C`/-_``CUU9#]&K_"Y,9X<[5[T\5#0&X5U/'*^2D-%&9+&I;G0?F5+%/"4/ MM@X1UM@!T^CG+=UN-WE/K=6^K2M$0U65@MIJ246N4Q8N\QIB<8'O_BA%^/.H M^;C!=W@*M,`!"<5Z,P8U,-EY(*>RQB%UNA50D2,6YN$<59BG>/+%J(47K]=B MD+:JD8H3JSD!)6X^:60VV9@.%:/*6=:S1GU7PS[P_*&#*)C^=?5M>I=@!CU_ M.U9N3*E?43)C49D*7/9]YNP9=6M`)\P]K$S+_G@QYW!(1.+#B;:^MO*4)4X^ MB&^O(C;//QJPQ>J>\7/U-3%&_*-/\IX\6>*#OYG&RV"]#:,^2*#59[(+RA%@7_S$,[RNX^NUS%V>^T-'G@?YO%M3_GL_+/M/$)M*1? MWKF]'VM/*)_<^+3R1M-YY8U6]T4W;EN_."<@LCR'=K%M%$-!J[D%U3>>70E-?#IE;#X_+6H>PLN+`[RII5P4SIGVGEQT M'PZ"J$<$Z3$QE+O%.M9A$?+MXMU]$@4Y]8QH!7 M]XP"?9Z\4;F5\M_K+KFZA_$)OR+W)9["MGG3'!9'7/JOP/R?R877=/V%^3C/ M8KEKB-*3_M5CN_L+USEWT&:KQ2+`>5`RHB<\[P%V@I'->XY>1L*#"_N^DL>C M:A&*8^WBD.EN2N(:?]NP@.]W?*]K*@T+F-:><0'GM>Y]\[7W6<=^X;'ONYB% MVN?]P@NQM(MXEXA?7>%];[ MF">C,^U+&D[A?\!*0LD6(X\C*LXZQ'T2C"QGB>.8;UG+\-OKHHXM;K:X^7K< M[!=U`M>`B6&R%\885`+NE0A(<%8*)TV'XZ& M5I?`;8Q.UVT93-90Z^`Y7S7S;!0H M9TOWU5?"XEQ(X-"J4DL3A\V+?4'`YQ!&A>NU!-$2Q*F%1`N?%CXM?/;0ZW>T MDBY>X9?I!\I4_M:\/`?`G8V1\-[N8F_CHP&IQ)3#04DY$2I+J&B)[]S*04]L MC3AMB*.EK;&./:Q>)9AVH8XSMG[<#[6BVNX*A/26BNE)9DW M'@$Q.U8;$FP)XN0RI(5/"Y\6/GNH_7^7",@D2>Z,1$M]6 M&B'9%XA_;]ND)=Y+:P=WZGRO[LDI]UR(\-!F4DN;+>!:P+6`NV3`G;#=EY`O MU#-P0[B"^O"KUC5POJZ30R":>M7-UGN^I[*`Y1#;OC@=K:6GTW;>VQT) MCV\J>3MWR=[;5&I)L27%R]6J#C&:IJ,L$[3%JTO%*_5,_0?+L@YJ^IQXLL3% MV$QBZ@?CY3S4!/Y@-E-KW%]"@.LR&(BIV[ZO=\\@_M7JC"UI'P[M7D7!%XVJ MZKK-[[^30O`BD:_GCA?+'"]3C#V"E>QUU+K(64UM,/9S=[YJO M,/LO9^+A(6QTY>M=PZ=3C3P,BB;]8=&DGX\CG879-$HR-M.H6S\3,Q&#&^`( M6LJ6*L/R!,7[',%D`BC_^E&GX)`P)\S&*2YJ6DO"+ MHB#+M3P-*&0\"QYQK@]^_^]5D`*+?D.S";4@GM'6F!P;0X#0M<4JRL-E%,(^ M;Q[IBK@8<13&5_#%U0)6^*A5IU!FG4O&O5$YV98/M>3'7/=YZ0"Q"H8"-(Z% M!EL:G[SJU&N'QHD+Y\WE=UJ@/:S/`ZZCAHHM5VNX(H@HV,Y%69:CNXHPTP:GX:K MGR8+@(6`WCW+\JW0>GLC8_6"+Y<'6AG+'>1\'#?()G[2<"6B@$2Q(#L:%("* M#5.#)T7PO9*]=[1^=DSL/>PYPLD`O>.)!,MEFGP/%W!DT>,QSZ>K]'@(W9(\ MB+15G,(;;V/X'9-4%DL69_1Z^`#Z4\JB`&DV3]9T!`V5/+HDQ`#3DDW%93>H MQ!5/1"NO21P)8C\F?^LH8FXT[>RB=:3K^&A0_W4%9&(9QJ:G\K4<]332$90V MW5`O'N$%5T(J*6]UL'V@2C_ZASX.&D?.U+%*@2`L@D*B*O$'(;^PX> M@G0F]*J;`'4J8<551&3]0>>FO@)'XP<+"AYN6QPR[E(+4-6+HN0A^WB\HW1_ M5&1WZ M;6DQ)[-Y'5OO-K3+V9-W9BLXSV8&.I?5VT=%5IQ3ITQ&T#[XSCH:"&PA2$WS MA.=HN*>4@85L$@SVK.6*V3$V6_[O+5=:;J2`2AWS$(Z.,^1&KFX>A!L]I=T< MCQG9A]$,YF&*6X*#RN"U\:Q!/SCF*=J.NFURAUN8UO;TQKC*&7AJ#/ODKIHM M8O#RG#9&1Y$45>NT,;WC>FWX1[S\8PB8$$[YD\:+990\@@WSC0[YBXPB*#/@ MM2NN:I7Q5E#"'.VI]VKODAN94!HMF@`\AAK.9@-'ZQ4)Y+>!30J>\@V)X>$^R M7"9IOHK#_!$?7L!*+H/S=%)BE>P/I4..078>OU(#LWF:+-95[O=<`/B6!=1? M#8#AK\5OYJP7L4!6*])3Y&/A!RY2$(M!:.7VY-;/[*:O' MQL19_O$_W\;:[__Z<]-,Z6B5T+;@Q-6:VC;$4*OF,1R=;Y:OTXT%P@ M"NX4K!3V"KQ@BFT-(KP8+%)Y>48T$`,'"!>L&CP52(#O2E8Y?(R#*$<&B.>/1&UGO:;0FR[:5\^B:%X%G1<3-@=@CZC/JU4.][M88 M1,'TKZMOT[LD0@%!P3KB1(@TBV3&(JX$'FO#-3Q4Q3+FC&A`X#]8:=-H->/Y M9$>U8M1F<.FX_F`*+YM1=Y-""RA(%CABL`+]$Q8SU7*6+L(X$`<,.D1&3%(8 M0(!AJ-0K69SMZ::K:)^".,,L6U&.SQJKLD[&JC@?ZAZ=#QW,#_D2EJ1:`C[! MDC9X49B=&44K8E/**%K)`T MKN-IAYZ@_9'$5X6!+\]+^\JR'"@7SU88_86M7S'EZ`'D?:B8<+KVLUDD8T^27>!]&M`297.? M+'E$*H[WUV]5'R0E2M9%*7;B+S.Q1+&KJZOK/AK*ETSP'!D&\L;)!,T[X"&% M>O9D'O,^$X3.&RW_"7?!XL?HMC/6CS4T5T4I;,H%V*1OZU=7MV`'R_<5@%>ZV2R_RU`N?,F*L:Q\0!I7:L"WL;X9#I(5E/Y76X(>K6_ M3D?A_8?!%<^#,S>NFV>Q3](_7=0;7$!]IB;-8(NQ*.`/94Y&5+I)UCR'.8 MCT#1D"KJIR2R/L[A)A/&6N__5/_6"@<5[IAPQY$_SNY4FKMREB\^>/;SQ8+7 MW1H58PS"@`R^*0`PI2!^J@`5\)8*I68ZG=U9G]X$"GL`/D9VC'QIM@E/AJ!_ MCRWB274AT`O5H@8D]=20V1,W6>+K+!L!8'@@Y=D2/C;C0I'YO#3,L)Q?_V\+ M9."#H#M)YE@KPE(.F#J7V6,M:G??QT\-M+AD(L%AT'S8G^[.% M2`)=L$,H*$WQ69"H)6A.^%-`^J0$&V76%%(!EHK[`O$_GU3%6%>K:6UID$N_ M'29-Y[,O=46:9F\SL`M&EEP4_X->O85?@Z$K`9"_'2[^6!J^E37.L;AM-)W/ M:FU#/84?21.S"5IKC$@3J^S@=`C4!>:@'%D!>^Z-4:[,GX.UG]\=&+=XWDP9R`61]7R'B:^BTRZB43QX!&>\_:D+3\ M1OG"%M(U,/-B4F)E-/!X6'-R;BD;WA43+>J_Y.;QQG!^J0Q9 M^_>^2[[\=&Z)^?<__CXOW]QDV?TOL:J"G\_RRU'4(HZ/*HLGFI95^0D)2"#] M7&6/J.N5GV&38@R*\MM__S?+^D?[95-,J9CGPTM`LGS3;Z!8O9^6Y>4$OKZ? MEMGX^.< M6<40OLX&U9O8(P%)79>''O6#)$RH"'R7!9Q[OAW9\"BF+LC7SB.&)"82(BL>?YRYAXXSK.M\'%NPFPHAS? MFLZF=RL?$3DPFEP]^`0R_M3K_*F>K`T2H;KS?[K-\RJ<#$.MI&?CAN1+\6AV M]-ML.K\OWTF'/S#"E0"5X=>B_//V]L^KZ:S*T`PZ&S82SJ;)&1!PE(A(CM([""@ M41+I:R,B(I)]&,A13@:>2D8C,)O67,`7>$?<]CE00=Q`,(>X7AK&21@(D@HO M\$,W8*G7.0=B;W$0FW"V!=K+J^FX&#S64F^]A*JW(@+!.6=>8*>"IHXO0C=6 M)"5\'L3T[.V2PKV#Q72VM;Y^+.7\ZV1'^2R`!,0_'U?2E]-: M&YU.9:[CYJJ68B9?AG^4:]8M39,AA%0B"!>`!V4+K4QE2.M+*1=L_5)N:3RN MM5;=F2@?[J/K;:3MSG5HKO[3-_]C_B6'#UX@"VJ+`E094Y>Y'-0GE]$X!M%L M1$%"0GN9!5''8\$R$]H19?VC_$5)7^&(4'`GY#X+J)V(1,2Q0;D=\G`9YD.2MGI"MU=2Z*LH*(S:#O^;PO(IS8)K&.0C9OLEEF7K/PO^F@R.K,MZUVC%E3FA_`5N^F6">B@\#P$6QE5'S- MS1+X,/"7:CI3L=,"V,)X#$HGII#.7TN*@R$+?+& M179=C&602L44LR&2%GRS5'^@HG9-V0M^>/;S$:K.E&\RZ-MM6F"F>7E[WFQ0 MUFCT!2WKV\Z(7=?VT?WHD%4D)M5L>='VN?[_0:>)UF\DU`9-V5E`1O*%S=GLQ\ M5ZYJI=FZ(?W&5H[*E%^\5/DL,_'&0TFCX1W:4IK[]9#FH7SX#SU%YE!P`8*! M?DS_!1D^OC70]Y!A5K=.Z#D=N95=H#B>O`9**A28@X#A=-V/5J;9M2O:47#U MD(;<=T#E>@XZ!&;=#K/'TO3H,6%^8'TJYW)4H!)@*M):FY=\95%T*C8!;&0P'\X'BO^B7Z"%RN6DFV7]9)C?34##&&A/X3@K[E03`2WB+-50[_V15+/>P`8*CB( MZ6BTH?MK+SL[;@@3T0(*Q.PFKQ.P:O+&3VZD%C&I39JV4PX;933&B':VE4UR M6MNCMI37AGE.=8:!SJD"\I)I7TL'H7MQ+)^$3MS2QUA43?:?N12#J;0&9)G" M9YE^.T!E4F9WR>L'UL!,%F?4:6`--:Q@""O>;#+"%@N\:Z-0\5.9VJF+7#&2 MCWRY^#]UL:6NIMZ&?^HKO&;+Q63M977W[V_P:OUOUM-4FWJ@L.D#D/S=73:# M9\JM7-=*&&RN$(H'[%H@ZUK/8X`%N"&X[OSK[6*27G MZJ))8I^VMZ+S+=M[P,NCZGPP&?N99@09<^EHC:6?8,?]%([]D)=XP]2I.#_+Q6#_SZYE])O\N[[.!^7MW![&Z M:@I(+',R'ZB)+O*3AV)8W?[BTPO?YJY+/-?CF)+]-S/K!25"=E_FOYA_M/$E M1V0UNV@/3JWGO_@K!WMO,7I50O;KF>?];>-DF<4).OJ'9-_?N:=>\'D#NM=H MW-=!3@VXWEG_N%IYJ4XQ"DS^V8D#?99R[H,R.)+5$J[/R:O MN%O$7==^Z?66/Y_1DTR'E^="`7OY$UZOS>NU:0DMY]QCQQ^._%P._]`;\T(LOB.+9ZRJLGX: M3\OR9Y7WM,8/_RWYT'.AN-[8S4OB*DZWYNWXNQ_@<1>USP(_N<[6 MUMZV^VZ8_0LZ_:U]+:\V[Y-X#/=+&'G5]5]U_6U9%EDQ0NY8"/F^>=GK;?KA M;].KP^D@\_GO,G%DU?,G`VS+S!J)Q>,6831!U*?_U<-N3I+LMV/+V9W:K!T] MFU51-LLT\J/UNT)%_-6'9TR.U8Y\4/K M>EZ,AW(^U(/N*+E^/\<]J?Y3U%42J$YZ7HOEZJ62WVXMV7:'W32&/U;RI64Z MJF-Q;[<`0L9=)4EB+=&D*:JK$T_;EV"K6[A',XF#2N<7"_&3;(:I[N55/C/= MQL!(VZ(1&&VW6!(1)XGO>8)0SXWC-#!]P(1/$T\L-A(P2YV]?6-?V*S9V4I8 M]@*WVZVK#:X?"BI(ZL:A<&Q&G=B-ZKX'3NJ3XX$;%^-Y);L![H1?1T1.DA#A MI6[*F1<38;L*8#=.6.+N";"&9D^0G\9QS)EC>U'L^'8843\*&`U-]X54^$<% M>9^D2T5N6L;5VA14N*95@S()MS(Y% M-?]8*:I@&.UB"VSJJ-%)!>\W]^U@NPBVNY/MLU&-[]6=@3HSD6I[9T;AQ2I[T$B6PT$KYW=&Y3H$2NM^/,<^8F,] M=*$]GA-`*;Z`:M>4O\,]'\S'JH(/%E^UB_;:XKQPJV2Y8_Y5 MSZ&K9Q@OW7ISB_'RMQC7:Z/NO;9QH@$*NL\"<$1L/=GBML4,3CR?#0K3Z:G4 MPX:U@\O(E+ML]B^02:L&/"^3D73IX#0;@U$Y%E`.@L(>M.=ZT@&P:<.E#VB_ M\\T9;==;L=8V6S+A]#PHW;RP:7S>;HW^^W2"PX#RH1JA]QE;M;2_QY[IOT^K M?^9@\`VF-Q/IF%PP`=\I$[#NSRA?]/GQ/C=M%&&)_Y%+R"%W\NL-K7-Y*F)L MFLNYSR.?VX+;QH",8QYT.G^WFB@>;=,GPNV5).ET.M,?X7-D8T_,19R;3VL@ M$>^74B(:Q->HMN,(#/4X]A,O"`/B@>7NF';S04B#L[=7])\G0._*?;\@G#]- MYS6ZJ6T[*>'"\:A@C">!(VJO$PUH".CV/WCQ=X[P%D&6NS"3+0A[#4?Q:)S: M*6&<4=>)4S?P>5)WL/9(9ZJ"O]2,^R2H6,1^,ZC@$Q@BER-AFE/M.D>!4$*I M1SW?<;@=)I1&#C=S%#SA/=62=AT,^T*Z8?9%ZHC8#P.;QRX3+/3LD-<3'W@< ML(N'M-^\,I)LJ%I);H;R!Y-?.X+%D2N[Z1AQ&B2&E$5)H+O#'(+F`.@ MWD`2GO"!#&SA1-07L8"KD##C26;!5>H0M8K59?`>H-F#-];D@GI_:W(["-*)12G5(!CB* MQSMJB4,XWPZJQ?D*D8HY@8K7:D*\,PI!KB?<=D([MB,1A=3UB`$VBEFG]_<; M>,!=@'8S4(=O8@/&:6P[06R',4D=&W;B^+9I8$Y"W^^P+I"OU#_R)I8&7>3E MAV(RQ;:B[V0M&3EW?&_5D=H[8J.WW3TCM&Z2CS$+G(BE-":^'Q"?,-1$A+J4.)XO0BH$]PT;]F.V;0QZ1RA[WN+3,=4`^`AS M1`D8/86QR#<>M1[A#;<[V` MT5CPFH-OR'(A^Z%A:T9WT+8W""[.;`>T<\*\V!-QPH1+:Y&>!O&Z;<.N]SS\ M_G9]"*,/>1@DP-,),`+73R/F\GH^BT\H/)0RHY90QS_^H)TC=VOJ MY+CH)JM2-^XK-C8:-5.X.PO^.%-]EDIFN.GO^:WG7[=ZYF+`K_\VN/811KS4 MVN#R4+L\&]SNE#C_&IX^67@::&XD.X'CO`9+%5`@]9GA1(^8)P(@J:\N+.OW M:3U#0,:2:YK%DYY/9DTH%%]SG4_R$8Y\A"]-EL*]&BZ-%%%H$U\->L@GV1BG M(;53I5YIYGG1S*DVTF.)!5#L*!_*:?>8'5&3>$V;BW2\W*'<3"AY!*$C$V_. M3552,XA-*4*EJFN2(P%4?__,&LW'8^M+-I[KWOLXY47V_Y>#8/Z:%UC>@?-* M*Y5X.,Q'^6RF;X\JUCET0-(Q)1<<$ZFQ6]3=X&%KU7PVP4TV`PG4&*G\*[QY MHK"A\RFEHP\'QY@YESJ4V)GE@F_&8RAQ71N;KD_G-[>*C]UECUA3UIJ]8\!J MKRA+O@"K98DL"!>H7RESKL#J]UKOM;E>'47:!-LP8GX<,K+[^>Q^6JJT+K-0 M>PB6(K/VTO`@'G#3NU\F<1[+9 M%J)@#VU$G0.)P5Y4O=ND=1WP7_-*Z1O%75'I)O\_C"[XS,L^#^2G1RYD6RQ; MPTDK_WWQZ6+A9BA*6W$%%NB^#YPH)91L2.$R%<5S@B\7E"ZYI-8D=QQSN^F&*Q!HH]0=T4VDA8%#G" M=@F`REW.79,W%PG!_`ZHJS(9-H,ZPY&%($3D_]]-PL%`VH!7V2/Z],/)4":[ M7)JK^+Z9;;LS[EF:,"\.(DI23H,PX6$0F;PA6W1'L_O=4,W^T!YUXQM.DC*/ M\1!$@Y.R.+1#.S4Y7G'*R+)K_NPMH3C"Y=0[_]A,3=MU@PYQA_'B[)E=&'J>']DA`>H)(B^A)/(#

DEBQW'JD`0@K5-:`DX[,"]!O+#ZCJ!M3$ID,A@K,`4EBITD38,Z/NG$ MG0S*98X(YYJI'V;ZU*-E\+K9_2,.:IQY&'H*2F89W^ M%+J\<_B$N1/4FJE(7.<[#'_6*'[U11W)%Z7:^JC>5T5+/N_2 M&.HU$]/Q?:#M"S(_K8SJ7OOY@4Y2W2*\1YZFFA-\D(6Q40]HE>+$3ABG([IB% M;LAB&X=KFQ*\@*3!*F_3*BUD$8;]X%S6^MIPLMBU4R=E`>74"1WN1K%GX'2\ MH&N_'P+GQ^SA0P9:;8$]678"TQ&V@[H3F(EN0)PD$%%49XB!TM2Q$M>!V09A M+RB?.G1!D\"Q07]F;N"1@(9!$M5=[$C8*>`A]GY@JNH(Y>S)L[?+J<*KP=@7V`VF5!P#7'X"*C)#+T$7$RN\GQ5CBZHVH_3"V&^5.K.O\-AN/ M\/-,Y4O,9&='[/J+'^:Z<%QG+\#/,#TFOX%[=(XY9IB@@!XA6`5;>IRKE)K% M.//0&F42<.QFE,&JLB?>G6Q951>7XY MLPH!)^?I>'"4C>)H6HC[,#V2"J)/6?7&_O&^5+OXG8(D<`ZRU?=$]'6;S_95 M3J,`JG=#>0P00V/Y<_^1]:S.\R^S##=GR3"V$(NQ:M,TT(0LI#_0JY<$&]IE MQ;+3^C&[4TBK=DJ-"NI=9O@T$$M!M>AQ&I*J)V:1H;2XFGHL\"[<_6R#_C.G M+7,]K=OZ$8<&OG$+DZ6_`D/X9.")>+7('NET'H;O(,:=8@N6%#V!1%OD/9M] MQ&M=]:/53<=,KPS-P).5(!?7`[X=QFJ_7^<&+'DU[*][W57#;;Y_1(1!WW9Q M)8$_;_$:EIF:^V*U:@>_]7TN"G)$W9HVDB5A'-[F^-4@<$OF\5>-3C44+<>@.\T''L@ MYP9!:]L2G>0AU[$!?+NI$![12=IZ.:J$&#?"'V!1`%^L]V2@B.73'U]W6>_Q MOH"9'_!R'T-/DU@%`KZPSM`1J#;`1/`ZL-C^93>UPLW-,-^04ZIW]>6MQ^[L\SA=1OZ&$4EQ%7D=1L!]?L[7%XO8H!:.'A@PK>TMX8A!A+< M!G_XAB5[P_S^7PW$2FZ9>')1>JH]^IKPVRWBB)*XR92N&#O$-IISXC M[RRS3?N^%I!^T$6V],7UVC"R'4DQZH:!7B[:Z-L/!ED'WO`#S&&V;3"L=43P MPZE`L+Y&!Q..OB*8`3P.W;\'<.W]O,P4I)/,@_FJJ8I1JU[`^KN!<=;*C=X$ MJZH2\P\\;(\+R_9!HKD#BYXQ96GN&=&#XM^A"%+G.K+5)^+&1=$9+SG`5E"S MWL]?%ZJ_T93^(:>@"IQ`-.XG5=1N&VRGH^VI`*"F#G,\NEI6%35.J'8Y2*BJ M-,!B2IV>0FC]K68[>H]N1I_;0>I2J&Q8.8/+8Y4U1;&V]1U6L_1>LI1:18C_ M!"MMK4^9)/(U4LFBFY&D@@H2*(=!7@]T>#]#^`<*?H>-2YP^'50P?&@]BYI. MA"VT^Q#G;H;^0WV?6;9\P'77+%^M\*WEH!QK;U_ROZO!OB%>+@L,X87:]J_+ M=;$DOU1N0]&[=X8+M1Q_<@6CO%W@FZ'J+TY[R[3%>E8'9=1TZ=!*\`WB![LO MUU!4UXH2Y++-WTBP./8B%MNA9_FQ"*3I:4EF<3X%`S#/&>[^GI+GM=(_MP/O M!+%(61`(D4HG]0-FV=)`82S&)NU#V^*.@G@TC*D$F/V&2V:D5);:!YB2.,V%8"P(> M7BC@-O^XDG38`]Y(Q;>@PJ-/TGQ*YA]^2@>M3LMWN92!ZTGA.MQR69JRD(<. M=V283``,`W'/$.>T!A^RWXI-LXG*JBH?X1LRPSLFSK#FH2(L\3R1))++4'I> M:C$_D*"(%4@O<$4Z!918XW;X)<*=5NNS6=QL>&<^?TY\ZQ4^ZQB`>QQU@D0H?!]/'4LZ3-;&=BD^YXYHY) M,Y3ZIWPOL_K^4U72+0/1TR^@]P_;5&78[9W`+4T55LHIX<[EZ-4X2-S(MI/( MXY([/+5%RWL2!?$!6D:+#3'CKQ/X;94_A4!V1.I'TO,=)V)6)/%,@P$M>M&4 MIY!YO[?F:OOI^M,.TRLL2R90YD00BH0;^*RM%YS8G4P[9^P2X:>+$G(L@\"VS M%Q[Y'C_`&^OSL[S]3('?5OE3.'=/VB'8O!7*V!,"=]I;5E(8ELF\XP&%LV;^ MI1!!3(5550L+D=;T6,>4?/,YT\!/?>:EX&^&IQX2X=C""1TH4EPK MMLUZSW&F*!O%`=<3\I@D+Q;X%,(^Y,SQ`B<1GF,%W(=ZO@59<\$FM>.[T?+T M7(&IO_)QI6C9L.%VD]^=3<-J]4?83Z`R8\*,A3XXU"I%]ELZ',[@/]\WQ)@&%R$YB(^"=5.=(@^=Y0/#TCQ M`C%/F$`0!!&LZ,+`2H*41Q'$`'.O8>H[P82-&EQK1/=\'3'YD."?J`EP9@R+ MN)DH0_C_?8F6]WVYWN2U9G.H#_#0#U2-`JA(+==-DLBW[#A,`Q>,)[5EY$+( MFP8XQ[>^!DWS;+V__Y]\O<:_GM#1#Q*/NY[KI4D<@?#7]1ZE8%;C8^C&[/:6@$*XOI2T";.Y()X'`&I""D9MRRYJ"VD+O*U#PERWR MLBRPL2E+1%#`OTXHBKV6T(GP^I44YC3&D[:D:)S&43REB8?8:-MO%C_>U#%M M)[*8A-(I%);+W`CK#5`U8:'OQ(DW34/>5Z'H)7[)693$EAN!._*4<6D%OD,J M>A)R@S-1T0G]KT+%L_U21K&((^GB\;+`26U+NDK!P`:MI_RWG`=?@8(O\$LO M3IGP>"@$LZ6,DBB0'BDJI.?"VF=:\D,9<*&JU5VV+?Y/WUMB]D3@![%=?E)7 M'-*/'U>IV21I-3UT0_8YG)=N`#6J@*P?>VXH?-^SVML_8#DO_^50HA%=4UFN M9OT!_08?>:/=5Y449BHKS&=@^.]G?S.;AK8U_'O[>_;=3$-`_VVTSPA_^H_9 MIKPETA7R^H+SNP]!6C<\5^!Z].?U:64:JT]*[<@YCXWGZL7 M59YO%6)DG=UB+"BKI]E>=6#FLZJHO_2HO13E$,A#Y_O71'&(=%&+'G5N MT/>CUG@(N;<93.`1<'070[B%1JG5!_5#U3:P)*K[ZGPI]O#V]GO[?)WO[G'[F(@5'XK\ ML59\7JN\IT.VVZV)!8B^N]D5^%0]S/=%K<[^ST1+(MN&.T-[WV^WHW?W([>+%><>/GP^SB)WRC'WI)R+#,S1X"*_GRA(VLC MP`GN)@VD:1#BG=<#?,2_=Z@*PA-U;'3H2>C.A#$@,$2=HXUJ\&11+6?_VV05 M0AKK#&UO_[1#`UL_S995N=NA)=SFZ_)1(34(]*&_@-R@N8*%0`%`.,=B2QB) M!]R:ZQ&'ULT&T9%$QJE,=H7`IONCKZ8O[:MR>X=G3LRGS.NVVP8\0%-&@B=L M\T?$#SV!,;R:H/&;Q3Z+"VJV6;,L%'@7T2Z;8TB4NJVR1K>D]FZHWE7Y+JL4 MYC8CU`W9.%DIQN>J673$Q6E9;6;,>O??+>RW:M8:'%CE=_IBWO9M-_FBJ13U M#WXB^4V3K-'>):6X05:]260_8;Z?R1:JC]#>#L^W*LO]MMSG!'=6Q2."X.`C M:+=%[^SVP;%X3N5,\Z._-EN52&DP",6I'WSZ@2@9SHH&^X/8_9D8!DIB*!4JAJCN M)B*TC'G]']\Q%-L(55;T//C5=8N[V7WY"*^IYLHE^]_3O.$$[IYE2YPF M-6Q*)[QKNIA`+8=>T0=>;G,H0VH$;F+@S1`#7G63@=\UV$1S[LRXOB':WJF5 M(@*:O_G)&Z;CPQC1/^0*^B'5^G5.,WWC:W\IK>D5^4T0X6\B0D$U#JY`Z7B) MCB+&"M59BA893<$#"CX5`H=%.J2Q<22IFB+=0^=Z[1@0#Z_1(2;ZF^,8S#?_6S!F]X,NH&*U@Z M0M`=CQK2]V.7:*]/U>"RL']N-C/L>)N=.6D`/QXY=*>[.L>.Y.')!E5P&U/% M!?FR=Y52%U)5]H1OJ'H1GCPX)*`2JR$^[L7DWKO1D^K\KL)C2?E2E]*FP*B/ MO+<]O(22T@!I5')7#@_76:,D@.7`@92,Q2YX7M66)MJUX'_]JZ1Z?C-7IYW0 MPW_"Q8_W?&8V MP6:X"T9_&W2KS5T2M3HY_%"43;U^ZEY^8&G7%M_=BK7*Z52C.BP(!JF+7W7$ M.7]L!\8MN8CCH#E/?/NX=9D]L[`Z,_Z7[I-?,6\!W$++&&Q3`NQP7D M-^6V?Z/U1U?-33\RZ$?1.E["`-#>QF=TKAP__6.[^7)@)TQ^_G'PD'[7B@[; M'SOB/(Q]&4JT5+UR"!#':XUCA_C.C7I=BQZWO>O)&)F=]X%2(!;H"5'I%[JQ M![^"8:WMO0UG!W_O7OZTNJ^\GH_&I@=48[@)^JF#P!F." ML7PT37HTS!#.-=L"=4KT1_+?J+DR,`J\/PI;)IKQ&W.+IOS6[!*E:A%!YFO/ MI_<:/V,6AJ@]V=I>B'%;EE_HSJF\US]2"R4HXI;$!T`L([]16VI]K7EB[Z_, M+/(GN8N$=F!A:6C:Z!NU:*7[[31%F]DS)8;@.1*BZ"UJ[![NE`M!Q;36=`2U MF;7[?*U6"E2ZU5U:@NG\ZL=%FR3$[&VMCC&/3S%C@[*]AP7-VNP4MM4CWAY9 MT>Y MJ5:$!\K.MN"CABX>[Z9P7S>['3P08@CNQ33K%0BDH`39KM>Y57'"K'G4AL>. M-@4.O:HG7H\$`W)SN4'.HV^5R>]`24#PC%$M\B->D@8_=O6"ZA,M-TANB84* MMJO:1'R\3OGQ1W$C#I0FD%'/+"_PHV3\M[FZ+.Y(U4#IJ$:Q#`A@WM^W[PBU M<--/K<$1/3)!H_1:"0/4!_Z:Y*#Q,D">;#@B[:?QECQM]\.M@5&E\YQ+'(H` M>A"0!<401_3*-GKHKB52:=$0!IE$M$GF1?#7NRK;#&XDQ5+("$Q3IV6@?P\D M4%P,J'.STX0,&/"(XTE]OQ\:"06(=#5[16MRN-*:6$_2OB2&;_;-:-[-1QMK M4+NKQ/85OI%NSKI.JJ?;%ZET(J(9BJO-OGQ'2`O=UNVW3J^FQ'7$I\M!#2I$ MMYN;+=W;7)<0^ZJ9:0RHR,N'1;*NRJ=9G#?[&LS^0[-^R+;YDWHV_C>36;4C MR>9@"Y\F;_X0?Q@`2$Q0N6V*]=(`);?+>1O7P2X)E]46HKV"PMS$?-;J,\KJ M+_CWS\7R#E8M/=;/]LF38=)_F(P)NO6=[E%COE.#N<,%V/5(#_G520_/7SKB M.AK#?UM:DI%1"_:XZ MC(2&&2$(8E&5CS#7IFRFQ&04>H/@_GOI1G26?>56@YZ[WEW2`(CL.KHYUU'K MW3(C^K2=AA/KQ#6V[1^Z3WRB3XS,^^1U)L]^'U[788_-()5K,Z*8A;Q, M7J?=LRW^]_W2#2]F[D%=H0RM5[J"PUU#6I<1_YBN]!9FAUBW`ALTQ]HG?Y)V MTE]Z27\E>=6/DWT=K%1$!WF%HF0+_UZHS>RO4(U_C4[*#RW[/!7>/IS=I9W6XYU??%RN`;<6MXCMU)2B#J)V1C_!4;EBT% M8_O00?7<:^CU0DJ'UCQM%\)[M%KMWA\*F)(H'[BG960L.S+&E,5'?^ MZ;F7JS35V;2N+;HVD%D#FLJB["A_50)QYP9QJ]O>V;+==O4/7N)L_W;7'; M]\Z#.??9SMZ9>Y@&`7(IP^BU#^J.C@'CNAF2205&\%KNR=")_=`-KG9:4B9/().`:)!(8YML,41&8RC41JPJSPTP.\0?S%HG_*GB@! MIF7U.5<'(M7FURDZC\&G95GO(N53) M]@2]1Y18%B1(P6/I(DTSCZ2?^A9/;3\('3Z-D,Z0Q^289[C^MZ$:Q1BR"O$;27DZPQ*2.6\M!S.?=\!W);DIK` M($4P&=T#DHYE>*FDIUCKF.]!M1+[CN\S1R:>9+[A*(?QGM#X8&0[-+#GB?MS M*1:T#C.;-Y\0M@0FG1C0TN6,G('OR3`57A2FKFTG(C$LM'&:IM8D=8Q):,\7 M[7HJG;`>)V11!($H!.=TDRBV@R@RUI-R9Q*2N'UX3BY6J2H7>;ZLTZK:#NAGTX(A/T1?_V;#ZDR:]Z>\K+#_?T[;NWO M_R0#[+*407)G/BQ,$B+GM@54>5X4,):F_F0)'8QO"'C5"-.U'Q\5VBOY+:\6 M1:W8#R[R.\^5D>!>&$G+=J'`ALHY,'E)!%.";>8?U>"@0*^6_T3"E';`8\?C4+2P)`@L%R)*N^*U#]"$>A8+KB_Y M3_FE*W4)!2Q8=Q2$@4BM*$JY9:X/L$4XI5'T[3/%!E%>(_1S@\V"*+#!)YD/ MGN"[4D)B--=A,UA&3(4>E^.7"/U0X,DUJ-SCLKG=KYJU,`<=+KYS/!4B#*`H M#-P@M%@H?*>]QCT14^YCVQM+?526UTA](A0*-W5#']MUJ4BD;0?,E(/@HU"- M3`DH)]'\3+$_Y[NVG/]_]JZMN6T<6;^?JOT/K-1,C5.E>'B_9':WBA=Q)W6R MF^PD>_),2[3$#45J",J.__UI@*0NEFU9%"B!4D]-S4@R`0*-[D:CT=W?QSR; M?(V+F1_-Z7WG1UK+[M--FC2`A/O2W@_,H>(H+AR`0)][FJ,JZM*O:VG;?MU- M-M]C:!SGM*N"O@8GT:$::(ZFFF:H6*!WFG+J:KB-!J#PFM+:"9;Y`UB([PHY MH%U)4`,V*E@)1X-_`@T,6;.I9F_`:KGFV94$W71)^-.HH#B=%Q8=>\1;^V`5 M\GYH6`L6=>&8:[:9GU\C2!>;_KI:.)[#E9;*G`;%<`C6>RU)?I*O%:[Q?,NP MPZ?FS:L8T8HI^;#A.F=SXLGNJPC5N8WQ>!W362*-YYIS@D(/2]<3Y* MK*BBOJ)*&?$+:9=Y9XNO)5P_J6X&=0T]^M.V?%3XW^RB2ZK-O`IV>L#J\RPU M>)4$1,,@5L7\=E;BN:E<61*AOJQ:):Z%G[/@VF6EYHC5Q*7!1@UB>5,VMW[/ M:G9Q-198%J%5*>F+$GW?&PW3I8JLLJM?/_ZU;NT3KKT9S$[YL/ZS2C?:T-O%A^HDY..MSL M;V\4\XU4Y/?UE^7#OY;CU_;>A(%?3+N@)<_UX] MO_%3I:'4E5)B2G/^0V*VAM28BSOGL*:R*23&+5@B[Z?)&-0TWUUJN4V_'!*\ ML13+X6IOQ"+D$\3;WC4[]:VY-`A^#U(*13[DP^[X4#CB"44PY#SD/.2\<^,\ MD??>5H9A38V:8ML$X4/S??CS\0&7)X&WLWZO/E#_5KX@438F;[O@VA-0^/2, M&\2CNJQZY2K;KO_?4IF*QZ_]U:<7R9EU<`#R(_*C$/S8A/@C0R)#"L&0F\!R MW1J?T>C[A!73?5=?/8]&<7Q[>SY6)VNWS.0[Y8GR65IS.UAV2<*?N*G'72SW M$@D[H!3C5JZD,C2EV"X^CY=;" M%)5*%I=>3UNT2S;\T?^"LK5/?D\T]\7J]5OG_)\1>*EC>UMO6#:WA8RDBYO%ES?'D*;0>ZJU^^$CJ/ZFJX9 MNBH/AYKC.PWT:N!M(\HY:H>C[!Q(SO9-TU=T7S&KC,,'2W80A+6'L,<;,^DZ[GR6%[7MG1+&1I.$%B6 MX9N68U3`D+*A:+ZSK6L4HZMY/P_$XFF.YYN>[@:^ZO@@B#4LHJ[XOFQLJYI' M`*2\QO@2PHVB*KX6:D/3]&0#-*`LVPQI,K2LH>H.M^!+8.OO:HQ'Y1_5U6Q+ M,\,@!+6H&;`ZJL?FK6FV8VA;(#FJ>?IYM]410>#:RM"6+7WHP8P-3_%TIB-" M`S9`;PLW2F>(8_O-M8R2+!X/HR*#9X@[&BUF"V:$!#$L2K(GA)'GN(I.P5Y! MRCV**JH/APW8B2>K\A/XMPZH@$>CWC6FP^?PDF2%6J`%X5#7P=QP'46S7=MH ML*,T6W&VYZ"KFOG8)MIW#G=QMFAA%7DRJ%++`P7DJ!374M&]!BM'44-WB^"* M:CB/R5V]^K4#VF%+AI81!K!7Z13(2E8#4VZ0MX(PE+<-%T4%(>8PH*60K>`# M:U2]+_&$%?5H5-#O<926TV]QFM*_[A!!W0K`*':'=A!ZLF,/?5"R#'<\FIW`AO^?I+"8UEN&N.9F6K=G!<&C8:JC(+N@76V%STDS+ ML[:!#'5YB[N[G=-_LBB%HPZ5%C\OYA3S8)>J',I>H(6>'3B!9AB&HL*6R.:D MNSX,8&O+/BJ_P0DTFL0?HYM=*Z.`T>O#_F9X?BA;+FQPU"B$6:B*Y=KV$ZB[ M^F/K:+^YZ-USF^L'JAN&P'$AR(:IZ:Y&YQ2`(:4&AK.-#N?8CS'*.I[3Z]?' M'(:NZ2J>8<+``T6W`U>E<_%"6;#91A!LF9"6;!^FJ?>=30L]8'BN[YH>G#!@FS-"QW4-MD(^G!XU ML-(YZH%]9_.!E@NJ`4*&:3)+L@KD:0?L;*!9BJ[!\1`4@!9XLNP,XVC"NIF^&ZAP*C:M8!@, M&^,A`*OR%%AYG:)X4!R8"N3B)D[S^QKX!9XA#,RE1@++)A3R99&6M`*IM,(N MENZGR6A:P].`>)05/,UX;>G6P<1VHM209EWI:U8-KR6I6G<8Z@\*HU.]EO92 M)"26*O`,^LX+$HXX8MQ!?%;`FOLXU\ MUSVTS782>YN^KU_T:^\I%"?WP[]RO#MJM*WULG$]UG_@&DN]MF0'#&'3,*EO MV/Z9&XJ-=2"(C6G^W!+6HVT[X]@O%'N@)P0MZ?7]^W*X9@>UT04K//F5[7/_ MS!EXV_#I'8YGG@2RUT6Q5U/7M%.>$B\!KF,H;O;X9D7]!"OJ"OBVH7HG/`H7%]*#87+S:J-C`Y MEJL0??$/E9B>G/@ZWI[_$8&Q?97FA+R5;HM\]IP?_I1Z2!2.XZ9N^J15-&XU M&4591A&W6E%HY#!.=`?GI!,ZZ#!>=% M?@=D)LS14"^/=/,@D2KP](68-;)OT-H.*M5RV11\I+T]'E"M5%1<)N+$^<3P2?<1X18A:7"-D*01GS6#TJC/)JA>^AC=;*S+]Z1D MYCMI`D,WO&1K!OU:P&A42E$Q([](:9Q-8"VK]O."*HIK:?-=44IRNMA4]1") MU.J$OJR*C6>\TP3(0V,0+Q*OGJMB:4?T8G9,W[O>-PQ@E),21@Q/E.F#=)^4 MTSJH]HG.&SDSK:R)@VZ&QBQ<1]OH%>7D1CA$I^H1AA80_#N'7+%\D^5%( MSK*KI2J]6FI<(4C[8]!^+==86B8;70L;O/Q^@%UZ`1'A7+WBG:VGL^'!]OBXCU'&HX]J12@&CW\'#-^_0 MUIYDAG(GX:=E#<>D*J)8I8BV\7[O0BD_.%WNV**F.]SPB$19;@X&P?FNMZ9Q M.\3A>O=@O:],;LZSB\F@.F-NT`:JS4WA7PQ#7)"M1-N1Q?R9*<.4?GLAW-V: MEQ6;115UH:/6I\P5NXA"V$UL[86$3=0H"%)$2%RVBF7;)8)')?1) M9=<:J"JW\AJMR28*9QW3\KX<'M,&EFTBCR&/=7J;:^L=`5$CCR&/L7;F0.<8 M,8`\)A!?'6;L"G=3B<*[O4'(`TWG=DB]>.GMR2W<8\FLW3PT:U<@*=V5@M(! MW9!62"ND%=**F[F&NAWYJ@VM]JY4]U(MH`UBZC;GR45OI?64WE&3TDNC<-(% MK9I&XA3&-!E(DSB+BRAE-0:B\2S)$E+2D)V[F-5[8L"D):ORY-=EFZ81D;*\ ME%;]E[F4E,N23[2P5'A"Q%`^9=8&&W,&NBV*@M>X?U)X([3FM]5J#390<>M* M7DDF+9[AAFJ16%&HZ`9$C_XTRK,L'K&J7+3&%WNDB%EK^AN\BB[VJI=I'(W_ M7$1%&1>LU-BG-((F`^E_HXQ$P`PORA?6R\)Z65@O"\AFP7M;)"(_ULK!>UL70'NME]>%*$?D:ZV6=Z-(2ZV5ASN[1`@:, MP3%0G'K!-;0=U@=!.3Q1]+"B&RB'*(50WT@F_SBYWK--2B'*(=8+TL4 MWNE:&K%>5DN7$>HXU''M2*6H`\W`>EF7%*F/];).5+Q!X7:XOHS*#6?-#8K# M+5%;E(7E8!Z>[WI?Z18W'S>*?__901E8_,`)+H8A+LB4HNT.+Z=U@^6T7BRG M)2L*"N$^0L@UB^CDUL?I4IQN3IOB]/)RUY__^NN"O)M$T?S]E]$T'B_2^-/M M,"N3\N%;,HX_9+%\1[^%SDX\6H)&XV M;L+\O@(K>S"V[W__R_](TE^W7_-'#'.$1HL"2``-_XA3.@^?SG?9F*;Z4*'X M([[]VYLPH+E3_U;^_35X(R5C^"$:E>\<6[&'$LSXAE3WB9<+[WI$>N%=>'F7@$THEB<&^5`$/A2.>$(1 M##D/.0\Y[]PX3^2]5^#:!P(XLZNO]/'W20G=CVI/_P?JW\H7),K&[<)1Q$C& M%(QQ@W@4SV[BHDV9"-&H>;;Z]"(YTY]&Q81?_BKR(_+C0?SX.7I@%V_(D,B0 M0C#D1GFG5V>;889VJ['26F] MWF)1?:'Z:D2\XC5O&!Q8, M0-6'JN^HJD]7L%0?%\L-[W%WDMBC[K0ID#@G-"$AOX'7L'R3-E[@0P$Z>Y?= MIO.K-["+-J(P3.>G*>'$3SC+XG+EK8MR82AW*'A'PXIO=28714KY M';M1'%$!J[> M-%&(SL]A=C`7\]]X.[CMU+D5>VM/,%%XY[B'!;$5HW!V"^HZU'7"1':@JD-5 MAZH.59VHJNY*,_D%X1Y,,?1)H2I$58BJ\"2JT+0Z\OI=HMFW=XW5EPIVOJJ2 MYG-E.+],HR+V(D*?G\WCC+#PBR\E-/DTIQ^)6U>0_$K'N4]ESB`TY*'BJ):A M>I[K.X8_]"Q#MQW'"#Q=[;XRYR-Q4ZZM!LE*=E;5-@]])>M/FL.?\C&GPIVOG87PM3UW M)'V>;R5,V[ZV34NQ+>-G?O4PU0/K8>KZSRTK!+9MIQ[[A<=NUYN!:F*_L"

%BHXT7&^\9^`$O9I>4E)K$T M_!$7HX3$TN1-Y,T#2FE.)D4\H3@Z'X`3DXPD(^G_HG0!G)BT*0%Y1@6/ M&H\63P[^M"A)"02ELG\3I;3ZD1254G=U(<6A;,\4`T_""7/KH`\40QX81O=RM8`")I`#07AN$R(O7AAM(U];_#)J15]Z5#2"*AHD'!(."2<$X3CFS.VP)HH(=&TJH4R<,0:]?&UPRPU$@;@8 M@4#Z('V0/B+9]:\\)?7>X&_"#[B9_'B\%(%PPAP2KC1K8/`[)&#:'`I?UX>. M[@3Q^*<1':\X4+;.:6-#PB'AD'!XQ7'(B6>>%'C%(;+W09S3BR$;/`/2\)2" M(G/F-R#*M8I7@B@0)]]#D#Y('Z3/`6;_I=R`A'EQ&R<<@Y[P]-E1NMN9WI#8 M&M<;DD.)>-EG$Q3>(Y24.*<;%N-H^!AX`X.RB81#PB'A>DRX$Y;[Z@*']XA5 M"%C)1^G92H_H&A#&==(/Z&MMX-@FSP26B\"Y1GDZWC&I6]D[_E')/!JP)XHB MBF*/K2J^I;58._N:6R0H\E5?^8J_4O])55\-$,8!%[5C5V*/STP5?(,45^D\ MK`A\9V>ZL<>VO$=G-+-:WXN,N14Y-3NSOW&JZ%RN<(?MD4PW(V( M^#EZF(%`N_=1,5[OCY:;9R]Q"5G,JM_V1D=4-,77]5#5S*'IA$/7,4R]0D?T M+"O0_<[1$4\"A1@EA73'JO7GMPSC& M=!\1*89IS"CVI91GK/&8X@3`FUB_TH(TG7HI2.P[6/,\!3K6^(OS(J%H>/"N M<9Q*]PF\L-R`;[QO8#&B&A8C6JT_%X3`HZQ#*WOHE1.X6(A#P[R6#=WD"G&H M'8AP:#AMX>K:0B.J%N+"NCQE85];=N M6?/L./"/A'Q_=TLM[X2N2DQ*J8C*?2!I+TKY*==VQ[KOM"YI44XIWQZ[Y#8] MC"_X%2M?XBG.-F>M87^2K[577UAU=`_0WF__Z$X@GM!^_HCG.:QS-@D2,DIS MLBCV6$EF5[GN7Y0\-D))&XN*/0\72T`_9'>C<690]2$4>$Q/#O M6$I*`@^RM8*?:QZ7REQBLUE=@"39+?6_LSN2X@)XGBS0J4OKJNR2^AW%AT_D6Z3+,I&293"+V21PB_0R=;:MJ$[NX?BTE-# M=/)>^CV.4IA:!`;]MSA-,U@8Z6I:_5B`Q255B\6>AIF,TD65`IGDL[@LZ$*/ M8%246.3M`'J#5])-\&-T`_VD$>Q$49D7#U));\:@(7W1]Z1DW ML8DTAZ6-V7;.&"0A4J6A!VL4&L'.'"7T77=QMH"ATUF-H`'&`4H=XU!S<.R)=!NO"Y4-8M3>^)^FHRFFU-*@:;);0)-8&+/T`_^`CU3 MVK&/BZ*@LZUO->MIL3<`+>EUZ28=8&@-@>CZ,8ZXR],[.CMX=$*-5Z7KK6NTFC3J1 M@/E6G$/WHGHW^$]&"W-)7ZB"(0-&U5=T6PL,[13,-A8B\%R?0&:>QH#XQDN7 M`1_5Q?Q*8]_$8+PTZTJ8JJTLZEJS5%)4[4I/Q7Z0.OBCIR+`V)5J@VOI`SUZ MC9:ZA&U3(DZH(#IB'!4RGL,)S4$FCRBD&I\ETWHC;6A=I-U&!E MVS@++MIM)X"Q'!4S\HN4QMD$UK)J3P.-F)[9>%>4DIPN-MT_U_0@M2:VK<3* M0"#QIKX$,X3Z'L;TO1O&X"_,]H$1PQ,EZ,@UW?>4"5K+8:5=R^D"]&R65XZ_ MAF/C-%D:)K#/%_&?"UI"_1#E*;ZFO/0@)VLM&O7@\";%.C"^2=&5^8]V@4I. MVX:VWK9EZX:MQVKB6,]EK+2D[O^S=V6];5Q9^GV`_@^&T0\90';??>E)![AK M1C/M>$T:>0K*5%DJA"+5+-*)YM?/N<5%I%A<791(J6#$CDV1=_C0 M7(H'XO*(9[&._7Y3??UUW8#^YX=13TH@#]GXJ!=#36#5`O\PP,]%OBWD M#P)Y;;VSQ?XAL/^YEW6G-2W7']ST=YS+."FX3W94O]7KG<.8_C#K;@OU$YH? M;+SE_6'2`VO*)[1[*_9WIT]^+X4\0ZJYQ10GK35[U2!;.VSML`FHR!G??@U? M:X>M';9V>"`[U.KP"UQ.0FM:.VSM\-'L<.[F3VN-#V&-I[(3Z>A*1JV/:WW< MGI?.(.AO<"OD2:O-M[JWT[OUV3B$;V=7.HI>IW^=O_BNVR\/LV5A'^`>]9M+ MF&[L.QZ/1=P-!`1/5]YT^TN-K;R?@+R_$XT5SY8=_*[,G\B7*#]A;:!G1#7F M\)^-0CRC6"F]KQS=K&`96/JO->/N\F8X5K-LC"Y\T-[9XQ,V0LANFO^2SZ=M MA.UJD?U!7KC7NMS'HED/&7D_'QVC9U*)5L=: M'3MH-U>QQO*`5L=:':MYGSAC#4X,M#IV1'KU;<'NT74J6^-=/B#0&67-?:OJ M<[?>$^G"W;?,29DGW=H](BO==`7E8=9/MEBU6+58M5B=2M?@J+%J]6KW0&*[ M3[SY_V)]?!)L62\652\AVW4&V^P;'IC8-SO,, MN*5-FPW1_5?\&C>Z?RPM*ZRD=399*[JPR:OHO1BMT(:QD*JE4-EG,+WT3YU^ MKY=WJJU#MYR]^-^L5V:@#&OM MJ]V7U>[+:O=EM;0>'ZWMOJPC7R]Q2ONR=FE M#?;MOJQ3:"FV>MWNRWJDIF6[+ZN]L_M@`P/\#'-T<+A.0FO2^]K](*T=/M+T M,&:\MDZ3^NV^K$=:WH`;2ZZ?Q^:&)ZT-6#=V4?M8!-M`>/ATY?T= MDXW5N%OS/WUUP&>RN2\G>#8*\8Q"J?2^;U^G];E=I[5VG1;"N#7"78RPT5M$ MCQY]/-X5I\^/>\5IO;@G___]WT;EJ\LLN_G[9!'8AQR(3.F=+\H.9':C0?X) ME-+"4W[_X2__\>+%]W=OJ(C_<4RZZ5V8!<+#GS=YKTST]Y)6?\B__.-E].GR MTWO\_I-_^>(B[Q376;?\Q\M7].6+X@)>SCK#5T8[;[06R$N&/)(<42(Y4UI[ M'JQS+U^,>L7XXT;EQ>P&`ZJ`(HUY*XF9)[NQMW<_ M\BZ[3?]D_L@&%^'?HV)X>]X#D8TJNWP+5CSX=)7UWMZDCRAC?_`E+X9@9^6_ M*M>47Q@X?;++_$?X\*$'VXY9,?@EZXX6%3`!@]_3<@B6^>IS>FYGCK0L/?RW M"?F_5:1\NKW)S9]%^=O5U6__,^K>IO?_U._]DI?PS(_I8ZH?>Y-??\X'\V"3 M.:RM\\H2&I``?)FG"$45!0_.V.!`SQ>Q?I_H!?([$)\H>&\Q1$C/1[ M"B?=UTI(E:RWDBS2.TN6>.M#%)$Q1KDQE&%E(S;4&<0"5FB59-%KQI^K9*LG ME^>]=^.+PRLB:KZB$@5`?19E;TPO5-MW^;Y^6RH,Y_BG.B M8E1CP1CQP3B.M2':J.B"DE@CRN.\$9:)L1+LCS*&-WN]YD$Y`E$\G*=<%).6 M0F&'73248P-G._PY/I>LI.`Y:\1$T3:GZ%.5TF&=W:)P"/;(.HVP<\&C2(BE M?JE>+-4?%/^77]3ZA29S#6JH5)0PJ8P57`B+I_!B0UD-O**I M5&,5RT>%J`&/H;9!,E(+P8`(#F'I*(%85$T:-$(ZA/#*Q/FI0'E>I<+D379+ M]&HXKZLM@AD$>.`(4H,N^85M\&4H&.F""-%:D>KJF-FI"[;!BSH7W%AEXG3P MW19.X1W2EFJ)&8G714O&G,`K^9C,FD4 M5E8XH@VR@@E#&)D":F)]B$"0IH<`]#['QXCK%D?58N,U>H#312()CPH1C,1= MU3AH68>O.(R^G@*\NSC:5W@^IZ4,22:4ADD`L5Y%2".81E4S,8$/,K6ZH:GT0X-9QUC2< M-T65D/TSCCAOQ#Y7\]$L4'/YU?Y` M&:&H\1S3B)BQ'%&FV73^15ED:H!2*61L#J<:-IK%:;$9\^.@7V[.SO?.<+2S M$51,*R0954(X9&>-$*]5;>D=(LDF`:WA]Q$`I0T!2ADU6$`8CB%O-)%H&VCT M@C-,6;"(UP#Z#+'<+I_AT0E.F&&&ZN@H5R[B""F-8UY&"&:>`Y:;#7T[++7E M01..6)"1.FRQP&IJZ%3X4#N@T5"H?2R`)CS1>]:_V6(6QN>="M'TEBJ=&3]C MJ_JF$ZG-(2DJO3G$9N$"37Q%KNJ`\0?(=I MV".LJCO-V6F?/KL-1:X`<2'R5MY`X&.QI)8:'B57C(63#O72]X;PW'!2]LNC48%F3PBP4(RA!WN@H)79&,CA@=.#3T-(S MYI>FP`EIU&17LG$PM%9ER/0]6S>0Z7Q0W%-/P7:=`HV[2U6,KCM(&$[)RF&@ M.D2&O`5$:XL(D,(YRXV%--@1YS"+:%9$")S7!=540_"-T.N3!*FQ,D(D2$AO MP*%A'$-4B$X'%:WTR,C5SDPTZ,RVY.Q(X+QGK/-P.D28$"3$J*T2$(M@IJ=P M&FS#:CAE$V/NCP+GN,IX7I:C=<-L&S*4G5NN5#@2K=+!*.2UQDYJ&UT00FB4 M^C`'RE3JF'U0'#=D)SOCZ+"V.DA/J>/.":*=B&,<%031ZE#9_[+(WRV#B^2^7+)A%F@@IF M$,?!..^Q)!'YJ2O5*)A5"./79!<%;9C+AC&N*7TVB;%E5CBP=NU\-)'QJ,TL ML@3,[6HMYK)!C'?DLF&,UV92W^8DA/&&*A%T5(;![T;-HE)KU#IX=[G.V!R# M-!`V#@;7/>7]D%]G10_"7`>P#0"24=;=5L&L=&D2$EMG?.0`F%=TUD!5EH"" MB5_U&ZR:4+#].6D6RM69P2H"R!90"DX%=2:("&DD5:!Y9I9$1FHM0*E^%6^: MPW$/-IK%6BF9&,?J?@1V?CG^\7$,/U>JGX6C*_._-?F<53QP;30-BA!LTK:%607? MV+J!F7D<=J:P>0XWEMX90CAXCX33B"J"P#1FT^\(U5U(3+/O37-YU>]>Y(-R M/(R]VWE#3*!>BQB858P'([R@T^%+`/),"RX@-$89,R8:8W=?8I:9Z+HNO(6$/&M>V M`")UTA*!#;(I&D;@<-241FID75_^6VC#3-!"$U'(=`#3%]U1NJ=3 MX3T7M&QS/**%=0)P-D+VR!U"Q@6,C9XURK"4=<5.H17E5,VEZ3O2V#"#RZ?C M/(,(2V*%8(&(%`54#F2F/3S4S=%+Q#`23!^6P:5W09)=='9E+V!%M,`@/HFB M#(Q0/.FZ>W`XKF[8<&OVZBELE+GURHE-L(@H)(*$1-1)HO%,.5$@=;YI:^5< MQ]S5U=_-Q451399TS>4@KP+>%1M:V'MB;@:8O\)B5CM/]R[S?X_@3>$K_#:; M15GQ^K22?I=!@NMUA"F*(%8/1@7P*-$YBXU)>XYX5:+X_F_KZ+SCY!)>N,R& M-:W[V371JJ0_&G2N()A/I?V:>RTX?'SW;H+RJI3#(*P)XL001S7VGFD]N[.B MHZ7W72$=G]%[$MDLAV0K#EVZ[1@T)E(8!(&J@/AT&E`YM,PA;XK#A]=!&K17 MF''IL($0!DY=A$`'C1`<.T+G=7"%YKENO[Q+)6:/&_;/>V6J@(':KN;G37:+ MR2M,9_2>5VO[/Z:K$E7ZF0%`G?SC59X/JP6#4SNX6P!9VEOXRTV_S+H_#OJC MF_*\6F`Y61()CRQZD.],OA@`('TO]/!V#%5C0!OD MM%8V1*TDB=A%)T5TUA*G/$2-+`'M*Z"W!O1.!'>UBG\67W)P>W.Y',!6+<@8 MK_/ZN7S(?C+X%/_8P[ONC"]7@&G;YD-;M?O\M-*J,#3N6>I M88%BH0`$2@&*]&N^9G6W;(*.,=E$_X$Y_715#+9G-(T]6R0T9++>,2&UXPH8 M9=0A@BWRM8R2'1E=<'[K?9^%0ZES]?9SM[BLV65:EZ'Q^10(11&\2+EX@,-" M!Q"I(T,, MI3H`12RF&7W)%1@@Q]0NRX_O(\`%\)N6'HAO'`2)1Y#>Q[38.+\L.J;;+=)# M9O(S99D/R\:E-V]]&&3E)266&&>#89`EX>B$ME1`OHN7ZB-4[F5^3U=ZCVI[ MT@7'(&'27%-(<,$(I8E.*:O`J4JRU&D]/MN;5,@>Q6OV!T,(KBZ*SL=\\+7H MY/\L>OD&<(F4==0003C$FS0`TE(I3B#/7G)VBCV.N?@?[7^YRP">]:FVN/Q-4FTUTR*`H`DS!G'P ME"1"2`*21DN%6;Z'F/>5TCX:\=_][D7Z'D-SW1_5K1LX'1OTP=`0C#.$,JLE MYL9!YJN4D2P2"/J7KF>@O6QP$;!OASR)LM\#.-_V:IL$)P._M9YB"G&"=]Y* M*<`/`OPV."&4\;AV-.!;X9\'KT%1?/JC?\JBT`0;;!U.FP$('$&6I.WURK,` M$@INJ7O4K"@`O&\1Q8>\FX-WMZ,2&"U+G]V6V9=A/IC4J9;*>B"6C_G-<'P7 M4P^O7E$TO#HV0=V-"5NEI3#,H%3))MBGVQ="P@'BC0LB%4"IWU<0&Z#;1RKG MH"@%P#,^D?XHAE=S9U(;%4P;9LRF*S14(!\YP81%RR`JP)I2+Q;[@?M'!6M% ML8]LQUVK_I>I^LPLN+;=?\3.;Z$U2Z3W1@T1.;F(_&K M"=^_=::,0U"PJU16@[B/2&;S@/?"O1K?]]SL;?Z`$RX0BK$BT44-H;?PE;TQ MI$'R3"Q5)XC>ZX!;+XTY^:8O::@N!/2_3)WOO_J#W]-<9W93#+/N5H.6"]$4 M@4,":S@=!$.1:4CF9VM7L$1+'D4LU%\VTC.C/;4G;R:BO%B[R?FNL&?3

M!<02QBA.E1)1"$9-L!Y.LM13H&\J2NY_^MUCJ^YD5/#!DEK/HT1:F$3&N+.QZ6%W5)4W-Y-EQ_-+CE>E1FOGBZ1% M%N1&"1(X$F13JT$(20-ER-ME#9V="&N)6"!UIUVGJX>U+/&*$<4854Y2$I## M$4BE:08.2USW!3KSJ=,Z2OZ_O>M_;MM&]O\*)WWOFL[(#D&0()GV,D.0X#5M M6K=I.IW[J4-)E,TK1>I(*8[?7_]V`8*D)$K^$MJUD[33CDV3P&*QV/WL8H'= M(K?=A,:C&T']2UK-8":2\_1L\5-2_96N[W2]@0_3[@B/^Y;OF'$+-V5Q_@:6VER%8T&__@NTQ9NRKL\* MK63.%G'V0;]QZ[)SP@&)(68<Q]9ML1J+38=(D`.0T`:C'7XE8,VA?TG)J?VW*VG1-$>V>+[;W)-V52-.HQ M2A?PPESN09\5(L_.,[#0G:V^I1ZDG#FAZ5#?CBS+%*9KFQ208QQ%!$RP-UB4 MP%.:Y",)W1IP>;-VRH%VWJ8UP.0;9,+VD88M(N:'GN=QZIN@\[D5`G3VX5]9 M5FTO=.UTJG\<0Z7AQIH!33V'_V M:J?P;;]B+6Z\U\;/Z:7QMEPFQ<&*M\?JYO;*%/]G`[!K<356X5SYZZ7J:@KN MA6JHY9)QYU*_C[H.\0`_Y:.LF(-N>&G9(U"M')3O*`T:67&8`Y.1B&9C M$PV3>*G<'Z!9^6-(?U$:92\'?)Y.86[&E-LOZZSW75Q64L@_=DIG95Y6+[]2 M'H@B&2Q;J>#02V2,ZF]]`>O-6,+'%\9*`H]Z'&F25VP_V#"DGOA'LEQ]^Q5A MYK=:88PS%%P%J*ZVU4]6@,H"HVX`(JU!!RZJ4CGD`#UQH90M^,25-9:B8N.N M>1S:6*29HY(V,0#E2T3\/LVOP!KT+)"::,\B[K>U4:1KI6,W>(`3-&_#>)B" M!+\&WP%GIUE7/7FO&QD](#O&95+?G#?78*1M.58<(R,K\&T>@7FL#:`$G'3@ M"AC>SD`##\K-^87D!SA0*Q=)=(8S;XJ.0!76WLQCKXEIV1T^(Z@-N!]'#N8P[K,,PQJSXU:QW>P MJ\XZ3B1:+HNB41ZX92<_KE)P;E7.&WR0R4A9M4+;GQH7:3+_[R:IUFE5&^O2 M.,L3^&1B_`A+(H$F)?#&X'4VQ6."^`HVB:;ZF*&>=W/^3Y-\K1R&/X#1N!=A+%2P`-4P3D;3,SI&XT&* M^P1.2OYY4DN?XFTV/P?>H(G\`?B5(C-!BE0%%J.-V2$?I_![GM1UMLC@`7`R M49'2BS2?2TN.5@OX<%;`BKLR$)GMK[=4UJE$T846TA7MA/-=.A&5VHJBV#]N_D&^_T?I![\]BZ&N62M]` M:B/YV?1*OI/,`&%7P#GX8ZT#6EK9#+DN97N@IC8V>%I,-=-NOX(B7%^F:;$U M`3J`IGL[-9Z_31?X;6G\7((J9=\T1FMG6(A`\LT\O857I>`V`>S,C'%X^A[S=7L.]S45MC?V5'1X[_A/(PPH3Q?K!]M; M,G`EK>$_P/R-FWT%XG;M;M%$>@E+Z85/C.=:#6'H4*GDGK6_5@IZYG^BW-$? MTQR4GA&#NBMF&?@#OX#"*M#K>_UZ8KSY90M-[+Z\!2>>5UNVVD=;S\[^C(0F=N6!T MJ0NU\1S#("K!09O\ZP3[&V.S0IX\&0$[-88D89`=\])`*-$`<>-[["\\F&-`/FF\3N;LE87I6'QC;K;:IC@Z.CAU2EA?4HB,P*&G)P*P> MFVRP=Y?XOU%H*T9R7J>=[>YG2=S"H=0/2EB6(;E:<(%^Z/8Y.`?9V M(;#16EUK`;"E1(*A(;Q3"(3E]6)[5ZF6%D7J#^@(E#"8AWJQR4%[IQ^`,@"9 MB^1]634X!O2E"BTU^"?]D-5RKWPF\Q-;HS;9U<\'=;I4_PB'GHI@?!*2?:T( MXH:*]*/>)U56;NI.BB>-C9=R-2#D"@A7J0POSK>D#7=29A<8,`%3BSM_"),% M?_TN"C1&?@Y<+:0^G,I;?G'_!;1VO=:;@[+[$E#X.OF`Z&6>K@!?9%T,"1JJ MUDU0Z1MHY3PKBG;1RNW7RS1_WT_BP+_^L(%UU82L;;0M77AI*:]Y56S!K1C25WJOR%S M_[\D7MSCIE2PJK+<(*Q9W1VZTI<^]13?3H2%?#,QPK=OE#>.+\D0\2H9:V.* MWE?N,*YG[04V^]]ZK[HYK*@S-:3GU;R2?I#NVP35!N8V(&Y&%S'/AY*VE.^( M6AU+Y*0&)MRI37=@ZU0G'^R$UG7W.TI-AKK!/4%Z.[HQ@Z_6^1MU@GN'QE^` M,Y#@->("C7"^P9$-`" M"%*F$!"+'HSFF5;!"C2M5@C4AKK:@66JIQF(/5BPJOZ2"'V?J[Z?V]%;\_I` ME$(^N`%]=/'_%/T4WN/J-\<-"&PM?SG:YF3:EYVBAT78(%]K3+!,9FKU2_6V MJLKWV3S=PL02EB;M&<46G(&<904>,4E,8F7^LD).ED-4FE:I(OLE7G4:88U&Z,^C:L`5*; MU`?,B%?!=]QY2_2=\G/5"L*;5;,I^#7@G84$,M+!TTHC@5]0,=1EOD$25*P3 MP=MNL*6)XF!P)T^J,FIG!CE'B9KC:ETIZ/HB"]2NR^UW5D)J<&U>SZ, M2[%*\W8.4)M@`B9`9X/H:%UC*J!'W6HI+0(>)48AEO,L(W1Z\^QPKWI_4T8. M9E5Y@@DPY3*;=61?J(]G\H`FIGJKU;.4`MID-:6+13;+TF)VA0+6_V(.`WF? M5E>:E-\+#/L9\M2^E'.T:GKOYMZB@4\ZE>)!)/9X@!BSF5'>\)5I6J0+U"$R M(WX[7U\=X]&9[&TZ?9DW[]6-.]J>09FH^3\DI*UN5V"H3M._I-#4:Z!H*8/B M.ZZ6DLLMB=06(2MF6+HI[;8*%8%;YY1ZAY"V5R3&K9$ETB;4FZ;Y]8%-JL8- M;8*%^*WNO=NU[[8^A_KI+7@51;_5[I""HIWON4APM6,X=Y/C^0N\\QX-A-I: M[1_#+N8[9D4YP3**J\YPK)N#VHL1L,)WYFB/.^UB+7&Z`[$]&F4,Y! ML-ZG.2XEQ7@MT4KR8$G5>-J^Q&4ZV?KNF+3+286O9N#OUH>.U^R'SB9W.Q6A M@DC=1M+1H_]#>]R'S"4Z[;WUB<%OJ3.6:;I6YX&PAT(.$A[CWSLETIU%.I3\ MU)T)W=I/6)1YKBCQ?VA>$D1D) M*\#+LC@HCL!C9NS2,(Y,QFS6OSMV*@LV_%G*7IZ](NK"OIW.=X@J%V?ZY.P; MU&^W+;D8NTX0,2LT><1%$5'#A]2]];H_H_BFOX@0"W1Z!>X2T MA+X%B:M`XF46=GB!V+@>OO#GUKU]'3?720%OB-WAD%9`+59-3C/!\OHZ`95R:Q>.9U#6F ML'VG*TWFD:$BP.TU;X^*3P\R>UL]GBUVJ;OGN0I%&-O,<7A`349CB]@LT$76 MA&\'`W-%S(>8K&O8\O%3,U@[^_;UH(EGQY;%?,I)Y`O&;=_VM+`[EO"'K@FT M[8]EX"#Q'\\3;$\5/6NN^_LWH*XX.W!W5BN%\MOVKC2LO)7G?OZPR:\LT_1A8:@I MEXR5KQVO?15%7`0TI)XC8N$3CX8DT%<'6D$H/@E^EIM;6K2]:GD'Q=&A5AR1 M(/29:X+E(@'QM'9$B7PX]L$8_S;VC2>.0<2=F`D_,BU!W-!SXXCKNGLV<[W/ ME)]W5I>!1<$/8$Q8%@]]:@K'M#4_8\?W/P5^#M;_&!4#@0L3>^AHV9'ON`!5 M*?@Q82RX93/;Y@\GE?UJ'0_,Q/%DTHFPC"3S;&X3XCH>`;#3W&S?OC"Q!X%CHAS:U>!2;%C%];NFRS%$4?A8V9X]YTKZLRU`E$^IXS;46 MQP_<,+($]7U!79<`Q`RQH'/`(W!_XJTR,T]U6;^3)Z/O1Q1MVPXYI0(\0RL$ M3>CA927:1[0$?S!1E(/\^Q@XGF8,33.B+C/]@##'#6EDN9'F:.QP\KEP]*.1 MN>]9W`Z%YWD1)R;S8L#C$IG;PF3,&S38GQ`C#S-&A('O$A%'(@3;(2.U4N6% MA)B.&PW&=>Y%Y3VV-7MGMX6[CNE0SICMF#PR3<<]=F1`"I.[`>"NYXC6&`&5+2`D8)1?SAS M_N#A2X*`"2>P;1*:EA]+MR[V76:1X!-FRH@(VG?`CE@`GZ/(IY8( M`$9+!$U]:@?^PVVH/KYU>A?'+@Y#YMC@?X0^L3CX(T$3\F*N$YN#D8:_B9M8 MP?'L?5K]@:L]GN]E27Y7![L>L<$C>T(Y.[IA-YG%L1B7BC MP0!84R:P[*3Y[R.<.$;O]E"G1Y@XO>I>.KEX(,H#(V7CCW>UW6]V?[\=1',\%Y53`/&O.!@ MLRZ7(%8S7'U9(07L%SP<4F==OMQQGMPL2.^QO)W<6R_Q.G.SG[@"C\F'!QG9M'(CT/B(L=XP#SAA$,+ MQGPH;LW3[&6@+Q:*\^3\L$!T]@$6!">F;P>@!NT8`P"67A`P4/KLU0*XD'[W M8J_QKL]0G4`\W[9\2@!J@_?2)IY0TWGVZN2$ M6">4*`(.]=31$I6SS;)]1?$XEN>NKB?&$MQWL?PZ_A!P9@EBZ6U(AUO`BU\; M.@[VA^N9(;5,WDX)B]T8ZQD3>XB0MI=],A2--Y\8 M007U'!(P@/8L\(5/0J;3)[W8%HJ($Y.V\:FNPY%L<[65V&*UR/FKXMY^N''].HF/8>[5D"HE@)8*"XL:/@'JW@31_4_V-,>(>5R619RY2IC<=:[I6[7F-F_ M6L&JHN81_P'PBTU]"R.C@2<(T-OD'[B$!LZ0'G)-&_AI^UM$'Z%J=P1QEJ=5 MB)>AE=5-&,E\&H-WZ#$,0]B$60#,M0@![`)&_@8C@S:-MZD^?M^_7]V=DOXJWQ_=F; MG\1OQNN?PSXQV_TI:O*L^.OEHBS71;E.W\`OQ@?YJ"KQA-+%>KUZ^>+%Y>7E MZ8=IE9^6U?D+\''H"_SS"WSQ6?/^&L3WG\^`?'EWU3/9N&X>($?SUD6%@_M* M!<]`1?HVY[XI8L%HQ&W7C%TWMJ(88#[CNN4\F::Y#KA=\\V?^33?IDC"G1*P M](L;D,1@D02,^D%`+%A)@GLAZ"Q7`)H`O&V&0R1=]\V-2=*3$%0S`V^IK_[Y MC.@/DVIVS80T;[S`@WTGNBG].9[,O`L'2_BH:>J$>M2,F>=X'F!M<#D$C6Q0 M,I8%2)3%5K`_3B#I[QGCK::D/T8BW`B\B,B!1<9CZG`_,F&,X':"%0DYN=48 M=V3E+GW<9!'N\D'1!*:RVJL=- M"G2I@[M[1U7QI)T\)=RVC[>7K-N;ENI3(]XOH#A0^^P?6U6D#A1`Z]`L``00E#@``!#D!``#E75ESVS@2 M?M^J_0]:S[,BWD?,SQ!*;HEF!4S&N<%,7LXV#P]/3TX3FDZ0="QP-#T\S! M3ZV]$OQ__958GW_5UXV^J7]XSJ.S'FM7EK)TI2>("XQ__^>+C9*&!"R`SH MA*13R#]@,AUPH<$YRI/\+KZGD#.TYW@Q"[@A'R<48E;"A+5:MS1ST>9?:A2* MEQE\/LN3Z2QE+1X(-.D2"I2D^<&6;>G),_">I`E.X'`+MQ4%F7A!IM.DX`]0 M/LRB"Y(5[*%ASURCB2T4Y9O8RMWM]849G.7,6Q'OCLY1RA^[T02@N$>4&3&! M(L&HV>A#RI!L^!MME6G>B#T5,/?I77R!\LEU2I[R'QDJHX3]VM[>=N5(;L`= MDYT_Y,>VH*8@04VXA&0UXM:;6"$HRH0DQ_.'N(3HM<$-UM3J2#7L&Z+\TR.T MZJP.*T.JX3\_#?.!-:8K)/7I!!M\F?9<+&Q)=Z.W;$1%??"HU]TL*,*9)QBR!N5TZX`2WA MV",NRAR",A8._!::@LS-L^O$,UX]N4>Z&C" M0I8F`_=K2#2J)7B-BH),?("\H"4NF).R\06K9]S4>==I2#2J%6XM%"6:V&;: MUZPGR,`1C%OT)=M2@BMOY;0]PH)-:>.<:EE1AO"'^!SE$%V0Z0RRO,5(6*\C MU;#A$Z+1$+/XK^WLX?!RI#;@BI5*7@"J?[U/4=:2GH)*E]K8NQG_]X&DZ36A M'/$CFM94EM2&C`J"_UA8\!^4EJL`OIS.OSK&8X>5++61K?JB%IJ51F*4XC*= M2]\RH:4HM^:X!9=%9?!<0!;Q#)^DZBK](+W6ZH4.L=6V7KQ05JT"K-^RI*#& M@GV5SJMDE:8$;SZ@BXKF2Z@QRL/Y@F>9]\<(S0;LT34'D!;YZAO^,)M]35\N MQOZR_#K8S)ZE*(3T\QFK*M@4"#0,N@FFUO<=V^GK.AA]SP.WKQNF;D8ZT@S7 MVFQ`RA>4"5V!)KD%%R6E:UGVO0U9R@5:9.@.\IUCVK-&@R'%/4(CH)_/]+/> M$R3C23'_N"@!4;S#CLVU[Z7$@/7_TWF)_:2`Z4H_IF1ZO%N(6$"8R=*=RU>C M>"_!_ES]62:/*)WW&\4%HO2%]1M\Y(0:I[?2#W3/-#3#,DZ;#&_R)%&#EPJN M##$F);/V`3`PR]G$Y!L4+?J%&K5`LRW-TAT)S#!.C!F"85)!B+5D^CWE0W'Q M\AND$8LB1HS7S>&;JZ M9H)X%E@GQ@(AX"@9+^8V'M0C[%/A@+DZ,B2,$_:)N5\@1"I(L.JH>(:L8#,? M/NN9\>"4C6XU1*A3"WQ+"TW+D-`7J)PT'!5;",:G4R9\H22OBY#K%7EK'11& MUJD&%^)+)[#>2X4/FLZ_R;-;F1H[N'Y7RZSZP M.6H8$P6,"J??)BA,TJ1@T1??Y\)7ER8D97CGG*ZO.[DJ_-^D&CB@0Z1'?\'L M[YKIS=/W76'>,C<.921XU(S.8EU')."E,O5WCUYX9JI]TF]3(=!LQ^2CRCM@ MPYL!#*=+K?Q-6Y#V!(- M6!.0K6L2)A5=T>!HOVWO1#@>,B611Q0E'"^4WJ,DNLDNT"PI4+IF?5T4TJ@< M:([C:#Y"ISK3D$\4*2"JH,X#W^V80;0Z6+.1E(P3G-1-3IN5`V2:R#5U"=11 M,RV13QTI(*J@S@8$38//KG`0&H;OQC(VO"E:&1`\#1$"D:HY1\.>[3W3CSU: M;%C5#;!"";V$FHTK4H,7L<"M$>338&L/N>"-Y8?.(K<<-/CF2=:$>TH>$X;]^=\@8P;@JR:O6GAFO2J16*@0H=+W8T26DS-2$LQVR1ABB#7S9.C(\F00U M]V"Q4?H+B[[YU2)WV662STB.TKOX.GG>OM-KC2/'%AE@V[)]UKP^]D#KVR8+ M\%Q'8_^$$-J^A;180+@C,_+M@$8=@*[F>-#F=/`FVSWC5---M5$/'`/KEH$D M[*&SWRW=)`/<#;4JKIAKQ:DUO<`Q'=OR;`ED]B]=.==00J$8KL/T8:ZXO(TNNO?LA4RRP*@C$P%I<5GU;?Q)T0RYP M,3:P:3@K M6;!!+XL[8\D0,_0HO.4(#L<67\&&Z)' MUI8%,V]X*,(RLOEJEB"['EGEX:QFO_9LV5\OUL"^`YTN-YO?HXZ M"AY02H!T7?-T2^[6F@[&5BD\V-G;+1-GE3.Y`Y)>^U38],$);=T[W0W?'3)) M(*BJYV1K=\SG5\]`<9*_[OYMF)%5Z@:^J7E@>R=[J*1+'DD`MZ,MY8VOV%2T MI[R[Q)RT!;FED9PD!TYNFY4#1S,T7\]O-$7[<72D3#Y:B-=L&PQ>GY-;> MKO@UR0A_Y]E-5@!E82`+`39+69R4^0K%A,`G3F[@FS`KF!]N+-!E1 MEQK2BJ;:P4SNTA5*;G=9+4BT&@LJI`-/,[PH=D_V./Y?E@/;5\,(P5[)FC&_ M@Y3-V.+:4]AK4H&-/1SJL813#6HX=+1OMI=YC\)&34+G$;*R-D6]$@F0Y?FF M;Y]L#_%F;^RD5=X,B)KST7EQ%W\A))J?!@;ZF&#(1R2MBWKW*P6&`2Y(.=RF M*&\BRN]",5)R[`A25N;X"V2L6TOYA;[1-,F2O."=W"-]+PTW-D+#_9<*5P\.N>(#T.(80RSVH=DJ,$(22DI5'DI'- MUC=W%'MU`C?R#,\]W<7K4PDK1'I`30YG`4XSM[8D`\?U8N09+81@R8C%:%HD4X*.82#IB[=SX;6I9GG;%I=GY/:HQ$XNH:1;\F=C,@<.I3D MT47@IGX9Z#+)\0(/B%[A^`8L9&<-&A8%3<*RX`?`OI,'F/$3/-GXBBG47G4M MK`Z&H1M9AHSLF;)=G%+6'=5BVL59J]5>T[HD^AZ5P/80^&YXLAGUCGS=<-SJ M"'A5$*@2IJH+1BH%5W#6T$U,!8$9&MC"(.'<0Q>Q?5?D[,P9DC=.74)R27"Y M?LQF:V/4JO+CJJETF_H:OR&ZR.Y>\AN5TPXL^/EI<9"T,SN^\V=$:KTU5S%U M5*T"L-CH%&WR9]E$JT%%E(K4=*@8GE00$TM*II$4#9? MQ<4ES]4/QQ1@8\>?TDJ5-#C/5Y?\WP.=WX>HNCX%S:Q;O5157T?-E#_NCF`L M_1E9U:$`Q%55"H"KO0!678W#)T2CY?D.%0-'M157TUE*7@"J?^4'OY5XO[+V MQ8&4!Y*FUX1RM#JS9.U\#'\=QVIF7TX71V8ZLZOY:?DTX#^%3)']Y_]02P,$ M%`````@`87"O1`VUI-.`*P``[18"`!,`'`!H:"TR,#$T,#,S,5]D968N>&UL M550)``-6`7535@%U4W5X"P`!!"4.```$.0$``.Q=67/C.))^WXC]#]Z:9[=Q M'QU=.X&SIR;<715V]_7U"RY*-T4!1)R79%1W3)$H[$ MEQ^`3"`!_/+WK^/1R>F#R)RV1X\B4M;T[^G7SRZ2AD*TY/[U*? MS#^%+__\%!?)R=S79=(B794P%`K/_O/;^>4,C=-T4I3Q9)"\"7"= MG/R29Z/D(KDZJ?[]X^+=HP)NLNPVR6^RT3@I?AIDX[,JT9F.B[1X?_4A3XJ@ MF!FT08)*D)]O\N0JE'`3`(($X#D\?]N0H?QVF[Q]4Z3CVU$`YZQ%D6Q2QNFH MV%FR)_FZ$_!#-DH':;*[A$\SMB2BR<;CM*SZ6J$F0Y--RM"_0O?<*F*-C-V+ M6$O=]?.W)O"D"-H:5B.7CD=5M[N\29+R0YP'(6Z2,AW$VX7>I8R.!6\H:Y?B M789>D"_1[GU:?/2:W!:KC,>XB_N:1.&_$Q_C3:-I75R=F2D._&MW&:5YWB_=5Y-KD^#SH=SE'9+&.- MC-V+6(L"]?.W)7!P)L;)Q_CK-CVO2-B^"/4P6IN^-8$^!P5D^58S;D7"]D6H MBEW#B?L^7>L"U(1C3?*V MQ,GB27`.+I/!-`^@J^L\F=M46\3:EJUK\>J!5S-W:\(6A8OS2;50\R')+V^" MR[)-P/4Y.A2J)GA;,[8DXD52E/ET4`8E3:Y-J.=ZV^"]*4>'0M7"K4;&#D6L M8_9MS]>2@)?)=8VQY&FJEBNOI;0UB5L6I8YR5J=M2Y"J$^NX2(8F&]\FDZ+& M3+@Y3Z>"J2]Q/E2#X/_5M1YV+Z?3!KA0:O8M25;_^F$43VK2LZ72.VWL^]OJ M_Q?9:.2SO$)\CZ9M*ZO3AER6V>#/N03_BD?3A0,_'<^^VD=CNY7<:2-KC44U M&O+Z4C8;!RG3X?U!K(^*J9546E24>>J4 M,A@:JB#FRG!$Y*)ES$BWK67WA%'YX"3+ATG^]LT2C[ONL]-H?Y5GX[;5DK6. M1!`\?#'KVS\/1EF8%M^^"8Y45^V,.M M2#49JN%PIJQX5*WW![FGH;?J;^&/VZR(1[_FV?2V"$6,IE5DRNH]`?4UW=2) M^A$@4E!#SC$7CFDAH14*$,8,=%\`+S;W&QO`%-M!K%*VT\#KCXEK+\GLF'AMYLD,J MY`=I'V+4/UD?M?0'5U?J80M'GSCK-S?191FJ3*[3@1J-T@JPY8['?!OZMT>^ MT@-^U<@]6K3-`PYZXL;A#/1V@#F0TK>: M'VOS1$0IK!"B2"#,$:7.(+UH7YA'\?%:Q7MK;#L#]L+HY7'AZ(S-XZ'`P56_ MUC[8F#[24AL@L>*$6D/?':NNO:6F11@)@0K!W,GA2QBI'[S&3Q!^U[INO*_<'69?$>%38K;9-#*8-2T MXL@8&OQMJ:@37CG!N`9!;Q9Y#3RQN-E*!GYA].L)W3XLG?DRS/NK'5J_P0YJ M4%J$C#'$,HZ$8`I"`-#]:J-SIIEW3(Z>Z-Q.[:62[SU]/3NN1!SN"Z6:,% M=$`8"A$!),BIH6)$0%X^,-(&D*R'5.$P?#32-7\.NNX:JR[-QXND@BO\^L2X&`7K M8W*]MY&XN?A(4RJ\%@P3B2'5VA+@@[%"@)0&AMFG$6?$<^#,H3#$6&`@$IZ*@SF`!EL@#=:(\.=Q=(VXH)\#ESH"J,'NO[E M['&P:2_EZ47`?JJ,4$&2#Q<##-"5P94.$ M.880)J3?ZJ<]5SULB^+O28)(!C]0"N$%IX@XAH!%^`Y_:HAH9ONT?##@*/G8 M>YAV$WW].+YPN/XUBR<@F@O%F8302\X(QPZ+A;H4%EJ+,FRGD!VD?8G1T06JO ME*O[QL-G>1DJ&Z:#RR3_G`Z2RKC;&`2_/D.$A%2$>`:QI<;I4),F"W/00KOU M1/#S./M06R-9!Z#U,0A]R+-!D@P+'R"SP<7]E9X60>ZB2#;9BC5R M1P)RHPSC6#%LB3.2"KAHLP>N+S^J)E&>@T?5/NK/-=Q2,B?#F,P`=D"%(=IY M*Q>MA,*JXXJ:.V9N]:>%+KGVCVPT_!0/_E3C;-I"R.;CXB)%!(=8(L,L`EP! MS.024^=DLUB7SH+D7@[;]E)#'W2[2$9)7"2+X=?&WXKXJDSRMG;L:]838<

JG2^;^/JUTDUTM)*\"5[/)PXLG M&Y-U?=&1L!HZC(%1`BLOD6=R.5$@XO1Q!0N^''ZVII+^0I/_D8R&/LNK$"TS MS?/5,7';LD2A20H!#;``Q'*`%"-XV>%.-A!I799(00RTUE1R2JV781"']JYUG!O4[!AG9X&4SX%(+4'=GS>Q M'#3?3U9M3[=5=.28@IH*[Z'GE%=[0&`Q(G/*9#.J=19_>,F5XB9PE`-@/*0RC&-JZ[KH<]7#L<2.*2@--Y0J3ZQD MQ#INS`)_JT&S=>EG'#M6FX\'BAW;35\_8L<.'#OFPAPG:)AS-7#5+I`!$<&>XU9Z8MP"&VDA>/6Q8[7) MTU(\3C.%_"#M0XQ>:^S8L7'UF&+'*F=5*P$9L"38?S:8A&HAJR'TR&[)ZEPC M]6+'=@.M]T%HVWGIS\EDNLDUV[VPB'*"M618*^2`<49B)!:($&F:;2>^B,BR MIOY6YTKHB9:KK@ZKT*\V'.919-W.UC1HBAX4&@@=+G5-E MH11:WMGJ"AJ,FJVKOHCPM3T(?`#-/+?=3"V)HQP!5-VVJ)@P5"Q;YQ1H]@+" MBPAD:\J[EJ`^V/`8..^NKI)!.;N1;*?+WQJ5%VECG)!`"0TYA_3^B/?YPD]2TW+ MFRQ/RV^U]F6>9HB8%,P)XK@F`&$+*1`5JDY`:WC`^1CW49IJ=.5VQYZ(]&&N M?2_HUJ7<=5DBIHTW7G%)0SL]"]Z-DG>MLSITI&/?8&BNKJW:WPNAE\:#(UVS M/[SZ#Z'V,LF#9W&WW':W+/SNXG+KXR1;!CW$GH-0>284-, MPT6`CE=/]U'9=QQH$YX^J#";^8*[>1Y4,?KG-$^+83J[B'+[.S6;^VL\IY+J1UU M4%)D%T@909J]&=+=DS7M4:=7W#I=$BL\P=`;Y+RATAB#K=P>]OE<]7`L4>U(,>LLYCZ8 MQ<@)"HBQ=_@C95!?5S8>351[;3X>**I]-WT=^6KG_?Q=\:KBT$ZAZ`]S1=!# MS!U&`#L=?(1@[C$<@-$`\X`.Z\OU/[8UU?WU%X]1NR%U;6*0XIJ7#` MX5\B<%]V5K/8F*8Z?;HFUR%B!QA$7NQ1/`X]I@I`RZ3GW%CNA%G8P,@TO')L M]T6@EVQ*'8?J7M>I)LR-)%A(0)#C6B$&G%Q@$S[Y9V/)'9P\+1UO:J:0'Z1] MB-&QFYBOA:L[<;3CHWA*.(>0(AQR;`$FW'"VD-4+U>RVJ:,[BE=;(_6.XNT& MVLX*OJR,W.0Z':A@`U<]8OE([7R[:9.NZ^6-E.+.`D,(A4)(8QF1U6WC;V]5MY(.>>8$MPRK%#EI0&. MJA98(+#COMD=&IV=`>JSXW>!7R^+%8^?O_T8*M[B(Z[)$4D/C#:<(B&$,]0" M9."L2[>D<]_./^FJ:?@^53O:Q>SJ+9PI3XKWBT\?J. M6ODC+B``0%5!;QQ#001=FF,$X[NRL/'J'*ED??_YWE?P8! M3'R;EO%H!77J98PH=\IY+RUTP=U"7""\,+B(E:#98947<4G&KISI!/#^-M,6 M%WB8.29!XGM0MFZ$;^IH$V6F&HT++]6#<1<4;OTPQ%US1R-E_&V4X\CXQXJ.0`E.W[; M"4%.M6),`".9]$HK:I;>OE;-[@!Z&6\['8*2NZND#_>BQHOS&_R-.N_56XQ" M!P26<4"TQ4XP!9<;]88TC$,"KY&'W<'>!]6J=K^_,GD2(/3Q(!VEY;??XJ_I M>#K669YG7^8KE>&7^R/>*SBW2S&1X,$.T11)JC!53@NL\1T*E&#:\,#%J]Z7 MZ!#_G>?@5;*<9_'D3AY;:2\9ZK@($$S<*+U./XV2BV20I)_7G+S>O]`(2&:- M=M12A%UH/@%Z`2R5I-D$XU<"@NSMVI]].R*.-)A=Z.%/PN M?Q3F!(,UY\X+"QV"U'F^\,:\,`V9]ZKW1KH`OLN5&1-:G0[7/X6P1VD11DAZ MQ`V%$@A/W9).U=#II6SG(=_U(ZIUKF0+AD\@ MQV4RF,ZN[EV\LFVEEU+CDK6-^2*BN"00(T=9]0P]HDC;^5/PX3^W M/<2VO[9NN\AL;9X("4D!08!2Y0"AE`@$[MJ(#2>RV2BY\R"Y\>JQEK148ZYL M@DD7UWM]/ZE^3,?)AR1/L^&:HT??I8FD\5H`Y@U1QE(K!!-Z`0SDOB_5[G38 MJ`6E9.W@L;/9 M.!R+EOK7SIH#-H=1SIY*^7_VKJVY;1Q9_R7<+X^XSLZIV4DJR/ M1[ETX,D@>&I/0RDV0'C-A9.R.212-Y.\"AXE=).>N-0/#F\UOTD:SJSBB&(E M,168*[A#$U(]LH*RP_G1>@+L;20D<:Q,W,RX%48*2(RCW#F^,"OVQ"^VG?B(P9;!CFADE*$P7'(P7.^JQSI.38KDV9>2D$%C#B\I+L[%. M2+IY7ZVF\1>3VV-)!J=_)'`:M3A&L!5QH7CL%34-Q!1&-2]+7(K=(!Y"7'J$ MZU*GSQ^+AZB"-4>F6=[?SS:)-%]5)\E/]C<#$@AA*X7'TDE'I5+.-?@`FIEB M7^SV[W"G5`GTAMJ./E3SM`I^F/1:+6[J9;->/Z3LR+K\1\N.=/)W@B;"P[BT M($.:\;CFF-KA(+7/"SL6N[!;;E,JA5AGT_Q'XMQD-7_\5*WN9XLZO3+.:K_5 MW?I:8(AR@QD0(*("&2-:-&%:*HS,JQ90[DYL[Q9UWPB5S=I=KM=QBLDN6\== MZ^/=9%7].'S/^:T_#W?)U%:UV,QN9O.'U)QKFW0[J];N>\K`KFZ>BL#=?WW8 MU*Q[]^7UU'=R))*H3NM`.-*-VAJ((=JIGHT-7=XT7E=!OB2F)=( M_1W#IJ$?]W^@I>M!P5$#$=`X9"%S1M9_O,$-8Y`C0Y6[[I1J="G97(Z5+4/8 M#OLG>U)[L+97`X%"6":DL)PY1#1$5C744@)'W(9X%#)PDER>#?=;%[+1I'>] M:=D:7J8^;I;3_[[[FD!J;PGQ^MF@&,:(`4PIBR@Y:QQQ.WI\9DRO6"9*?^QY MK0Z>"%`(,&+2F5&=GUC1YXM"R!2^>X?A-X-E$A2=FV:>B[=U^^S*:5 M>2IM=>Q:UJEO!\\@E5`3`KR-&IE2*%U[WU(AP4BN:O7/W7(8=>;T7JMN;W&R M_;P^_?U`.-#$(:X%<,)B)AP6#27,J)%UP"QB3I0$;(B-_8?);]'XL)S/_7+U M]V1U'&1]A^J%7@B$V*DQ1I*&S MSG$CB0`-=5Z!O)5>[+)D*<;W!,_@$8;:Q54RSO#QR;\YQ!"7#%]LY_"A^KI< MI;ZKORZ^+%?WDRU!K>&+4UX/U%"E/+=(<(<`XM:8:"42J@W%G,'6;I2EPQ=' MB-"/VU^>'L8X^6M!84.8)(`X%H'0&DCFM[@@X41FQZ5^PQG],OA@.*,4:*,- M:[RJXOU;8FYBY/&0QI&W`F.D;DQ!H;TT0OW3I.(L[!Z MN[(QNA#'^$3B`KF`U3Q^\_:7:E&M)O.Z_\-]Y$+4ER8)= MOA,89E)+KBA(_R#,2#0V:ARP\I(.E6.?US`CEZ>O=9>"B`V31=HT$-GVHFRL MD185Y.A[@0'I=#R;H910:A2-4DJ;PUDKF:>$%"[T.J02TB=ZP^PO]?1:CY8? MG@L>.IKJ#UM`O0/$&)\"44]T(,#$>-6,GOCSTUYQ/CK7R^W1*0YC8/*9\=*Z M"D@\UKY.%H]N/FMN9!\^Z%O?284Z&790&=4#!AD<6LU2U9/?)I];^//ZN9"J$$,&%+`>&Z6(M@XV,].6YE6-*!99 MZ($[9R+0G3>U._U?M3O]8[7Z-IL>,7&./A^@QU0(S75R66*-(.&[F0*4:

145[):BVH>?#UH0C7!<]YBRN!=[*]!NY?O< MHF#%:@V>S;/>D!@F)/^M6CRTA.&?'@F*.\RX!M`1I`4'SCO5S%X0.U3?L6Y\ M+!,)R<1D"(YN,\$2P'&'NGJ>#C((=CVH,E*+62\]@*@&_!<7XO(R[ MTMI*&3Z?#\\@%T_7Z^IHO;2G!P*R5AJI./7`8!G_5F8GK)K:O$)HI16=,HS- M0F0(7C8VKOL^V]27@XZ5"UET#&TPE()3"@-@IH[;E$%@'!\S(B2RM( M97A\-CI%LV0:)T;YS)BZ&$.JHIYN*E>+=>E.R?L'5"GO24TWLV^SS>-%4VCV M3V^UFBQNG]Q,C\^/;/.MZLG_=DJ"S=D?#U&RXTY$-!%4.4ET5.TE`-I;SQWC MI+5.2/'TFS82UX=H[)"4<]X8(=V44MY;$K=TBJ2F'-(MAE9).53$ZWBJSH"B M\T11G&-;);27SP45%4'O:#0*D[I`4GE.UQ`OY6`]MG.C9T.Q M_K7J=0:&@T15LG%YIFQQ\WX^69Q4-ZK$<$&"U/7+F&B>"J0D<82H!E4DM!YO M1"]3.EYO<.,!]1^1[0?=T84EKUA2AY?0W8WD#L70#KX37.I]3CGVRCB!M1(J M6G1;O8>RP0K+G&KD7I3%AZZ&GPEJYX#"_SS,'^/WY._+Q9_5>E/=U#.H*3P6 M5VA]+0A`C2=."4^D\SJ:]KY9>^*^>N'(,P%,`U4QX@S)*'(Z\%#:6G MD#FBB,9`,JCISBB2$(VLJ]ZXY*$_7#O+0T,ZR9:>89 MIYV7&%/.`SH2_O>%YR#72K?4MACK+Q\+7J?R!XIPS"`F&`J#04,%E"0O]C%< MINN%;/4S(!Q2$%HMEE?K@UJ.--384@(-`CR*]4ZD"55RO.9Q'D,.I*&/G=8''HZD2BTU= M5&=5JH!W6S6_?[^:38^&(`>=2,#*:8BADMQC(U#*;M@Q77F:M_]=SG=14,K' MS)?.9V%$>T8M$5AJ#@UI$+%Q![DRKTK_DGII MR`?;IC^W$_CY)`+]9+;Z=2$!>,F0Y`UB[>-Q2)Q1O.($YR:N&P/Y9&,/RY:I7 MR"460U#0E4R%K71-I-=SQ?*R9?D_.`.@>3^]V&V>?QUD6J^ MUHZ8=YN[:O7I;K+8*CB_Q$]LUD><%4-/(3`K&3=&`0^,1''A/7MW/#8L3P'N MW;?R5WIZUL"9\$\:B&/C'BB\2<,7BS[$J)]TL!1A16(.$V505*X7B^QXX9=WK>"P)0( M0Z!4D5"+E(!D1Z%S8RGBT[?X#(77XL?V[]]>MQ(_/E$P%YIXWV5`@FT_Y+@=KMQBGLF<5SV3?/+QLM/`.P M+/;]_I!0V%XL7*N'S=UR=2#_H.6-X*$"0*7R^QA"(G24_)W(6X!'TH(W&^-E M"12Z\^SC^_=?'U;3NR1UD\V!#?OU4P%@I4&ZNB]4G*"3'-/F(K`7`.8=]R4, MGK-Y#JWNEP^+(VK9P5<" M)4@IQABQ$4D=EQ5FKIDO4J"YV.U/'N0IA[VG_?8@``.@D[<-_'QM M^]>%FDXCE)/%M/I[MKF+%L8RU4.??JI63<^K]ZOEMUDJ*Y&S590:,A#J*=*, MXU0MS!%*`-0-7ASRO,L3O><$][6=C`3&SF)7.ZY.3@(_]'1PC#N(!#1>"F@! M%YJAW2P]RRRP`OKF]F5].CVAUY-[.(GANV_5ZJ^[V?3NR8OYUVP^?S>==@L_ M'/M.\!C'[1)X!"&!R#FF\>[`9,CD'2DE?$'G\Z;-@=LC3J.V7SMX$HN-%2RG MB"ANC*7$>(RH16QW6"L]5!_C`>5N+%A>DVQ^F\SFJ1R>7Z[J!3F`B+X>,F"N MI$\E5>.JCT:%\\3L5CY"(L_J*N'-&ZVDG@GI<-'65_-./ZINU&+Q,)G/'S\M M?W]6`_4RE4OXTE0'>PXOIF>^5].'U*+>W$6CI>=`;8DI!NHDT$(@3JTDEEMB M\$Y`/%%Y18U*N`_+*P'7P8)1+8D?"'GWY371PR^`E@D%3*S!%'NJ(&-&6[^`CUI!>4+AR9E0\O;3OG%"ZNT<>1WW"D*1C0O<*_5\ M;KJ\5.P2_K_QJ"(]X#B$/.Z,S+Q3!-]BEC3\] M'(##*IXJ#ELGD?*`,.B\$083P[W5K?ZK0E1=5>]%XY1RR&D.)8T$`4`=VV+( M%,+CZ+UX!NN+]5+L!MSD;?52M!QRK`!7PONT]2$D34,\REVPW`4BO$U-*:+AR\B$ON4U0\M8I;L>!//:CC>9A&9TC%(A[HL4/\1V7[0 M'5Y4._52O"I)/=.59JMI;;6D7?]%6=#6_E?M[P5F@$NE-8@AG`-G!<2TF3G6 M>F3--2[+O&4Y8+NGAZS(;DTYG%FR M[\JZ)'87AGY1'>+XRNF-%F`)/7CX4 M.,*"8@2<\=$_2=$/5QEBX!6@>91A8"DRHQ>,V-!89F7C8OUJ>H!X[U"4=W!M[749W)XN9# MM4X^]9N35EG+6\%%Y1DJZ@6((F>]\HZ`QA>OC1!],?T_K!810NS5'G=D-*0;H/@YT3.H(8 MP03/>`X6&3K5<]%C9/'"4(Y:-/>6G/]EM5P7*;%[>+3@HL8*(?4>,VR$MDY8 M\XPIS[LU7,&B,9RJJ%M!R[C7@FNW053IO)RW7PW,$ MHMHOHIWU,K-AP@ M8`T(D"1UDZ:<`,$E$0T65&4&';O_6D7I6U:[G^>^R5@#%C M5GHD+,$(&8V9_O_JKF4U8A@&?E(EOV1!+WY^0'^@L.&8RL6..XQAM`U.TF[9Z1/(3O(Q&IZ[JX[.QBES\>8OUA%+CY(/S. M>X.)7I%3+`?5H`B%HK*TS#I'`-):1\2Z(WV3SN!C*)X&0O.\_I[N[O(>K*;9 M[]PSQ2!$NLL?=1ZD7MM,91VQ[*RQ,TWDT2""@*0@>8/"!;F1$PGJ;E(TZ>`= M6V./8]E;8^=ZQ:.Q,4-&%LJ7D[#4/JRWC,@Y69=?-6FC'5QG%6AV5MJIEO#2 M1.-=8F,#,VLE&?)&4*!!\OCQ=58!9F^9G>G\'L$5&JS@G%(`GX,L6>LW,@IT MW8_9%G:#H\OL<3"'KI/^P_>#R6"1@'(7J?5[C?];I&=WP@=P7'V=!R(>1V^WA;<.T5UM?5VMUIGY_FH;GH M43X^`5!+`P04````"`!A<*]$_(<=BX]\``!US`8`$P`<`&AH+3(P,30P,S,Q M7VQA8BYX;6Q55`D``U8!=5-6`753=7@+``$$)0X```0Y`0``W%UK;^,XEOV^ MP/X';LV7'B#IB'JKT3T#B2(+!527"Y7JZ0$:"T.QZ43;CI25Y%1E?_U23]N) M(XN2*#']I1Z.HWONN>2YE]05]?,_O]]OP2--TC".?GD'?U3>`1JMXG48W?[R M[K?K2_<:??CP[I__^,__^/F_+B__[7WY"/QXM;NG40900H.,KL&W,+L#O],; M$F[9KZ67E]6W0?DO]N&?/^5_W`0I!=_3\*=T=4?O@X_Q*L@*LW=9]O#3U=6W M;]]^_'Z3;'^,D]LK55&TJ^:W7OU&_K_+^FN7^4>74+W4X(_?T_4[P)R+TL)V M!R/UU[^_^/XWK?@V=!SGJOAI\]4T//5%=EEX]>]?/UX7?EZ&49H%T8J^8VP` M4/*1Q%OZA6Y`_O=O7SZ\"L^YRK]Q%=';G.K/-`GC]746)-G'X(9N&8[B:G<) MW9R^Q#9)CJZ04^3D%$$SI^AO9RZ*2KX/>YE_[R/Y5?3._?(L,%]8K<3VX,OV>T6A-UZ5X'ET;A.M?WK%_+7?I MY6T0/"S],%W%419&.[I>/-"D2"^I&ZW9#Q[B--B^3^+=0^K>I%D2K+*E:[FF M;A/%-11H.SHVB&=8AFX[KF*IIN$L"S-+&EW^=EVC*CX2:_8=#V$O8Y'0--XE MJS*?,;QY)B]=^,)D31-64]6_%22K,Q&MOG'%0*_H0W9Y%-Q-$M]/Y%X\S?@N:61.GZ3PU.P^ ML/8A6FUW>9EZ&EW^Z39.=PG]RA3$8[3]N<1$]4R"--O0?$_5?-6%>H/+TO5E MUJ2^+G->+!@>$2=G\2O#Z5)\I))T56)YH<$ORH>Q>@`8]>"5&%V#O`?@C M]P$43LR@TX-(;Q?N:>(ICY)/Y.]+:9^2Z,Y:OTAN@RC\O\(N8J;C;;@N_L.R MSFP0XBN:ZIO>4IMG?@> MY"DF1S(IN&0L4.;ZZBFN[MN[:!G(@]A6[-@XMEWQ_H=O\W@>*TRR]O@L2FM\M7G\.GH[K4<,Q;4P0QA!AS2>JIGB(>(;I M^!#:OJYPS%N!*,1.Z&I7BE4TA]!!A1T4X"]``?^RP`]J!^:]W]"?\#/S?X)( M2B0,4WA[0C$F([FSE.PM'F)RDX1-F&(9ZSV]`.5^"Y(U"<+D7\%V1]TTW=T_ M%/*'OS_057EG_AXN+8R1"K&%"'8C+'+@%[AY.I5%0.'B1*2O*0LFI]"@+-@GRI!\^AFL:K0O@EJVK&K*( M[A/L>9:O0.+5P"W=LF?/DEQHI\J1ZPH4>`KI=BU#GN0+ZHQ94E@\YK(&=8;,*#R>TF3& MW%.0NPIJ7]]\:CP5O*E2XZ"!\U=,C<,($9D:1PB5^-2X*+&^9U_,T@]1^1SL M[S2\O6-)W7VD27!+BQ_Z#'WCY5*''LOLR+8QTG1%M4P--6[8JH,G292"L`M. MFS5`$)0(P297SL=".>,-B$NGP&T./%]V[I+\>9[LCH*'PL&I\JNHD2$XVTHP M*";/O8LZV99>LWH,E'Y?@&:T5:Z77P&Y\P)(R=LS@#?Q]F99-1Q%PI6KAIM`KIP?-S^_8CS7!LDSB*HCO(]377@(0@ MFR%2?=W52$>E'=>H.)T\P%D\>7:$].BQUKF:`;F8;!$E,1&11%($.1=/,:@[ M3N>[N^6GW?T-31:;Q683KFBZ=&UL$J(IJL(D`F/#(ZY16_"0VJE>[G%9P:5L M":>H6DM`'6O3/@2UBYE@;OB4JJ)EL0$+X;2LJP/5BH0W%SU'($30]%RN[W() MUA6M$N"7[IU0UP$A9&D*Z00Q5 MMQS'\1MY]:"/N,2/__+3B6`-#&P+9+S3O@=S'551+&F]U)'QU6`"'Z?BBU,N MQ?(V2#:Y^.NJGR_\;=/1_N3(HJ<#/'BNJT/)Z**O1P>NM)^WXK$UZ^IN<;,- M;\NA[C&36+5UW]<-Q754S_.L&HVB8K^C!HN$(%BG2SR@>H9%QVSCZ3/J-^2$XY1\GIQ#$:D?-GA_%9GEX1X0$M7L^FCT$!/B%*E!)<7-KA:.6FYM MC<&L)#>R1G$E'G_@#9].^\-R;`NR6>LIIN.Y#E14?TN+W(RY8CVAR;/F=A/C&BWDS!BV=I\P7RJ;ICJ9+I-!V(#5]5;-LQ+&+5U_<58O(D M[^QI%+:(R`J^2R,P8 MGKSH]BSEEGSPK^S MTX?GNEQB\\H[!ULF30$%/!18.&6&BYUNNB** *3GY?(83(:IQ0$"+3/2A M21)=Z`4]'CY*>)\PI5OVT]OW-&(Y>,ODQEW?AU&8KVFR\)'FYT!$*5TZ4%-- MAZC$)AK1;1>ZQ*^M&TCC6GR,9%)P<5*AO`"W)22-O87CU_ZD\$:1S[+CNR"Y92M`BZB*H6#=4*&IZ;JO0)59@S;T,`.@<1U`VLN`\'V8`TQ@58+B MWI3I0US7#1K!G/%NUAS2A<[1)6CGYB4EK;LX`QB41'>&^?!B=VT%5^!F#=MON2D162&,"B)Q@QR MX?D[+0?3T5EA/L51?&RM*I.:VU.V8T(#8P/:OF];IN[XGEL99JM);/&4,,.M M":YG%MD=3>KEV4^<$C,"E]T$9UH:^>3G$%NC0!6\O\]W%_LL92WJ-![=DFC5 MB`[%HD8F=X-(>:A:OL-_T24SA`:N-M>T.!"FE*G:[-+WL*6SM9QF&8;'+%FZT=@SV/J.M\6UEQ'! M54XS)\("5H\6UW[4==6."5CC%9$:4E727#2GU\[0U'J*G%9A&UJI:MOY&8=C221J+&^>[P>-2=+PK:&E M9W@&LE7/(]"!R,>^YOB-05-S>+:@^UL1O1%]*%)C[02=IV[@#M"HK(VX\R/+ M=D^?;9[.G$JB0B,XTG5;AY,:SN=]\HUOPMQ#S?V?YA2)U*.;.*'E][X&WVGZ M:QC%29@]U56<&ZV/KX+_=\=^_"O-[N+UOO1+EYB!MU2#%7TN&TR0B:=3-T@Y MONYY/&HF$V[!^OBQ_?8[+(MJ[EY1M?DF0]*:DY^0B@9!C[9&8&K:H`/!K1O,T8*XYA*\A'R+=5 M2R.NZ2NU.4=#7"\1[6M#^+9IGHU]GMZQ2N-1F154T;I9EH0WNRRXV;),$(//0<*RK72UZ*`2LG,< MI%*X<3SB+M@XR>JL>R?/SLP?ZSPZ:C-M^FH&ZZZ__959T3 M+%O>,I0@C@#COGBYY>XF#==AD#SQ/FC=F^)NM%,F(K0%._7#V*SRU:-U@:B41M>%^/'^&>QQBAA4<>Q"U M9BXV)[_XB6:+#5L4+FW+^W:G2_$:P^&FRM?X"WU@92%30#HWI(?)X4+&3<8!`>B\%SE%D"5)'3,XWKJS.1WUW=M/:7;P^+/E.Y9A::8% M76SYKF>RR]=&(#8-KI93KBL+%O)\WN=K`]X.4SYVNFFN.&+X=#/GY%@[I5#$ M(WK:&DE[T2B),O4$_[QA=``%G14"!TG$9"C]3)/K.S8@O"`-5\7V[G:7,1W+ M&[CW9]3O]WD]K+F6@WW5@8;A(-/W[+U@&;C3V[]$8Q"\)U'`+/9PJ"L*ATTS`9`L*G=C5BP""#`O,%V,>GPGT!RN<1#J#/=YA" M3XY;)%-TU"015^%NQM-.AD%[`L^;'H^:?XO>7P;[&>+"B_V;$RQ;1PA:Q#5- MRX&NG?<\5C!-7^,2\JFQ"1;X@^Z5D?8$)@A7GYT!N2(U>'_@1//\J9[X/%6\ MR!%E\IC[33&C!:;SOL%T0T"2-#*;^ZU["%.'8<06TAI8`6>I(\4P7$MQ5`@U M3)#IZD8-0[$]KE:JL6U/LB[X(8S`.MYN@R3=KP-:&K:G8;U/=IB6\,'J?[+G M]%#M"\S2=9L>,3JH];1?;*24Y1'=XVY*'4+CN+)ZJ/-+:*NF#WU%<5T#VKJA MZD1KEA4V]$875B[KPKM4RR)M.G'EXWY$>15&NTB!/2JB99380U:'BFRO"+TE MF>WG8!^A'4#EJ,T4!WW-K[1\-/?SSM7AFF9;)C20A3W+,QS#M%1<>^%CK\>S MG-)`G^=1!`'-&%.&>[R.#4DC+:JMH]J=.=<:^*S]XPUL[HB.[L">D1F&F93) M41YV>G2?S!9$(3V.QTLR;!@8FS96%-,D4,6Z!NN'!HFKVEQG/8I#\58WFT:- MQ/CMBN*"(&L>FW]-Q1&1D?H5^T7Y#:61@8X.Z$<<0JTH<3]:!BH0:9I"7,LC MAJ[8KD::5\P1B%5=H+QSX7B[6UXCQT.(R`L+A7PR+\_F&5=4QI/Z7K%^FV+? MS]5A(OOD8:Q;4L@ MKX>5XJ@"VS\@@R1VDE@(%=EY*DU..OF%=G!@Y);:X>YU$]N1:.PLMU]HFB6[ M5;9+F!'$K-X>/"SM$]=5D>=C8KNJJIH^TWR";*3I&H:>#SM.Y4$VQ,W;(UB@ MPC7?CG<;2RW3<11R)9E[X_@2"QA]0V:5&ZV_T&V0S_55%CZ&64C3_=$$7^GW MS&,D_+F$R-)=CTUK2W&)8II(1W:-17%0N3DX M'R)_>7]$!1CL$1\AF_K.Q3^?Z(Y*O1"MY>"Q16)%1$,2917B6BQ^ M,`]:&,;%ZSG99S1YI.[W,%VZAFZ81%=TQ<>JBA'&KEJ;=0GATLZAMB8M3+^R MK[-5(L/%JXJ#*>VSW!;+YI"2LQ.1$RRU7S#4>;7=GUM)M&PT=UK7W$-IZJQ9 M^8AZ)IE^?!^$T=)W#--1,5J`)?=9&H:&OD$JB^#0E3J58):]&DXJ9(HTPB.Q&./-][^M/N';?Q$Z37- MM_B9U[_2?(]_Z1*'(.2JT/455JM!15-J\7,<%W%I45\;@I6HA@4:7."/$AFO M#/4FL9L(3<$?GP3UHDY,<]II;MJ:TP:R*8GV#';C>7/:*+2=%5A!"1:@>I.;3Z5&I;Q=L>9BFT^]W@31ZWBUR]_;6CR+)QWA M1^@Z$U_SS8K7`&SJ*`1I&J_"8D_Q6YC=@>2HKGW8)>DN*-]?^__D75MSX[BQ M_BM\2B55WE.\X%KG"0#!W:UR9:9F)B5#)%NW1B2Q.1'EV_.]#4J0DCW4! M0`"$DY?-9G=6_?77X-<--"[SZ%OS>TVXRA_M2XUE'2V?OLV7F^Y]V^9''Y8_ MVHU&=5UNZ_]13T1?V^0"XJQ/+1JT$D=C22J*Z0;]][@9DO_C?P8S^T0+=W89N<8%1 M@^[1JXQNF!ZSU&A(LN_%QSUQ9BN0^KP'4G#;]4E]+=*4,)52_-2VH].7`8DEB3/$)$9&8PCP7+%8MRBQ2EV^MR-[#E-9OL*[P68=1#'%5(F[!K4$,[)G9, MWM#EU'W=_)8LU9)Y!,TA5LMCW+E4*(^F:922S9*$$H;B-.$PSR2!-"WVJID# M1&:-P"ZKQ>?M?+,U%[&K9G0^L)\1&7YKFQVTF^BN?%RNVT/MT=U\U78-+&C8 M=5[-ACLCS.;!0[,$XHQK)(6)80 M*!``N!ALQ7D!^F)'KAL1HGZTZ_FN+O_UW'RO\GOSE]WQAP)*QD26",B2##.!4T`+P6B:$HX$U;K_ MP\B`X]6-`Z:H`V5Z(LN(.[5D[9PVO42MSYB;@U0G6+F@+*-(#$19QOGP\QFH M\81HOHC0S-VW95L.\%TJ^ORU+-MN(5LLENUB[GQU.,=:\Y?A.OE?-]7SM[KY MB=5SF\C.//G3'7M(>()QAHE$G-`D)S@F`WJ:28.W<2:'[%C]]E?V=XBCO\Z? M#,]>!4*7UG,,DZ-UI]$F<77XQ()KIB_H?F"A#B23A,;*R3<>PH&GE^VT@+2? M9G].!@.$1"9Q,Q,F'!<\$P(/<)*"*VT:=XW!:SZJ;Z(]\@LORG3B9G8*SUFH MU/)0"%$:DUBL!LA)_C%D^$)"<1VS0#*$KU;+- M.^QQ4W9YB'7;\_LMW2D`10)8BN(\!AB!)$?Q/GD0!!5W%5JRYGJ59$`9#3"C M/P?5"#F];]`RF=/O M&;3M4.5JW*GGBH_-^/HZK\OY>O%YOCJ8_;BIFF2U?>D-QS`#$&&6Y30',*4` M23@8AC13>J'`GC7'N6)`V1T(:7$>?5H#4@,QLT7UU60Q`0[V7:>[W^T,.1K=5UTZ`UD4&>W& ME1ZL&2UCE*=?10&,92Q-84K2#*<02I'RP6`F,ZW.J;F5:=3';.5X!)?&"N2` M1BL:-,W2[EF"]'1(D]1PE4C7D>M:9$2-J1KU11>G7,0T8QC`7$*()$KW/;D" M%V/VFRE:\+[AS.SF-D/ZC,3'`7,CA6>B.]M.\J*N-YH\AJDUNDY@S$VXEUI;HVOOC$GTDAPW'`X5G.4 MZ/.A.[<*%]F,9C1,]3'PX[(`F1*CTAYXU=2^W-,6U;I>+OK_,^,IB3,`LD)2 MG&&1,PD/)1<%A6+#P)E]Q\KU"DPT?ZJ>UUOUA6QWK%_M'01!N)[,O=[1A+,P7>]*F+)VND_A/`;3=R[0(3`3F"HA!Y0EO((E5:`_") MQ^NF6)5/OWE\OO[=G3OWUK*Y2G M;ZNR_;/5P^_K^EMYWPF($)`@2!F4I&"2(,SC9F*>IP6/"Y!GJENM0X`:7*DP MB,^V>B4]T<';J'4W.OC;7E=_\-A)^G$W4FP6&4$,$M?UQW_9^'!1N00Q3GP5 M->[&B]6:QS0FH\LAYX/A755*[MDP*J(\!4FYC;D[Q?#A0<.%62J$`#G"*2&( M)4DVD+NP[KH3Z0SR-MNAJF&9GU$ELU)JF4X=%K_9P$1$GS58# M6B_T85T&*9`6K5,7*W]C7GW6>S@RT%W5-\ND0"S%L8PYX$@@@@K>OCV($&AF MV$3U@)?NS[K6T,,IEPZ/>BVOS<_5>9E+:C1US!\KRK,1E^R8S1S46;I>U__D MW>D:W)2"Z>ME8^35Z/AK*-[^TIVWMA)Z'#F(Q55MGS8,>IK_+B.@G"BFC819 M`K$?D>O919NGTUG''=W39R.'OE4>QJN3S0&?RO:L87?)_:MU]MW+VC,.(2DX M01F@60(YST%<%*+Y*Z4BR1&VOP5@)*#@&OU[?]ZVXG8N.>G4C@VKS7Z]QXBZ M[LJ_SV"Z:*Y[#*JO%OJ(X%KMD5^F=G0GW%+DID_G$_ALU-6V2KA*^N]_>5=_ M'([=;:N?:Y,9("(F":,%)"+#<2HR$1>"\U1@F6=4]8EV>P8=I^\>Z%"5'QTU M;0KS-U6[NIA;9/QJYIV&;+W,^@YX5DZ*T_!MEO1L\7X]GRFSGY;9[59"M%Z++R)^]QS$E_+'EC=T_'-6"")@ MBE(L4\P0D"QF&$-`*$LAS:#2WG%'IEWGF`/:;HGG%5[-34ZV2;^<7`+@6S/- M7*(Z.F"-_M&BC3JXOJ^0T"/SPH8F1U$)9"^3*^\J+T-;_Z6:WM2'AW9':[FN M^YE"MU8HJGI;?_XZWY1\7I>+X3'7`RR2BRR)J8QEEN2"Q)(PV<&B1:586^=OE=OG8`?E<;K>KW;,(W94Z MLPR"%.88,`@+S+.L(`@6'"(J"$BEVALV%LRXEN8]'DTQ'L.)^B"WEE@-1`IL^%)97W(Z5:9Y=WVH(WLKMYNYO?;62Z3 MA"/$".8,%XS3]B::KJ8%F4@+KEJJF/VZPPJD`?1JSC=@\EY0G&3F4ITPCLI` MOIFQ7OR[ MO4CE_?-FN7TY[$?27:XR9M%$_M!WG&4NHP`(V^$'>P,TE%B*.19%`RG,>:ZT9A8+9^=;FULUH[^=- MU'L:=:YVHGET5N#(V^CNY:?3MBI/]C;RT;JM>T=T*-%05/%0X+KW2'EBT*]K!`( M>^K/A'IBT?!M4&,V%9X#/>_YZ=U,-JB:?O^2%2\JJ^,GN+G4[?[5B@PBQ*3D M<4%Q`U]@&./!!4A88/,I==S_<7.J6^/'=T(*2S"3*SJ>SK%N% M5XU"'%?_-;,M`VJ\S[A,PZ>S9T[]P,WWLOD',XA!QBG*.$ME+*2@64H&)(`* MKKE-SK9YQYFVAZ'=PW'`L_+FMRDIUM[OIGV\L,/L?W>;)JF7-[2YBE`@8N[2 MP[?;UMR2J;4=^<2#!FW*N*WJNFA8.OE'>/E0;$QP07(,61Y M0@FG_7H;2T26`MUMR3XP.1;A7^?+=?3G)J76?XG:T18MCM6AVJ=/@^W*7B*F MK-S!!4M;SL^\%=/--/Y\>XC@N3]ZUSDS_!>-.Q/L8[80A"O[F7V&.9R.#/=3,7J.L9IT!"G,9I^\@=0T1`LK;NTHU(1B;T1&-8T3*VL$6__]<=V>*VE.VCZWB5^NH;F]VJAZBHX7J=EFB M?KZKEXOE?//B61[.\7?A>Q]->2`?\'@_*LMCT4:!UGS2\N&AO-]VEW*?N'Z; M"R$)C1GA"88)$EPF9`]&(*V7"-P@<%Q\-?BB'<#^]OOQKPXXBL2(,LMK$.P4 M5>/BXJ]XND:M;JED+52!Z*IC)U7*(,N4*BORY_+QJ7NS/8YB+L!@%&*:I18T M2M'2="JU`VA)IU1Y':54#BBUIE57V?2I5CLP^GJE27#8BJ7KC)IF&5&DL5JT M:O[MXZ_ENMS,5]V.NZ?E>ME.M+?+[Z7\T=Y95-;]YGB4(4I M9CF$^T5,1K5FK>,L.=?.Q_XF19-IZD@2%570&W]&C8WKU+G1LTNL7-(O*VR& MHE=VG/E9GRQ2I-L9[`O*(I$0)JS(8UC(&`A1%&@PDL:(Z-5R.K_L36_,)IR: M-&EU31TP9*HHT\P?7_%PO2FJR5[#=]]440P1IE,F*!80`9QQC/2&\R$D$I;YL=;<;Y:=4`7E4?P#.X^&,OG M92'Q2Z7N*E4X+&J\WNJ-3=.G6LU957F4]9+[)Y39'F73WR=ARY'*]FA25^_? MROEJ^_7OS3RW+1][,TF2IEPTL]@D:7)%C/.4@<&,Y%!I-XKI;SM6ZAVFZ$_S MIV__&PW0#/3%C+>KVNR<,CU%GI8M90UVSIJ9\IJR=UUU3SE\6FM'43.]PHZ# M7]D9(3IJNEENYX^M)@U&FE]L;P%B<5YD@C'`TC1LK^%K;M'S_-'=H*8"]_4 M&!H#^81&N5#9&U6:'PBKZW);S](\IX(R#(M89+3Y*Q-LOR8'^.@U:0GD.]=%78T:"YI?\[!C5_Y8 M;KL'W)-9P0L:4P'3F#*2Q3!OI*,[/Y#F:4RPUFW>!C_O^"O_5*Z&0X?W+2#- M[]R$+[5OWC%5>M__`"9JT43B,E%.Q.`M'1>$801W@8C$&`\J:P-)4SS^^MRN M0WQXV!7J[849PX;L&8HYR.,")VD.0(PX!FRHS@'*]$KF$68TAPH/,`:;O'QK3GG";J@/198#42#;'A261]RQM>> MR?5VN7WY^W)1'JT?]#?\MWK\1SO6WF3)N:OWS<5(OG^VW-UHNA MZW5XEQIC&A,(TI07(,MX@C.1%!@#*2D0`N@=<9P,I?/RJD-^=!67\;UHWN.G MN(CZ+D*G)\)#U+I[]P?8T1YW&\T!>7=4_="N[Z[)BEH?HLZ)Z6Y-MVM`HIRLYWZR7Z\?Z8[GY_'6^*0\&)44$8TXSP&*8DHSQ MC!>"B`SD$&*A54&;6W&<+OKW/@9\40,PZA!J9HT1-*JIOA\&]53[+6N-'D^F MQ&<9NJ"DXUD-1`DM.%+9'G#&A;/6>X0&+QX>7(D+"E(@05/\4Y)*!)H9`(:` M4`8;O25:+R>$B-]UQ^+H:MPS+ZH:5]_AD*A=EX<#W>%>B=>AUWQG=__>ELG+ MO@'5_-XBK30;"&_- M\0_?.OS_-U\][RZ5K>OGI]T_Z[[S`\J,4"EC!!'&#(AVTM/N)VCK#L'2&&M- M2#Q#\YB']VBC([CF;P-X"9QN@@TN9N:YLW/EE[O6EZAW)NJ\N8DZ?Z+>H9O3 M@0TI&=J(BE*>\QK^X%*87^_/OV'@/PBC$H^HGMI;*CM`QRC9_7;Y?;E]^0D9 MAB2/88ZAE$3P(LNR.!F0`9*CL98EJ(!KH4$8SM`YDEEPMC8223' M#KS)(X,78:8./>XUTX6CP`:<(EQYK)`6G)*MG`H^;JK[LESTCR=_+^OM M6V%93;!]$ZRGR*^Y/<+7TGM`Z%EH%3B[H*0V&0]$*JVZ5+D;H.IGV%\M%EU> M*_JM6BWNYO?_9$_5\WH[:]05)QE-!VT[3WJ5R5S?QDR,;Y_*6>/S1Y0ZRJYI\\SC*),D1X M+`2,!4T!!ED\@&2PP.[RX5ADOA+E9H?S)KH;3NDL&JA1AS6ZWX%UJM6C0^@B MO_J,GK?$^VD(]?Y`5GX(M7@/H7:9KWV&W'LB'Q=Z)VG^"M_6\K^MN+[+PL": M\Z,J!KLAL%Q*[$X550\#V':ILUIWIXI(SA.99;%@I'WM+"T0I0.N%$BEP\O> MP#@N&`Y'Z[X.HG*_!^?YJA3/FTUC<-8886G, MXXS$(,=QRA#(]H6`U#L5:VS$<2+=X8J^-L"BAVK3]>N,[@>%.KU\ MU[/68OJE8>V7EK6;J,TSD@+AIF*@&1QP88Y4W^7U`V:ZW+S]H_*I[$J1\9";;0=E MPMS\)<`(>LS-MB,90&Z^&%$?N;D!X"HWZX3K/R$W:_EK,S?K$ZV2FV^7_WI> M+I;;%W97;S?S^^T,)SQ'$O(<-U4`HCG+8KD[8IS^F[MK6XX;1[*_PK?MCE!O M\`+>'@&2F-"$VW+8VNZ8Z(>*#(!)!)A5N!SVTQ"OZE.F25ZXV- MAU5(G`KSBC(#>R-A+@A\Z;N;/`C%,<3T.2`(\R!T$2#C#8.X;L:ZW27PRXKS MXPF1P*?.00^[$JIA1E@*F6X2RF"(7PW5,"4FA]?WI7,SM>'H#G3H)2RZV%K6 M/_]K[3PNZ^5=U\:#GM0^C#;\MQ3-/'5W]52 M;V?WR_:N7$]J[?E%#%-41''D%:'GI4$\-%K+,=U1JLX=ULWGV*8C.PG6'#JXDT72S(]LX8;`=5,WST.RY$E_DT5[=G MC32U87;$"9'7[VQ+XH(!PSD[W:BBGCW=[48@?P?^J-8+Z$8^+L(LP_29/K)J MQ5DQ#I*F(.7*)4S1DM4CP\`HX)TV,6:PRACB35W9RU&2M^SR< M2E:%^+)$BP3!OTY-9U#`GI$*2]4.7GWSAEU6]2-T`H"3+8%PD M/DQ!`0`-9=ZG) M'!50>BJ)-.E!2S3<+`>O4TOS#F%_-NKQZ:'Y699[C1U_+^F=L$619ICDL@&& M69$$""8P](.5]!H=L&JV'/DZA'3"];"-\ MGD$U3T8=(^B$;,XGU1+MDV#(ZR>C)%'#4G?RS^W#3_(3Z>>F_J-<;\J^\W@G MA,.8B1MF&!0PP2`M,/+=%(^Y=($A8.UK.'\@Q5I$`3H4H4,@_O;<81R^KB&= MX9,G.>2>+6+1RRN?2-E)*7/5BUYJQ8I@)%!\ONCE+!&':V#D\6>^)$:B+8V" M"<8K^)YW?$SDI3CTH@)`@`(WC3P4IN.8J>TLP9]#,:O@GR#BE.#+X,\6P9=BRVO!ET<0B^`?'PM"F(<8 M^K$?`Q>C*$!1-HY%AF:]LRD^@&*!IQ_('S(T:`:%9^5<#WM\,FX#<XX MAI<"R/54#L\/*Y9UZF M^!1!`4G"FF#FJ)SYD%N0,LN4@1?]$6T0(H&M%4];K@A374I"1QLR$HQ2E!0! M!N2_LA!C$.!@TJ$L"YF;ZXC]O&*5&&$-*7+W4?`O-82Y.[M"TT$;GVX89HRC MW8QZYD0;R(@PR-(,YJ#%A]=D<^DQOR*;;4$C;:[(+N4\5B/TJ:K+RTWYN%YD M($Q##!!(0EBD`"'?F[;JHA@44@LWY\-17'2Y7F_+FWS; M5O7=E[*MFIL.S7K_/>[B1]FN*@)OX>(`1A!'"ISCB<7YI>H2_\@J]`@J-U*SLW]:>47)T?;5%NA1:^5FK59&JXC?4*X?JR[HWXLZSN[HG. MP>>R7=Z5X[__TE:K`RB&97BX#I>GALJ08DT/IU)V$U[Z>R!B\4.,K4F<_Z8W'MN M/6;:O42>OC,RI#3S!]UF3*\,?V]B*S*OY]'^9T))5Y6[1_+AVWI+2!PT]R' M&89^&.$4@JC`T_YN[C.U0S<.4G$R`._NVFZKUKDEF)QG"HIJ43,O23!.&\^Z MVG:WFMO6?9U#7#C41*>ST<1"68&GSBV)34X.FQ:_1GDXM,PU[QC^GBUE^TS6 MS8?#\N>F[L6V0[J^;C;+A_U_GS7KS>=F\Z]R\[5<-7=U]7_#383!J$6"41PE M($GR*/&R`H#=<29VO8*I[8)=B!7'OO^IVPE7]PC$))4K@IQDV@_T"-/9-"\S M<]%F,V:=SQ8/[0"K+CCNFN#T!A[M=GOA3%;V47%]\3*:$@.=G^7&V9EX\:*S MCNY^Y5H\=R)8VC5S+(F@LB:E#4M"TPS^B?\Y;^#B-_#R.W``5 M9.4;%@F,1RN"&&`K@JL8=,51]L]7![C#0K)[?:G=X:2+SCS/GIPGLF.KB@MPXGFP_4">CA& M'DDO4(QB#P9Y6HP-KW`,(ZZG6LRA-+K4M27,GO>EX8@JU8V6!<^/$B1-Q$/F M>?'10Q\[$;JB'*=K!/MC[=Y2A`!DD"QU`0;03](B"XNQX2Y9"*>Q>(LL]C$4 M!Y/#;>18]T5G$WBV&D@;=WP*?H0VH8?LYS$XIU.6&B;%FV6),BK4+^O4@[2R MZ#)?N"+'C).-LT1I47];NW^/Y+(F\+H9N;[:W)?M]?VR'C8T_T%^8C/5QRZB M/(WB+(,N=K/4)Z%F5P.+@RSB.G6S!K2VHI-U=PG(N:/P3J6@EON8H]C$!KQ6 M%Y\,#P+M6>MTYM*"R'I7FM*;;.ZZH29?SKFQH7LZ6;*XL8\765?7U3K.@MB* MF_:VK#9;HC"O+IYTEN4D9$S5.HLTS6(7)&$@&I\,1C(");/U MP^<+:EC3EDTH=+H%N<:KRRTQ""!&(/(2$*`P3*(4C8^"XQPBKO[:UH#6O8[? MO[-&5F;TOIKXM1$;"#2>)BATN*V)`/O%U7<6Y<_>EK1V.GWX2"W*B[98/,MQ MZJ/MYV8`^L:0O21BD8'$!P4*8>87.0!A$*=3;1$*(E]+C)4#57=D;6Z=>G?: MU=]'N>WQZMLWE^1EQ3%5OX.U1U)Z\#D\X/PVJ+Y82K^7X,GD-!4A4^YL>>^! M4C(;LL*C"B>Q5/K0J%O5=]]6]^7-]J$D@_4`^GWVUS%Z.M-.@A`D&?!22/#D M/DP\,`$IBC1AK`%2-+KBT#6@=D;873'^H%+#H=W;K)^]\D652\Y6%5G@#;XX M(^0(H6HD53YAKE.RP#=B%4SJ?'2^ODF,M,.53XH=8+XF2K6!C:ZYK*$7WV`! M6:JNZ`=Q5_ZK7+97=;E`O@O)LC4*$Y![01*%$$_GT7D0!XOGLOW>J&S()PR- M1PKVK>!6@J<)VH7SDX!SFIKU"-:,S\X&3KN=I7WM-CKZRYZCJ6'.E>6.5M^F M3XO#Q3OU[3Y-NAVS[+=F!B<_#4Y>=B^<3.<@78':^!F;:=5WC-3#@=R<[\S' M>(.V2^C9)\D!^C.#Z[^;11SG7AZZ?N&&@1<2A+XWOHR(@QP4AC(#%FCF,H/- MWXVI@,'D,\V9@6QGV9,97%ON:$.9@6R'&\H,R&=L469`2-61&?#X[J-E!ERV MJ\H,^!U@(#,@<[Y9=C:B(C>5&S"!,Y@=4'S&P@:; MYW1G"-)=9E&.\`[<;2I/D.YV4YD"-<2F7('BT9(M<'GPP^4+?-8KRQ@$G*`_ M9\#DZUNDN1=D.$MAG*5^$*$(96,?9^SB/#*4,C!A,YE\;2A:D^]Q0KD`_9HM2!4JKCDR!RWT?+5'@,UY5GB#@`@-I0O5< M+J(49%$&XSSV`I"[/HZ\8,IE\M`UE2:P8#.8)A!XQD('D]MTIPFR_651FF"] MKTVE";)];BI-(';8E"80.%K2!![W?;@T@A@#BW*:!$+"LSTG%?W?8550QV,\_E?"KVN7L8^.JVT]0UW&[N MF[;K:(P]Z+K02U,O\#R0(.CO2KUS-V"]7C1K#`TJ=['_-'*'SUE.`/F^>7$J MF211"XO\$FD%@5PBJH5(<5$5))1-9H_9?EQV9[-EAPS/-Z.1.XDX9)I,BBYIQKOY(^J5UB<*UEFN7^WJ/7:`N1JR2N:=*1$V0/DLM;:6;:ZL MV0#KRS)=5LU!Q/L253:T'$4&!4HW(VZNI@]OOR1_6X?9S>H=I^7Z_: MJKMD_Y5&110F^BX/PV^PKIF&4?='@X_-MMXL0N!#&$41R'&!$(F?052,X_E%`#B62>*#F(LFRPX@ M7VH^@TRFM8\>'D66.S90R+6@T4/EG#6,$*5L2Y:CQA]?IDORR9L.^/!NP,5>'MGU/!YQ.Q0X1V6B.N>< M#0YV^(5S(=`_ISJ"=GK40T/^BS[_7[\#Y[!7AUKA)/$BT#<'TT-D^DZC?7CV3)DNG MU;CE;/PT[A&^T/FNG<$<+XT[12Q4*G+.^?`GPM?AR*>4>?-!3ZUYC9X)S+EJ MO.Q6/OLQ][*&JQ6A>4GH^KO:W,/MIGDD4WUU7;:/5=U-^B]M\URMZ:,(1_&" M$(<^BN(`I`4N0`A<#XUX8R_&/"M+8R"UKCZKVEE.1CG4*N>))L.;G4G.TV@3 MYQ+'G)O9UJCOPL,BZ]C>L)>+6.>R=N`K3T_F.7OV.9.!4M>[YB8#WYKX74P* ML63`BLG!N')6Y883JVOCGC>?C%C"0V/9)\F>WG3/5?1;"_08=?=<11'%A>[[]X/^K!X>KE:K;;O`04!6L2[V/0]X?E%$*)BV;2,_8]TO53"R8FVFV)R& M@'/^INCZNR9KDN0]/#@-!3BWX-%ET0Y%['20Q^?. M*&CGRKP;9O:5T>8.P:6/"K>(-HLYQ=61]8DZSLV'()7&G6OF(I%"#8^.'[OH MF\>A#V"<97D(,ASX8>Y'TS8M1)BMKYLY?#S?OU!OM\_'K['O50=T&Y^_5/7P MAW[5]LRXL%]/Q\[WX5`Y\97G,?%I,@Q;X5"@IX'AU\/9>R>8GP3OO3A_/@'2 MG@67XPKMD>IY69&?[=YV[6+L(HAABA,,4A)5/0`*#+(ILOI^XIL)6-PPE<>M MK^7CLJKI/OT8MT:,WM>6* MS)/=\^;TS_PH5]M-]5QF]\NJ781%ZJ(D\>,P3T$>YR`+IDU3#&`X:[_25J,4 M;X6^70?V9CG+P2Y:.UXW]6]C\;CSG=KF/);T[ZV=ICMWV-S3`AE:A$[_Y&B@ MLZ(6:F@>;6:V"6[3VFK/.POIPS2%>]/T\_XT[9BA?V'BQNG/R*['N?KYQ5S- M/O1<5=\CW?HY*_%FS2&-+)>K^Y="V4LD_6MTMAV8C^>UTTQ?=A6NY-G%MWVV MV7I`8#UO$AK)6^!XTXGS"^Q7MZ_M7`0@SX(PP"'THBB#>19YTS(@C4.F/D66 MFV!-4OQ2KD>M_SYJ_R98S3EU3EI+$YP7V:LQ].+#S+EK,A<=4X] MQ7GJ"=EZ.X>LS3_/.$1_MBEKAGSLW%(:2WHR2;E.57_(V)O27PZXK/N+`8LP M0'F<()+C@M#/R1>*(=SM"A>!EK:50L@,97FZS@C%O*7X8%"YH[1G5D,^=3G= M[NR->B\'@(<'V=TD,4SF^P;H)A/SW?] MQ(XJ>W&.9R7ZS,;<">&53+TEBBK;JD;I?.74P$_EW?+A]^6&J@2LR<@U?:.T MK%=5N;XN?VP0`?>?!8H*E&4AB.,,PQ@5H1]AG*4Q\G,$PYCIK3VY(RI6P$_5 MIKKK^.?4.DE\LDF=?BKYE*[#YPP`G65-56X/HO,7!>ET*#GN9TK1.B;J3DB= M7.HM43K)1C4J9RNGSEW6))$IKY<_\FJ]>FC6V[:<+J(B%V>0/O>4!P&(,HBS M(L$HC-(L1F&./,:O<D'$J4TA,<8L40U1]*^W9>:0 MP!]KA[M(FY_P1[5>1&D2%0DH8@1'@>7^G`R:JW^\-IQ5H&$B.'0(/+MULN'K^5S66_+;V7[7*W*RZ_? M?N\JX!=%E`$4@LR+HX2(7Q07J8=1[*91D(',Y3I$FCN6FF02S2I0^;GF5:B:MBC3K)%\GI4L.T]8HF"1SW@B93)KX]G=@ M??.)\/KPSVU;K6^J%3T/&8;U8R^$@1_Y/HHRDM,E,:##>D'J^6[H\ST$/',L M'3M`W>E%!]#91RBJ9K/IY=@FTL2LP+Z1.*GJ]I*.LW5ND>5I[D=A#,FZ,T!Q&"7#SE<8%:$KM%_-_O/Z]JPI M)J<#);QQS<$:Y^:U&L*$-["9N%*[BSTQPK*3S4^?3?HB:,&Q'6U1,IA5)"]O MR[8M;^B:A#V3R*HQB*8G6:P#H/!*VSVH=[05]LI("[ MZ^039$[I4NTJ-IFSR$M\DC@"[W?%.N@7SLYK%+V3O?3:MYW7"@:O*1'1>7R? M$%Q-CK1$G'59VQCY6GC+(TE4N;K-"*YJ@Y>KZJ':_.S/3OTD#5U`TM(0%BX( M0Y#X+LZ2+`!!D,6`Z>F.^:.H+H-LEG6W2/M6KK;=UCB\:\LNWJX%ZR%F,,HF MNWK(Y%/4+K-L;IT>E3/",E0S<92A4_6.LUFU1-XD&/*ZKE$2-2P]-:ZKQ[*_ M%-,=J*891HD;X0S`+`_S)(D2-`P`O!BSOA_$^:N*18>B&=[:YBN>$.#GM*2H MI89/0G2RPMQO0"$[@BT`.%@Z?WO_I7D'U%&<`O-WW$6!-W.]+Z)VP^&MGP0Y MR>?\P(NRG*1Z7A%GXQ!!AEF[7W+_KD[%XRO=$&*)0_44$#1#]S1P(Z!]"C@2 M4[^1GZ[%LRHI/%J3,H<3F^20%_HA010RGT42OY!?;Z\;LAYK:MJIHWHF561)IYG5:EB&-[/G$K>'7 M_T_>U?4VCF/9O\*'!F86<,V*$B5*W4^22/8$FZYDD^H&%O-@*+:J2AC'REIR M565^_5!?MI(X-DF1DGJW@4:G\^%[[KG2X>4E>?DUVYVPYT9QZ)#8)82$%D5^ M[,+PD$;'EM!1JL%&QE+PLH*G1WA4Z135[Q&85)3O&9`H*]XCD#E0NU5(%9;N MT^Z?5>Z!C,U&N(?Z\4:WM1`C(MM5:XYZ-V9:E'?51J:JZ!&SB$+DNMQ$`'W; M]1`]%CT"*EJ!5?ILPR)=80)9"PKLJOUZLH5'-#*BA%77.&%J M8ON6N"':>LK)TY(ZB([IE708_%S/4Z&NFVUMA-(8>1B&-F,\CD$8QO8AKXY\ MX5JNXJ=/H)W2Q4M5XJ3UTP!GPQ5T-+J45=0`;1KJOF9%]5SU=R`_\Q-660?> MEU8E*H1W*?%,^#&MS!SVT5."`T8BU[%=BT'')Z@S8WDNE=F;)/O9YBL'CVFK M$&I';Z3).B^G8_`D71?@%-V)461D@]$K+LYL*U)E;2:;B93AYWH>'O$D[#I[ MR'>!19+GGAD?5V=K7->)+9]%V*=!T.U/0BQRA0XEJWZV89VXOHIN[D!@@77R MK"07RIQ=S+Z,TR4G%],Q)9QX&6=,+>U28>YRQG7*V=/YUB!:IL^VAL'/]3P= M&O:#7Q].'J$0!P@Z-G4]$D-BNW9$#LO]-(9#]X2+6S*MKF?WA5\KGSD<2*]8 MIC8>LY)"_-XF<2$^1]LI?BUP1%$/Q3-)\C0Y([!K7)6B0?+U6_(C>]P_1OEN MEW_/ME_BY(G_I'Q>!C'V2(AMUPD#Q_4=',+#9!6Z$1ZJ9LJM;BPL\=,#` MJD4&]EO^K($SZJ=![]3CH2Y_HX1"BQHN0!>>`UC0H9V!.+Y'I*16#H['C*5S MN&\"2JJ)0+&9]0DAYPK10B#I9_X+Z_I>AYLMW61?LH=->I>NTNQ;?4@(.V', MY_F8^''@0Q13%[,.$8&^4%O4$6",D5$^MJ_VN@&[`,W5*-7%,RU@L#L@EKC< MTWB(!.;\\XF.)AVN(]:),>DB%G41ZYP`1R]F%#")TL-\`J=^*RJ7Z[H;_#[9 M'%XR'M-#AE.`I.C>NNHJN:0Z.+"J3'VI@W_J]5N`[UGYM?KH(ENGS3'LZG>3 MS:;*DW;)]^U_[K=U#P?^H9NTN02$_\*J)G/0M:H#H_)>.66<4,^A\C*2I_GH M[Y'#V' M[1&#-H_1>TR'\ZG>#PW%S;NTVG?#,]RWE0`+1]BW0IO&OF\AWXRR^ID."E3N/3"V*%>Y,6A[T*'QBAF_L&^$TEV!=9DU'#ZV8"J MIIO?6E@73BD8IEA,_"9A5T[_*HC@B+&>UV<%./+=`:TWAX_>G5>,OS,JJ#T$ M,Q%"_7Z]Z:UKA#A%.>R?BZG;MZ]O#XM-2^Q2%WO((3X78^:PT(V[C4\NC`-? M71`'F34LB5?]XUH+4-3P>FMP@[1Q&-\JZC@:U0/U\4#[74U[`Q7<"M`^@D2> M(U%8)+5$8I8RJ<>SLT*ID;Q!4^K?M_LB77>3^3A_?,S*"A]+TQX@V[=MAP0^ M=<;N9D(]`B."DSR35`KE>G>I9MJK'AAN0BWZWIP*8I]PLF, M\Z(LEA'R&>0#!_3LR,-\1/'"`X@@8D*MWLQ8-BS3O=?] MA1RW!?I*58NZY-PDP2U:4,.=(,T5IO)"IJL_)#/14D/.GAZ*_*Z#LNO'@=`]LUH,F5;$)D7Z MW!WZ^P#2"B0HCR@EI%(/M>>5<716Y81PCH0*;T0;EUBU/6:#";Z\;>PB#:=W MA.EC;_K-7AI]R0T\7K(W\:Z^INO]AN?LX;;,UMEF7V;?TG85/$L+^F.UV:_3 M->,4\`'I:=\\DS>?.<9J9T/!,_C[K\DN;>Y7"CPW)(@AW[40C4++PV';JXXX MD14(]2^9")KI-;;6FVKVW?<''!T"G4>@>N!`SZ?JCSJOJJDXJ/U2O.]M[)"+ MI?,SCK;<,#=)H,W<@:PU)&?F#1/%?B83BZF\?WUO\Y1!$!ZO!F*+GD]_0-UH M%?DPIC:!'HV#^A\6.QUDFR*I9C%3XC2]6?D=49/JL#P'G@1'IC]+*.6&*=4H M&AEI#%)\9MB90V!G,@;-@HI\?N^=EM'I8_+8M9M%T/>)YP<^P1ZU401M$G9V M702E^L`.-C;-.+$`%439;M+Z&!XB^H;(U:+48>HYC>Y;CNA[73DIBBNC!$),[J2?_Z:8K-14@ MT"`J5'M:*W`F6"<$M'_W5=UY@;-5*VMWQ!RKM"@3-Y,M&6``Z^G^P.I M&&O&?GWHP$A#BP4XH!$+J8\"1&+B=_C\P!)JRS4ZJ(GFXM(%QFOE#K'CQ7>4 MZ;J9T.J9FYN)ZAQG](9 M9=NL^)JN?\WS=;&TF6\QA`/"/->G./0()MA%?A"Z&'M8:H.XH@G#,M^!`5\J M-)*"K,Z`TD="8J-M2+7.M3 MIJHS=\GWWQ+^OF;)IE@BSPNTTJ@HCQY>DP!BC2EE?.")P@#2QO/39$5$7)3;G)BYJ3KRG+0,HD9`6/AE+ M/R4_2%:L-GFQWZ6?TA]EQ-W[Y](.?12[T(J0$[J!']I\^MW8M+#CA8&BM0X?=DMVZ7H;S8HA'R((H1QA8E/G3<9CX7 M>TXDUH!+CR7#RM0A!!5$T%]U!C5*A5L_==![7K?&9U9.N&9*JO`YLY')53MH MIH'DRT?-+C-Q0O?U,CC]83.=SN0F'C)QZ0\WFYOR:[I[;;!H+4:(L0@Z%.&0 MV9:-G1#%G47J!$+=Q#V+&#;\5W'MFA<79]#0@0]VEF('2C4 M]D#A8XWK'H0#WF\YAD1TSQ@YLKHW(B\RNF>,'U7=>\T3V%9'E*KK2^N3`Q^: M>PBK+6/IMFCV'"6['?^,^N8-\,3_=J!4]BEY5RJ5>)N%5*HASP<_-!)266>@ M91ZGNS+)MO3Q:9,_IVF7DV*+>@PSGU#H13:!5NSPG)1%."96[&+1N[8'6C$] MZ6]F364.6GS@`%!%0@8R>EEIQR-3^5UV#&MXPV^NFMKAQ`,R@8'$WM9S,?D5%+.YT>GN*:/2:NBJ@^E5T#8 M+[#PCK3KXFX&XJ[-E5S_HR5[S+_NFE+-R.+>A"P\SL>BY^.OW";/U;?JH:@] M*O\K_\6RN-K>IKLL7]<;%)<4$1="ES''ZU3S>K9HFLM M46WBK3P#/.B-;]-LZS40GS,[\J9\&F:RD6]2"EZW@9@\'$)=Z?-MN4M6Y3[9 M7&>?TYO/O27.JC-^O>S93(M^K^[S/>U5-8062R>RD!7P-";@DR%D^3A`?H?. M#0.A+H\C0S(\"O5<`1ON2U6@+>I5_[P=GZH4,J]W`R1-J:"Y-;GH:=R+(FY5 MN!7=;3UV>"_.F.8:6;EQ:O7_*JCB??QG&ES%CO^J0>;?:0*]5HBTP#4!^E@^ M/86<(HS3SS8G\3J?]-T1SQ$:''_P*7.V_=(ULPX?BAKRTG$\CP3,]@ER;#N. M'"\BG;W8LH4:;PXV,LIL$K3H0`=/7+('4GAQ9!V//;FQ\AWBP#\Z;!(UR($< M"@]DXW&I-C0-X?3R`'/6^]-#AA["IA\$-/F1:WZ2Q(6Z'A8>SDPY'YZ/O]*? MP&/ M5Y]<->N`3+_<`L/?G,/N]J0.6'X M+X^X!B@_/4Y/&=OI1_=)O<]G\8(IWV!7+9?N]GQ^NN,(PFKYM+U'M2B+XZ%V M%D4L=#D0Y-DH\B*/4&A9-(YL"_.,1JKQA6[;AG.!%R#;?0'=O<1G;QT>AWC! MY<0).9<;SB_0W=[J!J9KJB%)Y;E5/4-!F?6;9-MJLLV=Q7&U6J4:`XU4C$H\2!$<\F MW!"[4>CXB,1-(Q$8(4NN:^+HX`R+].%F.RIEQ8;('8"8#QW3^YS-Y$V5[MQ=%6EX] M/B79KC(=\TG&E[0WXA'/=ICG4P/98XU;-EL?3*R8XH_)J9R`U\A`C]06VY1*?(&M,\*JB^>9Z*0V M=UZW&-=*DWA-(OU2F;M+G_)=50XY):!Q%!#7)]#&R&.NY<08V0QC1"GRHL`1 MZG>DTYYA-6LA2A<9=#`I6%@8F43)M8$&'3C`FTDR*<#:N;J!1LYG(F5:77I= M']!.E\0ED&TVV,L0;_,BJW/(;K'80BXEF$''CAT'1;8-XX#%/O29AX.8B%Z^ MJL66P5>Q@_=RGMY79C@0[$I,;,\0HS&6* MZ83F)1&7IBGRC,U$/%31GYJ$J)(@+`AQ4GP-M^OJ/]6]O-^2395NAV6<[';/ M/%?X(]GLTR6RN&V?("N`)(#8\3%S6N,4Q[[4@4P]%@W+1X6N+M"NJB_2(TY) M1=%$KYC0C,^LG/X<2*V_Z$%<@*0$'4I0PQQ9FH2H.Z-8>JF?B9!I=BHW^;3* MYD&K574-7'&7KE)N^F&3?DS+>+_;<0S+@"+(,(J8Y>`P0C9R7;>UR=PH$+I+ M0(LATSE2BPWL#N`68)O6$Y1DL\F_\]PT!9_S'5CG^X?R\WX#DNY/^*_\!&U4 MO\X_0=>IWN#?./U?@0,75;^(YD>'GN_M=YT%-U8\I:OJ]K[-LVQ^-BAJ@MG: M6`&3S-TZXN]ZL>+(%J#%-G8N=X:FDC2/HRN2PM;G?Y M4[HKG_^>;M8LW]US4>Z,>RR&3L`S3T@M&V+L,M0I,4.VHW2YW#"+IE?2CB`5 M;YL;2*B88(W/I9QR]?`M0(<05!`_\*'E0Y%42C:-B`E1=T;-]%(_$UG3[-0[ M5]GII$Q\AUI]U+2>5W>60NA!XEM^8!%"0L8H]<+.$@MCH=[S`S[>L(0U=S&L M&C`@4=D!H,*9F'`9IDM.I1JF&C13R=%;0L[MD5)G;R9",\2#U_N4AI(A64#O MC+C0\CWB,BY2U/)]+\1^5Z5G<42#99F7R4:F?B[ZR5+"<0`A_#I\JOYDF'!( M,B532S=!DDHI?;+)EZ!&J+$U$WE0!'^RBJY&@;`H=)E,U:2B#+?KJI[U5*WP M-9VM`FPQZ#G4#CU.1!23F!VF;13Y0ETD-)DRG&]TZ!9U,YBR+@&E'4))_1A* MJIB@C,BGG,(9,;>1+E"^'[QWU]2HBD M3[MTE=4;NOG7F[3=Z!T^5MN&FDW@[X)<^@A'5D@B-P@=1`/F>#`ZY%O0$KK, M9G10AN7P.BV*GT'/&[#NN5._TDG/#_EJ^$BA$ZZELB@'XE)YK)J%4=8$AJX%R#`FO1Q@B*PA*P)'2-,M"APQB*T+*-`X$XT9Z,3[JP/* ME$@N$"QMSV8A9!$*^3^0^7'@MY^.+>Q&2'YEX.)'CK(D<$DW#-:[+Q:ZA1F: MR5,NB_ID:5O2:>'G^#I+'K)-5F9IU:2Y[MG\-=]P1@I:W\)Z;/5)"`G<((`! M]!"+;>:[5F>?,N++#)C:C)HN[%R%T=7UU:@_"CP3$WMW_ M!=#__OWJT_](CJWZ^!8;;B>A6FX$[D$\9/[E\W3G5T0I.R-4VEF?B93I]RLW M_+@J;AB_39ZK39G=@F(<8(]Y&+(`(<>+8MMF<6W+7626NC6R$D44B#X8$48>$G=4HD.M`.M"4> M9Q!FW9;XWM,72QE#*9X)MJDRYN3Q0U-)*G,#CM+40`9C)C/ MC<51!&,;.WYG"6+7DZEX*'S\J!LB-T=\ZM,\8>*D)W0F.%.>NDTE.U)2,X"\ MFGVNID2&7\O3,]195LIT7QV%HD+I0ZT#C!C6*/Z MR/[2+@S]+-LD=@")8H(T$G]R>G2*.A"6Y2Y[V)?UU3)E#FZ3>IX[84]*A<4U M#73/1*9T>/*FZZ0FEVW!$XVMTFVOMK&R5-6)IN>^64`:1@2 MQJ@=1)8+F4])XCM?M@N#G3RX('A%Q?L_6';`M6#4C9/0D:F!7O1Z>X-NLH2U[2XM MDVR;KFFR^S=W5]O;-JZE_XH^=H#,+B7JC;N?2(F\*+:8!FWW+B[V@Z'82J)= MU\KZI3.YOWY)R9(=Q[%)BI28##!HX*;FDB*E*X<--&=_R\/1&>$&DJ*HF:!43M1&9E--U#IP M7H?.^_3R4&\#\$+QTHJF7:?L@J89Y-L133-I46VMZN@>AU&"?)VZ2(4ZK>#2'>$:4S;-35FMYPRJ3U[D4C[4P8IA0%$8Y] M/XE@`J.0YJA7UA@GLU7Y()183MXT&I`:=J@==L=8Y/Z].-L7^XKMMZ\ MWFS_W4,W$$6*Y3)%,=2A74[Y;/&M)7,OI>QFDD(5@VQH#;6 ME09G73,09AD`)$AA[".8^SE-:=]2'OC#4JRK7S_*1M2-C:SJ.G.Z*911TJPM M=TZ>,"EE1]*<.B(O0RRXFO.$.7?G`(*PASA$,+F"9D,A@Q@'%S;"Z[X;?;&2TX_2^U. M&L3%HI[OQ+Z^YC:]*3AY`<`X-Z<:\BAT(01PKPHO[3HS]C4-GWB$ZZ*N!WE; M(N!,THPF*R)-6$X_MI0KU'6B8R'AW6Q_+Q:E'_]1_D\8RP#/LE1!(/< M!R3U"69=0Q%#0$TH5+]]'*78H_(:6!['I:P5RJS)BH5-PK340H$K8WIQ0L)% MP=`ES!G%T#;@E60,HT)*,_;G>5FUF1?+?Y3%FJX6>;$M9R#'"28@SA*:892B M,,1IUQ:.$NG\0KL!R\JQQ^6UP#R!S*-B.89C4U`/??ZN"\@HU*EIB!YK!G3D M+2[>D)+!U#F@)L-MJ`WV)>4\A%7++^R_F'?H,>6` M3@R"_RKG&$*#E#KD^Q+6#_Y/9C$-:<[_2PBBD1_Z*"7OE++>M! MA\438!1T0(V8ZP)@C1/%PJP<'09&_+'!;PQU+4X<&.-ZN.N!G4%C5-^6ZZI> M=,E%3&.?^`CZE"4@(`0"`/KD(D-25Q3J?_M8X[Q%I3-[T&1-?NS;(TQ3!*2Y M,J@'+TBX(@QZA#FD$)H&G)&*(50H:<9A4L+X)YM9G/#4(LEYZL%HCFB"Q'4^ M75,H)ZJJH?K]8^G&\22Z0::A',KC">0*.@&HK<7%<*>[2HJ8,L(P;TX(7) M;VB`'BT.C'M-X/70'J&^9^)PP\'WYJS6T75(,QPG<0K]C*0Q37T0@(S0?J<& MB50W4`QI:J3=%"^N(VI1'E\0I;ZY8A"]LDL=HS&KM?*A3ZJY71@7"+J\)<,$ MLP[HD4EK7F_6,$>2_&$WT1`I-N6"MR[>1FGV!>/UFG?`4L@F>3[\RFWQ+#[" M?Q;KQ=WBZO,>QF[_[-S;&,2_#[MEAO1P]BDAA5A._4 M'&D-/-:MNX+_U;ST/M4MY-_$=15#[Z:8P+>CAS,+#G4BDMUXK67O-X2U^,>) M7HJ]X.,%+E4"[,4L+5>,%J[H7T_5NODWF\^KMG@]"VA`0(JQ']$X@2"&D4\Z MJ+$?!MTU23_&FW;IP)22N)>7+?W0*%()9%S"^D`U6 MB6N)6]O>660ZXQV+L6E(7_@@T6D0!8;CTW!WC!:A^'SOOJRV.SZT>ZB9N-TY M@S"C-"28SP%C=@BFT`\GB%`Z,,>)4'MD$\8H+1>.$Z.LN6WR&'5DV;N-46>\ M8S%&#>D+'R1&#:+`<(P:[HX)BWX^A2$%44XCWRT\"N6NK'QUYC\?N/F)4>. M$TV-=*6/%V/-T&(O\AITF[EXO+F"_V_B-K9^KG/1A"S`2Q:_#4=:L=TO:%PZZC7S8?7>`U MY](AP7>"CO5>`O`4U*@&XW9'RX"*WH7)MAVE8_^RBQVAH_ MI@.V74>.%[7/K!=>M",G`.88$YPF(`[3B%#<9Q]YZ$O=Z^,L>,M1^VA/B6MQ MVW@W&"EN3]D#)HS;9[>I?+BXK>A?H.C5RM?8>0RPRK3),>@?X0= M/^<[G+!_BJ@]KH.O17!'NYM+T=Q5BLY%=E>Q3C9M^LP15ZM--?][L=R5LP2A M&"(0)"Q/LYRP,".L`PQC7SV63X+2IVKE;1_KW8;# MWOQF+%Q/X^K1M]Y:]+(CH?>DO[S?2?%+5XTS#=;L'BZ%RFF)L#?5'>2:$>\K M:6;@Q=VRW)^NH3',(."Q&,;09UGNYZR/SP%@=,QPIX[.-T@>S(KG=ZG]8KSUB,6_J]X(/$JP$$&+^O9)@KIHA/%VO' M$0[#(`898#YW+,@3<(`/8"3U%)UKF,12C1U[^M-)#QEG^G+ISN!JI/\SRIX:#+2Y_VNQN+D5S M5RDRO/QIWYU31/F7A6M_1OP<)EF2AE`<3$%1S%C2GT^)D'I!>!J8SBV`.A&P ME9T]>ERVZ6='PJ\#2Z!6?#5.)-7M(!\O8&HS82\N#G..?/C;9\7F MD2WK/S?X;M.$WEDF;N&.4YJGD,00TPR!A&6I3Z#O,QZ/935M2!L65:F#)0JV M`IC7(//^N\,V^BME%WBZI`@FZ'5E3!NQY714FB-(>ES]46Y%6[?K^E>U*!?D M^3_YB/^\^OI4BA/.JX?]VXA5>4#"LB`-,0DY$A`SR@#TXPX)00%621'JI7]%C_33'=L^$$.1@6_WKX(I<[)-`[%6K MW[P>M'=`/9U(JC-[03HMNLD10;5I83U:GU<7W\^K>?VS_%)O-C.$MH4 M2/=VO/B?W68K\IO-C_I;*0RLEN6+IG_4JB,S`1C3!-&412C%/L@CFG58$0F5 M[B29!*#MJM7!)F];>^O.*F^U'Y3B4_'S7`3671M+C20UT[A;+NUQWM-JB=&) MDWN#/*&\K4G>)V'4;^*OWTT*9<-+%^+`I)W"D7`R+0>U0Z-4,;C]K:A6`M#7 MU?=B67Z]_[I]+-=XLRFWFYF/(A)F)$P)P133-$$1[)KD<%CW^)IL%MYF=[>I%E6Q?E8,+8/( MEHL0UEG6$GJ!JE-RSFM>;9[J3=4L47!Z&XQ>"W)DJ;Y`UP7%-4&R(\)IQ)3: M?!]4E+&\?.(I8M4L!\P`)0"R-`^93UA,,H#CM&L#1+[2+;U*7VPY)S[&T@A1 M\9,+4_7/Y@-%*5(C3$Y[K'&E)C;',$:6D^.F+^B'%E&."(8>]MI`3U&=MA\- MCJ_WK%H5/`T3^UXV7(8P3F@`$D"#&`4^RX,(XUZ&DEQI+6!00[:GT4?81*A= ME/?E6MS"?=_!].[+\D+4M4"MY%1W+%85IZPGA/;`O`;9V#/-"R1=FC&:X-81 M/3)CR^D,SAQ!TGK53`8WO$%6K_-Z=[>]WRWQ?%[O^#1R1F`:$)`$-,D!A!DF M((BZ-B$E2N7"00U9UJL>FW=?K[V[8L$5ZV[KE7^)S1ZJN]&&,2HG4Z.1J293 M+WGL@'D=LI%EZA))%V3*"+>.R)096VH+G<_(N=E9`E%"4Y"%Q,;+/7$29='.5D:@4(U07IKBZH39RVO;0?5)](1]1EJ MA=3!0T52KBK.X^/L\\^GHEJW6\N^U*N'+]6OB4>'^H:YA!QO$W&7)K?A] M*YK"WV=HC?O!>6['])4N?L>^^R$KKA,2VME/%2LT3Q:=E5 MU)UWUJ*>[\27MTKQ+ISV`K)QY_VK_C@[C8R/(MJ%/,EK8]U0$L]$P]'\,G&\ M',_.>N0.KYCE?U[-UR4/\'G9_GF\-MU"Z]:EPY2E.&0D2%@$@QR".`$=`!^K M52;,M6I[,_6C.'`B=AP=!\ZJN*N66GN.#-(M-S^8AFG%,+C'Z'WJ4/XF&#_: MZ]-R/]D^'VD2+\POS#O"D2F'!<-JVWUXL$AVQ9=OY;RL?HEC9C,_3S#!09`0 M'^$TPI@>]NT$.(5JFVB,-&E_-\T>D]BVN05-2O@&T.RMZ0VRZJG>#"1L@=9]7OWC*6J]YMB,:]1%/0B/>$&`^RB'L M"S]I3/%0C5-IR[JX'8$9+&I*).JJF7'V3,J8%)LCR=<1%B7=TB'86<'2,N:J M4NE3-&3**O8=GN2$LS3T*6!\KDP#&+"`0T"]0,*0A4.U2JM1ZZ+5;K%5J@F: MYE5[8FJ-4*.STH;@T[GIY))VCCRUV>@0]IT5N6%679^'#B?-P"3TMG@6*2%> M+5[B^7*H4\U`0&*89GY(PB#)4`IBUL^,80Z4ENWM(K&]4;*;3CVU6&^\8CY? M[\I%M[S?UOCJ9I@?5?J,S6N->&OHA'=L1YF=">_1-XXZU>,O,BX;>9HLP;;6 M_-FD%YV5<"O&2L^XS5-LX>8;<<5CM=KQS_9_6:\VLR1(HHABG/'_>3@B/H7] M[M4(Q5SQZVVQE%-\RU"4)+]'+2TG?\B<'K=V(XZ><^0$WB&_J"F\QDTY-][! M!N]@A+.WYIQC_(+*C^1*1V1^+&NU;]8Q0/)0H1>EE,T;A\1)X%,2QHD?HRA* M`Y2D--PC@7&8)P:N.!O2O.U5^9,KSJH.JODKS@8Y89"(C\6_4>'N03MQ/X[[<\[Z?\ MTR?Q*S.*D\0/?!A1%C)`*(*XJV?#`"'%U2^##5NO*F?%4\73[K9$LJBVN[5R MPFR29SE='9M@O?-;>Y#B-I(]3*_#>>,U2&^:.D182U+-I,Z`I$$]-,!!R1)%/$&0=*I:FS$`EPA24L2H13\?9TZ[+ MGL[EL=;26#U7F4YIK7O)>GKK=%U"DG$C:>\@5SHBYV-9JYT.&R!YJ.SWMR2< MNXN2QSN7C%>EQCDA$$B/A;_1H7[ M<'N+PW6)"\RJ"[0)-[DMRD8LE!-BGQ<3;;?MI^!>Q1/GU M;ED][/4_S].4IG$$DIAE#(8Q"KJ[]B"%0.7\LXWF->OY6+W;RYIZ%: M\22[+5@LFVT$]0&LHOH:]8*<[([.O);>'E"*XZP"Y^\\8/[TNDI1`]7[*D.\ M%8E58/&"MMKPA2.B:L6TVGY75K]L:UZ6BPWC!'S?UO/_??E`6+F8(0IBA`,_ M1;$/D@2(C1Q=PX2KNN*-6P-;LYRA=@"]=;D4.BO*CMO'LGL)LKD$>2.`=V]$ MJM_$-91NR>+NJ$PKUG0[DIM)0(.N>W;1Z_&-?S/79;XN56^-<>V(]ADTZ/5% M74:I4E[&>G6)84PB&+,$@Q2C*&0TRF+0UP8PTT^71%EP;;\<;2T4!B+%0,S]8Q`YP%D)`\10Q$ M@1^3@':OF,&,(=_`0I$I*-,N%)TK+%JK*^JYRG2-T;J7K-<;G5XHDF3<2!UR MD"L=D>JQK-6N3QH@65KV!22\6H@_Q%Z$7\52!)W;VI`?]\6Z^T0&55M5V4\5ELVX03H_F$2>5AK.L)I\>OME%2`W<89:9'+(6!'^$\ M@1#1.(`0QP>YR"*P'[%T);EUW$RKZN.U`VAFM);BF/W''J>2'GA?XU36*+UQ MJD29TCAER_K//S@3_,?#QKK5XLS<*:\V\V6]V:W+PRZ/!)(XH8`+"&9\^D0# MU)?M61`QE55"ZV`L+R)^WST]+Q1_.J3KX]A[1O)')%HA M&C1[4.C1:38^Q=N)]Q+);OM'O?U'N;TMJL4,)#D+,YC2@$4P@0$,DSX:131, MU53?4*.6U9T=/4W@_:IW\\=2O"-YM]MR==]Z3QRBLHZ;HEM6KR=@6E67VVUR MQQB]#F3#-8?I/9=;[_8BWY:D5XZ_BQ)KV`7.2*EINUY)IA7B5*7Q='M>AV$& MPY1"GX0)(!&-8,;`89M>QN?7&HJHW=:80EBT1R^;9;X7FXOUM%"?7R4)'(5: M/>5[M4&XE[]IU.XMJJZ+W&"2W=*VX>:[E'/ M!(;5=A9&&4UP%B<)BZ/8CVF$$8LS%"(0YSE4FM^;;=FRRO5@FP=D%]T#LL75 M!V3'(%U.[*;C6TWZ7E+]ZJW>HP<>;KP]VK&?&5=A\H(RVO&((SIIR;C3E\DM M4BB?#=8_?]:K9B/S;;'^NOZ^%7MRFTKM;;EN7@>=L4"I6G'U7"Z+]48L:7@;`?;"9@)[ M?$MFB"-3K9@EMBQ_;UGF`/FP]EJ(7H-1;.#P&I1CIXO7>;N4,AIDW1$Y-&K2 M:>IHG"X=Z6O:V>#=]K%>5__D&6L2X!"P)"`!PWX.@B3AD_%]DP'76TW)4VYG M5*EK!(U/A'MXC>2UGP[0.75RE?7-*J]#=*T%YAV03:=EIQS):9@VL^YIE[XI M;VO60'KTM>KS9K/CS<5A@!*>_B$A.$H0#^ M5?8!=I!26GHL_7,RV67)CL2IFV29340.^_:C:A4WHVTIT(LA/?A>?Y8?&!Y] M+\V^WB^VJVK[63*!*."DR&:0%RA/L<3"Q*0%!+U,Y!)H"AVI2WXAG>3$UU-, M0Z$-8:=.;E,KJI.*BZ=\Z,8J*Z^Y/#*6/R!K;;WJBOYF]].)6B8"(0H9892B M(A>YQ!"84!`P)UOY?/_`DC(IG7;Z\%>2%SL[$PV-S4U`9V)7"AK9.C>0W)%- M'X"1.*;7%%2X]61IE,VFY-6APDV7;:B/HJFK[;JNW]3N2[]X?WP,6F984"$E MX8F`,`,X![HK:D888Y`3NS]E@4(-[)E3-J9>PE(NH3#>]\P$!-V4T\E.%U:; M_)Z?#%4V"=656C:'RF_]##\FNE>)C4CYK^HW6M]PEI[D;4?BAL<#(YQ8Z:%G MHP999^X=6=7W>J[JPW9/-U^XISSE-&$R(T3"!*0$(V0BIY`SQ[:K?<,-+'R= MVW'3L^5EIPLUU4X7CWG=N7T*"#N2NZF0,_K?/C,LK+%Z9*($)#1-&4`)X10S M">59#(0#Y-;19^!DK$[>/EU^K/IDZLMD#&=WK(T8;7_%2*PPUFS#-F)T@]RQ M27>1SMNC=M`,M1_OBWK=COP"4$L#!!0````(`&%PKT1[_.D9:4T``"+@`P`3 M`!P`:&@M,C`Q-#`S,S%?<')E+GAM;%54"0`#5@%U4U8!=5-U>`L``00E#@`` M!#D!``#L75MSV\:2?M^J_0]:GV=%<[^DDCTUUQQ7Z5@NR]X];RB(A"1L*$(! M2-LZOWX')$%1$D6"$`#23%(5RZ:FA]U??YCIGND9_/+W[W>CDZ])7J39^-=W M\"?P[B09#[)A.K[Y]=V7RU-U:=Z_?_?W__[/__CEOTY/_Z4_G9_8;#"]2\:3 M$Y,G\209GGQ+)[_7\5% M#>+)[!MO)Y/[G\_.OGW[]M/WJWST4Y;?G"$`\-E2ZM46Y;].JV:GY4>G$)UB M^-/W8OCN)-@U+FKTOVCY\_?R@R?MO^%9:RBE/)O]=MFT2-CY%-R?5+^_/+I_9,.;K/L/LEOL]%=4OPTR.[. MRD9G.B[2XN+Z8YX4`>T97DI&?;_/D.O1P&ZR&!."YS7_;(#!YN$]^?5>D M=_>C8/%9BRK99!*GHV)GS9[)=:?@QVR4#M)D=PV?"[:DHLGN[M))^0`5:CPT MV7@2'IKPS&U5L89@]RK6GBB__IHHB/,QO4']S3YT:\3F^&FV;RNI(MJ3D^[O[.,W+A^+B M^CP;WYP'GP[GJ&S6L89@]RK6HD!]^;84#AG"7?(Y_K[-SVL:MJ]"/8Q>;=^: M0E^#`[)\:QBWIF'[*M3$Y+7V+2ETGOXQ3<.<^+!9CQ?-VO[Z6FB\UKHU92;I M38TD[F6[UA6H"<%L%6U+Q4U),\NE@$IPTOC'A>VZV M#=Z;)#I4JA9N-00[5+%.V+==KB4%+Y.;&F/)\U8M?WDMI[W2N&55ZCAG?=NV M%"D?8AT7R=!D=_?)N*@Q$VZ6Z50Q]2W.AVH0\K^ZTA/']P$1B,^2T:2H/BD' M;7P*X&+3_6^+CZ.+_"8>I_^>*?"X<5)..>/AJG(7USX=Q^-!&H\>]U3454@2 MXL%R#V-4@O;KNZ!IU&K_D=4,$,>$PL9HBY#$$G)*A%10"V;44^A&9> M.DSLRG7U459,\^1S<+4.&O[>%8QKOBIBSF*HPR1.%:=:84&LJ1`E@&]%=)7] M*A^<9/DPR7]]!]^=A-]<)WF^F%PWE'7,GH/)BV$KS@S[=[3 MP6TZ6N[D7>?9W5X9F!V4XP)4RP'K[/F(U=$XMC9"_6LX6R43)L!:S97!7C", MK%/`&R41$AIJ;_8SG%U.KXKDCVG0U)6;#;,0?@,4ZYI'GCH5K(*&*HB#?1P1 M65G&C'1_#2L-F9"U#O[*T-`9I>9;>4N[5^M?`DQJ.$Q+B.+1XT!7Z(?PC_NL MB$>_Y=GTO@A=C*9EC>/ZC6CU/2TVD+0?!:(P]D+.,1>.:2&A%1R("GF)'3X> MVK^->-D/X)T^GHN=;/@0WR4VNXO3\0:B-^PQXH0Q@QT7P`O-O0[A#5\.0%ZC MXV'NH9$MVX<#MY#[V=K>[6UT&>:I27*3#M1HE):`+3=(YU4K_TSNKI)\#3%K MRT:($`^)0@Q80#@CT++E'"@%H\=#PM3A M8U[F$I.'3>RI)QL!B@EE7&$K+:%($N9H90&5>&LL_0I[T)^:/9U@W\?$^CP\ M"5^\)4)\12)RE@B():="<`F7K4:TK4#YYZHLC7*>E4F(DIA MA1!%`F&.*'4&ZW,Z81IGO@S*O3U\;VD9;:`(D5)]0Z2IEC M:!DB>NZ/:)&D!=]N9DLC1/?`E/-TG+P/B<<.,]%2)/)(.BJ10TA#((@7P<+* M.BLU;,@7?/A\:7,J:HKGSD'ODSAM*/=I1IX.BL;[B[)-7[<3I)XY%-@D`Z*4]\NR+`^4W=K!PW:TRR MC;U'C&G#F#`AGX0T/+&:4>.-A;)$QZ"F4]OA1\U]D:Y-^+LDX4+!2;:BWJ=D MD*1?RS']RWWY^)3E%&7;[/K]N+A/!JT,@DV_.#*&"D:EHDYXY03C&@2_6>0U M\,3BILM0AS_+]D7=GCS31W0W7T.[N-[!^@V!7X/>(F2,(99Q)`13$`*`'I>9 MG3--ER?($;.U/[AW'E@?%]AFM8?K!\%GC2+L#%.(`PW:YKU3/QZ\U#WI"[JW1`CH@#(6(`!+TU%`QHB!G#;W- MCMS;+>&YL]\?IZ_Y]WU*1F75ZR1[;6E]/1]V[B:BFA+OB4$<6\7#7[6W`23K M(54X#%L-><*/FR==X]QEJ/TI*5?4PF^?!5.C$&V-;]X<4&_N/M*4"J\%PT1B M2+6V!/@0G!$@I8%AQFS(-W'"H,Y0`8;X(W6R'!GL;0->22/FT==X;N/NN'UE[C]53B\4BYJG&26A#@U MT(,+BSU'=%[\33E3FNRG<'CA2S489-/9_7$S3S[,_ZQSNJ%>!Y$RP`IIL9-A MXB486:Y!9;VWC?=!#G!%NV>V9#VXHZ>RRC6E,/5Y6$L^<@HJH(021`EJ)'06 MB,INR-76A_#'6>/>+PV[\$;G\UKMFS][FM^Y+'2M,7_MU$\DG-<&*8PX MP=12Y`SQ&8]^4ZCK30E5OYBE9ZZ>;[V#_\(UO;7UE+T.Z\8#'_ MNJRZ[7=\ M0M?;BZO1L\L<&Z^8/N\PTL$@AP2QEE"@)-):\\I6@%S3M:T#+"WHG$[]N6%G MRLVOVIH=L5E>(EDB4)KZ.G?[. MR=,RUCV$BKN_YZ"G<'&9YZ_D_A_+\IZ29=NCQ#KBD0\)@;).2>^MY#@D!R%2 M8$82"9@CVX]V=53[,QIEWTI7^"RWV?1J,,L@<#;`LL+!V>Z#\XP2D[5+C>>U/AZ#WL<)9#I&+*P+#('"1S\`: MEO<$)L_O!GXE-]LB'7DD&`U#(+.``:-#V@Q,93/E_)@J>+LD6OM0]TROF8J% MFDYNLSS]=[)N?[>&5,21(L!SI)%7,$19G'-;V8C"0W0\H6]?='HCQ'NAT?NB MF.Y&H;E$Q`B2/`RU4C&$`42.N"5>E(&F56\'&/SV2Y]&\.Z%.A?32?ERON'Z M4J8Z8I%Q3"$K-07$:B8P]]Q55BI-FMYQ3&$R](X6UEB'_W39 M<6WGKCT9TQ#57J*#N+@MEP;##_?'-"3KH]EBX<3$>?X0IJ%9?K4I3*@C'Q$0 MS!9E"2VT$G(LN,<+NQTWHFF!SP&RJ:G#GT<&'<#:RS&^%RL_'Y))C96[#6*1 M=`2&V4Q[@'D9^!!*Z<)*3[5L6NQQ@.LG+9&G133[X,S*F_BJV[#^D8R&/LO+ M\R';R5-+/F+>0"P#BM`!!#FGGE3/BB>H\:UF![ALTA*+NH"U#SI=3&Z3?([! M=NZ\;!PIR*`50$A@K57>NY"'519Y99JNKQW@`DE+1'DSAOV=+]]I7'E-),(& M2(Y`2,J9@[:T#/'*NK(F[GA6/]J:D-I!LC^>U"5'90>%0#!+?1@"'2@/M'-1 MI0?>:->THF#W=8T7KX`Y:$8T@Z\/&E0S7ODZM_(RXS((OR^3Q-_RK-BTZK59 M,)(<^("60XH%\+6QQB^C+T=$T[W``SQ+W!)16L6SIPQH>C>=G76V27#*(*VN M:IG?PU+>C'V7Y9/%(9!7[=N<+;7R%9$@7`-E-94*$R<]9N4;$A;3-`1-)[(# M/&G<7F:U#^3W.N*%W+')>!?$(J>Y5]Q!P0B!@`/*B:NLQ*3Q2?;=3R#_*--B MBVCVG&I]R,:#7;*MQ_81%,8@)0'&&%`BM/?E951SNP!EC5^8`(YV&&H#Q_Z" MZ:U1=(1866CA-5'A/^B%*$?9:!H!%P?+C]/XZMT ME$[2I*PXGFU0WF:CX(ZB',LF#S5VHNIV$6%KK:12P@`@":FC%Q14UCMOQ?$L M#'>Z1]41WGUN-WR,'VJ6"*\5B(SD+*`$O20$,VU0>`@KRQ231_3NQO:=_ABUM M#%K1M'X6M58HTL)1;1@2$"&AM"><^X6%T$'7=*O\`/>N^AE[VD"YKQK?+7>D M[':Q0)BO)='<`.Y/9X^J<2>W!W`>5&J5L&U`S`%%+"0+* M&5Q>32`XK2RT%#;=3C_`DM_.B=0:RCT?.]A:0_BL:02`LH`CX1C@`1^@.:D" M.PBE;;IN?(#I6!LN??U001,T>TG;EW=(?XS3X?NQB>_3$'"N:+XIA=\J'$GH ME++>.R0UH-`+2W%EL62LZ:OC#C`%ZX`_K>/;!Z,^E?<\C9.AB_/R8M_BR4;= M=3I(-\U>VX4C+SS&2ABB+::6$!7"OLIB+F33%>H#K![L@%&MX[N?.$@GUUF> M/#E[LU-(M$8^@L99[:&0R#MK*'!:+.,_)45_+QWI/.'O@%==0-S[.;IMP='+ MQA$63B*J&(2<8HXI<58N'Q:FFH9']7,S.2?-.+DIG^$?C39O1G0_P\].8TT$ MB#$`:"0P@Q);:)UP2XLL:GJS\P%6)/8RL.R(YR'LM+YAAS6BAI5'2)%%#I2K MIB%16*8,'KBFX<[N98I'M0[=!M:]'MQ]O'KZXKH\BN9'V;?BRSB>A@SA\?*) M?9WD76JTVPG>%V)AF!!*!2=8@37#8:R08%:%KC&$WJNM.W;=6%J>V0JJ?LRS MKVG`53]\*9*0CBUO?52#2?IUSJOM]N_>610X+HC2)*`"F'<>8,@J5+1$1[0G MW@XYLIX1[V.."4:\'X>A(3G?7/7^I%VDN`KC(U``<2N!Q%I0N+`#:>2:'K4[ M0.9TZ>27?&H,<3]K>O\W+>:[')^S3\D@&P_2V<'31ZT_9^T-:%U\7<2!4H[+ M,!M3*10$ECI3H2HUT<>T;MC!D'<`/NF#Z;_%Z;BTY6)<'F6[N%ZIQMU`V`U2 M$914$Z.)T%HYY027\_74TL9@?_>7;?28T.^7)%E73NF#>*M'3C8P;;59!)P& MV`M+RLH7I@T(#W9E!:#PB%ZMH,/>IFL5PXI+4N*QSBS[I946]O"=/QP$.D]W=)^-BVSRZ M7B#B6'(G@"$:*LF%1WI>LE5:IIK/J`=8&7=0;&O%&UMXMN:EXW?W<9K/$Z7S M;'QSGGY-AHLS7./A8_A8O42C'(&_5RW6<.NM748A(&6>8`&\8MB5"])F"1\3 M/=R@^315^/SG(&'/;NOGUJU!N0^:V&3^48<2GP3;@H;08+P,3P5S3=+C^ MPLN14ZLYUGN:7P[#:UKND@$@0ZX$-(X1!&'@7SY?)IPL1W7Y=ZY"QK M`?3]SI6+8]@A1'UJRDI92J-)M$:_$4":86$@T01Q(P5@?ND&;$%31>JUY:0'^//"VCCZ*M*JP-G44:0:<)XY!)2@627#BR0`0STO@HW`&. MH7WRL3W$>]DSB1\6ZPEJ\,/<"[-?KD8WN(]W/R_7X15\SW)3\G^=WBR/YYN5!P<35*;[8.C#OT M$EDKA"O?L\R9-^7-PQ)5A9'8X<:WAC<-#[O?@NZ2)__/WI4UMY$CZ7^TB_MX MQ.GQKMMVM!TQ,4\(6BQ)W*%(#T6Y[7^_`,FB9(E'%5B72MT/W6Y'`41F?DAD M)A*9+Y[*MR6'KHW$S4NW3]\W2W4_B]75[/YDO^*S8X-T@$F%H)`,`LY!BF>5 M].K(Z=$;B&T`KFFV=^D/U\A,QU%QXH"405AK*Z0'%$&FD2M?BV'C9>XS_@$^Q.[9PFN`^YU4 M53O8%_1SL9HMI\^OB$Z@LLXT@4/OB#(J482\<0QHH];BV3'2RIWV9FBS&W:+MP4G\(J\7IKA"6.)"*.,<_/D8< M%],#MH"=W5_-E_V#WCV*ZOV/NK0B``.(B!11R(LVU>VKI)^E$L'D[F<92?Q,/:(<8D=-0B((2DW/.2 M`@M\;J.:`9X:%\OPQ0U/%@L[4?;+^VB9O5LNIYM2A<7JQ^RJN/^RG)_4\T<' M!26\0%%I448!Y`#:Z!:4%!J8[=0/4,4W#9+&F-I)/:34B?OS:GE]LLCZDZ\" MTIA@R+3ET!AIG#0*[6@0VNG&+/4S/L MZ=UL,4LT1_.FV!C`)^/2U28($F+$I$>I:KPG0D'E;4DY-3CW]!E@4G33^&F% MP=VDN<0U/EQ%YRG=(MY.5C=G#)67GP?N$:#`D725@PFQ`*)(%XP&KXNDXMP( MX``K=S1OM%S,SBY`LG]F4JEHZ8&O@P"4:0Q8)((98Q1%7)3`Q\#D)B$/L&QZ MTQ"YG)N=W/,O%\O?%[I3>542-,^-#2E%ACI'H;!6<$:DU6I';SR?7:Y=,\`J M%TVCIVG>=O/H-O(Y*L;S9LVS+X,CCBLLI&7,.Q,M>"EP20M@;H09E,V)]\6[ MV$M8VPU,4KPO[9(MY>6*3^+E\)!@M>,D'KJ84ZHC79S0/74T'L3C\:C;1$PC MS.W$GDD/NH]RXI1I>R5`+EEKT98*G.]F#4*(M[ M-7UR3)Z@J:9&(*T]E-!89[&T>_H8SNUR/\#&9>U!J"GN=E1A9&?5ITSQ0]F2 MV]YKV^^^3GX6]W_,%LO5;/VK5+!J,?U]EFT#G#^*]6W*A"NU\IEZ)%VM(KC( M?8YH/!549$EJ^"3+\)JT)+MDW0#3'ILVYHYV2J1JMYEUL2A.A\:/C`@. M2"J`L<98@3CVBEE0TB:QR4W-J)T4^?KI$Z#,H#18T"5`.`;/2* M&"BOB^)&(=FU'&IG/8Y1C=7D;A=X2NDCVY46T\>%1G5:UJ5]MUH^?*_R'KGF M3$%R#[R"D6S(J.6(&Z[W-HL6N:'3(>8Q-HVT=EG=R1WPLT8J97F)4Q?"1X8$ M`[P`'@(FC+".$JNM*:G36.>^-QD@CEJ3^YDV-YFL[DU_':JN??##C\7ZTW4\ M]NNJM=H_$`3G4M)4T!M9%KG(/=L'B[S.[HXXP$A<5R#M13#=FWB'V5DN7ZW7 MJ]FWAW6JZ)C*AW]/S5T6-RX..-G1M['?"`Q!@QT@QC-`B$?.QW]O^><1)+G' M^`!S<[H"=E^RZ>C==$:#4&XEIQPS#I7C5FD6*2CI@(YEG_#UM>>KVK^L"ZV)6H?4]RK^"&9,Z97:(K+R%T)*96&62T> M-PMUN1%J.,!;CJ9!U@W+NS][GP<@W<^X[BC7V6*R^O4^,B]1_(S8#0,JY_HW M]DL!<$&,@=PKQKB$2J1(YXZ7S&9?L`S0"VH=;2?/XZXE-8R@8DG3AI*+(HR_ MS12(`92JJ&80A-AYPQ2A)2^`T-E!H.&AMC<4U8Y27B*AP:#U*<\NQ>O3N0(4 MB%EH`5"*0D$H(A[OM8B`(^KY_:H0>X&,AN+3/_$DCP0M]FY?4V9'VPL)&`O. M(#7<::ZII(Q')W0G">MT[I7D`'=+OU;)P`0YE"WUG+IZQT&-.8.CU#DF'`", M>8@<254H=OQ1J(/.<#T="\,!W@51M$M$.4"H9]D^M68-`!J,@5=<>TJ`4-CO M'WQYZ%!NVYL!ZO5QPOT"8?81%EV;(`VQO+K3]6;5]Y\>UO?KR6(:23FG;VK-$SR&CC@E)?388ZUI-%3W M?(7:Y.JA-U#0H$U&]PBXI_;<4S+J0^[83.FYFZ7<>\&T95!9Q_WCYN/YH?HW M4`ZA75:W7FC-%C.[O'IXVC"P:B&UVX1C`O`.Q;>W(4YVPIK__8.@:#)+G8AT M$RL5P9A2;X3!Q`.ET-G$CU-[\+ZX^J^;Y8__GA:S[?:+?WB^Z^)?A6TNS9_% MS:;JR6+]<7)WR*L^]FD0R@G(#1>2`A@].)*ZKVQI@-;8$:2GY@IMV2CGJFO? M>I(WD?+59/X^`OWG_Q:'DNJ.?AOB81&/"2M3ZV8(M(!:^9("ZF5N!9D!V8"- MR?XRUC4O?)-J7B[6/OK+D_F_BLG*14&SJ"NF.-;?]+&->\V$MSYVN<_XB\GWX26/02;/R':^DH)%!X:\OU0F]S ML_L'9!HW(.@+.-:>A#^7S15.Z/:#WT8*&-101@_1N/*!F MF@W*_!+6M2?\Q_/&Q[\YE(]^XNO`>%1%W$95Y9V5CDNA])X*:7,S@094O:M! M`%S&O+8AL(5G=1`\^3X`**SVE&EIO(;"0>ODGA*AI"%ZWXR(5+4BZFE)'/4Z>MU$2`4X8O2LD=L:/YXL]OWB:OZ0$'28N,>, MAZ]17#JNZ-^G&731U,%YI)DW6%!L-<(6*4CV'.,D]]IW0.'>UK'T\J%WER+I M2;%\G*RV-=5ML9[,YF]-T6!$N=):0Z,8X-IX;-16^1,J/#X;06DS\7)_$:@G M\\GBJOAR6Q3K32W\Z2R1-9D_R:K2OVKA]6MZN7TV2;/U%01I*)1">,$I(HXA M8#>]G3;\-T38MZNV*B/S8$;FT"377;IRFY2KG[/S=<[:7D`@F@O%F8302\X( MQPZ+DO.*BMSR[0/<,X/#3^?EZMU_+'I[&K7GBP:SL4? M1[4T]JL(7#!.`4'60,NUC0(&OI2!D-D]-`>43/2WN7&IU+O8>9]7RZNBF.X> MFFV:$Z<>U8]E(D]V6JLP.J2L/V48QXIA2YR15,"29@_.B=S7P@-*.MT M?$B]2(1=0/7/8EY,[HM2[=O)K_O)=92PB7P]?(7>RN\$[!AF0@-C*#`2$4XP M*#FCJ,^-NPTHK7:\X&Y6MFVB?OM*:WE=KMPL[[XO%\7AAD--31V$U=!A#(P2 M6'F)/)/[`RKZ*+E)A0/*)!X?MAL39Q?>FXKV^OK^'\5\ZI>K5-Y_]_;BA,MV M;$B()"D$-,`"$,L!4HS@_69UQ+_^%.C7`-:&Q=0%")ML_Z$@!EIK*CFEULMX M>,#=2P+"N^`TJ#?S-PKB_.GI(D]W_:VCIO,U7242.%4LPJ:YQ`&FK!`3`>4JD5 MQQ<5Q1CR?>Q04B45E(8;2I4G5C)B'3>FY+_5(+M%YO`47VO(["E5LI[DQI'% M,(Q421%GE!9P\=A9`PM51)3QI1S&GC)(_]-=*GWABB-%NK?B3KC,3=R MI=ZYS7&:CC^+'T7\BZKF1J7)`N4$:\FP5L@!XXS$2)0<(=+DWB8/4/D/$F>G MS(TV!-@1I%\NMT+WB6W7L.V'&1W7Z_]"<%AH('A46)PJ"Z70R%#1X3`78 M7PGX>Y#J:[O,UJDN`D<`&:N<8L)0L:?.*8"ZRMLJVF#XD]5@+WAD;J$H% MIQY6$^*^C%)Q1',B!7*,(&]*N7`I1A31;0VQR]YN??ER4N9VL;HHJ6N[TP""C/8\98SR>,Y`Y#R3>U@63 MWAIYOD%?E]1644!G1@;+$/9Q-V"(&43:"9*Z6FW+D7FN1A24:4KPAQ*=&V-P MG_NXSP2FMK8S1(XKJ1WC##H*H<1\5]G9>$G/Q]Z[I+8VE0%0`H`$UE+&E0#> M,.)*ZC!%(SKIFQ)SIC89V1F>5(_;4L(!45/@4`DVPHE(H)%.L<$LI9BJW,<,`MV@C M\CYX8=<(:[OI"ULUJ@`%58:6(P)2_4FG?":,FFXIE:?39=KR<\OW:IS MF;B_?QB2/0<,AAHC+8Q#G#KI-8NF&(*IFN8;V9!59?K<$[Z$F=VEET2BU)5H@E M1("BW/)*@TTM:1!&S;*V,QBET_I#A2S7EQ\'Z(R5%C'*553/6'/*Q.YXI\QE M-P@:(%@:LFLNYF&G-HW[^;U8W!>Z6!37LTH.W^\C@A M,9!CJIQ]B6"/63,7,;.3O)R=#)(.W03]=[>5BYN46&0FJ]6OZ^7JK\EJ>O_E MX=O_%5?KK\M(U.Q\@LY%$P?NM;/*>RZE=M1!29$M.64$R6U,/62U=#GL.N5Y M!_&S:,I%JU*/?Q84%$.XE9#9C42D*@(JQX22DT;%0O:AN0]XOCHS'6=KE+^XUR-[U9 MJ8>&,ZQ]9+@13%,L99EO`^GY1^$MT^EGB]G];3%]MUQ.3X\&9'QL@U["U&[\@-U"_YS\]4>T,U:SR;P26IY^'PAC M$AO'B4?>4BPD!7LV,:=&%5!H$2P7\+1U-?YA]I^'V72V_E57>[]\(+Z?ZH0" M/O19X%#;:-YJ&YTAP:15&.PRHQ`USI]]#%YG;:,>Z&\H=(8@YB$ M?[<6;?GI.(JGM+.8>TH,F$0Z";%6"S=:-.9)NQJ"LGC;R;5A,8]SWKPK%G$'S3>; M\"[YLNMMF_?=O<7]^;OH.O,$!:USFGG(@>;6J>@WD<0''/]+!![!8=LP'I[? M/;;([7'4>AI&04D./:8*0,NDY]Q8[H39G4,8F>P>0(,,F+RJDWT8`G];!24Q M-Y)@(0%!CFN%&'"RY$W\TXAJ_`T-;`T5E*PGP'X+2BKA'$**<,BQ!9APPUFY MUNCBCB!*UYDTJQ64K,?PVN#XDDR;XF9VI:+EDW:3NED5F]VUS7`XA9-J8X-2 MW%E@"*%0"&DL(S*ULAUAU"IA7>UU/WKI):I-#8HYQQ3@EN&%4IV/>`H46"!P([[W$R'`?8R[5+AM,'[ M3MSJAV_WQ7\>XE)=NO3[&G_XC$=R9$20'AAM./U_]JZLN8U;6?\E[,LCUG-R M*R=VV3[)(XH6Q_+4E4A?DE*L?W\!DD/9$K?!K)HX#[&K/`#17W]H-(!&-Q)" M.$,M0`;N9D8TJU#UEFMM"EY3LRU$.QH:B'T7O?J3;0+$UDB-*<*"*,B\(M;O MY#->>C2A&*[&&K[,F"Q,!^#,Y0._8]\'[X`BBD"E".8:$(:4W$=M>.5-G9S0Z3 M..)G4"YZ$><:!V6Q5=!X*J4G$&')676P23"QN4'/_\@->'-SV+K"^J#H'\4F MV>_WJ^5C.2_F^NF_ZV+^V^+P*D_=;,K'"&ZQKDG?9AT'!A%4&!O$H+2*&T_\ M83*G=X>=^[5R1^U%<1LY-__'D[M7=?9!_&H1<=_+C5FN-VMXALRO/PX>`T*\ M1,)1ZGFZ6(+"6ZBYQ$1(GYN4@/ZRO3GT;*R@#+\SLVCX*6\TL[L@,<8,*\,% M10!YC)36%62`\=SL!^P7$6O[J/VHL$NJ_O&03O:67ZH!'BK<'UOJV^HZ0"LC MVG&>:J"-5A@J=)`?ZVQ;RG]1N#L*MZ;._BSO88CO%L>.HMKJ.CC`:,KH[`41 M2'*NJ#V<>"#J=^[+(#=0Y`)T__;WLBLZQZX`@IUHQ)H"13'JE%36' M0[)#+L$O#N?LUMI761\T37*_^V*BJLN-G]V4=^7FZ3^S[^7] MP[U>KE;+OW=GT?%?GE,4'.%KG6Z"X-%WTA1)JC!53@NL\1X%2C#-?HWTZ\8K MB[@=ZJZVWW!L++\O9XO]>&SQ)7XPU[-UA&#A[LK;\O-=\:&X*(;$ MS?L.PEACHH?$%'`40Z"\5=XHJAF#CMELV_OK>BV'R[TK="B7XD.10O4BD$V= MBM,=!:>EQDQPCZ!R%B$A0$*"(P-2`NKL(ES_R+"Q;MR*UK0W%(]W6\]W#YOU M9K9(Z-6D[ZOV(:Y%!FO.G1<6.@2I\[S:N7IALEE;^\YM:L7=V^1M4[5U>7YF MHM3E_'3E]@:]!8R0](@;"B40F!N$\6&_:I42N>3\=0_7X3%9$Q7VD`%N4][^ M1-5>T]6:Y?U]N;G?AG0NYKNHCMMB<9.RZ-9)8%NKGT"$`L@1H7W<<8BX_Q`\ MZD!RC:Q$W%V,^^EH?2MN9W?_F6W2W'HIQ#6)J*]J'QR1!B#J(#2<>+D\=8!ZC[-^R%S5PTQ^SCFC+(7L//3 M_&KMO_)"6X*Z^[F]G"TB$!^+FX=M-;KJS?@P<]P6GS>U)O/Q!L%&TZE9>N2N M%?=*2^_V::()-L@/5#+BY\%>LTB?:!$`57&MH4.4L=0*P40E(X'<3TC)+6AEV0Z*#?1Z,JG'D:^B7-AR;:+' MQXSE4D+'334J;/P$/.(&FCBFRRSFBC^U^K2,"^-R,5>+1?D8\9FMSJ>D M.MLF<``HE\@!&.6.NWDH4BSE;L0R`C`Q3=?5T[(;'',U_^EKN:JI^.--`M5& M86NHM58!1X2A4!W8;D!N7,B(PD+:U7LK,-96>[I!WU:I+M:;#ZG*\,G%^=B7 M(5HT!^.R%$D9([6:);P+*QIL\MU\>_#<^&DK&Q; M*A&=F^]Q1/:]/0VW@^%0L3N'^_>:YS'/]_9$<4D@1HXR:Z!%%&E[<'U<=K:] M$<9.MN<+=('L5!]&2,.951Q1K"2F`G,%#_,14CVA,BTML:')2X9Z8$_C)0/' MRL1EF%MAI(#$.,I]);.%(O?5XX@6NVX(UCOT4WQZ$/T^A*SCEE(/N)(*I)!) M@[5QEB&6F_WHC:R>C!*8,=T\PH06%Z1VZ\ M.$B/=2[+1ABDWPW'.@*Z?YK]>,2S?`T^JV,8"OB M)//8*VHJB"F,CFTFU4:8U*H/JK4(]5!KYG\7#]'IK!;ZY]A87Q17<2^[SX`$ M0MA*X;%TTE&IE',5/H!FOV0>84*J_E;6+I#ORPQ^*.[2#/IIT"E">SOEUNN' M])QKFT7S@B6\NI^@B?`P3DO(D&8\SE>F#CA([7/O_T>80ZH[8]@5VK4/4'X6 MSLU6=T^?BM5]N=BJ)X[J^-G(Q6:!(K^,PTRYX'2WFQZ\1MT%"K5\.XHI@ZU--DMMK!:?$402D=L8@ MMP_0L93KRU&J_4AXS6N(DVV"DTQPKB4F"E`DL-)85S)&ADVH"$MS-2^[`760 MR3GD?"WF#W=Q45"+33DO M[QXVY6.Q?Y12%FOW/3UD+^:[VA+WWQYVJGWWY16G+KRC:/>'@F146>))*I3E MM`*,JXJX6`.9&Q3REJS!U81Z655O2$WTL==H*)9^.M[!A7*U'?YJ(`(:ARQD MSLCM?][@"F/DR)2*2`Y$SN58E3GKI@XP?-]$Q??`EUPZ[9431!(;-W$5>D*" M"85T36/QSM7<&^#]Q?PQK?0?A,`>.@>%\@!)3A71O,(-I;" M.C\&^E"D^]>;391F<6OB.&^+8[D>)%6+^?[6Y[F^8KVD-CG=!6@X49%XB(/(0\8,,57PA@-236B7VPY! MEKUC/LC,'_(`N!,#X*1PZ3D#`X1!PC%2R!L',1!"*SK092_V$HB+[IS`AD$#*0<&:D$J'(C(?NKPYJ;[M70X>8S;-M1].+(_0Q)'NAWW M-@C^PCGKA99!44*9)X``ZQ!RQKEG/)6_G!?N[="J$P:<6U0:H]T'LS[%7WJ! MR,53S)-M@I6429`@4X@"`23PK)+/.#FA!W^M:7K9#;9]<,?=?[M;/A5Q)_58 MK%)@T\43R!,M@O+2&Z,05!;$J08!!A5:4BHS(=ZTH-^7X0JM8%H[OJP*8C+1 M1TYO9-)/?WWWY4MY4YB=VWPN=<&UK8-GD$JH"0'>6HVBKY]R*.VED&`"Z0S: M9T9W^`[LZUQS$'U-\Z"4=!("'B7V$%N`TOYQ+S5D(K=(R0A9-;#7DPMY;7-T M="M\M&S%<8-T??M`.-#$(:X%<,)B)AP6E23,J`F%UK6KV&7W8/=NG_9H?%C> MW?GEZN_9:GZM:7K=,C"N;!32R&B2C30>J90A=B>KA6Y"5U^=$*L;F(>B5$T> M!0BE4`P@J&DJQ$LE\H>)8@G++FU4ESS?MKD5/VYFJTU_%&JBY2O84Q/<_KVD MGR]]KCQB#=((%[>IA!D$TJ,\K%RUWDO$Q81\ZU[(D@=K+_D"9T_;7/E1W)]& M?(8PIYH$0VSZTA/!; M69\H@#*5%X0*0T$-(R3E"]I)E3+B9_*F=H:2W?KD%O,W29H6H!WD5G*[P9S. MI63T!Y#A2")+250=Q]@``)S1"##A^4`%\*[9>3F7!W/N$_%K?#%.NJ4UYYSXAQAVKN+#G$_$M:++;JB=3!:6BHL1)PP3T'*>XH. MG;7/4OIV[K\/8V78>,%&ISUCJ#B!-"$R.QHH8:G<(Q"=6&HKA?'_RI MZ,N!_[;XLES=;Y6GG_;_>'VDT-6]!84-89(`XAC%7&L@F:]P$4Y,J"1>R>SSTP[I<%.MUY0E?6!'/M@L,2*>C MT8=20JD15RD;=>5C*)F[)H[P%J7/-;%-S/NQ:-OA75P%?_HN>.AHJ@YG`?4. M$&-\BNS:R9'.C*9CD5K2Y_'==Q::M4.,MME-HUW]-EL\N;NRRMIV>I6ZV"85 M&F+8064D-U11CG6*;MF.&!OCKD6E+<[-ACK`(2`N:;8A>?;UNSS__O3W__%BL'LN; M,WN*L]\'Z#$50G-MXHX,:P0)/XP4H.R]PP@+;#37SNRWTZ<9L M%7W3"P443W\?M"`:X6AO,&5Q_?!6H(/%\?F)X6M7NG@#^FX-Q1[]]&,[E]^O M>%UP3?-`HP>B?%RD!'<((&X3V_=2$EBMU\79 M`@^[#P*R5AJI./7`8!G_K\R!Z)K:W,H-8UQQNB1%%II]\*`Z-'/?R\TV%NQ< MG:W7'P>OO032I$3H2F!`;23W]BP>600$SWU9--[=2S?\:(QL'USYXR&YWBF4 M,$&07*Z7\7E'.'.Z46!`$PL\A\@2`ICF1%5@$8:GO.`T#B-I#=7>8L(&C--N M,R2,"6RU@T!99:+!9IPQLXNXDQA".GA\MEMLRLW37^6\^,$^[=W6E(701WR.#=QC M3(PA4XH%:DRSD^%EPRJE>[.R3=6=RCBGO)K%8KWM9Q#S\AR8^^[+CX/Y,<)^ M.]S/:;C5XZPKC%"SC@,A#F$871'H!.*`&6@IIT1(Z2W5_.)!X\!HZ1^%NL8@ M->PY"&LP!-(!%U$S*2N`VO'=:2G2Q$$7G0?7'U;I:S1:WVSB3N%*^ M8NE6ZS5"[9O]1DCIWY3WEE`/*)*:46-\.JLBJ2"EJ^20DDSI!J%_W;\\+6R`?"]7G=FX/$NV MF+^_FRVNJFW4Q<\%"7"J@&H4CTZ,DL01HBI4D=`32D^;R::7%G%X)?1![4/. MRQK5CTZV"4X:'V<]]LHX@;42BJ*]?(ZR*:76'I8>IQ*7-E1([3"A_WFX>TJ) M9/Y8+OXLUM$_V8Y@*^&Y:*&+S8(`U'CBE/!$.J\1D+Z:M0N:((AH#R:"FLAJWA.CB$?8;NM(=%9?:TTEM+M7D MT.EQ*J4L]0IQQ`GPFF'-3#7...S>/*-OB^L@'P?=+GXH;PQ:RBEB,--;:40(,`CY/A M,!$(51,ZFLA3X`D69*%7>^FQY:JXB7AOS5?ZZ7,+SXF/HZA2"X>CHQ6M)_6> M8(\/HAI#IZ?ANLI9MHSA*(Z13EG!WZ^)IV_<>3"$2NJ))H(J)XG6"!Z<,L9) M;LGL,3K*@R]-O:NKG[0`<0K^MEX_%'.[S;OW?I?".@FR_N%P8NV^%ZN;,DIV MCM"U.PO`8\649X+8:$6B\RF-.'B(@G9__-1W1MT^672L6G>7ZAF%13XY^U\( MM_YML9/_KZ*\_9JJ7Z820K=%]>_O5^7-V:O27@<2L'(:8J@D]]@(E")W#TI7 MGN;Z%V/V%VF_I*DN/N<+N_$:`GA!/M&;5$8*DY-*1" MQ$;K,R%_IG^6#ZVNWI:'SY<%_'R5@'Y6KOZQ8Y0^/7J\/Q]O,Z<-$ M_VVY>-@<:7/(NW?+]>1V_^_+=*;?ENL_9^NWL^GRTV+^OUW<=T>/USQ"=[E^ MH8*5HAS9YH7"#AA[9(2`,*2^0^;8O&`XJ"D0MQ&N>@S*R0H+*Y'H7<16JL6`Z:ND:0I`*@X.T."HO*Z-A;*C7 M4"5?!&E$:@:TO,I,AO"UD>]PK++AQ#>BM M79FM=>)G$25]B4CPW_OY^MO/BW(2SR;@]69],UN]NYDL=D;93_$GUG='@D)] M;Z$07@OIG$$!.4VBT#Y&T0)U(M7@S^CEM37^:^M%JUN(QBT@T+9V`N[LF]K(`W,P&%Y M_T)]4/OK%#K>12Z439F=)E1840Z]K](@@D^MAF[L-UW9MRV,AN;>^4,OVK=< MIQ":.>&,]!)3YA$)`M,:GWAC]>5Z7;FW+8P:YX\_'7 MR>JOV?JE=^Q&WR\$!H:D50K*?S#")-31265QJI&0USM9&W+="3VS?M3Z=?)U M_OG^9;HL>G**\5VL12$F0FK&45X/ M66=Q:V80)*F^W1;VES:?E_>+(R;LBU\I."/&""&8CY2T422I@&J_!&AJ5ZJ\ M'J#:4'!MD;"YB[UY-*N&>3XOD/^N8V.MAF\GA[H`G?-S!7#GB9/:Q`TRZXU` MT27;G=,9G/I,GE&M10NLTA=Y&[.1^?1IM>DE\3P7JR$'I?Q209045&,E+&$J M:(ZL5+5>#"C5D,ZHZ*`%YNF!LFGJYWESCI\79CJ-($P6T]G?\_5-].26Y:"< MZ;O9ZO-\L<'I]]7R87Y7)GDDJ*BNEBP8#YQ8(6G9>A089PC;BEX2R]22L8PJ M$MI28YE`T)AE-T'-5Y>OO/3I`H0$3!1V02OLD516D'J7023WQD/Y<,JP\;Z6 M*-_2HT7)PF\>9JL_;N;3FVUT_(_Y[>V;Z;39D]JQWRD"I5%-HT`P9I@`"$OK M2UX0EWH-YA4G/!_74X\*+=(XZQA#@PAU9VL57G+"C'3.<^8")=P341L8QJ9> MF+DEV;3&M;D@,2;.?IC,;\LFB&&YVHAS#PS^=,F"2J-#V9$^ZHSH@D%@KM8; MA*A4_S:W;)QL^?Q,0/K+77BR[_*/9A_,8G$_N;W]]F[YVZ/I:Y=E0YZ/55_9 MQ^?V\C-?9]/[]?QAYFZBD]=RVD,76RPX:&25(I)[S;STS-&:00(SJ:W^\@HO M=V^\C`.^K,3INX.\^?CTT/T+SXD-%91Y1SD-W&`AG/%.X%IU:JPP>%K^5_'LMD>-T/%!AI*J/@2HZX(9(%494O1/UV$N^N`\.6S M\"_&,"`\VA*$:1K*ZC/LB?"LQB::'A>D0A.YJ9@28WG\VH>BYKM]L293VWFDC&B M3<%8MD2[%#PQ?@6>^Q\J)*&*4X+`A6C1>\.P@&I/CB:7NV2HY%O!\PS:-<=S M8U*LEVZV6L<=5\'BX[;BT>\4T:0590VJ!RPL\1BYLFU*L-)YY'AR;X>,"GU; M1+M-4C8'__,FPC]9?'@[NUN7@);Q40[4]L>%`HLJL/)@!#.SI(ZR`U MRS6CY*86&:!=8C://1R>T_Y"P.&%H>[2,@O:*08@,<>!VE"9(M)']W;\*3KM M`=X.#7L)GY;L6+H>O[QFT/VS#Q<(J#'QMJ(>-#$!,8&KFTL&;U-=NPSO@>%= MN[/)GT4\/NO:#C^MEG>=M/!_>;4"HL.(,0^!"NJ4]:"\>Z2I3.U=D:&'E@-KMP9$ULR=85V2 MP,X%8:*%C;V4P2)I14U=8U-U>%9U23DQ>KMX-'9NW'*QR:^YG]S^,O]8FF=[ MHX?-XL/F?67K@O\[>F&K(RERAQVB%A^4E`JA->!*,\H(D02=5C&3K< M[?!*F]1,J^9Z?T1[OO_V+#7P<#/?NI?-89[I8*$":_`NDI=)3)B,1PN:!X^0 MY)Q[C%-C>1D]Q;3''LN,D.BOYG#PF3L6*2[+.2Y62^\(@3V+F8?>'I>ZKC7O MA$<'1&)@#NUSM`X6&"."@"&P`A/C:`V.ER@U=RHKKR-_#FV.Q-`WR]C8L5^4IK\7JS^N'B41<4BZ\,\ASRXS5T0GG0GLDB3C="S4S3;=CUS?W MZ[OU9/$A:O8]_#M\&3^\8*$U<@*%*,)*(55V@":BHBYU*'5R348QT+[9L.6' M]%9PR_KN?W[0[=-J/\*P7:L(4DFF@P;F.$<@0_1-=_14!(O>.BY_V0Z!6$]6 MZSP;T+3$EMU)21*@8Q"0X3.I2(BNK[>*"\2]M-H&X2J:ELVI+BB3ZK+$XWPP M^TG*/CA-8IM@LY\!`5^C,SR_.YXDV_C'"L.L\1"T]%2!!L4"-K7*\,FU':]_ MR]!;]EYLAKM\>/?#<7G7D(U!R\/7+_/5YCN=1CM>7JT@0"Q2T;WG("1%@G)L M*YH*S%*U_.L?2WYT,1@3@ZL5CB)M7"4.H"HA2+. M(CQ:F!1W/Q/Q*B<#8SH&.1G6K<9`&43[$CC&UC`N(Z(5/377J3+2.$B^=:MA M\>$J(/W!.3+Q^&,V_W03%:EYF*TFGV:5D;D95=V/T!S;08$=,SPP;;!$S`46 M_Z5KU<23Y\XT[LU]C5!E!',6(O9BW>_!Z$-78M;>+@I'C/1!>A"*6&RUMY;4 M&"B6VEDPH]F?8Q6RP4`>A:!5!QQMU!G M(7@7$R]Q5FI*D?8.4:NH,$[7U@82,KEU;N-LA6OL,1N4>Y.P]Z=/_K[QR=_. MRL9\\<_WVD.4(^[)*6GK=S>%I`+QUDB+R"@:HPH3P]$%I0D-F5.:-:@C MN\I^CH>=+^[FT_],;N][NKR^7[.06@NJ$9'!*^=M8,Z&BKY4)/>1SK"CY/@3 ML<^";@RBL;MCRWY6G3\:/UNK`$$=15&M4$%Q?M\:Z% M]`<&<6NA(#@`[(#Z0"BRN^1-C)5G)TN],]-\83)?;3AV#W;X^F4VW>;"=V-) MG%RTD`".8)`N@-91I)66J**R#B[Y=>_B--^KV;$MS=WNXWVZ/JQ>.(2,%Q,L&`F,A,*5T17/'3FNE'^:QX"QYR0K$T0J.GS_, M/T038@BQV5^[B,89H4Z&Z+^`M=(C'&Q%;\EDJE=Z>8\%60G-&1".3F3>SN_^ M"JM9Z5S,(K.M^Q290VL7.@0;N8`(C;#7*H#CNT<:3((4J3G]E_>HD(7(M`!A MUB+SFG*%NCU^3:`.'QL:[J1@V$:UY90"1QDB4E!78Z%(A>G7@`= M*.JS&21YC>KL\Y?CE"H;]2%$.QL\8TI78Z8,&'VR:4U'BO'`U-!])MWOYG(H M?K[,?+R17OFSXQ0&4LX'2QZ;1ABF?VNCP M\N(M;7)XIQB=NHO_^8_RP^4AX__\'U!+`P04````"`!A<*]$$\X;]!P.``!V MF```#P`<`&AH+3(P,30P,S,Q+GAS9%54"0`#5@%U4U8!=5-U>`L``00E#@`` M!#D!``#M75MSXC@6?M^J_0]>GGH>")#+S"35F2D2DAFFT@T5TM.S3U/"%J!J M(]&2G(3]]7LDWXWOD,'=\)(R]CF?SDU'1Y*MO/_U=6D;SY@+PNAUJW?2;1F8 MFLPB='[=^C1I]R>WPV'KUU_^_:_W_VFW_[IY?#`&S'26F$KCEF,DL66\$+DP M/N/I/;&!3;3;'K7A7KT*ZTJ8"[Q$!I*2DZDC\3WCRP&>(<>6URV'?G60368$ M6]"ZC15XC"#R6"(^Q_(C6F*Q0B:^;BVD7%UU.B\O+R<+QE:8+Y@-#T],MNR< M=GOGW;.S7LL`+:FX6BRJT8,Z7V(7G9T4\#4F&E$0)LK_/7AX>)=GD+(L`P=`R0Y8IQ:=`-W\V0F&I61[3G M"*V4'\[:W5Y;><*-G`=F(JE#-*IS*F,'VU+X=]HAU`G(T#(Z%>7AS,9B1P)I MK*TE4@&Q*XDT5BV)\B(I0YY-%O6K[?.UU:UV[W1+,<).64T,GV\G8EQV$#>5 MN\%SIFSCUY6-*)*,K^_A=SG1;,YC*'F(N(T>4\Z/+N$MQZHFRA1SIPTC)7N0SJ)8O*K8IL'DR9\\= MDSE4\G7IW);&Y_^HE=3BJ`[G4`IIV--*XD09@U_M$*:F0!8FE4WC\ZB+[4V" M7\U%91$")GVUO1"$/F,A*XL18?.NMQ>%(F+JH;A719*0R[ULAP`UY1#$K"R% MSZ,N=B"!7/'J(OA,^BI/"$0IDQI)W_/OKE:$SIAW"VZJ,?S*'\@?\J5 M-XKF5[6=%5>S`4F@N(H4]AI@P?$,N'7PZ@G"WR:R3Z`*]@DVX.,%AAZM@,5T M;*W$0RBBCZ"R]W5+@+5M[*O^#^MDX5E5G8"%4-)]")Q>R1YG(D> M7)XQWDW2^;R[OLTKNF*`)2*VV-(C/DJN8\Y5.)Z6@B.F8V,:&C M;^FC`";72:K8[/9*.LF'/#@OW;+EDDBUW"CZU+IE5!(ZAV*]HI?R8/)SW-E/ M*3DN`F<@:ADQP*.+`E/4R'DET/)SW]E/YYO=*M=AAYL#P0P",HNE%HIND*W6 M^"8+C.48P818+K`D(&E%]Y5"S',A]+?>A>YS$["MWFK0'@R!#0_9T-"0'6/@ M1R]Z-M^)XXI]U:W@JP-,CJ$I`A-!O7"+Q.+>9B_B$T6.1?3R;CUG%:`6>.^\ MP'LANBI*%+ZA&S#>.7X3!]W?HM8?@:>T=+MU:AIL@5?/*GDU;."0O3K`Q-\V MK^*U*%N>5[I!I@PVY^'R;AC\/#A[0WVFJS`'$(((K&3Z=(2">CYMS2**%.D. M1Y+:Z5=)D18!]N59]N]."J+P048CMS9@9NL4LW M%JBR7!I<&FX31\_&/?"$IG:UY9!>^="'IR?ALL5(ER- MZJ/9`Z/S!\A'EAN\5=R4!Y,_RL$PMSG*A7"JZE.`;5LA>MWJZ*3`NC628PFT M_)38.TM9MRIPV>%FPB$%R^,G]%HM\479"NK$R[0>I-D-S7_`%J_3/3:Y"RJ$ MR[3N$+'_(,4]D"A;0>R?I\9^P'[`!J\5^AOH0B\AU%?N'3`5O,Z3M]`7,!VOJ&A&_P5OPMD+:CEV`<2,3 MI*!'_)C6(P!,OS/@PQDAWM$[GB'J=)DBK((>]&-:#\KQU2'W*2'N$*?JR\\Q MYI,%XKB:IU+X"]:?NBD]Z9T"^L'PH0S`,C38T2&\SN9*'DS!6E,WI?-DNN=P M>\XC%I([IH1<0N>W"_5AE\[2]=!_B<#.1;X'JV2?!F9]QSM/VPT/K'VJ2477C#0+^6[9<82HJ M+V-E(.0GH-/3M`2DD-H:RHAB'7VBH/LOB%M]4Y+G>FN]%5#ST]CIZ7GWHJSO M#-V`X;=PP%DNU?QWRY7-UABG/QW;B-8:EK9MJS@`-L>QK`#PF\VFT$T?(R/N MC]%*_7UDMGW/N.I#.XN#3.1BKY^7]KK;B*%::7O-'#T<]\-$,O.+:Z<_D>WX MKV8Z2WUK=_V^9#O%WM]XM3?3^[I)/P:"1HU(J\=@B#NI1O&;AY-?"I^>II7" M6WM&\7B[_[I]WNSVI$ M^X"74\Q;^K27Z];F;6+;RJX^NW``CTA'-?8;9\[JNJ7/&[PB$B];AGNZA'LJ MXI7%EHC0(3Q0.K0,EQ!BA##K21-:#O<*^4X5R7N]5,D3M_^DHO&85$S==)I:?NUZ*@,9X2F68*]S!"F6^)=/61TU5,=D>@]A63-RP/PT,(6HI9:CU6?(68DAF*ZYNFF;2_9+>90?013HJ33 MBJ@:IY<:MH=48AATY2.XHO]*A*]-QK-R.ECRRB+0LO"Z4+QS@2R$SM]:F8$V M698ZP=.]#TNW4$N!.=RD-8'F\5<''DLVI&*%33W+CN6Y*@S['[;441S*6PZR M'\@,CV:1G*:.`-%YSNTZGR`Q\)QUAL``.X5L@(DXAL+C'IG$)G)]A[B]?L)\ M2:CFO,]3HUD\?9:B;%P*'6#2]YZ$ MBD1OU0^OMTF3`\(A1S"WM-@7MCN;.6"?3^V>@0(*'MO')@O8"$& M:"W0#.9`W@QB"\,5(^^_K*Z@UE`M`"/;2]#JO^E$4G0-,Q7A??LA]M%192&; M^0$1]"%1PURY8/5M16"^/\<\+XYV:Y1'K.I<>)H8U6MWMT+`Q@:2.MX?!.&8 MS?PD\9GQ+^I]3[0B$MFA-'K_EJI=S??T9TER35 MG?"[&7\Q12TD!,(7TS5O:?U.K%;)J7CBWM[FXA$1/Z!7LG26:MW.Y,1=XHB5 MQ$5$39V%*KG=1#Z:Z14WT7?D@G'R/VQ%=8>.L=LQEH<>MN[\=7ABK0-VZ5 M[G>,;+GXC&U;C2YQO3*>-5`'3E18/<#SI`8I3YHGOWX?Y7?]/LH$\V>(FZ0> M>11[7W[,.0&J3ZW?H`7U@=V(^N7=:'9/7L-CP5P5MP5I;!V4W'N"":+:VY7, M3X^(6A-DXZ"@""Q2@[%YQ8?>6C1AVH+H^LXF_I9,(L`+J1K7:?]P[+7Z3W8? M&?T3RG1U\5Q`/UKIXZP%Z_G@==:$Y`W'!R'*JW+G#[#K3%.;/;RIOI@@KDH%40+/OF/+GV.[T+*@^-V_O>W'57_GU5CRA(%;; M"@F!TQ[O3?",H/&^E%!+F72N_O&ZY4#-FHB:(J*FO2L2OH.:W@MRGC=-E3'C M$F2VB.G-+-6@&$]2^22-2U-C8.=/;()-1JT^I3"3Y`*&V(12151-U>MI07BA M6IE$S=,J8S8[=O_]:%*]LM1[+]A3CUO)^-RDJ1R96O]4MK"+80;:]?F(?PP]N;Q@\&\W\%_*$3K9/"T05S2LV M'?5?,,!^)(B:I@FUY^7\MS1'3-71+&F6?\(CQ2)\J_;WWN1V"^QAXNWWG:.^ MI97>-)5X=62XX?1?C/@]">?];X*\WX61':O$G.V39Q[R]V2LR%N);P'\/9GJ M:<'Q&QG+A_ZNS!6^P_D6P$TTE7J+9@23EL\+8B[T1[GB,\@Y,LVBC%3`N?^7 MC+38TQP73MXT,OG]@V,]6VYT#/BKQ/^W1Y4?AM]S8` M^ZX0E4A#(9RXW$/:-TW&+35/4^_.]AT)X'RZ&H M\4^54^XWSOB?*/(SSBWC*\8W=IAS*1JG3V)-_I[QNZ\.D6MW@`U6.?QOC!/K MX+6Y_[E5&UL550%``-6`753=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`87"O1$+,PK,%#0``S*T``!,`&``` M`````0```*2!(Z8``&AH+3(P,30P,S,Q7V-A;"YX;6Q55`4``U8!=5-U>`L` M`00E#@``!#D!``!02P$"'@,4````"`!A<*]$#;6DTX`K``#M%@(`$P`8```` M```!````I(%ULP``:&@M,C`Q-#`S,S%?9&5F+GAM;%54!0`#5@%U4W5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`&%PKT3\AQV+CWP``'7,!@`3`!@````` M``$```"D@4+?``!H:"TR,#$T,#,S,5]L86(N>&UL550%``-6`753=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`87"O1'O\Z1EI30``(N`#`!,`&``````` M`0```*2!'EP!`&AH+3(P,30P,S,Q7W!R92YX;6Q55`4``U8!=5-U>`L``00E M#@``!#D!``!02P$"'@,4````"`!A<*]$$\X;]!P.``!VF```#P`8```````! M````I('4J0$`:&@M,C`Q-#`S,S$N>'-D550%``-6`753=7@+``$$)0X```0Y 9`0``4$L%!@`````&``8`#@(``#FX`0`````` ` end XML 57 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Impairment of Long-lived Assets (Details) (USD $)
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Asset Impairment Charges [Abstract]    
Impairment of long-lived assets $ 0 $ 0
XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 76 200 1 true 30 0 false 8 false false R1.htm 0001000 - Document - DEI Document Sheet http://www.hooperholmes.com/role/DeiDocument DEI Document true false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.hooperholmes.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 1001500 - Statement - Consolidated Balance Sheet (Parentheticals) Sheet http://www.hooperholmes.com/role/ConsolidatedBalanceSheetParentheticals Consolidated Balance Sheet (Parentheticals) false false R4.htm 1003000 - Statement - Consolidated Statements of Operations (unaudited) Sheet http://www.hooperholmes.com/role/ConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (unaudited) false false R5.htm 1004000 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet http://www.hooperholmes.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (unaudited) false false R6.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.hooperholmes.com/role/BasisOfPresentation Basis of Presentation false false R7.htm 2107100 - Disclosure - Liquidity Sheet http://www.hooperholmes.com/role/Liquidity Liquidity false false R8.htm 2110100 - Disclosure - (Loss) Earnings Per Share Sheet http://www.hooperholmes.com/role/LossEarningsPerShare (Loss) Earnings Per Share false false R9.htm 2113100 - Disclosure - Impairment of Long-lived Assets Sheet http://www.hooperholmes.com/role/ImpairmentOfLongLivedAssets Impairment of Long-lived Assets false false R10.htm 2122100 - Disclosure - Share-Based Compensation Sheet http://www.hooperholmes.com/role/ShareBasedCompensation Share-Based Compensation false false R11.htm 2131100 - Disclosure - Discontinued Operations Sheet http://www.hooperholmes.com/role/DiscontinuedOperations Discontinued Operations false false R12.htm 2134100 - Disclosure - Inventories Sheet http://www.hooperholmes.com/role/Inventories Inventories false false R13.htm 2135100 - Disclosure - Restructuring Charges Sheet http://www.hooperholmes.com/role/RestructuringCharges Restructuring Charges false false R14.htm 2136100 - Disclosure - Loan and Security Agreements Sheet http://www.hooperholmes.com/role/LoanAndSecurityAgreements Loan and Security Agreements false false R15.htm 2137100 - Disclosure - Commitments and Contingencies Sheet http://www.hooperholmes.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R16.htm 2138100 - Disclosure - Litigation Sheet http://www.hooperholmes.com/role/Litigation Litigation false false R17.htm 2139100 - Disclosure - Income Taxes Sheet http://www.hooperholmes.com/role/IncomeTaxes Income Taxes false false R18.htm 2141100 - Disclosure - Segments Sheet http://www.hooperholmes.com/role/Segments Segments false false R19.htm 2201201 - Disclosure - Basis of Presentation (Policies) Sheet http://www.hooperholmes.com/role/BasisOfPresentationPolicies Basis of Presentation (Policies) false false R20.htm 2322301 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.hooperholmes.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) false false R21.htm 2331301 - Disclosure - Discontinued Operations (Tables) Sheet http://www.hooperholmes.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) false false R22.htm 2335301 - Disclosure - Restructuring Charges (Tables) Sheet http://www.hooperholmes.com/role/RestructuringChargesTables Restructuring Charges (Tables) false false R23.htm 2341301 - Disclosure - Segments (Tables) Sheet http://www.hooperholmes.com/role/SegmentsTables Segments (Tables) false false R24.htm 2401402 - Disclosure - Basis of Presentation (Details) Sheet http://www.hooperholmes.com/role/BasisOfPresentationDetails Basis of Presentation (Details) false false R25.htm 2407401 - Disclosure - Liquidity (Details) Sheet http://www.hooperholmes.com/role/LiquidityDetails Liquidity (Details) false false R26.htm 2410401 - Disclosure - (Loss) Earnings Per Share (Details) Sheet http://www.hooperholmes.com/role/LossEarningsPerShareDetails (Loss) Earnings Per Share (Details) false false R27.htm 2413401 - Disclosure - Impairment of Long-lived Assets (Details) Sheet http://www.hooperholmes.com/role/ImpairmentOfLongLivedAssetsDetails Impairment of Long-lived Assets (Details) false false R28.htm 2422402 - Disclosure - Share-Based Compensation Employee Share-Based Compensation Plans (Details) Sheet http://www.hooperholmes.com/role/ShareBasedCompensationEmployeeShareBasedCompensationPlansDetails Share-Based Compensation Employee Share-Based Compensation Plans (Details) false false R29.htm 2422403 - Disclosure - Share-Based Compensation Stock Option Valuation Assumptions (Details) Sheet http://www.hooperholmes.com/role/ShareBasedCompensationStockOptionValuationAssumptionsDetails Share-Based Compensation Stock Option Valuation Assumptions (Details) false false R30.htm 2422404 - Disclosure - Share-Based Compensation Option Roll-Forward (Details) Sheet http://www.hooperholmes.com/role/ShareBasedCompensationOptionRollForwardDetails Share-Based Compensation Option Roll-Forward (Details) false false R31.htm 2422405 - Disclosure - Share-Based Compensation Award Activity (Details) Sheet http://www.hooperholmes.com/role/ShareBasedCompensationAwardActivityDetails Share-Based Compensation Award Activity (Details) false false R32.htm 2431402 - Disclosure - Discontinued Operations Operation Assets (Details) Sheet http://www.hooperholmes.com/role/DiscontinuedOperationsOperationAssetsDetails Discontinued Operations Operation Assets (Details) false false R33.htm 2431403 - Disclosure - Discontinued Operations Narrative (Details) Sheet http://www.hooperholmes.com/role/DiscontinuedOperationsNarrativeDetails Discontinued Operations Narrative (Details) false false R34.htm 2434401 - Disclosure - Inventories (Details) Sheet http://www.hooperholmes.com/role/InventoriesDetails Inventories (Details) false false R35.htm 2435402 - Disclosure - Restructuring Charges (Details) Sheet http://www.hooperholmes.com/role/RestructuringChargesDetails Restructuring Charges (Details) false false R36.htm 2436401 - Disclosure - Loan and Security Agreements (Details) Sheet http://www.hooperholmes.com/role/LoanAndSecurityAgreementsDetails Loan and Security Agreements (Details) false false R37.htm 2437401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.hooperholmes.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R38.htm 2438401 - Disclosure - Litigation (Details) Sheet http://www.hooperholmes.com/role/LitigationDetails Litigation (Details) false false R39.htm 2439401 - Disclosure - Income Taxes (Details) Sheet http://www.hooperholmes.com/role/IncomeTaxesDetails Income Taxes (Details) false false R40.htm 2441402 - Disclosure - Segments (Details) Sheet http://www.hooperholmes.com/role/SegmentsDetails Segments (Details) false false All Reports Book All Reports Element hh_DisposalGroupIncludingDiscontinuedOperationConsideration had a mix of decimals attribute values: -5 -4. Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearFive had a mix of decimals attribute values: 0 2. Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearFour had a mix of decimals attribute values: 0 2. Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearOne had a mix of decimals attribute values: 0 2. Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearThree had a mix of decimals attribute values: 0 2. Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearTwo had a mix of decimals attribute values: 0 2. Element us-gaap_ProceedsFromDivestitureOfBusinesses had a mix of decimals attribute values: -5 -3. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant had a mix of decimals attribute values: -2 -1. 'Monetary' elements on report '2401402 - Disclosure - Basis of Presentation (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2407401 - Disclosure - Liquidity (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2422405 - Disclosure - Share-Based Compensation Award Activity (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2431402 - Disclosure - Discontinued Operations Operation Assets (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2431403 - Disclosure - Discontinued Operations Narrative (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2439401 - Disclosure - Income Taxes (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2441402 - Disclosure - Segments (Details)' had a mix of different decimal attribute values. Process Flow-Through: 1001000 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 1001500 - Statement - Consolidated Balance Sheet (Parentheticals) Process Flow-Through: 1003000 - Statement - Consolidated Statements of Operations (unaudited) Process Flow-Through: 1004000 - Statement - Consolidated Statements of Cash Flows (unaudited) hh-20140331.xml hh-20140331.xsd hh-20140331_cal.xml hh-20140331_def.xml hh-20140331_lab.xml hh-20140331_pre.xml true true XML 59 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Litigation (Details) (USD $)
In Millions, unless otherwise specified
0 Months Ended
Mar. 11, 2013
Commitments and Contingencies Disclosure [Abstract]  
Settlement $ 0.05
XML 60 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Valuation Assumptions
The fair value of the stock options granted during the three month period ended March 31, 2014 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

 
Three Months Ended March 31,
 
2014
Expected life (years)
5.24
Expected volatility
85.0%
Expected dividend yield
—%
Risk-free interest rate
1.8%
Weighted average fair value of options granted during the period
$0.38
Schedule of Stock Option Activity
The following table summarizes stock option activity for the three month period ended March 31, 2014:
 
 
Number of Shares
 
Weighted Average Exercise Price Per Share
 
Weighted Average remaining Contractual Life (years)
 
Aggregate Intrinsic Value (in thousands)
Outstanding balance at December 31, 2013
 
4,150,550

 
$
0.75

 
 
 
 
Granted
 
462,600

 
0.56

 
 
 
 
Exercised
 
(37,500
)
 
0.45

 
 
 
 
Expired
 
(505,550
)
 
1.20

 
 
 
 
Forfeited
 
(83,500
)
 
0.57

 
 
 
 
Outstanding balance at March 31, 2014
 
3,986,600

 
0.68

 
8.5
 
$222
Options exercisable at March 31, 2014
 
1,388,700

 
$
0.99

 
6.8
 
$51